PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ELLENBERGER, TE; BRANDL, CJ; STRUHL, K; HARRISON, SC				ELLENBERGER, TE; BRANDL, CJ; STRUHL, K; HARRISON, SC			THE GCN4 BASIC REGION LEUCINE ZIPPER BINDS DNA AS A DIMER OF UNINTERRUPTED ALPHA-HELICES - CRYSTAL-STRUCTURE OF THE PROTEIN-DNA COMPLEX	CELL			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; LAMBDA-REPRESSOR; 2.8-A RESOLUTION; COILED COIL; FOS; JUN; RECOGNITION; DOMAIN; YEAST; SITE	The yeast transcriptional activator GCN4 is 1 of over 30 identified eukaryotic proteins containing the basic region leucine zipper (bZIP) DNA-binding motif. We have determined the crystal structure of the GCN4 bZIP element complexed with DNA at 2.9 angstrom resolution. The bZIP dimer is a pair of continuous alpha helices that form a parallel coiled coil over their carboxy-terminal 30 residues and gradually diverge toward their amino termini to pass through the major groove of the DNA-binding site. The coiled-coil dimerization interface is oriented almost perpendicular to the DNA axis, giving the complex the appearance of the letter T. There are no kinks or sharp bends in either bZIP monomer. Numerous contacts to DNA bases and phosphate oxygens are made by basic region residues that are conserved in the bZIP protein family. The details of the bZIP dimer interaction with DNA can explain recognition of the AP-1 site by the GCN4 protein.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute	ELLENBERGER, TE (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1990, X PLORV 2 1 MANUAL; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COHEN DR, 1990, ONCOGENE, V5, P929; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	54	864	898	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1223	1237		10.1016/S0092-8674(05)80070-4	http://dx.doi.org/10.1016/S0092-8674(05)80070-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473154				2022-12-24	WOS:A1992KE60400016
J	CHEN, YCJ; GUO, YL; HSU, CC; ROGAN, WJ				CHEN, YCJ; GUO, YL; HSU, CC; ROGAN, WJ			COGNITIVE-DEVELOPMENT OF YU-CHENG (OIL DISEASE) CHILDREN PRENATALLY EXPOSED TO HEAT-DEGRADED PCBS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYCHLORINATED-BIPHENYLS PCBS; BIRTH-DEFECTS; DIBENZOFURANS; CONTAMINANTS; DIOXINS; TAIWAN; BLOOD	Objective.-To compare the cognitive development in Taiwanese children who had been exposed prenatally to high levels of heat-degraded polychlorinated biphenyls (PCBs) with control children who were exposed to background levels. The disorder was called Yu-Cheng, "oil disease," in Taiwan. Design.-Matched-pair cohort study. Setting.-Communities in central Taiwan in which there had been a cooking-oil contamination and mass poisoning by heat-degraded PCBs in 1978 through 1979. Participants.-One hundred eighteen children born between June 1978 and March 1985 during or after their mothers' consumption of contaminated rice oil; 118 children matched for age, sex, neighborhood, maternal age, and parental education and occupational class; and 15 older siblings of exposed children, born before the poisoning. Main Outcome Measures.-Cognitive development measured from 1985 through 1990 using the Chinese versions of the Stanford-Binet test and the Wechsler Intelligence Scale for Children, Revised. Results.-The exposed children scored approximately 5 points lower on the Stanford-Binet test at the ages of 4 and 5 years and approximately 5 points lower on the Wechsler Intelligence Scale for Children, Revised, at the ages of 6 and 7 years. Children born up to 6 years after their mothers' exposure were as affected as children born within a year or two after exposure when examined at 6 and 7 years of age. Older siblings resembled the control children. Conclusion.-Children prenatally exposed to heat-degraded PCBs had poorer cognitive development than their matched controls. The effect persisted in the children up to the age of 7 years, and children born long after the exposure were still affected.	NATL CHENG KUNG UNIV,COLL MED,DEPT ENVIRONM HLTH,TAINAN,TAIWAN; NIEHS,RES TRIANGLE PK,NC 27709	National Cheng Kung University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	CHEN, YCJ (corresponding author), NATL CHENG KUNG UNIV,COLL MED,DEPT PSYCHIAT,138 SHENG LI RD,TAINAN 70428,TAIWAN.		Rogan, Walter/I-6034-2012	Rogan, Walter/0000-0002-9302-0160; GUO, Yue Leon/0000-0002-8530-4809				Anastasi A., 1982, PSYCHOL TESTING, V5th; CHEN CC, 1988, CHIN PSYCHIATRY, V2, P257; CHEN JH, 1979, MANUAL CHINESE VERSI; CHEN PH, 1981, CLIN MED TAIPEI, V7, P71; CHEN YC, 1989, CHIN PSYCHIATRY, V3, P89; CHEN YC, 1990, CHIN PSYCHIATRY, V4, P40; CHEN YCJ, IN PRESS J FORMOSAN; Crow K D, 1970, Trans St Johns Hosp Dermatol Soc, V56, P79; DEVOOGT P, 1989, TOPICS ENV HLTH, V4, P3; DYMENT PG, 1971, B ENVIRON CONTAM TOX, V6, P532, DOI 10.1007/BF01796861; ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; FUNATSU I, 1972, Kurume Medical Journal, V19, P43; GLADEN BC, 1991, J PEDIATR-US, V119, P58, DOI 10.1016/S0022-3476(05)81039-X; HARA I, 1985, ENVIRON HEALTH PERSP, V59, P85, DOI 10.2307/3429879; Harada M., 1976, B I CONSTITUTIONAL S, V25, P1; HSU CC, 1988, CHIN PSYCH, V2, P26; HSU CC, 1989, CHIN PSYCHIATRY S1, V3, P101; HSU ST, 1985, ENVIRON HEALTH PERSP, V59, P5, DOI 10.2307/3429867; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JENSEN AA, 1989, TOPICS ENV HLTH, V4, P345; KURATSUNE M, 1989, TOPICS ENV HLTH, V4, P381; LAN CF, 1981, CLIN MED TAIPEI, V7, P96; LIU SH, 1985, ANN REP BUREAU HLTH, V1, P269; MASTROIACOVO P, 1988, JAMA-J AM MED ASSOC, V259, P1668, DOI 10.1001/jama.259.11.1668; MASUDA Y, 1985, ENVIRON HEALTH PERSP, V59, P53, DOI 10.2307/3429874; NICHOLSON WJ, 1987, REV HUMAN HLTH EFFEC; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; ROGAN WJ, 1989, TOPICS ENV HLTH, V4, P401; SAFE S, 1990, CRIT REV TOXICOL, V21, P51, DOI 10.3109/10408449009089873; SAMUELSSON B, 1989, Neurofibromatosis, V2, P78; SHALAT SL, 1989, BRIT J IND MED, V46, P823; SVENSSON BG, 1991, NEW ENGL J MED, V324, P8, DOI 10.1056/NEJM199101033240102; TILSON HA, 1990, NEUROTOXICOL TERATOL, V12, P239, DOI 10.1016/0892-0362(90)90095-T; YEH TL, 1988, CHIN PSYCHIATRY, V2, P172; YU ML, 1991, NEUROTOXICOL TERATOL, V13, P195, DOI 10.1016/0892-0362(91)90011-K; 1977, MANUAL CHINESE 4TH V	36	208	217	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3213	3218		10.1001/jama.268.22.3213	http://dx.doi.org/10.1001/jama.268.22.3213			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433761				2022-12-24	WOS:A1992KA65400027
J	HEDBERG, CW; LEVINE, WC; WHITE, KE; CARLSON, RH; WINSOR, DK; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT				HEDBERG, CW; LEVINE, WC; WHITE, KE; CARLSON, RH; WINSOR, DK; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT			AN INTERNATIONAL FOODBORNE OUTBREAK OF SHIGELLOSIS ASSOCIATED WITH A COMMERCIAL AIRLINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMID	Objective.-To determine the source of an international outbreak of shigellosis associated with consumption of food served by a Minnesota-based airline. Design.-Cohort studies of players and staff of a Minnesota-based professional football team and passengers on flights with a confirmed case of outbreak-associated Shigella sonnei infection. Setting.-Community- and industry-based studies conducted from October through November 1988. Participants.-Sixty-five football team players and staff, and 725 airline passengers in the cohort studies. Results.-Twenty-one (32%) of 65 football players and staff developed shigellosis that was associated with consumption of cold sandwiches prepared at the airline flight kitchen (relative risk [RR], 17.1; 95% confidence interval [CI], 2.4 to 120; P<.001). Confirmed or probable shigellosis was identified among 240 passengers on 219 flights to 24 states, the District of Columbia, and four countries between September 14 and October 13. An outbreak-associated strain of S sonnei was isolated from football players and staff, airline passengers, and flight attendants. Thirty (4.1%) of 725 passengers on 13 flights with confirmed cases had confirmed or probable shigellosis. Illness was associated with consumption of cold food items served on the flights and prepared by hand at the airline flight kitchen (RR, 5.7; 95% CI, 1.4 to 23.5; P<.01). Conclusions.-This international outbreak of shigellosis was identified only because of the occurrence of an index outbreak involving a professional football team. Prevention of Shigella transmission in mass catering establishments may require reduction of hand contact in the preparation of cold food items or elimination of these items from menus.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ENTER DIS BRANCH,ATLANTA,GA; HENNEPIN CTY COMMUNITY HLTH DEPT,MINNEAPOLIS,MN; UNIV TEXAS,SCH MED,HOUSTON,TX 77025	Centers for Disease Control & Prevention - USA; University of Texas System	HEDBERG, CW (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,POB 9441,MINNEAPOLIS,MN 55440, USA.							BARRY AL, 1985, MANUAL CLIN MICROBIO, pCH102; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BRYAN FL, 1981, FOOD TECHNOL-CHICAGO, V35, P78; LEE LA, 1991, J INFECT DIS, V164, P894, DOI 10.1093/infdis/164.5.894; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; ROTHMAN KJ, 1979, EPIDEMIOLOGIC ANAL P, P5; TAUXE RV, 1987, AM J EPIDEMIOL, V125, P150, DOI 10.1093/oxfordjournals.aje.a114498; WINSOR DK, 1988, J INFECT DIS, V158, P1108, DOI 10.1093/infdis/158.5.1108	9	67	67	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3208	3212		10.1001/jama.268.22.3208	http://dx.doi.org/10.1001/jama.268.22.3208			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433760				2022-12-24	WOS:A1992KA65400026
J	GOULD, TH; CROSBY, DL; HARMER, M; LLOYD, SM; LUNN, JN; REES, GAD; ROBERTS, DE; WEBSTER, JA				GOULD, TH; CROSBY, DL; HARMER, M; LLOYD, SM; LUNN, JN; REES, GAD; ROBERTS, DE; WEBSTER, JA			POLICY FOR CONTROLLING PAIN AFTER SURGERY - EFFECT OF SEQUENTIAL-CHANGES IN MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							POSTOPERATIVE PAIN; SERVICE; ANALGESIA	Objective-To observe the effects of introducing an acute pain service to the general surgical wards of a large teaching hospital. Design-A study in seven stages: (1) an audit of current hospital practice succeeded by the sequential introduction to the general surgical wards of (2) pain assessment charts; (3) an algorithm to allow more frequent use of intramuscular analgesia; (4) increased use of local anaesthetic techniques of wound infiltration and nerve blocks; (5) an information sheet for patients about postoperative pain; (6) the introduction of patient controlled analgesia; (7) a repeat audit of hospital practice. Data were collected on each patient 24 hours after operation. Setting-University Hospital of Wales, which has both district general and tertiary referral functions. Patients-2035 patients over nine months from all surgical specialties (excluding cardiac) at the hospital. General surgical operations were studied in detail and separated into major, intermediate, and minor for data collection. Main outcome measures-A change in the median visual analogue pain scores 24 hours after surgery for pain during relaxation, pain on movement, and pain on deep inspiration at each stage of the study. Results-There was a reduction in median visual analogue scores during the study. The median (95% confidence interval) scores for pain during relaxation decreased from 45 (34 to 53) in stage 1 to 16 (10 to 20) in stage 7 for major surgical procedures. Pain on movement decreased from 78 (66 to 80) to 46 (38 to 48), and pain on deep inspiration decreased from 64 (48 to 78) to 36 (31 to 38). The reductions in median scores for intermediate and minor operative procedures showed similar patterns. Conclusions-The introduction of an acute pain service to the general surgical wards led to considerable improvement in the level of postoperative pain as assessed by visual analogue scores. Simple techniques of regular pain assessment and the more frequent use of intramuscular analgesia as a result of using an algorithm were particularly effective.	UNIV HOSP WALES,DEPT ANAESTHET,CARDIFF,WALES; UNIV WALES COLL MED,DEPT ANAESTHET,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								BAHAR M, 1985, ANASTHESIA, V40, P5529; BANOS JE, 1989, METHOD FIND EXP CLIN, V11, P123; FELL D, 1982, BMJ, V283, P92; Lee A, 1990, ANAESTHESIA, V46, P1028; LEHMANN KA, 1985, PATIENT CONTROLLED A, P134; LIU WHD, 1991, BRIT J ANAESTH, V67, P768, DOI 10.1093/bja/67.6.768; MACINTYRE PE, 1990, MED J AUSTRALIA, V153, P417, DOI 10.5694/j.1326-5377.1990.tb125503.x; MAGNANI B, 1990, PATIENT CONTROLLED A, P85; MATHER LE, 1975, BRIT J ANAESTH, V47, P1269, DOI 10.1093/bja/47.12.1269; MELZACK R, 1975, PAIN, V1, P275; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Siegel S., 1988, NONPARAMETRIC STAT B, P213, DOI DOI 10.1177/014662168901300212; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; Smith G., 1984, QUALITY CARE ANAESTH, P164; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; WHITE WD, 1979, BRIT MED J, V2, P166, DOI 10.1136/bmj.2.6183.166; ZAR JH, 1984, BIOSTAT ANAL, P219; 1990, WORKING PARTY PAIN S; 1991, CURRENT PROBLEMS, V31, P3	21	161	163	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1187	1193		10.1136/bmj.305.6863.1187	http://dx.doi.org/10.1136/bmj.305.6863.1187			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467721	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JY77700020
J	KADLUBAR, FF				KADLUBAR, FF			DETECTION OF HUMAN DNA CARCINOGEN ADDUCTS	NATURE			English	Article							SENSITIVITY				KADLUBAR, FF (corresponding author), US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.							Carson R., 1962, SILENT SPRING; GAYLOR DW, IN PRESS ENV HLTH PE; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; GUPTA RC, 1985, CANCER RES, V45, P5656; MILLER JA, 1983, ENVIRON HEALTH PERSP, V49, P3, DOI 10.2307/3429574; RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	8	6	6	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					189	189		10.1038/360189a0	http://dx.doi.org/10.1038/360189a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436097				2022-12-24	WOS:A1992JX75200070
J	SWAI, AB; KITANGE, HM; MASUKI, G; KILIMA, PM; ALBERTI, KGMM; MCLARTY, DG				SWAI, AB; KITANGE, HM; MASUKI, G; KILIMA, PM; ALBERTI, KGMM; MCLARTY, DG			IS DIABETES-MELLITUS RELATED TO UNDERNUTRITION IN RURAL TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PROTEIN-CALORIE MALNUTRITION; INSULIN-SECRETION; PREVALENCE; COMMUNITY; CHILDREN; FETAL	Objective-To investigate the relation between undernutrition and diabetes. Design-Survey of glucose tolerance in rural Tanzania. Setting-Eight villages in three widely separated regions of Tanzania. Subjects-8581 people aged 15 and above: 3705 men and 4876 women. Main outcome measures-Oral glucose tolerance, body mass index, height, and low haemoglobin and cholesterol concentrations. Results-In the eight villages 42.7-56.9% of all men and 30.0-45.2% of all women had a body mass index below 20 kg/m2; the lowest quintile was 18.2 kg/m2 in men and 18.6 kg/m2 in women. The prevalence of diabetes did not change significantly from the lowest to the highest fifths of body mass index in men (lowest 1.6% (95% confidence interval 0.8% to 2.9%) v highest 1.3% (0.7% to 2.5%)) or women (1.1% (0.6% to 2.1%) v 0.5% (0.2% to 1.2%)). In men and in women prevalence of impaired glucose tolerance was greater in the lowest fifths of height (8.2% (6.3% to 10.6%), and 11.1% (9.2% to 13.3%)) respectively and body mass index (9.6% (7.5% to 12.1%), and 8.4% (6.7% to 10.5%)) than in the highest fifths (impaired glucose tolerance 4.7% (3.4% to 6.5%); and 5.1% (3.9% to 6.7%); body mass index 5.1% (3.7% to 7.0%), and 7.7% (6.2% to 9.6%). Conclusion-Rates of diabetes were not significantly associated with low body mass index or height, but overall rates were much lower than those in well nourished Western populations. Increased impaired glucose tolerance in the most malnourished people may reflect the larger glucose load per kilogram weight. The role of undernutrition in the aetiology of diabetes must be questioned.	UNIV NEWCASTLE UPON TYNE,CTR HUMAN DIABET & METAB RES,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,DAR ES SALAAM,TANZANIA; MINIST HLTH,DAR ES SALAAM,TANZANIA	Newcastle University - UK; University of Dar es Salaam								ABOUBAKARE A, 1986, LANCET, V1, P1135; ALBERTI K G M M, 1988, Diabetes Research and Clinical Practice, V5, pS449; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BAJAJ JS, 1984, DIABETES MELLITUS; BECKER DJ, 1971, DIABETES, V20, P542, DOI 10.2337/diab.20.8.542; BENNETT PH, 1992, INT TXB DIABETES MEL, P147; COOK GC, 1967, NATURE, V215, P1295, DOI 10.1038/2151295a0; DAVIES JNP, 1948, LANCET, V1, P317; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; FLEMING A. F., 1984, PRINCIPLES MED AFRIC, P705; GOPALAN C., 1952, Indian Journal of Medical Sciences, V6, P277; GUPTA OP, 1976, EXCERPTA MED INT C S, V390, P23; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HEARD CRC, 1967, DIABETES, V16, P96, DOI 10.2337/diab.16.2.96; Himsworth H. P., 1949, P ROY SOC MED, V62, P323; KEEN H, 1984, BRIT MED BULL, V40, P359, DOI 10.1093/oxfordjournals.bmb.a072005; KHARDORI R, 1985, DIABETES CARE, V8, P302, DOI 10.2337/diacare.8.3.302a; KIMATI VP, 1985, E AFR MED J, V62, P105; LESTER FT, 1984, IDF B, V29, P14; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MCLARTY DG, 1990, DIABETIC MED, V7, P670, DOI 10.1111/j.1464-5491.1990.tb01470.x; MCLARTY DG, 1989, LANCET, V1, P871; McMillan D E, 1979, Diabetes Care, V2, P202, DOI 10.2337/diacare.2.2.202; MRISHO F, 1986, MALNUTRITION TANZANI, P7; NORUSIS MJ, 1986, SPSS PC SPSS IBM PC; NWOKOLO C, 1980, LANCET, V1, P457; OLURIN EO, 1969, BMJ-BRIT MED J, V4, P534, DOI 10.1136/bmj.4.5682.534; PITCHUMONI CS, 1988, PANCREAS, V3, P220, DOI 10.1097/00006676-198804000-00018; RAO RH, 1988, ENDOCR REV, V9, P67, DOI 10.1210/edrv-9-1-67; RAO RH, 1984, DIABETES CARE, V7, P595, DOI 10.2337/diacare.7.6.595; SHAPER AG, 1960, LANCET, V1, P1223; SMITH SR, 1975, METABOLISM, V24, P1073, DOI 10.1016/0026-0495(75)90101-8; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; SWAI ABM, 1991, DIABETES, V40, P516, DOI 10.2337/diabetes.40.4.516; SWAI ABM, IN PRESS DIABETES CA; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TANNER M, 1987, ACTA TROP, V44, P137; WALKER M, 1988, J EPIDEMIOL COMMUN H, V42, P299, DOI 10.1136/jech.42.3.299; WEST KM, 1971, DIABETES, V20, P99, DOI 10.2337/diab.20.2.99; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P231; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P74; WHINCUP PH, 1988, BMJ, V197, P980; 1987, PRELIMINARY REPORT H; 1989, ARCH INTERN MED, V149, P2650; [No title captured]	47	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1057	1062		10.1136/bmj.305.6861.1057	http://dx.doi.org/10.1136/bmj.305.6861.1057			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467685	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JW70100018
J	GOLDFARB, LG; PETERSEN, RB; TABATON, M; BROWN, P; LEBLANC, AC; MONTAGNA, P; CORTELLI, P; JULIEN, J; VITAL, C; PENDELBURY, WW; HALTIA, M; WILLS, PR; HAUW, JJ; MCKEEVER, PE; MONARI, L; SCHRANK, B; SWERGOLD, GD; AUTILIOGAMBETTI, L; GAJDUSEK, DC; LUGARESI, E; GAMBETTI, P				GOLDFARB, LG; PETERSEN, RB; TABATON, M; BROWN, P; LEBLANC, AC; MONTAGNA, P; CORTELLI, P; JULIEN, J; VITAL, C; PENDELBURY, WW; HALTIA, M; WILLS, PR; HAUW, JJ; MCKEEVER, PE; MONARI, L; SCHRANK, B; SWERGOLD, GD; AUTILIOGAMBETTI, L; GAJDUSEK, DC; LUGARESI, E; GAMBETTI, P			FATAL FAMILIAL INSOMNIA AND FAMILIAL CREUTZFELDT-JAKOB DISEASE - DISEASE PHENOTYPE DETERMINED BY A DNA POLYMORPHISM	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; HUMAN PRION PROTEIN; ALZHEIMERS-DISEASE; SPONGIFORM ENCEPHALOPATHY; SICKLING HEMOGLOBIN; MUTATION; BIOLOGY; VARIANT	Fatal familial insomnia (FFI) and a subtype of familial Creutzfeldt-Jakob disease (CJD), two clinically and pathologically distinct diseases, are linked to the same mutation at codon 178 (Asn178) of the prion protein gene. The possibility that a second genetic component modified the phenotypic expression of the Asn178 mutation was investigated. FFI and the familial CJD subtype segregated with different genotypes determined by the Asn178 mutation and the methionine-valine polymorphism at codon 129. The Met129, Asn178 allele segregated with FFI in all 15 affected members of five kindreds whereas the Val129, Asn178 allele segregated with the familial CJD subtype in all 15 affected members of six kindreds. Thus, two distinct disease phenotypes linked to a single pathogenic mutation can be determined by a common polymorphism.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; NINCDS,CENT NERVOUS SYST STUDIES LAB,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892; UNIV BOLOGNA,INST NEUROL,I-40126 BOLOGNA,ITALY; UNIV BORDEAUX,SCH MED,DEPT NEUROL,BORDEAUX,FRANCE; UNIV BORDEAUX,SCH MED,DEPT PATHOL,BORDEAUX,FRANCE; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405; UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; UNIV AUCKLAND,DEPT PHYS,AUCKLAND,NEW ZEALAND; LAB NEUROPATHOL R ESCOUROLLE,PARIS,FRANCE; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48104; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bologna; UDICE-French Research Universities; Universite de Bordeaux; Universite de Franche-Comte; UDICE-French Research Universities; Universite de Bordeaux; Universite de Franche-Comte; University of Vermont; University of Helsinki; University of Auckland; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; University of Michigan System; University of Michigan; Washington University (WUSTL)			Cortelli, Pietro/K-6063-2016; Petersen, Robert/B-5075-2011; Wills, Peter R./B-9611-2012	Petersen, Robert/0000-0002-3154-0072; Wills, Peter R./0000-0002-2670-7624; Cortelli, Pietro/0000-0002-3633-8818	NIA NIH HHS [1 R01 AGNS08155-02, AG-08012-02] Funding Source: Medline; NINDS NIH HHS [NS 14509-13] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008012] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; BROWN P, 1992, ANN NEUROL, V31, P282, DOI 10.1002/ana.410310309; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BROWN PN, UNPUB; BUGE A, 1978, REV NEUROL, V134, P165; CASTANO EM, 1988, LAB INVEST, V58, P122; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; GAJDUSEK DC, 1990, VIROLOGY; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, ANN NEUROL, V31, P274, DOI 10.1002/ana.410310308; GOOSSENS M, 1975, FEBS LETT, V58, P149, DOI 10.1016/0014-5793(75)80246-8; GUIDON G, 1978, THESIS U RENNES; HALTIA M, 1979, Journal of the Neurological Sciences, V42, P381, DOI 10.1016/0022-510X(79)90171-0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HSAIO K, 1992, NAT GENET, V1, P68; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LANGDOWN JV, 1989, BRIT J HAEMATOL, V71, P443; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LITTLE BW, 1986, ANN NEUROL, V20, P231, DOI 10.1002/ana.410200209; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MAY WW, 1968, ARCH NEUROL-CHICAGO, V19, P137, DOI 10.1001/archneur.1968.00480020023002; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MEDORI R, 1992, NEUROLOGY, V42, P669, DOI 10.1212/WNL.42.3.669; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; MOOPENN WF, 1977, EUR J BIOCHEM, V77, P561, DOI 10.1111/j.1432-1033.1977.tb11699.x; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PENDLEBURY W, UNPUB; PETERSEN RB, 1992, PRION DISEASE HUMANS; PETERSEN RB, IN PRESS NEUROLOGY; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; TANAKA MT, 1992, ACTA NEUROL SCAND, V85, P327; YSOHIDA K, 1992, ANN NEUROL, V31, P328	40	588	616	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					806	808		10.1126/science.1439789	http://dx.doi.org/10.1126/science.1439789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439789				2022-12-24	WOS:A1992JV69200040
J	SHULL, MM; ORMSBY, I; KIER, AB; PAWLOWSKI, S; DIEBOLD, RJ; YIN, MY; ALLEN, R; SIDMAN, C; PROETZEL, G; CALVIN, D; ANNUNZIATA, N; DOETSCHMAN, T				SHULL, MM; ORMSBY, I; KIER, AB; PAWLOWSKI, S; DIEBOLD, RJ; YIN, MY; ALLEN, R; SIDMAN, C; PROETZEL, G; CALVIN, D; ANNUNZIATA, N; DOETSCHMAN, T			TARGETED DISRUPTION OF THE MOUSE TRANSFORMING GROWTH FACTOR-BETA-1 GENE RESULTS IN MULTIFOCAL INFLAMMATORY DISEASE	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MUCOSAL IMMUNE-SYSTEM; NECROSIS FACTOR-ALPHA; FACTOR-BETA; EXPRESSION PATTERNS; LYMPHOCYTES-B; TGF BETA-1; CELLS; INHIBITION; EMBRYO	Transforming growth factor-beta1 (TGF-beta1) is a multifunctional growth factor that has profound regulatory effects on many developmental and physiological processes. Disruption of the TGF-beta1 gene by homologous recombination in murine embryonic stem cells enables mice to be generated that carry the disrupted allele. Animals homozygous for the mutated TGF-beta1 allele show no gross developmental abnormalities, but about 20 days after birth they succumb to a wasting syndrome accompanied by a multifocal, mixed inflammatory cell response and tissue necrosis, leading to organ failure and death. TGF-beta1-deficient mice may be valuable models for human immune and inflammatory disorders, including autoimmune diseases, transplant rejection and graft versus host reactions.	UNIV CINCINNATI, COLL MED, DEPT PATHOL & LAB MED, DIV COMPARAT PATHOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati	SHULL, MM (corresponding author), UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026471] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD026471] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; CHIN YH, 1992, J IMMUNOL, V148, P1106; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; COX DA, 1991, EUR J BIOCHEM, V197, P353, DOI 10.1111/j.1432-1033.1991.tb15918.x; CRONIN ME, 1988, PRIMER RHEUMATIC DIS, P120; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; ESPEVIK T, 1988, J IMMUNOL, V140, P2312; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; GAMBLE JR, 1988, SCIENCE, V242, P97; GATHERER D, 1990, DEVELOPMENT, V110, P445; GLODE LM, 1976, J IMMUNOL, V117, P2061; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; JOHNS LD, 1991, J IMMUNOL, V147, P1792; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KEHRL JH, 1991, J IMMUNOL, V146, P4016; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LONDEI M, 1984, NATURE, V312, P639, DOI 10.1038/312639a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; ORTALDO JR, 1991, J IMMUNOL, V146, P3791; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEVELOPMENT, V110, P609; RACKE MK, 1991, J IMMUNOL, V146, P3012; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; RISTOW HJ, 1986, P NATL ACAD SCI USA, V83, P5531, DOI 10.1073/pnas.83.15.5531; ROBERTS AB, 1909, PEPTIDE GROWTH FACTO, V1, P419; ROOK AH, 1986, J IMMUNOL, V136, P3916; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; TALAL N, 1988, PRIMER RHEUMATIC DIS, P136; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOKUYAMA H, 1989, CELL BIOL INT REP, V13, P251, DOI 10.1016/0309-1651(89)90147-1; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1988, J IMMUNOL, V140, P3026; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415	52	2550	2656	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					693	699		10.1038/359693a0	http://dx.doi.org/10.1038/359693a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436033	Green Accepted			2022-12-24	WOS:A1992JU65000045
J	GOODE, HF; BURNS, E; WALKER, BE				GOODE, HF; BURNS, E; WALKER, BE			VITAMIN-C DEPLETION AND PRESSURE SORES IN ELDERLY PATIENTS WITH FEMORAL-NECK FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; DIETARY SUPPLEMENTATION; PLASMA; ZINC; FEMUR	Objective-To evaluate the contribution of specific nutritional deficiencies (as indicated by zinc; vitamin A, C, and E; albumin; and haemoglobin concentrations) to the risk of pressure sores. Design-Observational cohort study. Setting-St James's University Hospital, Leeds. Subjects-21 elderly patients presenting consecutively to the orthopaedic unit with femoral neck fracture. Main outcome measure-Full thickness epidermal break over a pressure bearing surface. Results-10 patients (48%) developed a pressure sore during their hospital stay. Indices of zinc status and concentrations of albumin, haemoglobin, and vitamins A and E were similar in patients who developed a pressure sore and those who did not. Mean leucocyte vitamin C concentration, however, was 6.3 (SD 2.2) mug/10(8) cells in patients who developed a pressure sore as compared with 12.8 (4.6) mug/10(8) cells in patients who did not. Conclusions-Low concentrations of leucocyte vitamin C appear to be associated with subsequent development of pressure sores in elderly patients with femoral neck fractures.	GEN INFIRM,DEPT MED ELDERLY,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	GOODE, HF (corresponding author), ST JAMES UNIV HOSP,MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							AGREN MS, 1990, THESIS LINKOPING U L; Allman R M, 1989, Decubitus, V2, P30; BARRETT JD, 1988, J HYPERTENS, V6, P49; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; Breslow R, 1991, Decubitus, V4, P16; BROWN KM, IN PRESS P NUTR SOC; CATIGNANI GL, 1983, CLIN CHEM, V29, P708; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DENSON KW, 1961, CLIN SCI, V21, P157; GOODE HF, 1991, AGE AGEING, V20, P345, DOI 10.1093/ageing/20.5.345; GOODE HF, 1990, CLIN SCI, V79, P247, DOI 10.1042/cs0790247; GOODE HF, 1989, ANN CLIN BIOCHEM, V26, P89, DOI 10.1177/000456328902600114; HUGHES AW, 1986, INJURY, V17, P19, DOI 10.1016/0020-1383(86)90007-0; MACHLIN LJ, 1984, HDB VITAMINS NUTRITI; MORGAN AG, 1975, INT J VITAM NUTR RES, V45, P448; PENN ND, 1991, AGE AGEING, V20, P169, DOI 10.1093/ageing/20.3.169; SCHORAH CJ, 1986, ANN CLIN BIOCHEM, V23, P566, DOI 10.1177/000456328602300513; TAYLOR TV, 1974, LANCET, V2, P544; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; 1990, LANCET, V335, P1311	20	40	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1992	305	6859					925	927		10.1136/bmj.305.6859.925	http://dx.doi.org/10.1136/bmj.305.6859.925			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU649	1458073	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JU64900021
J	NEVINS, JR				NEVINS, JR			E2F - A LINK BETWEEN THE RB TUMOR SUPPRESSOR PROTEIN AND VIRAL ONCOPROTEINS	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; CELLULAR TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; HUMAN MYC PROMOTER; HUMAN CYCLIN-A; TRANS-ACTIVATION; CARCINOMA-CELLS; INFECTED CELLS; T-ANTIGEN	The cellular transcription factor E2F, previously identified as a component of early adenovirus transcription, has now been shown to be important in cell proliferation control. E2F appears to be a functional target for the action of the tumor suppressor protein Rb that is encoded by the retinoblastoma susceptibility gene. The disruption of this E2F-Rb interaction, as well as a complex involving E2F in association with the cell cycle-regulated cyclin A-cdk2 kinase complex, may be a common mechanism of action for the oncoproteins encoded by the DNA tumor viruses.			NEVINS, JR (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, GENET SECT, DURHAM, NC 27710 USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, COMMUNICATION; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DULBECCO R, 1965, P NATL ACAD SCI USA, V53, P403, DOI 10.1073/pnas.53.2.403; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREARSON PM, 1965, CANCER RES, V25, P737; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT S, UNPUB; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KIT S, 1965, VIROLOGY, V27, P453, DOI 10.1016/0042-6822(65)90133-9; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRAUS VB, IN PRESS MOL CELL BI; KRAUS VB, UNPUB; LEDINKO N, 1967, CANCER RES, V27, P1459; LEES E, IN PRESS GENES DEV; LEES JA, UNPUB; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevins J R, 1990, Semin Cancer Biol, V1, P59; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHWARZ JH, UNPUB; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TAKAHASH.M, 1966, P SOC EXP BIOL MED, V122, P740; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOOZE J, 1984, DNA TUMOR VIRUSES; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YODER SS, 1983, MOL CELL BIOL, V3, P819, DOI 10.1128/MCB.3.5.819; ZIMMERMAN JE, 1970, VIROLOGY, V42, P1147, DOI 10.1016/0042-6822(70)90365-X	100	1540	1586	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					424	429						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411535				2022-12-24	WOS:A1992JT77500025
J	DESIMONE, R				DESIMONE, R			THE PHYSIOLOGY OF MEMORY - RECORDINGS OF THINGS PAST	SCIENCE			English	Editorial Material							INFERIOR TEMPORAL CORTEX; SHORT-TERM-MEMORY; HIPPOCAMPAL-FORMATION; RECOGNITION MEMORY; NEURONS; LESIONS; ASSOCIATION; RESPONSES; MACAQUE; PRIMATE				DESIMONE, R (corresponding author), NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892, USA.		Desimone, Robert/G-1121-2018					BAKIN JS, 1990, BRAIN RES, V536, P271, DOI 10.1016/0006-8993(90)90035-A; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; COLOMBO M, 1990, SCIENCE, V247, P336, DOI 10.1126/science.2296723; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ESKANDAR EN, IN PRESS J NEUROPHYS; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GALFAN D, 1992, BEHAV NEUROSCI, V106, P30; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDMANRAKIC PS, 1990, COLD SPRING HARB SYM, V55, P1025; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; MAUNSELL JHR, 1991, VISUAL NEUROSCI, V7, P561, DOI 10.1017/S095252380001035X; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; MIHASHITA Y, 1988, NATURE, V335, P817; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MISHKIN M, 1991, 1990 YAK INT S PERC, P7; MISHKIN M, 1982, PHILOS T R SOC LOND, V298, P83; MITZ AR, 1991, J NEUROSCI, V11, P1855; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NADEL L, 1992, J COGNITIVE NEUROSCI, V4, P179, DOI 10.1162/jocn.1992.4.3.179; PACKARD MG, 1989, J NEUROSCI, V9, P1465; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROLLS ET, 1989, EXP BRAIN RES, V76, P153; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; THOMPSON RF, 1991, NEUROPSYCHOLOGIA, V29, P571, DOI 10.1016/0028-3932(91)90011-V; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355; ZOLAMORGAN S, IN PRESS J NEUROSCI	32	59	60	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					245	246		10.1126/science.1411523	http://dx.doi.org/10.1126/science.1411523			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411523				2022-12-24	WOS:A1992JR86000021
J	HYMAN, AA; MIDDLETON, K; CENTOLA, M; MITCHISON, TJ; CARBON, J				HYMAN, AA; MIDDLETON, K; CENTOLA, M; MITCHISON, TJ; CARBON, J			MICROTUBULE-MOTOR ACTIVITY OF A YEAST CENTROMERE-BINDING PROTEIN COMPLEX	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DYNEIN; KINETOCHORES; SPINDLE; MITOSIS; INVITRO; CELLS	DURING cell division, sister chromosomes segregate from each other on a microtubule-based structure called the mitotic spindle. Proteins bind to the centromere, a region of chromosomal DNA, to form the kinetochore, which mediates chromosome attachment to the mitotic spindle microtubules1,2. In the budding yeast Saccharomyces cerevisiae, genetic analysis has shown that the 28-base-pair (bp) CDEIII region of the 125-bp centromere DNA sequence (CEN sequence) is the main region controlling chromosome segregation in vivo3,4. Therefore it is likely that proteins binding to the CDEIII region link the centromeres to the microtubules during mitosis. A complex of proteins (CBF3) that binds specifically to the CDEIII DNA sequence has been isolated by affinity chromatography5. Here we describe kinetochore function in vitro. The CBF3 complex can link DNA to microtubules, and the complex contains a minus-end-directed microtubule-based motor. We suggest that microtubule-based motors form the fundamental link between microtubules and chromosomes at mitosis.	UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara	HYMAN, AA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.		Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Hyman, Anthony A/0000-0003-3664-154X				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; EUTENEUER U, 1982, J CELL BIOL, V94, P644, DOI 10.1083/jcb.94.3.644; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1991, J CELL SCI, P125; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; PALMER RE, 1989, J CELL BIOL, V109, P3355, DOI 10.1083/jcb.109.6.3355; PETERSON JB, 1976, J CELL SCI, V22, P219; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; YAMAMOTO A, 1990, CELL STRUCT FUNCT, V15, P221, DOI 10.1247/csf.15.221	20	104	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1992	359	6395					533	536		10.1038/359533a0	http://dx.doi.org/10.1038/359533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406970				2022-12-24	WOS:A1992JR85900059
J	SAWIN, KE; LEGUELLEC, K; PHILIPPE, M; MITCHISON, TJ				SAWIN, KE; LEGUELLEC, K; PHILIPPE, M; MITCHISON, TJ			MITOTIC SPINDLE ORGANIZATION BY A PLUS-END-DIRECTED MICROTUBULE MOTOR	NATURE			English	Article							KINESIN-LIKE PROTEIN; CHROMOSOME SEGREGATION; DROSOPHILA; INVITRO; GENE; EXTRACTS; FLUX; IDENTIFICATION; MOTILITY; ENCODES	INTRACELLULAR microtubule motor proteins1,2 may direct the motile properties and/or morphogenesis of the mitotic spindle (reviewed in ref. 3). The recent identification of kinesin-like proteins important for mitosis or meiosis4-9 indicates that kinesin-related proteins may play a universal role in eukaryotic cell division, but the precise function of such proteins in mitosis remains unknown. Here we use an in vitro assay for spindle assembly, derived from Xenopus egg extracts10,11, to investigate the role of Eg5, a kinesin-like protein in Xenopus eggs12. Eg5 is localized along spindle microtubules, and particularly enriched near spindle poles. Immunodepletion of Eg5 from egg extracts markedly reduces the extent of spindle formation in extracts, as does direct addition of anti-Eg5 antibodies. We also demonstrate that Eg5 is a plus-end-directed microtubule motor in vitro. Our results suggest a novel mechanism for the dynamic self-organization of spindle poles in mitosis.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV RENNES 1,CNRS,URA 256,DEPT BIOL & GENET DEV,F-35042 RENNES,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	SAWIN, KE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Sawin, Kenneth/0000-0002-2607-2219	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HYMAN AA, 1991, J CELL SCI S, V14, P125; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MACKETT M, 1990, NUCLEIC ACIDS RES, V18, P1082, DOI 10.1093/nar/18.4.1082; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCINTOSH JR, 1981, INT CELLBIOL 1980 19; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1990, CELL MOTIL CYTOSKEL, V16, P93, DOI 10.1002/cm.970160202; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MURRAY AW, 1952, METHOD CELL BIOL, P581; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PICKETTHEAPS JD, 1982, CELL, V29, P729, DOI 10.1016/0092-8674(82)90435-4; REBHUN LI, 1988, CELL MOTIL CYTOSKEL, V10, P197, DOI 10.1002/cm.970100124; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WOLF KW, 1991, EUR J CELL BIOL, V55, P235; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	38	550	561	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					540	543		10.1038/359540a0	http://dx.doi.org/10.1038/359540a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406972				2022-12-24	WOS:A1992JR85900061
J	SEUBERT, P; VIGOPELFREY, C; ESCH, F; LEE, M; DOVEY, H; DAVIS, D; SINHA, S; SCHLOSSMACHER, M; WHALEY, J; SWINDLEHURST, C; MCCORMACK, R; WOLFERT, R; SELKOE, D; LIEBERBURG, I; SCHENK, D				SEUBERT, P; VIGOPELFREY, C; ESCH, F; LEE, M; DOVEY, H; DAVIS, D; SINHA, S; SCHLOSSMACHER, M; WHALEY, J; SWINDLEHURST, C; MCCORMACK, R; WOLFERT, R; SELKOE, D; LIEBERBURG, I; SCHENK, D			ISOLATION AND QUANTIFICATION OF SOLUBLE ALZHEIMERS BETA-PEPTIDE FROM BIOLOGICAL-FLUIDS	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE; MUTATION; GENE; CLEAVAGE; CELLS	CEREBRAL deposition of the beta-amyloid peptide (A-beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A-beta (ref. 1) and the subsequent cloning of its precursor protein2-5, no direct evidence for the actual production of discrete A-beta has been reported6-11. Here we investigate whether A-beta is present in human biological fluids using antibodies specific for an epitope within A-beta that spans the site of normal constitutive cleavage12,13. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A-beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A-beta and a novel A-beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A-beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A-beta.	ATHENA NEUROSCI INC, 800F GATEWAY BLVD, San Francisco, CA 94080 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HYBRITECH INC, SAN DIEGO, CA 92196 USA; BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				Schlossmacher, Michael/0000-0002-0394-0300				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MORI H, 1992, J BIOL CHEM, V267, P17082; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OI VT, 1990, METHODS CELLULAR IMM; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG RW, 1984, J IMMUNOL METHODS, V18, P157; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	27	1641	1793	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					325	327		10.1038/359325a0	http://dx.doi.org/10.1038/359325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406936				2022-12-24	WOS:A1992JP50300058
J	ARTHUR, LO; BESS, JW; SOWDER, RC; BENVENISTE, RE; MANN, DL; CHERMANN, JC; HENDERSON, LE				ARTHUR, LO; BESS, JW; SOWDER, RC; BENVENISTE, RE; MANN, DL; CHERMANN, JC; HENDERSON, LE			CELLULAR PROTEINS BOUND TO IMMUNODEFICIENCY VIRUSES - IMPLICATIONS FOR PATHOGENESIS AND VACCINES	SCIENCE			English	Article							T4 MOLECULE; CELLS; ANTIGENS; MHC; BETA-2-MICROGLOBULIN; RECEPTOR; COMPLEX; HIV; HISTOCOMPATIBILITY; ASSOCIATION	Cellular proteins associated with immunodeficiency viruses were identified by determination of the amino acid sequence of the proteins and peptides present in sucrose density gradient-purified human immunodeficiency virus (HIV)-1, HIV-2, and simian immunodeficiency virus (SIV). Beta2 microglobulin (beta2m) and the alpha and beta chains of human lymphocyte antigen (HLA) DR were present in virus preparations at one-fifth the concentration of Gag on a molar basis. Antisera to HLA DR, beta2m, as well as HLA class I precipitated intact viral particles, suggesting that these cellular proteins were physically associated with the surface of the virus. Antisera to class I, beta2m, and HLA DR also inhibited infection of cultured cells by both HIV-1 and SIV. The specific, selective association of these cellular proteins in a physiologically relevant manner has major implications for our understanding of the infection process and the pathogenesis of immunodeficiency viruses and should be considered in the design of vaccines.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; INSERM,UNITE RECH RETROVIRUS & MALAD ASSOCIEES,F-13273 MARSEILLE 9,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm)	ARTHUR, LO (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702, USA.		Bess, Jr., Julian/B-5343-2012		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BENVENISTE RE, UNPUB; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BESS JW, UNPUB; CHERMANN JC, UNPUB; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FERNANDEZLARSSON R, 1992, P NATL ACAD SCI USA, V89, P2223, DOI 10.1073/pnas.89.6.2223; GELDERBLOM H, 1987, Z NATURFORSCH C, V42, P1328; GELDERBLOM HR, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P50; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HENDERSON LE, 1990, J MED PRIMATOL, V19, P411; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KANNAGI M, 1987, J VIROL, V61, P1421, DOI 10.1128/JVI.61.5.1421-1426.1987; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KUBOTA K, 1984, J IMMUNOL, V133, P3203; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; MANN DL, 1988, J IMMUNOL, V141, P1131; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; SCHMIDT W, 1981, IMMUNOGENETICS, V13, P483, DOI 10.1007/BF00343716; SCHOLS D, 1992, VIROLOGY, V189, P374, DOI 10.1016/0042-6822(92)90719-6; SHEPPARD HW, 1992, J ACQ IMMUN DEF SYND, V5, P143; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WRIGHTHAM M, 1991, CLIN EXP IMMUNOL, V85, P75, DOI 10.1111/j.1365-2249.1991.tb05685.x	32	494	511	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1935	1938		10.1126/science.1470916	http://dx.doi.org/10.1126/science.1470916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470916				2022-12-24	WOS:A1992KD08800031
J	STEINHART, R; REINGOLD, AL; TAYLOR, F; ANDERSON, G; WENGER, JD				STEINHART, R; REINGOLD, AL; TAYLOR, F; ANDERSON, G; WENGER, JD			INVASIVE HAEMOPHILUS-INFLUENZAE INFECTIONS IN MEN WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; INTRAVENOUS DRUG-USERS; HEMOPHILUS-INFLUENZAE; BACTERIAL PNEUMONIA; AIDS; BACTEREMIA; ADULTS; SURVEILLANCE; DISEASE	Objective.-To determine the incidence of invasive Haemophilus influenzae disease in men with the acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV) infection and the proportion of disease due to serotype b. Design.-Population-based, active surveillance. Setting.-San Francisco (Calif) Department of Health. Participants.-All men 20 to 49 years of age with invasive H influenzae disease. Results.-The cumulative incidences of invasive H influenzae disease in men 20 to 49 years of age with AIDS and in HIV-infected men 20 to 49 years of age without AIDS were 79.2 and 14.6 per 100 000, respectively, but only 33% of cases were due to serotype b. The corresponding rates for invasive H influenzae b disease were 11.3 and 7.6 per 100 000. Conclusions.-Men with AIDS or HIV infection are at increased risk of invasive H influenzae infections, including H influenzae b, but such infections are still infrequent in this population.	UNIV CALIF BERKELEY,SCH PUBL HLTH,EPIDEMIOL PROGRAM,140 WARREN HALL,BERKELEY,CA 94720; BUR EPIDEMIOL & DIS CONTROL,SAN FRANCISCO,CA; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL,DEPT HLTH,ATLANTA,GA 30333	University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; GRANOFF DM, 1980, J INFECT DIS, V141, P40, DOI 10.1093/infdis/141.1.40; HECHT FM, 1991, NEW ENGL J MED, V326, P1569; MUSHER DM, 1983, ANN INTERN MED, V99, P444, DOI 10.7326/0003-4819-99-4-444; PELTOLA H, 1990, REV INFECT DIS, V12, P708; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; ROLSTON KVI, 1987, AM J MED, V83, P604, DOI 10.1016/0002-9343(87)90789-3; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SIMBERKOFF M, 1989, 29TH INT C ANT AG CH, P174; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WALLACE RJ, 1981, J INFECT DIS, V144, P101, DOI 10.1093/infdis/144.2.101; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; WHITE S, 1985, CHEST, V87, P486, DOI 10.1378/chest.87.4.486; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1988, MMWR, V37, P593	24	74	75	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3350	3352						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1453528				2022-12-24	WOS:A1992KB73200028
J	FREIJE, D; HELMS, C; WATSON, MS; DONISKELLER, H				FREIJE, D; HELMS, C; WATSON, MS; DONISKELLER, H			IDENTIFICATION OF A 2ND PSEUDOAUTOSOMAL REGION NEAR THE XQ AND YQ TELOMERES	SCIENCE			English	Article							HUMAN SEX-CHROMOSOMES; SHORT ARM; HUMAN SPERMATOCYTES; PAIRING REGION; DNA; SEQUENCES; HOMOLOGY; AMPLIFICATION; POLYMORPHISM; EVOLUTION	The telomeres of Xq and Yq have been observed to associate during meiosis, and in rare cases a short synaptonemal complex is present. Molecular cloning of loci from Xqter and Yqter has revealed that their sequence homology extends over 400 kilobases, which suggests the possibility of genetic exchange. This hypothesis was tested by the development of two highly informative microsatellite markers from yeast artificial chromosome clones that carried Xqter sequences and the following of their inheritance in a set of reference pedigrees from the Centre d'Etude du Polymorphisme Humain in Paris, France. From a total of 195 informative male meioses, four recombination events between these loci were observed. In three cases, paternal X alleles were inherited by male offspring, and in one case a female offspring inherited her father's Y allele. These data support the existence of genetic exchange at Xq-Yq, which defines a second pseudoautosomal region between the sex chromosomes.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV HUMAN MOLEC GENET,660 S EUCLID ST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHGRI NIH HHS [HG00100, HG00201] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AFFARA NA, 1986, NUCLEIC ACIDS RES, V14, P5353, DOI 10.1093/nar/14.13.5353; ANDERSSON M, 1986, SCIENCE, V233, P786, DOI 10.1126/science.3738510; ARVEILER B, 1989, GENOMICS, V4, P460, DOI 10.1016/0888-7543(89)90269-3; BENGTSSON BO, 1987, ANN HUM GENET, V51, P57, DOI 10.1111/j.1469-1809.1987.tb00865.x; BICKMORE WA, 1987, NUCLEIC ACIDS RES, V15, P6261, DOI 10.1093/nar/15.15.6261; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; CHANDLEY AC, 1984, CYTOGENET CELL GENET, V38, P241, DOI 10.1159/000132070; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FREIJE D, 1992, AM J HUM GENET, V51, P66; GREEN P, UNPUB CRI MAP VERSIO; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Koller PC, 1934, J GENET, V29, P159, DOI 10.1007/BF02982193; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; LUTY JA, 1990, AM J HUM GENET, V46, P776; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PEDICINI A, 1991, GENOMICS, V11, P482, DOI 10.1016/0888-7543(91)90167-D; ROUYER F, 1986, NATURE, V319, P291, DOI 10.1038/319291a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOLARI AJ, 1980, CHROMOSOMA, V81, P315, DOI 10.1007/BF00368145; SPEED RM, 1988, HUM GENET, V78, P260, DOI 10.1007/BF00291673; SPEED RM, 1990, HUM GENET, V84, P547; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R	31	152	156	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1784	1787		10.1126/science.1465614	http://dx.doi.org/10.1126/science.1465614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465614				2022-12-24	WOS:A1992KB96400036
J	PEREZSTABLE, EJ; SABOGAL, F; OTEROSABOGAL, R; HIATT, RA; MCPHEE, SJ				PEREZSTABLE, EJ; SABOGAL, F; OTEROSABOGAL, R; HIATT, RA; MCPHEE, SJ			MISCONCEPTIONS ABOUT CANCER AMONG LATINOS AND ANGLOS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEXICAN-AMERICANS; UNITED-STATES; BREAST-CANCER; ACCULTURATION; HISPANICS; POPULATION; BEHAVIOR; SYMPTOMS; SMOKING; HEALTH	Objective.-To collect information regarding knowledge about and attitudes toward cancer in a sample of adult health plan members, self-identified as Latino or Anglo. Design.-Cross-sectional survey. Setting.-Prepaid health plan. Respondents.-A random sample of 844 Latinos (mean age, 50.5 years) and 510 Anglos (51.8 years) completed the interview. Main Outcome Measures and Results.-Latinos were significantly more likely than Anglos to think that sugar substitutes (58% vs 42%), bruises from being hit (53% vs 34%), microwave ovens (47% vs 23%), eating pork (31% vs 11%), eating spicy foods (15% vs 8%), breast-feeding (14% vs 6%), and antibiotics (32% vs 12%) could cause cancer (P<.001 for each). Compared with Anglos, Latinos more often misidentified constant dizziness (39% vs 25%) and arthralgias (35% vs 20%) as being symptoms of cancer. A higher proportion of Latinos believed that having cancer is like getting a death sentence (46% vs 26%), that cancer is God's punishment (7% vs 2%), that there is very little one can do to prevent getting cancer (26% vs 18%), that it is uncomfortable to touch someone with cancer (13% vs 8%), and that they would rather not know if they had incurable cancer (35% vs 23%; P<.001 for each). Latino ethnicity was a significant predictor of these knowledge and attitude items in multivariate logistic regression models adjusted for sex, education, age, employment, marital status, county of residence, and self-perceived health status. Conclusions.-We conclude that misconceptions about cancer are more prevalent among Latinos than Anglos and that selected attitudes about cancer among Latinos fit a cultural theme of fatalismo. These data can enable development of culturally appropriate cancer control interventions for Latinos.	KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA	Kaiser Permanente; University of California System; University of California San Francisco			Hiatt, Robert/AAQ-1537-2021		NCI NIH HHS [CA 50030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajzen I., 1980, UNDERSTANDING ATTITU; [Anonymous], 1980, ACCULTURATION THEORY; Brislin R.W., 1973, CROSS CULTURAL RES M; DALY MB, 1985, JNCI-J NATL CANCER I, V74, P753; HAFFNER SM, 1985, AM J CLIN NUTR, V42, P1266, DOI 10.1093/ajcn/42.6.1266; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MARCUS AC, 1985, AM J PUBLIC HEALTH, V75, P169, DOI 10.2105/AJPH.75.2.169; MARIN G, 1989, AM J PUBLIC HEALTH, V79, P196, DOI 10.2105/AJPH.79.2.196; MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005; MARIN G, 1991, APPLIED SOCIAL RES M, V23, P130; MAURER JD, 1990, VITAL HLTH STAT, V20, P1; OTT L, 1988, INTRO STATISTICAL ME, P220; ROOT RK, 1987, WESTERN J MED, V146, P213; ROSENWAIKE I, 1987, AM J PUBLIC HEALTH, V77, P603, DOI 10.2105/AJPH.77.5.603; SABOGAL F, 1987, HISPANIC J BEHAV SCI, V9, P397, DOI 10.1177/07399863870094003; SAMET JM, 1988, J NATL CANCER I, V80, P432, DOI 10.1093/jnci/80.6.432; Sandoval M. C., 1986, CROSS CULTURAL TRAIN, P151; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; TRIANDIS HC, 1984, J PERS SOC PSYCHOL, V47, P1363, DOI 10.1037/0022-3514.47.6.1363; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; 1980, 1980 CENSUS POPULATI; 1986, SPSSX USERS GUIDE; 1992, MMWR, V41, P354; 1985, STUDY HISPANICS ATTI; 1984, CONDITIONS HISPANICS	27	223	223	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3219	3223		10.1001/jama.268.22.3219	http://dx.doi.org/10.1001/jama.268.22.3219			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433762				2022-12-24	WOS:A1992KA65400028
J	ANNAS, GJ				ANNAS, GJ			HEALTH WARNINGS, SMOKING, AND CANCER - THE CIPOLLONE CASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; GREENHOUSE L, 1992, NY TIMES        0301, P1; GREENHOUSE L, 1992, NY TIMES        0505, pB10; SLADE J, 1992, JAMA-J AM MED ASSOC, V268, P524, DOI 10.1001/jama.268.4.524; 1989, DHHS CDC898411 DEP H; 1991, DHHS PHS9150213 DEP	6	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1992	327	22					1604	1607		10.1056/NEJM199211263272219	http://dx.doi.org/10.1056/NEJM199211263272219			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ432	1435897				2022-12-24	WOS:A1992JZ43200027
J	BERKY, ZT; LUCIANO, WJ; JAMES, WD				BERKY, ZT; LUCIANO, WJ; JAMES, WD			LATEX GLOVE ALLERGY - A SURVEY OF THE UNITED-STATES-ARMY-DENTAL-CORPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CONTACT URTICARIA; RUBBER GLOVES; HOSPITAL PERSONNEL; ANAPHYLAXIS; DERMATITIS; HEALTH; VINYL	Objective.-To assess the prevalence of latex glove allergy in a population of health care providers (dentists) with a high occupational exposure to latex gloves. Design.-A survey instrument was distributed to all active-duty dental officers in the US Army (n=1628). The survey was designed to identify those individuals who had symptoms of allergy to latex gloves. Setting.-US Army dental facilities worldwide. Results.-The response rate to the survey was 64% (n=1043). There were 143 (13.7%) responses indicating latex glove allergy. If nonrespondents were assumed to be allergy-free, the prevalence rate would be 8.8%. Conclusion.-Latex allergy, as ascertained by self-report in this survey, appears to have a substantial prevalence in this health care provider population.	USA,DENT CLIN,FT RICHIE,MD; WALTER REED ARMY MED CTR,DERMATOL SERV,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	BERKY, ZT (corresponding author), CRAVEN DENT CLIN,FT KNOX,KY 40121, USA.							BAUER X, 1990, LANCET, V335, P912; BELSITO DV, 1990, DERMATOL CLIN, V8, P61, DOI 10.1016/S0733-8635(18)30523-0; CONDESALAZAR L, 1990, DERMATOL CLIN, V8, P49, DOI 10.1016/S0733-8635(18)30521-7; DOOMSGOOSSENS A, 1988, J AM ACAD DERMATOL, V18, P1360, DOI 10.1016/S0190-9622(88)80116-6; FISHER AA, 1991, CUTIS, V47, P301; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; GONZALEZ E, 1988, J AM DENT ASSOC, V117, P467, DOI 10.1016/S0002-8177(88)73019-6; HEALEY MP, 1990, J AM DENT ASSOC, V121, P672, DOI 10.14219/jada.archive.1990.0273; KORNIEWICZ DM, 1990, J CLIN MICROBIOL, V28, P787, DOI 10.1128/JCM.28.4.787-788.1990; KOTILAINEN HR, 1989, ARCH INTERN MED, V149, P2749; LAWLOR K, IN PRESS CUTANEOUS S; MARCH PJ, 1988, J AM DENT ASSOC, V117, P590, DOI 10.14219/jada.archive.1988.0046; MASO MJ, 1990, J AM ACAD DERMATOL, V23, P733, DOI 10.1016/0190-9622(90)70283-N; MAYER R, 1988, JAMA-J AM MED ASSOC, V259, P3184; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; PALMER C, 1989, ADA NEWS, V20, P1; RICH P, 1991, J AM ACAD DERMATOL, V24, P37, DOI 10.1016/0190-9622(91)70006-N; RUDZKI E, 1989, CONTACT DERMATITIS, V20, P247, DOI 10.1111/j.1600-0536.1989.tb03140.x; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SOCKIN S M, 1991, Journal of Allergy and Clinical Immunology, V87, P269, DOI 10.1016/0091-6749(91)91803-2; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1986, CONTACT DERMATITIS, P604; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; TURJANMAA K, 1984, ALLERGY S2, V40, pS35; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; 1990, ARMY DEFENSE MATERIA; 1990, FDA DRUG B, V20, P2; 1988, FACTS AIDS DENTAL TE; 1988, MMWR, V379, P377	39	78	79	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2695	2697						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1433688				2022-12-24	WOS:A1992JX68000032
J	WEIDNER, G; CONNOR, SL; HOLLIS, JF; CONNOR, WE				WEIDNER, G; CONNOR, SL; HOLLIS, JF; CONNOR, WE			IMPROVEMENTS IN HOSTILITY AND DEPRESSION IN RELATION TO DIETARY CHANGE AND CHOLESTEROL LOWERING - THE FAMILY HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CHOLESTEROL, DIETARY; DIET THERAPY; DEPRESSION; HOSTILITY; DIETARY FATS	RANDOMLY SELECTED FAMILIES; BODY-WEIGHT; MEN; WOMEN; BEHAVIOR; CHILDREN; DISEASE; TRIALS; LIPIDS; AGE	Objective: To describe changes in negative emotions among participants of a cholesterol-lowering study. Design: Cohort study. Quantitative evaluation of changes in negative emotions in relation to diet and plasma cholesterol levels before and after a 5-year dietary intervention program aimed at reducing plasma cholesterol levels. Setting: Community-dwelling families of the Family Heart Study, Portland, Oregon. Participants: One hundred forty-nine men and 156 women from 233 families (mean age, 37.7 years). Measurements: Changes in negative emotions including depression and aggressive hostility as measured by the Hopkins Symptom Checklist (SCL-90). Results: Improvement in overall emotional state was noted for the entire sample. Those who consumed a low-fat, high complex-carbohydrate diet at the end of the study showed significantly greater improvements in depression (P = 0.044; difference in improvement, 2.9 points) and aggressive hostility (P = 0.035; difference in improvement, 3.3 points) as well as a reduction in their plasma cholesterol levels (P = 0.024; difference in improvement, 2.7%) compared with those who ate a high-fat "American diet." Conclusions: Participation in a cholesterol-lowering program may not be associated with a worsening in emotional state. To the contrary, improvements in diet appear to be associated with reductions in depression and aggressive hostility as well as with lowered plasma cholesterol levels.	OREGON HLTH SCI UNIV, DEPT MED, PORTLAND, OR 97201 USA	Oregon Health & Science University	WEIDNER, G (corresponding author), SUNY STONY BROOK, DEPT PSYCHOL, STONY BROOK, NY 11794 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025687, R01HL040368, R01HL020910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25687, HL20910, HL40368] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BECK AT, 1985, AM J PSYCHIAT, V142, P559; CONNOR SL, 1982, CIRCULATION, V65, P1290, DOI 10.1161/01.CIR.65.7.1290; CONNOR SL, 1984, CIRCULATION, V70, P76, DOI 10.1161/01.CIR.70.1.76; CONNOR SL, 1992, J AM DIET ASSOC, V92, P41; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; DEROGATIS LR, 1977, SCL 90 VERSION MANUA, V1; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HOLLIS JF, 1984, PREV MED, V13, P276, DOI 10.1016/0091-7435(84)90084-7; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MURPHY CM, 1989, J CONSULT CLIN PSYCH, V57, P579, DOI 10.1037/0022-006X.57.5.579; PIERCE DK, 1984, PREV MED, V13, P390, DOI 10.1016/0091-7435(84)90030-6; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; WEIDNER G, 1987, PSYCHOSOM MED, V49, P136, DOI 10.1097/00006842-198703000-00004; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; [No title captured]	18	111	112	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					820	823		10.7326/0003-4819-117-10-820	http://dx.doi.org/10.7326/0003-4819-117-10-820			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416556				2022-12-24	WOS:A1992JX83800004
J	HAHN, K; DEBIASIO, R; TAYLOR, DL				HAHN, K; DEBIASIO, R; TAYLOR, DL			PATTERNS OF ELEVATED FREE CALCIUM AND CALMODULIN ACTIVATION IN LIVING CELLS	NATURE			English	Article							SWISS 3T3 FIBROBLASTS; FLUORESCENT ANALOG; LEADING-EDGE; MYOSIN; ACTIN; STIMULATION; TRANSPORT; BINDING	THE temporal and spatial dynamics of intracellular signals and protein effectors are being defined as a result of imaging using fluorescent reagents within living cells1-5. We have described a new class of fluorescent analogues2 termed optical biosensors6, which sense chemical or molecular events through their effects on protein transducers7. One example of this new class of indicators is MeroCaM, an environmentally sensitive fluorophore which when it is attached to calmodulin reflects the activation of calmodulin by calcium in vitro2. We report here that the rise in free calcium and MeroCaM activation occur in the same period during serum stimulation of quiescent fibroblasts. MeroCaM activation also correlates with the spatial pattern of increased free calcium and the contraction of transverse fibres during wound healing1,8-10. Finally, migrating fibroblasts in the later stages of wound-healing exhibit an increasing gradient of free calcium and MeroCaM activation from the front to the rear.	CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University				Hahn, Klaus/0000-0002-1970-7562; Taylor, D. Lansing/0000-0001-6947-1343				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; BRIGHT GR, 1989, J CELL PHYSIOL, V141, P410, DOI 10.1002/jcp.1041410223; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BYRON KL, 1989, J BIOL CHEM, V264, P18234; Cohen P, 1988, CALMODULIN; CONRAD PA, 1989, CELL MOTIL CYTOSKEL, V14, P527, DOI 10.1002/cm.970140410; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; GIULIANO KA, 1990, CELL MOTIL CYTOSKEL, V16, P14, DOI 10.1002/cm.970160104; HAHN KM, 1990, J BIOL CHEM, V265, P20335; HAHN KM, IN PRESS FLUORESCENT; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOLEGA J, 1991, CURR TOP MEMBR, V38, P187; LUBYPHELPS K, 1985, J CELL BIOL, V101, P1245, DOI 10.1083/jcb.101.4.1245; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; TAYLOR DL, 1992, AM SCI, V80, P322; TAYLOR DL, 1980, J CELL BIOL, V86, P599, DOI 10.1083/jcb.86.2.599; TAYLOR DL, 1989, CELL STRUCT FUNCT, P297; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; ZAVORTINK M, 1983, EXP CELL RES, V149, P375, DOI 10.1016/0014-4827(83)90350-6	26	156	164	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					736	738		10.1038/359736a0	http://dx.doi.org/10.1038/359736a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436037				2022-12-24	WOS:A1992JU65000058
J	KOKAME, K; FUKADA, Y; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y				KOKAME, K; FUKADA, Y; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y			LIPID MODIFICATION AT THE N-TERMINUS OF PHOTORECEPTOR G-PROTEIN ALPHA-SUBUNIT	NATURE			English	Article							NH2-TERMINAL BLOCKING GROUP; AMINO-ACID-SEQUENCE; ROD OUTER SEGMENTS; MYRISTIC ACID; BETA-GAMMA; SUBSTRATE-SPECIFICITY; CDNA SEQUENCE; TRANSDUCIN; MYRISTOYLTRANSFERASE; BINDING	MYRISTATE is a fatty acid (fourteen-carbon chain with no double bonds, C14:0) linked to the amino-terminal glycine of several proteins 1-7, including alpha-subunits of heterotrimeric (alpha/betagamma) G proteins8,9. We report here a novel modification at the N terminus of the alpha-subunit of the photoreceptor G protein transducin, Talpha, with heterogeneous fatty acids composed of laurate (C12:0), unsaturated C14:2 and C14:1 fatty acids, and a small amount (approximately 5%) of myristate. Both the GTPase activity of Talpha/Tbetagamma and the Tbetagamma-dependent ADP-ribosylation of Talpha catalysed by pertussis toxin were inhibited by the lauroylated and myristoylated N-terminal peptide of Talpha. The myristoylated peptide gave 50% inhibition at a 3.5 to approximately 4.5-fold lower concentration than the lauroylated peptide in each assay, indicating that the strength of the interaction between Talpha and Tbetagamma is altered by heterogeneous fatty acids linked to Talpha. This suggests that a looser subunit interaction in transducin which is due to an abundance of N-linked fatty acids other than myristate would favour the rapid turnover and catalysis essential for the visual excitation in photoreceptor cells.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; UNIV ELECTROCOMMUN,DEPT APPL PHYS & CHEM,CHOFU,TOKYO 182,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Kyoto University; University of Electro-Communications - Japan; Osaka University			吉孝, 深田/G-5090-2014	Kokame, Koichi/0000-0002-9654-6299				AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; OZOLS J, 1984, J BIOL CHEM, V259, P3349; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SHULTZ AM, 1985, SCIENCE, V227, P427; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TOMER KB, 1983, J AM CHEM SOC, V105, P5487, DOI 10.1021/ja00354a055; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	29	189	192	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					749	752		10.1038/359749a0	http://dx.doi.org/10.1038/359749a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436039				2022-12-24	WOS:A1992JU65000063
J	TATE, ME; ENNEKING, D				TATE, ME; ENNEKING, D			A MESS OF RED POTTAGE	NATURE			English	Editorial Material											TATE, ME (corresponding author), UNIV ADELAIDE,WAITE AGR RES INST,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA.							BARULINA H, 1930, T PRIKL BOT GENET S, V40, P302; CANDOLLE AD, 1886, ORIGIN CULTIVATED PL; COKE LA, 1992, PLANT VAR SEEDS, V5, P1; DANCKWORTT PW, 1935, Z UNTERSUCHUNG LEBEN, V69, P458; HARPER JA, 1962, POULTRY SCI, V41, P1968, DOI 10.3382/ps.0411968; Hegi, 1925, ILLUSTRIERTE FLORA M; RESSLER C, 1969, J AM CHEM SOC, V91, P2758, DOI 10.1021/ja01038a058; 1959, FAO TABULATED INFORM, P297	8	36	36	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					357	358		10.1038/359357a0	http://dx.doi.org/10.1038/359357a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406942				2022-12-24	WOS:A1992JQ62400023
J	HUNT, AJ; DAVIES, PM; MCMANUS, TJ; WEATHERBURN, P; HICKSON, FCI; CHRISTOFINIS, G; COXON, APM; SUTHERLAND, S				HUNT, AJ; DAVIES, PM; MCMANUS, TJ; WEATHERBURN, P; HICKSON, FCI; CHRISTOFINIS, G; COXON, APM; SUTHERLAND, S			HIV-INFECTION IN A COHORT OF HOMOSEXUAL AND BISEXUAL MEN	BRITISH MEDICAL JOURNAL			English	Article							SEXUAL-BEHAVIOR; GONORRHEA		UNIV ESSEX,DEPT SOCIOL,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT GENITOURINARY MED,LONDON SE5 8RX,ENGLAND; DULWICH HOSP,PUBL HLTH LAB SERV,LONDON SE22 8PT,ENGLAND	University of Essex; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Public Health England	HUNT, AJ (corresponding author), S BANK UNIV,DEPT SOCIAL SCI,LONDON SE1 0AA,ENGLAND.		Weatherburn, Peter/AAC-2701-2019	Weatherburn, Peter/0000-0002-4950-6163				ADIB SM, 1991, AIDS, V5, P757, DOI 10.1097/00002030-199106000-00018; CARNE CA, 1987, LANCET, V1, P656; DAVIES PM, 1990, LONGITUDINAL STUDY S; STALL RD, 1988, AM PSYCHOL, V43, P878, DOI 10.1037/0003-066X.43.11.878; WAUGH MA, 1991, LANCET, V337, P375, DOI 10.1016/0140-6736(91)91017-O	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					561	562		10.1136/bmj.305.6853.561	http://dx.doi.org/10.1136/bmj.305.6853.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393036	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JM49500018
J	TEMPLE, JMF; SYKES, AM				TEMPLE, JMF; SYKES, AM			ASTHMA AND OPEN CAST MINING	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL SWANSEA,SWANSEA SA2 8PP,W GLAM,WALES	Swansea University								KIRN TF, 1988, JAMA-J AM MED ASSOC, V260, P455; LLOYD OL, 1978, LANCET, V1, P318; NEWHOUSE ML, 1965, BRIT J IND MED, V22, P261; WILLIAMS SM, 1992, BRIT MED J, V304, P1359, DOI 10.1136/bmj.304.6838.1359; 1985, OFFICIAL J EUROPEAN, V175, P40	5	25	25	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					396	397		10.1136/bmj.305.6850.396	http://dx.doi.org/10.1136/bmj.305.6850.396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392920	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JK31400015
J	DAVIES, PH; FRANKLYN, JA; SHEPPARD, MC				DAVIES, PH; FRANKLYN, JA; SHEPPARD, MC			TREATMENT OF AMIODARONE INDUCED THYROTOXICOSIS WITH CARBIMAZOLE ALONE AND CONTINUATION OF AMIODARONE	BRITISH MEDICAL JOURNAL			English	Article							INDUCED HYPERTHYROIDISM				DAVIES, PH (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							GAMMAGE MD, 1987, Q J MED, V283, P83; MARTINO E, 1987, HORM RES, V26, P158, DOI 10.1159/000180696; MEHRA A, 1991, AM HEART J, V122, P1160, DOI 10.1016/0002-8703(91)90488-4; REICHERT LJM, 1989, BRIT MED J, V298, P1547, DOI 10.1136/bmj.298.6687.1547; WIMPFHEIMER C, 1982, BRIT MED J, V284, P1835, DOI 10.1136/bmj.284.6332.1835-a	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					224	225		10.1136/bmj.305.6847.224	http://dx.doi.org/10.1136/bmj.305.6847.224			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392826	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JG11200023
J	DEWIND, CM				DEWIND, CM			A TALE OF ONE CITY	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					260	260		10.1136/bmj.305.6847.260	http://dx.doi.org/10.1136/bmj.305.6847.260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392851	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JG11200070
J	FFYTCHE, TJ; BRANDT, F; CERCHEZ, J; STOICESCU, S; STINGL, P; FILITIS, M				FFYTCHE, TJ; BRANDT, F; CERCHEZ, J; STOICESCU, S; STINGL, P; FILITIS, M			OCULAR COMPLICATIONS OBSERVED IN LEPROSY PATIENTS IN ROMANIA	BRITISH MEDICAL JOURNAL			English	Article									EYE CLIN HOSP,BUCHAREST,ROMANIA		FFYTCHE, TJ (corresponding author), ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.							BORTHEN L, 1902, BLINDENVERHALTNISSE; COURTRIGHT P, 1988, PREVENTION BLINDNESS; FFYTCHE TJ, 1983, LEPROSY REV, V54, P271; GIBSON J B G, 1950, Med J Aust, V1, P8; Hobbs H E, 1971, Lepr Rev, V42, P131; LOWE J, 1955, P ROY SOC MED, V48, P107, DOI 10.1177/003591575504800210; PENDERGAST JJ, 1940, ARCH OPHTHALMOL-CHIC, V23, P112; SHIELDS JA, 1974, AM J OPHTHALMOL, V77, P880, DOI 10.1016/0002-9394(74)90393-6; SUZUKI T, 1980, Folia Ophthalmologica Japonica, V31, P1719; WANGSPA S, 1976, T ASIA PACIFIC ACADE, V5, P153	10	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					240	242		10.1136/bmj.305.6847.240	http://dx.doi.org/10.1136/bmj.305.6847.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392833	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JG11200031
J	DEVARY, Y; GOTTLIEB, RA; SMEAL, T; KARIN, M				DEVARY, Y; GOTTLIEB, RA; SMEAL, T; KARIN, M			THE MAMMALIAN ULTRAVIOLET RESPONSE IS TRIGGERED BY ACTIVATION OF SRC TYROSINE KINASES	CELL			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE; C-JUN; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; UV RESPONSE; DNA DAMAGE	Exposure of mammalian cells to DNA-damaging agents induces the ultraviolet (UV) response, involving transcription factor AP-1, composed of Jun and Fos proteins. We investigated the mechanism by which UV irradiation induces the c-jun gene. The earliest detectable step was activation of Src tyrosine kinases, followed by activation of Ha-Ras and Raf-1. The response to UV was blocked by tyrosine kinase inhibitors and dominant negative mutants of v-src, Ha-ras, and raf-1. This signaling cascade leads to increased phosphorylation of c-Jun on two serine residues that potentiate its activity. These results strongly suggest that the UV response is initiated at or near the plasma membrane rather than the nucleus. The response may be elicited by oxidative stress, because it is inhibited by elevation of intracellular glutathione. Using tyrosine kinase inhibitors, we demonstrate that the UV response has a protective function.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	DEVARY, Y (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Gottlieb, Roberta/0000-0002-1432-006X				AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1985, DNA REPAIR; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EISEMAN E, 1992, NATURE, V355, P78; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRILING RS, 1991, P NATL ACAD SCI USA, V87, P6258; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MUSTELIN T, 1990, ONCOGENE, V5, P809; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Romerdahl C A, 1989, Cancer Commun, V1, P209; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIMM DS, 1992, RADIAT RES, V129, P149, DOI 10.2307/3578151; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4	71	865	886	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1081	1091		10.1016/S0092-8674(05)80058-3	http://dx.doi.org/10.1016/S0092-8674(05)80058-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473146				2022-12-24	WOS:A1992KE60400004
J	ALLEN, S; SERUFILIRA, A; BOGAERTS, J; VANDEPERRE, P; NSENGUMUREMYI, F; LINDAN, C; CARAEL, M; WOLF, W; COATES, T; HULLEY, S				ALLEN, S; SERUFILIRA, A; BOGAERTS, J; VANDEPERRE, P; NSENGUMUREMYI, F; LINDAN, C; CARAEL, M; WOLF, W; COATES, T; HULLEY, S			CONFIDENTIAL HIV TESTING AND CONDOM PROMOTION IN AFRICA - IMPACT ON HIV AND GONORRHEA RATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REPRESENTATIVE SAMPLE; CHILDBEARING WOMEN; AIDS; RISK; KNOWLEDGE; RWANDA; ATTITUDES; INFECTION; BEHAVIOR	Objective.-We evaluated the impact of human immunodeficiency virus (HIV) testing and counseling on self-reported condom and spermicide use and on corresponding HIV seroconversion and gonorrhea rates in urban Rwandan women. Design.-Prospective cohort study with 2 years of follow-up, comparison of outcome variables before and after an intervention, and condom use measured in a control group that did not receive the intervention. Setting.-Outpatient research clinic in Kigali, the capital of Rwanda. Participants.-One thousand four hundred fifty-eight childbearing women, 32% of whom were infected with HIV, were enrolled in a prospective study in 1988, and followed at 3- to 6-month intervals for 2 years. Follow-up was available for 95% of subjects at year 1 and 92% at year 2. Interventions.-An acquired immunodeficiency syndrome (AIDS) educational videotape, HIV testing and counseling, and free condoms and spermicide were provided to all participants and interested sexual partners. Main Outcome Measures.-Self-report of compliance with condom-spermicide use and observed incidence of HIV and gonorrhea. Results.-Only 7% of the women reported ever trying condoms before the intervention, but 22% reported condom use with good compliance 1 year later. Women who were HIV-positive were more likely to adopt condom use than HIV-negative women (36% vs 16%; P<.05). Independent predictors of condom use, both in HIV-positive and in HIV-negative women, included HIV testing and counseling of the male partner, having a nonmonogamous relationship, and believing condoms were not dangerous. Human immunodeficiency virus seroconversion rates decreased significantly (from 4.1 to 1.8 per 100 person-years; P<.04) in women whose partners were tested and counseled. The prevalence of gonorrhea decreased substantially (13% to 6%; P<.05) among HIV-positive women, with the greatest reduction among condom users (16% to 4%; P<.05). Conclusion.-A confidential HIV testing and counseling program was associated with increased use of condoms and reduced rates of gonorrhea and HIV in urban Rwandan women. The lack of risk reduction in HIV-negative women whose partner's serostatus was unknown was of concern. Interventions that promote HIV testing and counseling for both members of a couple should be considered in other high-prevalence areas.	WHO,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA 27,SWITZERLAND; PROJET SAN FRANCISCO,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; BELGIAN RWANDAN,KIGALI,RWANDA; MINIST HLTH,NATL AIDS CONTROL PROGRAM,KIGALI,RWANDA	World Health Organization; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALLEN, S (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94105, USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NIAID NIH HHS [R01 AI23980] Funding Source: Medline; NIMH NIH HHS [MH 42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMCHAK DJ, 1990, AIDS, V4, P245, DOI 10.1097/00002030-199003000-00011; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; ALLEN S, 1988, 14TH INT C AIDS STOC; BAJOS N, 1989, BEH, V11, P42; BECKER MH, 1988, AM J PUBLIC HEALTH, V78, P394, DOI 10.2105/AJPH.78.4.394; BOGAERTS J, 1989, SEX TRANSM DIS, V16, P123, DOI 10.1097/00007435-198907000-00001; Bradbeer C, 1990, Int J STD AIDS, V1, P233; CARAEL M, 1988, AIDS, V2, P201; CARAEL M, 1988, AIDS HLTH PROMOTION, P6; CARBALLO M, 1989, J SEX RES, V26, P287, DOI 10.1080/00224498909551516; CLEARY PD, 1991, AM J PUBLIC HEALTH, V81, P1586, DOI 10.2105/AJPH.81.12.1586; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; COATES TJ, 1988, AIDS, V2, pS239, DOI 10.1097/00002030-198800001-00037; COCHRAN SD, 1991, SOC SCI MED, V33, P25, DOI 10.1016/0277-9536(91)90447-K; FORSTER SJ, 1989, AIDS, V3, P147, DOI 10.1097/00002030-198903000-00005; GILLIES P, 1990, AIDS, V4, P943, DOI 10.1097/00002030-199010000-00001; GOLDBERG HI, 1989, B WORLD HEALTH ORGAN, V67, P85; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; KEGELES SM, 1990, AIDS, V4, P585, DOI 10.1097/00002030-199006000-00016; Kizer K. W., 1990, AIDS and Public Policy Journal, V5, P24; KONDELULE JK, 1989, AIDS, V3, P513, DOI 10.1097/00002030-198908000-00005; KREISS J, 1989, 5TH INT C AIDS MONTR; LINDAN C, 1991, AIDS, V5, P993, DOI 10.1097/00002030-199108000-00011; MANN J, 1987, NEW ENGL J MED, V316, P345; MAY JF, 1990, STUD FAMILY PLANN, V21, P20, DOI 10.2307/1966588; MBIZVO MT, 1989, CENT AFR J MED, V35, P519; MCKUSICK L, 1990, AM J PUBLIC HEALTH, V80, P978, DOI 10.2105/AJPH.80.8.978; MUSKA S, 1990, 6TH INT C AIDS SAN F; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; RWANDAN HIV, 1989, LANCET, V1, P941; SHEON A, 1989, 4TH INT C AIDS ASS C; SOLOMON MZ, 1989, AM J PUBLIC HEALTH, V79, P453, DOI 10.2105/AJPH.79.4.453; VANDEPERRE P, 1987, AIDS, V1, P207; Vermund Sten H., 1990, Annals of Epidemiology, V1, P141, DOI 10.1016/1047-2797(90)90005-D; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WILSON D, 1990, SOC SCI MED, V31, P609, DOI 10.1016/0277-9536(90)90097-C; WILSON D, 1988, CENT AFR J MED, V34, P95; WOFSY CB, 1988, WESTERN J MED, V149, P687; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1990, MMWR, V39, P137; 1990, WHO AIDS SERIES, V8	45	199	199	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3338	3343		10.1001/jama.268.23.3338	http://dx.doi.org/10.1001/jama.268.23.3338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB732	1453526				2022-12-24	WOS:A1992KB73200026
J	ALLBRITTON, NL; MEYER, T; STRYER, L				ALLBRITTON, NL; MEYER, T; STRYER, L			RANGE OF MESSENGER ACTION OF CALCIUM-ION AND INOSITOL 1,4,5-TRISPHOSPHATE	SCIENCE			English	Article							DIFFUSION; OSCILLATIONS; INDICATORS; KINETICS; RECEPTOR; BINDING; MUSCLE; CELLS; CA-2+; PHOSPHATES	The range of messenger action of a point source of Ca2+ or inositol 1,4,5-trisphosphate (IP3) was determined from measurements of their diffusion coefficients in a cytosolic extract from Xenopus laevis oocytes. The diffusion coefficient (D) of [H-3]IP3 injected into an extract was 283 mum2/s. D for Ca2+ increased from 13 to 65 mum2/s when the free calcium concentration was raised from about 90 nM to 1 muM. The slow diffusion of Ca2+ in the physiologic concentration range results from its binding to slowly mobile or immobile buffers. The calculated effective ranges of free Ca2+ before it is buffered, buffered Ca2+, and IP3 determined from their diffusion coefficients and lifetimes were 0.1 mum, 5 mum, and 24 mum, respectively. Thus, for a transient point source of messenger in cells smaller than 20 mum, IP3 is a global messenger, whereas Ca2+ acts in restricted domains.	DUKE UNIV,DEPT CELL BIOL,DURHAM,NC 27710	Duke University	ALLBRITTON, NL (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Meyer, Tobias/0000-0003-4339-3804	NIAID NIH HHS [5F32AI0814203] Funding Source: Medline; NIMH NIH HHS [MH45324] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHMED Z, 1988, CELL CALCIUM, V9, P57, DOI 10.1016/0143-4160(88)90025-5; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BORSE N, 1992, SCIENCE, V256, P1021; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BURGESS GM, 1985, BIOCHEM J, V232, P237, DOI 10.1042/bj2320237; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Cohen P, 1988, CALMODULIN; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CRANK J, 1975, MATH DIFFUSION, P12; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DONAHUE BS, 1987, CELL CALCIUM, V8, P437, DOI 10.1016/0143-4160(87)90027-3; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HODGKIN AL, 1957, J PHYSIOL-LONDON, V138, P253, DOI 10.1113/jphysiol.1957.sp005850; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KUSHMERICK MJ, 1969, SCIENCE, V166, P1297, DOI 10.1126/science.166.3910.1297; KUSHMERICK MJ, 1980, BIOPHYSICAL CHEM 2, P570; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MINTA A, 1989, J BIOL CHEM, V264, P8171; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASI E, 1985, BIOPHYS J, V47, P735, DOI 10.1016/S0006-3495(85)83972-2; NEHR E, 1992, J PHYSL, V450, P273; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARYS JB, 1992, J BIOL CHEM, V267, P18776; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SHAYMAN JA, 1988, BIOCHEM BIOPH RES CO, V151, P114, DOI 10.1016/0006-291X(88)90566-9; SULPICE JC, 1990, METHODS INOSITIDE RE, P45; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TIMMERMAN MP, 1986, FEBS LETT, V209, P1, DOI 10.1016/0014-5793(86)81073-0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WANG JH, 1952, J AM CHEM SOC, V74, P1611, DOI 10.1021/ja01126a524; WANG JH, 1953, J AM CHEM SOC, V75, P1769, DOI 10.1021/ja01103a539; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	48	881	892	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1812	1815		10.1126/science.1465619	http://dx.doi.org/10.1126/science.1465619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465619				2022-12-24	WOS:A1992KB96400044
J	TAGGART, AKP; FISHER, TS; PUGH, BF				TAGGART, AKP; FISHER, TS; PUGH, BF			THE TATA-BINDING PROTEIN AND ASSOCIATED FACTORS ARE COMPONENTS OF POL-III TRANSCRIPTION FACTOR TFIIIB	CELL			English	Article							RNA POLYMERASE-III; HUMAN U6 GENE; DNA-BINDING; INVITRO TRANSCRIPTION; ACCURATE TRANSCRIPTION; PROMOTER; COMPLEXES; UPSTREAM; INITIATION; ACTIVATION	RNA polymerases I, II, and III require the TATA-binding protein (TBP) to initiate promoter-specific transcription. We have separated HeLa TBP into four phosphocellulose fractions that elicit polymerase specificity in supplying TBP activity to TBP-depleted pol II and pol III transcription reactions. Polymerase specificity might arise in part through distinct TBP-associated factors (TAFs), which have recently been identified in pol I and II transcription. However, the requirement for pol III TAFs has not been established. Here we show that classical pol III transcription involves a minimum of two novel TAFs: TAF-172 and TAF-L. Not only does TAF-172 activate pol III transcription, but it also inhibits the binding of TBP to the TATA box, thereby repressing pol II transcription. The TBP-TAF-172-TAF-L complex can replace TFIIIB both in transcription reactions reconstituted with TFIIIC and in template commitment assays. Thus SL1, TFIID, and TFIIIB might be functionally similar TBP-TAF complexes that direct pol I, II, and III transcription, respectively.			TAGGART, AKP (corresponding author), PENN STATE UNIV,DEPT MOLEC & CELL BIOL,CTR GENE REGULAT,UNIV PK,PA 16802, USA.				NIGMS NIH HHS [GM47855-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDOW S, 1990, GENE, V86, P217, DOI 10.1016/0378-1119(90)90282-V; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CARLES C, 1991, J BIOL CHEM, V266, P24092; COLBERT T, 1992, IN PRESS GENES DEV; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORTES P, 1992, J MOL CELL BIOL, V12, P413; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOSTROZA JA, 1992, CELL, V70, P477; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9163; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; Weinmann Roberto, 1992, Gene Expression, V2, P81; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	66	142	146	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1015	1028		10.1016/0092-8674(92)90396-T	http://dx.doi.org/10.1016/0092-8674(92)90396-T			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458533				2022-12-24	WOS:A1992KB99000013
J	MOFFATT, CJ; FRANKS, PJ; OLDROYD, M; BOSANQUET, N; BROWN, P; GREENHALGH, RM; MCCOLLUM, CN				MOFFATT, CJ; FRANKS, PJ; OLDROYD, M; BOSANQUET, N; BROWN, P; GREENHALGH, RM; MCCOLLUM, CN			COMMUNITY CLINICS FOR LEG ULCERS AND IMPACT ON HEALING	BRITISH MEDICAL JOURNAL			English	Article							CHRONIC VENOUS ULCERS; COMPRESSION; TRIAL	Objective-To evaluate the effectiveness of community clinics for leg ulcers. Design-All patients with leg ulceration were invited to community clinics that offered treatment developed in a hospital research clinic. Patients without serious arterial disease (Doppler ankle/brachial index > 0.8) were treated with a high compression bandage of four layers. Setting-Six community clinics held in health centres in Riverside District Health Authority supported by the Charing Cross vascular surgical service. Patients-All patients referred to the community services with leg ulceration, irrespective of cause and duration of ulceration. Main outcome measures-Time to complete healing by the life table method. Results-550 ulcerated legs were seen in 475 patients of mean (SD) age 73.8 (11.9) years. There were 477 venous ulcers of median size 4.2 cm2 (range 0.1-117 cm2), 128 being larger than 10 cm2. These ulcers had been present for a median of three months (range one week to 63 years) with 150 present for over one year. Four layer bandaging in the community clinics achieved complete healing in 318 (69%) venous ulcers by 12 weeks and 375 (83%) by 24 weeks. There were 56 patients with an ankle/brachial arterial pressure index < 0.8, indicating arterial disease. The 50 patients with pressure index <0.8>0.5 were treated with reduced compression, and 24 (56%) healed by 12 weeks and 31 (75%) by 24 weeks. The figures for overall healing for all leg ulcers were 351/550 (67%) at 12 weeks and 417/550 (81%) at 24 weeks, compared with only 11/51 (22%) at 12 weeks before the community clinics were set up. Conclusions-Community clinics for venous ulcers offer an effective means of achieving healing in most patients with leg ulcers.	UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,DEPT SOCIAL POLICY,SURREY TW20 0EX,ENGLAND; W LONDON HOSP,RIVERSIDE DIST HLTH AUTHOR,FAMILY & COMMUNITY SERV UNIT,LONDON W6 7DQ,ENGLAND; UNIV HOSP S MANCHESTER,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND	University of London; Royal Holloway University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	MOFFATT, CJ (corresponding author), CHARING CROSS HOSP,DEPT SURG,LONDON W6 8RF,ENGLAND.		Franks, Peter J/G-3592-2013	Franks, Peter J/0000-0002-9782-0181; Moffatt, Christine/0000-0002-2436-0129				BACKHOUSE CM, 1987, BRIT J SURG, V74, P626, DOI 10.1002/bjs.1800740732; BALE S, 1989, CARE, V7, P90; BLAIR SD, 1988, BRIT MED J, V297, P1159, DOI 10.1136/bmj.297.6657.1159; BLAIR SD, 1988, PHLEBOLOGY, V3, P129; CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; CORNWALL JV, 1986, BRIT J SURG, V73, P693, DOI 10.1002/bjs.1800730905; POSKITT KR, 1987, BRIT MED J, V294, P674, DOI 10.1136/bmj.294.6573.674; WRIGHT D, 1987, Journal of Cardiovascular Surgery, V28, P97; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	11	191	193	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1389	1392		10.1136/bmj.305.6866.1389	http://dx.doi.org/10.1136/bmj.305.6866.1389			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486301	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992KB85600019
J	VOSS, LD; MULLIGAN, J; BETTS, PR; WILKIN, TJ				VOSS, LD; MULLIGAN, J; BETTS, PR; WILKIN, TJ			POOR GROWTH IN SCHOOL ENTRANTS AS AN INDEX OF ORGANIC-DISEASE - THE WESSEX GROWTH STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT STATURE; HEIGHT; RELIABILITY; CHILDREN; NEED	Objective-To establish whether poor height or height velocity, assessed during the year of school entry, might identify children with previously undiagnosed organic disease. Design-Observation of a total population and their case controls. Setting-Community base. Subjects-All 14346 children in two health districts entering school during two consecutive years were screened for height by school nurses, and those whose height lay below the 3rd centile according to Tanner and Whitehouse standards (n=180) were identified. After excluding 32 with known organic disease, five from ethnic minorities, and three who refused to take part, the remaining 140 short normal children were matched with 140 age and sex matched controls of average height (10th-90th centile) and their height velocities over 12 months measured. Main outcome measures-Height, height velocity, previously diagnosed organic disease, and organic disease diagnosed as a result of blood tests and specialist examination. Results-Twenty five of the 180 short children (14%) were already known to have chronic organic disease which could explain their poor growth. Blood tests and specialist examination revealed a further seven with organic disease, which was acquired rather than congenital in three, and a second cause of short stature in one with known organic disease. These eight conditions had been missed at the school entry medical examination. The shorter the child, the more likely an underlying organic disorder, with seven of the 12 children whose heights were more than 3 standard deviations below the mean having some organic disease. Height velocity measured over 12 months, however, did not distinguish short normal children from those with disease or from their matched controls. Conclusions-Height, but not height velocity, is a useful index for identifying unrecognised organic disease at school entry. The shorter the stature the greater the prevalence of organic disease. The frequency of newly diagnosed remediable disease in this study (1 in 3-4000) is similar to that of neonatal hypothyroidism, which is routinely screened for. Routine investigation of all very short school entrants is recommended.			VOSS, LD (corresponding author), SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AYNSLEYGREEN A, 1983, ARCH DIS CHILD, V58, P535; BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; BROOK CGD, 1989, CLIN PAEDIATRIC ENDO, P118; CHINN S, 1989, ARCH DIS CHILD, V64, P1545, DOI 10.1136/adc.64.11.1545; CROSS AW, 1985, J PEDIATR-US, V107, P653, DOI 10.1016/S0022-3476(85)80388-7; DONALD RA, 1984, ENDOCRINE DISORDERS; HINDMARSH PC, 1988, ACTA PAEDIATR SCAND, P73; KENNEDY FD, 1988, ARCH DIS CHILD, V63, P1261, DOI 10.1136/adc.63.10.1261; LACEY KA, 1974, LANCET, V1, P42; PARKIN JM, 1989, CLIN PAEDIATRIC ENDO, P96; SMITH GC, 1990, ARCH DIS CHILD, V65, P225, DOI 10.1136/adc.65.2.225; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TANNER JM, 1986, HUMAN GROWTH COMPREH, V3, P95; VIMPANI GV, 1981, ARCH DIS CHILD, V56, P922, DOI 10.1136/adc.56.12.922; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; VOSS LD, 1987, LANCET, V2, P447; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340; ZERFAS AJ, 1986, HUMAN GROWTH, P490	19	73	75	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1400	1402		10.1136/bmj.305.6866.1400	http://dx.doi.org/10.1136/bmj.305.6866.1400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486305	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992KB85600023
J	MENDELSON, NH				MENDELSON, NH			PRODUCTION AND INITIAL CHARACTERIZATION OF BIONITES - MATERIALS FORMED ON A BACTERIAL BACKBONE	SCIENCE			English	Article							BACILLUS-SUBTILIS; CELL-WALLS; BIOTECHNOLOGY; PRECIPITATION; GROWTH; THREAD	The addition of soluble metal salts of calcium, iron, or copper to cultures of Bacillus subtilis grown in web form nucleated precipitation at the surface of the bacterial cell walls. The mineralized cell filaments can be drawn into a fiber that when dried consists of a bacterial thread backbone carrying an inorganic solid. The ratios of organic to inorganic components (by weight) in the stiff brittle materials, called bionites, were: 1.08 for fe(2) bactonite, 1.8 for calbactonite, 2.3 for fe(3)bactonite, and 5 for cu(2)bactonite. X-ray photoelectron spectra suggest that the fe(3)bactonite contains Fe2O3, that calbactonite contains calcium carbonate, and that cu(2)bactonite contains CuCl (Cu I). Acid-base reactions of the bionites are compatible with these identifications. Burning out the organic phase of the febactonites yields a black magnetic material, presumably magnetite. The burnt cubactonite appears to yield elemental Cu(s). Calbactonite upon hydration was able to retain a genetically engineered enzymatic activity.			MENDELSON, NH (corresponding author), UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, TUCSON, AZ 85721 USA.							ABELSON PH, 1983, SCIENCE, V219, P611, DOI 10.1126/science.6572016; BEVERIDGE TJ, 1980, J BACTERIOL, V141, P876, DOI 10.1128/JB.141.2.876-887.1980; BEVERIDGE TJ, 1989, SPEC PUBL SOC GEN MI, V26, P65; BEVERIDGE TJ, 1976, J BACTERIOL, V127, P1502, DOI 10.1128/JB.127.3.1502-1518.1976; CALVERT P, 1988, J MATER SCI, V23, P3801, DOI 10.1007/BF01106796; CHALOUPKA J, 1964, FOLIA MICROBIOL, V9, P9, DOI 10.1007/BF02875894; Doyle R.J., 1989, METAL IONS BACTERIA, P275; FERRIS FG, 1988, GEOLOGY, V16, P149, DOI 10.1130/0091-7613(1988)016<0149:MIBBBS>2.3.CO;2; HEUER AH, 1992, SCIENCE, V255, P1098, DOI 10.1126/science.1546311; HUGHES MN, 1989, METALS MICROORGANISM, P337; KOSHLAND DE, 1991, SCIENCE, V252, P1593, DOI 10.1126/science.252.5013.1593; Krumbein WE, 1986, BIOMINERALIZATION LO, P55; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MANN S, 1986, BIOMINERALIZATION LO, P39; MARQUIS RE, 1976, CAN J MICROBIOL, V22, P975, DOI 10.1139/m76-142; MENDELSON NH, 1976, P NATL ACAD SCI USA, V73, P1740, DOI 10.1073/pnas.73.5.1740; MENDELSON NH, 1989, J BACTERIOL, V171, P1055, DOI 10.1128/jb.171.2.1055-1062.1989; MENDELSON NH, 1990, SCI PROG, V74, P425; MENDELSON NH, 1977, MICROBIOLOGY 1977, P5; MORITA RY, 1980, GEOMICROBIOL J, V2, P63, DOI 10.1080/01490458009377751; PAUTARD FGE, 1970, BIOL CALCIFICATION, P106; POOLEY HM, 1976, J BACTERIOL, V125, P1127, DOI 10.1128/JB.125.3.1127-1138.1976; POOLEY HM, 1976, J BACTERIOL, V125, P1139, DOI 10.1128/JB.125.3.1139-1147.1976; Rouxhet PG, 1991, MICROBIAL CELL SURFA, P173; SALHI B, 1991, THESIS U ARIZONA TUC; SWAISGOOD HE, 1985, ENZYMES IMMOBILIZED, P1; THWAITES JJ, 1991, ADV MICROB PHYSIOL, V32, P173, DOI 10.1016/S0065-2911(08)60008-9; THWAITES JJ, 1985, P NATL ACAD SCI USA, V82, P2163, DOI 10.1073/pnas.82.7.2163; ZIOLO RF, 1992, SCIENCE, V257, P219, DOI 10.1126/science.257.5067.219	29	27	27	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1633	1636		10.1126/science.1455245	http://dx.doi.org/10.1126/science.1455245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1455245				2022-12-24	WOS:A1992KA89600031
J	HOWARD, PK; SEFTON, BM; FIRTEL, RA				HOWARD, PK; SEFTON, BM; FIRTEL, RA			ANALYSIS OF A SPATIALLY REGULATED PHOSPHOTYROSINE PHOSPHATASE IDENTIFIES TYROSINE PHOSPHORYLATION AS A KEY REGULATORY PATHWAY IN DICTYOSTELIUM	CELL			English	Article							LEUKOCYTE-COMMON ANTIGEN; ANTERIOR-LIKE CELLS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; GENE-EXPRESSION; RAS GENE; DISCOIDEUM; RECEPTOR; ENCODES	We have cloned a Dictyostelium phosphotyrosine phosphatase (PTP1) with a catalytic domain showing approximately 38%-50% amino acid identity to those of other PTPs. PTP1 contains an approximately 99 amino acid insert and bacterially produced PTP1 possesses PTP activity. PTP1 is expressed at a very low level in vegetative cells, induced by 4 hr, and maximally expressed at the tight aggregate stage. PTP1-lacZ studies indicate that PTP1 is spatially localized to prestalk and anterior-like cell types. PTP1 gene disruptants show accelerated development, whereas strains overexpressing PTP1 to a high level fail to aggregate. Strains overexpressing moderate levels exhibit severe morphological defects following aggregation, including multiply tipped aggregates and morphologically aberrant fruiting bodies. Western blot analysis using anti-phosphotyrosine antibodies shows specific changes in the mutant strains when compared with wild-type cells. The results indicate that reversible protein-tyrosine phosphorylation and PTP1 play important regulatory roles during Dictyostelium development.	SALK INST BIOL SCI,SAN DIEGO,CA 92186	Salk Institute	HOWARD, PK (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093, USA.							AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BURKI E, 1991, GENE, V102, P57, DOI 10.1016/0378-1119(91)90538-M; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1990, DEV GENET, V11, P410, DOI 10.1002/dvg.1020110514; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; ESCH RK, 1991, GENE DEV, V5, P9, DOI 10.1101/gad.5.1.9; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; KAMPS MP, 1988, ONCOGENE, V2, P305; Kimmel AR, 1991, CURR OPIN GENET DEV, V1, P383, DOI 10.1016/S0959-437X(05)80304-1; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUSPA A, 1992, GENOMICS, V13, P49, DOI 10.1016/0888-7543(92)90201-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MANN SKO, 1992, IN PRESS P NATL ACAD; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWEIGER A, 1990, FEBS LETT, V268, P199, DOI 10.1016/0014-5793(90)81007-B; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Williams JG, 1991, CURR OPIN GENET DEV, V1, P358, DOI 10.1016/S0959-437X(05)80300-4; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1989, DEVELOPMENT, V7, P91; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	55	66	67	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					637	647		10.1016/0092-8674(92)90597-6	http://dx.doi.org/10.1016/0092-8674(92)90597-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423620				2022-12-24	WOS:A1992JY67600011
J	KEYSE, SM; EMSLIE, EA				KEYSE, SM; EMSLIE, EA			OXIDATIVE STRESS AND HEAT-SHOCK INDUCE A HUMAN GENE ENCODING A PROTEIN-TYROSINE PHOSPHATASE	NATURE			English	Article							SIGNAL TRANSDUCTION; IONIZING-RADIATION; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; SKIN FIBROBLASTS; POSITIVE CONTROL; HEME OXYGENASE; ACTIVATION; CELLS; PURIFICATION	REACTIVE oxygen species have been implicated both in the ageing process and in degenerative diseases, including arthritis and cancer1,2. Bacteria adapt to the lethal effects of oxidants such as hydrogen peroxide by inducing the expression of protective stress genes3,4 . Analogous responses have been identified in human cells. For example, haem oxygenase is a major stress protein in human cells treated with oxidants5, and reactive oxygen intermediates activate NF-kappaB, a transcriptional regulator of genes involved in inflammatory and acute-phase responses6. We report here the isolation and characterization of a novel complementary DNA (CL100) corresponding to a messenger RNA that is highly inducible by oxidative stress and heat shock in human skin cells. The cDNA contains an open reading frame specifying a protein of M(r) 39.3K with the structural features of a non-receptor-type protein-tyrosine phosphatase7 and which has significant amino-acid sequence similarity to a Tyr/Ser-protein phosphatase encoded by the late gene H1 of vaccinia virus8. The purified protein encoded by the CL100 open reading frame expressed in bacteria has intrinsic phosphatase activity. Given the relationship between the levels of protein-tyrosine phosphorylation, receptor activity, cellular proliferation and cell-cycle control, the induction of this gene may play an important regulatory role in the human cellular response to environmental stress.			KEYSE, SM (corresponding author), UNIV EDINBURGH,IMPERIAL CANC RES FUND,DEPT BIOCHEM,MOLEC PHARMACOL UNIT,HUGH ROBSON BLDG,EDINBURGH EH8 9XD,SCOTLAND.		Keyse, Stephen M./B-9575-2009	Keyse, Stephen M./0000-0002-5150-8221	Cancer Research UK [12053] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		AMES BN, 1985, GENETIC TOXICOLOGY E, P11; BAIROCH A, 1991, PROSITE DICT PROTEIN; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARLES CH, 1992, ONCOGENE, V7, P187; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; Maniatis T., 1982, MOL CLONING; MILLAR BA, 1992, CELL, V68, P407; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; TYRRELL RM, 1986, CANCER RES, V46, P2665; ZIEGLERSKYLAKAKIS K, 1987, MUTAT RES, V192, P65, DOI 10.1016/0165-7992(87)90127-8	31	591	618	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					644	647		10.1038/359644a0	http://dx.doi.org/10.1038/359644a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406996				2022-12-24	WOS:A1992JT82400060
J	HANDEL, N; SILVERSTEIN, MJ; GAMAGAMI, P; JENSEN, JA; COLLINS, A				HANDEL, N; SILVERSTEIN, MJ; GAMAGAMI, P; JENSEN, JA; COLLINS, A			FACTORS AFFECTING MAMMOGRAPHIC VISUALIZATION OF THE BREAST AFTER AUGMENTATION MAMMAPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MAMMOPLASTY; IMPLANTS; PROSTHESES; MORTALITY; DIAGNOSIS; LESIONS; BIOPSY	Objective.-To measure the effect of various parameters on mammographic visualization of the breast after augmentation mammaplasty. Design.-Preoperative and postoperative mammography was performed in patients undergoing augmentation mammaplasty. The area of breast tissue visualized on each film was measured. Changes in the area visualized were correlated with a variety of different parameters. Setting.-The Breast Center, Van Nuys, Calif, a free-standing multidisciplinary breast diagnostic and treatment facility. Patients.-The 68 women (126 breasts) represent a consecutive sample of patients undergoing augmentation mammaplasty for whom preoperative and postoperative mammograms were available. Main Outcome Measures.-Area visualized was correlated with degree of capsular contracture, implant position, type of mammography, preoperative breast size, implant size, and implant type. Results.-The major factor affecting mammography is capsular contracture. Little or no capsular contracture results in a 30% reduction in the area visualized; moderate or severe contracture results in a 50% reduction. Other important factors include implant position (improved visualization with implant beneath pectoral muscle) and type of mammography performed (slightly more tissue seen with displacement technique). Very small preoperative breast size yields increased visualization. Implant size and type have little or no effect. Conclusions.-In most women with breast implants, there is a decrease in measurable breast tissue on the postaugmentation mammogram. Capsular contracture and implant position exert a profound effect; type of mammography performed and preoperative breast size are also significant.			HANDEL, N (corresponding author), BREAST CTR,14624 SHERMAN WAY,VAN NUYS,CA 91405, USA.			Jensen, Jay/0000-0002-2369-8291				BAKER JL, 1975, OCT AESTH BREAST S S; BEISANG AA, 1991, PLAST RECONSTR SURG, V87, P855; BORGEN PI, 1991, AM SURGEON, V57, P8; CATHCART RS, 1989, ANN PLAS SURG, V22, P533, DOI 10.1097/00000637-198906000-00011; DERSHAW DD, 1989, RADIOLOGY, V170, P69, DOI 10.1148/radiology.170.1.2909122; DOUGLAS KP, 1991, SOUTH MED J, V84, P49, DOI 10.1097/00007611-199101000-00013; EKLUND GW, 1988, AM J ROENTGENOL, V151, P469, DOI 10.2214/ajr.151.3.469; ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P879, DOI 10.1097/00006534-199105000-00012; GALLAGER HS, 1971, CANCER, V28, P1505, DOI 10.1002/1097-0142(197112)28:6<1505::AID-CNCR2820280624>3.0.CO;2-W; GRACE GT, 1990, ANN PLAS SURG, V25, P119, DOI 10.1097/00000637-199008000-00008; GUMUCIO CA, 1989, PLAST RECONSTR SURG, V84, P772, DOI 10.1097/00006534-198911000-00008; HAYES H, 1988, PLAST RECONSTR SURG, V82, P1, DOI 10.1097/00006534-198882010-00001; HERMAN S, 1984, PLAST RECONSTR SURG, V73, P411, DOI 10.1097/00006534-198403000-00012; HESTER TR, 1990, PLASTIC RECONSTRUCTI, P131; Hester TR, 1988, PERSPECT PLAST SURG, V2, P135; LEIBMAN AJ, 1990, RADIOLOGY, V174, P195, DOI 10.1148/radiology.174.1.2152981; LEIS HP, 1989, BREAST CANCER CONSER, P3; LEIS HP, 1986, SURGERY BREAST DIAGN, P100; LITTLE G, 1980, PLAST RECONSTR SURG, V65, P30, DOI 10.1097/00006534-198001000-00006; McCurdy JA, 1990, AM J COSMETIC SURG, V7, P235; MELMED EP, 1988, PLAST RECONSTR SURG, V82, P285, DOI 10.1097/00006534-198808000-00013; MITNICK JS, 1989, SURG GYNECOL OBSTET, V168, P30; MONSEES BS, 1991, PERSPECT PLAST SURG, V5, P103; RINTALA AE, 1974, PLAST RECONSTR SURG, V54, P390, DOI 10.1097/00006534-197410000-00002; SCHWARTZ GF, 1978, CANCER, V41, P1147, DOI 10.1002/1097-0142(197803)41:3<1147::AID-CNCR2820410352>3.0.CO;2-9; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERSTEIN MJ, 1988, ARCH SURG-CHICAGO, V123, P681; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P635, DOI 10.1016/S0959-8049(05)80115-7; SILVERSTEIN MJ, 1989, RADIOLOGY, V171, P633, DOI 10.1148/radiology.171.3.2717734; SILVERSTEIN MJ, 1987, CANCER, V59, P715, DOI 10.1002/1097-0142(19870215)59:4<715::AID-CNCR2820590409>3.0.CO;2-C; SILVERSTEIN MJ, 1990, PLAST RECONSTR SURG, V86, P1126, DOI 10.1097/00006534-199012000-00014; STRAX P, 1990, CANCER, V66, P1136; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VANA J, 1981, CANCER, V48, P1043, DOI 10.1002/1097-0142(19810815)48:4<1043::AID-CNCR2820480432>3.0.CO;2-K; Walt A J, 1990, Bull Am Coll Surg, V75, P6; WERTHEIMER MD, 1986, JAMA-J AM MED ASSOC, V255, P1311, DOI 10.1001/jama.255.10.1311; Whidden PG, 1986, TRANSPLANT IMPLANT T, V3, P43	37	72	73	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1913	1917		10.1001/jama.268.14.1913	http://dx.doi.org/10.1001/jama.268.14.1913			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404718				2022-12-24	WOS:A1992JR43900043
J	CLARKE, AR; MAANDAG, ER; VANROON, M; VANDERLUGT, NMT; VANDERVALK, M; HOOPER, ML; BERNS, A; RIELE, HT				CLARKE, AR; MAANDAG, ER; VANROON, M; VANDERLUGT, NMT; VANDERVALK, M; HOOPER, ML; BERNS, A; RIELE, HT			REQUIREMENT FOR A FUNCTIONAL RB-1 GENE IN MURINE DEVELOPMENT	NATURE			English	Article							EMBRYONIC STEM-CELLS; LEUKEMIA INHIBITORY FACTOR; MOUSE PGK-1 GENE; RETINOBLASTOMA GENE; ALTERED EXPRESSION; DIFFERENTIATION; DISRUPTION; CARCINOMA; MUTATIONS; SARCOMAS	HUMAN retinoblastomas can occur both as hereditary and as sporadic cases. Knudson's proposal1 that they result from two mutational events, of which one is present in the germ line in hereditary cases, has been confirmed by more recent molecular analysis, which has shown both events to involve loss or mutational inactivation of the same gene, RB-1 (ref. 2). RB-1 heterozygosity also predisposes to osteosarcoma, and RB-1 allele losses are seen in sporadic lung, breast, prostate and bladder carcinomas3-7. RB-1 is expressed in most, if not all, tissues and codes for a nuclear phosphoprotein which becomes hypophosphorylated in the G0 growth arrest state and in the G1 phase of the cell cycle2. To gain a further insight ino the role of RB-1 we and other groups8,9 have generated mice carrying an inactivated allele of the homologous gene, Rb-1 (ref. 10), by gene targeting". We report here that young heterozygous mice do not appear abnormal and do not develop retinoblastoma at a detectable frequency. However, homozygous mutant embryos fail to reach term and show a number of abnormalities in neural and haematopoietic development. Broadly similar results are reported by the other groups8,9.	UNIV EDINBURGH, DEPT PATHOL, CANC RES, CAMPAIGN LABS, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, AFRC, CTR GENOME RES, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; UNIV AMSTERDAM, DEPT BIOCHEM, AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	University of Edinburgh; University of Edinburgh; University of Amsterdam; Netherlands Cancer Institute			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; DIVE C, IN PRESS FRONTIERS P; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SHEW JY, 1989, ONCOGENE RES, V4, P205; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YOKOTA J, 1988, ONCOGENE, V3, P471	30	913	927	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					328	330		10.1038/359328a0	http://dx.doi.org/10.1038/359328a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406937				2022-12-24	WOS:A1992JP50300059
J	CHRISTEN, WG; MANSON, JE; SEDDON, JM; GLYNN, RJ; BURING, JE; ROSNER, B; HENNEKENS, CH				CHRISTEN, WG; MANSON, JE; SEDDON, JM; GLYNN, RJ; BURING, JE; ROSNER, B; HENNEKENS, CH			A PROSPECTIVE-STUDY OF CIGARETTE-SMOKING AND RISK OF CATARACT IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; LENS OPACITIES; NUCLEAR; PREVALENCE; ALCOHOL; PLASMA; EYES	Objective.-To examine the association between cigarette smoking and the incidence of cataract. Design, Setting, and Participants.-The design was a prospective cohort study using data from the Physicians' Health Study, a randomized trial of aspirin and beta carotene among 22 071 US male physicians aged 40 to 84 years that began in 1982. This analysis includes the 17 824 physicians who did not report cataract at baseline and did provide complete risk factor information. Based on information reported at baseline, 10% were current smokers, 39% were past smokers, and 51% were never smokers. Main Outcome Measure.-An incident cataract was defined as a self-report confirmed by medical record review to have been first diagnosed after randomization, age-related in origin, and responsible for a decrease in best corrected visual acuity to 20/30 or worse. Main Results.-During 60 months of follow-up, 557 incident cataracts among 371 participants were confirmed. Compared with never smokers, current smokers of 20 or more cigarettes per day had a statistically significant increase in the risk of cataract (relative fisk [RR], 2.16; 95% confidence interval [CI], 1.46 to 3.20; P<.001). Similar results were obtained after simultaneously controlling for other potential cataract risk factors in a logistic regression model (RR, 2.05; 95% CI, 1.38 to 3.05; P<.001). Among the 557 eyes with cataract, nuclear sclerotic changes were present in 442 while posterior subcapsular changes were present in 204. After controlling for other potential cataract risk factors, current smokers of 20 or more cigarettes per day had statistically significant increases in nuclear sclerosis (RR, 2.24; 95% CI, 1.47 to 3.41; P<.001) and posterior subcapsular (RR, 3.17; 95% CI, 1.81 to 5.53; P<.001) cataract. Past smokers had an elevated risk of posterior subcapsular (RR, 1.44; 95% CI, 0.97 to 2.13; P=.07) but not nuclear sclerosis cataract. For current smokers of fewer than 20 cigarettes per day, no increased risks were observed of total, nuclear sclerosis, or posterior subcapsular cataract. Conclusions.-These data provide support for the hypothesis that cigarette smoking increases the risk of developing both nuclear sclerosis and posterior subcapsular cataract.	HARVARD UNIV,SCH MED,DEPT MED,CHANNING LAB,PHYSICIANS HLTH STUDY,900 COMMONWEALTH AVE E,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,EPIDEMIOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NEI NIH HHS [EY03355] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, AM J EPIDEMIOL, V133, P541; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331; EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; PERKINS ES, 1984, BRIT J OPHTHALMOL, V68, P293, DOI 10.1136/bjo.68.5.293; ROSNER B, 1982, BIOMETRICS, V38, P105, DOI 10.2307/2530293; SPERDUTO RD, 1984, OPHTHALMOLOGY, V91, P815; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; 1983, DHHS NIH822469 PUBL, P7; 1980, WORLD BLINDNESS ITS	24	168	168	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					989	993						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501324				2022-12-24	WOS:A1992JK12900022
J	BALLEM, PJ; BELZBERG, A; DEVINE, DV; LYSTER, D; SPRUSTON, B; CHAMBERS, H; DOUBROFF, P; MIKULASH, K				BALLEM, PJ; BELZBERG, A; DEVINE, DV; LYSTER, D; SPRUSTON, B; CHAMBERS, H; DOUBROFF, P; MIKULASH, K			KINETIC-STUDIES OF THE MECHANISM OF THROMBOCYTOPENIA IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOMOSEXUAL MEN; HEMATOLOGIC MANIFESTATIONS; PATHO-PHYSIOLOGY; GLYCOPROTEIN-IB; HIV INFECTION; PURPURA; MEGAKARYOCYTES; PLATELETS; AUTOANTIBODIES; INTERLEUKIN-6	Background. Isolated thrombocytopenia accompanied by increased amounts of platelet-associated antibody is a common manifestation of human immunodeficiency virus (HIV) infection, and the thrombocytopenia often improves with zidovudine. It is not clear whether the mechanism of HIV-related thrombocytopenia primarily involves autoimmune destruction of platelets or reduced platelet production by megakaryocytes. Methods. We studied the survival of In-111-labeled autologous platelets and performed platelet imaging in 24 men with isolated HIV-related thrombocytopenia (1 6 who received no treatment and 8 who received zidovudine). We also studied 20 HIV-infected men with normal platelet counts (10 who received no treatment and 10 who received zidovudine) and studied 12 healthy seronegative men as controls. Results. Mean(+/-SD) platelet survival was significantly decreased in both the untreated and the zidovudine-treated patients with HIV-related thrombocytopenia (to 92+/-33 and 129+/-44 hours, respectively; both P<0.001), as compared with the normal controls (198+/-15 hours). Mean platelet survival was also significantly decreased in the HIV-infected patients with normal platelet counts (untreated, 162+/-23 hours, P<0.01; zidovudine-treated, 166+/-35 hours, P<0.05). Imaging studies, however, revealed no evidence of increased clearance of autologous platelets in the liver or spleen in any of these groups. Mean platelet production was significantly depressed in the untreated patients with thrombocytopenia (23,000+/-11,000 platelets per cubic millimeter per day, P<0.001) as compared with the healthy controls (45,000+/-6,000 per cubic millimeter per day). Mean platelet production was significantly increased, however, in the men treated with zidovudine, both in those with thrombocytopenia (60,000+/-31,000 platelets per cubic millimeter per day, P<0.01 vs. controls) and in those without thrombocytopenia (68,000+/-22,000 per cubic millimeter per day, P<0.01). Conclusions. Although there was a moderate reduction in platelet survival in HIV-infected persons, these patients, regardless of platelet counts, also had decreased production of platelets, possibly due to viral infection of the megakaryocytes. Zidovudine appears to improve platelet production.	ST PAULS HOSP, DEPT MED, VANCOUVER V6Z 1Y6, BC, CANADA; ST PAULS HOSP, DEPT NUCL MED, VANCOUVER V6Z 1Y6, BC, CANADA; ST PAULS HOSP, DEPT PATHOL, VANCOUVER V6Z 1Y6, BC, CANADA; CANADIAN RED CROSS SOC, BLOOD TRANSFUS SERV, VANCOUVER, BC, CANADA; UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA	St. Paul's Hospital; University of Saskatchewan; St. Paul's Hospital; University of Saskatchewan; St. Paul's Hospital; University of Saskatchewan; University of British Columbia								ABRAMS DI, 1984, AM J CLIN PATHOL, V81, P13, DOI 10.1093/ajcp/81.1.13; ABRAMS DI, 1986, ANN INTERN MED, V104, P47, DOI 10.7326/0003-4819-104-1-47; ASANO S, 1990, BLOOD, V75, P1602; BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BALLEM PJ, 1989, BLUT, V59, P111, DOI 10.1007/BF00320260; BASCH RS, 1990, P NATL ACAD SCI USA, V87, P8085, DOI 10.1073/pnas.87.20.8085; BEARDSLEY DS, 1984, J CLIN INVEST, V74, P1701, DOI 10.1172/JCI111587; BETTAIEB A, 1989, BRIT J HAEMATOL, V73, P241, DOI 10.1111/j.1365-2141.1989.tb00259.x; BIK T, 1982, BLOOD, V59, P482; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; CHOW FPR, 1991, BLOOD S, V78, pA148; COX LH, 1991, BLOOD, V77, P286; GERNSHEIMER T, 1989, NEW ENGL J MED, V320, P974, DOI 10.1056/NEJM198904133201505; HANSON SR, 1985, BLOOD, V66, P1105; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; HEYNS AP, 1985, PLATELET KINETICS IM, V2, P97; HILL RJ, 1990, J CLIN INVEST, V85, P1242, DOI 10.1172/JCI114559; HIRSCHEL B, 1988, ANN INTERN MED, V109, P718, DOI 10.7326/0003-4819-109-9-718; HIRSH J, 1966, BRIT J HAEMATOL, V12, P44, DOI 10.1111/j.1365-2141.1966.tb00125.x; HYMES KB, 1988, NEW ENGL J MED, V318, P516, DOI 10.1056/NEJM198802253180812; JERUSHALMY Z, 1963, P SOC EXP BIOL MED, V114, P687, DOI 10.3181/00379727-114-28771; KARPATKIN S, 1988, P NATL ACAD SCI USA, V85, P9763, DOI 10.1073/pnas.85.24.9763; KLAASSEN RJL, 1989, BLUT, V59, P75, DOI 10.1007/BF00320253; LEIDERMAN IZ, 1987, BLOOD, V70, P1267; LIPSON RL, 1959, AM J CLIN PATHOL, V32, P526; LOUACHE F, 1991, BLOOD, V78, P1697; MATHIAS CJ, 1984, SEMIN NUCL MED, V14, P118, DOI 10.1016/S0001-2998(84)80025-2; MONTANER JSG, 1990, J ACQ IMMUN DEF SYND, V3, P565; MONTE D, 1992, BLOOD, V79, P2670; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; MURPHY EA, 1971, THROMB DIATH HAEMOST, V25, P53, DOI 10.1055/s-0038-1654280; PENA JM, 1990, ACTA HAEMATOL-BASEL, V83, P86; PERKOCHA LA, 1988, AM J HEMATOL, V29, P94, DOI 10.1002/ajh.2830290207; POTTAGE JC, 1988, JAMA-J AM MED ASSOC, V260, P3045, DOI 10.1001/jama.260.20.3045; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SCADDEN DT, 1989, BLOOD, V74, P1455; SCOTT S, 1978, BLOOD, V52, P47; STELLA CC, 1987, J CLIN INVEST, V80, P286, DOI 10.1172/JCI113071; STELLA CC, 1988, HAEMATOLOGICA, V73, P25; STRATTON JR, 1989, J NUCL MED, V30, P629; SZATKOWSKI NS, 1986, BLOOD, V67, P310; TERADA H, 1966, BLOOD-J HEMATOL, V28, P213, DOI 10.1182/blood.V28.2.213.213; VANDERLELIE J, 1987, BRIT J HAEMATOL, V67, P109, DOI 10.1111/j.1365-2141.1987.tb02304.x; WALSH CM, 1984, NEW ENGL J MED, V311, P635, DOI 10.1056/NEJM198409063111004; WOODS VL, 1984, BLOOD, V63, P368; WOODS VL, 1984, BLOOD, V64, P156; ZAULI G, 1992, BLOOD, V79, P2680; ZON LI, 1987, BRIT J HAEMATOL, V66, P251, DOI 10.1111/j.1365-2141.1987.tb01307.x; ZUCKERFRANKLIN D, 1989, P NATL ACAD SCI USA, V86, P5595, DOI 10.1073/pnas.86.14.5595; ZUCKERFRANKLIN D, 1989, AM J PATHOL, V134, P1295; 1987, MMWR MORB MORTAL S1, V36, pS3	51	162	169	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1779	1784		10.1056/NEJM199212173272503	http://dx.doi.org/10.1056/NEJM199212173272503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1435932	Bronze			2022-12-24	WOS:A1992KB97500003
J	WRIGHT, J; FORD, H				WRIGHT, J; FORD, H			LETTER FROM AFRICA - ANOTHER AFRICAN DISASTER	BRITISH MEDICAL JOURNAL			English	Article											WRIGHT, J (corresponding author), GOOD SHEPHERD HOSP,SITEKI,SWAZILAND.		Wright, John/H-1624-2012	Wright, John/0000-0001-9572-7293					0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1479	1480		10.1136/bmj.305.6867.1479	http://dx.doi.org/10.1136/bmj.305.6867.1479			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493396	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992KC91800027
J	HUPP, TR; MEEK, DW; MIDGLEY, CA; LANE, DP				HUPP, TR; MEEK, DW; MIDGLEY, CA; LANE, DP			REGULATION OF THE SPECIFIC DNA-BINDING FUNCTION OF P53	CELL			English	Article							CASEIN-KINASE-II; CELLULAR TUMOR-ANTIGEN; HEAT-SHOCK PROTEINS; EPIDERMAL GROWTH-FACTOR; VIRUS-40 T-ANTIGEN; ESCHERICHIA-COLI; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; NUCLEAR-LOCALIZATION	The DNA binding activity of p53 is required for its tumor suppressor function; we show here that this activity is cryptic but can be activated by cellular factors acting on a C-terminal regulatory domain of p53. A gel mobility shift assay demonstrated that recombinant wild-type human p53 binds DNA sequence specifically only weakly, but a monoclonal antibody binding near the C terminus activated the cryptic DNA binding activity stoichiometrically. p53 DNA binding could be activated by a C-terminal deletion of p53, mild proteolysis of full-length p53, E. coli dnaK (which disrupts protein-protein complexes), or casein kinase II (and coincident phosphorylation of a C-terminal site on p53). Activation of p53 DNA binding may be critical in regulation of its ability to arrest cell growth and thus its tumor suppressor function.			HUPP, TR (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADDISON C, 1990, ONCOGENE, V5, P423; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALL PA, 1992, IN PRESS ONCOGENE; HARLOW E, 1988, ANTIBODIES LABORATOR; Hoekstra M F, 1992, Trends Cell Biol, V2, P153, DOI 10.1016/0962-8924(92)90022-F; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1515; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	92	968	994	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					875	886		10.1016/0092-8674(92)90562-Q	http://dx.doi.org/10.1016/0092-8674(92)90562-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423635				2022-12-24	WOS:A1992JZ63300016
J	FINK, JN; KELLY, KJ				FINK, JN; KELLY, KJ			IMMUNOLOGICAL ASPECTS OF GRANULOMATOUS AND INTERSTITIAL LUNG-DISEASES AND OF CYSTIC-FIBROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; INDUCED PULMONARY-DISEASE; LOWER RESPIRATORY-TRACT; CHRONIC INFLAMMATION; IMMUNE-COMPLEXES; UNKNOWN CAUSE; TOMOGRAPHY; ACTIVATION; FARMERS; DRUGS				FINK, JN (corresponding author), MED COLL WISCONSIN,ALLERGY IMMUNOL,MILWAUKEE,WI 53226, USA.			Kelly, Kevin/0000-0002-2954-6117				BANKS DE, 1986, ANN ALLERGY, V57, P389; CANLIN A, 1988, J LEUKOCYTE BIOL, V43, P299; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CARROLL JL, 1989, IMMUNOLOGIC DISORDER, P475; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P488; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P321; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; DOLL NJ, 1981, J ALLERGY CLIN IMMUN, V68, P281; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FEW F, 1986, J CLIN IMMUNOL, V6, P225; FINK JN, 1991, IMMUNOLOGICALLY MEDI, P399; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; Gocke D J, 1971, J Exp Med, V134, P330; GREENBERGER PA, 1988, ALLERGY PRINCIPLES P, P1219; Hamman L, 1935, Trans Am Clin Climatol Assoc, V51, P154; HASLAM P, 1975, CLIN EXP IMMUNOL, V20, P379; KASAHARA K, 1989, CLIN IMMUNOL IMMUNOP, V51, P419, DOI 10.1016/0090-1229(89)90040-8; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KRAUSEHOOYMAN L, 1983, INT ARCH ALLER A IMM, V71, P245, DOI 10.1159/000233398; KUNKEL SL, 1984, J CLIN INVEST, V74, P514, DOI 10.1172/JCI111449; Liebow A, 1969, FRONTIERS PULMONARY, P102; LYNCH JP, 1991, IMMUNOLOGICALLY MEDI, P189; MARX JJ, 1990, AM J IND MED, V18, P263, DOI 10.1002/ajim.4700180304; MARX JJ, 1973, J IMMUNOL, V111, P590; MOSS RB, 1986, AM REV RESPIR DIS, V133, P648; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1206; NEELD DA, 1990, AM REV RESPIR DIS, V142, P1200, DOI 10.1164/ajrccm/142.5.1200; OLIVEIRA DBG, 1989, KIDNEY INT, V35, P923, DOI 10.1038/ki.1989.76; Parrillo J E, 1977, Trans Assoc Am Physicians, V90, P135; Pepys J, 1969, HYPERSENSITIVITY DIS; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSSMAN MD, 1991, IMMUNOLOGICALLY MEDI, P217; SALVAGGIO JE, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P435; SANS J, 1988, J BIOL CHEM, V263, P1374; Stankus RP, 1988, INTERSTITIAL LUNG DI, P111; WILSON MR, 1977, J ALLERGY CLIN IMMUN, V60, P218, DOI 10.1016/0091-6749(77)90133-6	38	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2874	2881		10.1001/jama.268.20.2874	http://dx.doi.org/10.1001/jama.268.20.2874			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433703				2022-12-24	WOS:A1992JY66800011
J	MARTIN, P; LEWIS, J				MARTIN, P; LEWIS, J			ACTIN CABLES AND EPIDERMAL MOVEMENT IN EMBRYONIC WOUND-HEALING	NATURE			English	Article							SCANNING ELECTRON-MICROSCOPY; EPITHELIAL-CELLS; GENE-EXPRESSION; MIGRATION; XENOPUS; VISUALIZATION; MICROFILAMENT; MORPHOGENESIS; CULTURE	SKIN wounds in embryos heal rapidly and perfectly. Even though the epidermis appears to be stretched taut over the surface of a structure such as a growing limb bud, its response to wounding is to close over the lesion, rather than to gape more widely. In adult wounds, the epidermis seems to migrate by means of lamellipodia, crawling over the exposed connective tissue1-5. But in embryonic wounds we do not see lamellipodia. The epidermis at the edge of the wound looks smooth, as though under a circumferential tension. Here we show that a cable of filamentous actin appears to run continuously around most of the wound margin. It is confined to the single row of basal cells at the free edge of the epidermis. We suggest that the actin cable acts as a contractile 'purse string' to close up the embryonic wound.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,OXFORD OX1 3PS,ENGLAND	University of Oxford	MARTIN, P (corresponding author), UNIV OXFORD,DEPT HUMAN ANAT,OXFORD OX1 3QX,ENGLAND.		Lewis, Julian H/E-8733-2010	Martin, Paul/0000-0002-2665-5086				Bard J. B. L., 1990, MORPHOGENESIS CELLUL; BELOUSSOV LV, 1975, J EMBRYOL EXP MORPH, V34, P559; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; Bereiter-Hahn J., 1986, P443; BUCK RC, 1979, INVEST OPHTH VIS SCI, V18, P767; DIPASQUALE A, 1975, EXP CELL RES, V94, P191, DOI 10.1016/0014-4827(75)90545-5; FRISTROM D, 1988, TISSUE CELL, V20, P645, DOI 10.1016/0040-8166(88)90015-8; Gabbiani G, 1977, Int Rev Cytol, V48, P187, DOI 10.1016/S0074-7696(08)61745-3; GEIGER B, 1987, J CELL SCI S, V8, P251; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; MARTIN P, 1992, MECH DEVELOP, V38, P209, DOI 10.1016/0925-4773(92)90054-N; MAUPINSZAMIER P, 1978, J CELL BIOL, V77, P738; MCDONALD K, 1984, J ULTRA MOL STRUCT R, V86, P107, DOI 10.1016/S0022-5320(84)80051-9; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; ODLAND G, 1968, J CELL BIOL, V39, P135, DOI 10.1083/jcb.39.1.135; PANG SC, 1978, AM J ANAT, V153, P177, DOI 10.1002/aja.1001530202; RADICE GP, 1980, DEV BIOL, V76, P26, DOI 10.1016/0012-1606(80)90360-7; SHERRATT JA, IN PRESS B MATH BIOL; SMEDLEY MJ, 1984, J EMBRYOL EXP MORPH, V83, P109; STANISSTREET M, 1982, J EMBRYOL EXP MORPH, V67, P195; STANISSTREET M, 1980, J EMBRYOL EXP MORPH, V59, P341; THEVENET A, 1981, ARCH ANAT MICROSC MO, V70, P227; Trinkaus J.P., 1984, CELLS ORGANS; VAUGHAN RB, 1966, J CELL SCI, V1, P407; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	28	349	355	6	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					179	183		10.1038/360179a0	http://dx.doi.org/10.1038/360179a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436096				2022-12-24	WOS:A1992JX75200067
J	LAMPL, M; VELDHUIS, JD; JOHNSON, ML				LAMPL, M; VELDHUIS, JD; JOHNSON, ML			SALTATION AND STASIS - A MODEL OF HUMAN GROWTH	SCIENCE			English	Article							LONGITUDINAL BONE-GROWTH; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; LINEAR GROWTH; FACTOR-I; CHILDREN; HORMONE; PROTEIN; CHONDROCYTES; VELOCITY	Human growth has been viewed as a continuous process characterized by changing velocity with age. Serial length measurements of normal infants were assessed weekly (n = 10), semiweekly (n = 18), and daily (n = 3) (19 females and 12 males) during their first 21 months. Data show that growth in length occurs by discontinuous, aperiodic saltatory spurts. These bursts were 0.5 to 2.5 centimeters in amplitude during intervals separated by no measurable growth (2 to 63 days duration). These data suggest that 90 to 95 percent of normal development during infancy is growth-free and length accretion is a distinctly saltatory process of incremental bursts punctuating background stasis.	UNIV VIRGINIA, HLTH SCI CTR, NATL SCI FDN, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; University of Virginia; University of Virginia	LAMPL, M (corresponding author), UNIV PENN, DEPT ANTHROPOL, PHILADELPHIA, PA 19104 USA.		Lampl, Michelle L/B-1619-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NICHD NIH HHS [KO4HD00634] Funding Source: Medline; NIDDK NIH HHS [DK 38942] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTSSONWIKLAND K, 1988, J CLIN ENDOCR METAB, V67, P493, DOI 10.1210/jcem-67-3-493; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORTELL R, 1990, J CELL BIOCHEM, V44, P81, DOI 10.1002/jcb.240440203; BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; BUTLER GE, 1990, ANN HUM BIOL, V17, P177, DOI 10.1080/03014469000000952; Cameron N., 1986, HUMAN GROWTH, V3, P3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Gordon CC, 1988, ANTHR STAND REF MANU, P3; Hamill PV, 1977, VITAL HLTH STAT 11, V11, P1; HARRISON GA, 1990, ANN HUM BIOL, V17, P407, DOI 10.1080/03014469000001182; HEALY MJR, 1988, NESTLE NUTRITION WOR, V14, P41; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; HERMANUSSEN M, 1986, ACTA PAEDIATR SCAND, V75, P601, DOI 10.1111/j.1651-2227.1986.tb10258.x; HUNZIKER EB, 1989, J PHYSIOL-LONDON, V414, P55, DOI 10.1113/jphysiol.1989.sp017676; KARLBERG J, 1987, STAT MED, V6, P185, DOI 10.1002/sim.4780060210; LAMPL M, UNPUB; LLOYD D, 1986, CELL CYCLE CLOCKS, P27; MARSHALL WA, 1971, ARCH DIS CHILD, V46, P414, DOI 10.1136/adc.46.248.414; MARTHA PM, 1989, J CLIN ENDOCR METAB, V69, P563, DOI 10.1210/jcem-69-3-563; MARTORELL R, 1975, AM J PHYS ANTHROPOL, V43, P347, DOI 10.1002/ajpa.1330430308; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAURAS N, 1987, J CLIN ENDOCR METAB, V64, P596, DOI 10.1210/jcem-64-3-596; Meredith HV, 1936, CHILD DEV, V7, P262; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; POLYCHRONAKOS C, 1988, EUR J PEDIATR, V147, P582, DOI 10.1007/BF00442467; ROCHE AF, 1980, AM J CLIN NUTR, V33, P2041, DOI 10.1093/ajcn/33.9.2041; Scammon RE, 1927, AM J PHYS ANTHROPOL, V10, P329, DOI 10.1002/ajpa.1330100303; SCHEVEN BAA, 1991, ACTA ENDOCRINOL-COP, V124, P602, DOI 10.1530/acta.0.1240602; SCHOLL D. A., 1954, DYNAMICS GROWTH PROC, P224; SMITH DW, 1976, J PEDIATR-US, V89, P225, DOI 10.1016/S0022-3476(76)80453-2; STEVENSON S, 1990, J ORTHOPAED RES, V8, P132, DOI 10.1002/jor.1100080117; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TANNER JM, 1990, FETUS MAN PHYSICAL G; TOGO M, 1982, ANN HUM BIOL, V9, P425, DOI 10.1080/03014468200005961; VALK IM, 1983, GROWTH, V47, P53; VANDERLINDEN FP, 1970, GROWTH, V34, P385; VELDHUIS JD, 1992, METHOD ENZYMOL, V210, P539; WALES JKH, 1987, ARCH DIS CHILD, V62, P166, DOI 10.1136/adc.62.2.166; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIT JM, 1987, ACTA PAEDIATR SCAND, P40; [No title captured]	46	233	238	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1992	258	5083					801	803		10.1126/science.1439787	http://dx.doi.org/10.1126/science.1439787			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439787				2022-12-24	WOS:A1992JV69200038
J	NITSCH, RM; SLACK, BE; WURTMAN, RJ; GROWDON, JH				NITSCH, RM; SLACK, BE; WURTMAN, RJ; GROWDON, JH			RELEASE OF ALZHEIMER AMYLOID PRECURSOR DERIVATIVES STIMULATED BY ACTIVATION OF MUSCARINIC ACETYLCHOLINE-RECEPTORS	SCIENCE			English	Article							PROTEIN KINASE-C; DISEASE; DOMAIN; PHOSPHORYLATION; LOCALIZATION; CLEAVAGE; SUBTYPES; PEPTIDE	Altered processing of the amyloid precursor protein (APP) is a central event in the formation of amyloid deposits in the brains of individuals with Alzheimer's disease. To investigate whether cellular APP processing is controlled by cell-surface neurotransmitter receptors, human embryonic kidney (293) cell lines were transfected with the genes for human brain muscarinic acetylcholine receptors. Stimulation of m1 and m3 receptor subtypes with carbachol increased the basal release of APP derivatives within minutes of treatment, indicating that preexisting APP is released in response to receptor activation. Receptor-activated APP release was blocked by staurosporine, suggesting that protein kinases mediate neurotransmitter receptor-controlled APP processing.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	NITSCH, RM (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-604,CAMBRIDGE,MA 02139, USA.		Slack, Barbara/AAU-9917-2021	Slack, Barbara/0000-0002-7619-410X				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NITSCH RM, UNPUB; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; 1989, TRENDS PHARM SCI S, pR7	33	846	880	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					304	307		10.1126/science.1411529	http://dx.doi.org/10.1126/science.1411529			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411529				2022-12-24	WOS:A1992JR86000036
J	MONTEIRO, CA; TORRES, AM				MONTEIRO, CA; TORRES, AM			CAN SECULAR TRENDS IN CHILD GROWTH BE ESTIMATED FROM A SINGLE CROSS-SECTIONAL SURVEY	BRITISH MEDICAL JOURNAL			English	Article							HEIGHT; BOYS	Objective-To formulate and evaluate a new method to measure secular trends in child growth based on the cross sectional collection of heights of children and young adults. Design-Trends in child growth obtained from comparison of two national surveys made with an interval of 15 years were compared with estimates obtained from comparison of height deficits of children and young adults in the more recent survey. Setting-Brazil. Subjects-Random sample of children (6 and 7 years old) and young adults (21 and 22 years old) living in Brazil in 1974 and 1989 (a total of 23 271 subjects in 1974 and 5479 in 1989). Main outcome measures-Increments in average heights of 6 and 7 year old children in a 15 year period. Results-Mean height of 6 year old children increased 4.0 cm (boys) and 3.3 cm (girls) from 1974 to 1989. Similar results were obtained by subtracting, in the 1989 survey, mean height deficits found at ages 21 and 6 (3.8 cm for males and 3.5 cm for females). Positive changes in the mean height of 7 year old children could also be predicted by subtracting, in the 1989 survey, height deficits found at ages 7 and 22. Conclusions-Findings of this study support the hypothesis that secular trends in child growth can be estimated by comparing height deficits observed in children and young adults.	WHO,NUTR UNIT,CH-1211 GENEVA 27,SWITZERLAND; UNIV GENEVA,COMMUNITY HLTH UNIT,CH-1211 GENEVA 4,SWITZERLAND	World Health Organization; University of Geneva			Monteiro, Carlos Augusto/F-9892-2012	Monteiro, Carlos Augusto/0000-0002-3777-1533; Torres-Cantero, Alberto M./0000-0001-5402-1016				BILLEWICZ WZ, 1982, ANN HUM BIOL, V9, P309, DOI 10.1080/03014468200005811; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; Eveleth P.B., 1976, WORLDWIDE VARIATION, V8; HAUSPIE RC, 1980, ANN HUM BIOL, V7, P429, DOI 10.1080/03014468000004541; Martorell R., 1990, ANN NESTLE, V48, P85; MONTEIRO CA, 1989, IN PRESS B WHO; SATYANARAYANA K, 1989, ANN HUM BIOL, V16, P289, DOI 10.1080/03014468900000422; Van Wieringen J., 1978, HUMAN GROWTH, P445, DOI [10.1007/978-1-4684-2622-9_16, DOI 10.1007/978-1-4684-2622-9_16]; WATERLOW JC, 1988, NUTRITION WORKSHOP S, V14; 1989, PERFIL ESTATISTICO C; 1989, GLOBAL NUTRITION STA; 1990, APPROPRIATE USES ANT	12	7	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					797	799		10.1136/bmj.305.6857.797	http://dx.doi.org/10.1136/bmj.305.6857.797			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422358	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JT25600018
J	HENDERSON, E; HAYDON, PG; SAKAGUCHI, DS				HENDERSON, E; HAYDON, PG; SAKAGUCHI, DS			ACTIN FILAMENT DYNAMICS IN LIVING GLIAL-CELLS IMAGED BY ATOMIC FORCE MICROSCOPY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; MOLECULAR-RESOLUTION; DNA	Observation of filamentous actin (F-actin) in living cells is currently limited to the resolution of the light microscope. Higher resolution procedures require sample fixation and preclude dynamic studies. The atomic force microscope (AFM) can image and manipulate samples at very high, sometimes atomic resolution by scanning a fine tip over the surface of interest and detecting physical interactions between the tip and sample. This study demonstrates that F-actin can be readily resolved in living cells with the AFM and that the dynamic properties of F-actin are easily observed.			HENDERSON, E (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,SIGNAL TRANSDUCT TRAINING GRP,AMES,IA 50011, USA.			Sakaguchi, Donald/0000-0003-4537-0972				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUTT HJ, 1990, BIOPHYS J, V58, P1473, DOI 10.1016/S0006-3495(90)82492-9; BUTT HJ, 1990, J STRUCT BIOL, V105, P54, DOI 10.1016/1047-8477(90)90098-W; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; EDSTROM RD, 1990, FASEB J, V4, P3144, DOI 10.1096/fasebj.4.13.2120098; GOULD SAC, 1990, J VAC SCI TECHNOL A, V8, P369, DOI 10.1116/1.576398; HENDERSON E, 1992, NUCLEIC ACIDS RES, V20, P445, DOI 10.1093/nar/20.3.445; HOH J H, 1992, Trends in Cell Biology, V2, P208, DOI 10.1016/0962-8924(92)90248-L; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; KELLER D, 1992, SPIE P, V1639, P91; MARTI O, 1988, J MICROSC-OXFORD, V152, P803, DOI 10.1111/j.1365-2818.1988.tb01452.x; OMIE J, 1991, SCIENCE, V252, P691; PARPURA V, COMMUNICATION; PUTMAN CAJ, IN PRESS ULTRAMICROS; PUTNAM CAJ, 1992, REV SCI INSTRUM, V63, P1914; RADMACHER M, 1992, STRUCTURE CONFORMATI, V66, P24; SAKAGUCHI DS, 1989, DEV BIOL, V134, P158, DOI 10.1016/0012-1606(89)90086-9; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; VESENKA J, IN PRESS ULTRAMICROS; VESENKA J, 1992, SPIE P, V1639, P38; WEISENHORN AL, 1990, BIOPHYS J, V58, P1251, DOI 10.1016/S0006-3495(90)82465-6; WEISENHORN AL, 1990, SCANNING MICROSCOPY, V4, P511; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003	24	375	393	4	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1944	1946		10.1126/science.1411511	http://dx.doi.org/10.1126/science.1411511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411511				2022-12-24	WOS:A1992JP59400031
J	BIX, M; RAULET, D				BIX, M; RAULET, D			INEFFICIENT POSITIVE SELECTION OF T-CELLS DIRECTED BY HEMATOPOIETIC-CELLS	NATURE			English	Article							THYMUS	SUCCESSFUL intrathymic differentiation of alpha-beta-TCR+ T cells depends on positive selection of CD4+CD8+ thymocytes by thymic major histocompatibility complex (MHC) molecules1-9. Positive selection allows the maturation of only those T cells capable of restricted antigen recognition in the context of the hosts' MHC alleles. Studies of normal or T-cell receptor-transgenic mice engrafted with MHC-different bone marrow or thymuses support the conclusion that positive selection is directed by MHC molecules expressed on non-haematopoietic cells, presumably thymic epithelial cells1-3,8-10. Here we present contrary evidence that class I MHC molecules expressed by haematopoietic cell types direct positive selection of CD8+ T cells, though at a reduced rate compared with positive selection directed by thymic epithelial cells. The identity of cell types that direct positive selection bears directly on mechanistic models of the process, including the idea that thymic epithelial cell MHC molecules uniquely present specialized peptides that mediate positive selection, and the notion that thymic epithelial cells express unique differentiation-inducing cell surface molecules.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,489 LIFE SCI ADDIT,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649; Bix, Mark/0000-0003-4617-0497				BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; SPRENT J, 1978, J EXP MED, V147, P1159, DOI 10.1084/jem.147.4.1159; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	3	142	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					330	333		10.1038/359330a0	http://dx.doi.org/10.1038/359330a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406938				2022-12-24	WOS:A1992JP50300060
J	EYSENCK, HJ				EYSENCK, HJ			PSYCHOSOCIAL FACTORS, CANCER, AND ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PERSONALITY; PREDICTOR; STRESS				EYSENCK, HJ (corresponding author), UNIV LONDON,INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							EYSENCK H J, 1991, Integrative Physiological and Behavioral Science, V26, P309, DOI 10.1007/BF02691067; Eysenck H.J., 1991, ADULT EPQ R; EYSENCK HJ, 1990, PERCEPT MOTOR SKILL, V71, P216; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1991, PSYCHOL INQ, V2, P320; GROSSARTHMATICE.R, 1991, PSYCHOL REP, V65, P1027; GROSSARTHMATICEK R, 1991, PSYCHOL REP, V68, P1083, DOI 10.2466/PR0.68.4.1083-1087; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSHANS EM, 1990, J AM ACAD DERMATOL, V23, P153, DOI 10.1016/S0190-9622(08)81224-8; KISSEN DM, 1992, J PSYCHOSOM RES, V6, P123; PELOSI AJ, 1992, BRIT MED J, V303, P1295; QUANDERBLAZNIK J, 1991, PERS INDIV DIFFER, V12, P125, DOI 10.1016/0191-8869(91)90095-S; SCHMALE AH, 1971, SOC SCI MED, V5, P95, DOI 10.1016/0037-7856(71)90090-4; SCHMITZ PG, 1992, PERS INDIV DIFFER, V13, P683, DOI 10.1016/0191-8869(92)90239-L; SPIEGEL D, 1989, LANCET, V2, P888; VETTER H, 1991, PSYCHOL INQ, V2, P322; Vetter H, 1991, PSYCHOL INQ, V2, P286	17	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					457	459		10.1136/bmj.305.6851.457	http://dx.doi.org/10.1136/bmj.305.6851.457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK680	1392961	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JK68000025
J	GIMENO, CJ; FINK, GR				GIMENO, CJ; FINK, GR			THE LOGIC OF CELL-DIVISION IN THE LIFE-CYCLE OF YEAST	SCIENCE			English	Editorial Material									MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	GIMENO, CJ (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266, R01GM035010, R37GM035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40266, GM35010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HANSEN EC, 1886, C R TRAV LAB CARLS P, V2, P92; HAWTHORNE DC, 1955, GENETICS, V40, P511; HERSKOWITZ I, 1992, NATURE, V357, P190, DOI 10.1038/357190a0; HICKS JB, 1977, GENETICS, V85, P395; LODDER J, 1970, YEASTS TAXONOMIC STU, P51; MORTIMER RK, 1986, GENETICS, V113, P35; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; SCHERR GH, 1953, BACTERIOL REV, V17, P51, DOI 10.1128/MMBR.17.1.51-92.1953; THOMAS JH, 1987, GENETICS, V115, P229	11	53	54	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					626	626		10.1126/science.1496375	http://dx.doi.org/10.1126/science.1496375			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496375				2022-12-24	WOS:A1992JF85200024
J	SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B				SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B			HOW STRICTLY DO DIALYSIS PATIENTS WANT THEIR ADVANCE DIRECTIVES FOLLOWED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOOSING DEATH; RESUSCITATION; WITHDRAWAL; CARE	Objective. - The Cruzan case and the Patient Self-Determination Act will encourage patients to specify in advance which life-sustaining treatments they would want if they become mentally incompetent. However, strictly following such advance directives may not always be in a patient's best interests. We sought to determine whether patients diff er in how strictly they want advance directives followed. Design. - Interview study. Setting. - Seven outpatient chronic dialysis centers. Participants. - One hundred fifty mentally competent dialysis patients. Intervention. - Using a structured questionnaire, we asked the subjects whether they would want dialysis continued or stopped if they developed advanced Alzheimer's disease. We then asked how much leeway their physician and surrogate should have to override that advance directive if overriding were in their best interests, Subjects granting leeway were also asked what factors should be considered in making decisions for them. Results. - Subjects varied greatly in how much leeway they would give surrogates to override their advance directives: "no leeway" (39%), "a little leeway" (19%), "a lot of leeway" (11%), and "complete leeway" (31%). Subjects also varied in how much they wanted various factors considered in making decisions, such as pain or suffering, quality of life, possibility of a new treatment, indignity caused by continued treatment, financial impact of treatment on family members, and religious beliefs. Conclusions. - Strictly following all advance directives may not truly reflect patients' preferences. To improve advance directives, we recommend that physicians explicitly ask patients how strictly they want their advance directives followed and what factors they want considered in making decisions.	DEPT VET AFFAIRS,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	SEHGAL, A (corresponding author), UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,BOX 0903,SAN FRANCISCO,CA 94143, USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BOPP J, 1990, HASTINGS CENT REP, V20, P42, DOI 10.2307/3562976; BUCHANAN AE, 1991, ANN INTERN MED, V114, P895; Dresser R S, 1989, Law Med Health Care, V17, P234; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FULLER, 1941, COL L REV, V41, P799; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1991, JAMA-J AM MED ASSOC, V265, P1874, DOI 10.1001/jama.265.14.1874; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; Rhoden N, 1989, Law Med Health Care, V17, P264; ROBERTS JC, 1988, ACTA MED SCAND, V223, P181; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1989, USRDS1989 NAT I HLTH	23	239	239	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					59	63		10.1001/jama.267.1.59	http://dx.doi.org/10.1001/jama.267.1.59			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1489360				2022-12-24	WOS:A1992GW84800024
J	BOSENBERG, MW; PANDIELLA, A; MASSAGUE, J				BOSENBERG, MW; PANDIELLA, A; MASSAGUE, J			THE CYTOPLASMIC CARBOXY-TERMINAL AMINO-ACID SPECIFIES CLEAVAGE OF MEMBRANE TGF-ALPHA INTO SOLUBLE GROWTH-FACTOR	CELL			English	Article							STIMULATING FACTOR CSF-1; CELL-SURFACE; KIT LIGAND; MOLECULAR-CLONING; FACTOR RECEPTORS; PLASMA-MEMBRANE; SI-LOCUS; PRECURSOR; TRANSMEMBRANE; PROTEIN	Membrane-anchored transforming growth factor a (proTGFalpha) belongs to a group of transmembrane proteins whose extracellular domains are selectively cleaved and released into the medium. We demonstrate that the carboxy-terminal valine in the cytoplasmic tail of proTGFalpha is required for cleavage of the growth factor ectodomain in response to various activators. This cleavage process occurs outside Golgi or lysosomal locations, affects cell surface proTGFalpha, and requires little or no membrane traffic. We propose that cleavage and release of proTGFalpha ectodomain involve a specialized proteolytic system and depend on the recognition of a simple and specific determinant located in the proTGFalpha cytoplasmic tail.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	BOSENBERG, MW (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Pandiella, Atanasio/O-5180-2014	Pandiella, Atanasio/0000-0002-4704-8971; Massague, Joan/0000-0001-9324-8408				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KISHIMOTO TE, 1989, SCIENCE, V245, P1338; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Sambrook J., 1989, MOL CLONING LAB MANU; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STEIN J, 1991, ONCOGENE, V6, P601; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	50	130	133	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1157	1165		10.1016/S0092-8674(05)80064-9	http://dx.doi.org/10.1016/S0092-8674(05)80064-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473151				2022-12-24	WOS:A1992KE60400010
J	VANKAER, L; ASHTONRICKARDT, PG; PLOEGH, HL; TONEGAWA, S				VANKAER, L; ASHTONRICKARDT, PG; PLOEGH, HL; TONEGAWA, S			TAP1 MUTANT MICE ARE DEFICIENT IN ANTIGEN PRESENTATION, SURFACE CLASS-I MOLECULES, AND CD4-8+ T-CELLS	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; H-2-DEFICIENT LYMPHOMA VARIANTS; LYMPHOCYTES-T; ENDOPLASMIC-RETICULUM; LYMPHOBLASTOID-CELLS; SELF-PEPTIDES; MHC MOLECULES; H-2 ANTIGENS; EXPRESSION; PROTEINS	The transporter associated with the antigen processing 1 (TAP1) gene encodes a subunit for a transporter, presumed to be involved in the delivery of peptides across the endoplasmic reticulum membrane to class I molecules. We have generated mice with a disrupted TAP1 gene using embryonic stem cell technology. TAP1-deficient mice are defective in the stable assembly and intracellular transport of class I molecules and consequently show severely reduced levels of surface class I molecules. These properties are strikingly similar to those described for the TAP2 mutant cell line RMA-S. Cells from the TAP1-deficient mice are unable to present cytosolic antigens to class I-restricted cytotoxic T cells. As predicted from the near absence of class I surface expression, TAP1-deficient mice lack CD4-8+ T cells.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	VANKAER, L (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309				AOSAI F, 1991, EUR J IMMUNOL, V21, P2767, DOI 10.1002/eji.1830211118; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODMER JG, 1992, IMMUNOGENETICS, V36, P135, DOI 10.1007/BF00661090; BOEHMER HV, 1978, P NATL ACAD SCI USA, V75, P2439, DOI 10.1073/pnas.75.5.2439; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUCHMEIER MJ, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, IMMUNOGENETICS, V32, P440; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NEEFJES JJ, 1992, EUR J IMMUNOL, V22, P1609, DOI 10.1002/eji.1830220639; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; van Bleek G M, 1992, Trends Cell Biol, V2, P202, DOI 10.1016/0962-8924(92)90247-K; WALDEN PR, 1990, P NATL ACAD SCI USA, V87, P9015, DOI 10.1073/pnas.87.22.9015; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1978, NATURE, V271, P251, DOI 10.1038/271251a0	58	617	625	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1205	1214						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473153				2022-12-24	WOS:A1992KE60400014
J	MAZUR, P; COLE, KW; HALL, JW; SCHREUDERS, PD; MAHOWALD, AP				MAZUR, P; COLE, KW; HALL, JW; SCHREUDERS, PD; MAHOWALD, AP			CRYOBIOLOGICAL PRESERVATION OF DROSOPHILA EMBRYOS	SCIENCE			English	Article							MOUSE EMBRYOS; MELANOGASTER EMBRYOS; SURVIVAL; PERMEABILIZATION; FROZEN; EGGS	The inability to cryobiologically preserve the fruit fly Drosophila melanogaster has required that fly stocks be maintained by frequent transfer of adults. This method is costly in terms of time and can lead to loss of stocks. Traditional slow freezing methods do not succeed because the embryos are highly sensitive to chilling. With the procedures described here, 68 percent of precisely staged 15-hour Oregon R (wild-type) embryos hatch after vitrification at -205-degrees-C, and 40 percent of the resulting larvae develop into normal adult flies. These embryos are among the most complex organisms successfully preserved by cryobiology.	UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Chicago	MAZUR, P (corresponding author), UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE,TN 37831, USA.				NICHD NIH HHS [HD17607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017607] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON KV, 1981, DEV BIOL, V82, P127, DOI 10.1016/0012-1606(81)90434-6; Ashburner M., 1978, GENETICS BIOL DROS A, P1; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; EDGLEY M, 1988, CAENORHABDITIS GENET; Hadley N.F., 1986, SCI AM, V254, P104; LIMBOURG B, 1973, DEV BIOL, V35, P382, DOI 10.1016/0012-1606(73)90034-1; LYNCH DV, 1989, CRYOBIOLOGY, V26, P445, DOI 10.1016/0011-2240(89)90069-2; MAZUR P, 1992, CRYOBIOLOGY, V29, P210, DOI 10.1016/0011-2240(92)90021-S; MAZUR P, 1992, CRYOBIOLOGY, V29, P39, DOI 10.1016/0011-2240(92)90005-M; MAZUR P, 1990, CELL BIOPHYS, V17, P53, DOI 10.1007/BF02989804; MAZUR P, IN PRESS CRYOBIOLOGY; MYERS S P, 1990, Cryobiology, V27, P651; MYERS SP, 1988, CRYOBIOLOGY, V25, P544, DOI 10.1016/0011-2240(88)90401-4; MYERS SP, 1989, CRYOBIOLOGY, V26, P472, DOI 10.1016/0011-2240(89)90071-0; RALL WF, 1987, CRYOBIOLOGY, V24, P387, DOI 10.1016/0011-2240(87)90042-3; RAMINANI LN, 1975, J INSECT MORPHOL EMB, V4, P517; SCHNEIDER U, 1983, BIOL REPROD, V29, P121, DOI 10.1095/biolreprod29.1.121; SCHREUDERS PD, IN PRESS CRYOBIOLOGY; STEPONKUS PL, 1990, NATURE, V345, P170, DOI 10.1038/345170a0; STEPONKUS PL, IN PRES CRYOBIOLOGY; STRONGGUNDERSON JM, 1989, ENVIRON ENTOMOL, V18, P756, DOI 10.1093/ee/18.5.756; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHITTINGHAM DG, 1972, SCIENCE, V178, P411, DOI 10.1126/science.178.4059.411; Wieschaus E., 1986, P199; ZALOKAR M, 1977, EMBO WORKSHOP GIF SU	25	153	166	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1932	1935		10.1126/science.1470915	http://dx.doi.org/10.1126/science.1470915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470915				2022-12-24	WOS:A1992KD08800030
J	HUGO, P; KAPPLER, JW; GODFREY, DI; MARRACK, PC				HUGO, P; KAPPLER, JW; GODFREY, DI; MARRACK, PC			A CELL-LINE THAT CAN INDUCE THYMOCYTE POSITIVE SELECTION	NATURE			English	Article							ANTIGEN-PRESENTING ABILITY; THYMIC EPITHELIAL-CELLS; T-CELLS; SELF-RECOGNITION; STROMAL CELL; DIFFERENTIATION; EXPRESSION; APPEARANCE; KINETICS; GROWTH	THE thymus positively selects thymocytes that bear T-cell receptors which recognize antigen presented by self major histocompatibility complex (MHC) proteins1,2. positive selection is usually driven by MHC products on radiation-resistant cortical epithelial cells3-5. It is unknown whether positive selection is mediated by all thymic epithelial cells or by some specialized subsets4. Here we introduce an H-2(b)-expressing thymic epithelial cell line into the thymuses of lethally irradiated H-2k animals reconstituted with H-2b/k F1 BM or fetal liver cells. I-A(b)-restricted T cells are found in these animals, demonstrating that selection occurs on the introduced epithelial cells.	DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	HUGO, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,1400 JACKSON ST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Godfrey, Dale/0000-0002-3009-5472; Marrack, Philippa/0000-0003-1883-3687				BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; Benoist C, 1989, Semin Immunol, V1, P117; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERRIH S, 1985, J IMMUNOL, V135, P1165; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; FISCHER M, 1991, J IMMUNOL, V146, P3452; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; LO D, 1986, J IMMUNOL, V137, P1772; LONGO DL, 1983, J IMMUNOL, V130, P2525; MCDEVITT HO, 1972, J EXP MED, V135, P1259, DOI 10.1084/jem.135.6.1259; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NISHIMURA T, 1990, J IMMUNOL, V145, P4012; PARDOLL D, 1992, CURR OPIN IMMUNOL, V4, P162, DOI 10.1016/0952-7915(92)90006-Z; POTWOROWSKI EF, 1986, IN VITRO CELL DEV B, V22, P557; RANSOM J, 1991, CELL IMMUNOL, V134, P180, DOI 10.1016/0008-8749(91)90341-8; Shortman K, 1990, Semin Immunol, V2, P3; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZLOTNIK A, 1983, J IMMUNOL, V131, P2814	25	102	102	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					679	682		10.1038/360679a0	http://dx.doi.org/10.1038/360679a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465132				2022-12-24	WOS:A1992KD08200058
J	MOLLON, JD; BOWMAKER, JK				MOLLON, JD; BOWMAKER, JK			THE SPATIAL ARRANGEMENT OF CONES IN THE PRIMATE FOVEA	NATURE			English	Article							COLOR-VISION; MACACA-FASCICULARIS; SENSITIVE CONES; WORLD PRIMATE; PIGMENTS	THE retinae of Old World primates contain three classes of light-sensitive cone, which exhibit peak absorption in different spectral regions1-4. But how are the different types of cone arranged in the hexagonal mosaic of the fovea? This question has often been answered with artists' impressions5-7, but never with direct measurements. Staining for antibodies specific to the short-wave photopigment has revealed a sparse, semiregular array of cones8; but nothing is known about the arrangement of the more numerous long- and middle-wave cones. Are they randomly distributed, with chance aggregations of one type, as Hartridge postulated in these columns nearly 50 years ago9,10? Or do they exhibit a regular alternation, recalling the systematic mosaics seen in some non-mammalian species6,11? Or, conversely, is there positive clumping of particular cone types, as might be expected if local patches of cones were descended from a single precursor cell? We have made direct microspectrophotometric measurements of patches of foveal retina from Old World monkeys, and report here that the distribution of long- and middle-wave cones is locally random. These two cone types are present in almost equal numbers, and not in the ratio of 2:1 that has been postulated for the human fovea.	UNIV LONDON, INST OPHTHALMOL, BATH ST, LONDON EC1V 9EL, ENGLAND	University of London; University College London	MOLLON, JD (corresponding author), UNIV CAMBRIDGE, DEPT EXPTL PSYCHOL, CAMBRIDGE CB2 3EB, ENGLAND.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X				AHNELT PK, 1987, J COMP NEUROL, V255, P18, DOI 10.1002/cne.902550103; [Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BOWMAKER JK, 1987, VISION RES, V27, P2101, DOI 10.1016/0042-6989(87)90124-6; BOWMAKER JK, 1991, J EXP BIOL, V156, P1; BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P131, DOI 10.1113/jphysiol.1980.sp013071; CICERONE CM, 1989, VISION RES, V29, P115, DOI 10.1016/0042-6989(89)90178-8; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DEMONASTERIO FM, 1981, SCIENCE, V213, P1278, DOI 10.1126/science.7268439; DOBELLE WH, 1969, SCIENCE, V166, P1508, DOI 10.1126/science.166.3912.1508; HAROSI FI, 1987, J GEN PHYSIOL, V89, P717, DOI 10.1085/jgp.89.5.717; HARTRIDGE H, 1947, PHILOS T ROY SOC B, V232, P519, DOI 10.1098/rstb.1947.0004; HARTRIDGE H, 1946, NATURE, V157, P482, DOI 10.1038/157482b0; Hartridge H, 1944, NATURE, V153, P45, DOI 10.1038/153045a0; Knowles A., 1977, PHOTOBIOLOGY VISION; LIEBMAN PA, 1964, J OPT SOC AM, V54, P1451, DOI 10.1364/JOSA.54.001451; Lythgoe J.N., 1979, ECOLOGY VISION; MARC RE, 1977, SCIENCE, V196, P454, DOI 10.1126/science.403607; MOLLON JD, 1989, J EXP BIOL, V146, P21; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; POKORNY J, 1991, PIGMENTS PERCEPTION; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; WALRAVEN PL, 1974, VISION RES, V14, P1339, DOI 10.1016/0042-6989(74)90007-8; WILLIAMS DR, 1991, PIGMENTS PERCEPTION	24	114	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					677	679		10.1038/360677a0	http://dx.doi.org/10.1038/360677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465131				2022-12-24	WOS:A1992KD08200057
J	BARRETTCONNOR, E; HOLBROOK, TL				BARRETTCONNOR, E; HOLBROOK, TL			SEX-DIFFERENCES IN OSTEOPOROSIS IN OLDER ADULTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; ISCHEMIC-HEART-DISEASE; POSTMENOPAUSAL WOMEN; RISK-FACTORS; MEN; MASS; CALCIUM; STEROIDS; HORMONES; PREMENOPAUSAL	Objective.-To describe the association of non-insulin-dependent diabetes mellitus (NIDDM) with bone mineral density (BMD). Design.-A survey of men and women from an established epidemiologic cohort who were separately screened for diabetes by oral glucose tolerance test between 1984 and 1987 and for osteopenia by BMD measured in 1988-1989. Setting.-A community-based population of older adults, Rancho Bernardo, Calif. Participants.-The first 627 consecutively seen white men and women aged 55 to 88 years. Main Outcome Measures.-Bone density measured by single photon absorptiometry at the ultradistal wrist and midradius and by dual x-ray absorptiometry at the femoral neck and lumbar spine. Main Results.-Among the 236 men and 391 women, whose average age was 72 years, 41 men and 39 women had NIDDM, 56 men and 110 women had impaired glucose tolerance, and 139 men and 242 women had normal glucose tolerance. Men with diabetes had BMD levels similar to those men with normal glucose tolerance, whereas women with diabetes had significantly higher BMD levels at all sites than women with normal glucose tolerance. The increased bone density in diabetic women was unexplained by age, obesity, cigarette smoking, alcohol intake, regular physical activity, and the use of diuretics and estrogen. The multiply adjusted mean BMD in women with NIDDM compared with normoglycemic women was 0.600 g/cm2 vs 0.548 g/cm2 at the midradius; 0.265 g/cm2 vs 0.230 g/cm2 at the ultradistal wrist; 0.654 g/cm2 vs 0.610 g/cm2 at the femoral neck; and 0.962 g/cm2 vs 0.859 g/cm2 at the spine. The sex differences were unexplained by survivor bias, prior obesity, or duration of diabetes. Differences were seen in women (but not men) whose diabetes was first detected at the screening evaluation, ie, before drug or dietary treatment. Similarly, in women (but not men) without diabetes increasing BMD levels at all four sites were associated with increasing postchallenge glucose levels independent of age and body mass index. Conclusions.-Older women with NIDDM or hyperglycemia had better BMD than women with normal glucose tolerance, independent of differences in obesity and many other risk factors. No differences in bone density by diabetic status were observed in men. We hypothesize that the sex differences may be explained by the greater androgenicity reported in women with hyperglycemic and hyperinsulinemic conditions.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,9500 GILLMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; ANDO S, 1984, J ENDOCRINOL INVEST, V7, P21, DOI 10.1007/BF03348370; AUWERX J, 1988, DIABETES, V37, P8, DOI 10.2337/diabetes.37.1.8; BARRETTCONNOR E, 1990, AM J EPIDEMIOL, V132, P895, DOI 10.1093/oxfordjournals.aje.a115732; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BENNETT AE, 1984, J CLIN ENDOCR METAB, V59, P70; BRODY S, 1987, ACTA OBSTET GYN SCAN, V66, P357, DOI 10.3109/00016348709103653; DAVIDSON BJ, 1983, OBSTET GYNECOL, V61, P275; DELEEUW I, 1977, DIABETES, V26, P1130, DOI 10.2337/diabetes.26.12.1130; DEUTSCH S, 1987, INT J GYNECOL OBSTET, V25, P217, DOI 10.1016/0020-7292(87)90238-4; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FORESTA C, 1984, HORM RES, V19, P18, DOI 10.1159/000179855; FRANCIS RM, 1986, BONE, V7, P261, DOI 10.1016/8756-3282(86)90205-X; GARG A, 1990, J CLIN ENDOCR METAB, V70, P1007, DOI 10.1210/jcem-70-4-1007; GIACCA A, 1988, BONE, V9, P29, DOI 10.1016/8756-3282(88)90024-5; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; HAFFNER SM, 1988, METABOLISM, V37, P683, DOI 10.1016/0026-0495(88)90091-1; HEATH H, 1979, J CLIN ENDOCR METAB, V49, P462, DOI 10.1210/jcem-49-3-462; HEATH H, 1980, NEW ENGL J MED, V303, P567, DOI 10.1056/NEJM198009043031008; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; ISAIA G, 1987, ACTA DIABETOL LAT, V24, P305, DOI 10.1007/BF02742962; JOHNSTON CC, 1985, METABOLISM, V34, P544, DOI 10.1016/0026-0495(85)90192-1; KELLY PJ, 1990, BRIT MED J, V300, P1361, DOI 10.1136/bmj.300.6736.1361; KHAW KT, 1991, CLIN SCI, V80, P199, DOI 10.1042/cs0800199; Kissebah AHK, 1985, METABOLIC COMPLICATI, P115; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; LEVY J, 1986, CALCIFIED TISSUE INT, V39, P316, DOI 10.1007/BF02555197; LICHTENSTEIN MJ, 1987, AM J EPIDEMIOL, V126, P647, DOI 10.1093/oxfordjournals.aje.a114704; MARSHALL DH, 1977, BRIT MED J, V2, P1177, DOI 10.1136/bmj.2.6096.1177; MCNAIR P, 1988, DAN MED BULL, V35, P109; MEEMA HE, 1967, CAN MED ASSOC J, V96, P132; MEIER DE, 1987, J AM GERIATR SOC, V35, P189, DOI 10.1111/j.1532-5415.1987.tb02308.x; PEDRAZZONI M, 1989, CALCIFIED TISSUE INT, V45, P331, DOI 10.1007/BF02556002; RICO H, 1989, CALCIFIED TISSUE INT, V45, P71, DOI 10.1007/BF02561404; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RINGE JD, 1976, AM J ROENTGENOL, V126, P1300, DOI 10.2214/ajr.126.6.1300; SCHEIDTNAVE C, 1991, MAY SAN DIEG EP RES; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SELBY PL, 1988, DIABETIC MED, V5, P423, DOI 10.1111/j.1464-5491.1988.tb01021.x; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SORENSEN OH, 1986, DIABETES 1985, P754; STANLEY HL, 1991, J AM GERIATR SOC, V39, P766, DOI 10.1111/j.1532-5415.1991.tb02698.x; STEINBERG KK, 1989, J CLIN ENDOCR METAB, V69, P533, DOI 10.1210/jcem-69-3-533; Verstraeten A, 1991, CLIN ORTHOP RELAT R, V264, P169; WEINSTOCK RS, 1989, J BONE MINER RES, V4, P97; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WINGARD D L, 1990, Diabetes Care, V13, P3; World Health Organization, 1985, DIAB MELL REP WHO ST, V727	49	147	155	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3333	3337						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1453525				2022-12-24	WOS:A1992KB73200025
J	ESKOLA, J; TAKALA, AK; KELA, E; PEKKANEN, E; KALLIOKOSKI, R; LEINONEN, M				ESKOLA, J; TAKALA, AK; KELA, E; PEKKANEN, E; KALLIOKOSKI, R; LEINONEN, M			EPIDEMIOLOGY OF INVASIVE PNEUMOCOCCAL INFECTIONS IN CHILDREN IN FINLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; STREPTOCOCCUS-PNEUMONIAE; ANTIBODY-RESPONSE; CONJUGATE VACCINE; B DISEASE; CHARLESTON COUNTY; SOUTH-CAROLINA; NEW-GUINEA; BACTEREMIA; INFANTS	Objective.-To study the epidemiologic characteristics of invasive infections in children caused by Streptococcus pneumoniae to provide background data for vaccination programs. Design.-A nationwide laboratory-based prospective surveillance of all invasive pneumococcal infections in children during 1985 through 1989. Setting.-A network of all microbiologic laboratories and pediatric wards in Finland. Patients.-Children aged 0 to 15 years who were admitted to a hospital with S pneumoniae isolated from blood, cerebrospinal fluid, or deep aspirate sample. Results.-Four hundred fifty-two invasive pneumococcal infections were diagnosed in 1985 through 1989. The annual incidence rate was 8.9 per 100 000 children less than 16 years of age (24.2 per 100 000 among children less than 5 years of age and 45.3 per 100 000 among those less than 2 years of age). The most common clinical entities were bacteremia without focus (310 cases), pneumonia (66 cases), and meningitis (51 cases), with other focal infections seen in 25 cases. The pneumococcal groups/types 14, 6, 19, 7, 18, and 23 comprised 78% of all invasive infections. Conclusions.-Streptococcus pneumoniae is a common cause of invasive infections in children in Finland. A pneumococcal conjugate vaccine containing the six most common groups/types could prevent up to 70% of invasive pneumococcal infections of children in Finland if fully protective in infancy.	NATL PUBL HLTH INST,DEPT BACTERIAL & RESP INFECT,SF-00280 HELSINKI 28,FINLAND	Finland National Institute for Health & Welfare	ESKOLA, J (corresponding author), NATL PUBL HLTH INST,DEPT INFECT DIS EPIDEMIOL,SF-00280 HELSINKI 28,FINLAND.							ANDERSEN AH, 1989, IEEE T MED IMAGING, V8, P50, DOI 10.1109/42.20361; BARKER J, 1989, J INFECT DIS, V159, P348, DOI 10.1093/infdis/159.2.348; BARRY MA, 1984, J INFECT DIS, V149, P449, DOI 10.1093/infdis/149.3.449; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRILES DE, 1992, INFECT IMMUN, V60, P111, DOI 10.1128/IAI.60.1.111-116.1992; BURKE JP, 1971, AM J DIS CHILD, V121, P353, DOI 10.1001/archpedi.1971.02100150127021; BURMAN LA, 1985, REV INFECT DIS, V7, P133; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; ENGELHARD D, 1991, 31ST INT C ANT AG CH; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FATTOM A, 1990, INFECT IMMUN, V58, P2309, DOI 10.1128/IAI.58.7.2309-2312.1990; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; GUIRGUIS N, 1983, B WORLD HEALTH ORGAN, V61, P517; HANSMAN D, 1977, AUST NZ J MED, V7, P267, DOI 10.1111/j.1445-5994.1977.tb03684.x; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009; LEINONEN M, 1986, PEDIATR INFECT DIS J, V5, P39, DOI 10.1097/00006454-198601000-00008; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MURPHY TV, 1991, 31ST INT C ANT AG CH; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016; ONYEMELUKWE GC, 1982, J INFECTION, V5, P157, DOI 10.1016/S0163-4453(82)91772-8; RILEY ID, 1986, LANCET, V2, P877; RILEY ID, 1977, LANCET, V1, P1338; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; SARNAIK S, 1990, PEDIATR INFECT DIS J, V9, P181, DOI 10.1097/00006454-199003000-00007; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; 1989, PEDIATR INFECT DIS J, V8, P21; 1985, NEW VACCINE DEV ESTA, V2, P44	36	201	214	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3323	3327		10.1001/jama.268.23.3323	http://dx.doi.org/10.1001/jama.268.23.3323			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1453524				2022-12-24	WOS:A1992KB73200023
J	GINSBURG, KS; LIANG, MH; NEWCOMER, L; GOLDHABER, SZ; SCHUR, PH; HENNEKENS, CH; STAMPFER, MJ				GINSBURG, KS; LIANG, MH; NEWCOMER, L; GOLDHABER, SZ; SCHUR, PH; HENNEKENS, CH; STAMPFER, MJ			ANTICARDIOLIPIN ANTIBODIES AND THE RISK FOR ISCHEMIC STROKE AND VENOUS THROMBOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIBODIES, ANTICARDIOLIPIN; CEREBROVASCULAR DISORDERS; THROMBOPHLEBITIS; PULMONARY EMBOLISM; LUPUS ERYTHEMATOSUS, SYSTEMIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-CARDIOLIPIN ANTIBODIES; PRIMARY ANTIPHOSPHOLIPID SYNDROME; RETINAL VASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; ANTICOAGULANT; ASSOCIATION; SLE	Objective: To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and venous thrombosis in healthy adult men. Design: A nested, case-control study in a prospective cohort. Setting. A nationwide study of physicians. Participants: The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22 071 male physicians. At entry, 68% of the participants submitted plasma samples that were subsequently frozen at -80-degrees-C. During 60.2 months of follow-up, follow-up for nonfatal outcomes was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus. Measurements: Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay. The mean anticardiolipin antibody titers of the case patients in the two diagnostic groups (ischemic stroke; venous thrombosis or pulmonary embolus) were compared with those of the control groups, and relative risks were calculated for patients in increasing percentile categories of anticardiolipin antibodies by conditional logistic regression. Results: The anticardiolipin antibody titers were higher in case patients with deep venous thrombosis and pulmonary embolus than in their matched controls (P = 0.01). Persons with anticardiolipin antibody titers above the 95th percentile had a relative risk for developing deep venous thrombosis or pulmonary embolus of 5.3 (95% Cl, 1.55 to 18.3; P = 0.01). The anticardiolipin antibody titers in case patients with ischemic stroke and controls were not significantly different (P > 0.2), and no clear trend of higher risks among those with elevated levels of anticardiolipin antibodies was observed. Conclusion: An anticardiolipin antibody level above the 95th percentile is an important risk factor for deep venous thrombosis or pulmonary embolus but not for ischemic stroke in healthy adult men.	BRIGHAM & WOMENS HOSP, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital					NCI NIH HHS [CA42182] Funding Source: Medline; NIAMS NIH HHS [AR36308, AR07530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308, T32AR007530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; [Anonymous], 1988, NEW ENGL J MED; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1989, AM J MED, V86, P391, DOI 10.1016/0002-9343(89)90335-5; ASHERSON RA, 1986, ARTHRITIS RHEUM, V29, P1292, DOI 10.1002/art.1780291019; ASHERSON RA, 1989, Q J MED, V73, P1103; ASHERSON RA, 1987, ANN RHEUM DIS, V46, P605, DOI 10.1136/ard.46.8.605; ASHERSON RA, 1989, ANN RHEUM DIS, V48, P358, DOI 10.1136/ard.48.5.358; BOEY ML, 1983, BMJ-BRIT MED J, V287, P1021, DOI 10.1136/bmj.287.6398.1021; CARRERAS LO, 1981, LANCET, V1, P244; COLACO CB, 1983, ANN RHEUM DIS, V42, P228; COLACO CB, 1985, CLIN EXP IMMUNOL, V59, P449; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COON WW, 1976, SURG GYNECOL OBSTET, V143, P385; COOPER RC, 1989, BRIT J RHEUMATOL, V28, P379; COULL BM, 1990, STROKE, V21, P1370, DOI 10.1161/01.STR.21.9.1370; CRONIN ME, 1988, J RHEUMATOL, V15, P795; DECATERINA R, 1990, AM J CARDIOL, V65, P922, DOI 10.1016/0002-9149(90)91439-D; DERKSEN RHWM, 1986, ARTHRITIS RHEUM, V29, P1295, DOI 10.1002/art.1780291021; DONALDSON MC, 1990, J VASC SURG, V11, P825, DOI 10.1067/mva.1990.20120; DREW P, 1987, ANN RHEUM DIS, V46, P612, DOI 10.1136/ard.46.8.612; FORT JG, 1987, ARTHRITIS RHEUM, V30, P752, DOI 10.1002/art.1780300705; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HALL S, 1984, J RHEUMATOL, V11, P846; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; HARRIS EN, 1985, J CLIN LAB IMMUNOL, V16, P1; HARRIS EN, 1988, ANNU REV MED, V39, P261, DOI 10.1146/annurev.med.39.1.261; HASSELAAR P, 1990, J RHEUMATOL, V17, P186; ISENBERG DA, 1986, MEDICINE, V65, P46, DOI 10.1097/00005792-198601000-00003; KALUNIAN KC, 1988, AM J MED, V85, P602; KHAMASHTA MA, 1988, ANN RHEUM DIS, V47, P849, DOI 10.1136/ard.47.10.849; KLEMP P, 1988, CLIN EXP IMMUNOL, V74, P254; KUSHNER M, 1989, STROKE, V20, P225, DOI 10.1161/01.STR.20.2.225; LAVALLE C, 1990, J RHEUMATOL, V17, P34; LEVINE SR, 1987, ARCH NEUROL-CHICAGO, V44, P876, DOI 10.1001/archneur.1987.00520200078024; LOCKSHIN M D, 1991, Current Opinion in Rheumatology, V3, P797, DOI 10.1097/00002281-199110000-00008; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MCNEIL HP, 1990, CLIN EXP RHEUMATOL, V8, P525; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MEYER O, 1987, J RHEUMATOL, V14, P502; MORTON KE, 1986, LANCET, V2, P1353; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; OUT HJ, 1989, ANN RHEUM DIS, V48, P1023, DOI 10.1136/ard.48.12.1023; POPE JM, 1991, AM J MED, V90, P299, DOI 10.1016/0002-9343(91)90569-J; RUIZARGUELLES GJ, 1989, J RHEUMATOL, V16, P381; SAMMARITANO LR, 1990, SEMIN ARTHRITIS RHEU, V20, P81, DOI 10.1016/0049-0172(90)90021-7; SLETNES KE, 1992, LANCET, V339, P451, DOI 10.1016/0140-6736(92)91057-F; STURFELT G, 1987, ARTHRITIS RHEUM, V30, P382, DOI 10.1002/art.1780300404	52	453	464	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					997	1002		10.7326/0003-4819-117-12-997	http://dx.doi.org/10.7326/0003-4819-117-12-997			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443986				2022-12-24	WOS:A1992KB98000004
J	THEOBALD, M; NIERLE, T; BUNJES, D; ARNOLD, R; HEIMPEL, H				THEOBALD, M; NIERLE, T; BUNJES, D; ARNOLD, R; HEIMPEL, H			HOST-SPECIFIC INTERLEUKIN-2-SECRETING DONOR T-CELL PRECURSORS AS PREDICTORS OF ACUTE GRAFT-VERSUS-HOST DISEASE IN BONE-MARROW TRANSPLANTATION BETWEEN HLA-IDENTICAL SIBLINGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; LYMPHOCYTES-T; EFFECTOR MECHANISMS; FREQUENCY-ANALYSIS; INVITRO; HELPER; INDUCTION; LEUKEMIA; INVIVO; SKIN	Background. Acute graft-versus-host disease (GVHD) is a serious complication of allogeneic bone marrow transplantation from an HLA-identical sibling. There is no practical test before transplantation that gives sufficient information to predict the degree of allogeneic reactivity between HLA-identical siblings. Methods. We determined the frequency with which host-specific interleukin-2-secreting donor T-cell precursors occurred in 16 consecutive pairs of HLA-identical siblings before they underwent marrow grafting. The results were correlated with the development of acute GVHD after transplantation. Results. High frequencies of host-specific T-cell precursors (greater-than-or-equal-to 1 per 100,000) were detectable before transplantation in eight donors whose siblings later had severe (grade II or III) acute GVHD. Among the donors to eight patients with mild (grade 0 or I) acute GVHD, low frequencies (<1 per 100,000) were found. Conclusions. Analysis of the frequency of such cells before transplantation may be a useful predictor of severe acute GVHD in allogeneic bone marrow transplantation between HLA-identical siblings. It is possible that the patients at risk for serious acute GVHD after marrow grafting may benefit from some alternative form of immunosuppressive therapy.	UNIV HOSP ULM, DEPT INTERNAL MED 3, BONE MARROW TRANSPLANTAT UNIT, ULM, GERMANY	Ulm University								ALDACCAK R, 1990, LEUKEMIA, V4, P222; CHAMPLIN R, 1990, BLOOD, V76, P418; CLEVELAND MG, 1988, J IMMUNOL, V141, P3349; DEBUEGER M, 1991, EUR J IMMUNOL, V21, P2839, DOI 10.1002/eji.1830211127; DELMONTE L, 1982, TRANSPLANTATION, V34, P100; EIERMANN TH, 1991, TISSUE ANTIGENS, V38, P193; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HAMILTON BL, 1987, J IMMUNOL, V139, P2511; Hansen J A, 1984, Prog Clin Biol Res, V149, P299; HOLLER E, 1990, BLOOD, V75, P1011; JOHNSEN HE, 1992, SCAND J IMMUNOL, V35, P353, DOI 10.1111/j.1365-3083.1992.tb02868.x; KAMINSKI E, 1988, BONE MARROW TRANSPL, V3, P149; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; KORNGOLD R, 1987, TRANSPLANTATION, V44, P335, DOI 10.1097/00007890-198709000-00002; MCCARTHY PL, 1991, BLOOD, V78, P1915; PERREAULT C, 1990, BLOOD, V76, P1269; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; PIGUET PF, 1990, GRAFT VS HOST DISEAS, P255; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; SPRENT J, 1986, IMMUNOL REV, V91, P195, DOI 10.1111/j.1600-065X.1986.tb01489.x; STORB R, 1989, BLOOD, V73, P1729; SYMINGTON FW, 1990, TRANSPLANTATION, V50, P518, DOI 10.1097/00007890-199009000-00033; TASWELL C, 1981, J IMMUNOL, V126, P1614; THEOBALD M, 1989, J IMMUNOL METHODS, V121, P19, DOI 10.1016/0022-1759(89)90415-8; THEOBALD M, 1990, TRANSPLANTATION, V50, P850, DOI 10.1097/00007890-199011000-00021; TRUITT RL, 1991, BONE MARROW TRANSPL, V8, P51; VANELS CACM, 1990, HUM IMMUNOL, V28, P39, DOI 10.1016/0198-8859(90)90101-T; VANELS CACM, 1990, TRANSPLANTATION, V50, P67, DOI 10.1097/00007890-199007000-00012; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; VOGELSANG GB, 1985, NEW ENGL J MED, V313, P645, DOI 10.1056/NEJM198509123131101; Waldmann H., 1979, LIMITING DILUTION AN	33	162	165	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1613	1617		10.1056/NEJM199212033272301	http://dx.doi.org/10.1056/NEJM199212033272301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1435898				2022-12-24	WOS:A1992KA26000001
J	MADHANI, HD; GUTHRIE, C				MADHANI, HD; GUTHRIE, C			A NOVEL BASE-PAIRING INTERACTION BETWEEN U2 AND U6 SNRNAS SUGGESTS A MECHANISM FOR THE CATALYTIC ACTIVATION OF THE SPLICEOSOME	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; GROUP-II INTRON; RIBONUCLEOPROTEIN-PARTICLES; SACCHAROMYCES-CEREVISIAE; SPLICING REACTION; SITE SELECTION; YEAST; U4; MUTATION	Prior to the chemical steps of mRNA splicing, the extensive base-pairing interaction between the U4 and U6 spliceosomal snRNAs is disrupted. Here, we use a mutational analysis in yeast to demonstrate a conserved base-pairing interaction between the U6 and U2 snRNAs that is mutually exclusive with the U4-U6 interaction. In this novel pairing, conserved sequences in U6 interact with a sequence in U2 that is immediately upstream of the branch point recognition region. Remarkably, the residues in U6 that can be consequently juxtaposed with the intron substrate include those that have been proposed previously to be catalytic. Both the first and second steps of splicing are inhibited when this base-paired structure is mutated. These observations, together with the high conservation of the U2-U6 structure, lead us to propose that it might be a component of the spliceosomal active site.			MADHANI, HD (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Madhani, Hiten/0000-0001-7400-6657	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021119, R01GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BORDONNE R, 1992, NUCLEIC ACIDS RES, V20, P479, DOI 10.1093/nar/20.3.479; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMM J, 1989, EMBO J, V8, P4179, DOI 10.1002/j.1460-2075.1989.tb08603.x; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KELLER EB, 1985, NUCLEIC ACIDS RES, V13, P4971, DOI 10.1093/nar/13.13.4971; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	63	383	393	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					803	817		10.1016/0092-8674(92)90556-R	http://dx.doi.org/10.1016/0092-8674(92)90556-R			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423631				2022-12-24	WOS:A1992JZ63300010
J	ABOULELA, F; MURCHIE, AIH; LILLEY, DMJ				ABOULELA, F; MURCHIE, AIH; LILLEY, DMJ			NMR-STUDY OF PARALLEL-STRANDED TETRAPLEX FORMATION BY THE HEXADEOXYNUCLEOTIDE D(TG4T)	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TELOMERIC DNA; PROTON RESONANCES; OLIGONUCLEOTIDES; SPECTROSCOPY; ASSIGNMENT; MISMATCH	MULTISTRANDED DNA structures based upon guanine association have been proposed to be important in the structure of chromosome telomeres1 and in immunoglobulin class switching2. Nucleic acids containing runs of guanine bases form a number of structures in vitro3-6, including fold-back structures (Fig. 1a)7-9 and parallel-stranded quadruplex structures in DNA2,10 and RNA11. The features of fold-back structures have now been determined at high-resolution12-14. The different structures are probably based on a tetrad of hydrogen-bonded guanine bases (Fig. 1b), with buffer conditions and sequence effects mediating isomerization between the different forms4,15-18. Here we use NMR spectroscopy to investigate the solution structure of the complex formed by the hexadeoxynucleotide d(TG4T) in the presence of sodium ions. We have observed the formation of a parallel-stranded quadruplex containing hydrogen-bonded tetrads of guanine. The parallel-stranded form differs significantly from the fold-back form, with individual nucleotide conformations being closer to those of B-form DNA.			ABOULELA, F (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.		aboul-ela, fareed/C-2887-2011					BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FAZEKERLY GV, 1984, NUCLEIC ACIDS RES, V12, P8269; FORSTER M, 1989, J MOL GRAPHICS, V7, P196, DOI 10.1016/0263-7855(89)80002-5; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LANE AN, 1991, BIOCHEM J, V279, P269, DOI 10.1042/bj2790269; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; LU M, 1992, BIOCHEMISTRY-US, V31, P2455, DOI 10.1021/bi00124a003; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P5263, DOI 10.1093/nar/19.19.5263; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PINNAVAIA TJ, 1975, J AM CHEM SOC, V97, P7198, DOI 10.1021/ja00857a059; RINKEL LJ, 1987, J BIOMOL STRUCT DYN, V4, P621, DOI 10.1080/07391102.1987.10507665; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SKLENAR V, 1986, FEBS LETT, V208, P94, DOI 10.1016/0014-5793(86)81539-3; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, J MOL BIOL, V222, P819, DOI 10.1016/0022-2836(91)90513-6; WANG Y, 1992, NATURE, V356, P126; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	31	193	200	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					280	282		10.1038/360280a0	http://dx.doi.org/10.1038/360280a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436110				2022-12-24	WOS:A1992JY96000059
J	CANNONALBRIGHT, LA; GOLDGAR, DE; MEYER, LJ; LEWIS, CM; ANDERSON, DE; FOUNTAIN, JW; HEGI, ME; WISEMAN, RW; PETTY, EM; BALE, AE; OLOPADE, OI; DIAZ, MO; KWIATKOWSKI, DJ; PIEPKORN, MW; ZONE, JJ; SKOLNICK, MH				CANNONALBRIGHT, LA; GOLDGAR, DE; MEYER, LJ; LEWIS, CM; ANDERSON, DE; FOUNTAIN, JW; HEGI, ME; WISEMAN, RW; PETTY, EM; BALE, AE; OLOPADE, OI; DIAZ, MO; KWIATKOWSKI, DJ; PIEPKORN, MW; ZONE, JJ; SKOLNICK, MH			ASSIGNMENT OF A LOCUS FOR FAMILIAL MELANOMA, MLM, TO CHROMOSOME-9P13-P22	SCIENCE			English	Article							CUTANEOUS MALIGNANT-MELANOMA; DYSPLASTIC NEVUS SYNDROME; CYTOGENETIC ANALYSIS; SYNDROME DNS; HIGH-RISK; INHERITANCE; LINKAGE; CANCER; UPDATE	Linkage analysis of ten Utah kindreds and one Texas kindred with multiple cases of cutaneous malignant melanoma (CMM) provided evidence that a locus for familial melanoma susceptibility is in the chromosomal region 9p13-p22. The genetic markers analyzed reside in a candidate region on chromosome 9p21, previously implicated by the presence of homozygous deletions in melanoma tumors and by the presence of a germline deletion in an individual with eight independent melanomas. Multipoint linkage analysis was performed between the familial melanoma susceptibility locus (MLM) and two short tandem repeat markers, D9S126 and the interferon-alpha (IFNA) gene, which reside in the region of somatic loss in melanoma tumors. An analysis incorporating a partially penetrant dominant melanoma susceptibility locus places MLM near IFNA and D9S126 with a maximum location score of 12.71. Therefore, the region frequently deleted in melanoma tumors on 9p21 presumably contains a locus that plays a critical role in predisposition to familial melanoma.	UNIV UTAH,SCH MED,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV CHICAGO,MED CTR,DEPT MED,CHICAGO,IL 60637; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	Utah System of Higher Education; University of Utah; University of Texas System; UTMD Anderson Cancer Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Yale University; University of Chicago; University of Chicago Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	CANNONALBRIGHT, LA (corresponding author), UNIV UTAH,SCH MED,DEPT INTERNAL MED,SALT LAKE CITY,UT 84112, USA.		Lewis, Cathryn/M-8766-2019; Hegi, Monika/O-4796-2015; Lewis, Cathryn M/A-5225-2010	Lewis, Cathryn/0000-0002-8249-8476; Hegi, Monika/0000-0003-0855-6495; Lewis, Cathryn M/0000-0002-8249-8476; albright, lisa/0000-0003-2602-3668	NATIONAL CANCER INSTITUTE [P30CA042014, P01CA048711] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42014, CA 48711] Funding Source: Medline; NCRR NIH HHS [RR 00064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON DE, 1991, ANTICANCER RES, V11, P433; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BALE SJ, 1989, J NATL CANCER I, V81, P70, DOI 10.1093/jnci/81.1.70; CANNONALBRIGHT LA, 1990, AM J HUM GENET, V46, P912; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EASTON D, 1990, CANCER SURV, V9, P395; EASTON DF, COMMUNICATION; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, GENOMICS, V14, P105, DOI 10.1016/S0888-7543(05)80290-3; FOUNTAIN JW, IN PRESS P NATL ACAD; FOUNTAIN JW, 1991, AM J HUM GENET, V49, P223; FREY C, 1991, J NATL CANCER I, V83, P170; GOLDGAR DE, 1991, J NATL CANCER I, V83, P1726, DOI 10.1093/jnci/83.23.1726; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; Greene MH., 1979, HEREDITARY VARIANT M; GRUIS NA, 1990, NEW ENGL J MED, V322, P853; HAPPLE R, 1982, J AM ACAD DERMATOL, V6, P540, DOI 10.1016/S0190-9622(82)80369-1; Hayward N., COMMUNICATION; JONASSON J, 1977, J CELL SCI, V24, P217; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; KWIATKOWSKI DJ, IN PRESS HUM MOL GEN; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; MACCLUER JW, 1992, CYTOGENET CELL GENET, V59, P148; NANCARROW DJ, 1992, GENOMICS, V12, P18, DOI 10.1016/0888-7543(92)90401-D; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1992, CANCER RES, V52, P2523; OLOPADE OI, 1991, P AM ASSOC CANC RES, V52, P1814; OLOPADE OI, 1990, P AM ASSOC CANC RES, V31, P1883; OTT J, 1985, ANAL HUMAN GENETIC L; PASCOE L, 1987, AM J HUM GENET, V40, P464; PETTY EM, UNPUB; PETTY EM, IN PRESS AM J MED GE; RODERICK TH, 1984, MOUSE NEWS LETT, V71, P8; Skolnick M, 1980, BANBURY REPORT, P285; SOBER AJ, 1991, DERMATOL CLIN, V9, P617; SWERDLOW AJ, 1984, LANCET, V2, P168; TRAUPE H, 1989, AM J MED GENET, V32, P155, DOI 10.1002/ajmg.1320320203; VANHAERINGEN A, 1989, GENOMICS, V5, P61, DOI 10.1016/0888-7543(89)90086-4; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEEKS DE, 1992, AM J HUM GENET, V50, P859; WISEMAN RW, UNPUB; 1992, JAMA-J AM MED ASSOC, V268, P1314; 1988, 1987 ANN CANCER STAT; 1988, CANCER UTAH STATISTI	51	482	500	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1148	1152		10.1126/science.1439824	http://dx.doi.org/10.1126/science.1439824			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439824				2022-12-24	WOS:A1992JX85200032
J	CATANIA, JA; COATES, TJ; STALL, R; TURNER, H; PETERSON, J; HEARST, N; DOLCINI, MM; HUDES, E; GAGNON, J; WILEY, J; GROVES, R				CATANIA, JA; COATES, TJ; STALL, R; TURNER, H; PETERSON, J; HEARST, N; DOLCINI, MM; HUDES, E; GAGNON, J; WILEY, J; GROVES, R			PREVALENCE OF AIDS-RELATED RISK-FACTORS AND CONDOM USE IN THE UNITED-STATES	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; SEXUAL-BEHAVIOR; TRANSMISSION; WOMEN; PREVENTION; FREQUENCY; PROMOTION; BIAS	A national probability survey of human immunodeficiency virus (HIV)-related risk factors among the general heterosexual population, the National AIDS (acquired immunodeficiency syndrome) Behavioral Surveys, has obtained data from 10,630 respondents. Data are presented on the prevalence of HIV-related risks in the general heterosexual population, on the distribution of the three largest risk groups across social strata, and on the prevalence and distribution of condom use among heterosexuals reporting a risk factor. Between 15 and 31 percent of heterosexuals nationally and 20 and 41 percent in cities with a high prevalence of AIDS reported an HIV risk factor. Condom use was relatively low. Only 17 percent of those with multiple sexual partners, 12.6 percent of those with risky sexual partners, and 10.8 percent of untested transfusion recipients used condoms all the time. Overall, the results suggest that current HIV prevention programs have, to a very limited extent, reached those heterosexuals with multiple sexual partners but have failed to reach many other groups of the heterosexual population at risk for HIV. New public health strategies may be needed for these specific risk groups.	UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA; UNIV NEW HAMPSHIRE, DEPT SOCIOL & ANTHROPOL, DURHAM, NH 03824 USA; SUNY STONY BROOK, DEPT SOCIOL, STONY BROOK, NY 11794 USA; UNIV CALIF BERKELEY, SURVEY RES CTR, BERKELEY, CA 94720 USA; UNIV MICHIGAN, DEPT SOCIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, INST SOCIAL RES, ANN ARBOR, MI 48109 USA; US BUR CENSUS, WASHINGTON, DC 20233 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System Of New Hampshire; University of New Hampshire; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Berkeley; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	CATANIA, JA (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046240, R01MH043892] Funding Source: NIH RePORTER; NIMH NIH HHS [MH43892, MH46240] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTER MJ, 1986, JAMA-J AM MED ASSOC, V256, P1307, DOI 10.1001/jama.256.10.1307; BAJOS N, 1991, SEXUAL BEHAVIOR FRAN, P405; BRADBURN NM, 1979, IMPROVING INTERVIEW, V42; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; CATANIA JA, 1990, EVAL PROGRAM PLANN, V13, P19, DOI 10.1016/0149-7189(90)90005-H; CATANIA JA, 1989, GERONTOLOGIST, V29, P373, DOI 10.1093/geront/29.3.373; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CATANIA JA, UNPUB; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P565; COATES T, 1990, AIDS 2ND DECADE; COATES T, 1989, 1989 AIDS CLIN REV; DONEGAN E, 1988, JAMA-J AM MED ASSOC, V260, P922; ECHENBERG D, 1985, MMWR-MORBID MORTAL W, V34, P573; FELDBLUM PJ, 1991, AIDS, V5, P1265, DOI 10.1097/00002030-199110000-00020; Fowler F. J., 1988, SURVEY RES METHODS; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; GOEDERT JJ, 1984, LANCET, V2, P711; GUYDISH J, 1991, PREVENTING AIDS DRUG, P28; GUYDISH JR, 1990, AM J PUBLIC HEALTH, V80, P995, DOI 10.2105/AJPH.80.8.995; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HANNAN J, 1991, HEMOPHILIA HIV RISK; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HINGSON R, 1989, PREV MED, V18, P806, DOI 10.1016/0091-7435(89)90016-9; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KANOUSE D, 1991, AIDS RELATED KNOWLED; KEETER S, 1988, AM J PREV MED, V4, P146, DOI 10.1016/S0749-3797(18)31187-5; KINSEY AC, 1953, SEXUAL BEHAVIOR HUMA; LANGE WR, 1988, AM J PUBLIC HEALTH, V78, P443, DOI 10.2105/AJPH.78.4.443; LAVRAKAS PJ, 1987, TELEPHONE SURVEY MET; LINDENBAUM S, 1991, EVALUATING AIDS PREV, P223; MCQUEEN D, 1989, STUDY LIFESTYLE HLTH; MILLER HG, 1990, AIDS 2 DECADE; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; PADIAN N, 1990, CONRAD W S, P25; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SHELTON JD, 1990, CONRAD W S, P327; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; SORENSEN J, 1991, PREVENTING AIDS DRUG, P62; STALL R, 1989, AIDS AGING SOC WHAT, P77; SYRJANEN K, 1984, BRIT J VENER DIS, V60, P243; THORNBERRY OT, 1988, WILEY S PRO, P25; TURNER CF, 1989, AIDS SEXUAL BEHAVIOR; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WATKINS JD, 1988, REPORT PRESIDENTIAL; WEDDINGTON W, 1990, MMWR-MORBID MORTAL W, V39, P274; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; 1991, HIV AIDS SURVEILLANC; 1982, COUNCIL AM SURVEY RE	49	273	274	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1101	1106		10.1126/science.1439818	http://dx.doi.org/10.1126/science.1439818			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439818				2022-12-24	WOS:A1992JX85200018
J	CHAN, AC; IWASHIMA, M; TURCK, CW; WEISS, A				CHAN, AC; IWASHIMA, M; TURCK, CW; WEISS, A			ZAP-70 - A 70 KD PROTEIN-TYROSINE KINASE THAT ASSOCIATES WITH THE TCR ZETA-CHAIN	CELL			English	Article							CELL ANTIGEN RECEPTOR; AMINO-ACID SEQUENCE; T-CELL; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; ETA-CHAIN; PHYSICAL ASSOCIATION; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; GAMMA-CHAIN	Protein-tyrosine kinases (PTKs) play an integral role in T cell activation. Stimulation of the T cell antigen receptor (TCR) results in tyrosine phosphorylation of a number of cellular substrates. One of these is the TCR zeta chain, which can mediate the transduction of extracellular stimuli into cellular effector functions. We have recently identified a 70 kd tyrosine phosphoprotein (ZAP-70) that associates with zeta and undergoes tyrosine phosphorylation following TCR stimulation. Here we report the isolation of a cDNA clone encoding ZAP-70. ZAP-70 represents a novel PTK and is expressed in T and natural killer cells. Moreover, tyrosine phosphorylation and association of ZAP-70 with zeta require the presence of src family PTKs and provide a potential mechanism by which the src family PTKs and ZAP-70 may interact to mediate TCR signal transduction.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	CHAN, AC (corresponding author), UNIV CALIF SAN FRANCISCO, DIV RHEUMATOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20684] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BUFERNE M, 1992, J IMMUNOL, V148, P657; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Frank S J, 1990, Semin Immunol, V2, P89; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GEISLER C, 1992, J IMMUNOL, V148, P2437; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LITTMAN DR, 1987, NATURE, V326, P85, DOI 10.1038/326085a0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NORMENT AM, 1989, J IMMUNOL, V142, P3312; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; White T.J., 1990, PCR PROTOCOLS GUIDE, P315; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	77	965	997	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					649	662		10.1016/0092-8674(92)90598-7	http://dx.doi.org/10.1016/0092-8674(92)90598-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423621				2022-12-24	WOS:A1992JY67600012
J	FUCHS, EJ; MATZINGER, P				FUCHS, EJ; MATZINGER, P			B-CELLS TURN OFF VIRGIN BUT NOT MEMORY T-CELLS	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; MIXED LEUKOCYTE REACTION; DENDRITIC CELLS; LYMPHOCYTES-B; BLOOD-TRANSFUSIONS; ACTIVE ENHANCEMENT; PRIMING INVIVO; SKIN-GRAFT; TOLERANCE; INDUCTION	There are three possible outcomes when a T cell recognizes a cell bearing a self or foreign antigen. (i) The T cell is not sufficiently signaled and is unaffected. (ii) The T cell is activated. (iii) The T cell is turned off. The differentiation state of the T cell is critical to the outcome. Although both virgin and memory T cells can be activated by antigens presented by "professional" antigen-presenting cells such as dendritic cells, they differ in their responses to B cells. Experienced T cells respond to antigen presented by B cells, whereas virgin T cells are rendered tolerant. These findings may relate to the phenomena of low- and high-zone tolerance, neonatal tolerance, and the beneficial effect of blood transfusions on allograft survival.	NIH,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								ASHWELL JD, 1988, J IMMUNOL, V141, P2536; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0; BIKOFF E, 1986, J IMMUNOL, V137, P28; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; BOOG CJP, 1985, NATURE, V318, P59, DOI 10.1038/318059a0; BURAKOFF SJ, 1978, J EXP MED, V148, P1414, DOI 10.1084/jem.148.5.1414; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; CHESNUT RW, 1982, J IMMUNOL, V128, P1764; CLAVERIE JM, 1986, ANN INST PASTEUR IMM, VD137, P425; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; EYNON EE, 1991, TRANSPLANT P, V23, P729; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; GOLOB K, UNPUB; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HAWRYLOWICZ CM, 1988, J IMMUNOL, V141, P4083; HORI S, 1989, J IMMUNOL, V143, P1447; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAKIUCHI T, 1983, J IMMUNOL, V131, P109; KRIEGER JI, 1986, J IMMUNOL, V137, P3117; KRIEGER JI, 1985, J IMMUNOL, V135, P2937; KURTJONES EA, 1988, J IMMUNOL, V140, P3773; LAFFERTY KJ, 1980, IMMUNOL REV, V51, P279, DOI 10.1111/j.1600-065X.1980.tb00325.x; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; LAUCHART W, 1980, TRANSPLANTATION, V29, P259, DOI 10.1097/00007890-198003000-00020; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCKEAN DJ, 1981, J EXP MED, V154, P1419, DOI 10.1084/jem.154.5.1419; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; OPELZ G, 1973, TRANSPLANT P, V5, P253; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; RAMMENSEE HG, 1991, BONE MARROW TRANSPL, V7, P26; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; RON Y, 1987, J IMMUNOL, V138, P2848; RYAN JJ, 1984, J IMMUNOL, V133, P2343; SHIMONKEVITZ RP, 1988, J EXP MED, V168, P143, DOI 10.1084/jem.168.1.143; STROM TB, 1977, TRANSPL P, V9, P965; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; WEBB SR, 1985, EUR J IMMUNOL, V15, P92, DOI 10.1002/eji.1830150118; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282	56	545	558	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1156	1159		10.1126/science.1439825	http://dx.doi.org/10.1126/science.1439825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439825	Green Submitted			2022-12-24	WOS:A1992JX85200034
J	WEIS, WI; DRICKAMER, K; HENDRICKSON, WA				WEIS, WI; DRICKAMER, K; HENDRICKSON, WA			STRUCTURE OF A C-TYPE MANNOSE-BINDING PROTEIN COMPLEXED WITH AN OLIGOSACCHARIDE	NATURE			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ASPARAGINE-LINKED OLIGOSACCHARIDES; PULMONARY SURFACTANT APOPROTEIN; SOLUTION CONFORMATION; 3-DIMENSIONAL STRUCTURES; CELL-ADHESION; LECTIN DOMAIN; RECEPTOR; RAT; REFINEMENT	C-type (Ca2+-dependent) animal lectins such as mannose-binding proteins mediate many cell-surface carbohydrate-recognition events. The crystal structure at 1.7 angstrom resolution of the carbohydrate-recognition domain of rat mannose-binding protein complexed with an oligomannose asparaginyl-oligosaccharide reveals that Ca2+ forms coordination bonds with the carbohydrate ligand. Carbohydrate specificity is determined by a network of coordination and hydrogen bonds that stabilizes the ternary complex of protein, Ca2+ and sugar. Two branches of the oligosaccharide crosslink neighbouring carbohydrate-recognition domains in the crystal, enabling multivalent binding to a single oligosaccharide chain to be visualized directly.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150				ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BILDERBACK D, 1988, NUCL INSTRUM METH A, V266, P636, DOI 10.1016/0168-9002(88)90457-3; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3671, DOI 10.1021/bi00284a021; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P1362, DOI 10.1021/bi00275a007; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR MANUAL; BRUNGER AT, 1992, ANTURE, V355, P472; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HOMANS SW, 1986, BIOCHEMISTRY-US, V25, P6342, DOI 10.1021/bi00368a076; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6649, DOI 10.1021/bi00395a014; IKEDA K, 1987, J BIOL CHEM, V262, P7451; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE YC, 1982, GLYCOCONJUGATES, V4, P57; PETERS D, 1981, J MOL STRUCT, V85, P107; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; SIEGELMAN M, 1991, Current Biology, V1, P125, DOI 10.1016/0960-9822(91)90299-C; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPRINGER TA, 1991, ANTURE, V349, P196; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT CS, 1992, J BIOL CHEM, V267, P14345; 1979, SUITE PROGRAMS PROTE	49	853	891	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					127	134		10.1038/360127a0	http://dx.doi.org/10.1038/360127a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436090				2022-12-24	WOS:A1992JX75200049
J	WIGGINS, S; WHYTE, P; HUGGINS, M; ADAM, S; THEILMANN, J; BLOCH, M; SHEPS, SB; SCHECHTER, MT; HAYDEN, MR				WIGGINS, S; WHYTE, P; HUGGINS, M; ADAM, S; THEILMANN, J; BLOCH, M; SHEPS, SB; SCHECHTER, MT; HAYDEN, MR			THE PSYCHOLOGICAL CONSEQUENCES OF PREDICTIVE TESTING FOR HUNTINGTONS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DNA MARKERS; GENE	Background. Advances in molecular genetics have led to the development of tests that can predict the risk of inheriting the genes for several adult-onset diseases. However, the psychological consequences of such testing are not well understood. Methods. The 135 participants in the Canadian program of genetic testing to predict the risk of Huntington's disease were followed prospectively in three groups according to their test results: the increased-risk group (37 participants), the decreased-risk group (58 participants), and the group with no change in risk (the no-change group) (40 participants). All the participants received counseling before and after testing. Standard measures of psychological distress (the General Severity Index of the Symptom Check List 90-R), depression (the Beck Depression Inventory), and well-being (the General Well-Being Scale) were administered before genetic testing and again at intervals of 7 to 10 days, 6 months, and 12 months after the participants received their test results. Results. At each follow-up assessment, the decreased-risk group had lower scores for distress than before testing (P<0.001). The increased-risk group showed no significant change from base line on any follow-up measure, but over the year of study there were small linear declines (P<0.023) for distress and depression. The no-change group had scores lower than at base line on the index of general well-being at each follow-up (P less-than-or-equal-to 0.045). At the 12-month follow-up, both the increased-risk group and the decreased-risk group had lower scores for depression and higher scores for well-being than the no-change group (P less-than-or-equal-to 0.049). Conclusions. Predictive testing for Huntington's disease has potential benefits for the psychological health of persons who receive results that indicate either an increase or a decrease in the risk of inheriting the gene for the disease.	UNIV BRITISH COLUMBIA,DEPT MED GENET,RM 416,2125 E MALL,VANCOUVER V6T 1Z4,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Adam, Shelin/0000-0002-4401-6157; Schechter, Martin/0000-0001-6063-2155				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; CRAUFURD D, 1989, LANCET, V2, P603; DEROGATIS LR, 1983, SCL90R ADM SCORING P; DUPUY H, 1969, PSYCHOL EXAMINATION; FOLSTEIN SE, 1983, NEUROBEH TOXICOL TER, V5, P605; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; KESSLER S, 1987, AM J ORTHOPSYCHIAT, V57, P212, DOI 10.1111/j.1939-0025.1987.tb03531.x; SKRAASTAD MI, 1991, AM J MED GENET, V38, P217; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WARE JE, 1979, R19873HEW RAND REP; WINER BJ, 1971, STATISTICAL PRINCIPL, P177	18	338	338	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1401	1405		10.1056/NEJM199211123272001	http://dx.doi.org/10.1056/NEJM199211123272001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX479	1406858	Bronze			2022-12-24	WOS:A1992JX47900001
J	BURSTIN, HR; LIPSITZ, SR; BRENNAN, TA				BURSTIN, HR; LIPSITZ, SR; BRENNAN, TA			SOCIOECONOMIC-STATUS AND RISK FOR SUBSTANDARD MEDICAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; HEALTH-INSURANCE; PREVENTIVE CARE; HEART-DISEASE; MASSACHUSETTS; AGE; PATTERNS; ACCESS; BOSTON	Objective.-To assess whether the socioeconomic status of the patient was associated with the risk of adverse events, defined as medical injuries caused by medical management, and the proportion of these events that resulted from substandard care. Setting.-51 hospitals in New York State. Methods.-Rates of medical injury and substandard care by gender, race, income, and payer status were developed from reviews of 30195 medical records in New York in 1984. We evaluated these socioeconomic parameters in a multivariate analysis, while controlling for hospital-level factors. Results.-We found that uninsured patients (odds ratio, 2.35; 95% confidence interval, 1.40 to 3.95) were at greater risk for substandard care. The characteristics of the hospitals to which patients were admitted did not affect this result. Race, gender, and income were not independently associated with risk for medical injury or substandard care in multivariate analyses. Conclusion.-Our findings suggest that the uninsured are at greater risk for suffering medical injury due to substandard medical care.	BRIGHAM & WOMENS HOSP,DIV GEN MED,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health								AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; BINDMAN AB, 1990, JAMA-J AM MED ASSOC, V264, P2899, DOI 10.1001/jama.264.22.2899; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BOMBARDIER C, 1977, NEW ENGL J MED, V297, P699, DOI 10.1056/NEJM197709292971305; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BRENNAN TA, 1991, JUST DOCTORING MED E; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; GREENBERGER NJ, 1991, BRIT MED J, V303, P1216, DOI 10.1136/bmj.303.6812.1216; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HELLER TA, 1984, J AM GERIATR SOC, V32, P782, DOI 10.1111/j.1532-5415.1984.tb06297.x; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, STATEWIDE PLANNING R; 1985, AM HOSPITAL ASS GUID; 1984, 1984 SOURCEBOOK ZIP	32	193	192	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2383	2387		10.1001/jama.268.17.2383	http://dx.doi.org/10.1001/jama.268.17.2383			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404794				2022-12-24	WOS:A1992JV69400023
J	SWAMINATHAN, S; FUREY, W; PLETCHER, J; SAX, M				SWAMINATHAN, S; FUREY, W; PLETCHER, J; SAX, M			CRYSTAL-STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN-B, A SUPERANTIGEN	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; USE PREDICTS REACTIVITY; MLSA-ENCODED ANTIGENS; T-CELL RECOGNITION; CLASS-II MOLECULES; BINDING SITE; TOLERANCE; CRYSTALLOGRAPHY; STIMULATION; REQUIREMENT	The three-dimensional structure of staphylococcal enterotoxin B, which is both a toxin and a super-antigen, has been determined to a resolution of 2.5 angstrom. The unusual main-chain fold containing two domains may represent a general motif adopted by all staphylococcal enterotoxins. The T-cell receptor binding site encompasses a shallow cavity formed by both domains. The MHCII molecule binds to an adjacent site. Another cavity with possible biological activity was also identified.			SWAMINATHAN, S (corresponding author), VET AFFAIRS MED CTR,BIOCRYSTALLOG LAB,POB 12055,UNIV DR C,PITTSBURGH,PA 15240, USA.							BERDOLL MS, 1985, STAPHYLOCOCCI, P247; Bergdoll M.S., 1979, FOOD BORNE INFECTION, P443; BERGDOLL MS, 1970, MICROBIAL TOXINS, P265; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSSON R, 1988, J IMMUNOL, V140, P2484; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEREWENDA Z, 1989, J APPL CRYSTALLOGR, V22, P123, DOI 10.1107/S0021889888012348; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FUREY W, 1990, AM CRYSTALLOGR ASS M; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IRWIN MJ, 1992, NATURE, V359, P841, DOI 10.1038/359841a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JOHNSON HM, 1992, SCI AM           APR, P92; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; LANGFORD MP, 1978, INFECT IMMUN, V22, P62, DOI 10.1128/IAI.22.1.62-68.1978; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUSSELL JK, 1991, P NATL ACAD SCI USA, V88, P7228, DOI 10.1073/pnas.88.16.7228; SCHEUBER PH, 1985, INFECT IMMUN, V50, P869, DOI 10.1128/IAI.50.3.869-876.1985; SPERO L, 1978, J BIOL CHEM, V253, P8787; STEIMA GN, 1982, BIOCHEM BIOPH RES CO, V105, P121; SWAMINATHAN S, 1988, J MOL BIOL, V199, P397, DOI 10.1016/0022-2836(88)90326-9; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	45	292	317	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					801	806		10.1038/359801a0	http://dx.doi.org/10.1038/359801a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436058				2022-12-24	WOS:A1992JV77700054
J	WEISSENBACH, J; GYAPAY, G; DIB, C; VIGNAL, A; MORISSETTE, J; MILLASSEAU, P; VAYSSEIX, G; LATHROP, M				WEISSENBACH, J; GYAPAY, G; DIB, C; VIGNAL, A; MORISSETTE, J; MILLASSEAU, P; VAYSSEIX, G; LATHROP, M			A 2ND-GENERATION LINKAGE MAP OF THE HUMAN GENOME	NATURE			English	Article							INVITRO AMPLIFICATION; DNA; GENE; OLIGONUCLEOTIDES; REPEAT; SINGLE	A linkage map of the human genome has been constructed based on the segregation analysis of 814 newly characterized polymorphic loci containing short tracts of (C-A)n repeats in a panel of DNAs from eight large families. Statistical linkage analysis placed 813 of the markers into 23 linkage groups corresponding to the 22 autosomes and the X chromosome; 605 show a heterozygosity above 0.7 and 553 could be ordered with odds ratios above 1,000:1. The distance spanned corresponds to approximately 90% of the estimated length of the human genome.	INST PASTEUR,UNITE GENET MOLEC HUMAINE,CNRS,URA 1445,F-75724 PARIS,FRANCE; CHU LAVAL,CTR ETUD POLYMORPHISME HUMAIN,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; CHU LAVAL,RESEAU MED GENET,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; INSERM,U358,F-75010 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Laval University; Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm)	WEISSENBACH, J (corresponding author), GENETHON,1 RUE INT,F-91000 EVRY,FRANCE.		Vignal, Alain/I-6253-2017	Vignal, Alain/0000-0002-6797-2125				BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BISHOP DT, 1990, AM J HUM GENET, V46, P254; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DIETRICH W, 1992, GENETICS, V131, P423; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1991, STAT METH BIOL MED S, V8, P81; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OTT J, 1992, AM J HUM GENET, V51, P283; RISCH N, 1990, AM J HUM GENET, V46, P242; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; VERGNAUD G, 1991, ELECTROPHORESIS, V12, P134, DOI 10.1002/elps.1150120207; VIGINAL A, IN PRESS METHODS MOL, V1; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE R, 1990, GENETICS MAPS LOCUS; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727; 1991, CYTOGENET CELL GENET, V58, P1	24	1913	1999	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					794	801		10.1038/359794a0	http://dx.doi.org/10.1038/359794a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436057				2022-12-24	WOS:A1992JV77700053
J	BLATTER, EE; EBRIGHT, YW; EBRIGHT, RH				BLATTER, EE; EBRIGHT, YW; EBRIGHT, RH			IDENTIFICATION OF AN AMINO ACID-BASE CONTACT IN THE GCN4-DNA COMPLEX BY BROMOURACIL-MEDIATED PHOTO-CROSS-LINKING	NATURE			English	Article							LAC REPRESSOR PROTEIN; GENE-CONTROL REGIONS; LEUCINE ZIPPER; DNA-BINDING; GEL-ELECTROPHORESIS; ACTIVATOR PROTEIN; OPERATOR DNA; RECOGNITION; SITE; BROMODEOXYURIDINE	THE bZIP DNA-binding proteins are characterized by a 50-amino-acid DNA binding and dimerization motif, consisting of a highly basic DNA-binding region ('b') followed by a leucine zipper dimerization region ('ZIP')1. The best characterized bZIP DNA-binding protein is GCN4, a yeast transcriptional activator2-6. GCN4 binds to a 9-base-pair two-fold-symmetric DNA site, 5'-A-4T-3G-2A-1C0T+1C+2A+3T+4-3' (refs 7-10). A detailed model known as the 'induced helical fork' model has been proposed for the structure of the GCN4-DNA complex4. Using a site-specific bromouracil-mediated photocrosslinking method, we show here that the alanine at position 238 of GCN4 contacts, or is close to, the thymine 5-methyl of A.T at position +3 of the DNA site in the GCN4-DNA complex. Our results strongly support the induced helical fork model4. Our site-specific bromouracil-mediated photocrosslinking method requires no prior information regarding the structure of the protein or the structure of the protein-DNA complex and should be generalizable to DNA-binding proteins that interact with the DNA major groove11,12.	RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140				ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; FISHER EF, 1979, NUCLEIC ACIDS RES, V7, P401, DOI 10.1093/nar/7.2.401; FLIESS A, 1988, NUCLEIC ACIDS RES, V16, P11781, DOI 10.1093/nar/16.24.11781; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOEDDEL DV, 1978, J MOL BIOL, V123, P661, DOI 10.1016/0022-2836(78)90211-5; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; HAYAKAWA T, 1988, NUCLEIC ACIDS RES, V16, P4761, DOI 10.1093/nar/16.11.4761; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HUTCHINSON F, 1973, Q REV BIOPHYS, V6, P201, DOI 10.1017/S0033583500001141; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; STRUHL K, IN PRESS TRANSCRIPTI; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WICK KL, 1991, J BIOL CHEM, V266, P6106	30	79	83	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					650	652		10.1038/359650a0	http://dx.doi.org/10.1038/359650a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406998				2022-12-24	WOS:A1992JT82400062
J	TULINIUS, H; EGILSSON, V; OLAFSDOTTIR, GH; SIGVALDASON, H				TULINIUS, H; EGILSSON, V; OLAFSDOTTIR, GH; SIGVALDASON, H			RISK OF PROSTATE, OVARIAN, AND ENDOMETRIAL CANCER AMONG RELATIVES OF WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL ASSOCIATION; CARCINOMA; LOCUS	Objective-To investigate the risk of prostate, ovarian, and endometrial cancer among relatives of patients with breast cancer. Design-Cohort study of 947 pedigrees in which the proband had breast cancer, linked with the Icelandic cancer registry. Setting-Iceland. Subjects-The 947 pedigrees included 29725 people, of whom 1539 had breast cancer, 467 had prostate cancer, 135 ovarian cancer, and 105 endometrial cancer. Main outcome measures-Risk of prostate, ovarian, and endometrial cancer among blood relatives of women with breast cancer compared with risk in spouses. Results-The risk of prostate cancer was significantly raised for all relatives (1.5), first degree relatives (1.4), and second degree relatives (1.3) of women with breast cancer. Risk of ovarian cancer was raised for all relatives (1.9) and first degree relatives (1.9) and risk of endometrial cancer was raised for all relatives only (1.9). The risk of prostate cancer was raised if the proband with breast cancer had a first degree relative with prostate cancer. Conclusions-Coaggreption exists between breast cancer and cancers of the prostate, ovaries, and endometrium. This risk relation is probably based on genes which act by increasing the risk for cancer at these sites. Environmental factors that are common among relatives may also play a part. Continued research is required into pathophysiological mechanisms that could explain these observations.	UNIV ICELAND,DEPT PATHOL,REYKJAVIK,ICELAND	University of Iceland	TULINIUS, H (corresponding author), ICELAND CANC REGISTRY,SKOGARHLID 8,IS-125 REYKJAVIK,ICELAND.							Cannon L., 1982, CANCER SURV, V1, P47; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KING MC, 1980, SCIENCE, V208, P406, DOI 10.1126/science.7367867; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1982, OBSTET GYNECOL, V59, P589; NAROD SA, 1991, LANCET, V338, P82; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; THIESSEN EU, 1974, CANCER, V34, P1102, DOI 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5; THOMPSON WD, 1991, INT J EPIDEMIOL, V20, P595, DOI 10.1093/ije/20.3.595; TULINIUS H, 1992, J MED GENET, V29, P158, DOI 10.1136/jmg.29.3.158; TULINIUS H, 1985, INT C SERIES, V685; TULINIUS H, 1985, NARINGSFORSKNING, V29, P17; VATTEN LJ, 1990, INT J CANCER, V45, P440, DOI 10.1002/ijc.2910450311; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104; 1990, EGRET REFERENCE MANU	17	149	152	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					855	857		10.1136/bmj.305.6858.855	http://dx.doi.org/10.1136/bmj.305.6858.855			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422397	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JT77700021
J	FANIDI, A; HARRINGTON, EA; EVAN, GI				FANIDI, A; HARRINGTON, EA; EVAN, GI			COOPERATIVE INTERACTION BETWEEN C-MYC AND BCL-2 PROTOONCOGENES	NATURE			English	Article							PROGRAMMED CELL-DEATH; APOPTOSIS; MICE; GENE	THE bcl-2 proto-oncogene is activated by translocation in a variety of B-lymphoid tumours and synergizes with the c-myc oncogene in tumour progression1. The mechanism of synergy is unclear but bcl-2 expression inhibits apoptosis2-6, a property presumably pertinent to its proto-oncogenic mode of action4. We have shown that the c-myc gene is a potent inducer of apoptosis, in addition to its established role in mitogenesis7. Here we show that expression of the bcl-2 protein, Bcl-2, specifically abrogates c-myc-induced apoptosis without affecting the c-myc mitogenic function. This provides a novel mechanism for oncogene cooperation, of potential importance both in carcinogenesis and in the evolution of drug resistance in tumours.	IMPERIAL CANC RES FUND, BIOCHEM CELL NUCLEUS LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ASKEW DS, 1991, ONCOGENE, V6, P1915; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404	16	765	802	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1992	359	6395					554	556		10.1038/359554a0	http://dx.doi.org/10.1038/359554a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406976				2022-12-24	WOS:A1992JR85900066
J	CLARK, MR; CAMPBELL, KS; KAZLAUSKAS, A; JOHNSON, SA; HERTZ, M; POTTER, TA; PLEIMAN, C; CAMBIER, JC				CLARK, MR; CAMPBELL, KS; KAZLAUSKAS, A; JOHNSON, SA; HERTZ, M; POTTER, TA; PLEIMAN, C; CAMBIER, JC			THE B-CELL ANTIGEN RECEPTOR COMPLEX - ASSOCIATION OF IG-ALPHA AND IG-BETA WITH DISTINCT CYTOPLASMIC EFFECTORS	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; PDGF RECEPTOR; MEMBRANE IMMUNOGLOBULIN; KINASE; STIMULATION; ANTIIMMUNOGLOBULIN; GENE	The B cell antigen receptor complex is a hetero-oligomeric structure composed of antigen binding, membrane immunoglobulin, and transducer-transporter substructures. The transducer-transporter substructure is composed of disulfide-linked dimers of immunoglobulin (Ig)-alpha and Ig-beta/gamma subunits that are products of the mb-1(alpha) and B29 (beta/gamma) genes. Although the receptor complex associates with Src family kinases that are activated after receptor ligation, the site of interaction of these and other cytoplasmic effector molecules with receptor subunits is unknown. The cytoplasmic tails of Ig-alpha and Ig-beta chains were found to associate with distinct sets of effector molecules. The Ig-alpha chain cytoplasmic domain bound to the Src family kinases Lyn and Fyn, phosphatidylinositol-3 kinase (PI-3 kinase), and an unidentified 38-kilodalton phosphoprotein; the cytoplasmic tail of Ig-beta bound PI-3 kinase and unidentified 40- and 42-kilodalton phosphoproteins. Binding activity was found to occur within a 26-amino acid sequence of Ig-alpha and Ig-beta that contains a motif [(Asp or Glu)-(any amino acid)7-(Asp or Glu)-Tyr-(any amino acid)3-Leu-(any amino acid)7-Tyr-(any amino acid)2-(Leu or Ile)] previously implicated in signal transduction via other receptors including the Fc(epsilon) receptor I and the T cell antigen receptor. These findings indicate that the subunits act independently to activate distinct second messenger pathways.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Campbell, Kerry S./T-1381-2019	Cambier, John/0000-0002-7803-242X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020519, R01AI021768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001864] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20519, AI21768] Funding Source: Medline; NIAMS NIH HHS [AR01864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CAMBIER JC, IN PRESS CURR OPIN I; CAMPBELL K, UNPUB; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL KS, 1990, LIGANDS RECEPTORS SI, pCH1; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHIEN N, UNPUB; CLARK MW, UNPUB; COGGESHALL KM, IN PRESS P NATL ACAD; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JENSEN W, UNPUB J C CAMBIER; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PLEIMAN CM, UNPUB; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	38	301	312	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					123	126		10.1126/science.1439759	http://dx.doi.org/10.1126/science.1439759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439759				2022-12-24	WOS:A1992JQ61900033
J	KRETSINGER, RH				KRETSINGER, RH			CALMODULIN AND MYOSIN LIGHT CHAIN KINASE - HOW HELICES ARE BENT	SCIENCE			English	Editorial Material							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; MONOPHOSPHATE				KRETSINGER, RH (corresponding author), UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901, USA.							IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRETSINGER RH, 1975, BIOCHIM BIOPHYS ACTA, V405, P40, DOI 10.1016/0005-2795(75)90312-8; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Raghunathan S., UNPUB	8	22	22	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					50	51		10.1126/science.1439768	http://dx.doi.org/10.1126/science.1439768			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439768				2022-12-24	WOS:A1992JQ61900023
J	NELSON, RJ; ZIEGELHOFFER, T; NICOLET, C; WERNERWASHBURNE, M; CRAIG, EA				NELSON, RJ; ZIEGELHOFFER, T; NICOLET, C; WERNERWASHBURNE, M; CRAIG, EA			THE TRANSLATION MACHINERY AND 70 KD HEAT-SHOCK PROTEIN COOPERATE IN PROTEIN-SYNTHESIS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; HSP70 FAMILY; YEAST; MEMBER; TRANSLOCATION; MITOCHONDRIA; SEQUENCE; CLONING; MUTANT; GENES	The function of the yeast SSB 70 kd heatshock proteins (hsp70s) was investigated by a variety of approaches. The SSB hsp70s (Ssb1/2p) are associated with translating ribosomes. This association is disrupted by puromycin, suggesting that Ssb1/2p may bind directly to the nascent polypeptide. Mutant ssb1 ssb2 strains grow slowly, contain a low number of translating ribosomes, and are hypersensitive to several inhibitors of protein synthesis. The slow growth phenotype of ssb1 ssb2 mutants is suppressed by increased copy number of a gene encoding a novel translation elongation factor 1alpha (EF-1alpha)-like protein. We suggest that cytosolic hsp70 aids in the passage of the nascent polypeptide chain through the ribosome in a manner analogous to the role played by organelle-localized hsp70 in the transport of proteins across membranes.	UNIV WISCONSIN,PROGRAM CELLULAR & MOLEC BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	NELSON, RJ (corresponding author), UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706, USA.							BAYLISS FT, 1971, SCIENCE, V174, P1339, DOI 10.1126/science.174.4016.1339; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARTER CJ, 1980, EUR J BIOCHEM, V107, P173, DOI 10.1111/j.1432-1033.1980.tb04638.x; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CULBERTSON MR, 1982, GENETICS, V102, P361; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FORCHHAMMER J, 1971, J MOL BIOL, V55, P563, DOI 10.1016/0022-2836(71)90337-8; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Hawthorne D C, 1974, Curr Top Microbiol Immunol, V64, P1; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; Maniatis T., 1982, MOL CLONING; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MASUREKAR M, 1981, J MOL BIOL, V147, P381, DOI 10.1016/0022-2836(81)90490-3; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SMITH JD, 1965, J MOL BIOL, V13, P617, DOI 10.1016/S0022-2836(65)80130-9; STOCKLEIN W, 1981, FEBS LETT, V136, P265, DOI 10.1016/0014-5793(81)80632-1; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; VANHOLDE KE, 1974, RIBOSOMES, P53; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WETTSTEIN FO, 1964, BIOCHIM BIOPHYS ACTA, V87, P525, DOI 10.1016/0926-6550(64)90131-8	47	448	473	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					97	105		10.1016/0092-8674(92)90269-I	http://dx.doi.org/10.1016/0092-8674(92)90269-I			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394434				2022-12-24	WOS:A1992JQ62300010
J	VOLLRATH, D; FOOTE, S; HILTON, A; BROWN, LG; BEERROMERO, P; BOGAN, JS; PAGE, DC				VOLLRATH, D; FOOTE, S; HILTON, A; BROWN, LG; BEERROMERO, P; BOGAN, JS; PAGE, DC			THE HUMAN Y-CHROMOSOME - A 43-INTERVAL MAP BASED ON NATURALLY-OCCURRING DELETIONS	SCIENCE			English	Article							HUMAN X-CHROMOSOME; CONTIGUOUS GENE SYNDROMES; SEX-DETERMINING REGION; DISTAL SHORT ARM; ENZYMATIC AMPLIFICATION; MOLECULAR-DETECTION; TURNER SYNDROME; PAIRING REGION; DNA-SEQUENCES; HUMAN GENOME	A deletion map of the human Y chromosome was constructed by testing 96 individuals with partial Y chromosomes for the presence or absence of many DNA loci. The individuals studied included XX males, XY females, and persons in whom chromosome banding had revealed translocated, deleted, isodicentric, or ring Y chromosomes. Most of the 132 Y chromosomal loci mapped were sequence-tagged sites, detected by means of the polymerase chain reaction. These studies resolved the euchromatic region (short arm, centromere, and proximal long arm) of the Y chromosome into 43 ordered intervals, all defined by naturally occurring chromosomal breakpoints and averaging less than 800 kilobases in length. This deletion map should be useful in identifying Y chromosomal genes, in exploring the origin of chromosomal disorders, and in tracing the evolution of the Y chromosome.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	VOLLRATH, D (corresponding author), MIT, WHITEHEAD INST, HOWARD HUGHES RES LABS, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Foote, Simon J/F-2802-2013; Bogan, Jonathan S/A-1575-2010	Bogan, Jonathan S/0000-0001-6463-8466; Foote, Simon/0000-0002-9142-2107				AFFARA NA, 1987, NUCLEIC ACIDS RES, V15, P7325, DOI 10.1093/nar/15.18.7325; AFFARA NA, 1986, NUCLEIC ACIDS RES, V14, P5353, DOI 10.1093/nar/14.13.5353; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVESALO L, 1981, ANN HUM GENET, V45, P49, DOI 10.1111/j.1469-1809.1981.tb00305.x; ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; BISHOP C, 1984, J MOL BIOL, V173, P403, DOI 10.1016/0022-2836(84)90388-7; BLAGOWIDOW N, 1989, AM J MED GENET, V34, P159, DOI 10.1002/ajmg.1320340204; BORGAONKAR DS, 1985, Y CHROMOSOME B, P15; BROWN CJ, 1990, AM J HUM GENET, V46, P273; BUHLER EM, 1980, HUM GENET, V55, P145, DOI 10.1007/BF00291764; CANTRELL MA, 1992, GENOMICS, V13, P1255, DOI 10.1016/0888-7543(92)90043-R; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; DAVIS RM, 1981, J MED GENET, V18, P161, DOI 10.1136/jmg.18.3.161; DISTECHE CM, 1986, P NATL ACAD SCI USA, V83, P7841, DOI 10.1073/pnas.83.20.7841; DISTECHE CM, 1986, HUM GENET, V74, P372, DOI 10.1007/BF00280488; FERGUSONSMITH MA, 1987, DEVELOPMENT, V101, P41; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FOOTE S, 1992, GENOMICS, V258, P60; FUSCOE JC, 1986, CYTOGENET CELL GENET, V43, P79, DOI 10.1159/000132301; GOULMY E, 1983, IMMUNOGENETICS, V17, P523, DOI 10.1007/BF00696875; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GREEN ED, 1991, GENOMICS, V11, P548, DOI 10.1016/0888-7543(91)90062-J; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; GUIOLI S, 1992, NAT GENET, V1, P337, DOI 10.1038/ng0892-337; INCERTI B, UNPUB NATURE GENET; JACOBS PA, 1966, NATURE, V210, P352, DOI 10.1038/210352a0; KOENIG M, 1985, NUCLEIC ACIDS RES, V13, P5485, DOI 10.1093/nar/13.15.5485; KOTECKI M, 1991, HUM GENET, V87, P234, DOI 10.1007/BF00204192; LINCOLN S, COMMUNICATION; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MULLER U, 1990, HUM GENET, V85, P205; MUNKE M, 1988, HUM GENET, V80, P219, DOI 10.1007/BF01790089; NAKAHORI Y, 1991, GENOMICS, V9, P765, DOI 10.1016/0888-7543(91)90373-M; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OREILLY AM, UNPUB; PAGE DC, 1987, DEVELOPMENT, V101, P151; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PAGE DC, 1990, NATURE, V346, P279, DOI 10.1038/346279a0; PAGE DC, 1986, COLD SPRING HARB SYM, V51, P229, DOI 10.1101/SQB.1986.051.01.028; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHARP CB, 1990, HUM GENET, V85, P330; SILVER J, 1987, MOL CELL BIOL, V7, P1559, DOI 10.1128/MCB.7.4.1559; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SIMPSON E, 1987, NATURE, V326, P876, DOI 10.1038/326876a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SKARE J, 1990, AM J MED GENET, V36, P394, DOI 10.1002/ajmg.1320360405; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; VOGT P, 1991, HUM GENET, V86, P341; WEISSENBACH J, 1991, CYTOGENET CELL GENET, V58, P967, DOI 10.1159/000133184; YEN PH, 1991, P NATL ACAD SCI USA, V88, P8944, DOI 10.1073/pnas.88.20.8944	61	416	456	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1992	258	5079					52	59		10.1126/science.1439769	http://dx.doi.org/10.1126/science.1439769			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439769				2022-12-24	WOS:A1992JQ61900024
J	SOMERS, WS; PHILLIPS, SEV				SOMERS, WS; PHILLIPS, SEV			CRYSTAL-STRUCTURE OF THE MET REPRESSOR-OPERATOR COMPLEX AT 2.8 A-ANGSTROM RESOLUTION REVEALS DNA RECOGNITION BY BETA-STRANDS	NATURE			English	Article							ESCHERICHIA-COLI; METHIONINE BIOSYNTHESIS; ARC REPRESSOR; PROTEIN; BINDING; COREPRESSOR; PHAGE-434; PROGRAM; REGION; FAMILY	The crystal structure of the met repressor-operator complex shows two dimeric repressor molecules bound to adjacent sites 8 base pairs apart on an 18-base-pair DNA fragment. Sequence specificity is achieved by insertion of double-stranded antiparallel protein beta-ribbons into the major groove of B-form DNA, with direct hydrogen-bonding between amino-acid side chains and the base pairs. The repressor also recognizes sequence-dependent distortion or flexibility of the operator phosphate backbone, conferring specificity even for inaccessible base pairs.	UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds				Phillips, Simon/0000-0001-8922-0250				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DAVIDSON BE, 1989, MOL MICROBIOL, V3, P1639, DOI 10.1111/j.1365-2958.1989.tb00149.x; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOWER DR, 1991, J MOL GRAPHICS, V9, P257, DOI 10.1016/0263-7855(91)80021-Q; FREEMONT PS, 1991, BIOCHEM J, V278, P1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HARRISON SC, 1990, REV BIOCH, V59, P933; HE YY, 1992, NATURE, V359, P431, DOI 10.1038/359431a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KNIGHT KL, 1989, J BIOL CHEM, V264, P3639; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; OLD IG, 1991, PROG BIOPHYS MOL BIO, V56, P145, DOI 10.1016/0079-6107(91)90012-H; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SAINTGIRONS I, 1986, J BIOL CHEM, V261, P936; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SIM GA, 1960, ACTA CRYSTALLOGR, V13, P511, DOI 10.1107/S0365110X60001266; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; 1979, 4 DAR LAB SERC COLL	46	284	290	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					387	393		10.1038/359387a0	http://dx.doi.org/10.1038/359387a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406951				2022-12-24	WOS:A1992JQ62400046
J	BIRKHEAD, JS				BIRKHEAD, JS			TIME DELAYS IN PROVISION OF THROMBOLYTIC TREATMENT IN 6 DISTRICT HOSPITALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYMPTOMS; THERAPY	Objective-To measure the delays between onset of symptoms and admission to hospital and provision of thrombolysis in patients with possible acute myocardial infarction. Design-Observational study of patients admitted with suspected myocardial infarction during six months. Setting- Six district general hospitals in Britain. Subjects-1934 patients admitted with suspected myocardial infarction. Main outcome measures-Route of admission to hospital and time to admission and thrombolysis. Results-Patients who made emergency calls did so sooner after onset of symptoms than those who called their doctor (median time 40 (95% confidence interval 30 to 52) minutes v 70 (60 to 90) minutes). General practitioners took a median of 20 (20 to 25) minutes to visit patients, rising to 30 (20 to 30) minutes during 0800-1200. The median time from call to arrival in hospital was 41 (38 to 47) minutes for patients who called an ambulance from home and 90 (90 to 94) minutes for those who contacted their doctor. The median time from arrival at hospital to thrombolysis was 80 (75 to 85) minutes for patients who were treated in the cardiac care unit and 31 (25 to 35) minutes for those treated in the accident and emergency department. Conclusion-The time from onset of symptoms to thrombolysis could be reduced substantially by more effective use of emergency services and faster provision of thrombolysis in accident and emergency departments.			BIRKHEAD, JS (corresponding author), NORTHAMPTON GEN HOSP, DEPT MED, NORTHAMPTON NN1 5BD, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; CAMERON M, 1975, BRIT MED J, V1, P384, DOI 10.1136/bmj.1.5954.384; COLLING A, 1976, BRIT MED J, V2, P1169, DOI 10.1136/bmj.2.6045.1169; EMERSON PA, 1989, Q J MED, V70, P213; KENNEDY JW, 1989, AM J CARDIOL, V64, pA8, DOI 10.1016/0002-9149(89)90922-3; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; PANTRIDG.JF, 1967, LANCET, V2, P271; PARRY G, 1991, BRIT HEART J, V66, P39; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1990, EUR HEART J, V11, P643, DOI 10.1093/oxfordjournals.eurheartj.a059770; RAWLES JM, 1989, ABERDEEN POSTGRAD ME, V23, P1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SMYLLIE HC, 1972, BRIT MED J, V1, P34, DOI 10.1136/bmj.1.5791.34; WILCOX RG, 1988, LANCET, V2, P525; 1987, LANCET, V1, P871	21	109	109	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 22	1992	305	6851					445	448		10.1136/bmj.305.6851.445	http://dx.doi.org/10.1136/bmj.305.6851.445			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392956	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JK68000020
J	LINDQUIST, M; EDWARDS, IR				LINDQUIST, M; EDWARDS, IR			ENDOCRINE ADVERSE-EFFECTS OF OMEPRAZOLE	BRITISH MEDICAL JOURNAL			English	Article							GYNECOMASTIA; THERAPY				LINDQUIST, M (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							CONVENS C, 1991, LANCET, V338, P1153, DOI 10.1016/0140-6736(91)92018-W; GUGLER R, 1984, LANCET, V1, P969; JENSEN JC, 1986, BRIT J CLIN PHARMACO, V21, P328, DOI 10.1111/j.1365-2125.1986.tb05199.x; SANTUCCI L, 1991, NEW ENGL J MED, V324, P635	4	46	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					451	452		10.1136/bmj.305.6851.451	http://dx.doi.org/10.1136/bmj.305.6851.451			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392958	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JK68000022
J	MALINSKI, T; TAHA, Z				MALINSKI, T; TAHA, Z			NITRIC-OXIDE RELEASE FROM A SINGLE CELL MEASURED INSITU BY A PORPHYRINIC-BASED MICROSENSOR	NATURE			English	Article							RELAXING FACTOR; ACETYLCHOLINE; RELAXATION	NITRIC oxide is an important bioregulatory molecule, being responsible, for example, for activity of endothelium-derived relaxing factor (EDRF)1-4. Acute hypertension5, diabetes6, ischaemia7 and atherosclerosis8 are associated with abnormalities of EDRF. Nitric oxide is thought to be a retrograde messenger in the central nervous system9. The technology is not yet available for rapid detection of NO released by a single cell in the presence of oxygen and/or nitrite, so the release, distribution and reactivity of endogenous NO in biological systems cannot be analysed. Here we describe a porphyrinic microsensor that we have developed and applied to monitoring NO release in a microsystem. We selectively measured in situ the NO released from a single cell with a response time of less than 10 ms. The microsensor consists of p-type semiconducting polymeric porphyrin and a cationic exchanger (Nafion) deposited on a thermally sharpened carbon fibre with a tip diameter of approximately 0.5-mu-m. The microsensor, which can be operated in either the amperometric or voltammetric mode, is characterized by a linear response up to 300-mu-M and a detection limit of 10 nM. Nitric oxide at the level of 10(-20) mols can be detected in a single cell.			MALINSKI, T (corresponding author), OAKLAND UNIV,DEPT CHEM,ROCHESTER,MI 48309, USA.							BAILEY F, 1991, ANAL CHEM, V63, P395, DOI 10.1021/ac00004a018; BENNETT JE, 1991, CHEM MATER, V3, P490, DOI 10.1021/cm00015a025; DOWNES MJ, 1976, ANALYST, V101, P742, DOI 10.1039/an9760100742; ENGSTROM RC, 1988, ANAL CHEM, V60, P652, DOI 10.1021/ac00158a010; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1988, MECHANISM VASODILATI, V4, P101; GERHARDT GA, 1984, BRAIN RES, V290, P390, DOI 10.1016/0006-8993(84)90963-6; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; MALINSKI T, 1991, J ELECTROCHEM SOC, V138, P2008, DOI 10.1149/1.2085915; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PIPER GM, 1988, AM J PHYSIOL, V24, P4825; Rosenthal AM, 1990, CELL CULTURE TECHNIQ, P117; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	20	1031	1089	3	97	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					676	678		10.1038/358676a0	http://dx.doi.org/10.1038/358676a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495562				2022-12-24	WOS:A1992JJ88200056
J	SHELDRICK, JH; VERNON, SA; WILSON, A				SHELDRICK, JH; VERNON, SA; WILSON, A			STUDY OF DIAGNOSTIC ACCORD BETWEEN GENERAL-PRACTITIONERS AND AN OPHTHALMOLOGIST	BRITISH MEDICAL JOURNAL			English	Article							EYE; DISEASE	Objectives - To identify diagnostic accord and disagreement between general practitioners and an ophthalmologist and thereby determine how undergraduate and non-specialist postgraduate ophthalmic training could be improved. Design - Comparison of diagnosis of presenting conditions by general practitioners and one ophthalmologist in patients consulting general practitioners for ophthalmic problems during March 1989 to February 1990. Setting - 12 general practices in west Nottingham. Patients - 1474 patients presenting to the study general practitioners with new ophthalmic conditions or new episodes of recurrent conditions. Main outcome measures - Diagnoses of general practitioners and ophthalmologist. Results - 1121 (76%) of patients with eye problems agreed to see the ophthalmologist and most were seen within three days. Sufficient data for comparison were available on 1103 patients. Diagnostic agreement was found in 638 cases (58%), but potentially serious misdiagnosis was found in only 15 cases; management in three of these cases would have ensured later identification. Most commonly confused conditions were infective and allergic conjunctivitis, blepharitis, and dry eyes. General practitioners assessed visual acuity in only 114 cases yet eight of the 15 patients seriously misdiagnosed had reduced acuity, an important diagnostic sign. Conclusions - Most ophthalmic disease seen in general practice does not require specialised equipment for diagnosis. Most cases of misdiagnosis have no serious consequences for the patient. Undergraduate and postgraduate training in ophthalmology should ensure that common conditions can be easily differentiated and more serious conditions identified and referred.	UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2RD,ENGLAND; UNIV NOTTINGHAM,ACAD UNIT OPHTHALMOL,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham; University of Nottingham								Brittain G P, 1988, Health Trends, V20, P43; CLAOUE CMP, 1986, BMJ-BRIT MED J, V292, P1450, DOI 10.1136/bmj.292.6533.1450; DART JKG, 1986, BRIT MED J, V293, P1477, DOI 10.1136/bmj.293.6560.1477; FEATHERSTONE PI, 1992, BRIT J GEN PRACT, V42, P21; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; JONES NP, 1990, J ROY SOC MED, V83, P770, DOI 10.1177/014107689008301207; LAVIN MJ, 1986, BRIT MED J, V292, P1448, DOI 10.1136/bmj.292.6533.1448; MACKEAN JM, 1982, BRIT MED J, V285, P1093, DOI 10.1136/bmj.285.6348.1093; MORRELL DC, 1971, BRIT MED J, V2, P454, DOI 10.1136/bmj.2.5759.454; VERNON SA, 1988, J ROY SOC MED, V81, P335, DOI 10.1177/014107688808100612; VERNON SA, 1983, J ROYAL SOC MED, V76, P79; WILSON A, 1987, J ROY COLL GEN PRACT, V37, P62	12	32	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1096	1098		10.1136/bmj.304.6834.1096	http://dx.doi.org/10.1136/bmj.304.6834.1096			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1445527	Bronze, Green Published			2022-12-24	WOS:A1992HR13600022
J	CORBOY, JR; BUZY, JM; ZINK, MC; CLEMENTS, JE				CORBOY, JR; BUZY, JM; ZINK, MC; CLEMENTS, JE			EXPRESSION DIRECTED FROM HIV LONG TERMINAL REPEATS IN THE CENTRAL-NERVOUS-SYSTEM OF TRANSGENIC MICE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; CELL-LINES; GLIAL-CELLS; T-CELL; INFECTION; TYPE-1; BRAIN; GENE; TISSUE	Infection with the human immunodeficiency virus (HIV) is frequently accompanied by the AIDS (acquired immunodeficiency syndrome) dementia complex. The role of specific HIV genetic elements in the pathogenesis of central nervous system (CNS) disease is not clear. Transgenic mice were constructed that contained the long terminal repeats (LTRs) of two CNS-derived strains and a T cell tropic strain of HIV-1. Only mice generated with CNS-derived LTRs directed expression in the CNS, particularly in neurons. Thus, some strains of HIV-1 have a selective advantage for gene expression in the brain, and neurons can supply the cellular factors necessary for their transcription.	JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED NEUROL & MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED & PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027297, P30AI028748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007000] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27297, AI28748] Funding Source: Medline; NINDS NIH HHS [NS07000] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1987, LANCET, V2, P234; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFINIS G, 1987, AIDS, V1, P229; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CORBOY JR, UNPUB; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; GRAY F, 1991, ACTA NEUROPATHOL, V82, P229, DOI 10.1007/BF00294450; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HO DD, 1985, NEW ENGL J MED, V313, P1494; Hogan B., 1986, MANIPULATING MOUSE E; HOLAND CA, 1985, J VIROL, V53, P152; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUNSCH C, 1989, J VIROL, V63, P5054, DOI 10.1128/JVI.63.12.5054-5061.1989; KURE K, 1990, ACTA NEUROPATHOL, V80, P393, DOI 10.1007/BF00307693; LANGLEY OK, 1984, HDB NEUROCHEMISTRY, pCH4; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LEONARD J, 1989, AIDS RES HUM RETROV, V5, P421, DOI 10.1089/aid.1989.5.421; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; LEVY JA, 1985, LANCET, V2, P586; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MANNOJI H, 1986, ACTA NEUROPATHOL, V71, P341, DOI 10.1007/BF00688060; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MYERS G, 1991, HUMAN RETROVIRUSES A; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; OVERBEEK PA, 1986, SCIENCE, V231, P1574, DOI 10.1126/science.3006249; POMERANTZ RJ, 1991, J VIROL, V65, P1041, DOI 10.1128/JVI.65.2.1041-1045.1991; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POPOVIC M, 1984, LANCET, V2, P1472; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PUMAROLASUNE T, 1987, ANN NEUROL, V21, P490, DOI 10.1002/ana.410210513; ROSEN CA, 1985, J VIROL, V55, P862, DOI 10.1128/JVI.55.3.862-866.1985; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SKOWRONSKI J, 1991, J VIROL, V65, P754, DOI 10.1128/JVI.65.2.754-762.1991; SMALL JA, 1989, J VIROL, V63, P1891, DOI 10.1128/JVI.63.5.1891-1896.1989; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; VAZEUX R, 1987, AM J PATHOL, V126, P403; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WALKER DG, 1989, J NEUROL NEUROSUR PS, V52, P583, DOI 10.1136/jnnp.52.5.583; WARD JM, 1987, AM J PATHOL, V127, P199; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WOLFS TFW, 1991, VIROLOGY, V185, P195, DOI 10.1016/0042-6822(91)90767-6	57	89	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1804	1808						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465618				2022-12-24	WOS:A1992KB96400042
J	HANNON, GJ; MARONEY, PA; YU, YT; HANNON, GE; NILSEN, TW				HANNON, GJ; MARONEY, PA; YU, YT; HANNON, GE; NILSEN, TW			INTERACTION OF U6 SNRNA WITH A SEQUENCE REQUIRED FOR FUNCTION OF THE NEMATODE SL RNA IN TRANSSPLICING	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PRE-MESSENGER-RNA; LEADER RNA; CAENORHABDITIS-ELEGANS; TRANSSPLICING INVITRO; A-PROTEIN; U1 SNRNA; BINDING; SM; SITE	Nematode trans-spliced leader (SL) RNAs are composed of two domains, an exon [the 22-nucleotide spliced leader] and a small nuclear RNA (snRNA)-like sequence. Participation in vitro of the spliced leader RNA in trans-splicing reactions is independent of the exon sequence or size and instead depends on features contained in the snRNA-like domain of the molecule. Chemical modification interference analysis has revealed that two short sequence elements in the snRNA-like domain are necessary for SL RNA activity. These elements are sufficient for such activity because when added to a 72-nucleotide fragment of a nematode U1 snRNA, this hybrid RNA could participate in trans-splicing reactions in vitro. One of the critical sequence elements may function by base-pairing with U6 snRNA, an essential U snRNA for both cis- and trans-splicing.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Hannon, Gregory/AAB-3568-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28799] Funding Source: Medline; NIGMS NIH HHS [GM31528] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Cao L, UNPUB; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JOSHUA GWP, 1991, MOL BIOCHEM PARASIT, V460, P209; LASALA D, UNPUB; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MARONEY PA, UNPUB; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PATTON JR, 1989, MOL CELL BIOL, V9, P3360, DOI 10.1128/MCB.9.8.3360; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SHAMBAUGH J, UNPUB; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; VANDOREN K, 1988, NATURE, V335, P556; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZENG WL, 1990, MOL CELL BIOL, V10, P2765, DOI 10.1128/MCB.10.6.2765	32	53	54	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1775	1780		10.1126/science.1465612	http://dx.doi.org/10.1126/science.1465612			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465612				2022-12-24	WOS:A1992KB96400034
J	KROENKE, K; LUCAS, CA; ROSENBERG, ML; SCHEROKMAN, B; HERBERS, JE; WEHRLE, PA; BOGGI, JO				KROENKE, K; LUCAS, CA; ROSENBERG, ML; SCHEROKMAN, B; HERBERS, JE; WEHRLE, PA; BOGGI, JO			CAUSES OF PERSISTENT DIZZINESS - A PROSPECTIVE-STUDY OF 100 PATIENTS IN AMBULATORY CARE	ANNALS OF INTERNAL MEDICINE			English	Article						DIZZINESS; AMBULATORY CARE; VESTIBULAR DISEASES; VERTIGO; PSYCHIATRIC STATUS RATING SCALES	DIAGNOSTIC INTERVIEW SCHEDULE; DIZZY PATIENT; GENERAL-POPULATION; MEDICAL OUTCOMES; CLINICAL METHODS; RELIABILITY; SYMPTOMS; VALIDITY; THERAPY; HYPERVENTILATION	Objective: To determine the causes of persistent dizziness in outpatients. Design: Consecutive adult outpatients presenting with a chief complaint of dizziness. Setting: Four clinics (internal medicine, walk-in, emergency room, and neurology) in a teaching hospital. Patients: Of 185 patients presenting during the 10-month study period, 51 (28%) had minimal or no dizziness at 2-week follow-up. Of the remaining 134 patients, 100 completed the study protocol (mean age, 62 years; range, 20 to 85 years). Measurements: Evaluation included a detailed study questionnaire, standardized physical examination, vestibular testing by a neuro-ophthalmologist, laboratory tests, audiometry, and a structured psychiatric interview. Data were abstracted onto a standard form and reviewed by three raters. Raters independently assigned diagnoses using explicit criteria, with the final cause determined by consensus. Results: Primary causes of dizziness included vestibular disorders (54 patients), psychiatric disorders (16 patients), presyncope (6 patients), dysequilibrium (2 patients), and hyperventilation (1 patient); dizziness was multicausal in 13 patients and of unknown cause in 8 patients. Many of those with a single primary cause, however, had at least one other condition contributing to their dizziness; only 52% of patients had a single "pure" cause. Thirty patients had a potentially treatable primary cause, the most common being benign positional vertigo (BPV) (16%) and psychiatric disorders (6%). Central vestibulopathies detected in 10 patients were presumably vascular or idiopathic in origin. No brain tumors or cardiac arrhythmias were found. Conclusions: Vestibular disease and psychiatric disorders are the most common causes of persistent dizziness in outpatients. In about 50% of patients with dizziness, more than one factor causes or aggravates symptoms. Life-threatening causes were rare, even in our elderly population.	UNIFORMED SERV UNIV HLTH SCI, DEPT NEUROL, BETHESDA, MD 20814 USA; WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	KROENKE, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI, DEPT MED, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA.			Kroenke, Kurt/0000-0002-0114-4669				AFZELIUS LE, 1980, LARYNGOSCOPE, V90, P649; Baloh R.W., 1990, CLIN NEUROPHYSIOL; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BRANDT T, 1980, ARCH OTOLARYNGOL, V106, P484; Brandt T., 1991, VERTIGO ITS MULTISEN; CLARK PI, 1980, CHEST, V77, P722, DOI 10.1378/chest.77.6.722; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; FEINSTEIN AR, 1985, J CHRON DIS, V38, P619, DOI 10.1016/0021-9681(85)90016-5; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; HELZER JE, 1985, ARCH GEN PSYCHIAT, V42, P657; HELZER JE, 1987, ARCH GEN PSYCHIAT, V44, P1069; HERR RD, 1989, ANN EMERG MED, V18, P664, DOI 10.1016/S0196-0644(89)80524-4; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOLT PE, 1989, BEHAV RES THER, V27, P453, DOI 10.1016/0005-7967(89)90016-8; JOHNSON JE, 1988, MIL MED, V153, P21; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; KROENKE K, 1991, CLIN RES, V39, pA579; KROENKE K, 1989, JAMA-J AM MED ASSOC, V262, P914; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MADLONKAY DJ, 1985, J FAM PRACTICE, V21, P109; MAGARIAN GJ, 1982, MEDICINE, V61, P219, DOI 10.1097/00005792-198207000-00002; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; OJALA M, 1988, ACTA NEUROL SCAND, V78, P26, DOI 10.1111/j.1600-0404.1988.tb03614.x; REILLY BM, 1991, PRACTICAL STRATEGIES, P162; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINS LN, PSYCHIATRIC DISORDER, P991; SKIENDZIELEWSKI JJ, 1980, ANN EMERG MED, V9, P353, DOI 10.1016/S0196-0644(80)80111-9; SLOANE P, 1989, J AM GERIATR SOC, V37, P101, DOI 10.1111/j.1532-5415.1989.tb05867.x; SLOANE PD, 1989, J FAM PRACTICE, V29, P33; Spitzer R., 1988, STRUCTURED CLIN INTE; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	36	187	192	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					898	904		10.7326/0003-4819-117-11-898	http://dx.doi.org/10.7326/0003-4819-117-11-898			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1443950				2022-12-24	WOS:A1992JZ27600004
J	DONALDSON, JG; FINAZZI, D; KLAUSNER, RD				DONALDSON, JG; FINAZZI, D; KLAUSNER, RD			BREFELDIN-A INHIBITS GOLGI MEMBRANE-CATALYZED EXCHANGE OF GUANINE-NUCLEOTIDE ONTO ARF PROTEIN	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; TRANSPORT; APPARATUS; VESICLES; COFACTOR; COMPLEX; COP	THE fungal metabolite brefeldin A is a powerful tool for investigating membrane traffic in eukaryotic cells1. The effects of brefeldin A on traffic are partly explained by its ability to prevent binding of cytosolic coat proteins onto membranes2-5. The non-clathrin coatomer complex6,7 binds reversibly to Golgi membranes in a GTP-controlled cycle8-10. The low-molecular-mass GTP-binding protein ADP-ribosylation factor (ARF), which also associates reversibly with Golgi membranes11,12, is required for coatomer binding13 and probably accounts for the control by guanine nucleotide of the coatomer-membrane interaction. Brefeldin A prevents the assembly of coatomer onto the membrane by inhibiting the GTP-dependent interaction of ARF with the Golgi membrane13, but the nature of this interaction has not been established. Here we demonstrate that Golgi membranes can specifically catalyse the exchange of GTP onto ARF and that brefeldin A prevents this function.			DONALDSON, JG (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.		finazzi, dario/GYV-1567-2022	Finazzi, Dario/0000-0001-5176-2839				BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; ORCI L, 1991, CELL, V64, P1183; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	26	638	648	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					350	352		10.1038/360350a0	http://dx.doi.org/10.1038/360350a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448151				2022-12-24	WOS:A1992JZ63000053
J	GU, Y; NAKAMURA, T; ALDER, H; PRASAD, R; CANAANI, O; CIMINO, G; CROCE, CM; CANAANI, E				GU, Y; NAKAMURA, T; ALDER, H; PRASAD, R; CANAANI, O; CIMINO, G; CROCE, CM; CANAANI, E			THE T(4-11) CHROMOSOME-TRANSLOCATION OF HUMAN ACUTE LEUKEMIAS FUSES THE ALL-1 GENE, RELATED TO DROSOPHILA-TRITHORAX, TO THE AF-4 GENE	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; FUSION MESSENGER-RNA; DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; BITHORAX COMPLEX; BCR SEQUENCES; CELL-LINE; RAR-ALPHA; EXPRESSION; LOCUS	The ALL-1 gene located at human chromosome 11 band q23 is rearranged in acute leukemias with interstitial deletions or reciprocal translocations between this region and chromosomes 1, 4, 6, 9, 10, or 19. The gene spans approximately 100 kb of DNA and contains at least 21 exons. It encodes a protein of more than 3910 amino acids containing three regions with homology to sequences within the Drosophila trithorax gene, including cysteine-rich regions that can be folded into six zinc finger-like domains. The breakpoint cluster region within ALL-1 spans 8 kb and encompasses several small exons, most of which begin in the same phase of the open reading frame. The t(4;11) chromosome translocation results in two reciprocal fusion products coding for chimeric proteins derived from ALL-1 and from a gene on chromosome 4. This suggests that each 11q23 abnormality gives rise to a specific oncogenic fusion protein.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University	GU, Y (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; CIMINO, Giuseppe/0000-0002-7781-0816	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P6322; CAPDEVILA MP, 1981, ROUX ARCH DEV BIOL, V190, P339, DOI 10.1007/BF00863271; CHU ML, 1990, EMBO J, V9, P985; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; COHEN A, 1991, BLOOD, V78, P94; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HEIM S, 1987, CANCER CYTOGENETICS; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; INGHAM PW, 1985, COLD SPRING HARB SYM, V50, P201, DOI 10.1101/SQB.1985.050.01.026; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LANGE B, 1987, BLOOD, V70, P192; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCKEON J, 1991, ROUX ARCH DEV BIOL, V199, P387, DOI 10.1007/BF01705848; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOZER BA, 1989, P NATL ACAD SCI USA, V86, P3738, DOI 10.1073/pnas.86.10.3738; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RABBITT RH, 1991, CELL, V67, P641; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STONG RC, 1985, BLOOD, V66, P439; STONG RC, 1986, BLOOD, V67, P391; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; WEI S, 1990, CANCER GENET CYTOGEN, V46, P1, DOI 10.1016/0165-4608(90)90002-R; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	39	832	876	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					701	708		10.1016/0092-8674(92)90603-A	http://dx.doi.org/10.1016/0092-8674(92)90603-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423625				2022-12-24	WOS:A1992JY67600017
J	HANDELI, S; WEINTRAUB, H				HANDELI, S; WEINTRAUB, H			THE TS41 MUTATION IN CHINESE-HAMSTER CELLS LEADS TO SUCCESSIVE S PHASES IN THE ABSENCE OF INTERVENING G2, M, AND G1	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-REPLICATION; PROTEIN-KINASE; NEGATIVE CONTROL; FISSION YEAST; CYCLE CONTROL; MITOSIS; COMPLEX; CHECKPOINTS; EXPRESSION	The ts41 mutation of Chinese hamster cells was first isolated and characterized by Hirschberg and Marcus (1982) who showed that at nonpermissive temperature, cells accumulate up to 16C equivalents of DNA. Here we show that the mutation is recessive and at nonpermissive temperature, cells replicate their genome normally, but instead of going on into G2, M, and G1, they pass directly into a second S phase. Entry into a second S phase does not require serum nor is it inhibited by G2 checkpoints or mitotic inhibitors. Temperature-shift experiments suggest that the ts41 gene product participates in two functions in the cell cycle: entry into mitosis and inhibition of entry into S phase. The ts41 mutation seems to define a class of cell cycle mutant that couples the sequential events of DNA replication and mitosis.			HANDELI, S (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,SEATTLE,WA 98104, USA.							ANDEREASSEN PR, 1991, J CELL SCI, V100, P299; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BREWER EN, 1968, EXP CELL RES, V49, P79, DOI 10.1016/0014-4827(68)90521-1; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CHARRON M, 1990, BIOCHEMISTRY-US, V29, P9531, DOI 10.1021/bi00493a006; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DAS M, 1981, P NATL ACAD SCI-BIOL, V78, P5677, DOI 10.1073/pnas.78.9.5677; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1989, J CELL SCI S, V12, P21; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAINSOD A, 1987, MOL CELL BIOL, V7, P775, DOI 10.1128/MCB.7.2.775; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HANKS SK, 1980, J CELL BIOL, V87, P285, DOI 10.1083/jcb.87.1.285; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRAI K, 1971, J VIROL, V8, P828, DOI 10.1128/JVI.8.6.828-835.1971; HIRSCHBERG J, 1982, J CELL PHYSIOL, V113, P159, DOI 10.1002/jcp.1041130125; HOLLIDAY R, 1990, New Biologist, V2, P719; HORAN PK, 1974, INT J CANCER, V14, P514, DOI 10.1002/ijc.2910140411; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KLEVECZ RR, 1982, EXP CELL RES, V140, P307, DOI 10.1016/0014-4827(82)90119-7; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEHMAN JM, 1970, J VIROL, V6, P738, DOI 10.1128/JVI.6.6.738-749.1970; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; RAO AP, 1976, J NATL CANCER I, V57, P11399; Rao P.N., 1982, PREMATURE CHROMOSOME, P1; REED SI, 1980, GENETICS, V95, P561; ROBERTS JM, 1986, CELL, V46, P741, DOI 10.1016/0092-8674(86)90350-8; ROBERTS JM, 1988, CELL, V52, P397, DOI 10.1016/S0092-8674(88)80032-1; SHAMANSKI FL, 1991, CELL, V66, P1289, DOI 10.1016/0092-8674(91)90050-9; SHERLINE P, 1984, EXP CELL RES, V153, P109, DOI 10.1016/0014-4827(84)90453-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH AV, 1991, DEVELOPMENT, V112, P997; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VARSHAVSKY A, 1983, MECHANISMS DNA REPLI, P463; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZETTERBERG A, 1991, COLD SH Q B, V56, P137	59	87	89	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					599	611		10.1016/0092-8674(92)90594-3	http://dx.doi.org/10.1016/0092-8674(92)90594-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423617				2022-12-24	WOS:A1992JY67600008
J	NEEDHAM, PR; DALEY, AG; LENNARD, RF				NEEDHAM, PR; DALEY, AG; LENNARD, RF			STEROIDS IN ADVANCED CANCER - SURVEY OF CURRENT PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									ST JOSEPHS HOSP,LONDON E8 4SA,ENGLAND		NEEDHAM, PR (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT CLIN PHARMACOL & THERAPEUT,LONDON E1 2AD,ENGLAND.							HANKS GW, 1983, POSTGRAD MED J, V59, P702, DOI 10.1136/pgmj.59.697.702; HERXHEIMER A, 1974, DRUG THER B, V16, P63; MOERTEL CG, 1974, CANCER-AM CANCER SOC, V33, P1607, DOI 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V; WEISSMAN DE, 1988, J CLIN ONCOL, V6, P543, DOI 10.1200/JCO.1988.6.3.543; WILLOX JC, 1984, BRIT MED J, V288, P27, DOI 10.1136/bmj.288.6410.27	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					999	999		10.1136/bmj.305.6860.999	http://dx.doi.org/10.1136/bmj.305.6860.999			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458150	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JV77600030
J	DERRICK, JP; WIGLEY, DB				DERRICK, JP; WIGLEY, DB			CRYSTAL-STRUCTURE OF A STREPTOCOCCAL PROTEIN-G DOMAIN BOUND TO AN FAB FRAGMENT	NATURE			English	Article							BINDING DOMAIN; IGG; RECOGNITION; REFINEMENT; SITES	PROTEIN G is a cell-surface protein from Streptococcus1,2 which binds to IgG molecules from a wide range of species with an affinity comparable to that of antigen3,4. The high affinity of protein G for the Fab portion of IgG poses a particular challenge in molecular recognition, given the variability of heavy chain subclass, light chain type and complementarity-determining regions. Here we report the crystal structure of a complex between a protein G domain and an immunoglobulin Fab fragment. An outer beta-strand in the protein G domain forms an antiparallel interaction with the last beta-strand in the constant heavy chain domain of the immunoglobulin, thus extending the beta-sheet into the protein G. The interaction between secondary structural elements in Fab and protein G provides an ingenious solution to the problem of maintaining a high affinity for many different IgG molecules. The structure also contrasts with Fab-antigen complexes, in which all contacts with antigen are mediated by the variable regions of the antibody, and to our knowledge provides the first details of interaction of the constant regions of Fab with another protein.	UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of York - UK	DERRICK, JP (corresponding author), UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, ENGLAND.			Derrick, Jeremy/0000-0002-4350-5354	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BJORCK L, 1990, P113; BJORCK L, 1984, J IMMUNOL, V133, P969; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DERRICK JP, 1992, J MOL BIOL, V227, P1253, DOI 10.1016/0022-2836(92)90535-R; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, P133; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES AT, 1978, J APPL CRYSTALLOGR A, V43, P489; LIAN LY, 1991, BIOCHEMISTRY-US, V30, P5335, DOI 10.1021/bi00236a002; MYHRE E B, 1990, P243; SAWYER JR, 1991, PROTEIN ENG, V4, P947, DOI 10.1093/protein/4.8.947; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; STONE GC, 1989, J IMMUNOL, V143, P565	19	153	167	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					752	754		10.1038/359752a0	http://dx.doi.org/10.1038/359752a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436040				2022-12-24	WOS:A1992JU65000064
J	HORTOBAGYI, GN				HORTOBAGYI, GN			DIAGNOSTIC BREAST IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HORTOBAGYI, GN (corresponding author), TEXAS MED CTR,MD ANDERSON CANC CTR,HOUSTON,TX 77025, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1926	1926						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404721				2022-12-24	WOS:A1992JR43900047
J	MCCARTHY, M				MCCARTHY, M			DO CYCLE HELMETS PREVENT SERIOUS HEAD-INJURY - CYCLING WITHOUT HELMETS	BRITISH MEDICAL JOURNAL			English	Article							BICYCLE				MCCARTHY, M (corresponding author), BLOOMSBURY & ISLINGTON HLTH AUTHOR,PUBL HLTH,LONDON NW1 2LJ,ENGLAND.		McCarthy, Mark/C-1117-2009					ADAMS M, 1990, CAPITAL KILLER AIR P; BULL JP, 1988, BRIT MED J, V296, P1144, DOI 10.1136/bmj.296.6630.1144; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; HAMMER M, 1987, WHEELS WHEELS STUDY; MCCARTHY M, 1991, PUBLIC HEALTH, V105, P327, DOI 10.1016/S0033-3506(05)80218-5; Rogers R, 1992, NEW LONDON; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1991, HLTH MOVE POLICIES P; 1991, ROAD ACCIDENTS GREAT; 1990, CATALOGUE, P328; 1992, CYCLING HLTH SAFETY; 1988, LANCET, V1, P159	12	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					881	882		10.1136/bmj.305.6858.881	http://dx.doi.org/10.1136/bmj.305.6858.881			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422407	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JT77700035
J	LEWIS, SJ; DAVIDSON, RN; ROSS, EJ; HALL, AP				LEWIS, SJ; DAVIDSON, RN; ROSS, EJ; HALL, AP			SEVERITY OF IMPORTED FALCIPARUM-MALARIA - EFFECT OF TAKING ANTIMALARIAL PROPHYLAXIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAVELERS	Objective-To investigate the effects of antimalarial chemoprophylaxis and other variables on the severity of falciparum malaria. Design-Review of consecutive malaria cases between 1987 and 1991. Setting-The Hospital for Tropical Diseases, London. Subjects-250 consecutive cases of mild and 51 consecutive cases of severe falciparum malaria. Results-Prophylaxis was taken in 52.4% (131/250) of the cases of mild malaria and 21.6% (11/51) of cases of severe malaria. Severe malaria was more common in white patients than in those of African origin and was also seen more commonly in people returning from central, southern, and east Africa than in those returning from west Africa. Patients with severe malaria presented sooner than patients with mild malaria. Conclusions-Prior chemoprophylaxis led to a reduction in the severity of falciparum malaria. Ethnic origin, time to presentation, and sex were also associated with the severity of malaria.	HOSP TROP DIS, LONDON NW1 0PE, ENGLAND; MIDDLESEX HOSP, ACAD DEPT GENITOURINARY MED, LONDON NW1, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London								BEHRENS RH, 1991, IN PRESS 2ND P INT C; BRADLEY DJ, 1989, J ROY SOC MED, V82, P8; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; HALL AP, 1972, P HELM SOC WASH, V39, P66; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; WESTEYN JCF, 1985, B WORLD HEALTH ORGAN, V63, P101; [No title captured]	8	61	62	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1992	305	6856					741	743		10.1136/bmj.305.6856.741	http://dx.doi.org/10.1136/bmj.305.6856.741			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1422328	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JQ52000019
J	LEE, EYHP; CHANG, CY; HU, NP; WANG, YCJ; LAI, CC; HERRUP, K; LEE, WH; BRADLEY, A				LEE, EYHP; CHANG, CY; HU, NP; WANG, YCJ; LAI, CC; HERRUP, K; LEE, WH; BRADLEY, A			MICE DEFICIENT FOR RB ARE NONVIABLE AND SHOW DEFECTS IN NEUROGENESIS AND HEMATOPOIESIS	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; MOUSE EMBRYO; ENCODED PROTEIN; CARCINOMA-CELLS; STEM-CELLS; BINDING	The retinoblastoma gene, a prototypic tumour-suppressor gene, encodes a nuclear phosphoprotein (Rb). To understand better the role of Rb in development and in tumorigenesis, mice with an insertional mutation in exon 20 of the Rb-1 locus were generated. Homozygous mutants die before the 16th embryonic day with multiple defects. The haematopoietic system is abnormal; there is a significant increase in the number of immature nucleated erythrocytes. In the nervous system, ectopic mitoses and massive cell death are found, particularly in the hindbrain. All spinal ganglion cells die, but the neural retina is unaffected. Transfer of the human retinoblastoma (RB) mini-transgene into the mutant mice corrects the developmental defects. Thus, Rb is essential for normal mouse development.	UNIV TEXAS, HLTH SCI CTR, INST BIOTECHNOL, SAN ANTONIO, TX 78284 USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMER RES LAB, CLEVELAND, OH 44106 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; Baylor College of Medicine	LEE, EYHP (corresponding author), UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, SAN ANTONIO, TX 78284 USA.		; Herrup, Karl/C-5313-2014	Bradley, Allan/0000-0002-2349-8839; Herrup, Karl/0000-0001-7786-5844				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Knudson A G Jr, 1989, Birth Defects Orig Artic Ser, V25, P15; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1991, PROG CLIN BIOL RES, V362, P221; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1990, TUMOUR SUPPRESSOR GE, P159; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VOGEL F, 1979, HUM GENET, V52, P1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	49	1150	1170	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					288	294		10.1038/359288a0	http://dx.doi.org/10.1038/359288a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406932				2022-12-24	WOS:A1992JP50300045
J	WAKABAYASHI, I; SAKAMOTO, K; YOSHIMOTO, S; MASUI, H				WAKABAYASHI, I; SAKAMOTO, K; YOSHIMOTO, S; MASUI, H			RELATION OF SERUM SIALIC-ACID TO LIPID CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article											WAKABAYASHI, I (corresponding author), HYOGO MED UNIV,DEPT HYG,1-1 MUKOGAWA CHO,NISHINOMIYA,HYOGO 663,JAPAN.							COMB DG, 1960, J BIOL CHEM, V235, P2529; LINDBERG G, 1991, BRIT MED J, V303, P1306, DOI 10.1136/bmj.303.6813.1306; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; RADHAKRISHNAMURTHY B, 1976, LAB INVEST, V34, P159; SHVARTZ OLS, 1971, PROBLEMY ENDOKRINOLO, V17, P37	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					562	563		10.1136/bmj.305.6853.562	http://dx.doi.org/10.1136/bmj.305.6853.562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393037	Green Published, Green Submitted			2022-12-24	WOS:A1992JM49500019
J	JOSEPH, CA; WATSON, JM; FERN, KJ				JOSEPH, CA; WATSON, JM; FERN, KJ			BCG IMMUNIZATION IN ENGLAND AND WALES - A SURVEY OF POLICY AND PRACTICE IN SCHOOLCHILDREN AND NEONATES	BRITISH MEDICAL JOURNAL			English	Article							VACCINATION; TUBERCULOSIS	Objective-To determine the policy and practice of district health authorities in England and Wales for BCG immunisation in schoolchildren and neonates. Design-Self completion postal questionnaire survey. Participants-District immunisation coordinators. Setting-199 district health authorities in England and Wales. Results-Questionnaires were received from 186 districts, a response rate of 94%. Considerable uniformity was observed in many aspects of BCG immunisation policy and practice but some important variations were found. 15 districts no longer carry out a routine schools programme. 148 districts offer BCG to selected groups of neonates and five to all neonates, but 31 districts do not offer BCG to this age group. The recommended action in response to different levels of tuberculin sensitivity in schoolchildren and neonates varied among districts. Conclusions-Despite the recommendations of the Joint Committee on Vaccination and Immunisation some districts do not offer BCG immunisation to neonates at high risk of tuberculosis and there are important variations in other aspects of BCG policy.			JOSEPH, CA (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,RESP DIS SECT,LONDON NW9 KEQ,ENGLAND.							CITRON KM, 1990, BRIT MED J, V301, P1275, DOI 10.1136/bmj.301.6763.1275; CUNDALL DB, 1988, ARCH DIS CHILD, V63, P964, DOI 10.1136/adc.63.8.964; CURTIS HM, 1984, LANCET, V1, P145; Dean A. G., 1990, EPI INFO VERSION 5 W; FRANKENBERG RA, 1991, J PUBLIC HEALTH MED, V13, P209, DOI 10.1093/oxfordjournals.pubmed.a042620; MILLER CL, 1984, BRIT MED J, V288, P564, DOI 10.1136/bmj.288.6416.564; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; RODRIGUES LC, 1991, J EPIDEMIOL COMMUN H, V45, P78, DOI 10.1136/jech.45.1.78; SPRINGETT VH, 1990, THORAX, V45, P83, DOI 10.1136/thx.45.2.83; SUTHERLAND I, 1989, J EPIDEMIOL COMMUN H, V43, P15, DOI 10.1136/jech.43.1.15; Watson J M, 1991, CDR (Lond Engl Rev), V1, pR13; 1985, BMJ, V291, P658; IN PRESS IMMUNISATIO; 1974, COMMUNICABLE DISEASE; 1927, ANNUAL REPORT; 1985, SCH BCG VACCINATION	16	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					495	498		10.1136/bmj.305.6852.495	http://dx.doi.org/10.1136/bmj.305.6852.495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392994	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JL60900015
J	HARDMAN, TC; DUBREY, SW; LESLIE, DG; HAFIZ, M; NOBLE, MI; LANT, AF				HARDMAN, TC; DUBREY, SW; LESLIE, DG; HAFIZ, M; NOBLE, MI; LANT, AF			ERYTHROCYTE SODIUM-LITHIUM COUNTERTRANSPORT AND BLOOD-PRESSURE IN IDENTICAL TWIN PAIRS DISCORDANT FOR INSULIN-DEPENDENT DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RED-CELLS; ESSENTIAL-HYPERTENSION; MELLITUS; CHILDREN; NEPHROPATHY; EXCHANGE	Objective-To investigate whether insulin dependent diabetes is responsible for the abnormal behaviour of the carrier in sodium-lithium countertransport and whether the diabetic state is associated with rise in blood pressure. Design-Case-control study. Setting-London teaching hospital. Subjects-44 twin pairs discordant for insulin dependent diabetes living in United Kingdom and 44 healthy control subjects matched for age, sex, and body mass index. None of the twin pairs or the controls had evidence of microalbuminuria. Main outcome measures-Sodium-lithium countertransport activity in erythrocytes and arterial blood pressure. Results-The mean (95% confidence interval) sodium-lithium countertransport activity (mmol Li per litre of red blood cells per h) of the diabetic twins (0.291 (0.244 to 0.338)) was similar to that of their non-diabetic cotwins (0.247 (0.204 to 0.290)); both values were significantly higher than that of the controls (0.187 (0.157 to 0.216), p<0.05). In addition, systolic blood pressure was higher in those twins with diabetes (127 (122 to 133) mm Hg) than in the non-diabetic cotwins (122 (117 to 127) mm Hg; p<0.01). There were no significant differences in mean diastolic blood pressure between any of the groups studied. Conclusions-The raised erythrocyte sodium-lithium countertransport activity in the diabetic twins compared with the controls seems to be inherited rather than a consequence of overt diabetes. The higher systolic blood pressure in diabetic twins than non-diabetic cotwins indicates that insulin dependent diabetes does exert a small influence on systolic blood pressure.	WESTMINSTER MED SCH & HOSP, CHARING CROSS & WESTMINSTER MED SCH, ACAD UNIT CARDIOVASC MED, LONDON SW1P 2AP, ENGLAND	Imperial College London			Leslie, Richard/AAF-6977-2020	Leslie, Richard/0000-0002-1786-1531; Hardman, Tim/0000-0002-1417-9019	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; CANESSA M, 1989, METHOD ENZYMOL, V173, P176; CARR S, 1990, NEW ENGL J MED, V322, P500, DOI 10.1056/NEJM199002223220803; EILERS RJ, 1967, AM J CLIN PATHOL, V47, P212, DOI 10.1093/ajcp/47.2.212; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; FOYLE WJ, 1991, J HYPERTENS, V9, P713, DOI 10.1097/00004872-199108000-00004; HALKIN A, 1991, CLIN SCI, V81, P223, DOI 10.1042/cs0810223; HUNT SC, 1991, HYPERTENSION, V17, P1; IBSEN KK, 1983, ACTA PAEDIATR SCAND, V72, P191, DOI 10.1111/j.1651-2227.1983.tb09695.x; JENSEN JS, 1990, DIABETOLOGIA, V33, P619, DOI 10.1007/BF00400206; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; LAURENZI M, 1989, HYPERTENSION, V13, P408, DOI 10.1161/01.HYP.13.5.408; LEWITTER FI, 1985, AM J HUM GENET S, V36, pS172; MANGILI R, 1988, NEW ENGL J MED, V318, P146, DOI 10.1056/NEJM198801213180304; MATHIESEN ER, 1985, DIABETES, V34, P1301, DOI 10.2337/diabetes.34.12.1301; ROWE DJF, 1990, ANN CLIN BIOCHEM, V27, P297, DOI 10.1177/000456329002700404; RUTHERFORD PA, 1992, CLIN SCI, V82, P341, DOI 10.1042/cs0820341; RUTHERFORD PA, 1990, CLIN SCI, V79, P365, DOI 10.1042/cs0790365; SCHIEKEN RM, 1989, AM J CARDIOL, V64, P1333, DOI 10.1016/0002-9149(89)90577-8; SMITH JB, 1986, CLIN CHIM ACTA, V157, P317, DOI 10.1016/0009-8981(86)90308-6; SMITH JB, 1982, CLIN CHIM ACTA, V122, P327, DOI 10.1016/0009-8981(82)90135-8; TARN AC, 1986, DIABETOLOGIA, V29, P275, DOI 10.1007/BF00452062; TREVISAN M, 1981, CLIN CHIM ACTA, V116, P319, DOI 10.1016/0009-8981(81)90051-6; TURNER ST, 1989, HYPERTENSION, V13, P378, DOI 10.1161/01.HYP.13.4.378; WALKER JD, 1990, BMJ-BRIT MED J, V301, P633; WEDER AB, 1986, J HYPERTENS, V4, pS373; 1980, DIABETES, V28, P1039; 1979, WHO TECH REP SER, V628	29	27	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1992	305	6847					215	219		10.1136/bmj.305.6847.215	http://dx.doi.org/10.1136/bmj.305.6847.215			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392822	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JG11200019
J	LIPSITZ, LA; GOLDBERGER, AL				LIPSITZ, LA; GOLDBERGER, AL			LOSS OF COMPLEXITY AND AGING - POTENTIAL APPLICATIONS OF FRACTALS AND CHAOS THEORY TO SENESCENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE-VARIABILITY; NONLINEAR DYNAMICS; SINUS ARRHYTHMIA; ELDERLY PERSONS; AGE; SYNCOPE; HORMONE; MEN	The concept of "complexity," derived from the field of nonlinear dynamics, can be adapted to measure the output of physiologic processes that generate highly variable fluctuations resembling "chaos." We review data suggesting that physiologic aging is associated with a generalized loss of such complexity in the dynamics of healthy organ system function and hypothesize that such loss of complexity leads to an impaired ability to adapt to physiologic stress. This hypothesis is supported by observations showing an age-related loss of complex variability in multiple physiologic processes including cardiovascular control, pulsatile hormone release, and electroencephalographic potentials. If further research supports this hypothesis, measures of complexity based on chaos theory and the related geometric concept of fractals may provide new ways to monitor senescence and test the efficacy of specific interventions to modify the age-related decline in adaptive capacity.	HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	LIPSITZ, LA (corresponding author), HARVARD UNIV,SCH MED,HEBREW REHABIL CTR AGED,RES & TRAINING INST,1200 CTR ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42172] Funding Source: Medline; NIA NIH HHS [AGO439O, AGO8812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOUD S, 1991, CIRC RES, V68, P1751, DOI 10.1161/01.RES.68.6.1751; CALLOWAY NO, 1966, J AM GERIATR SOC, V14, P342, DOI 10.1111/j.1532-5415.1966.tb05595.x; CASERTA F, 1990, PHYS REV LETT, V64, P95, DOI 10.1103/PhysRevLett.64.95; DAVIDSON MB, 1979, METABOLISM, V28, P688, DOI 10.1016/0026-0495(79)90024-6; DEBOER RW, 1984, IEEE T BIO-MED ENG, V31, P384, DOI 10.1109/TBME.1984.325351; FROLKIS VV, 1979, INTERDISCIPLINARY TO, V16, P87; GLENNY RW, 1991, J APPL PHYSIOL, V70, P2351, DOI 10.1152/jappl.1991.70.6.2351; GOLDBERGER A L, 1990, Scientific American, V262, P42; GOLDBERGER AL, 1990, UBIQUITY OF CHAOS, P23; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; GOLDBERGER AL, 1987, ANN NY ACAD SCI, V504, P195, DOI 10.1111/j.1749-6632.1987.tb48733.x; GOLDBERGER AL, 1991, NEWS PHYSIOL SCI, V6, P87, DOI 10.1152/physiologyonline.1991.6.2.87; GREENSPAN SL, 1991, AM J PHYSIOL, V260, pE486, DOI 10.1152/ajpendo.1991.260.3.E486; HELLMAN JB, 1976, J APPL PHYSIOL, V41, P734, DOI 10.1152/jappl.1976.41.5.734; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; JARISCH WR, 1987, EXPERIENTIA, V43, P1207, DOI 10.1007/BF01945526; KAPLAN DT, 1991, BIOPHYS J, V59, P945, DOI 10.1016/S0006-3495(91)82309-8; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LIPSITZ LA, 1989, J GERONTOL, V44, pM179, DOI 10.1093/geronj/44.6.M179; LIPSITZ LA, 1990, CIRCULATION, V81, P1803, DOI 10.1161/01.CIR.81.6.1803; MADDENS M, 1987, AM J CARDIOL, V60, P1368, DOI 10.1016/0002-9149(87)90621-7; MADER S, 1984, J AM GERIATR SOC, V32, P548, DOI 10.1111/j.1532-5415.1984.tb02245.x; Mandelbrot B.B, 1982, FRACTAL GEOMETRY NAT; MANDELL AJ, 1990, UBIQUITY OF CHAOS, P35; MOSEKILDE L, 1988, BONE, V9, P247, DOI 10.1016/8756-3282(88)90038-5; MUNSAT TL, 1984, CLIN NEUROLOGY AGING, P416; PAULUS MP, 1990, P NATL ACAD SCI USA, V87, P723, DOI 10.1073/pnas.87.2.723; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; RAPP FE, 1990, UBIQUITY CHAOS, P10; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SAMARAS TT, 1974, HUM DEV, V17, P314, DOI 10.1159/000271354; Scheibel A B, 1985, Clin Geriatr Med, V1, P671; SIMPSON DM, 1988, J GERONTOL, V43, pM21, DOI 10.1093/geronj/43.1.M21; SKINNER JE, 1991, CIRC RES, V68, P966, DOI 10.1161/01.RES.68.4.966; SMITH SA, 1982, BRIT MED J, V285, P1599, DOI 10.1136/bmj.285.6355.1599; SMITH TG, 1989, J NEUROSCI METH, V27, P173, DOI 10.1016/0165-0270(89)90100-3; TOBIN JD, 1981, AGING CHALLENGE SCI; URBAN RJ, 1988, J CLIN INVEST, V81, P1020, DOI 10.1172/JCI113412; WEI JY, 1987, CURR PROB CARDIOLOGY, V12, P7; WEST BJ, 1987, AM SCI, V75, P354; 1991, LANCET, V338, P1425	43	815	842	1	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1806	1809		10.1001/jama.267.13.1806	http://dx.doi.org/10.1001/jama.267.13.1806			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1482430				2022-12-24	WOS:A1992HK67200031
J	WICHMANN, H; HENGST, L; GALLWITZ, D				WICHMANN, H; HENGST, L; GALLWITZ, D			ENDOCYTOSIS IN YEAST - EVIDENCE FOR THE INVOLVEMENT OF A SMALL GTP-BINDING PROTEIN (YPT7P)	CELL			English	Article							EPITHELIAL-CELL LINE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; VACUOLAR BIOGENESIS; MOLECULAR-CLONING; PLASMA-MEMBRANE; YPT1/SEC4-RELATED CDNAS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; MUTATIONAL ANALYSIS	From the budding yeast S. cerevisiae, we have cloned a gene, YPT7, that encodes a GTP-binding protein belonging to the Ypt family of ras-related proteins. The 208 amino acid protein shares identical effector domain and C-terminal sequences with the mammalian Rab7 protein. YPT7 gene disruption did not impair cellular growth at temperatures ranging from 17-degrees-C to 37-degrees-C. ypt7 null mutants are characterized by highly fragmented vacuoles and differential defects of vacuolar protein transport and maturation. The uptake of alpha factor pheromone by wild-type and Ypt7p-deficient cells was found to be indistinguishable, but in mutant cells lacking Ypt7p, degradation of the endocytosed pheromone was severely inhibited. Our findings suggest a role of Ypt7p in protein transport between endosome-like compartments.			WICHMANN, H (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, W-3400 GOTTINGEN, GERMANY.			Hengst, Ludger/0000-0002-0605-0223				BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GUTHRIE C, 1991, METH ENZYMOL, V194; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; MAKAROW M, 1985, EMBO J, V4, P1861, DOI 10.1002/j.1460-2075.1985.tb03861.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRESTON RA, 1987, J CELL BIOL, V105, P1981, DOI 10.1083/jcb.105.5.1981; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; RAYMOND CK, 1992, IN PRESS INT REV CYT; REID GA, 1983, METHOD ENZYMOL, V97, P324; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Stevens B J, 1979, Methods Enzymol, V56, P718; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOOLFORD CA, 1990, GENETICS, V125, P739; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	79	210	213	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1131	1142		10.1016/S0092-8674(05)80062-5	http://dx.doi.org/10.1016/S0092-8674(05)80062-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473149				2022-12-24	WOS:A1992KE60400008
J	SUNDT, TM				SUNDT, TM			SURGERY FOR INTRACEREBRAL HEMORRHAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SUNDT, TM (corresponding author), MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3248	3248						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433770				2022-12-24	WOS:A1992KA65400035
J	KNEKT, P; HELIOVAARA, M; RISSANEN, A; AROMAA, A; AARAN, RK				KNEKT, P; HELIOVAARA, M; RISSANEN, A; AROMAA, A; AARAN, RK			SERUM ANTIOXIDANT VITAMINS AND RISK OF CATARACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DISCHARGE DATA; SENILE CATARACT; PREVENTION; VALIDITY; AGE	Objective-To investigate serum concentrations of alpha tocopherol, beta carotene, retinol, and selenium for their prediction of end stage cataract. Design-A case-control study, nested within a cohort study, based on the linkage of records of subjects aged 40-83 from a health survey with those from the national Finnish hospital discharge register. Subjects-47 patients admitted to ophthalmological wards for senile cataract over 15 years and two controls per patient individually matched for sex, age, and municipality. Main outcome measure-Concentration of serum micronutrients, development of cataract according to whether operation was performed. Results-Low serum concentrations of antioxidant vitamins predicted the development of senile cataract, the odds ratio between the lowest third and the two higher thirds of the distribution of serum concentrations of alpha tocopherol and beta carotene being 1-9 (95% confidence interval 0.9 to 4.1) and 1.7 (0.8 to 3.8), respectively. Patients with both alpha tocopherol and beta carotene concentrations in the lowest third had an odds ratio of 2.6 (1.0 to 6.8) of cataract compared with subjects in the top two thirds. The associations were strengthened by adjustment for potential confounding factors such as occupation, smoking, blood pressure, serum cholesterol concentration, body mass index, and diabetes. No association was found between the serum concentrations of selenium, retinol, and retinol binding protein and the risk of cataract. Conclusions-Low serum concentrations of the antioxidant vitamins alpha tocopherol and beta carotene are risk factors for end stage senile cataract. Controlled trials of the role of antioxidant vitamins in cataract prevention are therefore warranted.	UNIV TAMPERE, DEPT BIOMED SCI, TAMPERE, FINLAND	Tampere University	KNEKT, P (corresponding author), SOCIAL INSURANCE INST, POB 78, SF-00381 HELSINKI, FINLAND.							AARAN RK, 1988, J PHARMACEUT BIOMED, V6, P853, DOI 10.1016/0731-7085(88)80101-8; ALFTHAN G, 1982, ANAL CHIM ACTA, V140, P221, DOI 10.1016/S0003-2670(01)95468-6; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CHENG H, 1989, BRIT MED J, V298, P1470, DOI 10.1136/bmj.298.6686.1470; GERSTER H, 1989, Z ERNAHRUNGSWISS, V28, P56, DOI 10.1007/BF02025566; HELIOVAARA M, 1987, J CHRON DIS, V40, P251, DOI 10.1016/0021-9681(87)90161-5; HELIOVAARA M, 1984, ACTA MED SCAND, V216, P309; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; JACQUES PF, 1991, MICRONUTRIENTS HLTH, P359; KENNEDY RH, 1984, INVEST OPHTHALMOL  S, V25, P1; KNEKT P, 1988, AM J EPIDEMIOL, V127, P28, DOI 10.1093/oxfordjournals.aje.a114788; KNEKT P, 1988, SERUM ALPHA TOCOPHER, pML83; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; POIKOLAINEN K, 1983, DRUG ALCOHOL DEPEN, V12, P315, DOI 10.1016/0376-8716(83)90002-9; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; SHETTY PS, 1979, LANCET, V2, P230; TEIKARI JM, 1987, ACTA OPHTHALMOL, V65, P589; 1985, WHO TECH REP SER, V727	21	126	129	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1392	1394		10.1136/bmj.305.6866.1392	http://dx.doi.org/10.1136/bmj.305.6866.1392			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486302	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992KB85600020
J	BLOCK, SM				BLOCK, SM			MAKING LIGHT WORK WITH OPTICAL TWEEZERS	NATURE			English	Article							INFRARED-LASER BEAMS; MEMBRANE-GLYCOPROTEINS; FORCE; MANIPULATION; TRAP; PARTICLES; FIELDS		HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA	Harvard University	BLOCK, SM (corresponding author), ROWLAND INST SCI INC, 100 CAMBRIDGE PKWY, CAMBRIDGE, MA 02142 USA.							ASHKIN A, 1992, BIOPHYS J, V61, P569, DOI 10.1016/S0006-3495(92)81860-X; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; ASHKIN A, 1989, P NATL ACAD SCI USA, V86, P7914, DOI 10.1073/pnas.86.20.7914; ASHKIN A, 1989, BER BUNSEN PHYS CHEM, V93, P254, DOI 10.1002/bbpc.19890930308; BARTON JP, 1989, J APPL PHYS, V66, P2800, DOI 10.1063/1.344207; BARTON JP, 1989, J APPL PHYS, V66, P4594, DOI 10.1063/1.343813; BARTON JP, 1988, J APPL PHYS, V64, P1632, DOI 10.1063/1.341811; Bems M. W., 1991, INT REV CYTOL, V129, P1; BEMS MW, 1989, P NATL ACAD SCI USA, V86, P4539; BEMS MW, 1992, EXP CELL RES, V198, P375; BERG HC, 1976, J THEOR BIOL, V56, P269, DOI 10.1016/S0022-5193(76)80074-4; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOCK SM, 1990, NONINVASIVE TECHNIQU, V9, P375; BURNS MM, 1990, SCIENCE, V249, P749, DOI 10.1126/science.249.4970.749; CHARON NW, 1992, J BACTERIOL, V174, P832, DOI 10.1128/jb.174.3.832-840.1992; CHU S, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0292-70; DENK W, 1990, APPL OPTICS, V29, P2382, DOI 10.1364/AO.29.002382; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; HONG LA, 1991, EXP CELL RES, V197, P21, DOI 10.1016/0014-4827(91)90475-A; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1990, BIOPHYS J, V57, pA399; MISAWA H, 1992, APPL PHYS LETT, V60, P310, DOI 10.1063/1.106695; SATO S, 1991, OPT LETT, V16, P282, DOI 10.1364/OL.16.000282; SCHUT TCB, 1991, CYTOMETRY, V12, P479, DOI 10.1002/cyto.990120603; SEEGER S, 1991, CYTOMETRY, V12, P497, DOI 10.1002/cyto.990120606; SHEPHERD GMG, 1990, P NATL ACAD SCI USA, V87, P8627, DOI 10.1073/pnas.87.21.8627; SIMMONS RM, 1992, MECHANISM MYOFILAMEN; SIMON A, 1992, PHYS REV LETT, V68, P3375, DOI 10.1103/PhysRevLett.68.3375; STEUBING RW, 1991, CYTOMETRY, V12, P505, DOI 10.1002/cyto.990120607; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; TADIR Y, 1990, FERTIL STERIL, V53, P944; VISSCHER K, 1992, OPTIK, V90, P57; VISSCHER K, 1992, J OPTIK, V89, P174; WAYNE D B, 1991, Journal of Cell Biology, V115, p102A; WEBER G, 1992, INT REV CYTOL, V133, P1, DOI 10.1016/S0074-7696(08)61857-4; WRIGHT WH, 1990, IEEE J QUANTUM ELECT, V26, P2148, DOI 10.1109/3.64351	42	139	149	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					493	495		10.1038/360493a0	http://dx.doi.org/10.1038/360493a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448176				2022-12-24	WOS:A1992KA79700071
J	RICHARDSON, MA; GERLITZ, B; GRINNELL, BW				RICHARDSON, MA; GERLITZ, B; GRINNELL, BW			ENHANCING PROTEIN-C INTERACTION WITH THROMBIN RESULTS IN A CLOT-ACTIVATED ANTICOAGULANT	NATURE			English	Article							THROMBOMODULIN; COAGULATION; EXPRESSION; SUBSTITUTION; INHIBITION; INFUSION; SEQUENCE; MODEL	HUMAN protein C is a vitamin K-dependent plasma glycoprotein that circulates as an inactive zymogen. At the endothelial cell surface, thrombin in complex with the integral membrane protein thrombomodulin converts protein C to its active form by specific cleavage of an activation peptide1-3. The activated form of protein C has potent anticoagulant activity as a feedback regulator of thrombin generation (reviewed in refs 4-6), and also has profibrinolytic7-10, anti-ischaemic11 and anti-inflammatory properties12. Protein C is effective in the treatment of model and human thrombotic diseases4,13-16 but, except when it has been used to treat genetic or acquired deficiencies and microvascular thrombosis, it is administered as the activated enzyme, which has a short biological half-life. We have altered two putative inhibitory acidic residues near the thrombin cleavage site, which results in a 30-fold increase in substrate utilization by alpha-thrombin. We combined these changes with a genetically altered glycoform to generate a zymogen protein C with a 60-fold increased cleavage rate by free alpha-thrombin, independent of its cofactor thrombomodulin. We show that this 'proform' of protein C, unlike the natural circulating zymogen, can be activated by thrombin generated in clotting human plasma, resulting in an inhibition of further clot formation. Our data therefore show that we have engineered a site-activated agent, which only has anticoagulant activity when significant amounts of thrombin are being generated.	ELI LILLY & CO, LILLY RES LAB, LILLY CORP CTR, DEPT CARDIOVASC RES, INDIANAPOLIS, IN 46285 USA	Eli Lilly								BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; CHANG JY, 1985, EUR J BIOCHEM, V151, P271; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; EHRLICH HJ, 1989, J BIOL CHEM, V264, P14298; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; EMERICK SC, 1987, PHARM TOXICOLOGY PRO, P351; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; ESMON NL, 1982, J BIOL CHEM, V257, P859; FENG FN, 1989, BIOCHEMISTRY-US, V28, P3094; GARDNER JE, 1983, HUMAN PROTEIN C THRO, P265; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; GRINNELL BW, 1990, PROTEIN C RELATED AN, P13; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; GRUBER A, 1989, BLOOD, V73, P639; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; OKAJIMA K, 1990, AM J HEMATOL, V33, P277, DOI 10.1002/ajh.2830330413; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; ROMISCH J, 1991, FIBRINOLYSIS, V5, P191, DOI 10.1016/0268-9499(91)90023-W; SNOW TR, 1991, CIRCULATION, V84, P293, DOI 10.1161/01.CIR.84.1.293; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; YE J, 1991, J BIOL CHEM, V266, P23016; ZOLTON R P, 1973, Thrombosis Research, V3, P23, DOI 10.1016/0049-3848(73)90123-0	33	47	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					261	264		10.1038/360261a0	http://dx.doi.org/10.1038/360261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436107				2022-12-24	WOS:A1992JY96000052
J	GOODRICH, DW; LEE, WH				GOODRICH, DW; LEE, WH			ABROGATION BY C-MYC OF G1 PHASE ARREST INDUCED BY RB PROTEIN BUT NOT BY P53	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; BINDING; DIFFERENTIATION; MICROINJECTION; TRANSFORMATION; SUPPRESSION; ONCOGENE; DOMAINS; GROWTH	INACTIVATING mutations of the retinoblastoma gene (RB) are found in a wide variety of tumour cells1. Replacement of wild-type RB can suppress the tumorigenicity of some of these cells, suggesting that the RB protein (Rb) may negatively regulate cell growth2-4. As activation of c-myc expression promotes cell proliferation and blocks differentiation, it may positively regulate cell growth5-9. The c-myc protein is localized in the nucleus and can physically associate with RB protein in vitro10, hence c-myc may functionally antagonize RB function. Microinjection of Rb in G1 phase reversibly arrests cell-cycle progression11. Here we co-inject RB protein with c-myc, EJ-ras, c-fos or c-jun protein. Co-injection of c-myc, but not EJ-ras, c-fos or c-jun, inhibits the ability of Rb to arrest the cell cycle. The c-myc does not inhibit the activity of another tumour supressor, p53 (ref. 12). Thus, c-myc and RB specifically antagonize one another in the cell.			GOODRICH, DW (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.							BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; Bishop JM, 1982, RNA TUMOR VIRUSES, P999; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPOLLA JS, 1986, NATURE, V320, P760; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOIODRICH DW, 1992, CAN RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1991, COLD SH Q B, V56, P211; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER CW, 1990, CANCER RES, V50, P7950; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PREDERGAST GC, 1992, TRENDS GENET, V8, P91; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	33	107	110	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					177	179		10.1038/360177a0	http://dx.doi.org/10.1038/360177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436095				2022-12-24	WOS:A1992JX75200066
J	GIBBS, RA; TAYLOR, S; BENKOVIC, SJ				GIBBS, RA; TAYLOR, S; BENKOVIC, SJ			ANTIBODY-CATALYZED REARRANGEMENT OF THE PEPTIDE-BOND	SCIENCE			English	Article							PROTEINS; DEAMIDATION; ASPARAGINYL; RESIDUES	The generation of antibodies from a bifunctional cyclic phosphinate transition-state analog provided agents capable of efficiently catalyzing both steps of the overall conversion of a substrate containing an asparaginyl-glycyl sequence through a succinimide intermediate to the products aspartyl-glycyl and the rearranged isoaspartyl-glycyl sequence. This reaction provides a potential means in addition to amide cleavage for the deactivation of protein or peptide biological functions in vivo.			GIBBS, RA (corresponding author), PENN STATE UNIV,DEPT CHEM,152 DAVEY LAB,UNIV PK,PA 16802, USA.							AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; GIBBS RB, UNPUB; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MODRITZER K, 1975, SYN REACT INORG MET, V5, P45; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; NIMAN HL, 1980, P NATL ACAD SCI-BIOL, V77, P4524, DOI 10.1073/pnas.77.8.4524; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; Quin L. D., 1981, HETEROCYCLIC CHEM PH; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6	17	35	36	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					803	805		10.1126/science.1439788	http://dx.doi.org/10.1126/science.1439788			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439788				2022-12-24	WOS:A1992JV69200039
J	GAO, JL; XIA, XF				GAO, JL; XIA, XF			A PRIORI EVALUATION OF AQUEOUS POLARIZATION EFFECTS THROUGH MONTE-CARLO QM-MM SIMULATIONS	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; REACTION FIELD-THEORY; FREE-ENERGY; ELECTRONIC-PROPERTIES; COMPUTER-SIMULATION; POTENTIAL FUNCTIONS; LIQUID WATER; SOLVATION; MODEL; PROTEINS	A Monte Carlo quantum mechanical-molecular mechanical (QM-MM) simulation method was used to determine the contributions of the solvent polarization effect to the total interaction energies between solute and solvent for amino acid side chains and nucleotide bases in aqueous solution. In the present AM1-TIP3P approach, the solute molecule is characterized by valence electrons and nucleus cores with Hartree-Fock theory incorporating explicit solvent effects into the total Hamiltonian, while the solvent is approximated by the three-point charge TIP3P model. The polarization energy contributes 10 to 20 percent of the total electrostatic energy in these systems. The performance of the hybrid AM1-TIP3P model was further validated by consideration of bimolecular complexes with water and by computation of the free energies of solvation of organic molecules using statistical perturbation theory. Excellent agreement with ab initio 6-31G(d) results and experimental solvation free energies was obtained.			GAO, JL (corresponding author), SUNY BUFFALO,DEPT CHEM,BUFFALO,NY 14214, USA.							Allen M. P., 1987, COMPUTER SIMULATIONS; BARNES P, 1979, NATURE, V282, P459, DOI 10.1038/282459a0; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BASH PA, 1987, J AM CHEM SOC, V109, P8192; BENNAIM A, 1984, J CHEM PHYS, V81, P2016, DOI 10.1063/1.447824; Bernal JD, 1933, J CHEM PHYS, V1, P515, DOI 10.1063/1.1749327; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BOTTCHER CJF, 1973, THEORY ELECTRIC POLA; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CEPERLEY D, 1986, SCIENCE, V231, P555, DOI 10.1126/science.231.4738.555; CRAMER CJ, 1991, J AM CHEM SOC, V113, P8305, DOI 10.1021/ja00022a017; CRAMER CJ, 1992, SCIENCE, V256, P213, DOI 10.1126/science.256.5054.213; CRAMER CJ, 1991, J AM CHEM SOC, V113, P8552, DOI 10.1021/ja00022a069; DANG LX, 1991, J AM CHEM SOC, V113, P2481, DOI 10.1021/ja00007a021; DEWAR MJS, 1990, J COMPUT CHEM, V11, P541, DOI 10.1002/jcc.540110413; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; FLORIS F, 1989, J COMPUT CHEM, V10, P616, DOI 10.1002/jcc.540100504; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; GAO J, 1992, MCQUB; GAO JL, 1992, J AM CHEM SOC, V114, P1912, DOI 10.1021/ja00031a073; GAO JL, 1992, J PHYS CHEM-US, V96, P537, DOI 10.1021/j100181a009; Hehre W.J., 1986, AB INITIO MOL ORBITA; HWANG JK, 1988, J AM CHEM SOC, V110, P5297, DOI 10.1021/ja00224a011; JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; JORGENSEN WL, 1991, BOSS; KARELSON MM, 1989, J ORG CHEM, V54, P6030, DOI 10.1021/jo00287a012; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; Kirkwood JG, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749489; KOLLMAN PA, 1990, ACCOUNTS CHEM RES, V23, P246, DOI 10.1021/ar00176a002; LUZHKOV V, 1992, J COMPUT CHEM, V13, P199, DOI 10.1002/jcc.540130212; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCCREERY JH, 1976, J AM CHEM SOC, V98, P7191, DOI 10.1021/ja00439a015; MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2; MURRAY TJ, 1992, J AM CHEM SOC, V114, P4010, DOI 10.1021/ja00036a079; Onsager L, 1936, J AM CHEM SOC, V58, P1486, DOI 10.1021/ja01299a050; PEARSON RG, 1986, J AM CHEM SOC, V108, P6109, DOI 10.1021/ja00280a002; PERUTZ MF, 1990, MECHANISMS COOPERATI; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; Pople JA., 1970, APPROXIMATE MOL ORBI; PRANATA J, 1991, J AM CHEM SOC, V113, P2810, DOI 10.1021/ja00008a002; SHARP K, 1992, J PHYS CHEM-US, V96, P3822, DOI 10.1021/j100188a047; SMYTH CP, 1955, DIELECTRIC BEHAVIOR; STEWART JJP, 1990, J COMPUT CHEM, V11, P543, DOI 10.1002/jcc.540110414; STEWART JJP, 1986, MOPAC VERSION 5 QCPE, V6, P455; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; TAPIA O, 1990, J CHIM PHYS PCB, V87, P875, DOI 10.1051/jcp/1990870875; TAPIA O, 1980, J PHYS CHEM-US, V84, P2646, DOI 10.1021/j100457a034; THOLE BT, 1982, CHEM PHYS, V71, P211, DOI 10.1016/0301-0104(82)87020-1; VANBELLE D, 1987, J MOL BIOL, V198, P721, DOI 10.1016/0022-2836(87)90213-0; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; WAHSHEL A, 1972, J AM CHEM SOC, V94, P5612; WANG ISY, 1973, J AM CHEM SOC, V95, P8160, DOI 10.1021/ja00805a033; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; Warshel A, 1991, COMPUTER MODELING CH; WASZKOWYCZ B, 1991, J CHEM SOC PERK T 2, P225, DOI 10.1039/p29910000225; WEINER SJ, 1986, P NATL ACAD SCI USA, V83, P649, DOI 10.1073/pnas.83.3.649; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; WONG MW, 1991, J AM CHEM SOC, V113, P4776, DOI 10.1021/ja00013a010; ZHENG C, 1988, NATURE, V334, P726, DOI 10.1038/334726a0; ZWANZIG RW, 1954, J CHEM PHYS, V22, P1420, DOI 10.1063/1.1740409	65	584	589	2	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					631	635		10.1126/science.1411573	http://dx.doi.org/10.1126/science.1411573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411573				2022-12-24	WOS:A1992JU74500052
J	GAVIS, ER; LEHMANN, R				GAVIS, ER; LEHMANN, R			LOCALIZATION OF NANOS RNA CONTROLS EMBRYONIC POLARITY	CELL			English	Article							POSTERIOR DETERMINANT NANOS; SEGMENTATION GENE HUNCHBACK; EARLY DROSOPHILA EMBRYO; MATERNAL MESSENGER-RNA; ABDOMINAL SEGMENTATION; ANTERIOR LOCALIZATION; SEQUENCE SIMILARITY; PATTERN-FORMATION; BICOID PROTEIN; KRUPPEL GENE	Anterior-posterior polarity of the Drosophila embryo is initiated during oogenesis through differential maternal RNA localization. The RNA of the anterior morphogen bicoid is localized to the anterior pole of the embryo, where bicoid protein controls head and thorax development. The RNA of the posterior morphogen nanos is localized to the posterior pole, where nanos protein is required for abdomen formation. Here we show that the nanos 3' untranslated region, like that of the bicoid RNA, is sufficient for RNA localization. We have used the bicoid RNA localization signal to mislocalize nanos, producing embryos with two sources of nanos protein. Such embryos form two abdomens with mirror image symmetry. Embryos with nanos RNA localized only to the anterior have greater nanos gene activity than embryos with nanos RNA localized posteriorly. We propose a role for RNA localization in regulating nanos activity.			GAVIS, ER (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA.			Gavis, Elizabeth/0000-0003-0251-0760				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; FROHNHOIFER HG, 1987, THESIS EBERHARD KARL; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LANTZ V, 1992, DEVELOPMENT, V115, P75; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1989, DEVELOPMENT, V107, P21; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Lipshitz HD, 1991, CURR OPIN CELL BIOL, V3, P966, DOI 10.1016/0955-0674(91)90115-F; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MISMER D, 1987, GENETICS, V116, P565; MOHLER J, 1986, GENETICS, V112, P803; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1977, ROUX ARCH DEV BIOL, V183, P249, DOI 10.1007/BF00867325; PIGNONI F, 1992, DEVELOPMENT, V115, P239; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RAFF JW, 1990, DEVELOPMENT, V110, P1249; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wieschaus E., 1986, P199; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	66	310	315	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					301	313		10.1016/0092-8674(92)90358-J	http://dx.doi.org/10.1016/0092-8674(92)90358-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423595				2022-12-24	WOS:A1992JU39500015
J	WAKABAYASHI, K; TOKUNAGA, M; KOHNO, I; SUGIMOTO, Y; HAMANAKA, T; TAKEZAWA, Y; WAKABAYASHI, T; AMEMIYA, Y				WAKABAYASHI, K; TOKUNAGA, M; KOHNO, I; SUGIMOTO, Y; HAMANAKA, T; TAKEZAWA, Y; WAKABAYASHI, T; AMEMIYA, Y			SMALL-ANGLE SYNCHROTRON X-RAY-SCATTERING REVEALS DISTINCT SHAPE CHANGES OF THE MYOSIN HEAD DURING HYDROLYSIS OF ATP	SCIENCE			English	Article							ADENOSINE-TRIPHOSPHATASE; ACTIN-FILAMENTS; SKELETAL-MUSCLE; SUBFRAGMENT-1; SITE; EQUILIBRIUM; COMPLEXES; RADIATION; DOMAINS; ION	In the energy transduction of muscle contraction, it is important to know the nature and extent of conformational changes of the head portion of the myosin molecules. In the presence of magnesium adenosine triphosphate (MgATP), fairly large conformational changes of the myosin head [subfragment-1 (S1)] in solution were observed by small-angle x-ray scattering with the use of synchrotron radiation as an intense and stable x-ray source. The presence of MgATP reduced the radius of gyration of the molecule by about 3 angstrom units and the maximum chord length by about 10 angstroms, showing that the shape of S1 becomes more compact or round during hydrolysis of MgATP. Comparison with various nucleotide-bound S1 complexes that correspond to the known intermediate states during ATP hydrolysis indicates that the shape of S1 in a key intermediate state, S1-bound adenosine diphosphate (ADP) and phosphate [S1**.ADP.P(i)], differs significantly from the shape in the other intermediate states of the Sl adenosine triphosphatase cycle as well as that of nucleotide-free S1.	UNIV TOKYO, FAC SCI, DEPT PHYS, BUNKYO KU, TOKYO 113, JAPAN; NATL LAB HIGH ENERGY PHYS, PHOTON FACTORY, TSUKUBA, IBARAKI 305, JAPAN	University of Tokyo; High Energy Accelerator Research Organization (KEK)	WAKABAYASHI, K (corresponding author), OSAKA UNIV, FAC ENGN SCI, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN.		Amemiya, Yoshiyuki/M-7147-2018	Amemiya, Yoshiyuki/0000-0003-3306-3772; Tokunaga, Makio/0000-0003-4586-8922				AGUIRRE R, 1989, BIOCHEMISTRY-US, V28, P799, DOI 10.1021/bi00428a058; AMEMIYA Y, 1988, TOP CURR CHEM, V147, P121, DOI 10.1007/3-540-19040-6_13; AMEMIYA Y, 1983, NUCL INSTRUM METHODS, V208, P471, DOI 10.1016/0167-5087(83)91170-5; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; Bevington PR, 1969, DATA REDUCTION ERROR; CRAIG R, 1985, P NATL ACAD SCI USA, V82, P3247, DOI 10.1073/pnas.82.10.3247; CURMI PMG, 1988, J MOL BIOL, V203, P781, DOI 10.1016/0022-2836(88)90209-4; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; Feigin L.A., 1987, STRUCTURE ANAL SMALL; GEEVES MA, 1982, BIOCHEMISTRY-US, V21, P2782, DOI 10.1021/bi00540a032; GLATTER O, 1981, SMALL ANGLE SCATTERI, P119; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODY R S, 1980, Journal of Muscle Research and Cell Motility, V1, P101, DOI 10.1007/BF00711928; Guinier A., 1955, SMALL ANGLE SCATTERI; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIGHSMITH S, 1990, BIOCHEMISTRY-US, V29, P4087, DOI 10.1021/bi00469a010; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KRETZSCHMAR KM, 1978, BIOCHEMISTRY-US, V17, P2314, DOI 10.1021/bi00605a009; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MARGOSSIAN SS, 1981, BIOCHEMISTRY-US, V20, P2151, DOI 10.1021/bi00511a012; MENDELSON R, 1980, BIOCHEMISTRY-US, V19, P4103, DOI 10.1021/bi00558a031; MENDELSON RA, 1991, ADV BIOPHYS, V27, P145; SHRIVER JW, 1984, TRENDS BIOCHEM SCI, V9, P322, DOI 10.1016/0968-0004(84)90303-7; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; STONE DB, 1986, BIOPHYS J, V49, pA444; Tokunaga M, 1991, Adv Biophys, V27, P157, DOI 10.1016/0065-227X(91)90015-6; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAKABAYASHI K, 1991, HDB SYNCHROTRON RAD, V4, P597; WALKER M, 1988, J MUSCLE RES CELL M, V9, P359, DOI 10.1007/BF01773879; WELLS C, 1984, J MUSCLE RES CELL M, V5, P97, DOI 10.1007/BF00713154; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701	34	140	140	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					443	447		10.1126/science.1411537	http://dx.doi.org/10.1126/science.1411537			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411537				2022-12-24	WOS:A1992JT77500029
J	OROURKE, NA; DAILEY, ME; SMITH, SJ; MCCONNELL, SK				OROURKE, NA; DAILEY, ME; SMITH, SJ; MCCONNELL, SK			DIVERSE MIGRATORY PATHWAYS IN THE DEVELOPING CEREBRAL-CORTEX	SCIENCE			English	Article							VISUAL CORTICAL-NEURONS; FETAL MONKEY NEOCORTEX; GLIAL-CELLS; CULTURES; TRANSFORMATION; NEUROGENESIS; ASTROCYTES; ORIGIN; FERRET; BRAIN	During early development of the mammalian cerebral cortex, young neurons migrate outward from the site of their final mitosis in the ventricular zone into the cortical plate, where they form the adult cortex. Time-lapse confocal microscopy was used to observe directly the dynamic behaviors of migrating cells in living slices of developing cortex. The majority of cells migrated along a radial pathway, consistent with the view that cortical neurons migrate along radial glial fibers. A fraction of cells, however, turned within the intermediate zone and migrated orthogonal to the radial fibers. This orthogonal migration may contribute to the tangential dispersion of clonally related cortical neurons.	STANFORD UNIV,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University	OROURKE, NA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NEI NIH HHS [EY06314] Funding Source: Medline; NINDS NIH HHS [NS28587, NS09027] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028587] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; COOPER M W, 1989, Society for Neuroscience Abstracts, V15, P808; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; Fishell G., 1992, Society for Neuroscience Abstracts, V18, P926; GADISSEUX JF, 1989, DEV BRAIN RES, V50, P55, DOI 10.1016/0165-3806(89)90126-0; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GRAY GE, 1991, NEURON, V6, P211, DOI 10.1016/0896-6273(91)90357-6; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; JACKSON CA, 1989, J NEUROSCI, V9, P1242; KATZ LC, 1987, J NEUROSCI, V7, P1223; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; MOREST DK, 1970, Z ANAT ENTWICKLUNGS, V130, P265, DOI 10.1007/BF00520999; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; ROBERTS JS, IN PRESS DEV BIOL; SANDELL JH, 1988, J HISTOCHEM CYTOCHEM, V36, P555, DOI 10.1177/36.5.3356898; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; SHOUKIMAS GM, 1978, J COMP NEUROL, V179, P795, DOI 10.1002/cne.901790407; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SMITH SJ, 1990, BIOL MEMORY, V23, P49; STENSAAS LJ, 1967, J COMP NEUROL, V131, P423, DOI 10.1002/cne.901310403; STENSAAS LJ, 1967, J COMP NEUROL, V131, P409, DOI 10.1002/cne.901310402; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; 1970, ANAT REC, V166, P257	33	385	386	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					299	302		10.1126/science.1411527	http://dx.doi.org/10.1126/science.1411527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411527				2022-12-24	WOS:A1992JR86000034
J	JEUNEMAITRE, X; SOUBRIER, F; KOTELEVTSEV, YV; LIFTON, RP; WILLIAMS, CS; CHARRU, A; HUNT, SC; HOPKINS, PN; WILLIAMS, RR; LALOUEL, JM; CORVOL, P				JEUNEMAITRE, X; SOUBRIER, F; KOTELEVTSEV, YV; LIFTON, RP; WILLIAMS, CS; CHARRU, A; HUNT, SC; HOPKINS, PN; WILLIAMS, RR; LALOUEL, JM; CORVOL, P			MOLECULAR-BASIS OF HUMAN HYPERTENSION - ROLE OF ANGIOTENSINOGEN	CELL			English	Article							BLOOD-PRESSURE; MESSENGER-RNA; RENIN GENE; LINKAGE; RAT; SYSTEM; IDENTIFICATION; POLYMORPHISMS; SUBSTRATE; FAMILIES	Essential hypertension is a common human disease believed to result from the interplay of multiple genetic and environmental determinants. In genetic studies of two large panels of hypertensive sibships from widely separated geographical areas, we obtained evidence of genetic linkage between the angiotensinogen gene (AGT) and hypertension, demonstrated association of AGT molecular variants with the disease, and found significant differences in plasma concentrations of angiotensinogen among hypertensive subjects with different AGT genotypes. The corroboration and replication afforded by these results support the interpretation that molecular variants of AGT constitute inherited predispositions to essential hypertension in humans.	UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; COLL FRANCE, INSERM U36, F-75005 PARIS, FRANCE; BRIGHAM & WOMENS HOSP, DIV ENDOCRINE HYPERTENS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV UTAH, HLTH SCI CTR, CARDIOVASC GENET RES CLIN, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah	JEUNEMAITRE, X (corresponding author), UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.		JEUNEMAITRE, Xavier/AAQ-4853-2021; Williams, christopher S/A-1186-2009; Kotelevtsev, Yuri V/R-1772-2016	JEUNEMAITRE, Xavier/0000-0001-5925-381X; Kotelevtsev, Yuri/0000-0002-7255-7794; Williams, Christopher/0000-0002-1541-579X	NHLBI NIH HHS [HL45325, HL24855] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024855, R01HL045325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAL JF, 1991, AM J MED, V90, P17, DOI 10.1016/0002-9343(91)90501-N; BACHMANN J, 1991, J STEROID BIOCHEM, V40, P511, DOI 10.1016/0960-0760(91)90270-F; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BROWN AJ, 1981, AM J PHYSIOL, V241, pH381, DOI 10.1152/ajpheart.1981.241.3.H381; CAIN MD, 1971, J CLIN ENDOCR METAB, V33, P671, DOI 10.1210/jcem-33-4-671; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CLAUSER E, 1989, AM J HYPERTENS, V2, P403, DOI 10.1093/ajh/2.5.403; CORVOL P, 1989, CLIN EXP HYPERTENS A, V11, P1053, DOI 10.3109/10641968909035391; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; FASOLA AF, 1968, J APPL PHYSIOL, V25, P410, DOI 10.1152/jappl.1968.25.4.410; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GARDES J, 1982, HYPERTENSION, V4, P185, DOI 10.1161/01.HYP.4.2.185; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOTELEVTSEV YV, 1991, NUCLEIC ACIDS RES, V19, P6978, DOI 10.1093/nar/19.24.6978; KUNAPULI SP, 1986, NUCLEIC ACIDS RES, V14, P7509, DOI 10.1093/nar/14.18.7509; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LALOUEL JM, 1990, DRUGS AFFECTING LIPI, V10, P11; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LANGE K, 1986, ANN HUM GENET, V50, P283, DOI 10.1111/j.1469-1809.1986.tb01049.x; LATHROP GM, 1991, HDB STATISTICS, V8, P81; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MENARD J, 1991, HYPERTENSION, V18, P705, DOI 10.1161/01.HYP.18.5.705; MENARD J, 1973, ENDOCRINOLOGY, V92, P1382, DOI 10.1210/endo-92-5-1382; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PLOUIN PF, 1989, PRESSE MED, V18, P917; PRATT RE, 1989, AM J PHYSIOL, V256, pF469, DOI 10.1152/ajprenal.1989.256.3.F469; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RISCH N, 1990, AM J HUM GENET, V46, P242; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; Sealey JE, 1990, HYPERTENSION PATHOPH, P1287; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; SUAREZ BK, 1984, AM J MED GENET, V18, P135, DOI 10.1002/ajmg.1320180117; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, P1197; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WHITE R, 1987, ADV HUM GENET, V16, P121; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WILLIAMS RR, 1989, HYPERTENSION, V14, P610, DOI 10.1161/01.HYP.14.6.610; YONGUE BG, 1991, HYPERTENSION, V17, P485, DOI 10.1161/01.HYP.17.4.485	58	1612	1687	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					169	180		10.1016/0092-8674(92)90275-H	http://dx.doi.org/10.1016/0092-8674(92)90275-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394429				2022-12-24	WOS:A1992JQ62300016
J	THORPEBEESTON, JG; BANFIELD, PJ; SAUNDERS, NJS				THORPEBEESTON, JG; BANFIELD, PJ; SAUNDERS, NJS			OUTCOME OF BREECH DELIVERY AT TERM	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; RANDOMIZED MANAGEMENT; MODE	Objective-To compare neonatal mortality and morbidity in term infants presenting by the breech and delivered vaginally or by caesarean section. Design-Population based comparison of outcomes. Data derived from the St Mary's maternity information system. Setting-North West Thames Regional Health Authority, 1988-90. Subjects-3447 singleton fetuses presenting by the breech at term. Main outcome measures-Intrapartum and neonatal mortality, low Apgar scores, intubation at birth, and admission to special care baby units. Results-After the exclusion of babies with congenital anomalies the incidence of intrapartum and neonatal death associated with vaginal birth was 8/961 (0.83%) compared with 1/2486 (0.03%) in babies born by caesarean section (relative risk 20, 95% confidence interval 2.5 to 163). The numbers of low Apgar scores and neonatal intubation were doubled in babies born vaginally or by emergency caesarean section compared with those delivered by elective operation. Conclusions-The good neonatal outcome associated with elective caesarean delivery of the term breech fetus may influence the decision of women and their obstetricians about mode of delivery.	ST MARYS HOSP,DEPT OBSTET,LONDON W2 1PG,ENGLAND	Imperial College London								BINGHAM P, 1987, OBSTET GYNECOL, V69, P965; BINGHAM P, 1987, BRIT J OBSTET GYNAEC, V94, P746, DOI 10.1111/j.1471-0528.1987.tb03720.x; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; CHRISTIAN SS, 1990, AM J OBSTET GYNECOL, V163, P848; COLLEA JV, 1980, AM J OBSTET GYNECOL, V137, P235, DOI 10.1016/0002-9378(80)90780-2; FELDMAN GB, 1985, NEW ENGL J MED, V312, P1264, DOI 10.1056/NEJM198505093121926; GARDNER MJ, 1989, BMJ; GIMOVSKY ML, 1983, AM J OBSTET GYNECOL, V146, P34, DOI 10.1016/0002-9378(83)90923-7; HYTTEN FE, 1982, BRIT J OBSTET GYNAEC, V89, P879, DOI 10.1111/j.1471-0528.1982.tb05049.x; KIELY JL, 1991, BRIT J OBSTET GYNAEC, V98, P898, DOI 10.1111/j.1471-0528.1991.tb13512.x; PATERSON CM, 1991, BRIT MED J, V303, P818, DOI 10.1136/bmj.303.6806.818; REDIE D, 1967, BRIT J RADIOL, V40, P489; ROSEN MG, 1990, OBSTET GYNECOL, V76, P865, DOI 10.1097/00006250-199011000-00029; SACHS BP, 1983, JAMA-J AM MED ASSOC, V250, P2157, DOI 10.1001/jama.250.16.2157	14	85	86	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					746	747		10.1136/bmj.305.6856.746	http://dx.doi.org/10.1136/bmj.305.6856.746			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1422330	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JQ52000021
J	CHAIT, BT; KENT, SBH				CHAIT, BT; KENT, SBH			WEIGHING NAKED PROTEINS - PRACTICAL, HIGH-ACCURACY MASS MEASUREMENT OF PEPTIDES AND PROTEINS	SCIENCE			English	Article							ASSISTED LASER-DESORPTION; ELECTROSPRAY-IONIZATION; CONFORMATIONAL-CHANGES; PLASMINOGEN-ACTIVATOR; NUCLEOTIDE-SEQUENCE; RECOMBINANT-DNA; SPECTROMETRY; MATRIX; SPECTRA; LIPOPROTEINS	Two new technologies have made the study of proteins by mass spectrometry straight-forward. Proteins with molecular masses of up to more than 100 kilodaltons can be analyzed at picomole sensitivities to give simple mass spectra corresponding to the intact molecule. This development has allowed unprecedented accuracy in the determination of the molecular weights of proteins. A number of "case studies" are used to present the revolutionary impact that these powerful new ways of looking at proteins are having on biological research.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute	CHAIT, BT (corresponding author), ROCKEFELLER UNIV, NEW YORK, NY 10021 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038274] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM38274] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; ALPIN RT, 1990, FEBS LETT, V277, P212; ANNAN RS, 1992, RAPID COMMUN MASS SP, V6, P298, DOI 10.1002/rcm.1290060415; ASHTON DS, 1991, FEBS LETT, V292, P201, DOI 10.1016/0014-5793(91)80867-3; BACA M, 1992, J AM CHEM SOC, V114, P3992, DOI 10.1021/ja00036a066; BALDWIN M, UNPUB; BAPTISTA GB, 1991, RAPID COMMUN MASS SP, V5, P632, DOI 10.1002/rcm.1290051214; Barber M, 1987, Rapid Commun Mass Spectrom, V1, P80, DOI 10.1002/rcm.1290010505; BARBER M, 1981, J CHEM SOC CHEM COMM, P325, DOI 10.1039/c39810000325; BEAVIS R, UNPUB; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1991, CHEM PHYS LETT, V181, P479, DOI 10.1016/0009-2614(91)90384-L; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BEAVIS RC, 1991, NATO ASI SERIES B, V209; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; BIER ME, IN PRESS 40TH P ASMS; BOARD PG, 1986, GENE, V44, P127, DOI 10.1016/0378-1119(86)90051-X; BURLINGAME AL, 1992, ANAL CHEM, V64, pR467, DOI 10.1021/ac00036a025; CAPRIOLI RM, 1991, TECHNIQUES PROTEIN C, V2, P497; CASTRO JA, 1992, RAPID COMMUN MASS SP, V6, P239, DOI 10.1002/rcm.1290060403; CHAIT BT, IN PRESS 40TH P ASMS; CHOLOUPEK RC, 1989, J CHROMATOGR, V463, P375; CHOWDHURY SK, 1990, RAPID COMMUN MASS SP, V4, P81, DOI 10.1002/rcm.1290040305; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; COLLEN D, 1984, J PHARMACOL EXP THER, V231, P146; COTTER RJ, 1988, ANAL CHEM, V60, pA781, DOI 10.1021/ac00164a002; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; COX KA, 1992, BIOL MASS SPECTROM, V21, P226, DOI 10.1002/bms.1200210503; Dawson P. H, 1995, QUADRUPOLE MASS SPEC; DEEB SS, 1991, J BIOL CHEM, V266, P13654; DELAETER JR, 1988, J PHYS CHEM REF DATA, V17, P1791, DOI 10.1063/1.555816; DESIDERIO DM, 1991, MASS SPECTROMETRY PE; EHRING H, 1992, ORG MASS SPECTROM, V27, P472, DOI 10.1002/oms.1210270419; Elder J. H., UNPUB; FALICK AM, IN PRESS 40TH P ASMS; FENG R, IN PRESS ANAL CHEM; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; GANEM B, 1991, J AM CHEM SOC, V113, P7818, DOI 10.1021/ja00020a085; GANEM B, 1991, J AM CHEM SOC, V113, P6294, DOI 10.1021/ja00016a069; GANGULY AK, 1992, J AM CHEM SOC, V114, P6559, DOI 10.1021/ja00042a046; GIMON ME, 1992, ORG MASS SPECTROM, V27, P827, DOI 10.1002/oms.1210270711; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; GUEVREMONT R, 1992, J AM SOC MASS SPECTR, V3, P216, DOI 10.1016/1044-0305(92)87005-J; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HENRY KD, 1991, J AM CHEM SOC, V113, P5447, DOI 10.1021/ja00014a043; HERBERG F, UNPUB; HILL JA, 1991, RAPID COMMUN MASS SP, V5, P395, DOI 10.1002/rcm.1290050905; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HORIUCHI A, 1990, J BIOL CHEM, V265, P9576; HOU J, IN PRESS BIOCHEMISTR; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KATTA V, 1991, J AM CHEM SOC, V113, P8534, DOI 10.1021/ja00022a058; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEBLANC JCY, 1991, ORG MASS SPECTROM, V26, P831; LING V, 1991, ANAL CHEM, V63, P2909, DOI 10.1021/ac00024a020; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; LOO JA, 1991, RAPID COMMUN MASS SP, V5, P101, DOI 10.1002/rcm.1290050303; MACFARLANE RD, 1976, SCIENCE, V191, P920, DOI 10.1126/science.1251202; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MCCLOSKEY JA, 1990, METHODS ENZYMOLOGY, V193; MCEWEN CN, 1992, RAPID COMMUN MASS SP, V6, P173, DOI 10.1002/rcm.1290060304; MENARD R, 1991, FEBS LETT, V295, P27, DOI 10.1016/0014-5793(91)81376-J; MENG CK, 1988, Z PHYS D ATOM MOL CL, V10, P361, DOI 10.1007/BF01384871; MIRZA UA, UNPUB; NELSON RW, 1990, RAPID COMMUN MASS SP, V4, P348, DOI 10.1002/rcm.1290040911; PALEZEWSKI K, UNPUB; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; SCHAR M, 1991, RAPID COMMUN MASS SP, V5, P319, DOI 10.1002/rcm.1290050705; SCHMID K, 1973, BIOCHEMISTRY-US, V12, P2711, DOI 10.1021/bi00738a026; SEE YP, 1990, PROTEIN STRUCTURE PR; SEPNGLER B, 1992, ANALYSIS, V20, P91; SMITH RD, 1990, J AM SOC MASS SPECTR, V1, P53, DOI 10.1016/1044-0305(90)80006-9; SMITH RD, 1991, MASS SPECTROM REV, V10, P359, DOI 10.1002/mas.1280100504; SPENGLER B, 1991, RAPID COMMUN MASS SP, V5, P198, DOI 10.1002/rcm.1290050412; STRUPAT K, 1991, INT J MASS SPECTROM, V111, P89, DOI 10.1016/0168-1176(91)85050-V; SUNG LA, 1992, J BIOL CHEM, V267, P2616; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; VANBERKEL GJ, 1990, ANAL CHEM, V62, P1284, DOI 10.1021/ac00212a016; WHITEHOUSE CM, 1985, ANAL CHEM, V57, P675, DOI 10.1021/ac00280a023; WILKENS CL, IN PRESS 40TH P ASMS; WILKINS CL, IN PRESS 40TH P ASMS; YONEMOTO W, UNPUB	95	408	425	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1885	1894		10.1126/science.1411504	http://dx.doi.org/10.1126/science.1411504			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411504				2022-12-24	WOS:A1992JP59400020
J	PUGLIANO, N; SAYKALLY, RJ				PUGLIANO, N; SAYKALLY, RJ			MEASUREMENT OF QUANTUM TUNNELING BETWEEN CHIRAL ISOMERS OF THE CYCLIC WATER TRIMER	SCIENCE			English	Article							VANDERWAALS COMPLEXES; SPECTROSCOPY; DYNAMICS; CLUSTERS	A detailed experimental study of the water trimer is reported. A vibration-rotation-tunneling band of the perdeuterated cluster has been measured near 89.6 wavenumbers by tunable far infrared laser absorption spectroscopy. The data indicate a chiral six-membered ring structure with rapid quantum tunneling occurring between the enantiomers. The observed vibration involves torsional motion of the water subunits about each hydrogen bond axis. It is speculated that larger water clusters would also exhibit transient chirality and that similar effects may be found in liquid water.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley				SAYKALLY, RICHARD/0000-0001-8942-3656	NCRR NIH HHS [850RR05651A] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BALASUBRAMANIAN K, 1984, J PHYS CHEM-US, V88, P4688, DOI 10.1021/j150664a049; BLAKE GA, 1991, REV SCI INSTRUM, V62, P1701, DOI 10.1063/1.1142410; COHEN RC, 1992, J PHYS CHEM-US, V96, P1024, DOI 10.1021/j100182a006; COHEN RC, 1991, ANNU REV PHYS CHEM, V42, P369, DOI 10.1146/annurev.physchem.42.1.369; FRANKS F, 1976, WATER COMPREHENSIVE; FRASER GT, 1991, INT REV PHYS CHEM, V10, P189, DOI 10.1080/01442359109353257; HALLER EE, 1985, INFRARED PHYS, V25, P257, DOI 10.1016/0020-0891(85)90088-0; HONEGGER E, 1988, J CHEM PHYS, V88, P2582, DOI 10.1063/1.454038; HUTSON JM, 1990, ANNU REV PHYS CHEM, V41, P123, DOI 10.1146/annurev.pc.41.100190.001011; LOESER JG, IN PRESS J CHEM PHYS; OWICKI JC, 1975, J PHYS CHEM-US, V79, P1794, DOI 10.1021/j100584a010; PUGLIANO N, 1992, J CHEM PHYS, V96, P1832, DOI 10.1063/1.462084	12	397	403	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1937	1940		10.1126/science.1411509	http://dx.doi.org/10.1126/science.1411509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411509				2022-12-24	WOS:A1992JP59400029
J	JACKS, T; FAZELI, A; SCHMITT, EM; BRONSON, RT; GOODELL, MA; WEINBERG, RA				JACKS, T; FAZELI, A; SCHMITT, EM; BRONSON, RT; GOODELL, MA; WEINBERG, RA			EFFECTS OF AN RB MUTATION IN THE MOUSE	NATURE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PROSTATE CARCINOMA; SV40-TRANSFORMED CELLS; ENCODED PROTEIN; T-ANTIGEN; PRODUCT; EXPRESSION; TUMORS; CANCER; PHOSPHORYLATION	The retinoblastoma gene is mutated in several types of human cancer and is the best characterized of the tumour-suppressor genes. A mouse strain has been constructed in which one allele of Rb is disrupted. These heterozygous animals are not predisposed to retinoblastoma, but some display pituitary tumours arising from cells in which the wild-type Rb allele is absent. Embryos homozygous for the mutation die between days 14 and 15 of gestation, exhibiting neuronal cell death and defective erythropoiesis.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University	JACKS, T (corresponding author), MIT,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			Goodell, Margaret A./0000-0003-1111-2932				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; BUCHKOVICH K, 1989, CELL, V46, P447; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUNAGA E, 1980, HUM GENET, V56, P127; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; TANG A, 1988, SCIENCE, V241, P1797; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YOKOTA J, 1988, ONCOGENE, V3, P471	46	1541	1590	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					295	300		10.1038/359295a0	http://dx.doi.org/10.1038/359295a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406933				2022-12-24	WOS:A1992JP50300046
J	ALLISON, MC; HOWATSON, AG; TORRANCE, CJ; LEE, FD; RUSSELL, RI				ALLISON, MC; HOWATSON, AG; TORRANCE, CJ; LEE, FD; RUSSELL, RI			GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-INFLAMMATORY DRUGS; SMALL-BOWEL ULCERATION; SMALL-INTESTINE; PEPTIC-ULCER; RHEUMATOID-ARTHRITIS; ELDERLY PERSONS; DISEASE; PERMEABILITY; THERAPY; PERFORATION	Background. Long-term use of nonsteroidal antiinflammatory drugs (NSAIDs) may lead to inflammation of the small intestine associated with occult blood and protein loss. The aim of this study was to investigate the prevalence and structural correlates of this enteropathy. Methods. We examined the stomach, duodenum, and small intestine of 713 patients post mortem. Of these patients, 249 had had NSAIDs prescribed during the six months before death and 464 patients had not. All visible small intestinal lesions were removed for histologic examination, and specific etiologic factors were sought. The prevalence of nonspecific small-intestinal ulcers and ulcers of the stomach and duodenum was compared in the two groups of patients. Results. Nonspecific small-intestinal ulceration was found in 21 (8.4 percent) of the users of NSAIDs and 3 (0.6 percent) of the nonusers (difference, 7.8 percent; 95 percent confidence interval, 5.0 to 10.6 percent; P<0.001). Three patients who were long-term users of NSAIDs were found to have died of perforated nonspecific small-intestinal ulcers. Ulcers of the stomach or duodenum were found in 54 (21.7 percent) of the patients who used these drugs and 57 (12.3 percent) of those who had not (difference, 9.4 percent; 95 percent confidence interval, 3.9 to 15.1 percent; P<0.001). Conclusions. Patients who take NSAIDs have an increased risk of nonspecific ulceration of the small-intestinal mucosa. These ulcers are less common than ulcers ot the stomach or duodenum, but can lead to life-threatening complications.	GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,GASTROENTEROL UNIT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow; University of Glasgow								ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BEARDON PHG, 1989, Q J MED, V71, P497; BJARNASON I, 1986, GUT, V27, P1292, DOI 10.1136/gut.27.11.1292; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BJARNASON I, 1984, LANCET, V2, P1171; BJARNASON I, 1987, LANCET, V2, P711; Bjarnason I., 1988, RECENT ADV GASTROENT, P23; BOYDSTUN JS, 1981, DIGEST DIS SCI, V26, P911, DOI 10.1007/BF01309496; COLLINS AJ, 1987, BRIT J RHEUMATOL, V26, P295; DAY TK, 1983, BRIT MED J, V287, P1671, DOI 10.1136/bmj.287.6406.1671-a; DEAKIN M, 1988, BRIT MED J, V297, P488, DOI 10.1136/bmj.297.6646.488-b; GRAHAM DY, 1988, LANCET, V2, P1277; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; JENKINS RT, 1987, BRIT J RHEUMATOL, V26, P103; LANG J, 1988, J CLIN PATHOL, V41, P516, DOI 10.1136/jcp.41.5.516; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LEIJONMARCK CE, 1985, ACTA CHIR SCAND, V151, P273; MADHOK R, 1986, Q J MED, V58, P53; MORRIS AJ, 1991, LANCET, V337, P520, DOI 10.1016/0140-6736(91)91300-J; NEOPTOLEMOS JP, 1983, BRIT J SURG, V70, P244, DOI 10.1002/bjs.1800700422; SAVERYMUTTU SH, 1986, POSTGRAD MED J, V62, P967, DOI 10.1136/pgmj.62.732.967; SAW KC, 1990, J ROY SOC MED, V83, P114, DOI 10.1177/014107689008300219; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; SOMERVILLE K, 1986, LANCET, V1, P462; STURGES HF, 1973, AM J GASTROENTEROL, V59, P162; UPADHYAY R, 1990, ANN RHEUM DIS, V49, P359, DOI 10.1136/ard.49.6.359; WAYTE DM, 1968, AM J CLIN PATHOL, V49, P26	31	847	885	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					749	754		10.1056/NEJM199209103271101	http://dx.doi.org/10.1056/NEJM199209103271101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501650	Bronze			2022-12-24	WOS:A1992JL66100001
J	MACASKIE, LE; EMPSON, RM; CHEETHAM, AK; GREY, CP; SKARNULIS, AJ				MACASKIE, LE; EMPSON, RM; CHEETHAM, AK; GREY, CP; SKARNULIS, AJ			URANIUM BIOACCUMULATION BY A CITROBACTER SP AS A RESULT OF ENZYMATICALLY MEDIATED GROWTH OF POLYCRYSTALLINE HUO2PO4	SCIENCE			English	Article							URANYL PHOSPHATE TETRAHYDRATE; P-31 NMR; ACCUMULATION; WASTES	A Citrobacter sp. accumulates heavy deposits of metal phosphate, derived from an enzymatically liberated phosphate ligand. The cells are not subject to saturation constraints and can accumulate several times their own weight of precipitated metal. This high capacity is attributable to biomineralization; uranyl phosphate accumulates as polycrystalline HUO2PO4 at the cell surface. The precipitated metal is indistinguishable from crystalline HUO2PO4.4H2O grown by chemical methods.	ST MARYS HOSP,SCH MED,LONDON W2 1NY,ENGLAND; UNIV OXFORD,CHEM CRYSTALLOG LAB,OXFORD OX1 3PD,ENGLAND	Imperial College London; University of Oxford	MACASKIE, LE (corresponding author), UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Grey, Clare P/Q-8860-2017	Grey, Clare P/0000-0001-5572-192X; Empson, Ruth/0000-0002-0415-6083				AICKIN RM, 1979, MICROBIOS LETT, V9, P7; CHEETHAM AK, 1986, J CHEM SOC CHEM COMM, P195, DOI 10.1039/c39860000195; CLIFF G, 1975, J MICROSC-OXFORD, V103, P203, DOI 10.1111/j.1365-2818.1975.tb03895.x; DUNCAN TM, 1984, CHEM PHYS, V87, P339, DOI 10.1016/0301-0104(84)85115-0; DUNN HW, 1956, ORNL PUBL, V2092; GREAVES C, 1973, INORG CHEM, V12, P3003, DOI 10.1021/ic50130a054; GRIMMER AR, 1983, CHEM PHYS LETT, V99, P487, DOI 10.1016/0009-2614(83)80180-8; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; HOWE AT, 1980, J SOLID STATE CHEM, V34, P149, DOI 10.1016/0022-4596(80)90217-0; Macaskie L E, 1989, Adv Biotechnol Processes, V12, P159; MACASKIE LE, 1988, FEMS MICROBIOL LETT, V55, P157, DOI 10.1111/j.1574-6968.1988.tb13926.x; MACASKIE LE, 1987, J GEN MICROBIOL, V133, P539; MACASKIE LE, 1991, CRIT REV BIOTECHNOL, V11, P41, DOI 10.3109/07388559109069183; MACASKIE LE, 1990, J CHEM TECHNOL BIOT, V49, P357; MOROSIN B, 1978, ACTA CRYSTALLOGR B, V34, P3732, DOI 10.1107/S0567740878011991; PLUMMER EJ, 1990, B ENVIRON CONTAM TOX, V44, P173, DOI 10.1007/BF01700133; ROTHWELL WP, 1980, J AM CHEM SOC, V102, P2637, DOI 10.1021/ja00528a020; STRACHAN L, 1991, 201ST P AM CHEM SOC, V31, P128; WEIGEL F, 1976, J LESS-COMMON MET, V44, P99, DOI 10.1016/0022-5088(76)90121-1	19	230	242	4	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					782	784		10.1126/science.1496397	http://dx.doi.org/10.1126/science.1496397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496397				2022-12-24	WOS:A1992JG85100029
J	KHAW, KT; SNEYD, MJ; COMPSTON, J				KHAW, KT; SNEYD, MJ; COMPSTON, J			BONE-DENSITY PARATHYROID-HORMONE AND 25-HYDROXYVITAMIN-D CONCENTRATIONS IN MIDDLE-AGED WOMEN	BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-D STATUS; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; PROXIMAL FEMUR; PHYSICAL-ACTIVITY; DIETARY CALCIUM; CALCITRIOL; SECRETION; RISK; 25-HYDROXYCHOLECALCIFEROL	Objective-To examine the relation between bone density and indices of calcium metabolism including parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. Design-A cross sectional study. Setting and subjects-138 women volunteers aged 45-65 with no known osteoporosis and unselected for disease status recruited for a dietary assessment study from the community using general practice registers. Volunteer rate was 20%. Main outcome measure-Bone mineral density measured with dual energy x ray absorptiometry. Results-Bone density at the lumbar spine and neck and trochanteric regions of the femur was inversely related to serum intact parathyroid hormone concentrations and positively related to serum 25-hydroxyvitamin D concentrations. These associations were independent of possible confounding factors, including age, body mass index, cigarette smoking habit, menopausal status, and use of diuretics and postmenopausal hormone replacement therapy. These associations were apparent throughout the whole distribution of bone density and 25-hydroxyvitamin D and parathyroid hormone concentrations within the normal range, suggesting a physiological relation. Conclusions-The findings are consistent with the hypothesis that parathyroid hormone and 25-hydroxyvitamin D concentrations influence bone density in middle aged women. Findings from this study together with other work suggest that the role of vitamin D in osteoporosis should not be neglected. The associations with parathyroid hormone also indicate plausible biological mechanisms. The roughly 5-10% difference in bone density between top and bottom tertiles of serum 25-hydroxyvitamin D concentrations, though not large in magnitude, may have considerable public health implications in terms of prevention of osteoporosis and its sequelae, fractures.			KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN JM, 1973, NATURE, V241, P59; ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002-9343(88)90259-8; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; BOYCE WJ, 1985, LANCET, V1, P150; CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69, DOI 10.1210/jcem-72-1-69; CALVO MS, 1990, J CLIN ENDOCR METAB, V70, P1334, DOI 10.1210/jcem-70-5-1334; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; FRAME B, 1978, ANN INTERN MED, V89, P966, DOI 10.7326/0003-4819-89-6-966; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; GLOTH FM, 1991, J AM GERIATR SOC, V39, P137, DOI 10.1111/j.1532-5415.1991.tb01615.x; Gregory F., 1990, DIETARY NUTR SURVEY; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HOLICK MF, 1985, ANN NY ACAD SCI, V453, P1, DOI 10.1111/j.1749-6632.1985.tb11793.x; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JACOBSEN SJ, 1991, AM J EPIDEMIOL, V133, P996, DOI 10.1093/oxfordjournals.aje.a115819; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LINDALL AW, 1983, J CLIN ENDOCR METAB, V57, P1007, DOI 10.1210/jcem-57-5-1007; LIPS P, 1987, AM J CLIN NUTR, V46, P1005, DOI 10.1093/ajcn/46.6.1005; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; LUND B, 1975, LANCET, V2, P300; MAZESS RB, 1989, P SOC EXP BIOL MED, V191, P261; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PARFITT AM, 1988, DRUGS, V36, P513, DOI 10.2165/00003495-198836050-00001; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; RIGGS BL, 1983, AM J MED, V75, P889; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCRAGG R, IN PRESS ANN EPIDEMI; SILVERBERG SJ, 1989, NEW ENGL J MED, V320, P277, DOI 10.1056/NEJM198902023200503; STEVENSON JC, 1982, BRIT MED J, V285, P585, DOI 10.1136/bmj.285.6342.585; TSAI KS, 1989, J CLIN ENDOCR METAB, V69, P1024, DOI 10.1210/jcem-69-5-1024; TSAI KS, 1984, J CLIN INVEST, V73, P1668, DOI 10.1172/JCI111373; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1991, FORTIFICATION YELLOW, V40	40	186	192	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					273	277		10.1136/bmj.305.6848.273	http://dx.doi.org/10.1136/bmj.305.6848.273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392857	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JG74000014
J	ROBERTS, I; MARSHALL, R; NORTON, R				ROBERTS, I; MARSHALL, R; NORTON, R			CHILD PEDESTRIAN MORTALITY AND TRAFFIC VOLUME IN NEW-ZEALAND	BRITISH MEDICAL JOURNAL			English	Article											ROBERTS, I (corresponding author), UNIV AUCKLAND,INJURY PREVENT RES CTR,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Marshall, Roger/0000-0001-8278-167X				FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; READ RC, 1990, BRIT MED J, V300, P761, DOI 10.1136/bmj.300.6727.761; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; 1990, MORTALITY DEMOGRAPHI; 1990, NZ OFFICIAL YB 1990	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					283	283		10.1136/bmj.305.6848.283	http://dx.doi.org/10.1136/bmj.305.6848.283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392860	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JG74000017
J	RANDALL, T; MUIR, J; MANT, D				RANDALL, T; MUIR, J; MANT, D			CHOOSING THE PREVENTIVE WORKLOAD IN GENERAL-PRACTICE - PRACTICAL APPLICATION OF THE CORONARY-PREVENTION-GROUP GUIDELINES AND DUNDEE CORONARY RISK-DISK	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the workload implications for general practice of the Coronary Prevention Group and British Heart Foundation action plan for preventing heart disease. Design-Computer simulation of plan, including calculation of Dundee risk scores, with data from OXCHECK trial. Subjects-4759 patients aged 35-64 who had health checks during 1989-91. Main outcome measure-Effect of using different risk scores as thresholds on workload and coverage of patients at known risk. Thresholds of 6-20 were used for cholesterol screening (nearset) and 4-16 for special care (preset). Results-On the basis of workload a nearset of 8 and preset of 12 would be reasonable. This implies cholesterol measurement in 1794 (37.7%) patients and special care in 1074 (22.6%). However, many patients with single risk factors were not allocated to special care at these thresholds: 11 (37.9%) patients with cholesterol concentrations greater-than-or-equal-to 10 mmol/l, 21 (33.9%) with systolic pressure greater-than-or-equal-to 180 mm Hg, and 213 (40.7%) heavy smokers (>20 cigarettes/day) were missed. The distribution of scores was similar in those at established clinical risk, those with family history of heart disease, and others. Conclusion-The guidelines may help to make best use of resources within specific age-sex groups but sound protocols for unifactorial risk assessment and modification remain essential.	UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX4 1SX,ENGLAND	Radcliffe Infirmary; University of Oxford			Mant, David CA/C-7763-2009					MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; Scientific Steering Committee on behalf of the Simon Broome Register Group, 1991, BMJ, V303, P893; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; 1991, BMJ, V303, P748; 1980, EUR HEART J, V1, P73; 1989, BMJ; 1991, BMJ, V302, P1057	7	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					227	231		10.1136/bmj.305.6847.227	http://dx.doi.org/10.1136/bmj.305.6847.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392829	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JG11200027
J	CAMPS, M; CAROZZI, A; SCHNABEL, P; SCHEER, A; PARKER, PJ; GIERSCHIK, P				CAMPS, M; CAROZZI, A; SCHNABEL, P; SCHEER, A; PARKER, PJ; GIERSCHIK, P			ISOZYME-SELECTIVE STIMULATION OF PHOSPHOLIPASE C-BETA-2 BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; RECEPTOR; CELLS	HYDROLYSIS by phospholipase C (PLC) of phosphatidylinositol 4,5-bisphosphate is a key mechanism by which many extracellular signalling molecules regulate functions of their target cells1,2. At least eight distinct isozymes of PLC are recognized in mammalian cells3,4. Receptor-controlled PLC is often regulated by G proteins, which can be modified by pertussis toxin in some cells but not in others5,6. In the latter cells, PLC-beta1, but not PLC-gamma1 or PLC-delta1, may be activated by members of the alpha(q)-subfamily of the G protein alpha-subunits7-10. An unidentified PLC in soluble fractions of cultured human HL-60 granulocytes is specifically stimulated by G protein betagamma subunits purified from retina and brain11. Identification of a second PLC-beta complementary DNA (PLC-beta2) in an HL-60 cell cDNA library9 prompted us to investigate the effect of purified G protein betagamma subunits on the activities of PLC-beta1 and PLC-beta2 transiently expressed in cultured mammalian cells. We report here that PLC-beta1 and PLC-beta2 were stimulated by free betagamma subunits and that PLC-beta2 was the most sensitive to betagamma stimulation. Thus stimulation of PLC by betagamma subunits is isozyme-selective and PLC-beta2 is a prime target of betagamma stimulation. Activation of PLC-beta2 by betagamma subunits may be an important mechanism by which pertussis toxin-sensitive G proteins stimulate PLC.	GERMAN CANC RES CTR, DIV MOLEC PHARMACOL, W-6900 HEIDELBERG, GERMANY; IMPERIAL CANC RES FUND, PROT PHOSPHORYLAT LAB, LONDON WC2A 3PX, ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK			Parker, Peter j/D-5192-2013	Camps, Montserrat/0000-0002-9849-8657; parker, peter/0000-0002-6218-2933				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; LEE CH, 1992, J BIOL CHEM, V267, P16044; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARK D, 1992, J BIOL CHEM, V267, P16048; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q	24	572	576	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					684	686		10.1038/360684a0	http://dx.doi.org/10.1038/360684a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465133				2022-12-24	WOS:A1992KD08200060
J	NIXON, PA; ORENSTEIN, DM; KELSEY, SF; DOERSHUK, CF				NIXON, PA; ORENSTEIN, DM; KELSEY, SF; DOERSHUK, CF			THE PROGNOSTIC VALUE OF EXERCISE TESTING IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE FATIGUE; FITNESS; MODELS; ADULTS	Background. Previous studies have shown female sex, impaired pulmonary function, older age, malnutrition, and colonization of the respiratory tract by Pseudomonas cepacia to be associated with a poor prognosis in patients with cystic fibrosis. We sought to determine the prognostic value of exercise testing in addition to the other prognostic factors. Methods. A total of 109 patients with cystic fibrosis, 7 to 35 years old, underwent pulmonary-function and exercise testing in the late 1970s. They were followed for eight years to determine the factors associated with subsequent mortality. Survival rates were calculated with standard life-table methods. Cox proportional-hazards regression models were used to determine crude relative risks of mortality and relative risks adjusted tor age, sex, body-mass index, forced expiratory volume in one second (FEV1), end-tidal partial pressure of carbon dioxide (PCO2) at peak exercise, and oxygen consumption at peak exercise (V(O2peak)). Results. Patients with the highest levels of aerobic fitness (V(O2peak), greater-than-or-equal-to 82 percent of predicted) had a survival rate of 83 percent at eight years, as compared with rates of 51 percent and 28 percent for patients with middle (V(O2peak), 59 to 81 percent of predicted) and lowest (V(O2peak), less-than-or-equal-to 58 percent of predicted) levels of fitness, respectively. After adjustment for other risk factors, patients with higher levels of aerobic fitness were more than three times as likely to survive than patients with lower levels of fitness. Colonization by P. cepacia was associated with a risk of dying that was increased fivefold. Age, sex, body-mass index, FEV1, and end-tidal PCO2 at peak exercise were not independently correlated with mortality. Conclusions. Higher levels of aerobic fitness in patients with cystic fibrosis are associated with a significantly lower risk of dying. Although better aerobic fitness may simply be a marker for less severe illness, measurement Of V(O2peak) appears to be valuable for predicting prognosis. Further research is warranted to determine whether improving aerobic fitness through exercise programs will result in a better prognosis.	UNIV PITTSBURGH, DEPT PEDIAT, DIV PULMONOL, PITTSBURGH, PA 15260 USA; CASE WESTERN RESERVE UNIV, DEPT PEDIAT, DIV PULMONOL & CYST FIBROSIS, CLEVELAND, OH 44106 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL35334] Funding Source: Medline; NIDDK NIH HHS [DK27651] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BACEVICE AE, 1976, 29TH P ANN C ENG MED, V18, P39; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; Bouchard C., 1986, SPORT HUMAN GENETICS, P59; COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2; COX DR, 1972, J R STAT SOC B, V34, P187; FLEISS JL, 1981, STATISTICAL METHODS, P138; GASKIN K, 1982, J PEDIATR-US, V100, P857, DOI 10.1016/S0022-3476(82)80501-5; GODFREY S, 1974, EXERCISE TESTING CHI, P30; HUANG NN, 1987, AM J MED, V82, P871, DOI 10.1016/0002-9343(87)90147-1; ISSEKUTZ B, 1962, J APPL PHYSIOL, V17, P47, DOI 10.1152/jappl.1962.17.1.47; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P168; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419; MACLEAN GL, 1985, S AFR J WILDL RES, V15, P1; MURCIANO D, 1984, NEW ENGL J MED, V311, P349, DOI 10.1056/NEJM198408093110601; ORENSTEIN D M, 1991, Respiratory Care, V36, P746; ORENSTEIN DM, 1981, CHEST, V80, P392, DOI 10.1378/chest.80.4.392; ORENSTEIN DM, 1989, CHEST, V95, P344, DOI 10.1378/chest.95.2.344; ORENSTEIN DM, IN PRESS HUMAN KINET; SALH W, 1989, THORAX, V44, P1006, DOI 10.1136/thx.44.12.1006; TABLAN OC, 1985, J PEDIATR-US, V107, P382, DOI 10.1016/S0022-3476(85)80511-4; WAGENER JS, 1989, PERSPECTIVES CYSTIC, P236; ZINMAN R, 1989, J PEDIATR-US, V114, P368, DOI 10.1016/S0022-3476(89)80553-0	25	472	475	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1785	1788		10.1056/NEJM199212173272504	http://dx.doi.org/10.1056/NEJM199212173272504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1435933				2022-12-24	WOS:A1992KB97500004
J	WHITE, RJ; JACKSON, SP				WHITE, RJ; JACKSON, SP			MECHANISM OF TATA-BINDING PROTEIN RECRUITMENT TO A TATA-LESS CLASS-III PROMOTER	CELL			English	Article							RNA POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; HUMAN U6 GENE; ACCURATE TRANSCRIPTION; MULTIPLE FACTORS; TFIID COMPLEX; INITIATION; ACTIVATION; PURIFICATION; COMPONENTS	The TATA-binding protein (TBP) is required for transcription by RNA polymerase III (pol III), even though many pol III templates, such as the adenovirus VA(I) gene, lack a consensus TATA box. We show that TBP alone does not form a stable, productive interaction with VA(I) DNA. However, it can be incorporated into an initiation complex if the other class III basal factors, TFIIIB and TFIIIC, are also present. TFIIIB can associate with the evolutionarily conserved C-terminal domain of TBP in the absence of DNA or TFIIIC, suggesting that TFIIIB exists in solution as a complex with TBP. The stable association of TBP with an essential component of the pol III transcription apparatus may account for the ability of TATA-less class III genes to recruit TBP.			WHITE, RJ (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURKE DJ, 1985, J BIOL CHEM, V260, P816; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY MF, 1986, J BIOL CHEM, V261, P4309; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WHITE RJ, 1992, IN PRESS J CELL SCI; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	60	109	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1041	1053		10.1016/0092-8674(92)90398-V	http://dx.doi.org/10.1016/0092-8674(92)90398-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458535				2022-12-24	WOS:A1992KB99000015
J	OCALLAGHAN, E; GIBSON, T; COLOHAN, HA; BUCKLEY, P; WALSHE, DG; LARKIN, C; WADDINGTON, JL				OCALLAGHAN, E; GIBSON, T; COLOHAN, HA; BUCKLEY, P; WALSHE, DG; LARKIN, C; WADDINGTON, JL			RISK OF SCHIZOPHRENIA IN ADULTS BORN AFTER OBSTETRIC COMPLICATIONS AND THEIR ASSOCIATION WITH EARLY ONSET OF ILLNESS - A CONTROLLED-STUDY	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL COMPLICATIONS; PREGNANCY; DISORDER; PSYCHOSIS; DELIVERY; BIRTH; LIFE	Objective-To determine whether obstetric complications occur to excess in the early histories of individuals who go on to develop schizophrenia when compared with controls, and to seek clinical correlates of any such excess. Design-Contemporaneous maternity hospital records were identified and extracted verbatim, and these extracts evaluated for obstetric complications by two independent assessors who were blind to subjects' status. Subjects-65 patients having an ICD-9 diagnosis of schizophrenia, the records of the previous same sex live birth being deemed to be those of a control subject. Main outcome measure-Presence of one or more obstetric complications recorded in maternity notes of patients and controls. Results-When two recognised scales for specifying obstetric complications were used the patients with schizophrenia were significantly more likely than controls to have experienced at least one obstetric complication (odds ratio 2.44, 95% confidence interval 1.08 to 6.03). Patients also showed a greater number and severity of and total score for obstetric complications, fetal distress being the only complication to occur to significant individual excess (present in five (8%) patients, absent in controls). There was a marked sex effect, male patients being more vulnerable (odds ratio 4.24, 1.39 to 12.90) to such complications. Obstetric complications in patients were unrelated to family history or season of birth but were associated with a significantly younger age at onset of illness (mean difference -4.5 years, -1.2 to -7.8 years). Conclusions-Patients with schizophrenia, particularly males, have an excess of obstetric complications in their early developmental histories, and such complications are associated with a younger age at onset of their disease. Though the data are not conclusive, they also suggest that obstetric complications may be secondary to yet earlier events.	ST JOHN GOD PSYCHIAT SERV,BLACKROCK,DUBLIN,IRELAND; ROYAL COLL SURG IRELAND,DUBLIN 2,IRELAND	Royal College of Surgeons - Ireland								CHAMBERLAIN GVP, 1987, DEWHURSTS TXB OBSTET, P101; CHITKARA B, 1988, BRIT J PSYCHIAT, V152, P391, DOI 10.1192/bjp.152.3.391; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; EAGLES JM, 1990, LANCET, V335, P1139, DOI 10.1016/0140-6736(90)91136-X; GARDNER MJ, 1989, BRIT MED J; GOLDSTEIN JM, 1990, SCHIZOPHRENIA BULL, V16, P179, DOI 10.1093/schbul/16.2.179; JACOBSEN B, 1980, ACTA PSYCHIAT SCAND, V62, P337, DOI 10.1111/j.1600-0447.1980.tb07709.x; KERWIN R, 1991, BRIT MED J, V303, P188, DOI 10.1136/bmj.303.6795.188-b; LANE EA, 1966, J PSYCHOL, V64, P227, DOI 10.1080/00223980.1966.10544847; LEWIS S, 1991, BRIT MED J, V303, P582, DOI 10.1136/bmj.303.6802.582-b; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; Lewis SW, 1989, SCHIZOPHRENIA, P56; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MURRAY RM, 1991, CONCEPTS OF MENTAL DISORDER, P48; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; OCALLAGHAN E, 1991, BRIT J PSYCHIAT, V158, P764, DOI 10.1192/bjp.158.6.764; OCALLAGHAN E, 1991, AM J PSYCHIAT, V148, P479; OCALLAGHAN E, 1990, BRIT J PSYCHIAT, V157, P578, DOI 10.1192/bjp.157.4.578; OCALLAGHAN E, 1990, PSYCHOL MED, V20, P89, DOI 10.1017/S0033291700013258; PARNAS J, 1982, BRIT J PSYCHIAT, V140, P416, DOI 10.1192/bjp.140.4.416; POLLACK M, 1966, AM J ORTHOPSYCHIAT, V36, P510, DOI 10.1111/j.1939-0025.1966.tb02394.x; POLLACK M, 1968, AM J ORTHOPSYCHIAT, V38, P94, DOI 10.1111/j.1939-0025.1968.tb00560.x; WADDINGTON JL, 1991, ARCH GEN PSYCHIAT, V48, P271; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WILLIAMS MA, 1991, OBSTET GYNECOL, V78, P14; WOERNER MG, 1973, ACTA PSYCHIAT SCAND, V49, P712, DOI 10.1111/j.1600-0447.1973.tb04460.x; 1978, WHO ICD9; 1987, CENSUS 86	28	160	162	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1256	1259		10.1136/bmj.305.6864.1256	http://dx.doi.org/10.1136/bmj.305.6864.1256			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JZ521	1477568	Green Submitted, Green Published			2022-12-24	WOS:A1992JZ52100022
J	HENDRIX, RW; DUDA, RL				HENDRIX, RW; DUDA, RL			BACTERIOPHAGE-LAMBDA PAPA - NOT THE MOTHER OF ALL LAMBDA-PHAGES	SCIENCE			English	Article							EVEN-TYPE BACTERIOPHAGES; TAIL FIBER PROTEIN; ESCHERICHIA-COLI; RECEPTOR; COMPONENT; SEQUENCE; ENCODES; GENOME; GENE	The common laboratory strain of bacteriophage lambda-lambda wild type or lambdaPaP-carries a frameshift mutation relative to Ur-lambda, the original isolate. The Ur-lambda virions have thin, jointed tail fibers that are absent from lambda wild type. Two novel proteins of Ur-lambda constitute the fibers: the product of stf, the gene that is disrupted in lambda wild type by the frameshift mutation, and the product of gene tfa, a protein that is implicated in facilitating tail fiber assembly. Relative to lambda wild type, Ur-lambda has expanded receptor specificity and adsorbs to Escherichia coli cells more rapidly.			HENDRIX, RW (corresponding author), UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA.			Duda, Robert/0000-0002-9517-2731	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47795, R01 GM047795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; DICKSON RC, 1973, J MOL BIOL, V79, P633, DOI 10.1016/0022-2836(73)90068-5; DOVE WF, 1969, VIROLOGY, V38, P349, DOI 10.1016/0042-6822(69)90378-X; DREXLER K, 1991, J MOL BIOL, V219, P655, DOI 10.1016/0022-2836(91)90662-P; GEORGE DG, 1983, BIOCHEM BIOPH RES CO, V115, P1061, DOI 10.1016/S0006-291X(83)80043-6; HAGGARDLJUNGQUIST E, 1992, J BACTERIOL, V174, P1462, DOI 10.1128/jb.174.5.1462-1477.1992; Hendrix R. W., 1971, BACTERIOPHAGE LAMBDA, P355; HENDRIX RW, UNPUB; IIDA S, 1984, VIROLOGY, V134, P421, DOI 10.1016/0042-6822(84)90309-X; JACOB F, 1954, ANN I PASTEUR PARIS, V87, P653; KAISER AD, 1957, VIROLOGY, V3, P42, DOI 10.1016/0042-6822(57)90022-3; KAISER AD, COMMUNICATION; KAR S, 1983, THESIS U PITTSBURGH; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KOCH C, 1987, PHAGE MU, P75; LEDERBERG EM, 1951, GENETICS, V36, P560; MICHEL CJ, 1986, GENE, V44, P147, DOI 10.1016/0378-1119(86)90055-7; MONTAG D, 1987, J BACTERIOL, V169, P5884, DOI 10.1128/jb.169.12.5884-5886.1987; MONTAG D, 1987, J MOL BIOL, V196, P165, DOI 10.1016/0022-2836(87)90519-5; MONTAG D, 1989, J BACTERIOL, V171, P4378, DOI 10.1128/JB.171.8.4378-4384.1989; MOUNT DWA, 1968, VIROLOGY, V35, P134, DOI 10.1016/0042-6822(68)90313-9; POPA MP, 1991, J VIROL, V65, P3227, DOI 10.1128/JVI.65.6.3227-3237.1991; RANDALLH.L, 1973, J BACTERIOL, V116, P1436, DOI 10.1128/JB.116.3.1436-1446.1973; REEVE JN, 1979, MOL GEN GENET, V172, P243, DOI 10.1007/BF00271723; RIEDE I, 1987, J MOL BIOL, V194, P23, DOI 10.1016/0022-2836(87)90712-1; SAIGO K, 1978, VIROLOGY, V85, P422, DOI 10.1016/0042-6822(78)90449-X; SANDMEIER H, 1992, J BACTERIOL, V174, P3936, DOI 10.1128/jb.174.12.3936-3944.1992; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SHINAGAW.H, 1966, BIKEN J, V9, P135; THIRION JP, 1972, GENETICS, V71, P207; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WARD S, 1971, J MOL BIOL, V62, P479, DOI 10.1016/0022-2836(71)90149-5; WOOD WB, 1983, BACTERIOPHAGE T4, P259; [No title captured]	34	98	102	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1145	1148		10.1126/science.1439823	http://dx.doi.org/10.1126/science.1439823			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439823				2022-12-24	WOS:A1992JX85200031
J	MUST, A; JACQUES, PF; DALLAL, GE; BAJEMA, CJ; DIETZ, WH				MUST, A; JACQUES, PF; DALLAL, GE; BAJEMA, CJ; DIETZ, WH			LONG-TERM MORBIDITY AND MORTALITY OF OVERWEIGHT ADOLESCENTS - A FOLLOW-UP OF THE HARVARD GROWTH STUDY OF 1922 TO 1935	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR-DISEASE; SERUM-LIPIDS; RISK FACTOR; OBESITY; WOMEN; WEIGHT; LIPOPROTEINS; CHILDREN; HEALTH; DEATH	Background. Overweight in adults is associated with increased morbidity and mortality. In contrast, the long-term effect of overweight in adolescence on morbidity and mortality is not known. Methods. We studied the relation between overweight and morbidity and mortality in 508 lean or overweight adolescents 13 to 18 years old who participated in the Harvard Growth Study of 1922 to 1935. Overweight adolescents were defined as those with a body-mass index that on two occasions was greater than the 75th percentile in subjects of the same age and sex in a large national survey. Lean adolescents were defined as those with a body-mass index between the 25th and 50th percentiles. Subjects who were still alive were interviewed in 1988 to obtain information about their medical history, weight, functional capacity, and other risk factors. For those who had died, information on the cause of death was obtained from death certificates. Results. Overweight in adolescent subjects was associated with an increased risk of mortality from all causes and disease-specific mortality among men, but not among women. The relative risks among men were 1.8 (95 percent confidence interval, 1.2 to 2.7; P = 0.004) for mortality from all causes and 2.3 (95 percent confidence interval, 1.4 to 4.1; P = 0.002) for mortality from coronary heart disease. The risk of morbidity from coronary heart disease and atherosclerosis was increased among men and women who had been overweight in adolescence. The risk of colorectal cancer and gout was increased among men and the risk of arthritis was increased among women who had been overweight in adolescence. Overweight in adolescence was a more powerful predictor of these risks than overweight in adulthood. Conclusions. Overweight in adolescence predicted a broad range of adverse health effects that were independent of adult weight after 55 years of follow-up.	GRAND VALLEY STATE UNIV, ALLENDALE, MI USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR, DIV BIOSTAT, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Grand Valley State University; Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center	MUST, A (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR, EPIDEMIOL PROGRAM, 711 WASHINGTON ST, BOSTON, MA 02111 USA.							ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P180, DOI 10.1093/oxfordjournals.aje.a114376; CRONK CE, 1982, AM J CLIN NUTR, V35, P347, DOI 10.1093/ajcn/35.2.347; DAVIS MA, 1990, SEMIN ARTHRITIS RHEU, V20, P34, DOI 10.1016/0049-0172(90)90045-H; DEARBORN WF, 1938, MONOGR SOC RES CHILD, V3; DEUTSCH MI, 1985, ANN HUM BIOL, V12, P275, DOI 10.1080/03014468500007781; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONAHUE RP, 1985, AM J EPIDEMIOL, V122, P458, DOI 10.1093/oxfordjournals.aje.a114127; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; HARTZ AJ, 1986, J CHRON DIS, V39, P311, DOI 10.1016/0021-9681(86)90053-6; HAUST M D, 1990, Pediatric Pathology, V10, P253; HENRY RR, 1986, DIABETES, V35, P155, DOI 10.2337/diabetes.35.2.155; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HOFFMANS MDAF, 1989, J CLIN EPIDEMIOL, V42, P513, DOI 10.1016/0895-4356(89)90147-9; KANNEL WB, 1984, J AM COLL NUTR, V3, P139; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LAPIDUS L, 1990, BRIT MED J, V10, P253; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1989, AM J EPIDEMIOL, V130, P833; MOSSBERG HO, 1989, LANCET, V2, P491; MUELLER WH, 1982, SOC SCI MED, V16, P191, DOI 10.1016/0277-9536(82)90022-3; PAFFENBARGER RS, 1973, AM J EPIDEMIOL, V97, P314, DOI 10.1093/oxfordjournals.aje.a121511; PAFFENBARGER RS, 1969, AM J EPIDEMIOL, V90, P527, DOI 10.1093/oxfordjournals.aje.a121099; SCOTT EC, 1982, HUM BIOL, V54, P501; SORENSEN TIA, 1977, J CHRON DIS, V30, P359, DOI 10.1016/0021-9681(77)90030-3; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; VOORS AW, 1982, ARTERIOSCLEROSIS, V2, P346, DOI 10.1161/01.ATV.2.4.346; WAALER HT, 1984, ACTA MED SCAND, P1; WEBBER LS, 1983, J CHRON DIS, V36, P647, DOI 10.1016/0021-9681(83)90081-4; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL, V15, P231; WYLIE CM, 1984, J AM GERIATR SOC, V32, P670, DOI 10.1111/j.1532-5415.1984.tb02258.x; 1990, NUTRITION YOUR HLTH; 1990, SAS STAT USERS GUIDE; 1980, INT CLASSIFICATION D; 1990, DHHS PHS901148 PUBL; 1990, NATIONAL HLTH NUTRIT, V3	44	1585	1640	1	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1350	1355		10.1056/NEJM199211053271904	http://dx.doi.org/10.1056/NEJM199211053271904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406836				2022-12-24	WOS:A1992JW07700004
J	WILLIAMS, JW; SIMEL, DL; ROBERTS, L; SAMSA, GP				WILLIAMS, JW; SIMEL, DL; ROBERTS, L; SAMSA, GP			CLINICAL-EVALUATION FOR SINUSITIS - MAKING THE DIAGNOSIS BY HISTORY AND PHYSICAL-EXAMINATION	ANNALS OF INTERNAL MEDICINE			English	Article						SINUSITIS; TRANSILLUMINATION; RHINITIS; DIAGNOSIS, DIFFERENTIAL; TOOTHACHE	ACUTE MAXILLARY SINUSITIS; BACTERIAL SINUSITIS	Objective: To identify the most useful clinical examination findings for the diagnosis of acute and subacute sinusitis. Design: Prospective comparison of clinical findings with radiographs. Setting: General medicine clinics at a university-affiliated Veterans Affairs Medical Center. Patients: Two hundred forty-seven consecutive adult men with rhinorrhea (51%), facial pain (22%), or self-suspected sinusitis (27%) (median age, 50 years; median duration of symptoms, 11.5 days). Measurements: Patients were examined by a principal investigator (86%) or by a staff general internist, internal medicine resident (postgraduate year 2 or 3), or physician assistant, all blinded to radiographic results. All examiners recorded the presence or absence of 16 historical items, 5 physical examination items, and the clinical impression for sinusitis (high, intermediate, or low probability). The criterion standard was paranasal sinus radiographs (4 views), which were interpreted by radiologists blinded to clinical findings. Results: Thirty-eight percent of patients meeting entrance criteria had sinusitis. Sensitivity, specificity, and likelihood ratios were measured for clinical items. Logistic regression analysis showed five independent predictors of sinusitis: maxillary toothache (odds ratio, 2.9), transillumination (odds ratio, 2.7), poor response to nasal decongestants or antihistamines (odds ratio, 2.4), colored nasal discharge reported by the patient (odds ratio, 2.2), or mucopurulence seen during examination (odds ratio, 2.9). The overall clinical impression was more accurate than any single finding: high probability (likelihood ratio, 4.7), intermediate (likelihood ratio, 1.4), low probability (likelihood ratio, 0.4). Conclusions: General internists, focusing on five clinical findings and their overall clinical impression, can effectively stratify male patients with sinus symptoms as having a high, intermediate, or low probability of sinusitis.	VET ADM MED CTR, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University of Texas System; University of Texas Health San Antonio	WILLIAMS, JW (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR, 11C, 7400 MERTON MINTER BLVD, SAN ANTONIO, TX 78284 USA.		Williams, John/AAM-4572-2020; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558				AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; AXELSSON A, 1983, ANN OTO RHINOL LARYN, V92, P75, DOI 10.1177/000348948309200118; AXELSSON A, 1974, AM J ROENTGENOL, V122, P621, DOI 10.2214/ajr.122.3.621; BALLINGER PW, 1991, MERRILLS ATLAS RADIO, P364; BATES B, 1991, PHYSICAL EXAMINATION, P189; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FLEISS JL, 1981, STATISTICAL METHODS, P112; GLECKMAN RA, 1986, HOSP PRACT, V21, P92; GLECKMAN RA, 1986, HOSPITAL PRACT, V21, P100; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1990, SAS STAT USERS GUIDE, P175; HARVEY BS, 1987, PRIMARY CARE MED, P883; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MEYERS BR, 1984, J FAM PRACTICE, V18, P117; NORRBY R, 1983, SCAND J INFECT DIS, P14; Ramsey P G, 1985, Emerg Med Clin North Am, V3, P143; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; WALD ER, 1986, PEDIATRICS, V77, P795; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILLIAMS JW, 1992, IN PRESS J GEN INTER, P6; YARINGTON CT, 1979, OTOLARYNG CLIN N AM, V12, P447	32	180	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					705	710		10.7326/0003-4819-117-9-705	http://dx.doi.org/10.7326/0003-4819-117-9-705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1416571				2022-12-24	WOS:A1992JV42400001
J	BROCKDORFF, N; ASHWORTH, A; KAY, GF; MCCABE, VM; NORRIS, DP; COOPER, PJ; SWIFT, S; RASTAN, S				BROCKDORFF, N; ASHWORTH, A; KAY, GF; MCCABE, VM; NORRIS, DP; COOPER, PJ; SWIFT, S; RASTAN, S			THE PRODUCT OF THE MOUSE XIST GENE IS A 15 KB INACTIVE X-SPECIFIC TRANSCRIPT CONTAINING NO CONSERVED ORF AND LOCATED IN THE NUCLEUS	CELL			English	Article							POSITION-EFFECT VARIEGATION; CPG-RICH ISLANDS; CHROMOSOME INACTIVATION; MESSENGER-RNA; CONTROLLING ELEMENTS; H19 GENE; DNA; METHYLATION; EXPRESSION; REGION	The Xist gene maps to the X inactivation center region in both mouse and human, and previous analysis of the 3' end of the gene has demonstrated inactive X-specific expression, suggesting a possible role in X inactivation. We have now analyzed the entire mouse Xist gene. The mature inactive X-specific transcript is 15 kb in length and contains no conserved ORF. The Xist sequence contains a number of regions comprised of tandem repeats. Comparison with the human XIST gene demonstrates significant conservation of sequence and gene structure. Xist RNA is not associated with the translational machinery of the cell and is located almost exclusively in the nucleus. Together with conservation of inactive X-specific expression, these findings support a role for Xist in X inactivation, possibly as a functional RNA or as a chromatin organizer region.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	BROCKDORFF, N (corresponding author), MRC,CTR CLIN RES,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1989, NUCLEIC ACIDS RES, V17, P1315, DOI 10.1093/nar/17.4.1315; BROCKDORFF N, 1991, GENOMICS, V10, P17, DOI 10.1016/0888-7543(91)90478-W; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CJ, 1990, AM J HUM GENET, V46, P273; Cattanach B. M., 1989, MOUSE NEWS LETT, V83, P165; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1983, MOUSE NEWS LETT, V69, P24; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOVER GA, 1989, TRENDS GENET, V5, P100, DOI 10.1016/0168-9525(89)90038-3; FINI ME, 1989, J CELL BIOL, V6, P2045; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GOMEZMARQUEZ J, 1985, J BIOL CHEM, V260, P3490; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HERMAN GE, 1991, GENOMICS, V10, P961, DOI 10.1016/0888-7543(91)90186-I; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KANDA N, 1973, EXP CELL RES, V80, P463, DOI 10.1016/0014-4827(73)90324-8; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE SY, 1971, BIOCHEMISTRY-US, V10, P510, DOI 10.1021/bi00779a025; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LIEBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241; LYON MF, 1961, NATURE, V190, P373; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; NORRIS DP, 1991, MAMM GENOME, V1, P78, DOI 10.1007/BF02443782; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POIRIER F, 1991, DEVELOPMENT, V113, P1105; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1980, NATURE, V288, P172, DOI 10.1038/288172a0; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SHAPIRO LJ, 1979, SCIENCE, V204, P1224, DOI 10.1126/science.156396; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11262; VANDEPUTTE P, 1980, NATURE, V286, P218, DOI 10.1038/286218a0; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9	59	817	858	4	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					515	526		10.1016/0092-8674(92)90519-I	http://dx.doi.org/10.1016/0092-8674(92)90519-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423610				2022-12-24	WOS:A1992JW43500016
J	FISHMANLOBELL, J; HABER, JE				FISHMANLOBELL, J; HABER, JE			REMOVAL OF NONHOMOLOGOUS DNA ENDS IN DOUBLE-STRAND BREAK RECOMBINATION - THE ROLE OF THE YEAST ULTRAVIOLET REPAIR GENE RAD1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; EXCISION; INCISION; LOCUS	Double-strand breaks (DSBs) in Saccharomyces cerevisiae can be repaired by gene conversions or by deletions resulting from single-strand annealing between direct repeats of homologous sequences. Although rad1 mutants are resistant to x-rays and can complete DSB-mediated mating-type switching, they could not complete recombination when the ends of the break contained approximately 60 base pairs of nonhomology. Recombination was restored when the ends of the break were made homologous to donor sequences. Additionally, the absence of RAD1 led to the frequent appearance of a previously unobserved type of recombination product. These data suggest RAD1 is required to remove nonhomologous DNA from the 3' ends of recombining DNA, a process analogous to the excision of photodimers during repair of ultraviolet-damaged DNA.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM01722, GM20056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020056, R37GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; FISHMANLOBELL J, UNPUB; FISHMANLOBELL J, 1992, THESIS BRANDEIS U; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; KLEIN HL, 1988, GENETICS, V120, P367; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; RAY BL, 1991, MOL CELL BIOL, V11, P5372, DOI 10.1128/MCB.11.10.5372; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; RUDIN N, 1989, GENETICS, V122, P519; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P6516; SNOW R, 1968, MUTAT RES, V6, P409, DOI 10.1016/0027-5107(68)90058-4; SOKAL RR, 1969, BIOMETRY, P599; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; THOMAS BJ, 1989, GENETICS, V123, P725; WEIFFENBACH B, 1983, P NATL ACAD SCI-BIOL, V80, P3401, DOI 10.1073/pnas.80.11.3401; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; ZEHFUS BR, 1990, GENETICS, V126, P41	24	313	323	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					480	484		10.1126/science.1411547	http://dx.doi.org/10.1126/science.1411547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411547				2022-12-24	WOS:A1992JT77500041
J	LUO, Y; FUJII, H; GERSTER, T; ROEDER, RG				LUO, Y; FUJII, H; GERSTER, T; ROEDER, RG			A NOVEL B-CELL DERIVED COACTIVATOR POTENTIATES THE ACTIVATION OF IMMUNOGLOBULIN PROMOTERS BY OCTAMER-BINDING TRANSCRIPTION FACTORS	CELL			English	Article							HEAVY-CHAIN PROMOTER; POU-DOMAIN; GENE-TRANSCRIPTION; PROTEIN-BINDING; HELA-CELLS; EXPRESSION; OCT-1; DNA; ELEMENTS; INVITRO	A novel B cell-restricted activity, required for high levels of octamer/Oct-dependent transcription from an immunoglobulin heavy chain (IgH) promoter, was detected in an in vitro system consisting of HeLa cell-derived extracts complemented with fractionated B cell nuclear proteins. The factor responsible for this activity was designated Oct coactivator from B cells (OCA-B). OCA-B stimulates the transcription from an IgH promoter in conjunction with either Oct-1 or Oct-2 but shows no significant effect on the octamer/Oct-dependent transcription of the ubiquitously expressed histone H2B promoter and the transcription of USF- and Sp1-regulated promoters. Taken together, our results suggest that OCA-B is a tissue-, promoter-, and factor-specific coactivator and that OCA-B may be a major determinant for B cell-specific activation of immunoglobulin promoters. In light of the evidence showing physical and functional interactions between Oct factors and OCA-B, we propose a mechanism of action for OCA-B and discuss the implications of OCA-B for the transcriptional regulation of other tissue-specific promoters.			LUO, Y (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.							COCKERILL PN, 1990, MOL CELL BIOL, V10, P1293, DOI 10.1128/MCB.10.3.1293; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844	49	247	251	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					231	241		10.1016/0092-8674(92)90352-D	http://dx.doi.org/10.1016/0092-8674(92)90352-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423591				2022-12-24	WOS:A1992JU39500009
J	KOBAYASHI, T; STORRIE, B; SIMONS, K; DOTTI, CG				KOBAYASHI, T; STORRIE, B; SIMONS, K; DOTTI, CG			A FUNCTIONAL BARRIER TO MOVEMENT OF LIPIDS IN POLARIZED NEURONS	NATURE			English	Article							DEPENDENT SODIUM-CHANNELS; HIPPOCAMPAL-NEURONS; PLASMA-MEMBRANE; EPITHELIAL-CELL; INFLUENZA-VIRUS; TIGHT JUNCTIONS; GOLGI-APPARATUS; MAMMALIAN SPERM; MDCK CELLS; DOMAINS	IN polarized neurons, axons and dendrites perform different functions, which are reflected in their different molecular organization. Studies on the sorting of viral and endogenous glycoproteins in epithelial cells and hippocampal neurons suggest that there may be similarities in the mechanism of sorting in these two cell types1-3. The mechanisms that maintain the distinct composition of the two plasma membrane domains in these two cell types must, however, be different. We have proposed the existence of a functional barrier at the axonal hillock/initial segment which prevents the intermixing of membrane constituents1,2. Here we test this hypothesis by fusing liposomes containing fluorescent phospholipids into the plasma membrane of polarized hippocampal cells in culture. Fusion was induced by lowering the pH and mediated by influenza virus haemagglutinin expressed on the axonal surface of neurons infected with fowl plague virus. Labelling was found exclusively on axons after fusion. Although the fused lipids were mobile on the axonal membrane, no labelling was detected on the cell body and dendritic surfaces. These results suggest that there is a diffusion barrier at the axonal hillock/initial segment which maintains the compositional differences between the axonal and somatodendritic domains.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM, BLACKSBURG, VA 24061 USA	European Molecular Biology Laboratory (EMBL); Virginia Polytechnic Institute & State University			KOBAYASHI, TOSHIHIDE/S-8313-2019; Dotti, Carlos G/I-5533-2015; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Dotti, Carlos G/0000-0003-4052-1719; Kobayashi, Toshihide/0000-0002-4811-7270; Simons, Kai/0000-0002-9231-9996				ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Banker G., 1991, CULTURING NERVE CELL; COWAN AE, 1987, J CELL BIOL, V104, P917, DOI 10.1083/jcb.104.4.917; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FRIEND DS, 1974, J CELL BIOL, V63, P641, DOI 10.1083/jcb.63.2.641; GILULA NB, 1972, J CELL BIOL, V53, P494, DOI 10.1083/jcb.53.2.494; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; HUNNICUTT GR, 1990, J CELL BIOL, V111, P1605, DOI 10.1083/jcb.111.4.1605; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; Peters A, 1991, FINE STRUCTURE NERVO; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; VAN MEER G, 1985, BIOCHEMISTRY-US, V24, P3593, DOI 10.1021/bi00335a030; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; WEISS RL, 1977, J CELL BIOL, V72, P133, DOI 10.1083/jcb.72.1.133; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x	25	127	129	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	1992	359	6396					647	650		10.1038/359647a0	http://dx.doi.org/10.1038/359647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406997				2022-12-24	WOS:A1992JT82400061
J	ALCAMI, A; SMITH, GL				ALCAMI, A; SMITH, GL			A SOLUBLE RECEPTOR FOR INTERLEUKIN-1-BETA ENCODED BY VACCINIA VIRUS - A NOVEL MECHANISM OF VIRUS MODULATION OF THE HOST RESPONSE TO INFECTION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; INVERTED TERMINAL REPEAT; IL-1 RECEPTOR; BIOLOGICAL CHARACTERIZATION; IMMUNOGLOBULIN SUPERFAMILY; NUCLEOTIDE-SEQUENCE; B-CELLS; ANTAGONIST; EXPRESSION; BINDING	Vaccinia virus gene B15R is shown to encode an abundant, secretory glycoprotein that functions as a soluble interleukin-1 (IL-1) receptor. This IL-1 receptor has novel specificity since, in contrast with cellular counterparts, it binds only IL-1beta and not IL-1alpha or the natural competitor IL-1 receptor antagonist. The vaccinia IL-1beta receptor is secreted when expressed in a baculovirus system and competitively inhibited binding of IL-1beta to the natural receptor on T cells. Deletion of B15R from vaccinia virus accelerated the appearance of symptoms of illness and mortality in intranasally infected mice, suggesting that the blockade of IL-1beta by vaccinia virus can diminish the systemic acute phase response to infection and modulate the severity of the disease. The IL-1beta binding activity is present in other orthopoxviruses.			ALCAMI, A (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND.		Alcami, Antonio/F-8512-2015; Smith, Geoffrey L/G-2894-2012	Alcami, Antonio/0000-0002-3333-6016; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1992, CELL, V73; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; BUSBRIDGE NJ, 1989, BIOCHEM BIOPH RES CO, V162, P591, DOI 10.1016/0006-291X(89)92351-6; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1989, J IMMUNOL, V142, P4314; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; DUFF GW, 1983, NATURE, V304, P449, DOI 10.1038/304449a0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; Fenner F., 1989, SMALLPOX ITS ERADICA, VVolume 43; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; IKUTA K, 1980, J GEN VIROL, V47, P227, DOI 10.1099/0022-1317-47-1-227; ISAACS SN, 1990, VIROLOGY, V178, P626, DOI 10.1016/0042-6822(90)90367-Z; KATSUURA G, 1988, BIOCHEM BIOPH RES CO, V156, P61, DOI 10.1016/S0006-291X(88)80805-2; KENT RK, 1988, THESIS U CAMBRIDGE C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1989, IMMUNOL TODAY, V10, P61, DOI 10.1016/0167-5699(89)90308-3; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACDONALD HR, 1985, J IMMUNOL, V135, P3944; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Sambrook J., 1989, MOL CLONING LAB MANU; SHIELDS J, 1991, CLIN BIOTECHNOL, V3, P81; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399; TURNER PC, 1990, CURR TOP MICROBIOL, V163, P125; UEDA Y, 1972, VIROLOGY, V49, P794, DOI 10.1016/0042-6822(72)90535-1; UEDA Y, 1990, VIROLOGY, V177, P588, DOI 10.1016/0042-6822(90)90524-U; UEHARA A, 1987, BIOCHEM BIOPH RES CO, V146, P1286, DOI 10.1016/0006-291X(87)90788-1; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; URDAL DL, 1988, J BIOL CHEM, V263, P2870; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761; ZUIDEMA D, 1990, J GEN VIROL, V71, P2201, DOI 10.1099/0022-1317-71-10-2201; [No title captured]	78	425	439	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					153	167		10.1016/0092-8674(92)90274-G	http://dx.doi.org/10.1016/0092-8674(92)90274-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394428				2022-12-24	WOS:A1992JQ62300015
J	CLARK, DJ; FELSENFELD, G				CLARK, DJ; FELSENFELD, G			A NUCLEOSOME CORE IS TRANSFERRED OUT OF THE PATH OF A TRANSCRIBING POLYMERASE	CELL			English	Article							RNA-POLYMERASE; TRANSCRIPTIONALLY COMPETENT; CHROMATIN STRUCTURE; DNA-TEMPLATE; II INVITRO; 5S RNA; INITIATION; HISTONES; DISPLACEMENT; ELONGATION	We have determined the fate of a nucleosome core on transcription. A nucleosome core was assembled on a short DNA fragment and ligated into a plasmid containing a promoter and terminators for SP6 RNA polymerase. The nucleosome core was stable in the absence of transcription. The distribution of nucleosome cores after transcription was examined. The histone octamer was displaced from its original site and reformed a nucleosome core at a new site within the same plasmid molecule, with some preference for the untranscribed region behind the promoter. These observations eliminate several models that have been proposed for transcription through a nucleosome core. Our results suggest that a nucleosome core in the path of a transcribing polymerase is displaced by transfer to the closest acceptor DNA.			CLARK, DJ (corresponding author), NIH,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McKnight S L, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 2, P741; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VOORDOUW G, 1978, NATURE, V273, P446, DOI 10.1038/273446a0; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; WOLFFE A, 1992, CHROMATIN STRUCTURE; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	48	132	133	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					11	22		10.1016/0092-8674(92)90262-B	http://dx.doi.org/10.1016/0092-8674(92)90262-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394427				2022-12-24	WOS:A1992JQ62300003
J	MATSUMURA, K; TOME, FMS; COLLIN, H; AZIBI, K; CHAOUCH, M; KAPLAN, JC; FARDEAU, M; CAMPBELL, KP				MATSUMURA, K; TOME, FMS; COLLIN, H; AZIBI, K; CHAOUCH, M; KAPLAN, JC; FARDEAU, M; CAMPBELL, KP			DEFICIENCY OF THE 50K DYSTROPHIN-ASSOCIATED GLYCOPROTEIN IN SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR-DYSTROPHY	NATURE			English	Article							SKELETAL-MUSCLE; COMPLEX; PROTEIN	X-LINKED recessive Duchenne muscular dystrophy (DMD) is caused by the absence of dystrophin, a membrane cytoskeletal protein1,2. Dystrophin is associated with a large oligomeric complex of sarcolemmal glycoproteins3-10. The dystrophin-glycoprotein complex has been proposed to span the sarcolemma to provide a link between the subsarcolemmal cytoskeleton and the extracellular matrix component, laminin7,9. In DMD, the absence of dystrophin leads to a large reduction in all of the dystrophin-associated proteins4,9,10. We have investigated the possibility that a deficiency of a dystrophin-associated protein could be the cause of severe childhood autosomal recessive muscular dystrophy (SCARMD) with a DMD-like phenotype11-14. Here we report the specific deficiency of the 50K dystrophin-associated glycoprotein (M(r) 50,000) in sarcolemma of SCARMD patients. Therefore, the loss of this glycoprotein is a common denominator of the pathological process leading to muscle cell necrosis in two forms of muscular dystrophy, DMD and SCARMD.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; INSERM, U153, F-75005 PARIS, FRANCE; HOP BOLOGHINE, BIOL LAB, ALGIERS, ALGERIA; HOP BEN AKNOUN, SERV NEUROL, ALGIERS, ALGERIA; INST COCHIN GENET MOLEC, INSERM, U129, F-75014 PARIS, FRANCE	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)				Campbell, Kevin/0000-0003-2066-5889				BENHAMIDA M, 1992, J NEUROL SCI, V107, P60; BENJELLOUNDELLAGI S, 1990, NEUROLOGY, V40, P1903; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; McKusick V. A. E., 1991, MENDELIAN INHERITANC; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHLENDIECK K, IN PRESS NEUROLOGY	17	256	258	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					320	322		10.1038/359320a0	http://dx.doi.org/10.1038/359320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406935				2022-12-24	WOS:A1992JP50300056
J	GURSOY, S; STEURER, G; BRUGADA, J; ANDRIES, E; BRUGADA, P				GURSOY, S; STEURER, G; BRUGADA, J; ANDRIES, E; BRUGADA, P			THE HEMODYNAMIC MECHANISM OF POUNDING IN THE NECK IN ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SUPRAVENTRICULAR TACHYCARDIA		ONZE LIEVE VROUW HOSP, CTR CARDIOVASC, MOORSELBAAN 164, B-9300 AALST, BELGIUM; UNIV BARCELONA, HOSP CLIN, ARRHYTHMIA UNIT, BARCELONA 7, SPAIN	University of Barcelona; Hospital Clinic de Barcelona				BRUGADA, JOSEP/0000-0002-5662-8302				AKHTAR M, 1978, AM HEART J, V95, P22, DOI 10.1016/0002-8703(78)90394-0; FERRER MI, 1949, AM J MED, V6, P725, DOI 10.1016/0002-9343(49)90308-3; GOLDREYER BN, 1976, CIRCULATION, V54, P783, DOI 10.1161/01.CIR.54.5.783; NAITO M, 1983, AM HEART J, V105, P295, DOI 10.1016/0002-8703(83)90530-6; SGANZERLA P, 1989, EUR HEART J, V10, P32, DOI 10.1093/oxfordjournals.eurheartj.a059378; SWINSCOW TDV, 1980, STATISTICS SQUARE ON	6	51	53	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					772	774		10.1056/NEJM199209103271105	http://dx.doi.org/10.1056/NEJM199209103271105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501653				2022-12-24	WOS:A1992JL66100005
J	SLEVIN, ML				SLEVIN, ML			CURRENT ISSUES IN CANCER - QUALITY-OF-LIFE - PHILOSOPHICAL QUESTION OR CLINICAL REALITY	BRITISH MEDICAL JOURNAL			English	Article							ADVANCED BREAST-CANCER; OF-LIFE; CHEMOTHERAPY; MASTECTOMY; RESECTION; CARCINOMA; SURVIVAL; THERAPY				SLEVIN, ML (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND.							Aaronson N K, 1988, Recent Results Cancer Res, V111, P231; BECKMANN J, 1983, DAN MED BULL, V30, P10; BRINKLEY D, 1985, BRIT MED J, V291, P685, DOI 10.1136/bmj.291.6497.685; BUHL K, 1990, EUR J SURG ONCOL, V16, P404; CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GLIMELIUS B, 1989, EUR J CANCER CLIN ON, V25, P829, DOI 10.1016/0277-5379(89)90128-4; GOUGH IR, 1981, CLIN ONCOL, V7, P5; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Harris J., 1985, VALUE LIFE INTRO MED, P87; KAASA S, 1988, ACTA ONCOL, V27, P335, DOI 10.3109/02841868809093551; KIEBERT GM, 1991, J CLIN ONCOL, V9, P1059, DOI 10.1200/JCO.1991.9.6.1059; MAGUIRE P, 1989, BRIT J CANCER, V60, P437, DOI 10.1038/bjc.1989.301; MAGUIRE P, 1988, BRIT MED J, V297, P907, DOI 10.1136/bmj.297.6653.907; PRIESTMAN TJ, 1976, LANCET, V1, P899; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SLEVIN ML, 1991, BR J CANC S8, V63, P11; SPIEGEL D, 1989, LANCET, V2, P888; STEINBERG MD, 1985, AM J PSYCHIAT, V142, P34; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; WOLBERG WH, 1989, CANCER-AM CANCER SOC, V63, P1645, DOI 10.1002/1097-0142(19890415)63:8<1645::AID-CNCR2820630835>3.0.CO;2-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	25	65	66	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					466	469		10.1136/bmj.305.6851.466	http://dx.doi.org/10.1136/bmj.305.6851.466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK680	1392964	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JK68000030
J	PAPAVASSILIOU, AG; TREIER, M; CHAVRIER, C; BOHMANN, D				PAPAVASSILIOU, AG; TREIER, M; CHAVRIER, C; BOHMANN, D			TARGETED DEGRADATION OF C-FOS, BUT NOT V-FOS, BY A PHOSPHORYLATION-DEPENDENT SIGNAL ON C-JUN	SCIENCE			English	Article							DNA-BINDING DOMAIN; ACTIVATION; TRANSCRIPTION; ONCOGENES; CELLS	The proto-oncogene products c-Fos and c-Jun heterodimerize through their leucine zippers to form the AP-1 transcription factor. The transcriptional activity of the heterodimer is regulated by signal-dependent phosphorylation and dephosphorylation events. The stability of c-Fos was found to also be controlled by intracellular signal transduction. In transient expression and in vitro degradation experiments, the stability of c-Fos was decreased when the protein was dimerized with phosphorylated c-Jun. c-Jun protein isolated from phorbol ester-induced cells did not target c-Fos for degradation, which suggests that c-Fos is transiently stabilized after stimulation of cell growth. v-Fos protein, the retroviral counterpart of c-Fos, was not susceptible to degradation targeted by c-Jun.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAM, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Karamouzis, Michalis/AAD-2860-2020; Treier, Mathias/AAD-6388-2021					BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOHMANN D, UNPUB; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CURRAN T, 1987, ONCOGENE, V2, P79; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PAPAVASSILIOU AG, UNPUB; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	25	104	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1941	1944		10.1126/science.1470918	http://dx.doi.org/10.1126/science.1470918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470918				2022-12-24	WOS:A1992KD08800033
J	CHEN, J; KANAI, Y; COWAN, NJ; HIROKAWA, N				CHEN, J; KANAI, Y; COWAN, NJ; HIROKAWA, N			PROJECTION DOMAINS OF MAP2 AND TAU DETERMINE SPACINGS BETWEEN MICROTUBULES IN DENDRITES AND AXONS	NATURE			English	Article							POLARITY ORIENTATION; MOLECULAR-STRUCTURE; BINDING DOMAIN; PROTEIN TAU; EXPRESSION; BRAIN; CDNA; PHOSPHORYLATION; ORGANIZATION; SEQUENCES	NEURONS develop a highly polarized morphology consisting of dendrites and a long axon. Both axons and dendrites contain microtubules and microtubule-associated proteins (MAPs) with characteristic structures1. Among MAPs, MAP2 is specifically expressed in dendrites2 whereas MAP2C and tau are abundant in the axon2-5. But the influence of MAP2, MAP2C and tau on the organization of microtubule domains in dendrites versus axons is unknown. Both MAP2 and tau induce microtubule bundle formation in fibroblasts after transfection of complementary DNAs6,7 and a long process resembling an axon is extended in Sf9 cells infected with recombinant baculovirus expressing tau8,9. We have now expressed MAP2 and MAP2C in Sf9 cells in order to compare their morphology and the arrangement of their microtubules to that found in Sf9 cells expressing tau. We report here that the spacing between microtubules depends on the MAP expressed: in cells expressing MAP2, the distance is similar to that found in dendrites, whereas the spacing between microtubules in cells expressing MAP2C or tau is similar to that found in axons.	UNIV TOKYO,SCH MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	University of Tokyo; New York University			Kanai, Yoshimitsu/W-3486-2019	Kanai, Yoshimitsu/0000-0002-0375-6853				AIZAWA H, 1988, J BIOL CHEM, V263, P7703; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HEIDEMANN SR, 1981, J CELL BIOL, V91, P661, DOI 10.1083/jcb.91.3.661; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1988, J NEUROSCI, V8, P285; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PAPANDRIKOPOULOU A, 1989, NATURE, V340, P650, DOI 10.1038/340650a0; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; TAKEUCHI M, 1992, J NEUROCHEM, V58, P1510, DOI 10.1111/j.1471-4159.1992.tb11372.x; UMEYAMA T, IN PRESS J CELL BIOL; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; WEBB NR, 1990, MAXBAC BACULOVIRUS E; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	28	477	495	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					674	676		10.1038/360674a0	http://dx.doi.org/10.1038/360674a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465130				2022-12-24	WOS:A1992KD08200056
J	LAWN, RM; WADE, DP; HAMMER, RE; CHIESA, G; VERSTUYFT, JG; RUBIN, EM				LAWN, RM; WADE, DP; HAMMER, RE; CHIESA, G; VERSTUYFT, JG; RUBIN, EM			ATHEROGENESIS IN TRANSGENIC MICE EXPRESSING HUMAN APOLIPOPROTEIN(A)	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ATHEROSCLEROSIS SUSCEPTIBILITY; PLASMINOGEN ACTIVATION; HUMAN AORTA; QUANTIFICATION; LESIONS; FIBRIN; ACCUMULATION; MACROPHAGES; INHIBITION	ELEVATED plasma levels of the lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, myocardial infarction, stroke and restenosis (for reviews, see refs 1-3). Lp(a) differs from low-density lipoprotein by the addition of the glycoprotein apolipoprotein(a), a homologue of plasminogen that contains many tandemly repeated units which resemble the fourth kringle domain of plasminogen, and single homologues of its kringle-5 and protease domain4. As plasma Lp(a) concentration is strongly influenced by heritable factors and is refractory to most drug and dietary manipulation, the effects of modulating it are difficult to mimic experimentally. In addition, the absence of apolipoprotein(a) from virtually all species other than primates precludes the use of convenient animal models. Here we show that transgenic mice expressing human apolipoprotein(a) are more susceptible than control mice to the development of lipid-staining lesions in the aorta, and that apolipoprotein(a) co-localizes with lipid deposition in the artery walls.	UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LAWN, RM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CARDIOVASC MED,STANFORD,CA 94305, USA.		Chiesa, Giulia/G-8987-2012	Chiesa, Giulia/0000-0001-5553-1210; Hammer, Robert E./0000-0001-5487-7551				BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; CHIESA G, IN PRESS J BIOL CHEM; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MCCONATHY WJ, 1990, FASEB J, V4, pA1019; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SMITH EB, 1990, ATHEROSCLEROSIS, V84, P173, DOI 10.1016/0021-9150(90)90088-Z; STEWARTPHILLIPS JL, 1991, ATHEROSCLEROSIS, V90, P211, DOI 10.1016/0021-9150(91)90117-L; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	30	264	273	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					670	672		10.1038/360670a0	http://dx.doi.org/10.1038/360670a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465128				2022-12-24	WOS:A1992KD08200054
J	WORKMAN, JL; KINGSTON, RE				WORKMAN, JL; KINGSTON, RE			NUCLEOSOME CORE DISPLACEMENT INVITRO VIA A METASTABLE TRANSCRIPTION FACTOR NUCLEOSOME COMPLEX	SCIENCE			English	Article							POLYMERASE-II TRANSCRIPTION; XENOPUS-LAEVIS OOCYTES; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; POSITIONED NUCLEOSOMES; HYPERSENSITIVE SITES; DNA-REPLICATION; PHO5 PROMOTER; GAL4; ACTIVATION	In order to function, transcription factors must compete for DNA binding with structural components of chromatin, including nucleosomes. Mechanisms that could be used in this competition have been characterized with the use of the DNA binding domain of the yeast GAL4 protein. The binding of GAL4 to a nucleosome core resulted in a ternary complex containing GAL4, the core histone proteins, and DNA. This ternary complex was unstable; upon the addition of nonspecific competitor DNA, it dissociated into either the original nucleosome core particle or GAL4 bound to naked DNA. Nucleosome core destabilization by GAL4 did not require a transcriptional activation domain. These data demonstrate the displacement of nucleosome cores as a direct result of binding by a regulatory factor. Similar mechanisms might affect the establishment of factor occupancy of promoters and enhancers in vivo.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chen H. M., UNPUB; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; JUAN LJ, UNPUB; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAPP M, 1990, J BIOL CHEM, V265, P9357; SCHMID A, IN PRESS CELL; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	171	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1780	1784		10.1126/science.1465613	http://dx.doi.org/10.1126/science.1465613			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465613				2022-12-24	WOS:A1992KB96400035
J	ELREFAEY, H; HINSHAW, K; HENSHAW, R; SMITH, N; TEMPLETON, A				ELREFAEY, H; HINSHAW, K; HENSHAW, R; SMITH, N; TEMPLETON, A			MEDICAL-MANAGEMENT OF MISSED ABORTION AND ANEMBRYONIC PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article									ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen				Hinshaw, Kim/0000-0003-0468-4326				NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; 1990, BRIT J OBSTET GYNAEC, V97, P480; 1990, FERTIL STERIL, V56, P132; 1989, HUM REPROD, V4, P718	4	63	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1399	1399		10.1136/bmj.305.6866.1399	http://dx.doi.org/10.1136/bmj.305.6866.1399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486304	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992KB85600022
J	DAVIES, K				DAVIES, K			IMPRINTING AND SPLICING JOIN TOGETHER	NATURE			English	Editorial Material																		BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; FISHER EM, 1991, CELL, V63, P1205; HAMABE J, 1991, AM J MED GENET, V41, P64, DOI 10.1002/ajmg.1320410117; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LEFF SE, 1992, NATURE, V2, P265; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	12	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					492	492		10.1038/360492a0	http://dx.doi.org/10.1038/360492a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448175	Bronze			2022-12-24	WOS:A1992KA79700070
J	ZATORRE, RJ; JONESGOTMAN, M; EVANS, AC; MEYER, E				ZATORRE, RJ; JONESGOTMAN, M; EVANS, AC; MEYER, E			FUNCTIONAL LOCALIZATION AND LATERALIZATION OF HUMAN OLFACTORY CORTEX	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; TEMPORAL LOBECTOMY; BLOOD-FLOW; DISCRIMINATION; DEFICITS	ANATOMICAL and physiological investigations in monkeys indicate that olfaction is subserved by several cortical regions1,2. But the areas implicated in the human olfactory system have not been definitively identified by functional criteria. Behavioural evidence3,4 has suggested that laterally specialized mechanisms for odour processing may exist, but the neuroanatomical substrate remains unknown. We used positron emission tomography to study the cortical representation of human olfactory processing by comparing cerebral blood flow changes evoked during olfactory stimulation with those of a control task. We report here significant cerebral blood flow increases at the junction of the inferior frontal and temporal lobes bilaterally, corresponding to the piriform cortex, and unilaterally, in the right orbitofrontal cortex. The results complement and extend previous data implicating these regions in olfactory processing, and indicate that a functional asymmetry exists in the human brain favouring the right orbitofrontal area in olfaction.	MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL H3A 2B4, QUEBEC, CANADA	McGill University	ZATORRE, RJ (corresponding author), MONTREAL NEUROL HOSP & INST, MCCONNELL BRAIN IMAGING CTR, MONTREAL H3A 2B4, QUEBEC, CANADA.							EICHENBAUM H, 1983, BRAIN, V106, P459, DOI 10.1093/brain/106.2.459; ENGEN T, 1965, J EXP PSYCHOL, V70, P611, DOI 10.1037/h0022685; ESKENAZI B, 1983, NEUROPSYCHOLOGIA, V21, P365, DOI 10.1016/0028-3932(83)90023-4; ESKENAZI B, 1986, NEUROPSYCHOLOGIA, V24, P553, DOI 10.1016/0028-3932(86)90099-0; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Evans A C, 1992, Neuroimage, V1, P43, DOI 10.1016/1053-8119(92)90006-9; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; Mesulam M-M., 1985, CEREB CORTEX, P179, DOI DOI 10.1007/978-1-4757-9619-3_5; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; PRICE JL, 1991, OLFACTION, P101; RAICHLE ME, 1983, J NUCL MED, V24, P790; TAKAGI SF, 1991, CEREB CORTEX, V9, P133; TALAIIRACH J, 1988, COPLANAR STEREOTAXIC; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71	23	528	531	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					339	340		10.1038/360339a0	http://dx.doi.org/10.1038/360339a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448149				2022-12-24	WOS:A1992JZ63000049
J	KATZ, DA; LITTENBERG, B; CRONENWETT, JL				KATZ, DA; LITTENBERG, B; CRONENWETT, JL			MANAGEMENT OF SMALL ABDOMINAL AORTIC-ANEURYSMS - EARLY SURGERY VS WATCHFUL WAITING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTORS AFFECTING SURVIVAL; CORONARY-ARTERY DISEASE; EXPANSION RATE; NATURAL-HISTORY; RISK-FACTORS; MORTALITY; RUPTURE; EXPERIENCE; VARIABLES; COMPLICATIONS	Objective.-To compare two clinical strategies for the management of small abdominal aortic aneurysms (AAAs) less than 5 cm in diameter: early surgery (repair small AAAs when diagnosed) and watchful waiting (measure AAA size every 6 months and repair when the diameter reaches 5 cm). Data Sources.-We reviewed data from an earlier longitudinal study of patients with small AAAs to estimate incidence rates of rupture or acute expansion. Estimates for other parameters in the model were obtained by searching the medical literature (MEDLINE, 1966 to present). Data Synthesis.-We constructed a Markov decision tree to compare early surgery with watchful waiting in patients with asymptomatic AAAs less than 5 cm in diameter, with respect to long-term survival in quality-adjusted life years. The average annual rates of rupture or acute expansion for AAAs with a maximal transverse diameter of less than 4.0, 4.0 to 4.9, and at least 5.0 cm, are 0, 3.3, and 14.4 events per 100 patient-years of observation, respectively. At an average rupture rate of 3.3 events per 100 patient-years and an average operative risk for elective surgery (4.6%, 30-day mortality), our model predicts that early surgery improves survival in patients who present with a 4-cm AAA. The benefit of early surgery decreases with increased age at presentation. If the average rupture rate for AAAs less than 5 cm is assumed to be low (eg, 0.4 event per 100 patient-years), watchful waiting is favored, particularly as operative risk increases. The decision in this subgroup, however, is sensitive to possible future increases in operative risk. Conclusions.-In the majority of scenarios that we examined, early surgery is preferred to watchful waiting for patients with AAAs less than 5 cm in diameter. Watchful waiting is generally favored, however, for patients with a low risk of AAA rupture or acute expansion, including those patients who present with very small AAAs (eg, <4 cm). More accurate data concerning the rupture risk of AAAs less than 5 cm would improve clinical decision making.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT MED,TECHNOL ASSESSMENT PROGRAM,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,VASC SURG SECT,HANOVER,NH 03756	Dartmouth College; Dartmouth College	KATZ, DA (corresponding author), VET ADM MED CTR,DEPT MED 111B,WHITE RIVER JCT,VT 05001, USA.			Katz, David/0000-0001-5348-6532; Littenberg, Benjamin/0000-0002-7647-1808				ABERNATHY CM, 1986, JAMA-J AM MED ASSOC, V256, P597; Amundsen S, 1989, Eur J Vasc Surg, V3, P405, DOI 10.1016/S0950-821X(89)80046-5; BAIRD RJ, 1978, CAN MED ASSOC J, V118, P1229; BALLARD DJ, 1990, ABDOMINAL AORTIC ANE, P1; BECK JR, 1983, MED DECIS MAKING, V3, P411; BERGQVIST D, 1990, ACTA CHIR SCAND, V156, P63; Berne T V, 1969, Am Surg, V35, P36; BERNSTEIN EF, 1984, ANN SURG, V200, P255, DOI 10.1097/00000658-198409000-00003; BICKERSTAFF LK, 1984, J VASC SURG, V1, P6, DOI 10.1067/mva.1984.avs0010006; BODILY KC, 1985, AM J SURG, V149, P580, DOI 10.1016/S0002-9610(85)80129-X; BRECKWOLDT WL, 1991, J VASC SURG, V13, P798, DOI 10.1016/0741-5214(91)90044-U; BUTLER MJ, 1978, BRIT J SURG, V65, P839, DOI 10.1002/bjs.1800651204; COLLIN J, 1990, ANGIOLOGY, V41, P53, DOI 10.1177/000331979004100108; CRONENWETT JL, 1985, SURGERY, V98, P472; CRONENWETT JL, 1990, J VASC SURG, V11, P260; DARLING RC, 1977, CIRCULATION, V56, P161; DEBAKEY ME, 1964, ANN SURG, V160, P622, DOI 10.1097/00000658-196410000-00007; DENT A, 1986, BRIT J SURG, V73, P318; DIEHL JT, 1983, ANN SURG, V197, P49, DOI 10.1097/00000658-198301001-00008; DONALDSON MC, 1985, J VASC SURG, V2, P564; FIELDING JWL, 1981, BRIT MED J, V283, P355, DOI 10.1136/bmj.283.6287.355; FOSTER JH, 1969, SURG GYNECOL OBSTETR, V129, P1; Glimaker H, 1991, Eur J Vasc Surg, V5, P125, DOI 10.1016/S0950-821X(05)80675-9; GUIRGUIS EM, 1991, AM J SURG, V162, P481, DOI 10.1016/0002-9610(91)90266-G; HOLLIER LH, 1984, J VASC SURG, V1, P290, DOI 10.1067/mva.1984.avs0010290; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOHANSEN K, 1991, J VASC SURG, V13, P240, DOI 10.1016/0741-5214(91)90216-H; Johansson G, 1990, Eur J Vasc Surg, V4, P497, DOI 10.1016/S0950-821X(05)80791-1; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; JOHNSON G, 1980, ARCH SURG-CHICAGO, V115, P51; JOHNSTON KW, 1989, J VASC SURG, V9, P437, DOI 10.1067/mva.1989.vs0090437; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1467; KREMER H, 1984, KLIN WOCHENSCHR, V62, P1120, DOI 10.1007/BF01782469; LAWRIE GM, 1979, SURGERY, V85, P483; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LIMET R, 1991, J VASC SURG, V14, P540, DOI 10.1016/0741-5214(91)90249-T; LITTOOY FN, 1989, ARCH SURG-CHICAGO, V124, P419; MCCABE CJ, 1981, ARCH SURG-CHICAGO, V116, P1025; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; MURPHY JL, 1990, CAN J SURG, V33, P201; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; Olsen P S, 1990, Ann Vasc Surg, V4, P580, DOI 10.1016/S0890-5096(06)60843-1; OLSEN PS, 1991, J CARDIOVASC SURG, V32, P636; OURIEL K, 1990, J VASC SURG, V11, P493, DOI 10.1067/mva.1990.18639; PILCHER DB, 1980, AM J SURG, V139, P487, DOI 10.1016/0002-9610(80)90325-6; PLATE G, 1985, ARCH SURG-CHICAGO, V120, P590; PLATE G, 1988, ACTA CHIR SCAND, V154, P25; QUILL DS, 1989, SURG CLIN N AM, V69, P713; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SHACKLETON CR, 1987, J VASC SURG, V6, P583, DOI 10.1067/mva.1987.avs0060583; STERPETTI AV, 1991, SURG GYNECOL OBSTET, V173, P175; STERPETTI AV, 1985, AM J SURG, V150, P772, DOI 10.1016/0002-9610(85)90427-1; SULLIVAN CA, 1990, J VASC SURG, V11, P799; SZILAGYI DE, 1966, ANN SURG, V164, P678, DOI 10.1097/00000658-196610000-00014; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; THOMAS PRS, 1988, BRIT J SURG, V75, P733, DOI 10.1002/bjs.1800750804; 1987, VITAL STATISTICS US; 1990, USRDS1990 US REN DAT, P33	60	109	110	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2678	2686		10.1001/jama.268.19.2678	http://dx.doi.org/10.1001/jama.268.19.2678			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1433687				2022-12-24	WOS:A1992JX68000030
J	SWERDLOW, DL; WOODRUFF, BA; BRADY, RC; GRIFFIN, PM; TIPPEN, S; DONNELL, HD; GELDREICH, E; PAYNE, BJ; MEYER, A; WELLS, JG; GREENE, KD; BRIGHT, M; BEAN, NH; BLAKE, PA				SWERDLOW, DL; WOODRUFF, BA; BRADY, RC; GRIFFIN, PM; TIPPEN, S; DONNELL, HD; GELDREICH, E; PAYNE, BJ; MEYER, A; WELLS, JG; GREENE, KD; BRIGHT, M; BEAN, NH; BLAKE, PA			A WATERBORNE OUTBREAK IN MISSOURI OF ESCHERICHIA-COLI-O157-H7 ASSOCIATED WITH BLOODY DIARRHEA AND DEATH	ANNALS OF INTERNAL MEDICINE			English	Article						ESCHERICHIA-COLI INFECTIONS; MISSOURI; DIARRHEA; WATER SUPPLY	ESCHERICHIA-COLI O157-H7; HEMOLYTIC-UREMIC SYNDROME; SHIGA-LIKE TOXIN; HEMORRHAGIC COLITIS; MONOCLONAL-ANTIBODIES; SEROTYPE O157-H7; NURSING-HOME; INFECTIONS; 0157-H7	Objective: To describe and determine the source of a large outbreak of Escherichia coli O157:H7 (ECO157) infections in Missouri. Design: A case-control study and a household survey. Setting: A small city in a rural Missouri township that had an unchlorinated water supply. Patients: Case patients were residents of or visitors to Burdine Township with bloody diarrhea or diarrhea and abdominal cramps occurring between 15 December 1989 and 20 January 1990. Measurements: Escherichia coli O157 was isolated from 21 stool specimens. All isolates were resistant to sulfisoxazole, tetracycline, and streptomycin; produced Shiga-like toxins I and II; and had one 60-megadalton plasmid. Results: Among the 243 case patients, 86 had bloody stools, 32 were hospitalized, 4 died, and 2 had the hemolytic uremic syndrome. In the case-control study, no food was associated with illness, but ill persons had drunk more municipal water than had controls (P = 0.04). The survey showed that, during the peak of the outbreak, bloody diarrhea was 18.2 times more likely to occur in persons living inside the city and using municipal water than in persons living outside the city and using private well water (P = 0.001). Shortly before the peak of the outbreak, 45 water meters were replaced, and two water mains ruptured. The number of new cases declined rapidly after residents were ordered to boil water and after chlorination of the water supply. Conclusions: This was the largest outbreak of ECO157 infections, the first due to a multiply resistant organism, and the first shown to be transmitted by water. System-wide chlorination as well as hyperchlorination during repairs might have prevented this outbreak. Both bloody and nonbloody diarrhea may be common manifestations of this infection, which is probably underdiagnosed because of the failure of routine stool cultures to identify the organism. Cities with deteriorating water systems using untreated water risk widespread illness from contaminated drinking water.	MISSOURI STATE DEPT HLTH, JEFFERSON CITY, MO 65102 USA; US EPA, RISK REDUCT ENGN LAB, CINCINNATI, OH 45268 USA	United States Environmental Protection Agency	SWERDLOW, DL (corresponding author), CTR DIS CONTROL, ENTER DIS BRANCH, MAILSTOP C-09, ATLANTA, GA 30333 USA.							[Anonymous], 1989, STANDARD METHODS EXA, V17th; Barry A., 1985, MANUAL CLIN MICROBIO, V4th; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOPP CA, 1987, J CLIN MICROBIOL, V25, P1486, DOI 10.1128/JCM.25.8.1486-1489.1987; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; DOWNES FP, 1988, INFECT IMMUN, V56, P1926, DOI 10.1128/IAI.56.8.1926-1933.1988; Duncan L., 1987, Canada Diseases Weekly Report, V13, P5; GELDREICH EE, 1992, WATER RES, V26, P1127, DOI 10.1016/0043-1354(92)90150-3; GREENE KD, 1991, 91ST ANN M AM SOC MI, P374; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MCGOWAN KL, 1989, LANCET, V1, P967; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; NAYLOR GRE, 1983, LANCET, V1, P864; NEILL MA, 1985, ARCH INTERN MED, V145, P2215, DOI 10.1001/archinte.145.12.2215; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; RADETSKY M, 1986, PEDIATR INFECT DIS J, V5, P230, DOI 10.1097/00006454-198603000-00015; RAGHUBEER EV, 1990, J CLIN MICROBIOL, V28, P803, DOI 10.1128/JCM.28.4.803-805.1990; RATNAM S, 1988, J CLIN MICROBIOL, V26, P2006, DOI 10.1128/JCM.26.10.2006-2012.1988; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROSE JB, 1990, INVESTIGATION PREVEN, P223; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1985, INFECT IMMUN, V50, P695, DOI 10.1128/IAI.50.3.695-700.1985; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983	29	374	386	3	56	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					812	819		10.7326/0003-4819-117-10-812	http://dx.doi.org/10.7326/0003-4819-117-10-812			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416555				2022-12-24	WOS:A1992JX83800003
J	WETTERAU, JR; AGGERBECK, LP; BOUMA, ME; EISENBERG, C; MUNCK, A; HERMIER, M; SCHMITZ, J; GAY, G; RADER, DJ; GREGG, RE				WETTERAU, JR; AGGERBECK, LP; BOUMA, ME; EISENBERG, C; MUNCK, A; HERMIER, M; SCHMITZ, J; GAY, G; RADER, DJ; GREGG, RE			ABSENCE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN INDIVIDUALS WITH ABETALIPOPROTEINEMIA	SCIENCE			English	Article							APOLIPOPROTEIN-B GENE; CHOLESTERYL ESTER; DISULFIDE ISOMERASE; HYPOBETALIPOPROTEINEMIA; TRIACYLGLYCEROL; COMPLEX; DISEASE; CELLS	Abetalipoproteinemia is a human genetic disease that is characterized by a defect in the assembly or secretion of plasma very low density lipoproteins and chylomicrons. The microsomal triglyceride transfer protein (MTP), which is located in the lumen of microsomes isolated from the liver and intestine, has been proposed to function in lipoprotein assembly. MTP activity and the 88-kilodalton component of MTP were present in intestinal biopsy samples from eight control individuals but were absent in four abetalipoproteinemic subjects. This finding suggests that a defect in MTP is the basis for abetalipoproteinemia and that MTP is indeed required for lipoprotein assembly.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 07,INSERM,U327,F-75018 PARIS,FRANCE; HOP ST NICOLAS,SERV MED INTERNE,F-55107 VERDUN,FRANCE; HOP EDOUARD HERRIOT,MED INFANTILE CLIN B,F-69437 LYON,FRANCE; HOP ROBERT DEBRE,SERV GASTROENTEROL NUTR PEDIAT,F-75019 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,DEPT PEDIAT,F-75730 PARIS 15,FRANCE; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	WETTERAU, JR (corresponding author), BRISTOL MYERS SQUIBB,DEPT METABOL DIS,PRINCETON,NJ 08543, USA.				NHLBI NIH HHS [HL18577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOUMA ME, 1986, J CLIN INVEST, V78, P398, DOI 10.1172/JCI112590; GAY G, 1990, REV MED INTERNE, V11, P273, DOI 10.1016/S0248-8663(05)80857-4; HIGGINS JA, 1984, J LIPID RES, V25, P1295; HUANG LS, 1990, AM J HUM GENET, V46, P1141; IHM J, 1982, J BIOL CHEM, V257, P4818; JANERO DR, 1983, J BIOL CHEM, V258, P4496; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; LACAILLE F, 1989, ARCH FR PEDIATR, V46, P491; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SCOAZEC JY, 1992, GUT, V33, P414, DOI 10.1136/gut.33.3.414; TALMUD PJ, 1988, J CLIN INVEST, V82, P1803, DOI 10.1172/JCI113795; WETTERAU J, UNPUB; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006	19	598	625	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					999	1001						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1439810				2022-12-24	WOS:A1992JW79600036
J	BROWN, MM; HUMPHREY, PRD				BROWN, MM; HUMPHREY, PRD			CAROTID ENDARTERECTOMY - RECOMMENDATIONS FOR MANAGEMENT OF TRANSIENT ISCHEMIC ATTACK AND ISCHEMIC STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGIOGRAPHY		WALTON HOSP, DEPT NEUROL, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND	Walton Centre	BROWN, MM (corresponding author), ST GEORGE HOSP, SCH MED, DIV CLIN NEUROSCI, LONDON SW17 0RE, ENGLAND.		Brown, Martin M/B-3288-2009	Brown, Martin M/0000-0002-3273-1356				BORGSTEIN RL, 1991, CLIN RADIOL, V44, P402, DOI 10.1016/S0009-9260(05)80659-2; CAPLAN LR, 1991, AM J NEURORADIOL, V12, P593; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HUMPHREY P, 1990, J NEUROL NEUROSUR PS, V53, P966, DOI 10.1136/jnnp.53.11.966; KRETSCHMER G, 1990, ANN SURG, V211, P317, DOI 10.1097/00000658-199003000-00002; MURIE J, 1991, HOSPTIAL UPDATE  JUL, P557; MURIE JA, 1986, BRIT J SURG, V73, P867, DOI 10.1002/bjs.1800731103; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1988, BMJ, V296, P320	12	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	1992	305	6861					1071	1074		10.1136/bmj.305.6861.1071	http://dx.doi.org/10.1136/bmj.305.6861.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467689	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JW70100022
J	GORLICH, D; PREHN, S; HARTMANN, E; KALIES, KU; RAPOPORT, TA				GORLICH, D; PREHN, S; HARTMANN, E; KALIES, KU; RAPOPORT, TA			A MAMMALIAN HOMOLOG OF SEC61P AND SECYP IS ASSOCIATED WITH RIBOSOMES AND NASCENT POLYPEPTIDES DURING TRANSLOCATION	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; MICROSOMAL-MEMBRANES; SEQUENCE RECEPTOR; SECRETORY PROTEIN; ROUGH MICROSOMES; BINDING-ACTIVITY; 4.5S RNA	SEC61p is essential for protein translocation across the endoplasmic reticulum membrane of S. cerevisiae. We have found a mammalian homolog that shows more than 50% sequence identity with the yeast protein. Moreover, several regions of SEC61p have significant similarities with corresponding ones of SecYp of bacteria, indicating a strong evolutionary conservation of the mechanism of protein translocation. Mammalian Sec61p, like the yeast protein, is located in the immediate vicinity of nascent polypeptides during their membrane passage. It is tightly associated with membrane-bound ribosomes, suggesting that the nascent chain passes directly from the ribosome into a protein-conducting channel. These results define Sec61p as a ubiquitous key component of the protein translocation apparatus.	HUMBOLDT UNIV,INST BIOCHEM,O-1040 BERLIN,GERMANY	Humboldt University of Berlin	GORLICH, D (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,O-1115 BERLIN,GERMANY.		Hartmann, Enno/C-5687-2013; Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; ARNDT E, 1992, BIOCHIM BIOPHYS ACTA, V1130, P13; AUER J, 1991, BIOCHIMIE, V73, P683, DOI 10.1016/0300-9084(91)90048-6; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1976, BIOCHEM BIOPH RES CO, V68, P1, DOI 10.1016/0006-291X(76)90001-2; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOIVULA T, 1991, FEBS LETT, V288, P114, DOI 10.1016/0014-5793(91)81015-Z; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1982, NATURE, V297, P503; MICHALOWSKI CB, 1990, MOL GEN GENET, V224, P222, DOI 10.1007/BF00271555; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; OHKUBO S, 1987, MOL GEN GENET, V210, P314, DOI 10.1007/BF00325700; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TSCHAUDER S, 1992, IN PRESS MOL GEN GEN; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZIMMERMANN R, 1986, TRENDS BIOCHEM SCI, V11, P512, DOI 10.1016/0968-0004(86)90085-X	56	381	388	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					489	503		10.1016/0092-8674(92)90517-G	http://dx.doi.org/10.1016/0092-8674(92)90517-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423609				2022-12-24	WOS:A1992JW43500014
J	LIPSHULTZ, SE; ORAV, EJ; SANDERS, SP; HALE, AR; MCINTOSH, K; COLAN, SD				LIPSHULTZ, SE; ORAV, EJ; SANDERS, SP; HALE, AR; MCINTOSH, K; COLAN, SD			CARDIAC STRUCTURE AND FUNCTION IN CHILDREN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION TREATED WITH ZIDOVUDINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTOLIC WALL STRESS; MITOCHONDRIAL-DNA; HIV-INFECTION; AIDS PATIENTS; RAT HEARTS; MYOPATHY; THERAPY; DYSFUNCTION; HYPERTROPHY; MECHANICS	Background. Abnormalities of cardiac structure and function are common in children infected with the human immunodeficiency virus (HIV). It is unclear, however, whether these abnormalities are attributable to the disease itself, associated infections, or possible cardiotoxic effects of the most commonly used treatment, zidovudine. Methods. We performed echocardiography in 24 children with symptomatic HIV infection immediately before they started zidovudine therapy and a mean of 1.32 years after therapy began. Sixteen of these children were also studied a mean of 1.26 years before starting zidovudine treatment. Comparison groups included 27 age-matched children with symptomatic HIV infection who had not received zidovudine and 191 normal children. Results. As compared with the normal children, the children treated with zidovudine had progressive left ventricular dilatation and an increase in ventricular-wall stress at end-systole (a measure of ventricular afterload); dilatation and stress were significantly elevated both before and during zidovudine treatment. The ratio of ventricular thickness to internal dimension was below normal before zidovudine treatment began (P<0.001). After treatment with zidovudine, however, overall left ventricular mass was increased (P = 0.02), as was peak wall stress (a stimulus to ventricular hypertrophy) (P = 0.01). Ventricular contractility remained normal, but fractional shortening of the left ventricle was decreased (P = 0.004). No statistically significant differences were detected at follow-up in any of these measurements between HIV-infected children treated with zidovudine and those not so treated. Conclusions. Progressive left ventricular dilatation occurred in children with symptomatic HIV infection. Compensatory hypertrophy also occurred but was inadequate to maintain peak systolic wall stress within the normal range. The progressive elevation of ventricular afterload due to dilatation resulted in depressed ventricular performance, but intrinsic ventricular contractility remained normal. Zidovudine did not appear to worsen or ameliorate these cardiac changes.	CHILDRENS HOSP MED CTR,DIV INFECT DIS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BOSTON CITY HOSP,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston Medical Center; Boston University	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NCRR NIH HHS [5M01RR02172] Funding Source: Medline; NHLBI NIH HHS [R01HL48012-01] Funding Source: Medline; NIAID NIH HHS [U01AI25934] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025934] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDEN PB, 1987, NUTRITION HEART DISE, V2, P71; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; CALDWELL B, 1991, 7TH P INT C AIDS FLO, V2, P362; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; COLAN SD, 1987, J AM COLL CARDIOL, V9, P776, DOI 10.1016/S0735-1097(87)80232-2; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; COLAN SD, 1987, J AM COLL CARDIOL, V10, P1085, DOI 10.1016/S0735-1097(87)80350-9; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CONNOR E, 1991, SEMIN PEDIATR INFECT, V2, P285; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; DALAKAS M, 1990, NEW ENGL J MED, V323, P994; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEYTON LR, 1989, NEW ENGL J MED, V321, P1246, DOI 10.1056/NEJM198911023211806; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GLANTZ S, 1990, PRIMER APPL REGRESSI, P294; GREENE MG, 1991, HARRIET LANE HDB, P42; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311; HSIA J, 1991, CIRCULATION S2, V84, P3; LAMPERTH L, 1991, LAB INVEST, V65, P742; LEWIS W, 1991, LAB INVEST, V65, P228; Lewis W, 1992, Cardiovasc Pathol, V1, P53, DOI 10.1016/1054-8807(92)90007-B; LIPSHULTZ SE, 1990, CIRCULATION, V82, P118; LIPSHULTZ SE, 1990, AM J CARDIOL, V66, P246, DOI 10.1016/0002-9149(90)90603-X; LIPSHULTZ SE, 1989, AM J CARDIOL, V63, P1489, DOI 10.1016/0002-9149(89)90014-3; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA183; LIPSHULTZ SE, 1989, CIRCULATION S2, V80, P322; LIPSHULTZ SE, 1991, CIRCULATION, V84, P660; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; SALGO M, 1991, CARDIOMYOPATHY CONGE; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; STEIN KM, 1991, AM J CARDIOL, V68, P1091, DOI 10.1016/0002-9149(91)90502-C; WALTER EB, 1991, J PEDIATR-US, V119, P152, DOI 10.1016/S0022-3476(05)81057-1; WHARTON JM, 1987, AM J MED, V83, P571, DOI 10.1016/0002-9343(87)90774-1; WILKINS CE, 1989, TEX HEART I J, V16, P44; Zar JH., 1999, BIOSTAT ANAL; 1987, MMWR MORB MORTAL WKL, V36, P225	43	79	79	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1260	1265		10.1056/NEJM199210293271802	http://dx.doi.org/10.1056/NEJM199210293271802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1406818	Bronze			2022-12-24	WOS:A1992JV25900002
J	TYTGAT, J; HESS, P				TYTGAT, J; HESS, P			EVIDENCE FOR COOPERATIVE INTERACTIONS IN POTASSIUM CHANNEL GATING	NATURE			English	Article							XENOPUS-OOCYTES; SHAKER; DROSOPHILA; EXPRESSION; CDNA	CLONING and expression of voltage-activated potassium ionchannel complementary DNAs1-4 has confirmed that these channels are composed of four identical subunits5, each containing a voltage sensor. It has been generally accepted that the voltage sensors must reach a permissive state through one or more conformational ('gating') transitions before the channel can open6,7. To test whether each subunit gates independently, we have constructed cDNAs encoding four subunits on a single polypeptide chain, enabling us to specify the subunit stoichiometry. The gating of heterotetramers made up from combinations of subunits with different gating phenotypes strongly suggests that individual subunits gate cooperatively, rather than independently8. Nonindependent subunit gating is consistent with measurements of the kinetics of K+-channel gating currents9-13 and in line with the widespread subunit cooperativity observed in other multisubunit proteins14.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; GILLY WF, 1982, J GEN PHYSIOL, V79, P965, DOI 10.1085/jgp.79.6.965; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HURST R S, 1992, Biophysical Journal, V61, pA425; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; STUHMER W, 1991, PFLUG ARCH EUR J PHY, V418, P423, DOI 10.1007/BF00550881; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TYTGAT J, 1992, Biophysical Journal, V61, pA426; VANDENBERG CA, 1991, BIOPHYS J, V60, P1511, DOI 10.1016/S0006-3495(91)82186-5; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	26	126	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					420	423		10.1038/359420a0	http://dx.doi.org/10.1038/359420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406954				2022-12-24	WOS:A1992JQ62400058
J	SANDEMAN, DD; SHORE, AC; TOOKE, JE				SANDEMAN, DD; SHORE, AC; TOOKE, JE			RELATION OF SKIN CAPILLARY-PRESSURE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS TO COMPLICATIONS AND METABOLIC CONTROL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED AUTO-REGULATION; BLOOD-FLOW; MICROANGIOPATHY; PERMEABILITY; NEPHROPATHY; PREVALENCE; DURATION; RATS	Background. Microvascular disease is a major problem in patients with diabetes mellitus. It has been suggested that diabetic microangiopathy may result from an increase in capillary blood flow and capillary hypertension, but direct evidence of capillary hypertension in such patients is lacking. Methods. We measured capillary pressure at the summit of the capillary loop by direct microcannulation of skin nail-fold capillaries and a dynamic method of pressure measurement in 29 patients with insulin-dependent (Type 1) diabetes and 29 normal subjects matched for age and sex. Among the diabetic patients, 7 had had diabetes for less than one year, 12 had incipient nephropathy (albumin excretion, 20 to 200-mu-g per minute), and 10 had overt nephropathy (albumin excretion, >200-mu-g per minute). In addition, seven patients with no evidence of nephropathy were studied before and after three months of improved glycemic control. Results. The median capillary pressure in the diabetic patients was 20.4 mm Hg (range, 13.6 to 25.3), as compared with 16.7 mm Hg (range, 12.8 to 22.8; P<0.001) in the normal subjects. The values were higher in each subgroup of diabetic patients than in the corresponding group of normal subjects, but the values did not differ among the three subgroups of diabetic patients. In the seven patients who were studied before and after three months of improved glycemic control, the median capillary pressure fell from 20.0 mm Hg (range, 18.5 to 21.7) to 17.8 mm Hg (range, 14.1 to 20.3; P = 0.02). Conclusions. Nail-fold capillary hypertension may develop early in the course of diabetes, before the emergence of microvascular disease, and may be influenced by changes in metabolic control.			SANDEMAN, DD (corresponding author), UNIV EXETER,POSTGRAD MED SCH,BARRACK RD,EXETER EX2 5EQ,ENGLAND.			Shore, Angela/0000-0003-3039-308X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTURA BM, 1979, ADV MICROCIRCULAT, V8, P118; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; Christiansen J S, 1985, Diabet Med, V2, P235; DARTON K, 1991, RAYNAUDS SYNDROME, P69; DITZEL J, 1968, DIABETES, V17, P388, DOI 10.2337/diab.17.6.388; FLAVELL HJ, 1988, CLIN CHEM, V34, P1506; FOLKOW B, 1983, CIBA F SYMP, V100, P56; GATLING W, 1988, DIABETIC MED, V5, P343, DOI 10.1111/j.1464-5491.1988.tb01002.x; GUNDERSEN HJ, 1974, DIABETOLOGIA, V10, P225, DOI 10.1007/BF00423039; HANSSEN KF, 1986, DIABETOLOGIA, V29, P901; HILL MA, 1990, FRONT DIABETES, V9, P118; KALEY G, 1989, AM J PHYSIOL, V256, pH720, DOI 10.1152/ajpheart.1989.256.3.H720; KASTRUP J, 1985, DIABETOLOGIA, V28, P711; KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814; LANSMAN JB, 1988, NATURE, V331, P481, DOI 10.1038/331481a0; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MCMILLAN DE, 1983, DIABETES, V32, P56, DOI 10.2337/diab.32.2.S56; MOGENSEN CE, 1988, TOPICS RENAL MED, V6, P7; MOGENSEN CE, 1989, DIABETES NUTR METAB, V2, P227; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; OSTERGREN J, 1982, INT J MICROCIRC, V1, P300; PARVING HH, 1984, DIABETOLOGIA, V27, P547, DOI 10.1007/BF00276965; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; RAYMAN G, 1984, INT J MICROCIRC, V3, P285; RIPPE B, 1977, ACTA PHYSIOL SCAND, V101, P72, DOI 10.1111/j.1748-1716.1977.tb05985.x; SANDEMAN DD, 1991, CLIN SCI S24, V80, pP13; SHORE AC, 1990, INT J MICROCIRC CLIN, V9, P136; SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x; TOOKE JE, 1980, DIABETES, V29, P815, DOI 10.2337/diabetes.29.10.815; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; TOOKE JE, 1986, PROG APPL MICROCIRC, V11, P60; WILLIAMS SA, 1988, CLIN SCI, V74, P507, DOI 10.1042/cs0740507; WILLIAMSON JR, 1977, DIABETES, V26, P65, DOI 10.2337/diab.26.1.65; WILLIAMSON JR, 1985, DIABETES, V34, P703, DOI 10.2337/diabetes.34.7.703; WILLIAMSON JR, 1980, NEW ENGL J MED, V302, P399, DOI 10.1056/NEJM198002143020710; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1986, AM J MED, V80, P443, DOI 10.1016/0002-9343(86)90719-9; ZIEGLER D, 1988, KLIN WOCHENSCHR, V66, P1085, DOI 10.1007/BF01711924	40	162	165	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					760	764		10.1056/NEJM199209103271103	http://dx.doi.org/10.1056/NEJM199209103271103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501652				2022-12-24	WOS:A1992JL66100003
J	HANKINSON, SE; WILLETT, WC; COLDITZ, GA; SEDDON, JM; ROSNER, B; SPEIZER, FE; STAMPFER, MJ				HANKINSON, SE; WILLETT, WC; COLDITZ, GA; SEDDON, JM; ROSNER, B; SPEIZER, FE; STAMPFER, MJ			A PROSPECTIVE-STUDY OF CIGARETTE-SMOKING AND RISK OF CATARACT-SURGERY IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; EPIDEMIOLOGY; ALCOHOL; NUCLEAR; PLASMA	Objective.-To examine prospectively the association between cigarette smoking and the risk of cataract extraction in women. Design.-Prospective cohort study beginning in 1980 with 8 years of follow-up. Setting.-United States, multistate. Participants.-Registered nurses 45 to 67 years of age and free of diagnosed cancer. There were 50 828 women included in 1980 and others were added as they became 45 years of age. Main Outcome Measure.-Incidence of senile cataract extraction. Results.-We documented 493 incident senile cataracts diagnosed and extracted during 470302 person-years of follow-up. The age-adjusted relative risk (RR) among women who smoked at least 65 pack-years was 1.63 (95% confidence interval [CI], 1.18 to 2.26; P for trend, .02). A similar increase in RR was noted when smoking was assessed in terms of number of cigarettes currently smoked or number of cigarettes smoked by past smokers. Results were also similar after adjusting for other potential risk factors for cataract. Smoking was also strongly associated with posterior subcapsular cataract specifically (RR, 2.59; 95% CI, 1.49 to 4.50 for greater-than-or-equal-to 65-pack-year smokers relative to nonsmokers). Conclusion.-Smoking appears to increase the risk of cataract extraction.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA; MASSACHUSETTS EYE & EAR INFIRM, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	HANKINSON, SE (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; BUNCE GE, 1988, NUTR TODAY, V4, P6; CHRISTEN WG, 1991, INVEST OPHTH VIS SCI, V32, P1244; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; HANKINSON SE, IN PRESS BMJ; HARDING JJ, 1987, EYE, V1, P537, DOI 10.1038/eye.1987.82; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHWAB IR, 1988, ARCH OPHTHALMOL-CHIC, V106, P1062, DOI 10.1001/archopht.1988.01060140218027; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	29	124	124	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					994	998		10.1001/jama.268.8.994	http://dx.doi.org/10.1001/jama.268.8.994			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501325				2022-12-24	WOS:A1992JK12900023
J	MORSE, RM; FLAVIN, DK				MORSE, RM; FLAVIN, DK			THE DEFINITION OF ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENCE; ABUSE	To establish a more precise use of the term alcoholism, a 23-member multidisciplinary committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine conducted a 2-year study of the definition of alcoholism in the light of current concepts. The goals of the committee were to create by consensus a revised definition that is (1) scientifically valid, (2) clinically useful, and (3) understandable by the general public. Therefore, the committee agreed to define alcoholism as a primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic.	NATL COUNCIL ALCOHOLISM & DRUG DEPENDENCE,12 W 21ST ST,NEW YORK,NY 10010									CAMPBELL EJM, 1979, BMJ-BRIT MED J, V2, P757, DOI 10.1136/bmj.2.6193.757; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058; GORDIS E, 1989, ALCOHOL HLTH RES WOR, V13, P298; GRANT BF, 1989, INT REV PSYCHIATR, V1, P21; JELLINEK EM, 1960, DIS CONCEPT ALCOHOL, P33; KLEBER HD, 1990, J PSYCHIAT RES, V24, P57, DOI 10.1016/0022-3956(90)90036-P; LE AD, 1981, PSYCHOPHARMACOLOGY, V75, P231, DOI 10.1007/BF00432429; MEYER RE, 1988, ALCOHOLISM ORIGINS O, P1; MORSE RM, 1989, SUBST ABUSE, V10, P75; NARANJO CA, 1986, J CLIN PSYCHIAT, V47, P16; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; 1972, ANN INTERN MED, V77, P249; 1978, MENTAL DISORDERS GLO; 1976, ANN INTERN MED, V85, P764; 1972, AM J PSYCHIAT, V129, P127; 1980, DIAGNOSTIC STATISTIC; 1990, 7TH SPECF REP US C A; 1987, DIAGNOSTIC STATISTIC; 1981, B WORLD HEALTH ORGAN, V59, P225	21	155	162	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1012	1014		10.1001/jama.268.8.1012	http://dx.doi.org/10.1001/jama.268.8.1012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501306				2022-12-24	WOS:A1992JK12900027
J	KUMARESAN, JA; MAGANU, ET				KUMARESAN, JA; MAGANU, ET			CASE HOLDING IN PATIENTS WITH TUBERCULOSIS IN BOTSWANA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the effectiveness of daily supervised short course chemotherapy in a national tuberculosis programme. Design-Observation of programme during 1984-90. In October 1986 short course chemotherapy was introduced with patients receiving treatment daily from staff in their nearest health facility. Setting-Botswana national tuberculosis programme. Subjects - All patients with tuberculosis. Main outcome measures-Proportions of patients complying with and defaulting from treatment (missing greater-than-or-equal-to 43 days' treatment). Results-2938 cases of tuberculosis were recorded in 1990, 1528 of which were of sputum positive pulmonary disease. 2711 (92.3%) patients complied with treatment and 227 (7.7%) defaulted. Before introduction of short course chemotherapy compliance was about 60% compared with over 90% in 1987-90. Conclusions-A programme using daily supervised short course chemotherapy integrated into the primary health care system is an effective method of treating tuberculosis. The costs of the programme need to be evaluated.	MINIST HLTH,GABORONE,BOTSWANA		KUMARESAN, JA (corresponding author), COMMUNITY HLTH SERV DIV,EPIDEMIOL UNIT,PRIVATE BAG 00269,GABORONE,BOTSWANA.							ARMSTRONG RH, 1984, CENT AFR J MED, V30, P144; Bailey W C, 1988, Am Rev Respir Dis, V138, P1075; BARNUM HN, 1986, SOC SCI MED, V23, P847, DOI 10.1016/0277-9536(86)90212-1; Iseman M D, 1986, Semin Respir Infect, V1, P213; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; REED JB, 1990, J EPIDEMIOL COMMUN H, V44, P20, DOI 10.1136/jech.44.1.20; RIEDER HL, 1985, TUBERCLE, V66, P179, DOI 10.1016/0041-3879(85)90034-0; TACHEZY P, 1985, NATIONAL TUBERCULOSI, P17; TEFUARANI N, 1989, PAPUA NEW GUINEA MED, V32, P177	9	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					340	341		10.1136/bmj.305.6849.340	http://dx.doi.org/10.1136/bmj.305.6849.340			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392885	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JJ03200021
J	CHUA, A; KEATING, J; HAMILTON, D; KEELING, PWN; DINAN, TG				CHUA, A; KEATING, J; HAMILTON, D; KEELING, PWN; DINAN, TG			CENTRAL SEROTONIN RECEPTORS AND DELAYED GASTRIC-EMPTYING IN NONULCER DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							NONULCER DYSPEPSIA; DIAGNOSIS; MOTILITY; GUT; EPIDEMIOLOGY; FENFLURAMINE; DISORDERS; RESPONSES; ANOREXIA; PATHWAYS	Objective-To determine whether central serotonin receptors are involved in the pathophysiology of non-ulcer dyspepsia. Design-Between subjects study of solid phase gastric emptying and prolactin response to buspirone challenge. Subjects-12 patients fulfilling criteria for non-ulcer dyspepsia and 12 age and sex matched controls. Main outcome measures-Solid phase gastric emptying measured by scintigraphic assessment of the movement of a standard meal labelled with technetium-99m and indium-111; responsiveness of central serotonin 1A receptors measured by the prolactin release following challenge with oral buspirone 60 mg. Results-Solid phase gastric emptying was significantly delayed in the patients with non-ulcer dyspepsia (t1/2=90.6 (SD 14.5) minutes in patients and 54.6 (10.7) minutes in controls; 95% confidence interval 24.7 to 46.7 minutes, p<0.001). Prolactin release was significantly greater in patients compared with controls (1272.7 (1039.9) mU/l v 292.9 (136.1) mU/l; 352.1 to 1607.5 mU/l, p<0.01). Gastric emptying and prolactin release were significantly correlated (r=0.59, p=0.04) in the patients but not in the controls (r=0.23). Conclusion-Central serotonin IA receptors may have a role in the pathophysiology of non-ulcer dyspepsia of the dysmotility subtype.	ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT NUCL MED,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT PSYCHIAT,DUBLIN 8,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Dinan, Timothy/ABA-8284-2020	Dinan, Timothy/0000-0002-2316-7220				ADAMI HO, 1984, SCAND J GASTROENTERO, V19, P216, DOI 10.1080/00365521.1984.12005712; BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BLUNDELL JE, 1983, NUTR BRAIN, V6, P163; CAMILLERI M, 1986, DIGEST DIS SCI, V31, P1169, DOI 10.1007/BF01296514; CAMILLERI M, 1984, EUR J CLIN INVEST, V14, P420, DOI 10.1111/j.1365-2362.1984.tb01206.x; CAMILLERI M, 1985, GASTROENTEROLOGY, V88, P1852, DOI 10.1016/0016-5085(85)90010-1; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHUA A, 1988, GUT, V29, pA1437; COCCARO EF, 1990, ARCH GEN PSYCHIAT, V47, P594; COLINJONES DG, 1988, LANCET, V1, P576; COLLINS PJ, 1983, GUT, V24, P1117, DOI 10.1136/gut.24.12.1117; COOTE JH, 1974, J PHYSIOL-LONDON, V241, P453, DOI 10.1113/jphysiol.1974.sp010666; DAVIES RF, 1983, PHYSIOL BEHAV, V30, P723, DOI 10.1016/0031-9384(83)90169-5; DINAN TG, 1990, INT CLIN PSYCHOPHARM, V5, P119, DOI 10.1097/00004850-199004000-00006; DINAN TG, 1990, SCAND J GASTROENTERO, V25, P541, DOI 10.3109/00365529009095527; DUHAULT J, 1980, PROG NEURO-PSYCHOPHA, V4, P341, DOI 10.1016/0364-7722(80)90004-1; ELIASSON S, 1953, ACTA PHYSL SCAND, V30, P199; GERSHON MD, 1981, GASTROENTEROLOGY, V80, P1571; Gilman AG, 1980, PHARM BASIS THERAPEU; HARRISON RJ, 1986, TXB INTERNAL MED; HARVEY RF, 1983, LANCET, V1, P632; HOPKINSON GB, 1989, SCAND J GASTROENTERO, V24, P923, DOI 10.3109/00365528909089236; KALIA M, 1980, J COMP NEUROL, V193, P467, DOI 10.1002/cne.901930211; KHURANA RK, 1980, NEUROLOGY, V30, P805, DOI 10.1212/WNL.30.8.805; LOEWY AD, 1981, J AUTONOM NERV SYST, V3, P265, DOI 10.1016/0165-1838(81)90068-0; MALAGELADA JR, 1985, GASTROENTEROLOGY, V88, P1223, DOI 10.1016/S0016-5085(85)80083-4; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; PAGINI FD, 1984, AM J PHYSIOL, V246, pG253; ROWLAND N, 1984, LIFE SCI, V34, P2495, DOI 10.1016/0024-3205(84)90286-8; SILVERSTONE T, 1988, DRUG TREATMENT PSYCH; TALLEY NJ, 1985, SCAND J GASTROENTERO, V20, P896, DOI 10.3109/00365528509088842; THOMPSON WG, 1984, CAN MED ASSOC J, V130, P565; TIBBLIN G, 1985, SCAND J GASTROENTERO, V20, P29, DOI 10.3109/00365528509103932; VANPRAAG HM, 1980, COMPR PSYCHIAT, V21, P30, DOI 10.1016/0010-440X(80)90062-0; WOOD JR, 1985, GASTROENTEROLOGY, V89, P1411, DOI 10.1016/0016-5085(85)90663-8; YOU CH, 1981, ANN INTERN MED, V95, P449, DOI 10.7326/0003-4819-95-4-449; 1988, STAGRAPHICS 1988	37	40	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					280	282		10.1136/bmj.305.6848.280	http://dx.doi.org/10.1136/bmj.305.6848.280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392859	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JG74000016
J	GODFREYFAUSSETT, P; MORTIMER, PR; JENKINS, PA; STOKER, NG				GODFREYFAUSSETT, P; MORTIMER, PR; JENKINS, PA; STOKER, NG			EVIDENCE OF TRANSMISSION OF TUBERCULOSIS BY DNA FINGERPRINTING	BRITISH MEDICAL JOURNAL			English	Article							IS6110	Objective-To determine whether a subject who had died of tuberculous meningitis had been infected by a neighbour. Design-Retrospective comparison of isolates of Mycobacterium tuberculosis from the two cases and from 10 controls by DNA fingerprinting. Setting-Public Health Service Reference Laboratory for Mycobacteria and bacterial molecular genetics unit of the London School of Hygiene and Tropical Medicine. Subjects-Deceased and neighbour; 10 controls from the same city, from whom isolates had been collected over three months before the subject's death. Main outcome measures-Identity and similarity values (S(AB)) between fingerprint patterns from different isolates obtained by hybridisation of restriction fragments produced by PvuII with a probe from the insertion element IS6110/986, present in multiple copies throughout the genome of M tuberculosis. Results-Isolates from the two cases under investigation had identical fingerprints whereas those from the controls were all distinct. Two clusters of isolates with a similarity coefficient >0.25 were identified: in one, four out of five patients were born in the midlands (the birth place of the fifth was not known) and in the other all three patients were born in the Indian subcontinent. Conclusions-The data are consistent with, but do not prove, transmission of tuberculosis from the neighbour to the deceased. Geographical separation of the pools of infection may have led to the evolution of distinct clusters of fingerprint patterns. DNA fingerprinting of M tuberculosis is a powerful new tool for study of the epidemiology and pathogenesis of tuberculosis.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,BACTERIAL MOLEC GENET UNIT,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LABS,COVENTRY,ENGLAND; PUBL HLTH LABS,MYCOBACTERIUM REFERENCE UNIT,CARDIFF,WALES	University of London; London School of Hygiene & Tropical Medicine			Stoker, Neil G/L-8812-2016	Stoker, Neil G/0000-0001-7055-6184				BISHOP MJ, 1991, NUCLEIC ACID PROTEIN, P359; CAMPBELL A, 1981, ANNU REV MICROBIOL, V35, P55, DOI 10.1146/annurev.mi.35.100181.000415; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2052; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; OTAL I, 1991, J CLIN MICROBIOL, V29, P1252, DOI 10.1128/JCM.29.6.1252-1254.1991; SCHMID J, 1990, J CLIN MICROBIOL, V28, P1236, DOI 10.1128/JCM.28.6.1236-1243.1990; ZAINUDDIN ZF, 1989, J GEN MICROBIOL, V135, P2347	9	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					221	223		10.1136/bmj.305.6847.221	http://dx.doi.org/10.1136/bmj.305.6847.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392824	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JG11200021
J	AFZALPURKAR, RG; SCHILLER, LR; LITTLE, KH; SANTANGELO, WC; FORDTRAN, JS				AFZALPURKAR, RG; SCHILLER, LR; LITTLE, KH; SANTANGELO, WC; FORDTRAN, JS			THE SELF-LIMITED NATURE OF CHRONIC IDIOPATHIC DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTESTINAL PERFUSION; INGESTION	Background. Little is known about the clinical presentation and natural history of previously healthy patients in whom chronic idiopathic diarrhea develops. Methods. We reviewed the case records of 152 patients with chronic diarrhea who had no history of gastrointestinal surgery and who were evaluated in detail as part of a chronic-diarrhea protocol from 1985 to 1990. Patients were considered to have chronic idiopathic diarrhea if they had persistently loose stools for more than four weeks, no systemic illness, and no identifiable cause of diarrhea. Results. Seventeen patients (10 men and 7 women) ranging in age from 33 to 72 years met the criteria for chronic idiopathic diarrhea. Each patient had a history of a relatively abrupt onset of symptoms, often soon after returning home from a trip, starting two to seven months before evaluation. Their diarrhea did not occur during a local outbreak of diarrhea, and other family members did not become ill. Stool frequency ranged from 5 to 25 movements per day, stool weights ranged from 417 to 1480 g per day, and fecal electrolyte and osmolality values were consistent with a diagnosis of secretory diarrhea. The results of biopsies of the small intestine and colon were normal, as were small-bowel roentgenograms. Extensive studies for infectious causes of diarrhea were negative, and no patient responded to antibiotic therapy. In every patient the diarrhea stopped without specific therapy after 7 to 31 months (mean, 15) and did not recur during a follow-up period averaging 38 months. Conclusions. Sporadic idiopathic chronic diarrhea is a recognizable syndrome that can last many months, but is self-limited.	BAYLOR UNIV,MED CTR,DEPT INTERNAL MED,3500 GASTON AVE,DALLAS,TX 75246	Baylor University; Baylor University Medical Center	FORDTRAN, JS (corresponding author), BAYLOR UNIV,MED CTR,DEPT INTERNAL MED,3500 GASTON AVE,DALLAS,TX 75246, USA.				NIDDK NIH HHS [R01-DK37172-07] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; FINE KD, 1991, NEW ENGL J MED, V324, P1012, DOI 10.1056/NEJM199104113241502; FINE KD, 1989, GASTROINTESTINAL DIS, P290; FORDTRAN JS, 1986, CLIN GASTROENTEROL, V15, P477; GORBACH SL, 1989, GASTROINTESTINAL DIS, P1191; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; JANDA RC, 1991, GASTROENTEROLOGY, V100, P458, DOI 10.1016/0016-5085(91)90216-8; KREJS GJ, 1977, AM J DIG DIS, V22, P280, DOI 10.1007/BF01072184; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; PARSONNET J, 1989, ANN INTERN MED, V110, P985, DOI 10.7326/0003-4819-110-12-985; READ NW, 1982, DIGEST DIS SCI, V27, P193, DOI 10.1007/BF01296914; Schiller LA, 1991, DIARRHEAL DISEASES, P219; TOSKES PP, 1989, GASTROINTESTINAL DIS, P1289	13	47	51	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1849	1852		10.1056/NEJM199212243272605	http://dx.doi.org/10.1056/NEJM199212243272605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1448122				2022-12-24	WOS:A1992KD71400005
J	SABIA, PJ; POWERS, ER; RAGOSTA, M; SAREMBOCK, IJ; BURWELL, LR; KAUL, S				SABIA, PJ; POWERS, ER; RAGOSTA, M; SAREMBOCK, IJ; BURWELL, LR; KAUL, S			AN ASSOCIATION BETWEEN COLLATERAL BLOOD-FLOW AND MYOCARDIAL VIABILITY IN PATIENTS WITH RECENT MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; PHASE-I THROMBOLYSIS; 12-MONTH FOLLOW-UP; CONTRAST ECHOCARDIOGRAPHY; CORONARY-ARTERY; TIMI TRIAL; REPERFUSION; SIZE; OCCLUSION	Background. We hypothesized that successful reperfusion of an occluded infarct-related coronary artery even late after acute myocardial infarction would result in improved regional wall motion and that such improvement might be related to the presence of collateral blood flow within the infarct bed. Methods. We assessed regional wall motion by two-dimensional echocardiography at base line and one month after angioplasty was attempted in the occluded infarct-related artery in 43 patients who had had a myocardial infarction two days to five weeks earlier. A wall-motion score was assigned to each patient on a five-point scale (from 1 [normal function] to 5 [dyskinesia]). The percentage of the infarct bed perfused by collateral flow was assessed with myocardial contrast echocardiography. Results. In the 41 patients who had abnormal wall motion at base line, improvement in function was noted in 25 (78 percent) of the 32 in whom angioplasty was successful, as compared with only 1 (11 percent) of the 9 in whom it was unsuccessful (P<0.001). The percentage of the infarct bed supplied by collateral flow at base line was directly correlated with wall function and inversely correlated with the wall-motion score one month after successful angioplasty (r = -0.64, P<0.001). Among the patients in whom angioplasty was successful, the 23 in whom >50 percent of the infarct bed was supplied by collateral flow had better wall motion (P<0.001) and greater improvement in wall motion at one month (P = 0.004) than the 9 in whom less-than-or-equal-to 50 percent of the bed was supplied by collateral flow. The degree of improvement in function was not influenced by the length of time between the infarction and the attempted angioplasty. Conclusions. The myocardium remains viable for a prolonged period in many patients with acute infarction and an occluded infarct-related artery. Viability appears to be associated with the presence of collateral blood flow within the infarct bed.	UNIV VIRGINIA, SCH MED, DEPT MED, DIV CARDIOL, BOX 158, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	POWERS, ER (corresponding author), UNIV VIRGINIA, SCH MED, DEPT MED, DIV CARDIOL, BOX 158, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038345, K08HL001833] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08-HL01833, R29-HL38345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; CHAMBERLAIN DA, 1988, LANCET, V1, P545; Cohen M. V., 1985, CORONARY COLLATERALS, P93; COHEN MV, 1985, CORONARY COLLATERALS, P1; DALEN JE, 1988, AM J CARDIOL, V62, P179, DOI 10.1016/0002-9149(88)90208-1; FINCI L, 1990, AM J CARDIOL, V66, P660, DOI 10.1016/0002-9149(90)91125-P; FORCE T, 1988, J AM COLL CARDIOL, V11, P192, DOI 10.1016/0735-1097(88)90189-1; GENSINI GG, 1969, AM J CARDIOL, V24, P393, DOI 10.1016/0002-9149(69)90434-2; GOHLKE H, 1991, AM J CARDIOL, V67, P1165, DOI 10.1016/0002-9149(91)90920-G; Gorlin R, 1976, Major Probl Intern Med, V11, P59; GRILL HP, 1990, J AM COLL CARDIOL, V16, P1594, DOI 10.1016/0735-1097(90)90306-A; HABIB GB, 1991, CIRCULATION, V83, P739, DOI 10.1161/01.CIR.83.3.739; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; KAUL S, 1989, J AM COLL CARDIOL, V13, P468, DOI 10.1016/0735-1097(89)90528-7; KAUL S, 1985, J AM COLL CARDIOL, V6, P825, DOI 10.1016/S0735-1097(85)80490-3; KAUL S, 1986, J AM COLL CARDIOL, V7, P383, DOI 10.1016/S0735-1097(86)80509-5; KAUL S, 1991, J AM COLL CARDIOL, V17, P1403, DOI 10.1016/S0735-1097(10)80154-8; KAUL S, 1987, CIRC RES, V61, P77, DOI 10.1161/01.RES.61.1.77; KELLER MW, 1988, J AM COLL CARDIOL, V12, P1039, DOI 10.1016/0735-1097(88)90474-3; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; LANG RM, 1986, J AM COLL CARDIOL, V8, P232, DOI 10.1016/S0735-1097(86)80118-8; LIM YJ, 1990, AM J CARDIOL, V66, P556, DOI 10.1016/0002-9149(90)90481-F; MOOD AM, 1963, INTRO THEORY STATIST; MOORE CA, 1986, J AM COLL CARDIOL, V8, P1066, DOI 10.1016/S0735-1097(86)80383-7; Mulvihill DA, 1931, NEW ENGL J MED, V204, P1032, DOI 10.1056/NEJM193105142042003; REIMER KA, 1979, LAB INVEST, V40, P633; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; SABIA PJ, 1992, CIRCULATION, V85, P2080, DOI 10.1161/01.CIR.85.6.2080; SAITO Y, 1985, AM J CARDIOL, V55, P1259, DOI 10.1016/0002-9149(85)90485-0; SCHAPER W, 1979, BASIC RES CARDIOL, V74, P46, DOI 10.1007/BF01907684; SCHAPER W, 1971, COLLATERAL CIRCULATI, P155; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SCHRODER R, 1989, AM J CARDIOL, V64, P878, DOI 10.1016/0002-9149(89)90835-7; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; SPOTNITZ WD, 1990, AM J CARDIOL, V65, P1259, DOI 10.1016/0002-9149(90)90984-9; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; TOUCHSTONE DA, 1989, J AM COLL CARDIOL, V13, P1506, DOI 10.1016/0735-1097(89)90340-9; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	42	475	485	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1825	1831		10.1056/NEJM199212243272601	http://dx.doi.org/10.1056/NEJM199212243272601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1448120				2022-12-24	WOS:A1992KD71400001
J	BERKMAN, LF; LEOSUMMERS, L; HORWITZ, RI				BERKMAN, LF; LEOSUMMERS, L; HORWITZ, RI			EMOTIONAL SUPPORT AND SURVIVAL AFTER MYOCARDIAL-INFARCTION - A PROSPECTIVE, POPULATION-BASED STUDY OF THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; SOCIAL SUPPORT; ACTIVITIES OF DAILY LIVING; OUTCOME ASSESSMENT (HEALTH CARE); COMORBIDITY	SUDDEN CARDIAC DEATH; CORONARY HEART-DISEASE; SOCIAL SUPPORT; MULTIVARIATE-ANALYSIS; MORTALITY; PROGNOSIS; HEALTH; MEN; DETERMINANTS; ATTACK	Objective: To compare the survival of elderly patients hospitalized for acute myocardial infarction who have emotional support with that of patients who lack such support, while controlling for severity of disease, comorbidity, and functional status. Design: A prospective, community-based cohort study. Setting: Two hospitals in New Haven, Connecticut. Patients: Men (n = 100) and women (n = 94) 65 years of age or more hospitalized for acute myocardial infarction between 1982 and 1988. Measurements: Social support, age, gender, race, education, marital status, living arrangements, presence of depression, smoking history, weight, and physical function were assessed prospectively using questionnaires. The presence of congestive heart failure, pulmonary edema, and cardiogenic shock; the position of infarction; in-hospital complications; and history of myocardial infarction were assessed using medical records. Comorbidity was defined using an index based on the presence of eight conditions. Results: Of 194 patients, 76 (39%) died in the first 6 months after myocardial infarction. In multiple logistic regression analyses, lack of emotional support was significantly associated with 6-month mortality (odds ratio, 2.9; 95% Cl, 1.2 to 6.9) after controlling for severity of myocardial infarction, comorbidity, risk factors such as smoking and hypertension, and sociodemographic factors. Conclusions: When emotional support was assessed before myocardial infarction, it was independently related to risk for death in the subsequent 6 months.			BERKMAN, LF (corresponding author), YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, 60 COLL ST, NEW HAVEN, CT 06510 USA.				NIA NIH HHS [N01-AG-02105] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG002105] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERKMAN L, 1989, DEMOGRAPHY, V26, P661, DOI 10.2307/2061264; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLAZER DG, 1982, AM J EPIDEMIOL, V115, P684, DOI 10.1093/oxfordjournals.aje.a113351; BRACKETT CD, 1988, AM J CARDIOL, V61, P979, DOI 10.1016/0002-9149(88)90110-5; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; Charlson ME, 1984, J CHRON DIS, V37, P369; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; CROOG SM, 1977, HEART PATIENT RECOVE; HARRELL FE, 1986, PHGLM PROCEDURE SUGI, P437; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; KAPLAN GA, 1988, AM J EPIDEMIOL, V128, P370, DOI 10.1093/oxfordjournals.aje.a114977; KAPLAN JR, 1982, ARTERIOSCLEROSIS, V2, P359, DOI 10.1161/01.ATV.2.5.359; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KRANTZ DS, 1980, J HUM STRESS, V6, P27, DOI 10.1080/0097840X.1980.9936096; LOWN B, 1987, CIRCULATION, V76, P186; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MAYOU R, 1984, J PSYCHOSOM RES, V28, P17, DOI 10.1016/0022-3999(84)90036-9; MEDALIE JH, 1976, AM J MED, V60, P910, DOI 10.1016/0002-9343(76)90921-9; MERMELSTEIN R, 1986, J CONSULT CLIN PSYCH, V54, P447, DOI 10.1037/0022-006X.54.4.447; NEREM RM, 1980, SCIENCE, V208, P1475, DOI 10.1126/science.7384790; ORTHGOMER K, 1987, J CHRON DIS, V40, P949, DOI 10.1016/0021-9681(87)90145-7; POWELL LH, 1985, J CHRON DIS, V38, P253, DOI 10.1016/0021-9681(85)90068-2; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; RUBERMAN W, 1983, J CHRON DIS, V36, P151, DOI 10.1016/0021-9681(83)90089-9; RUBERMAN W, 1992, JAMA-J AM MED ASSOC, V267, P559, DOI 10.1001/jama.267.4.559; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SEEMAN TE, 1987, PSYCHOSOM MED, V49, P341, DOI 10.1097/00006842-198707000-00003; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; SEEMAN TE, 1988, SOC SCI MED, V26, P737, DOI 10.1016/0277-9536(88)90065-2; SEEMAN TE, IN PRESS ANN EPIDEMI; SOKOLOW M, 1987, CLIN CARDIOLOGY; WELIN L, 1985, LANCET, V1, P915; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; 1971, WHO5TH REP	38	581	586	0	34	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					1003	1009		10.7326/0003-4819-117-12-1003	http://dx.doi.org/10.7326/0003-4819-117-12-1003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443968				2022-12-24	WOS:A1992KB98000005
J	LLOYD, AM; WALBOT, V; DAVIS, RW				LLOYD, AM; WALBOT, V; DAVIS, RW			ARABIDOPSIS AND NICOTIANA ANTHOCYANIN PRODUCTION ACTIVATED BY MAIZE REGULATOR-R AND REGULATOR-C1	SCIENCE			English	Article							TISSUE-SPECIFIC EXPRESSION; CHALCONE SYNTHASE; TRANSCRIPTIONAL ACTIVATORS; GENE; HOMOLOGY; MYB; TRANSFORMATION; INDUCTION; INFECTION; ELICITOR	Anthocyanin pathway-specific transcriptional activators Rand C1 from the monocot maize were expressed in two dicots, Arabidopsis thaliana and Nicotiana tabacum. Expression of R caused augmented anthocyanin pigmentation in both plant species and augmented trichome (hair) production in Arabidopsis. Alone, C1 had no effect. Hybrid transgenic Arabidopsis expressing both C1 and R produced anthocyanins in root, petal, and stamen tissues that normally never express anthocyanins. When R was expressed in the transparent testa glabrous (without anthocyanins and trichomes) mutant of Arabidopsis, the deficiency was complemented and both anthocyanins and trichomes were restored.	STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305	Stanford University	LLOYD, AM (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279	NIGMS NIH HHS [GM 32422] Funding Source: Medline; PHS HHS [R37-H600198] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateson W., 1901, J R HORT SOC, V26, P1; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; Coe E. H. Jr., 1988, Corn and corn improvement. Third edition., P81; DAMIANI RD, UNPUB; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; DRUMMHERREL H, 1981, PHOTOCHEM PHOTOBIOL, V33, P391, DOI 10.1111/j.1751-1097.1981.tb05435.x; FEINBAUM RL, 1988, MOL CELL BIOL, V8, P1985, DOI 10.1128/MCB.8.5.1985; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; HABEREDER H, 1989, PLANTA, V177, P58, DOI 10.1007/BF00392154; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hunt A. G., UNPUB; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Koornneef M., 1981, ARABID INF SERV, V18, P45; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KUBASEK W, UNPUB; LLOYD AL, UNPUB; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; McClure J. W, 1975, FLAVONOIDS, P970, DOI DOI 10.1007/978-1-4899-2909-9_18; MEHDY MC, 1987, EMBO J, V6, P1527, DOI 10.1002/j.1460-2075.1987.tb02396.x; Mendel JG., 1865, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.1093/OXFORDJOURNALS.JHERED.A106151; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; RYDER TB, 1987, MOL GEN GENET, V210, P219, DOI 10.1007/BF00325687; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	30	404	451	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1773	1775		10.1126/science.1465611	http://dx.doi.org/10.1126/science.1465611			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465611				2022-12-24	WOS:A1992KB96400033
J	LOBO, SM; TANAKA, M; SULLIVAN, ML; HERNANDEZ, N				LOBO, SM; TANAKA, M; SULLIVAN, ML; HERNANDEZ, N			A TBP COMPLEX ESSENTIAL FOR TRANSCRIPTION FROM TATA-LESS BUT NOT TATA-CONTAINING RNA POLYMERASE-III PROMOTERS IS PART OF THE TFIIIB FRACTION	CELL			English	Article							HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; ACCURATE TRANSCRIPTION; MULTIPLE FACTORS; BINDING-PROTEIN; SNRNA PROMOTER; FACTOR-TAU; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; FACTOR-EPSILON	The TATA box-binding protein TBP directs transcription by all three eukaryotic RNA polymerases. In mammalian cells, TBP is found in at least three different complexes: SL1, D-TFIID, and B-TFIID. While SL1 and D-TFIID are involved in RNA polymerase I and II transcription, respectively, no unique function has been assigned to the B-TFIID complex. Here we show that the TFIIIB fraction required for RNA polymerase III transcription contains two separable components, one of which is a TBP-containing complex that may correspond to B-TFIID. For transcription of TATA-less RNA polymerase III genes such as the VAI, 5S, and 7SL genes, this complex cannot be replaced by either TBP alone or the D-TFIID complex. In contrast, TBP alone is active for basal transcription from the TATA-containing U6 promoter. This indicates different requirements for recruiting TBP to TATA-less and TATA-containing RNA polymerase III promoters.			LOBO, SM (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Hernandez, Nouria/0000-0003-1465-4585	NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [R01 GM38810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P2403, DOI 10.1093/nar/15.6.2403; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P583; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HARLOW E, 1988, ANTIBODIES LABORATOR; HERNANDEZ N, 1992, IN PRESS COLD SPRING; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3584	65	147	148	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1029	1040		10.1016/0092-8674(92)90397-U	http://dx.doi.org/10.1016/0092-8674(92)90397-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458534				2022-12-24	WOS:A1992KB99000014
J	MATSUMURA, K; ERVASTI, JM; OHLENDIECK, K; KAHL, SD; CAMPBELL, KP				MATSUMURA, K; ERVASTI, JM; OHLENDIECK, K; KAHL, SD; CAMPBELL, KP			ASSOCIATION OF DYSTROPHIN-RELATED PROTEIN WITH DYSTROPHIN-ASSOCIATED PROTEINS IN MDX MOUSE MUSCLE	NATURE			English	Article							SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; GLYCOPROTEIN COMPLEX; GENE; MICE; LOCALIZATION; SARCOLEMMA; EXPRESSION; FIBERS	DYSTROPHIN is associated with a complex of muscle membrane (sarcolemmal) glycoproteins that provide a linkage to the extracellular matrix protein, laminin1-8. The absence of dystrophin leads to a dramatic reduction of the dystrophin-associated proteins (156DAG, 59DAP, 50DAG, 43DAG and 35DAG) in the sarcolemma of patients with Duchenne muscular dystrophy and mdx mice2,6-8. Here we demonstrate that dystrophin-related protein (DRP, utrophin), an autosomal homologue of dystrophin9-17, is associated with an identical or antigenically similar complex of sarcolemmal proteins and that DRP and the dystrophin/DRP-associated proteins colocalize to the neuromuscular junction in Duchenne muscular dystrophy and mdx muscle. The DRP and dystrophin/DRP-associated proteins are found throughout the sarcolemma in small-calibre skeletal muscles and cardiac muscle of adult mdx mice. Because these muscles show minimal pathological changes18-20, our results could provide a basis for the upregulation of DRP as a potential therapeutic approach.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	MATSUMURA, K (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Ervasti, James/AAZ-4786-2020	Ohlendieck, Kay/0000-0002-6266-4510; Campbell, Kevin/0000-0003-2066-5889; Kahl, Steven/0000-0001-7085-9556				BUCKLE VJ, 1990, HUM GENET, V85, P324; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MAN NT, 1991, J CELL BIOL, V115, P1695; MATSUMURA K, 1988, MUSCLE NERVE, V11, P97, DOI 10.1002/mus.880110202; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHLENDIECK K, IN PRESS NEUROLOGY; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; TAKEMITSU M, 1991, BIOCHEM BIOPH RES CO, V180, P1179, DOI 10.1016/S0006-291X(05)81320-8; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269	21	451	457	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					588	591		10.1038/360588a0	http://dx.doi.org/10.1038/360588a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461282				2022-12-24	WOS:A1992KB95900086
J	COLEMAN, EA; FEUER, EJ				COLEMAN, EA; FEUER, EJ			BREAST-CANCER SCREENING AMONG WOMEN FROM 65 TO 74 YEARS OF AGE IN 1987-88 AND 1991	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; MAMMOGRAPHY; BREAST SELF-EXAMINATION; MASS SCREENING; PHYSICAL EXAMINATION	OLDER WOMEN; MAMMOGRAPHY; PHYSICIANS	Objective: To compare breast cancer screening rates from the 1991 survey with data from 1987-88 for women aged 65 to 74. Design: Surveys of women from five communities. Settings: Five control communities of the National Cancer Institute's Breast Cancer Screening Consortium. Participants: White, non-Hispanic women, ages 65 to 74; 499 in 1987-88 and 2156 in 1991. Response rates for the first survey wave ranged by area from 65% to 77% and for the second survey wave, from 62% to 85%. Main Outcome Measure: Mammogram and clinical breast examination during the past year and performance of monthly breast self examination, with the screening rates in wave 2 directly standardized to the income and education distribution of wave 1 in each area. Results: Mammography use between waves increased significantly (P < 0.05 after adjusting for education, income, and age) in all but one area (from 19% to 33% in wave 1 to 35% to 59% in wave 2). Among women who had a mammogram, the percent who also had a clinical breast examination decreased between waves from 95% to 85% (P = 0.001). Conclusions: Mammography in older women increased dramatically over 3 years, although the use of clinical breast examination may be decreasing.	NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	COLEMAN, EA (corresponding author), NCI, DCPC, APPL RES BRANCH, EPN 343, BETHESDA, MD 20892 USA.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085122] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-85122-01] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDA RF, 1990, AM J PREV MED, V6, P123, DOI 10.1016/S0749-3797(18)31016-X; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; Burg M A, 1990, J Aging Health, V2, P514, DOI 10.1177/089826439000200406; COLL PP, 1989, J AM GERIATR SOC, V37, P957, DOI 10.1111/j.1532-5415.1989.tb07281.x; COSTANZA ME, 1991, ARCH INTERN MED, V151, P1851, DOI 10.1001/archinte.151.9.1851; Fleiss JL, 1981, STAT METHODS RATES P; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; LANE DS, 1992, AM J PUBLIC HEALTH, V82, P199, DOI 10.2105/AJPH.82.2.199; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; RIES LAG, 1991, NIH912789 PUB; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; Sloane P D, 1991, Fam Med, V23, P40; VANOORTMARSSEN GJ, 1990, CANCER-AM CANCER SOC, V66, P1601, DOI 10.1002/1097-0142(19901001)66:7<1601::AID-CNCR2820660727>3.0.CO;2-O; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; ZAPKA JG, 1990, ADV CANCER CONTROL, V339, P259; 1990, JAMA-J AM MED ASSOC, V264, P54; 1990, FED REGISTER, V55, P53510	20	71	71	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					961	966		10.7326/0003-4819-117-11-961	http://dx.doi.org/10.7326/0003-4819-117-11-961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1443958				2022-12-24	WOS:A1992JZ27600012
J	TKACHUK, DC; KOHLER, S; CLEARY, ML				TKACHUK, DC; KOHLER, S; CLEARY, ML			INVOLVEMENT OF A HOMOLOG OF DROSOPHILA-TRITHORAX BY 11Q23 CHROMOSOMAL TRANSLOCATIONS IN ACUTE LEUKEMIAS	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA-BINDING PROTEIN; BITHORAX COMPLEX; HMG-I; CLONING; MOTIF; GENES; IDENTIFICATION; BREAKPOINTS	We have identified a human homolog of the Drosophila trithorax protein that is structurally altered by 11q23 translocations in acute leukemias. Human trithorax (HRX) is a predicted 431 kd protein containing two potential DNA-binding motifs consisting of zinc fingers conserved with the fly protein and nonconserved amino-terminal "AT hook" motifs related to the DNA-binding motifs in HMG proteins. 11q23 translocations disrupt the HRX gene between these two motifs, and in a t(11;19)-carrying cell line fusion transcripts are expressed from both derivative chromosomes. The more abundant derivative 11 transcript codes for a chimeric protein containing the AT hook motifs fused to a previously undescribed protein (ENL) from chromosome 19. These data suggest a novel role for a trithorax-homologous protein in multilineage human leukemias that may be mediated by DNA binding within the minor groove at AT-rich sites, implicated to play an important role in bacterial IHF-, yeast datin-, and mammalian HMG-mediated gene activation.			TKACHUK, DC (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971, CA55029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R01CA055029, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; CASTELLIGAIR JE, 1990, EMBO J, V9, P4267, DOI 10.1002/j.1460-2075.1990.tb07875.x; CHEN CS, 1991, BLOOD, V78, P2498; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; HARRIS BN, 1988, CANCER GENET CYTOGEN, V30, P171, DOI 10.1016/0165-4608(88)90108-2; HAYASHI Y, 1985, LEUKEMIA RES, V9, P1467, DOI 10.1016/0145-2126(85)90038-4; HEIM S, 1987, CANCER CYTOGENETICS; INGHAM PW, 1985, COLD SPRING HARB SYM, V50, P201, DOI 10.1101/SQB.1985.050.01.026; INGHAM PW, 1983, NATURE, V306, P591, DOI 10.1038/306591a0; JACOBS G, 1990, New Biologist, V2, P583; KANEKO Y, 1988, LEUKEMIA, V2, P672; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MANIATIS T, 1992, TRANSCRIPTIONAL REGU; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MITELMAN F, 1987, CATALOG CHROMOSOME A; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAIMONDI SC, 1989, BLOOD, V73, P1627; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SHIMIZU H, 1989, AM J PEDIAT HEMATOL, V11, P162; SMITH SD, 1989, BLOOD, V73, P2182; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; THOMPSON LH, 1985, SOMAT CELL MOLEC GEN, V11, P87, DOI 10.1007/BF01534738; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZIEMINVANDERPOE.S, 1991, P NATL ACAD SCI USA, V86, P10735	46	892	932	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					691	700		10.1016/0092-8674(92)90602-9	http://dx.doi.org/10.1016/0092-8674(92)90602-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423624				2022-12-24	WOS:A1992JY67600016
J	LEE, JJ; VONKESSLER, DP; PARKS, S; BEACHY, PA				LEE, JJ; VONKESSLER, DP; PARKS, S; BEACHY, PA			SECRETION AND LOCALIZED TRANSCRIPTION SUGGEST A ROLE IN POSITIONAL SIGNALING FOR PRODUCTS OF THE SEGMENTATION GENE HEDGEHOG	CELL			English	Article							DROSOPHILA HEAD DEVELOPMENT; ANTENNA IMAGINAL DISK; POLARITY GENE; PATTERN-FORMATION; ENGRAILED GENE; MESSENGER-RNA; FUSHI-TARAZU; MOLECULAR-GENETICS; EMBRYONIC PATTERN; LARVAL CUTICLE	The segment polarity genes engrailed and wingless are expressed in neighboring stripes of cells on opposite sides of the Drosophila parasegment boundary. Each gene is mutually required for maintenance of the other's expression; continued expression of both also requires several other segment polarity genes. We show here that one such gene, hedgehog, encodes a protein targeted to the secretory pathway and is expressed coincidently with engrailed in embryos and in imaginal discs; maintenance of the hedgehog expression pattern is itself dependent upon other segment polarity genes including engrailed and wingless. Expression of hedgehog thus functions in, and is sensitive to, positional signaling. These properties are consistent with the non-cell autonomous requirement for hedgehog in cuticular patterning and in maintenance of wingless expression.			LEE, JJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKER NE, 1988, DEVELOPMENT, V102, P489; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BROWER DL, 1981, DEV BIOL, V86, P448, DOI 10.1016/0012-1606(81)90203-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, IN PRESS EMBO J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN R, 1991, DEVELOPMENT, V112, P899; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYNIE JL, 1986, J EXP ZOOL, V237, P293, DOI 10.1002/jez.1402370302; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HOLMGREN R, 1981, P NATL ACAD SCI-BIOL, V78, P3775, DOI 10.1073/pnas.78.6.3775; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IVES B, 1950, DROS INF SERV, V24, P58; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN G, 1992, IN PRESS GENETICS; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KEITH TP, 1987, GENETICS, V116, P67; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KYTE J, 1982, J MOL BIOL, V157, P133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROOP DR, 1978, CELL, V15, P671, DOI 10.1016/0092-8674(78)90035-1; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER FR, 1979, DEV BIOL, V68, P96, DOI 10.1016/0012-1606(79)90246-X; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE JC, 1992, COMPUT APPL BIOSCI, V8, P249; WEIR MP, 1985, NATURE, V318, P433, DOI 10.1038/318433a0; Wieschaus E., 1986, P199; WILKINS AS, 1991, DEV BIOL, V145, P1, DOI 10.1016/0012-1606(91)90208-K	101	502	527	2	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					33	50		10.1016/0092-8674(92)90264-D	http://dx.doi.org/10.1016/0092-8674(92)90264-D			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394430				2022-12-24	WOS:A1992JQ62300005
J	BEAUDRY, AA; JOYCE, GF				BEAUDRY, AA; JOYCE, GF			DIRECTED EVOLUTION OF AN RNA ENZYME	SCIENCE			English	Article							GROUP-I INTRON; SITE-SPECIFIC MUTAGENESIS; SELF-SPLICING INTRON; TETRAHYMENA RIBOZYME; RIBOSOMAL-RNA; CATALYTIC ACTIVITY; DNA-POLYMERASE; SATURATION MUTAGENESIS; SECONDARY STRUCTURE; STRANDED-DNA	An in vitro evolution procedure was used to obtain RNA enzymes with a particular catalytic function. A population of 10(13) variants of the, Tetrahynena ribozyme, a group I ribozyme that catalyzes sequence-specific cleavage of RNA via a phosphoester transfer mechanism, was generated. This enzyme has a limited ability to cleave DNA under conditions of high temperature or high MgCl2 concentration, or both. A selection constraint was imposed on the population of ribozyme variants such that only those individuals that carried out DNA cleavage under physiologic conditions were amplified to produce "progeny" ribozymes. Mutations were introduced during amplification to maintain heterogeneity in the population. This process was repeated for ten successive generations, resulting in enhanced (100 times) DNA cleavage activity.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BEAUDRY, AA (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030882] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARFOD ET, 1988, GENE DEV, V2, P652, DOI 10.1101/gad.2.6.652; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; Chamberlin M., 1982, ENZYMES, V15, P87; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CHU CT, 1979, VIROLOGY, V98, P168, DOI 10.1016/0042-6822(79)90535-X; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DERBYSHIRE KM, 1986, GENE, V46, P145, DOI 10.1016/0378-1119(86)90398-7; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; Eadie GS, 1942, J BIOL CHEM, V146, P85; EIGEN M, 1988, J PHYS CHEM-US, V92, P6881, DOI 10.1021/j100335a010; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HOFSTEE BHJ, 1952, J BIOL CHEM, V199, P357; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JOHNSON KA, 1990, ENZYMES, V19, P159; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; JOYCE GF, 1987, NUCLEIC ACIDS RES, V15, P9825, DOI 10.1093/nar/15.23.9825; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P711, DOI 10.1093/nar/17.12.4885; JOYCE GF, 1992, ANTISENSE RNA DNA, P353; JOYCE GF, 1989, MOL BIOL RNA, P361; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KNOWLES JR, 1987, SCIENCE, V236, P1252; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KWOH DY, 1989, P NATL ACAD SCI USA, V86, P1173, DOI 10.1073/pnas.86.4.1173; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEHTOVAARA PM, 1988, PROTEIN ENG, V2, P63, DOI 10.1093/protein/2.1.63; Leung DW, 1989, TECHNIQUE, V1, P11; MATTEUCCI MD, 1983, NUCLEIC ACIDS RES, V11, P3113, DOI 10.1093/nar/11.10.3113; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; Robertson D. W., UNPUB; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZAKOUR RA, 1982, NATURE, V295, P708, DOI 10.1038/295708a0; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	75	348	444	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					635	641		10.1126/science.1496376	http://dx.doi.org/10.1126/science.1496376			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496376				2022-12-24	WOS:A1992JF85200026
J	HOSOBUCHI, M; KREIS, T; SCHEKMAN, R				HOSOBUCHI, M; KREIS, T; SCHEKMAN, R			SEC21 IS A GENE REQUIRED FOR ER TO GOLGI PROTEIN-TRANSPORT THAT ENCODES A SUBUNIT OF A YEAST COATOMER	NATURE			English	Article							SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; COATED VESICLES; CLATHRIN; STACK; COMPLEX; COMPLEMENTATION; IDENTIFICATION; BINDING; VECTORS	NON-CLATHRIN coated vesicles have been implicated in early steps of intercompartmental transport1-4. A distinct set of coat proteins are peripherally associated with the exterior of purified mammalian intra-Golgi transport vesicles5. The 'coatomer', a cytosolic complex containing a similar subunit composition to and sharing at least one subunit (beta-COP) with the coat found on vesicles, has been postulated to be the precursor of this non-clathrin coat6. Here we describe the characterization of SEC21, an essential gene required for protein transport from the endoplasmic reticulum to the Golgi in the yeast Saccharomyces cerevisiae. The 105K product of this gene, Sec21p, participates in a cytosolic complex that we show to be a yeast homologue of the mammalian coatomer. These observations demonstrate that a non-clathrin coat protein plays an essential role in intercompartmental transport.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV GENEVA, DEPT BIOL CELLULAIRE, CH-1211 GENEVA 4, SWITZERLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	HOSOBUCHI, M (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNN B, 1989, CURRENT PROTOCOLS MO, V2; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; HARLOW E, 1988, ANTIBODIES LABORATOR, V98, P100; HARLOW E, 1988, ANTIBODIES LABORATOR, V98, P114; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PAYNE GS, 1987, MOL CELL BIOL, V7, P3888, DOI 10.1128/MCB.7.11.3888; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVEIRA LA, 1990, J CELL BIOL, V111, P1437, DOI 10.1083/jcb.111.4.1437; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	31	171	175	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1992	360	6404					603	605		10.1038/360603a0	http://dx.doi.org/10.1038/360603a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461285				2022-12-24	WOS:A1992KB95900091
J	AYUS, JC; WHEELER, JM; ARIEFF, AI				AYUS, JC; WHEELER, JM; ARIEFF, AI			POSTOPERATIVE HYPONATREMIC ENCEPHALOPATHY IN MENSTRUANT WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						HYPONATREMIA; ENCEPHALOPATHY, HYPONATREMIC; POSTOPERATIVE COMPLICATIONS; MENSTRUATION	HYPERTONIC SALINE; BRAIN-DAMAGE; WATER; SEIZURES; SURGERY; ARREST; RAT	Objectives: To determine factors associated with the development of encephalopathy and with its clinical course in patients with postoperative hyponatremia. Setting: Consultation and referral services of two university medical centers and community hospitals. Design: Case-control study (risk factors for encephalopathy) and cohort study (clinical course among patients with encephalopathy). Patients: Case patients included 65 adults with postoperative hyponatremic encephalopathy; controls included 674 adult patients who had postoperative hyponatremia without encephalopathy and who were selected from 76 678 consecutive adult surgical inpatients. Measurements: Age, gender, menstrual status, neurologic symptoms, time to development and degree of hyponatremia, arterial blood gas determinations, serum chemistries, morbidity and mortality. Results: Case patients included 40 women (62%) and 25 men (38%) (P > 0.05); controls included 367 women (54%) and 307 men (46%) (P > 0.1). Of the 34 case patients who developed permanent brain damage or died, 33 (97%) were women (P < 0.001). Among the women with brain damage, 25 (76%) were menstruant (P < 0.001). The relative risk for death or permanent brain damage from hyponatremic encephalopathy in women compared with men was 28 (95% CI, 5 to 141) and in menstruant women compared with postmenopausal women, 26 (CI, 11 to 62). Arterial PO2 at diagnosis was significantly lower in female than in male case patients (34 +/- 5 compared with 91 +/- 3 mm Hg; P < 0.001). Further, of the 38 case patients who had respiratory arrest before the diagnosis of hyponatremic encephalopathy, 36 (95%) were women. Extent of or time to development of hyponatremia did not correlate with subsequent brain damage (P > 0.1). Conclusions: Women and men are equally likely to develop hyponatremia and hyponatremic encephalopathy after surgery. However, when hyponatremic encephalopathy develops, menstruant women are about 25 times more likely to die or have permanent brain damage compared with either men or postmenopausal women.	BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA	Baylor College of Medicine; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE ON AGING [R01AG008575] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG08575] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREOLI TE, 1992, CECIL TXB MED, P499; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7; AYUS JC, 1992, CLIN RES, V40, pA223; CHARLTON AJ, 1980, ANAESTHESIA, V35, P804, DOI 10.1111/j.1365-2044.1980.tb03922.x; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; DEUTSCH S, 1966, ANESTHESIOLOGY, V27, P250, DOI 10.1097/00000542-196627030-00003; FRASER CL, 1989, AM J PHYSIOL, V257, pE284, DOI 10.1152/ajpendo.1989.257.2.E284; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; FRASER CL, IN PRESS CLIN DISORD; GARCIA JH, 1980, BRAIN EDEMA PATHOLOG, P147; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; GUY AJ, 1987, BRIT J SURG, V74, P1027, DOI 10.1002/bjs.1800741123; HARRISON RH, 1956, J UROLOGY, V75, P95, DOI 10.1016/S0022-5347(17)66783-1; Helwig FC, 1935, J AMER MED ASSOC, V104, P1569, DOI 10.1001/jama.1935.02760180001001; HORNBEIN TF, 1989, NEW ENGL J MED, V321, P1714, DOI 10.1056/NEJM198912213212505; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; KOZAK LJ, 1989, DHHS PHS891250 DEP H; LEVINSKY NG, 1991, HARRISONS PRINCIPLES, P278; MELTON JE, 1983, AM J PHYSIOL, V244, pR724, DOI 10.1152/ajpregu.1983.244.5.R724; MORAN WH, 1964, SURGERY, V56, P99; NARINS RG, 1990, INTERNAL MED, P832; NATTIE EE, 1981, J APPL PHYSIOL, V51, P1086, DOI 10.1152/jappl.1981.51.5.1086; OELZ O, 1990, HYPOXIA ADAPTATIONS, P206; ROSOMOFF HL, 1963, ARCH NEUROL-CHICAGO, V9, P26, DOI 10.1001/archneur.1963.00460070036003; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P174; RYDER KW, 1984, J UROLOGY, V132, P995, DOI 10.1016/S0022-5347(17)49984-8; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; SCOTT JC, 1965, OBSTET GYNECOL, V26, P168; SHIMOJYO S, 1968, NEUROLOGY, V18, P127, DOI 10.1212/WNL.18.2.127; TIEN R, 1992, AM J MED, V92, P513, DOI 10.1016/0002-9343(92)90748-Z; VEXLER ZS, 1992, CLIN RES, V40, pA306; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168; ZIMMERMANN B, 1952, SURGERY, V31, P654; 1990, HLTH NUTRITION, P110; 1985, SAS USERS GUIDE BASI, P1290	39	328	334	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					891	897		10.7326/0003-4819-117-11-891	http://dx.doi.org/10.7326/0003-4819-117-11-891			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1443949				2022-12-24	WOS:A1992JZ27600003
J	IRWIN, MJ; HUDSON, KR; FRASER, JD; GASCOIGNE, NRJ				IRWIN, MJ; HUDSON, KR; FRASER, JD; GASCOIGNE, NRJ			ENTEROTOXIN RESIDUES DETERMINING T-CELL RECEPTOR V-BETA BINDING-SPECIFICITY	NATURE			English	Article							STAPHYLOCOCCAL-ENTEROTOXIN; STIMULATION; SUPERANTIGENS; MOLECULE; CHAIN	SUPERANTIGENS such as the staphylococcal enterotoxins bind to major histocompatibility complex (MHC) class II molecules and activate T cells through a specific interaction between the Vbeta region of the T-cell antigen receptor (TCR) and the toxin1-4. The TCR beta-chain alone is sufficient to produce the interaction with the enterotoxin-class II complex5. Identification of the regions of enterotoxins that interact with TCR has so far proved equivocal because of difficulties in distinguishing between direct effects on T-cell recognition and indirect effects resulting from alteration of binding to class II. For example, amino-terminal truncations of SEB abrogated T-cell stimulation whereas carboxy-terminal truncation of SEA stopped its mitogenic activity10,11. The most comprehensive study to date, accounting for both enterotoxin binding to class II and enterotoxin interactions with the TCR, identified two functionally important regions for SEB binding to TCR12. Although the amino-acid sequences of staphylococcal enterotoxins A and E are 82% identical6, they activate T cells bearing different Vbeta elements. We have assayed the binding of cells coated with these enterotoxins to soluble secreted TCR beta-chain protein and find that Vbeta3 binds enterotoxin A but not E, whereas Vbeta11 binds enterotoxin but not A. To map the amino-acid residues responsible for these different binding specificities, we prepared a series of hybrids between the two staphylococcal enterotoxins. We report that just two amino-acid residues near the carboxy terminus of the enterotoxins are responsible for the discrimination between these molecules by Vbeta3 and Vbeta11. The crystal structure of staphylococcal enterotoxin B (ref. 12) indicates that these form part of the outer rim of the site recognizing TCR.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV AUCKLAND, DEPT MOLEC MED, AUCKLAND, NEW ZEALAND	Scripps Research Institute; University of Auckland								BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BUELOW R, 1992, J IMMUNOL, V148, P1; CALLAHAN JE, 1990, J IMMUNOL, V144, P2473; COUCH JL, 1988, J BACTERIOL, V170, P2954, DOI 10.1128/jb.170.7.2954-2960.1988; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASCOIGNE NR, IN PRESS J SEMIN IMM; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HUFNAGLE WO, 1991, INFECT IMMUN, V59, P2126, DOI 10.1128/IAI.59.6.2126-2134.1991; JOHNSON HM, 1991, FASEB J, V5, P2706, DOI 10.1096/fasebj.5.12.1916093; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KUBO RT, 1989, J IMMUNOL, V142, P2736; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; PALMER MS, 1989, NUCLEIC ACIDS RES, V17, P2353, DOI 10.1093/nar/17.6.2353; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; SINGH BR, 1989, J BIOL CHEM, V264, P4404; SMITH HP, 1992, J IMMUNOL, V149, P887; Summers MD, 1987, TEXAS AGR EXPT STATI; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; TAKIMOTO H, 1990, EUR J IMMUNOL, V20, P617, DOI 10.1002/eji.1830200323; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405	23	77	80	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					841	843		10.1038/359841a0	http://dx.doi.org/10.1038/359841a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436060				2022-12-24	WOS:A1992JV77700067
J	STRYNADKA, NCJ; ADACHI, H; JENSEN, SE; JOHNS, K; SIELECKI, A; BETZEL, C; SUTOH, K; JAMES, MNG				STRYNADKA, NCJ; ADACHI, H; JENSEN, SE; JOHNS, K; SIELECKI, A; BETZEL, C; SUTOH, K; JAMES, MNG			MOLECULAR-STRUCTURE OF THE ACYL-ENZYME INTERMEDIATE IN BETA-LACTAM HYDROLYSIS AT 1.7 ANGSTROM RESOLUTION	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; BACILLUS-LICHENIFORMIS 749/C; REFINED CRYSTAL-STRUCTURE; MECHANISM; PENICILLIN; CATALYSIS; MUTANTS; RESISTANCE; SINGLE; PC1	The X-ray crystal structure of the molecular complex of penicillin G with a deacylation-defective mutant of the RTEM-1 beta-lactamase from Escherichia coli shows how these antibiotics are recognized and destroyed. Penicillin G is covalently bound to Ser 70 O(gamma) as an acyl-enzyme intermediate. The deduced catalytic mechanism uses Ser 70 O(gamma) as the attacking nucleophile during acylation. Lys 73 N(zeta) acts as a general base in abstracting a proton from Ser 70 and transferring it to the thiazolidine ring nitrogen atom via Ser 130 O(gamma). Deacylation is accomplished by nucleophilic attack on the penicilloyl carbonyl carbon by a water molecule assisted by the general base, Glu 166.	UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, ALBERTA, CANADA; DESY, EUROPEAN MOLEC BIOL LAB, W-2000 HAMBURG 52, GERMANY; UNIV ALBERTA, DEPT MICROBIOL, EDMONTON T6G 2E9, ALBERTA, CANADA; UNIV TOKYO, COLL ARTS & SCI, DEPT PURE & APPL SCI, MEGURO KU, TOKYO 153, JAPAN	University of Alberta; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Alberta; University of Tokyo			Betzel, Christian/G-8105-2018; Jensen, Susan/C-8701-2013	Betzel, Christian/0000-0002-3879-5019; 				Abraham EP, 1940, NATURE, V146, P837, DOI 10.1038/146837a0; ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARTWRIGHT SJ, 1989, BIOCHEM J, V263, P905, DOI 10.1042/bj2630905; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; Crowfoot D., 1949, CHEM PENICILLIN, P310; DALBADIEMCFARLAND G, 1986, BIOCHEMISTRY-US, V25, P332, DOI 10.1021/bi00350a008; DEXTER DD, 1978, J CHEM SOC, V185, P110; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; FRERE JM, 1985, CRC CR REV MICROBIOL, V11, P299; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; Hendrickson W. A., 1980, COMPUTING CRYSTALLOG; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; Herzberg O, 1991, CURR OPIN STRUC BIOL, V1, P946, DOI 10.1016/0959-440X(91)90090-G; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JACOB F, 1990, PROTEIN ENG, V4, P79, DOI 10.1093/protein/4.1.79; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; JAMES MNG, 1968, NATURE, V220, P168, DOI 10.1038/220168a0; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KNAP AK, 1991, BIOCHEM J, V273, P85, DOI 10.1042/bj2730085; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; MARTIN MT, 1988, BIOCHEM J, V254, P923, DOI 10.1042/bj2540923; MATTHEW M, 1976, J BACTERIOL, V125, P713, DOI 10.1128/JB.125.2.713-718.1976; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; OTWINOWSKI Z, 1990, AM CRYSTALLOGR ASS A; READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROSSMAN MG, 1972, INT SCI REV, V13; SWEET RM, 1970, J AM CHEM SOC, V92, P5489, DOI 10.1021/ja00721a032; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIRDEN R, 1990, BIOCHEMISTRY-US, V29, P145, DOI 10.1021/bi00453a018; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	49	541	546	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					700	705		10.1038/359700a0	http://dx.doi.org/10.1038/359700a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436034				2022-12-24	WOS:A1992JU65000046
J	MITCHELL, JM; SCOTT, E				MITCHELL, JM; SCOTT, E			PHYSICIAN OWNERSHIP OF PHYSICAL THERAPY SERVICES - EFFECTS ON CHARGES, UTILIZATION, PROFITS, AND SERVICE CHARACTERISTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICTS	Objective.-To evaluate the effects of physician ownership of freestanding physical therapy and rehabilitation facilities on utilization, charges, profits, and three measures of service characteristics for physical therapy treatments. Design.-Statistical comparison by physician joint venture ownership status of freestanding physical therapy and comprehensive rehabilitation facilities providing physical therapy treatments in Florida. Participants.-A total of 118 outpatient physical therapy facilities and 63 outpatient comprehensive rehabilitation facilities providing services in Florida during 1989. The data from the facilities were collected under a legislative mandate. Main Outcome Measures.-Visits per patient, average revenue per patient, percent operating income, percent markup, profits per patient, licensed therapist time per visit, and licensed and nonlicensed medical worker time per visit. Results.-Visits per patient were 39% to 45% higher in joint venture facilities. Both gross and net revenue per patient were 30% to 40% higher in facilities owned by referring physicians. Percent operating income and percent markup were significantly higher in joint venture physical therapy and rehabilitation facilities. Licensed physical therapists and licensed therapist assistants employed in nonjoint venture facilities spend about 60% more time per visit treating physical therapy patients than licensed therapists and licensed therapist assistants working in joint venture facilities. Joint ventures also generate more of their revenues from patients with well-paying insurance. Conclusion.-Our results indicate that utilization, charges per patient, and profits are higher when physical therapy and rehabilitation facilities are owned by referring physicians. With respect to service characteristics, joint venture firms employ proportionately fewer licensed therapists and licensed therapist assistants to perform physical therapy, so that licensed professionals employed in joint venture businesses spend significantly less time per visit treating patients. These results should be of interest to the medical profession, third-party payers, and policymakers, all of whom are concerned about the consequences of physician self-referral arrangements.	FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT FINANCE,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University								BURDA D, 1992, MOD HEALTHCARE  0629, V23, P3; CRANE TS, 1992, JAMA-J AM MED ASSOC, V268, P85, DOI 10.1001/jama.268.1.85; DOBSON R, 1986, NEW ENGL J MED, V314, P250; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, JOINT VENTURES HLTH, V2; MORREIM EH, 1989, JAMA-J AM MED ASSOC, V262, P390, DOI 10.1001/jama.262.3.390; PEAR R, 1992, NY TIMES        0406, pA2; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P98, DOI 10.1001/jama.268.1.98; Waldholz Michael, 1989, WALL STREET J   0301, pA6; Waldholz Michael, 1989, WALL STREET J   0301, pA1; ZIMMERMAN M, 1989, COMMUNICATION    MAY; 1989, FINANCIAL ARRANGEMEN; 1991, FINAL OCCUPATIONAL S; 1991, 91390 US DEP LAB PUB; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1986, FOR PROFIT ENTERPRIS, P153; 1992, SOURCES HLTH INSURAN	21	89	89	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2055	2059		10.1001/jama.268.15.2055	http://dx.doi.org/10.1001/jama.268.15.2055			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404742				2022-12-24	WOS:A1992JT52000029
J	YEN, TJ; LI, G; SCHAAR, BT; SZILAK, I; CLEVELAND, DW				YEN, TJ; LI, G; SCHAAR, BT; SZILAK, I; CLEVELAND, DW			CENP-E IS A PUTATIVE KINETOCHORE MOTOR THAT ACCUMULATES JUST BEFORE MITOSIS	NATURE			English	Article							KINESIN HEAVY-CHAIN; PROTEIN; SEQUENCE; GENE; ENCODES; DOMAINS	THE mechanics of chromosome movement, mitotic spindle assembly and spindle elongation have long been central questions of cell biology1. After attachment in prometaphase of a microtubule from one pole, duplicated chromosome pairs travel towards the pole in a rapid but discontinuous motion2,3. This is followed by a slower congression towards the midplate as the chromosome pair orients with each kinetochore attached to the microtubules f rom the nearest pole. The pairs disjoin at anaphase and translocate to opposite poles and the interpolar distance increases. Here we identify CENP-E as a kinesin-like motor protein (M(r) 312,000) that accumulates in the G2 phase of the cell cycle. CENP-E associates with kinetochores during congression, relocates to the spindle midzone at anaphase, and is quantitatively discarded at the end of the cell division. CENP-E is likely to be one of the motors responsible for mammalian chromosome movement and/or spindle elongation.	UNIV PENN,CELL BIOL GRAD GRP,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL SCI,BALTIMORE,MD 21205	University of Pennsylvania; Johns Hopkins University	YEN, TJ (corresponding author), FOX CHASE CANC CTR,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.		Cleveland, Don/AAN-9783-2021	Yen, Tim/0000-0003-2159-0997; Cleveland, Don/0000-0002-1934-3682				CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACDONALD HB, 1990, CELL, V61, P991; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; van Beneden E., 1883, ARCH BIOL, V4, P265; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	21	351	363	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					536	539		10.1038/359536a0	http://dx.doi.org/10.1038/359536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406971				2022-12-24	WOS:A1992JR85900060
J	SANO, T; SMITH, CL; CANTOR, CR				SANO, T; SMITH, CL; CANTOR, CR			IMMUNO-PCR - VERY SENSITIVE ANTIGEN-DETECTION BY MEANS OF SPECIFIC ANTIBODY-DNA CONJUGATES	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; CATALYTIC ANTIBODIES; ESCHERICHIA-COLI; AMPLIFICATION; MOLECULES; CHEMISTRY	An antigen detection system, termed immuno-polymerase chain reaction (immuno-PCR), was developed in which a specific DNA molecule is used as the marker. A streptavidin-protein A chimera that possesses tight and specific binding affinity both for biotin and immunoglobulin G was used to attach a biotinylated DNA specifically to antigen-monoclonal antibody complexes that had been immobilized on microtiter plate wells. Then, a segment of the attached DNA was amplified by PCR. Analysis of the PCR products by agarose gel electrophoresis after staining with ethidium bromide allowed as few as 580 antigen molecules (9.6 x 10(-22) moles) to be readily and reproducibly detected. Direct comparison with enzyme-linked immunosorbent assay with the use of a chimera-alkaline phosphatase conjugate demonstrates that enhancement (approximately x 10(5)) in detection sensitivity was obtained with the use of immuno-PCR. Given the enormous amplification capability and specificity of PCR, this immuno-PCR technology has a sensitivity greater than any existing antigen detection system and, in principle, could be applied to the detection of single antigen molecules.	LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	SANO, T (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.		Abrams, William R/A-5782-2008	Smith, Cassandra/0000-0002-0346-8907	NATIONAL CANCER INSTITUTE [R35CA039782] Funding Source: NIH RePORTER; NCI NIH HHS [CA39782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; BOLHUIS RLH, 1991, J CELL BIOCHEM, V47, P306, DOI 10.1002/jcb.240470404; CHISWELL DJ, 1992, TRENDS BIOTECHNOL, V10, P80, DOI 10.1016/0167-7799(92)90178-X; CIMINO GD, 1990, NATURE, V345, P773, DOI 10.1038/345773b0; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FEBER JP, 1976, LANCET, V2, P406; FEBER JP, 1978, ADV CIN CHEM, V20, P129; GEISOW MJ, 1992, TRENDS BIOTECHNOL, V10, P75, DOI 10.1016/0167-7799(92)90175-U; GIBBS RA, 1990, ANAL CHEM, V62, P1202, DOI 10.1021/ac00212a004; GIBBS RA, 1991, CURR OPIN BIOTECH, V2, P69, DOI 10.1016/0958-1669(91)90063-B; Hales C N, 1980, Methods Enzymol, V70, P334; LERNER RA, 1987, TRENDS BIOCHEM SCI, V12, P427, DOI 10.1016/0968-0004(87)90208-8; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MORRISON SL, 1988, CLIN CHEM, V34, P1668; MORRISON SL, 1989, ADV IMMUNOL, V44, P65; NOLAN O, 1990, BIOCHIM BIOPHYS ACTA, V1040, P1, DOI 10.1016/0167-4838(90)90139-7; PLUCKTHUN A, 1990, NATURE, V347, P497, DOI 10.1038/347497a0; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; REYES GR, CA39782 NIH GRANT; RODWELL JD, 1989, NATURE, V342, P99, DOI 10.1038/342099a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANO T, 1991, BIO-TECHNOL, V9, P1378, DOI 10.1038/nbt1291-1378; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; SCHULTZ PG, 1988, SCIENCE, V240, P426, DOI 10.1126/science.2833815; SHOKAT KM, 1990, ANNU REV IMMUNOL, V8, P335; VANVUNAKIS H, 1980, METHOD ENZYMOL, V770, P201; WAGNER MF, 1991, TRENDS BIOTECHNOL, V3, P375; WETZEL R, 1991, PROTEIN ENG, V4, P371, DOI 10.1093/protein/4.4.371; WHITE TJ, 1989, TRENDS GENET, V5, P185, DOI 10.1016/0168-9525(89)90073-5; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	31	640	853	11	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1992	258	5079					120	122		10.1126/science.1439758	http://dx.doi.org/10.1126/science.1439758			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439758				2022-12-24	WOS:A1992JQ61900032
J	HAAS, OA; ARGYRIOUTIRITA, A; LION, T				HAAS, OA; ARGYRIOUTIRITA, A; LION, T			PARENTAL ORIGIN OF CHROMOSOMES INVOLVED IN THE TRANSLOCATION T(9 22)	NATURE			English	Article							NUCLEOLUS ORGANIZER REGIONS; DNA METHYLATION; HUMAN LEUKEMIA; GENE ACTIVITY; WILMS-TUMOR; ALLELES; CANCER; TRANSGENES	FUNCTIONALLY equivalent genetic material can be labelled by an epigenetic marking process and used differentially depending on whether its origin is maternal or paternal1. This phenomenon is known as genomic imprinting and is manifested at either the chromosomal or gene level. Genomic imprinting seems to play an important role in cancer predisposition syndromes2-5 , and phenotypic consequences are evident in constitutional deletion syndromes and uniparental disomies1. Moreover, there seems to be a preferential retention of paternal alleles in sporadic tumours such as Wilms' tumour6, rhabdomyosarcoma7, osteosarcoma8 and retinoblastoma9. To investigate whether chromosomes involved in acquired abnormalities of haematologic neoplasms show a similar 'parent of origin' bias, we studied the inheritance of the translocated chromosomes 9 and 22 in cases of Philadelphia-chromosome-positive leukaemia, using unique specific chromosome band polymorphisms. Here we show that the translocated chromosome 9 was of paternal origin, whereas the translocated chromosomes 22 were derived exclusively from the maternal copy, in 11 cases with reliable polymorphisms. Our data therefore provide evidence that imprinting phenomena may play an important role in acquired tumour-specific chromosome rearrangements.			HAAS, OA (corresponding author), ST ANNA CHILDRENS HOSP, CHILDRENS CANC RES INST, KINDERSPITALGASSE 6, A-1090 VIENNA, AUSTRIA.		Haas, Oskar/AAM-5794-2020; Lion, MD, PhD, Professor, Thomas/C-3241-2016	Lion, MD, PhD, Professor, Thomas/0000-0001-9346-0994				ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COTE GB, 1989, ANN GENET-PARIS, V32, P69; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; HALL JG, 1990, AM J HUM GENET, V46, P857; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOWELL WM, 1980, EXPERIENTIA, V36, P1014, DOI 10.1007/BF01953855; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; LEACH RJ, 1990, CELL GROWTH DIFFER, V1, P401; LETTMANN C, 1991, NUCLEIC ACIDS RES, V19, P7131, DOI 10.1093/nar/19.25.7131; LION T, 1991, LEUKEMIA, V5, P156; MARKOVIC VD, 1978, HUM GENET, V41, P181, DOI 10.1007/BF00273100; MULLER H, 1975, CYTOGENET CELL GENET, V15, P239, DOI 10.1159/000130522; OLSON SB, 1988, CYTOGENETICS MAMMALI, P583; PAL N, 1990, ONCOGENE, V5, P1665; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHAEFERREGO KE, 1990, ONCOGENE, V5, P1669; SCHWEIZER D, 1980, CYTOGENET CELL GENET, V27, P190, DOI 10.1159/000131482; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SMITH SS, 1991, MOL CARCINOGEN, V4, P91, DOI 10.1002/mc.2940040202; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VERMA RS, 1989, HUMAN CHROMOSOMES MA; YAMADA T, 1990, LEUKEMIA, V4, P341	33	88	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					414	416		10.1038/359414a0	http://dx.doi.org/10.1038/359414a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406953				2022-12-24	WOS:A1992JQ62400056
J	GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M				GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M			CHILDHOOD-CANCER, INTRAMUSCULAR VITAMIN-K, AND PETHIDINE GIVEN DURING LABOR	BRITISH MEDICAL JOURNAL			English	Article							BENZO(A)PYRENE METABOLISM; DEFICIENCY; LEUKEMIA	Objective-To assess unexpected associations between childhood cancer and pethidine given in labour and the neonatal administration of vitamin K that had emerged in a study performed in the 1970 national birth cohort. Design and setting-195 children with cancer diagnosed in 1971-March 1991 and born in the two major Bristol maternity hospitals in 1965-87 were compared with 558 controls identified from the delivery books for the use of pethidine during labour and administration of vitamin K. Main outcome measures-Odds ratios for cancer in the presence of administration of pethidine or of intramuscular vitamin K. Both logistic regression and Mantel-Haenszel techniques were used for statistical analyses. Results-Children of mothers given pethidine in labour were not at increased risk of cancer (odds ratio 1.05, 95% confidence interval 0.7 to 1.5) after allowing for year and hospital of delivery, but there was a significant association (p=0.002) with intramuscular vitamin K (odds ratio 1.97, 95% confidence interval 1.3 to 3.0) when compared with oral vitamin K or no vitamin K. There was no significantly increased risk for children who had been given oral vitamin K when compared with no vitamin K (odds ratio 1.15, 95% confidence interval 0.5 to 2.7). These results could not be accounted for by other factors associated with administration of intramuscular vitamin K, such as type of delivery or admission to a special care baby unit. Conclusions-The only two studies so far to have examined the relation between childhood cancer and intramuscular vitamin K have shown similar results, and the relation is biologically plausible. The prophylactic benefits against haemorrhagic disease are unlikely to exceed the potential adverse effects from intramuscular vitamin K. Since oral vitamin K has major benefits but no obvious adverse effects this could be the prophylaxis of choice.			GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.			Golding, Jean/0000-0003-2826-3307				BUTLER NR, 1982, J ROY SOC MED, V75, P781; Butler NR, 1986, BIRTH 5 STUDY HLTH B; Chamberlain R., 1975, BRIT BIRTHS, V1; CORNELISSEN M, 1991, PEDIATR RES, V30, P550, DOI 10.1203/00006450-199112000-00011; DOGRA SC, 1987, INT J BIOCHEM, V19, P471, DOI 10.1016/0020-711X(87)90070-X; Elwood M, 1988, CAUSAL RELATIONSHIPS; Gilman E A, 1989, Paediatr Perinat Epidemiol, V3, P66, DOI 10.1111/j.1365-3016.1989.tb00371.x; GILMAN EA, 1988, J SOC RADIOLOGICAL P, V3, P3; Golding J, 1990, West Engl Med J, V105, P80; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; HILGARD P, 1977, BRIT J CANCER, V35, P891, DOI 10.1038/bjc.1977.135; ISRAELS LG, 1987, PEDIATR RES, V22, P405, DOI 10.1203/00006450-198710000-00008; ISRAELS LG, 1983, J CLIN INVEST, V71, P1130, DOI 10.1172/JCI110863; KNEALE GW, 1976, J NATL CANCER I, V56, P879, DOI 10.1093/jnci/56.5.879; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; STILLER CA, 1982, BRIT J CANCER, V45, P543, DOI 10.1038/bjc.1982.90; STJERNFELDT M, 1986, LANCET, V2, P687; von Kries R, 1992, Paediatr Perinat Epidemiol, V6, P7	21	224	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					341	346		10.1136/bmj.305.6849.341	http://dx.doi.org/10.1136/bmj.305.6849.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392886	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JJ03200022
J	SENDTNER, M; HOLTMANN, B; KOLBECK, R; THOENEN, H; BARDE, YA				SENDTNER, M; HOLTMANN, B; KOLBECK, R; THOENEN, H; BARDE, YA			BRAIN-DERIVED NEUROTROPHIC FACTOR PREVENTS THE DEATH OF MOTONEURONS IN NEWBORN RATS AFTER NERVE-SECTION	NATURE			English	Article							SPINAL-CORD MOTONEURONS; GROWTH-FACTOR; MESSENGER-RNA; EXPRESSION; SURVIVAL; NGF; NEURONS; AXOTOMY; CNTF; BDNF	MOTONEURONS innervating the skeletal musculature were among the first neurons shown to require the presence of their target cells to develop appropriately1,2. But the characterization of molecules allowing motoneuron survival has been difficult. Ciliary neurotrophic factor prevents the death of motoneurons3-6, but its gene is not expressed during development7. Although the presence of a neurotrophin receptor on developing motoneurons8-10 has suggested a role for neurotrophins, none could be shown to promote motoneuron survival in vitro3. We report here that brain-derived neurotrophic factor can prevent the death of axotomized motoneurons in newborn rats, suggesting a role for this neurotrophin for motoneuron survival in vivo.			SENDTNER, M (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM & NEUROBIOCHEM,W-8033 MARTINSRIED,GERMANY.		Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012; Barde, Yves/F-6019-2011	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Barde, Yves/0000-0002-7627-461X				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; Gudden B., 1870, ARCHIV PSYCHIAT NERV, V2, P693; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Oppenheim R. W., 1981, STUDIES DEV NEUROBIO, P74; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RAIVICH G, 1985, EMBO J, V4, P637, DOI 10.1002/j.1460-2075.1985.tb03677.x; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Shorey ML, 1909, J EXP ZOOL, V7, P25, DOI 10.1002/jez.1400070103; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1988, NEURON, V1, P335	23	682	704	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					757	759		10.1038/360757a0	http://dx.doi.org/10.1038/360757a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465147	Green Submitted			2022-12-24	WOS:A1992KE47200039
J	YANG, G; MASLAND, RH				YANG, G; MASLAND, RH			DIRECT VISUALIZATION OF THE DENDRITIC AND RECEPTIVE-FIELDS OF DIRECTIONALLY SELECTIVE RETINAL GANGLION-CELLS	SCIENCE			English	Article							CHOLINERGIC AMACRINE CELLS; RABBIT RETINA; MAMMALIAN RETINA; GABA-LIKE; NEURONS; ACETYLCHOLINE; MORPHOLOGY; IMMUNOREACTIVITY; DECARBOXYLASE; RESPONSES	Optical methods were used to locate the cell bodies of directionally selective ganglion cells in isolated rabbit retinas. These neurons detect the direction in which images move across the retinal surface and transmit that information to the brain. The receptive field of each identified cell was determined, after which the cell was injected with Lucifer yellow. An image of the receptive field border was then projected onto the fluorescent image of the dendrites, allowing precise comparison between them. The size of the receptive field matched closely the size of the dendritic arbor of that cell. This result restricts the types of convergence that can be postulated in modeling the mechanism of retinal directional selectivity.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROSURG,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NEI NIH HHS [R37-EY01075] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY001075] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1981, J NEUROCHEM, V37, P867, DOI 10.1111/j.1471-4159.1981.tb04473.x; AMTHOR FR, 1989, J COMP NEUROL, V280, P97, DOI 10.1002/cne.902800108; AMTHOR FR, 1984, BRAIN RES, V298, P187, DOI 10.1016/0006-8993(84)91167-3; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; BLOOMFIELD SA, 1992, J NEUROPHYSIOL, V68, P711, DOI 10.1152/jn.1992.68.3.711; BLOOMFIELD SA, 1991, NATURE, V350, P347, DOI 10.1038/350347a0; BLOOMFIELD SA, 1992, INVEST OPHTH VIS SCI, V33, P1173; BORGGRAHAM L, 1991, SINGLE NEURON COMPUT; BRANDON C, 1987, BRAIN RES, V401, P385, DOI 10.1016/0006-8993(87)91426-0; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; FAMIGLIETTI EV, 1983, BRAIN RES, V261, P138, DOI 10.1016/0006-8993(83)91293-3; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; KOCH C, 1982, PHILOS T R SOC B, V298, P227, DOI 10.1098/rstb.1982.0084; KOSAKA T, 1988, EXP BRAIN RES, V70, P605; LEVICK WR, 1983, PROGR RETINAL RES, V2, P267; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P121, DOI 10.1098/rspb.1984.0086; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MILLER RF, 1983, P NATL ACAD SCI-BIOL, V80, P3069, DOI 10.1073/pnas.80.10.3069; OMALLEY DM, 1989, P NATL ACAD SCI USA, V86, P3414, DOI 10.1073/pnas.86.9.3414; OYSTER CW, 1968, J PHYSIOL-LONDON, V199, P613, DOI 10.1113/jphysiol.1968.sp008671; PEICHL L, 1979, J PHYSIOL-LONDON, V291, P117, DOI 10.1113/jphysiol.1979.sp012803; TAUCHI M, 1985, J NEUROSCI, V5, P2494; TAUCHI M, 1984, PROC R SOC SER B-BIO, V223, P101, DOI 10.1098/rspb.1984.0085; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; VANEY DI, 1988, BRAIN RES, V438, P369, DOI 10.1016/0006-8993(88)91366-2; VANEY DI, 1984, PROC R SOC SER B-BIO, V220, P501, DOI 10.1098/rspb.1984.0016; VANEY DI, 1989, NEUROBIOLOGY INNER R, P154; VANEY DI, 1990, PROGR RETINAL RES, V9, P1; WYATT HJ, 1975, J NEUROPHYSIOL, V38, P613, DOI 10.1152/jn.1975.38.3.613	31	75	78	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1949	1952		10.1126/science.1470920	http://dx.doi.org/10.1126/science.1470920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470920				2022-12-24	WOS:A1992KD08800036
J	CITRON, M; OLTERSDORF, T; HAASS, C; MCCONLOGUE, L; HUNG, AY; SEUBERT, P; VIGOPELFREY, C; LIEBERBURG, I; SELKOE, DJ				CITRON, M; OLTERSDORF, T; HAASS, C; MCCONLOGUE, L; HUNG, AY; SEUBERT, P; VIGOPELFREY, C; LIEBERBURG, I; SELKOE, DJ			MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION	NATURE			English	Article							IDENTIFICATION; RECEPTOR; GENE	PROGRESSIVE cerebral deposition of the 39-43-amino-acid amyloid beta-protein (Abeta) is an invariant feature of Alzheimer's disease which precedes symptoms of dementia by years or decades. The only specific molecular defects that cause Alzheimer's disease which have been identified so far are missense mutations in the gene encoding the beta-amyloid precursor protein (beta-APP) in certain families with an autosomal dominant form of the disease (familial Alzheimer's disease, or FAD)1-5. These mutations are located within or immediately flanking the Abeta region of beta-APP, but the mechanism by which they cause the pathological phenotype of early and accelerated Abeta deposition is unknown. Here we report that cultured cells which express a beta-APP complementary DNA bearing a double mutation (Lys to Asn at residue 595 plus Met to Leu at position 596) found in a Swedish FAD family5 produce approximate 6-8-fold more Abeta than cells expressing normal beta-APP. The Met 596 to Leu mutation is principally responsible for the increase. These data establish a direct link between a FAD genotype and the clinicopathological phenotype. Further, they confirm the relevance of the continuous Abeta production by cultured cells6-8 for elucidating the fundamental mechanism of Alzheimer's disease.	ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; HARVARD UNIV,SCH MED,NEUROSCI PROGRAM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	CITRON, M (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.							CHEN WJ, 1990, J BIOL CHEM, V265, P3116; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, IN PRESS J BIOL CHEM; HARLIN MCC, 1991, NATURE, V353, P844; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, IN PRESS NATURE; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	19	1556	1665	1	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					672	674		10.1038/360672a0	http://dx.doi.org/10.1038/360672a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465129				2022-12-24	WOS:A1992KD08200055
J	MOORE, K; WENDON, J; FRAZER, M; KARANI, J; WILLIAMS, R; BADR, K				MOORE, K; WENDON, J; FRAZER, M; KARANI, J; WILLIAMS, R; BADR, K			PLASMA ENDOTHELIN IMMUNOREACTIVITY IN LIVER-DISEASE AND THE HEPATORENAL-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FUNCTIONAL RENAL-FAILURE; VASCULAR-RESPONSES; CIRRHOSIS; VASOCONSTRICTOR; PROSTAGLANDIN-E2; KIDNEY; HEMODYNAMICS; EXCRETION; ASCITES; SODIUM	Background. Severe renal vasoconstriction is central to the pathogenesis of renal failure in the hepatorenal syndrome. Endothelin-1 and endothelin-3 are potent, long-acting vasoconstrictors, and endothelin-1 has selective potency as a renal vasoconstrictor. These properties suggest a role tor endothelins in the hepatorenal syndrome. Methods. We measured plasma endothelin-1 and endothelin-3 concentrations using specific radioimmunoassays in subjects with the hepatorenal syndrome, liver disease but normal renal function, chronic renal failure, acute renal failure, liver dysfunction and renal impairment, or normal liver and kidney function. Results. The patients with the hepatorenal syndrome had markedly elevated mean (+/-SE) plasma concentrations of endothelin-1 (36+/-5 ng per liter [14.5+/-1.8 pmol per liter]) and endothelin-3 (43+/-3 ng per liter [16.3+/-1.0 pmol per liter]) as compared with the normal subjects (endothelin-1, 4+/-1 ng per liter [1.7+/-0.2 pmol per liter]; and endothelin-3, 18+/-1 ng per liter [6.8+/-0.4 pmol per liter]; P<0.001) and with the patients in the other four groups (P<0.001 to P<0.05). The plasma endothelin-1, but not endothelin-3, concentrations in these four patient groups were significantly higher than in the normal subjects (P<0.001 to P<0.05). The concentrations of endothelin-1 in renal arterial plasma and renal venous plasma, measured in five patients with the hepatorenal syndrome and three with chronic liver disease and normal renal function, were 20+/-4 ng per liter (7.9+/-1.8 pmol per liter) and 24+/-4 ng per liter (9.5+/-1.5 pmol per liter), respectively (P<0.05). Conclusions. The increase in plasma endothelin-1 and endothelin-3 concentrations in patients with the hepatorenal syndrome is consistent with the hypothesis that these substances have a role in the pathogenesis of the disease.	UNIV LONDON KINGS COLL, SCH MED & DENT, INST LIVER STUDIES, LONDON WC2R 2LS, ENGLAND; VANDERBILT UNIV, DIV NEPHROL, NASHVILLE, TN 37240 USA; VANDERBILT UNIV, CTR KIDNEY & UROL DIS, NASHVILLE, TN 37240 USA	University of London; King's College London; Vanderbilt University; Vanderbilt University	MOORE, K (corresponding author), ROYAL POSTGRAD MED SCH, DEPT CLIN PHARMACOL, DU CANE RD, LONDON W12 0NN, ENGLAND.			opoku, anita/0000-0001-7243-8157				ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; CLARKE JG, 1989, AM J PHYSIOL, V257, pH2033, DOI 10.1152/ajpheart.1989.257.6.H2033; EMORI T, 1991, BIOCHEM BIOPH RES CO, V174, P228, DOI 10.1016/0006-291X(91)90510-E; EPSTEIN M, 1987, HEPATOLOGY, V7, P1359, DOI 10.1002/hep.1840070629; EPSTEIN M, 1970, AM J MED, V49, P175, DOI 10.1016/S0002-9343(70)80073-0; FERNANDEZSEARA J, 1989, GASTROENTEROLOGY, V97, P1304, DOI 10.1016/0016-5085(89)91704-6; HEMSEN A, 1991, ACTA PHYSIOL SCAND, V142, P1; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; KAUFMANN H, 1991, LANCET, V338, P1542, DOI 10.1016/0140-6736(91)92370-H; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; MOORE K, 1991, GASTROENTEROLOGY, V100, P1069, DOI 10.1016/0016-5085(91)90284-R; MOORE KP, 1990, J HEPATOL, V11, P263, DOI 10.1016/0168-8278(90)90123-9; MOREAU R, 1989, GASTROEN CLIN BIOL, V13, P978; MUNGER KA, 1991, CONT ISSUES NEPHROL, V23, P297; PERNOW J, 1990, ACTA PHYSIOL SCAND, V140, P311, DOI 10.1111/j.1748-1716.1990.tb09005.x; PERNOW J, 1988, ACTA PHYSIOL SCAND, V134, P573, DOI 10.1111/j.1365-201X.1988.tb10642.x; RIMOLA A, 1986, J HEPATOL, V3, P111, DOI 10.1016/S0168-8278(86)80154-4; RINGLARSEN H, 1977, SCAND J CLIN LAB INV, V37, P635, DOI 10.3109/00365517709100657; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; TOMITA K, 1989, NEW ENGL J MED, V321, P1127; WILKINSON SP, 1978, KIDNEY LIVER DISEASE, P113; ZIPSER RD, 1983, GASTROENTEROLOGY, V84, P697	26	319	325	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1774	1778		10.1056/NEJM199212173272502	http://dx.doi.org/10.1056/NEJM199212173272502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1435931				2022-12-24	WOS:A1992KB97500002
J	HERD, RM; HUNTER, JAA; MCLAREN, KM; CHETTY, U; WATSON, ACH; GOLLOCK, JM				HERD, RM; HUNTER, JAA; MCLAREN, KM; CHETTY, U; WATSON, ACH; GOLLOCK, JM			EXCISION BIOPSY OF MALIGNANT-MELANOMA BY GENERAL-PRACTITIONERS IN SOUTH EAST SCOTLAND 1982-91	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To examine the management of patients who had a malignant melanoma excised initially by general practitioners in south east Scotland over the past 10 years and to assess the impact of the April 1990 contract on this. Design-A retrospective case-control study. Setting-South east Scotland. Subjects-All patients in south east Scotland who had malignant melanomas excised by general practitioners in 1982-91. Outcome measures-Demographic details of patients; Breslow thickness, clearance of excision. Results-42 patients had malignant melanomas excised by general practitioners in 1982-91: 15 in 1982-9 and 27 in 1990-1. These patients were significantly younger than those who had their tumours excised initially in hospital. Although the longest diameter of melanomas excised by general practitioners was significantly less than of those excised in hospital, the Breslow thicknesses were similar. Completeness of initial excision was doubtful or incomplete in nine (23%) general practitioner excisions compared with 4/o of hospital excisions, but the time interval between excision biopsy and wide excision was similar. Pathology requests accompanying excision biopsies mentioned melanoma as a possible diagnosis in 15% (6/40) of general practitioner cases compared with 79% of hospital cases. Thirty nine general practitioners responded to a questionnaire and only 12 had considered melanoma in the differential diagnosis. Conclusions-General practitioners need to think more often of malignant melanoma when they excise pigmented lesions and when they consider this tumour a possibility should perform an excision biopsy with a lateral clearance of at least 2 mm.	UNIV EDINBURGH, ROYAL INFIRM, DEPT PATHOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, DEPT SURG, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; ST JOHNS HOSP, PLAST SURG UNIT, Livingston, ENGLAND; BORDERS GEN HOSP, DEPT SURG, BORDERS, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	HERD, RM (corresponding author), UNIV EDINBURGH, ROYAL INFIRM, DEPT DERMATOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							BAGLEY FH, 1981, CANCER-AM CANCER SOC, V47, P2126, DOI 10.1002/1097-0142(19810501)47:9<2126::AID-CNCR2820470904>3.0.CO;2-C; BRAZIER JE, 1991, BRIT MED J, V303, P1472, DOI 10.1136/bmj.303.6815.1472-a; COX NH, 1992, BMJ-BRIT MED J, V304, P1177; ELLWOOD JM, 1988, PIGMENT CELL, V9, P118; HILLAN KJ, 1991, BRIT MED J, V303, P1180, DOI 10.1136/bmj.303.6811.1180; LANDTHALER M, 1989, CANCER-AM CANCER SOC, V64, P1612, DOI 10.1002/1097-0142(19891015)64:8<1612::AID-CNCR2820640810>3.0.CO;2-7; LEDERMAN JS, 1985, J AM ACAD DERMATOL, V13, P983, DOI 10.1016/S0190-9622(85)70249-6; Mackie R. M., 1989, MALIGNANT MELANOMA G; MCWILLIAM LJ, 1991, BRIT MED J, V303, P1177, DOI 10.1136/bmj.303.6811.1177; Pitcher R., 1991, BR J DERMATOL S38, V125, P93; RAMPEN FHJ, 1984, BRIT J DERMATOL, V111, P431, DOI 10.1111/j.1365-2133.1984.tb06605.x; SHRANK AB, 1991, BRIT J DERMATOL, V125, P599, DOI 10.1111/j.1365-2133.1991.tb14804.x; URIST MM, 1985, CUTANEOUS MELANOMA C, P71; WHIMSTER WF, 1991, BRIT MED J, V303, P1149, DOI 10.1136/bmj.303.6811.1149; WILLIAMS RB, 1991, BRIT MED J, V303, P1179, DOI 10.1136/bmj.303.6811.1179; 1989, GENERAL PRACTICE NAT	16	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1992	305	6867					1476	1478		10.1136/bmj.305.6867.1476	http://dx.doi.org/10.1136/bmj.305.6867.1476			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493395	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992KC91800025
J	ARONDEL, V; LEMIEUX, B; HWANG, I; GIBSON, S; GOODMAN, HM; SOMERVILLE, CR				ARONDEL, V; LEMIEUX, B; HWANG, I; GIBSON, S; GOODMAN, HM; SOMERVILLE, CR			MAP-BASED CLONING OF A GENE CONTROLLING OMEGA-3-FATTY-ACID DESATURATION IN ARABIDOPSIS	SCIENCE			English	Article							POLYMORPHISM LINKAGE MAP; THALIANA; DNA; METABOLISM; MUTANTS; PLASMID; PLANTS	A gene from the flowering plant Arabidopsis thaliana that encodes an omega-3 desaturase was cloned on the basis of the genetic map position of a mutation affecting membrane and storage lipid fatty acid composition. Yeast artificial chromosomes covering the genetic locus were identified and used to probe a seed complementary DNA library. A complementary DNA clone for the desaturase was identified and introduced into roots of both wild-type and mutant plants by Ti plasmid-mediated transformation. Transgenic tissues of both mutant and wild-type plants had significantly increased amounts of the fatty acid produced by this desaturase.	MICHIGAN STATE UNIV, US DOE, PLANT RES LAB, E LANSING, MI 48824 USA; YORK UNIV, DEPT BIOL, N YORK M3J 1P3, ONTARIO, CANADA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Michigan State University; United States Department of Energy (DOE); York University - Canada; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094				BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BROWSE J, COMMUNICATION; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; MARTINEZZAPATER J, UNPUB; MOORE L, 1979, PLASMID, V2, P617, DOI 10.1016/0147-619X(79)90059-3; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NIYOGI KK, 1992, PLANT CELL, V4, P721, DOI 10.1105/tpc.4.6.721; OWENS LD, 1985, PLANT PHYSIOL, V77, P87, DOI 10.1104/pp.77.1.87; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; QUINN PJ, 1988, SYM SOC EXP BIOL, V42, P237; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; STEPONKUS PL, 1990, PHILOS T ROY SOC B, V326, P571, DOI 10.1098/rstb.1990.0032; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501	24	386	470	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1353	1355		10.1126/science.1455229	http://dx.doi.org/10.1126/science.1455229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455229				2022-12-24	WOS:A1992JY95800037
J	SMITH, SB; FINZI, L; BUSTAMANTE, C				SMITH, SB; FINZI, L; BUSTAMANTE, C			DIRECT MECHANICAL MEASUREMENTS OF THE ELASTICITY OF SINGLE DNA-MOLECULES BY USING MAGNETIC BEADS	SCIENCE			English	Article							GEL-ELECTROPHORESIS; FLUORESCENCE MICROSCOPY; MANIPULATION; FLEXIBILITY; DYNAMICS; BINDING; DAPI	Single DNA molecules were chemically attached by one end to a glass surface and by their other end to a magnetic bead. Equilibrium positions of the beads were observed in an optical microscope while the beads were acted on by known magnetic and hydrodynamic forces. Extension versus force curves were obtained for individual DNA molecules at three different salt concentrations with forces between 10(-14) and 10(-11) newtons. Deviations from the force curves predicted by the freely jointed chain model suggest that DNA has significant local curvature in solution. Ethidium bromide and 4',6-diamidino-2-phenylindole had little effect on the elastic response of the molecules, but their extent of intercalation was directly measured. Conversely, the effect of bend-inducing cis-diamminedichloroplatinum (II) was large and supports the hypothesis of natural curvature in DNA.	UNIV OREGON,INST MICROBIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERMAN B, 1989, BIOPOLYMERS, V28, P1541, DOI 10.1002/bip.360280906; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BUECHE F, 1962, PHYSICAL PROPERTIES, P37; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.bb.20.060191.002215; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P557; CASSASA EF, 1967, POLYM LETT, V5, P773; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DIMARZIO EA, 1965, J CHEM PHYS, V42, P2101, DOI 10.1063/1.1696251; Flory P, 1989, STATISTICAL MECHANIC, P307; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; Johnson N.P., 1989, PROG CLIN BIOCH MED, V10, P1, DOI [DOI 10.1007/978-3-642-74760-1, 10.1007/978-3-642-74760-1_1, DOI 10.1007/978-3-642-74760-1_1]; KASEVICH M, 1990, 12TH P INT C AT PHYS, P53; Lorentz H. A., 1907, ABHANDLUNGEN THEORET, P23; MACQUET JP, 1978, BIOCHIMIE, V60, P901, DOI 10.1016/S0300-9084(78)80574-4; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOBEL ES, 1991, BIOPOLYMERS, V31, P1559, DOI 10.1002/bip.360311311; STIGTER D, 1991, BIOPOLYMERS, V31, P169, DOI 10.1002/bip.360310205; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; VOLLENWEIDER HJ, 1978, BIOCHEMISTRY-US, V75, P710; WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0; ZIMM BH, IN PRESS Q REV BIOPH	28	1478	1647	9	350	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1122	1126		10.1126/science.1439819	http://dx.doi.org/10.1126/science.1439819			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439819				2022-12-24	WOS:A1992JX85200022
J	DAYSON, D; GOOCH, C; THORNICROFT, G				DAYSON, D; GOOCH, C; THORNICROFT, G			THE TAPS PROJECT .16. DIFFICULT TO PLACE, LONG-TERM PSYCHIATRIC-PATIENTS - RISK-FACTORS FOR FAILURE TO RESETTLE LONG STAY PATIENTS IN COMMUNITY FACILITIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To identify patients who could not be resettled in the community as part of the closure plans of two psychiatric hospitals and to determine their numbers and risk factors for failure. Design and setting-Prospective study of the closure of Friern and Claybury psychiatric hospitals. Patients-The first third (369) of long stay psychiatric patients to be resettled. Outcome measures-Reasons for patients being readmitted to hospital and not leaving the patients' service needs. Results-22-6% of both hospitals' long stay patients-were not successfully resettled in the community. Eighteen continuing care places per 100 000 of catchment area population seem to be required for this group. Patients whose placements were unsuccessful were usually readmitted because of a deterioration of their mental state and aggressive behavior, both of which persisted and necessitated their continuing stay in hospital, often in a locked ward. Risk factors associated with failure were a high level of psychosis; a diagnosis of paranoid psychosis; incontinence; and being male. But having a social network, especially a large one, seemed to aid successful placement in the community. Conclusion-Rehabilitation efforts should be focused on the characteristics of these patients that put them at risk of failing to succeed in community placements.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	DAYSON, D (corresponding author), FRIERN HOSP,TAPS RES UNIT,LONDON N11 3BP,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ANDERSON J, IN PRESS BR J PSYCHI; CHRISTIEBROWN JRW, 1977, PSYCHOL MED, V7, P113; COID JW, 1991, BRIT MED J, V302, P603, DOI 10.1136/bmj.302.6777.603; DAYSON D, IN PRESS BR J PSYCHI; DUNN M, 1990, BRIT J PSYCHIAT, V157, P842, DOI 10.1192/bjp.157.6.842; HERXHEIMER A, 1991, DRUG THERAPEUTIC B, V29, P41; KENDELL RE, 1989, BRIT MED J, V299, P1237, DOI 10.1136/bmj.299.6710.1237; LEFF J, 1990, BRIT J PSYCHIAT, V157, P848, DOI 10.1192/bjp.157.6.848; STURT E, 1986, BRIT J PSYCHIAT, V148, P1; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; THORNICROFT G, IN PRESS TAPS PROJEC; WING JK, 1990, BRIT J PSYCHIAT, V157, P822, DOI 10.1192/bjp.157.6.822; Wing JK, 1974, DESCRIPTION CLASSIFI; 1992, HLTH NATION; 1991, HLTH NATION	15	26	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					993	995		10.1136/bmj.305.6860.993	http://dx.doi.org/10.1136/bmj.305.6860.993			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458147	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JV77600027
J	SHELDRICK, JH; VERNON, SA; WILSON, A; READ, SJ				SHELDRICK, JH; VERNON, SA; WILSON, A; READ, SJ			DEMAND INCIDENCE AND EPISODE RATES OF OPHTHALMIC DISEASE IN A DEFINED URBAN-POPULATION	BRITISH MEDICAL JOURNAL			English	Article							EYE DISEASE; OUTPATIENT; COMMUNITY; CASUALTY	Objectives-To estimate demand incidence and episode rates of ophthalmic disease in a defined urban population over one year. Design-Study of patients presenting with eye problems to general practice and eye casualty department. Setting-General practice and ophthalmic services in west Nottingham. Subjects-36018 people from the combined practice lists of 17 Nottingham general practitioners. Main outcome measures-Ophthalmic disorder, age and sex of patient, and where presented. Results-2587 consultations were recorded for ophthalmic problems, 1771 with general practitioners and 816 with eye casualty. Most consultations to general practice were by females (1066 (60%)), whereas men aged 15-44 accounted for most work in eye casualty. These men commonly presented with trauma. Infective conjunctivitis, the commonest condition, had an episode rate of 13.5/1000 population/year. Demand incidence for cataracts was 1.9/1000 population/year. Demand incidence for chronic conditions increased with age. Conclusions-As the average age of the population increases demand for ophthalmic services will rise. Planning and provision of resources to meet this increased demand should be considered now.	UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2RD,ENGLAND; UNIV NOTTINGHAM,ACAD UNIT OPHTHALMOL,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham; University of Nottingham								BANKES JLK, 1968, BRIT MED J, V1, P791, DOI 10.1136/bmj.1.5595.791; BRENNANME, 1975, COMMUNITY HLTH, V7, P13; Brittain G P, 1988, Health Trends, V20, P43; DART JKG, 1986, BRIT MED J, V293, P1477, DOI 10.1136/bmj.293.6560.1477; DUKEELDER S, 1965, SYSTEM OPHTHALMOLOGY, V8, P444; EDWARDS RS, 1987, BRIT J OPHTHALMOL, V71, P938, DOI 10.1136/bjo.71.12.938; Fraser R C, 1981, J R Coll Gen Pract, V31, P410; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; Hughes A. M., 1976, MINISTRY AGR FISHERI, V9; JAY JL, 1990, EYE, V4, P127, DOI 10.1038/eye.1990.16; JONES NP, 1986, BRIT MED J, V292, P188, DOI 10.1136/bmj.292.6514.188; KHAN HA, 1977, AM J EPIDEMIOL, V106, P17; MORRELL DC, 1971, BRIT MED J, V2, P454, DOI 10.1136/bmj.2.5759.454; PAGECHIAPELLA A, 1985, BR J OPHTHALMOL, V69, P865; PODOGOR MJ, 1983, AM J EPIDEMIOL, V118, P206; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; PORT MJA, 1988, OPHTHAL PHYSL OPT, V8, P323, DOI 10.1016/0275-5408(88)90182-2; SHAW DE, 1986, ARCH OPHTHALMOL-CHIC, V104, P1843; SHELDRICK JH, 1992, BRIT MED J, V304, P1096, DOI 10.1136/bmj.304.6834.1096; VERNON SA, 1983, J ROY SOC MED, V76, P279, DOI 10.1177/014107688307600408; WARDEN J, 1990, BMJ, V300, P1990; 1962, MORBIDITY STATISTICS; 1974, MORBIDITY STATISTICS; 1986, MORBIDITY STATISTICS; 1991, GLOBAL POPULATION ES, P364	26	30	33	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1992	305	6859					933	936		10.1136/bmj.305.6859.933	http://dx.doi.org/10.1136/bmj.305.6859.933			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU649	1458075	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JU64900024
J	AMATI, B; DALTON, S; BROOKS, MW; LITTLEWOOD, TD; EVAN, GI; LAND, H				AMATI, B; DALTON, S; BROOKS, MW; LITTLEWOOD, TD; EVAN, GI; LAND, H			TRANSCRIPTIONAL ACTIVATION BY THE HUMAN C-MYC ONCOPROTEIN IN YEAST REQUIRES INTERACTION WITH MAX	NATURE			English	Article							DNA-BINDING; PROTEIN; GENE; FOS; SEQUENCE; JUN; TRANSFORMATION; CEREVISIAE; ZIPPER; COMMON	THE c-myc protein (Myc) contains an amino-terminal transcriptional activation domain1 and a carboxy-terminal basic helix-loop-helix-leucine zipper (bHLH-Z) domain 2-5 that directs dimerization of Myc with its partner, the max protein (Max), and promotes DNA binding to sites containing a CACGTG core consensus sequence6-9. Despite these characteristics and the observation that Myc can modulate gene expression4,5,10, a direct role for Myc or Max as transcription factors has never been demonstrated. Here we use Saccharomyces cerevisiae as an in vivo model system to show that the Myc protein is a sequence-specific transcriptional activator whose DNA binding is strictly dependent on dimerization with Max. Transactivation is mediated by the amino-terminal domain of Myc. We find that Max homodimers bind to the same DNA sequence as Myc + Max but that they fail to transactivate and thus can antagonize Myc + Max function. We also show that the Max HLH-Z domain has a higher affinity for the Myc HLH-Z domain than for itself, and suggest that the heterodimeric Myc + Max activator forms preferentially at equilibrium.	IMPERIAL CANC RES FUND,GROWTH CONTROL & DEV LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,TRANSCRIPTION LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK; Cancer Research UK			Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER F, 1991, ONCOGENE, V6, P1099; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMITH M, 1979, CELL, V16, P753, DOI 10.1016/0092-8674(79)90091-6; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4277	31	424	431	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					423	426		10.1038/359423a0	http://dx.doi.org/10.1038/359423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406955				2022-12-24	WOS:A1992JQ62400059
J	SCHINDLER, C; SHUAI, K; PREZIOSO, VR; DARNELL, JE				SCHINDLER, C; SHUAI, K; PREZIOSO, VR; DARNELL, JE			INTERFERON-DEPENDENT TYROSINE PHOSPHORYLATION OF A LATENT CYTOPLASMIC TRANSCRIPTION FACTOR	SCIENCE			English	Article							HUMAN LYMPHOCYTES-T; PROTEIN-KINASE; ALPHA-INTERFERON; GAMMA-INTERFERON; CYCLIC-AMP; RECEPTOR; GENE; EXPRESSION; CELLS; ISGF3	The interferon-alpha (IFN-alpha)-stimulated gene factor 3 (ISGF3), a transcriptional activator, contains three proteins, termed ISGF3-alpha-proteins,that reside in the cell cytoplasm until they are activated in response to IFN-alpha. Treatment of cells with IFN-alpha caused these three proteins to be phosphorylated on tyrosine and to translocate to the cell nucleus where they stimulate transcription through binding to IFN-alpha-stimulated response elements in DNA. IFN-gamma, which activates transcription through a different receptor and different DNA binding sites, also caused tyrosine phosphorylation of one of these proteins. The ISGF3-alpha-proteins may be substrates for one or more kinases activated by ligand binding to the cell surface and may link occupation of a specific polypeptide receptor with activation of transcription of a set of specific genes.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NIAID NIH HHS [AI32489] Funding Source: Medline; NIGMS NIH HHS [GM07982-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Bourne H.D., 1990, ONCOGENES MOL ORIGIN, P97; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, IN PRESS P NATL ACAD; Gill G., 1990, ONCOGENES MOL ORIGIN, P67; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNY JR, 1991, J IMMUNOCHEM, V5, P1; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Hunter T., 1990, ONCOGENES MOL ORIGIN, P142; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHINDLER C, IN PRESS P NATL ACAD; SCHINDLER C, UNPUB; SHUAI K, UNPUB; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS S, IN PRESS MOL CELL BI; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897	35	792	820	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					809	813		10.1126/science.1496401	http://dx.doi.org/10.1126/science.1496401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496401				2022-12-24	WOS:A1992JG85100039
J	RASMUSSEN, BF; STOCK, AM; RINGE, D; PETSKO, GA				RASMUSSEN, BF; STOCK, AM; RINGE, D; PETSKO, GA			CRYSTALLINE RIBONUCLEASE-A LOSES FUNCTION BELOW THE DYNAMIC TRANSITION AT 220-K	NATURE			English	Article							TEMPERATURE-DEPENDENCE; NEUTRON-SCATTERING; MYOGLOBIN	WHEN the dynamic properties of many different proteins are plotted as a function of temperature, biphasic behaviour is observed, with a broad transition centred around 220 K. Atomic mean-square displacements from X-ray crystallography 1 and Mossbauer scattering 2-3 show this behaviour, as do electron transfer rates 4 and dynamic information from inelastic neutron scattering 5. Molecular dynamics simulations over a range of temperatures also exhibit a transition at about 220 K: high-temperature atomic fluctuations are dominated by anharmonic collective motions of bonded and nonbonded groups of atoms, but below 220 K the predominant dynamic behaviour is harmonic vibration of individual atoms 6. Here we show by high-resolution X-ray diffraction that crystalline ribonuclease A does not bind substrate or inhibitor at 212 K but will bind either rapidly at 228 K. Once bound at the higher temperature, inhibitor cannot be washed off after the enzyme is cooled to below the transition temperature. These results suggest that enzyme flexibility is required for catalytic function.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University	RASMUSSEN, BF (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,STRUCT BIOL LAB,WALTHAM,MA 02254, USA.		Petsko, Gregory/AAO-7962-2020					CARLISLE CH, 1974, J MOL BIOL, V85, P1, DOI 10.1016/0022-2836(74)90125-9; DOSTER W, 1986, BIOPHYS J, V50, P213, DOI 10.1016/S0006-3495(86)83455-5; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Douzou P, 1977, CRYOBIOCHEMISTRY; FINK AL, 1987, BIOCHEMISTRY-US, V26, P8571, DOI 10.1021/bi00400a012; GILBERT WA, 1982, J RAMAN SPECTROSC, V12, P173, DOI 10.1002/jrs.1250120217; HOWLIN B, 1987, J MOL BIOL, V196, P159, DOI 10.1016/0022-2836(87)90518-3; KARTHA G, 1973, SCIENCE, V179, P495, DOI 10.1126/science.179.4072.495; KELLER H, 1980, PHYS REV LETT, V45, P68, DOI 10.1103/PhysRevLett.45.68; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; PARAK F, 1980, FEBS LETT, V117, P368, DOI 10.1016/0014-5793(80)80982-3; PETSKO GA, 1985, METHOD ENZYMOL, V114, P141; RASMUSSEN BF, UNPUB J APPL CRYSTAL; RICHARDS FM, 1971, ENZYMES, V4, P647; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006	17	507	511	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					423	424		10.1038/357423a0	http://dx.doi.org/10.1038/357423a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1463484				2022-12-24	WOS:A1992HX17200070
J	BULTMAN, SJ; MICHAUD, EJ; WOYCHIK, RP				BULTMAN, SJ; MICHAUD, EJ; WOYCHIK, RP			MOLECULAR CHARACTERIZATION OF THE MOUSE AGOUTI LOCUS	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LIMB DEFORMITY; SEQUENCE-ANALYSIS; GENE; RECOMBINATION; MUTATIONS; MICE; ORGANIZATION; TRANSCRIPTS; CLEAVAGE	The agouti (a) locus acts within the microenvironment of the hair follicle to regulate coat color pigmentation in the mouse. We have characterized a gene encoding a novel 131 amino acid protein that we propose is the one gene associated with the agouti locus. This gene is normally expressed in a manner consistent with a locus function, and, more importantly, its structure and expression are affected by a number of representative alleles in the agouti dominance hierarchy. In addition, we found that the pleiotropic effects associated with the lethal yellow (A(y)) mutation, which include pronounced obesity, diabetes, and the development of neoplasms, are accompanied by deregulated overexpression of the agouti gene in numerous tissues of the adult animal.	UNIV TENNESSEE,SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	BULTMAN, SJ (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732	NIEHS NIH HHS [IAG 222Y01-ES-10067] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R13ES010067] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BULTMAN SJ, 1991, P NATL ACAD SCI USA, V88, P8062, DOI 10.1073/pnas.88.18.8062; CALARCO PG, 1976, J EMBRYOL EXP MORPH, V35, P73; CARPENTER KJ, 1958, AM J PHYSIOL, V193, P499, DOI 10.1152/ajplegacy.1958.193.3.499; Castle WE, 1910, SCIENCE, V32, P868, DOI 10.1126/science.32.833.868; Cuenot L., 1905, ARCH ZOOL EXP GEN, V3, P123; DERINGER MK, 1970, J NATL CANCER I, V45, P1205; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; Dunn LC, 1928, P NATL ACAD SCI USA, V14, P816, DOI 10.1073/pnas.14.10.816; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EATON GJ, 1963, GENETICA, V34, P155, DOI 10.1007/BF01664187; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENTON PF, 1951, P SOC EXP BIOL MED, V77, P420, DOI 10.3181/00379727-77-18800; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GRANHOLM NH, 1986, J REPROD FERTIL, V76, P279, DOI 10.1530/jrf.0.0760279; Green M. C., 1989, GENETIC VARIANTS STR, P17; HELLERSTROM C, 1963, METABOLISM, V12, P527; HESTON WE, 1961, J NATL CANCER I, V26, P969; Heston WE, 1942, J NATL CANCER I, V3, P303; HESTON WE, 1962, J NATL CANCER I, V29, P197; HESTON WE, 1947, J NATL CANCER I, V7, P463; HESTON WE, 1963, J NATL CANCER I, V31, P189; HOLLANDER W. F., 1956, JOUR HEREDITY, V47, P221; KOBORI JA, 1986, SCIENCE, V234, P173, DOI 10.1126/science.3018929; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBO RV, 1983, P NATL ACAD SCI-BIOL, V80, P4808, DOI 10.1073/pnas.80.15.4808; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PAPAIOANNOU V, 1979, J EMBRYOL EXP MORPH, V52, P153; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; Robertson GG, 1942, J EXP ZOOL, V89, P197, DOI 10.1002/jez.1400890203; RUSSELL LB, 1963, GENETICS, V48, P907; SAKURAI T, 1975, DEV BIOL, V47, P466, DOI 10.1016/0012-1606(75)90301-2; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1961, SCIENCE, V134, P368, DOI 10.1126/science.134.3476.368; SILVERS WK, 1958, J EXP ZOOL, V137, P189, DOI 10.1002/jez.1401370110; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SILVERS WK, 1958, J EXP ZOOL, V137, P181, DOI 10.1002/jez.1401370109; SIRACUSA LD, 1987, GENETICS, V117, P93; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEUCHI T, 1989, Journal of Investigative Dermatology, V92, p239S, DOI 10.1111/1523-1747.ep13075730; TRECO D, 1985, MOL CELL BIOL, V5, P2029, DOI 10.1128/MCB.5.8.2029; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; WOYCHIK RP, 1990, P NATL ACAD SCI USA, V87, P2588, DOI 10.1073/pnas.87.7.2588; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0	65	673	711	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1195	1204		10.1016/S0092-8674(05)80067-4	http://dx.doi.org/10.1016/S0092-8674(05)80067-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473152				2022-12-24	WOS:A1992KE60400013
J	SHERMAN, DR; GUINN, B; PERDOK, MM; GOLDBERG, DE				SHERMAN, DR; GUINN, B; PERDOK, MM; GOLDBERG, DE			COMPONENTS OF STEROL BIOSYNTHESIS ASSEMBLED ON THE OXYGEN-AVID HEMOGLOBIN OF ASCARIS	SCIENCE			English	Article							SQUALENE EPOXIDASE; RAT-LIVER	The parasitic nematode Ascaris infests a billion people worldwide. Much of its proliferative success is due to prodigious egg production, up to 10(6) sterol-replete eggs per day. Sterol synthesis requires molecular oxygen for squalene epoxidation, yet oxygen is scarce in the intestinal folds the worms inhabit. Ascaris has an oxygen-avid hemoglobin in the perienteric fluid that bathes its reproductive organs. Purified hemoglobin contained tightly bound squalene and functioned as an NADPH-dependent, ferrihemoprotein reductase. All components of the squalene epoxidation reaction-squalene, oxygen, NADPH, and NADPH-dependent reductase-are assembled on the hemoglobin. This molecule may thus function in sterol biosynthesis.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCRR NIH HHS [RR-00954] Funding Source: Medline; NIADDK NIH HHS [AM-20579] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020579] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barrett J., 1981, BIOCH PARASITIC HELM; BRYANT C, 1978, ADV PARASIT, V16, P3111; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHEAH KS, 1975, BIOCHIM BIOPHYS ACTA, V387, P107, DOI 10.1016/0005-2728(75)90055-9; CROMPTON DWT, 1986, T ROY SOC TROP MED H, V80, P697, DOI 10.1016/0035-9203(86)90368-8; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; Dresselhaus M., 1974, Getreide, Mehl und Brot, V28, P137; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; HAMADA K, 1963, J BIOCHEM-TOKYO, V53, P484, DOI 10.1093/oxfordjournals.jbchem.a127727; HAMADA K, 1962, J BIOCHEM-TOKYO, V52, P290, DOI 10.1093/oxfordjournals.jbchem.a127616; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; LEE DL, 1965, EXP PARASITOL, V16, P392, DOI 10.1016/0014-4894(65)90062-7; MBAYA B, 1987, BIOCHEM BIOPH RES CO, V147, P556, DOI 10.1016/0006-291X(87)90967-3; OKAZAKI T, 1967, BIOCHIM BIOPHYS ACTA, V140, P258, DOI 10.1016/0005-2795(67)90466-7; ONO T, 1985, METHOD ENZYMOL, V110, P375; PAWLOWSKI ZS, 1982, REV INFECT DIS, V4, P806; SHERMAN DH, UNPUB; SMITH MH, 1963, PROC R SOC SER B-BIO, V157, P234, DOI 10.1098/rspb.1963.0007; STEPHENSON LS, 1980, PARASITOLOGY, V81, P221, DOI 10.1017/S0031182000055177; WARREN K, 1988, BIOL PARASITISM; Warren K, 1989, TROPICAL GEOGRAPHICA; WEBER RE, 1980, AM ZOOL, V20, P79; WITTENBE.BA, 1965, BIOCHIM BIOPHYS ACTA, V111, P485, DOI 10.1016/0304-4165(65)90058-9; YAMAMOTO S, 1970, J BIOL CHEM, V245, P1670	25	23	24	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1930	1932		10.1126/science.1470914	http://dx.doi.org/10.1126/science.1470914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470914				2022-12-24	WOS:A1992KD08800029
J	BRUZIK, JP; MANIATIS, T				BRUZIK, JP; MANIATIS, T			SPLICED LEADER RNAS FROM LOWER EUKARYOTES ARE TRANSSPLICED IN MAMMALIAN-CELLS	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PRE-MESSENGER-RNA; 2'-OME RNA; C-ELEGANS; INVITRO; SEQUENCES; U2; OLIGONUCLEOTIDES; IDENTIFICATION; PRECURSORS	EXON sequences present on separate RNA molecules can be joined by trans-splicing in trypanosomatids, Euglena, and in the nematode and trematode worms1-3. Trans-splicing involves an interaction between a 5' splice site present in a spliced leader RNA and a 3' splice site located near the 5' end of pre-messenger RNAs. In vitro trans-splicing of artificial mammalian pre-mRNAs has been reported, but the efficiency of splicing appears to depend on sequence complementarity between the two substrates4-7. There has been speculation that some natural pre-mRNAs can be trans-spliced in mammalian cells in vivo8,9, but alternative interpretations have not been ruled out. Here we show that spliced leader RNAs can be accurately trans-spliced in mammalian cells in vivo and in vitro. Both nematode and mammalian 3' splice sites can function as acceptors for trans-splicing in vivo. These results reveal functional conservation in the splicing machinery between lower eukaryotes and mammals, and they directly demonstrate the potential for trans-splicing in mammalian cells.			BRUZIK, JP (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; Huang X Y, 1992, Genet Eng (N Y), V14, P211; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SHARP PA, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90753-1; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	36	66	84	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					692	695		10.1038/360692a0	http://dx.doi.org/10.1038/360692a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465136				2022-12-24	WOS:A1992KD08200063
J	SLOAN, S; RADEMAKER, AW; KAHRILAS, PJ				SLOAN, S; RADEMAKER, AW; KAHRILAS, PJ			DETERMINANTS OF GASTROESOPHAGEAL JUNCTION INCOMPETENCE - HIATAL-HERNIA, LOWER ESOPHAGEAL SPHINCTER, OR BOTH	ANNALS OF INTERNAL MEDICINE			English	Article						ESOPHAGOGASTRIC JUNCTION; HERNIA, HIATAL; GASTROESOPHAGEAL REFLUX; MANOMETRY; FLUOROSCOPY	REFLUX ESOPHAGITIS; PRESSURE; MECHANISMS; DIAPHRAGM; SMOKING	Objective: To examine the effects of hiatal hernia and lower esophageal sphincter (LES) pressure on the competence of the gastroesophageal junction under conditions of abrupt increases in intra-abdominal pressure. Design: Acute experiments. Setting: University-hospital-based gastroenterology practice. Participants: Sixteen asymptomatic volunteers and 34 patients with endoscopic findings suggestive of hiatal hernia. Intervention: A series of eight provocative maneuvers entailing abrupt changes in intra-abdominal pressure. Measurements: Five radiographic measurements relevant to the presence and extent of hiatal hernia were made from videotaped barium-swallow examinations. Lower esophageal sphincter pressure was measured immediately before each maneuver. The percentage of maneuvers that resulted in gastroesophageal reflux was calculated as the reflux score. A stepwise regression analysis was then used to model the relation between measured variables of the gastroesophageal junction (manometric and radiographic) with reflux score. Results: Patients with hiatal hernia had substantially higher reflux scores and lower LES pressures than either patients without hernias or volunteers. In diminishing order of significance, the terms in the model of susceptibility to reflux were axial length of hernia measured between swallows; LES pressure; and an interaction term in which a progressive increase occurred in the risk for reflux associated with a hypotensive lower esophageal sphincter as hernia size increased. Conclusions: Gastroesophageal junction competence during abrupt increases in intra-abdominal pressure is compromised by both hiatal hernia and low LES pressure. These factors interact with each other to determine susceptibility to reflux.	NORTHWESTERN UNIV, SCH MED,DEPT MED,SUITE 1526,WESLEY TOWERS, 250 E SUPER ST, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000669] Funding Source: NIH RePORTER; NIDCD NIH HHS [1RO1DC00669-01] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BERSTAD A, 1986, SCAND J GASTROENTERO, V21, P55, DOI 10.3109/00365528609034622; BOYLE JT, 1987, AM J PHYSIOL, V253, pG315, DOI 10.1152/ajpgi.1987.253.3.G315; BOYLE JT, 1985, GASTROENTEROLOGY, V88, P723, DOI 10.1016/0016-5085(85)90143-X; COHEN S, 1971, NEW ENGL J MED, V284, P1053, DOI 10.1056/NEJM197105132841902; DEMEESTER TR, 1981, J THORAC CARDIOV SUR, V82, P547; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503; Dodds WJ, 1990, J GASTROINTEST MOTIL, V2, P79; JOHNSON LF, 1978, AM J DIG DIS, V23, P498, DOI 10.1007/BF01072693; KAHRILAS PJ, 1988, GASTROENTEROLOGY, V94, P73, DOI 10.1016/0016-5085(88)90612-9; KAHRILAS PJ, 1990, GUT, V31, P4, DOI 10.1136/gut.31.1.4; KAUL B, 1986, SCAND J GASTROENTERO, V21, P31, DOI 10.3109/00365528609034617; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P88; LEVINE MS, 1989, RADIOLOGY ESOPHAGUS, P256; MITTAL RK, 1990, AM J PHYSIOL, V258, pG624, DOI 10.1152/ajpgi.1990.258.4.G624; MITTAL RK, 1988, J CLIN INVEST, V81, P1182, DOI 10.1172/JCI113433; MITTAL RK, 1989, AM J PHYSIOL, V256, pG139, DOI 10.1152/ajpgi.1989.256.1.G139; OTT DJ, 1985, GASTROINTEST RADIOL, V10, P317, DOI 10.1007/BF01893120; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P246; SLOAN S, 1991, GASTROENTEROLOGY, V100, P596, DOI 10.1016/0016-5085(91)80003-R; SONTAG SJ, 1991, J CLIN GASTROENTEROL, V13, P628, DOI 10.1097/00004836-199112000-00006; WRIGHT RA, 1979, DIGEST DIS SCI, V24, P311, DOI 10.1007/BF01296546	22	201	210	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					977	982		10.7326/0003-4819-117-12-977	http://dx.doi.org/10.7326/0003-4819-117-12-977			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443984				2022-12-24	WOS:A1992KB98000001
J	SETTE, A; CEMAN, S; KUBO, RT; SAKAGUCHI, K; APPELLA, E; HUNT, DF; DAVIS, TA; MICHEL, H; SHABANOWITZ, J; RUDERSDORF, R; GREY, HM; DEMARS, R				SETTE, A; CEMAN, S; KUBO, RT; SAKAGUCHI, K; APPELLA, E; HUNT, DF; DAVIS, TA; MICHEL, H; SHABANOWITZ, J; RUDERSDORF, R; GREY, HM; DEMARS, R			INVARIANT CHAIN PEPTIDES IN MOST HLA-DR MOLECULES OF AN ANTIGEN-PROCESSING MUTANT	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I; BINDING SITE; T-CELLS; REGION; GENE; SPECIFICITY; MUTATIONS; MHC	Class II major histocompatibility complexes bind peptides in an endosome-like compartment. When the class II null cell line 721.174 was transfected with class II DR3 genes, DR molecules were produced in normal amounts. However, the DR molecules were abnormally conformed and unstable because deletion of an antigen-processing gene had impaired intracellular formation of most class II-peptide complexes. Yet, 70 percent of the DR molecules still bore peptides, 80 percent of which were 21- to 24-amino acid fragments of the class II-associated invariant chain. These peptides were rare on DR3 from control cells. Thus, a defect in the main antigen-processing pathway revealed a process in which DR molecules bind long peptides derived from proteins present in the same compartment.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; NCI,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia	SETTE, A (corresponding author), CYTEL,3525 JOHN HOPKINS COURT,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022; Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015486, R01AI018634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18634, AI15486] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; Brodsky F M, 1992, Trends Cell Biol, V2, P109, DOI 10.1016/0962-8924(92)90015-F; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CEMAN S, 1992, J IMMUNOL, V149, P754; CEMAN S, UNPUB; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COTNER T, 1991, J IMMUNOL, V146, P414; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEMARS R, 1983, HUM IMMUNOL, V8, P123, DOI 10.1016/0198-8859(83)90008-3; DENAGEL DC, 1992, IMMUNOL TODAY, V13, P86, DOI 10.1016/0167-5699(92)90147-Y; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; LAMB CA, 1992, J IMMUNOL, V148, P3478; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LONG EO, 1992, NEW BIOL, V4, P274; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; RIBERBY JM, 1992, J IMMUNOL, V148, P2856; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SIDNEY J, 1992, J IMMUNOL, V149, P2634; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N; VANSCHOOTEN WCA, 1989, EUR J IMMUNOL, V19, P2075, DOI 10.1002/eji.1830191116; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	39	216	222	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1801	1804		10.1126/science.1465617	http://dx.doi.org/10.1126/science.1465617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465617				2022-12-24	WOS:A1992KB96400041
J	SCRUTTON, NS; DEONARAIN, MP; BERRY, A; PERHAM, RN				SCRUTTON, NS; DEONARAIN, MP; BERRY, A; PERHAM, RN			COOPERATIVITY INDUCED BY A SINGLE MUTATION AT THE SUBUNIT INTERFACE OF A DIMERIC ENZYME - GLUTATHIONE-REDUCTASE	SCIENCE			English	Article							ESCHERICHIA-COLI; ASPARTATE TRANSCARBAMOYLASE; DIRECTED MUTAGENESIS; DISULFIDE BRIDGE; RESOLUTION; DEHYDROGENASE; SPECIFICITY; COENZYME; SITE	When glycine418 of Escherichia coli glutathione reductase, which is in a closely packed region of the dimer interface, is replaced with a bulky tryptophan residue, the enzyme becomes highly cooperative (Hill coefficient 1.76) for glutathione binding. The cooperativity is lost when the mutant subunit is hybridized with a wild-type subunit to create a heterodimer. The mutation appears to disrupt atomic packing at the dimer interface, which induces a change of kinetic mechanism. A single mutation in a region of the protein remote from the active site can thus act as a molecular switch to confer cooperativity on an enzyme.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge				Berry, Alan/0000-0003-3502-0426				BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; DEMBOWSKI NJ, 1990, BIOCHEMISTRY-US, V29, P3716, DOI 10.1021/bi00467a018; DEONARAIN MP, 1990, P ROY SOC B-BIOL SCI, V241, P179, DOI 10.1098/rspb.1990.0083; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1491, DOI 10.1021/bi00120a028; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1498, DOI 10.1021/bi00120a029; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9601; ERMLER U, 1991, PROTEINS, V9, P174, DOI 10.1002/prot.340090303; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; HENDERSON GB, 1991, P NATL ACAD SCI USA, V88, P8769, DOI 10.1073/pnas.88.19.8769; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PAI EF, 1983, J BIOL CHEM, V258, P1751; PERHAM RN, 1991, BIOESSAYS, V13, P515, DOI 10.1002/bies.950131005; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCRUTTON NS, 1988, FEBS LETT, V241, P46, DOI 10.1016/0014-5793(88)81028-7; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Segel IH, 1975, ENZYME KINETICS, P460; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; VANVLIET F, 1991, P NATL ACAD SCI USA, V88, P9180, DOI 10.1073/pnas.88.20.9180; WENTE SR, 1991, J BIOL CHEM, V266, P20833; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WONG KK, 1988, BIOCHEMISTRY-US, V27, P7091, DOI 10.1021/bi00418a063	29	46	46	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1140	1143		10.1126/science.1439821	http://dx.doi.org/10.1126/science.1439821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439821				2022-12-24	WOS:A1992JX85200029
J	LANDSBERG, JP; MCDONALD, B; WATT, F				LANDSBERG, JP; MCDONALD, B; WATT, F			ABSENCE OF ALUMINUM IN NEURITIC PLAQUE CORES IN ALZHEIMERS-DISEASE	NATURE			English	Article							SENILE PLAQUES; DRINKING-WATER; MICROPROBE; BRAIN	CONTROVERSY exists over whether aluminium has a role in the aetiology of Alzheimer's disease. Alzheimer's disease is neuropathologically characterized by the occurrence of a minimum density of neurofibrillary tangles and neuritic plaques in the hippocampus and the association cortex of the brain1,2. The purported association of aluminium with Alzheimer's disease is based on: (1) the experimental induction of fibrillary changes in the neurons of animals by the injection of aluminium salts into brain tissue3,4; (2) reported detection of aluminium in neuritic plaques5-8 and tangle-bearing neurons9,10; (3) epidemiological studies linking aluminium levels in the environment, notably water supplies, with an increased prevalence of dementia11-14; and (4) a reported decrease in the rate of disease progression following the administration of desferroxamine, an aluminium chelator, to clinically diagnosed sufferers of Alzheimer's disease15. Here we use nuclear microscopy, a new analytical technique involving million-volt nuclear particles, to identify and analyse plaques in post-mortem tissue from patients with Alzheimer's disease without using chemical staining techniques and fail to demonstrate the presence of aluminium in plaque cores in untreated tissue.	RADCLIFFE INFIRM, DEPT NEUROPATHOL, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary	LANDSBERG, JP (corresponding author), UNIV OXFORD, NUCL PHYS LAB, SCANNING PROTON MICROPROBE UNIT, OXFORD OX1 3RH, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTAXO P, 1990, NUCL INSTRUM METH B, V49, P383, DOI 10.1016/0168-583X(90)90280-8; BENCH GS, 1989, NUCL INSTRUM METH B, V40-1, P655, DOI 10.1016/0168-583X(89)91069-0; CANDY J, 1988, INTERDISCIPL TOPICS, V25, P140; CANDY JM, 1986, LANCET, V1, P354; Candy JM, 1985, SENILE DEMENTIA ALZH, P183; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; Chu W. K., 1978, BACKSCATTERING SPECT, DOI 10.1016/B978-0-12-173850-1.50008-9; DUCKETT S, 1976, CR ACAD SCI D NAT, V282, P393; DUCKETT S, 1980, J NEUROPATH EXP NEUR, V39, P350, DOI 10.1097/00005072-198005000-00048; EDWARDSON JA, 1990, ENVIRON GEOCHEM HLTH, V12, P94, DOI 10.1007/BF01734057; FLATEN TP, 1990, ENVIRON GEOCHEM HLTH, V12, P152, DOI 10.1007/BF01734064; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; Johansson SAE, 1988, PIXE NOVEL TECHNIQUE, V1st; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KLATZO I, 1965, J NEUROPATH EXP NEUR, V24, P187, DOI 10.1097/00005072-196504000-00002; LANDSBERG JP, 1991, NUCL INSTRUM METH B, V54, P180, DOI 10.1016/0168-583X(91)95510-K; MARTYN CN, 1989, LANCET, V1, P59; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MICHEL P, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P387; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NERI LC, 1991, LANCET, V338, P390, DOI 10.1016/0140-6736(91)90531-S; NIKAIDO T, 1972, ARCH NEUROL-CHICAGO, V27, P549, DOI 10.1001/archneur.1972.00490180085017; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; SCHOFIELD RMS, 1988, NUCL INSTRUM METH B, V30, P398, DOI 10.1016/0168-583X(88)90032-8; STERN AJ, 1986, J NEUROPATH EXP NEUR, V45, P361, DOI 10.1097/00005072-198605000-00140; TERRY RD, 1965, J NEUROPATH EXP NEUR, V24, P200, DOI 10.1097/00005072-196504000-00003; WATT F, 1987, PRINCIPLES APPLICATI; WATT F, 1992, XRAY MICROANALYSIS B	30	242	245	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					65	68		10.1038/360065a0	http://dx.doi.org/10.1038/360065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436075				2022-12-24	WOS:A1992JW71700055
J	KENDLER, KS; HEATH, AC; NEALE, MC; KESSLER, RC; EAVES, LJ				KENDLER, KS; HEATH, AC; NEALE, MC; KESSLER, RC; EAVES, LJ			A POPULATION-BASED TWIN STUDY OF ALCOHOLISM IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL-FACTORS; DEPRESSION; GENETICS; SCHIZOPHRENIA; TRANSMISSION; INHERITANCE; SIMILARITY; CONTACT; MODELS; LISREL	Objective.-To clarify the role of genetic factors in the etiology of alcoholism in women. Design and Setting.-Personal structured psychiatric interviews conducted by researchers "blinded" to the status of the co-twin in an epidemiologic sample of 1030 female-female twin pairs of known zygosity from the population-based Virginia Twin Registry. Measures.-Three definitions of lifetime prevalence of alcoholism based on Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria: (1) alcoholism with tolerance or dependence; (2) alcoholism with or without tolerance-dependence; and (3) alcoholism with or without tolerance-dependence or problem drinking. Results.-Using narrow, intermediate, or broad definitions, the probandwise concordance for alcoholism was consistently higher in monozygotic than in dizygotic twin pairs. Multifactorial threshold models suggested that the heritability of liability to alcoholism in women is in the range of 50% to 60%. Conclusions.-The results support the hypothesis that genetic factors play a major role in the etiology of alcoholism in women. Women should be well represented in the efforts currently under way to elucidate the molecular basis of the genetic susceptibility to alcoholism.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI 48109; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,RICHMOND,VA 23298	Washington University (WUSTL); University of Michigan System; University of Michigan; Virginia Commonwealth University	KENDLER, KS (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHIAT,BOX 710,RICHMOND,VA 23298, USA.		Neale, Michael/AAD-5056-2020; Neale, Michael C/B-1418-2008; Kendler, Kenneth/AAF-2876-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009095] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-09095] Funding Source: Medline; NICHD NIH HHS [HD-26746] Funding Source: Medline; NIMH NIH HHS [MH-40828] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; BEARDSLEE WR, 1986, BRIT J PSYCHIAT, V149, P584, DOI 10.1192/bjp.149.5.584; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BROMET EJ, 1986, ARCH GEN PSYCHIAT, V43, P435; CADORET RJ, 1985, ARCH GEN PSYCHIAT, V42, P161, DOI 10.1001/archpsyc.1985.01790250055007; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; CLONINGER CR, 1988, ALCOHOLISM ORIGINS O; DEVOR EJ, 1989, ANNU REV GENET, V23, P19, DOI 10.1146/annurev.ge.23.120189.000315; Eaves L, 1989, GENES CULTURE PERSON; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; GOODWIN DW, 1977, ARCH GEN PSYCHIAT, V34, P751; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; GURLING HMD, 1984, ACTA GENET MED GEMEL, V33, P333, DOI 10.1017/S0001566000007376; HEATH AC, 1989, BEHAV GENET, V19, P9, DOI 10.1007/BF01065881; HELLER RF, 1988, GENET EPIDEMIOL, V5, P311, DOI 10.1002/gepi.1370050503; HELZER JE, 1991, PSYCHIATRIC DISORDER; HOLDEN C, 1991, SCIENCE, V251, P163, DOI 10.1126/science.1824800; HOLMES SJ, 1988, PSYCHIATRY, V51, P24, DOI 10.1080/00332747.1988.11024377; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; Joreskog K. G., 1989, LISREL 7 GUIDE PROGR; Joreskog KG, 1986, PRELIS PREPROCESSOR; KAIJ L, 1960, ALCOHOLISM TWINS; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P257; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1413; KENDLER KS, 1986, ANN HUM GENET, V50, P83, DOI 10.1111/j.1469-1809.1986.tb01941.x; LELAND J, 1982, GENDER PSYCHOPATHOLO; Loehlin J., 1976, HEREDITY ENV PERSONA, DOI DOI 10.7560/730038; LYKKEN DT, 1990, BEHAV GENET, V20, P547, DOI 10.1007/BF01065871; MARTIN NG, 1978, HEREDITY, V40, P97, DOI 10.1038/hdy.1978.10; MCGUE M, 1992, J ABNORM PSYCHOL, V101, P3, DOI 10.1037/0021-843X.101.1.3; MCGUFFIN P, 1989, BRIT J PSYCHIAT, V155, P294, DOI 10.1192/bjp.155.3.294; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; MORRISYATES A, 1990, ACTA PSYCHIAT SCAND, V81, P322, DOI 10.1111/j.1600-0447.1990.tb05457.x; NEALE MC, 1989, BEHAV GENET, V19, P37, DOI 10.1007/BF01065882; NEALE MC, 1991, STATISTICAL MODELLIN; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PEARSON K, 1901, P R SOC, V66, P241; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; REICH T, 1988, ALCOHOL CLIN EXP RES, V12, P458, DOI 10.1111/j.1530-0277.1988.tb00227.x; REICH T, 1972, ANN HUM GENET, V36, P163, DOI 10.1111/j.1469-1809.1972.tb00767.x; ROSE RJ, 1990, BEHAV GENET, V20, P763, DOI 10.1007/BF01065919; SPENCE J E, 1988, American Journal of Human Genetics, V43, pA159; Spitzer R. L., 1987, STRUCTURED CLIN INTE; WANBERG KW, 1970, Q J STUD ALCOHOL, V31, P40; ZUCKER RA, 1986, AM PSYCHOL, V41, P783, DOI 10.1037/0003-066X.41.7.783; 1987, DIAGNOSTIC STATISTIC; 1985, SAS USERS GUIDE STAT	50	344	347	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1877	1882		10.1001/jama.268.14.1877	http://dx.doi.org/10.1001/jama.268.14.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1404711				2022-12-24	WOS:A1992JR43900036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO PROHIBIT 415 INGREDIENTS FROM OTC DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-24	WOS:A1992JR43900009
J	SPECTOR, SL				SPECTOR, SL			ORAL STEROID-THERAPY FOR ASTHMA AND CONTACT-DERMATITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SPECTOR, SL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024, USA.							EPSTEIN E, 1973, CUTIS, V12, P47; FISHER AA, 1973, CONTACT DERMATITIS, P10; SPECTOR SL, 1985, CHEST, V87, pS73; SPECTOR SL, 1989, ANN ALLERGY, V63, P591	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1926	1926						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404722				2022-12-24	WOS:A1992JR43900046
J	DASILVA, LB; TREBES, JE; BALHORN, R; MROWKA, S; ANDERSON, E; ATTWOOD, DT; BARBEE, TW; BRASE, J; CORZETT, M; GRAY, J; KOCH, JA; LEE, C; KERN, D; LONDON, RA; MACGOWAN, BJ; MATTHEWS, DL; STONE, G				DASILVA, LB; TREBES, JE; BALHORN, R; MROWKA, S; ANDERSON, E; ATTWOOD, DT; BARBEE, TW; BRASE, J; CORZETT, M; GRAY, J; KOCH, JA; LEE, C; KERN, D; LONDON, RA; MACGOWAN, BJ; MATTHEWS, DL; STONE, G			X-RAY LASER MICROSCOPY OF RAT SPERM NUCLEI	SCIENCE			English	Article								The development of high brightness and short pulse width (<200 picoseconds) x-ray lasers now offers biologists the possibility of high-resolution imaging of specimens in an aqueous environment without the blurring effects associated with natural motions and chemical erosion. As a step toward developing the capabilities of this type of x-ray microscopy, a tantalum x-ray laser at 44.83 angstrom wavelength was used together with an x-ray zone plate lens to image both unlabeled and selectively gold-labeled dried rat sperm nuclei. The observed images show approximately 500 angstrom features, illustrate the importance of x-ray microscopy in determining chemical composition, and provide information about the uniformity of sperm chromatin organization and the extent of sperm chromatin hydration.	LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; LAWRENCE BERKELEY LAB,CTR XRAY OPT,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DIV MOLEC CYTOMETRY,SAN FRANCISCO,CA 94143; IBM CORP,THOMAS J WATSON RES CTR,YORKTOWN HTS,NY 10598	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco; International Business Machines (IBM)	DASILVA, LB (corresponding author), UNIV CALIF BERKELEY,DEPT PHYS,BERKELEY,CA 94720, USA.		Kern, Dieter P/A-3109-2011					ALLEN MJ, 1991, J CELL BIOL, V15, P50; ALLEN MJ, 1990, J CELL BIOL, V111, P110; ANDERSON EH, 1991, XRAY MICROSCOPY, V3, P75; BALHORN R, 1977, BIOCHEMISTRY-US, V16, P4704; BARBEE TW, 1990, OPT ENG, V29, P581; DASILVA LB, 1992, OPT LETT, V17, P754, DOI 10.1364/OL.17.000754; DOOHER GB, 1973, AM J ANAT, V136, P339, DOI 10.1002/aja.1001360307; HUNT J, 1991, SPIE P, V1410, P2; JACOBSEN C, 1991, OPT COMMUN, V86, P351, DOI 10.1016/0030-4018(91)90016-7; KOEHLER J K, 1970, Journal of Ultrastructure Research, V33, P598, DOI 10.1016/S0022-5320(70)90184-X; KOEHLER JK, 1983, GAMETE RES, V8, P357, DOI 10.1002/mrd.1120080406; MacGowan B. J., 1990, X-Ray Lasers 1990. Proceedings of the 2nd International Colloquium, P221; MACGOWAN BJ, 1990, PHYS REV LETT, V65, P420, DOI 10.1103/PhysRevLett.65.420; MEYERILSE W, 1991, XRAY MICROSCOPY, V3, P284; ROSEN MD, 1985, PHYS REV LETT, V54, P106, DOI 10.1103/PhysRevLett.54.106; SKINNER CH, 1990, J MICROSC-OXFORD, V159, P51, DOI 10.1111/j.1365-2818.1990.tb03018.x; TOMIE T, 1991, SCIENCE, V252, P691, DOI 10.1126/science.2024121	17	137	137	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					269	271		10.1126/science.1411525	http://dx.doi.org/10.1126/science.1411525			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411525				2022-12-24	WOS:A1992JR86000025
J	KANDEL, ER; ODELL, TJ				KANDEL, ER; ODELL, TJ			ARE ADULT LEARNING-MECHANISMS ALSO USED FOR DEVELOPMENT	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; REQUIRES NEURAL ACTIVITY; 3-EYED RANA-PIPIENS; NITRIC-OXIDE; CELLULAR MECHANISM; ARACHIDONIC-ACID; DEPRESSION; HIPPOCAMPUS; ENHANCEMENT; APLYSIA		COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	KANDEL, ER (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GRANT SGN, 1992, SOC NEUR ABSTR, V18, P639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOER M, 1992, SOC NEUR ABSTR, V18, P1311; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; IUMI Y, 1992, SCIENCE, V257, P1273; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PRISKY G, 1992, SOC NEUR ABSTR, V18, P1311; RAKIC P, 1992, CURR CONTENTS   0127; REH TA, 1985, J NEUROSCI, V5, P1132; Schatz C. J., 1992, SCI AM, V267, P60; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SCHWATZ CJ, 1990, NEURON, V5, P745; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHUMAN EM, 1991, SCIENCE, V254, P1503; SILVA AJ, 1992, P NATL ACAD SCI USA, V257, P201; Small S. A., 1992, Society for Neuroscience Abstracts, V18, P639; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; [No title captured]	37	147	149	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					243	245		10.1126/science.1411522	http://dx.doi.org/10.1126/science.1411522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JR860	1411522				2022-12-24	WOS:A1992JR86000020
J	LINSLEY, PS; WALLACE, PM; JOHNSON, J; GIBSON, MG; GREENE, JL; LEDBETTER, JA; SINGH, C; TEPPER, MA				LINSLEY, PS; WALLACE, PM; JOHNSON, J; GIBSON, MG; GREENE, JL; LEDBETTER, JA; SINGH, C; TEPPER, MA			IMMUNOSUPPRESSION INVIVO BY A SOLUBLE FORM OF THE CTLA-4 T-CELL ACTIVATION MOLECULE	SCIENCE			English	Article							COSTIMULATORY SIGNAL; ANTIGEN-B7; INTERLEUKIN-2; EXPRESSION; ANTIBODIES; RECEPTOR; ADHESION	In vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7 with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig suppressed responses to a second immunization. Thus, costimulation by B7 is important for humoral immune responses in vivo, and interference with costimulation may be useful for treatment of antibody-mediated autoimmune disease.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, WALLINGFORD, CT 06492 USA	Bristol-Myers Squibb	LINSLEY, PS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							BIERER BE, 1991, ADV CANCER RES, V56, P49; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GUCKEL B, 1991, J EXP MED, V174, P957, DOI 10.1084/jem.174.5.957; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JENKINS MK, 1991, J IMMUNOL, V147, P2461; Jerne N.K., 1963, CELL BOUND ANTIBODIE, P109; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LENSCHOW DJ, UNPUB; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LIU Y, IN PRESS CURR OPIN I; LIU YJ, IN PRESS EUR J IMMUN; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAN PH, UNPUB; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203	28	766	849	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					792	795		10.1126/science.1496399	http://dx.doi.org/10.1126/science.1496399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496399				2022-12-24	WOS:A1992JG85100033
J	CAPLAN, AJ; CYR, DM; DOUGLAS, MG				CAPLAN, AJ; CYR, DM; DOUGLAS, MG			YDJ1P FACILITATES POLYPEPTIDE TRANSLOCATION ACROSS DIFFERENT INTRACELLULAR MEMBRANES BY A CONSERVED MECHANISM	CELL			English	Article							HEAT-SHOCK PROTEINS; PREPRO-ALPHA-FACTOR; MITOCHONDRIAL PRECURSOR POLYPEPTIDES; POST-TRANSLATIONAL TRANSLOCATION; YEAST SECRETORY PATHWAY; ESCHERICHIA-COLI DNAJ; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CARBOXYPEPTIDASE-Y; STRESS PROTEINS	The role of S. cerevisiae YDJ1 protein (YDJ1p) in polypeptide translocation across membranes has been examined. A conditional ydj1 mutant strain (ydj1-151TS) is defective for import of several polypeptides into mitochondria and alpha factor into the endoplasmic reticulum at 37-degrees-C. These defects are suppressed by E. coli dnaJ or overexpression of S. cerevisiae SIS1 proteins. A different ydj1 mutant, which cannot be farnesylated (ydj1-S406), displays similar transport defects to the ydj1-151 strain. Furthermore, the ability of purified ydj1-151p to stimulate the ATPase activity of hsp70SSA1 was greatly diminished compared with the wild-type protein. Together, these data suggest that YDJ1p functions in polypeptide translocation in a conserved manner, probably acting at organelle membranes and in association with hsp70 proteins.			CAPLAN, AJ (corresponding author), UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.		Caplan, Avrom/GPT-0824-2022	Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041758] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41758, GM35367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10699; ALTMAN E, 1991, EMBO J, V10, P239, DOI 10.1002/j.1460-2075.1991.tb07943.x; ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIMURA T, 1989, J BIOL CHEM, V264, P3183; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Leung DW, 1989, TECHNIQUE, V1, P11; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; REID GA, 1982, J BIOL CHEM, V257, P3056; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Sherman F., 1986, METHODS YEAST GENETI; SHERMAN MY, 1992, EMBO J, V11, P71; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	65	233	236	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1143	1155		10.1016/S0092-8674(05)80063-7	http://dx.doi.org/10.1016/S0092-8674(05)80063-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473150				2022-12-24	WOS:A1992KE60400009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PRESCRIPTION DRUG-USER FEE STATUTE ENACTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-24	WOS:A1992KC83900006
J	VAUX, DL; WEISSMAN, IL; KIM, SK				VAUX, DL; WEISSMAN, IL; KIM, SK			PREVENTION OF PROGRAMMED CELL-DEATH IN CAENORHABDITIS-ELEGANS BY HUMAN BCL-2	SCIENCE			English	Article							CHROMOSOMAL BREAKPOINT; GENE-EXPRESSION; B-CELLS; NEMATODE; TRANSLOCATION; SURVIVAL; CLONING; PROTEIN; LOCUS	Programmed cell death is a physiological process that eliminates unwanted cells. The bcl-2 gene regulates programmed cell death in mammalian cells, but the way it functions is not known. Expression of the human bcl-2 gene in the nematode Caenorhabditis elegans reduced the number of programmed cell deaths, suggesting that the mechanism of programmed cell death controlled by bcl-2 in humans is the same as that in nematodes.			VAUX, DL (corresponding author), STANFORD UNIV, MED CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.		Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUX DL, 1992, INT IMMUNOL, V4, P821; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P29; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JONES D, 1986, J BIOL CHEM, V261, P2006; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	27	517	545	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1955	1957		10.1126/science.1470921	http://dx.doi.org/10.1126/science.1470921			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470921				2022-12-24	WOS:A1992KD08800038
J	ROYDEN, CS; BANKS, MS; CROWELL, JA				ROYDEN, CS; BANKS, MS; CROWELL, JA			THE PERCEPTION OF HEADING DURING EYE-MOVEMENTS	NATURE			English	Article							OPTICAL-FLOW; MOTION; IMAGE; DIRECTION	WHEN a person walks through a rigid environment while holding eyes and head fixed, the pattern of retinal motion flows radially away from a point, the focus of expansion (Fig. 1a)1,2. Under such conditions of translation, heading corresponds to the focus of expansion and people identify it readily3. But when making an eye/head movement to track an object off to the side, retinal motion is no longer radial (Fig. 1b)4. Heading perception in such situations has been modelled in two ways. Extra-retinal models monitor the velocity of rotational movements through proprioceptive or efference information from the extraocular and neck muscles and use that information to discount rotation effects5. Retinal-image models determine (and eliminate) rotational components from the retinal image alone6-12. These models have been tested13,14 by measuring heading perception under two conditions. First, observers judged heading while tracking a point on a simulated ground plane. Second, they fixated a stationary point and the How field simulated the effects of a tracking eye movement. Extra-retinal models5 predict poorer performance in the simulated condition because the eyes do not move. Retinal-image models6-12 predict no difference in performance because the two conditions produce identical patterns of retinal motion. Warren and Hannon13,14 observed similar performance and concluded that people do not require extra-retinal information to judge heading with eye/head movements present, but they used extremely slow tracking eye movements of 0.2-1.2 deg s-1; a moving observer frequently tracks objects at much higher rates (L. Stark, personal communication). Here we examine heading judgements at higher, more typical eye movement velocities and find that people require extra-retinal information about eye position15 to perceive heading accurately under many viewing conditions.	UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT PSYCHOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley								BRUSS AR, 1983, COMPUT VISION GRAPH, V21, P3, DOI 10.1016/S0734-189X(83)80026-7; DROULEZ J, 1990, BIOL CYBERN, V62, P211, DOI 10.1007/BF00198096; Gibson J. J., 1950, PERCEPTION VISUAL WO; Gibson JJ., 1966, SENSES CONSIDERED PE; HEEGER DJ, IN PRESS INT J COMP; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; LONGUETHIGGINS HC, 1981, NATURE, V293, P133, DOI 10.1038/293133a0; MATIN L, 1981, S STUDY MOTON PERCEP; REGAN D, 1982, SCIENCE, V215, P194, DOI 10.1126/science.7053572; RIEGER JH, 1985, J OPT SOC AM A, V2, P354, DOI 10.1364/JOSAA.2.000354; von Holst E, 1954, BRIT J ANIM BEHAV, V2, P89, DOI DOI 10.1016/S0950-5601(54)80044-X; WARREN WH, 1988, J EXP PSYCHOL HUMAN, V14, P646, DOI 10.1037/0096-1523.14.4.646; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0; WARREN WH, 1991, BIOL CYBERN, V65, P311, DOI 10.1007/BF00216964; WAXMAN AM, 1985, INT J ROBOT RES, V4, P72, DOI 10.1177/027836498500400306	16	261	262	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					583	587		10.1038/360583a0	http://dx.doi.org/10.1038/360583a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461280				2022-12-24	WOS:A1992KB95900084
J	MCPHEETERS, DS; ABELSON, J				MCPHEETERS, DS; ABELSON, J			MUTATIONAL ANALYSIS OF THE YEAST U2 SNRNA SUGGESTS A STRUCTURAL SIMILARITY TO THE CATALYTIC CORE OF GROUP-I INTRONS	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SELF-SPLICING RNA; RIBONUCLEOPROTEIN-PARTICLES; BINDING-SITE; CONSERVED NUCLEOTIDES; TRYPANOSOMA-BRUCEI; MAMMALIAN U2; U6 SNRNA; TETRAHYMENA	We have used an in vitro reconstitution system to determine the effects of a large number of mutations in the highly conserved 5' terminal domain of the yeast U2 snRNA on pre-mRNA splicing. Whereas many mutations have little or no functional consequence, base substitutions in two regions were found to have drastic effects on pre-mRNA splicing. A previously unrecognized function for the U2 snRNA in the second step of splicing was found by alteration of the absolutely conserved sequence AGA upstream of the branch point recognition sequence. The effects of these mutations suggest the formation of a structure involving the U2 snRNA similar to the guanosine-binding site found in the catalytic core of group I introns.			MCPHEETERS, DS (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032637, R01GM032637, F32GM012544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12544, GM32637] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; Ares M. Jr, 1989, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V94, P13; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BURKE JM, 1989, FEBS LETT, V250, P129, DOI 10.1016/0014-5793(89)80704-5; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; KHELLIL S, 1991, NUCLEIC ACIDS RES, V19, P877, DOI 10.1093/nar/19.4.877; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PAN ZQ, 1989, GENE DEV, V3, P1887, DOI 10.1101/gad.3.12a.1887; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REDDY R, 1990, NUCLEIC ACIDS RES, V18, P2231, DOI 10.1093/nar/18.suppl.2231; REDDY R, 1989, METHOD ENZYMOL, V180, P521; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHUMYATSKY G, 1992, NUCLEIC ACIDS RES, V20, P2159, DOI 10.1093/nar/20.suppl.2159; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU J, 1992, IN PRESS MOL CELL BI; YARUS M, 1989, NUCLEIC ACIDS RES, V17, P6969, DOI 10.1093/nar/17.17.6969; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1992, J MOL BIOL, V225, P945, DOI 10.1016/0022-2836(92)90095-2; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; YARUS M, 1991, NUCLEIC ACIDS RES, V19, P1297, DOI 10.1093/nar/19.6.1297; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	70	94	95	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					819	831		10.1016/0092-8674(92)90557-S	http://dx.doi.org/10.1016/0092-8674(92)90557-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423632				2022-12-24	WOS:A1992JZ63300011
J	HELMS, JB; ROTHMAN, JE				HELMS, JB; ROTHMAN, JE			INHIBITION BY BREFELDIN-A OF A GOLGI MEMBRANE ENZYME THAT CATALYZES EXCHANGE OF GUANINE-NUCLEOTIDE BOUND TO ARF	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; COATED VESICLES; TRANSPORT; COMPLEX; IDENTIFICATION; PURIFICATION; ENDOSOMES; COFACTOR; CELLS	A WIDE variety of membrane transformations important in intracellular transport are inhibited by the fungal metabolite brefeldin A (refs 1-4), implying that the target for this drug is central to the formation and maintenance of subcellular compartments5. Brefeldin A added to cells causes the rapid and reversible dissociation of a Golgi-associated peripheral membrane protein (M(r) 110,000)6 which was found to be identical to one of the subunits of the coat of Golgi-derived (non-clathrin) coated vesicles, beta-COP7,8, implying that brefeldin A prevents transport by blocking the assembly of coats and thus the budding of enclosed vesicles9. In addition to the coatomer (a cytosol-derived complex of seven polypeptide chains, one of which is beta-COP10), the non-clathrin (COP) coat of Golgi-derived vesicles contains stoichiometric amounts of a small (M(r) approximately 20,000) GTP-binding protein, the ADP-ribosylation factor (ARF)11. Binding of ARF to Golgi membranes is necessary before coatomer/beta-COP can bind these membranes (ref. 12; and D. J. Palmer et al., manuscript submitted), so the primary effect of brefeldin A seems to be on the reaction responsible for ARF binding. Indeed, like beta-COP, ARF is dissociated from the Golgi complex by treatment with brefeldin A and brefeldin A prevents ARF from associating in vitro13, but the mechanism of this action by brefeldin A has been unclear. Here we report the discovery of an enzyme in a Golgi-enriched fraction that catalyses guanine nucleotide (GDP-GTP) exchange on ARF-1 protein, and which is inhibited by brefeldin A. We suggest that activation of ARF proteins for membrane localization by compartmentalized exchange enzymes is in general the first committed step in membrane transformation pathways.			HELMS, JB (corresponding author), SLOAN KETTERING MEM CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, SCIENCE, V257, P862, DOI 10.1126/science.1323875; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCLEICHER M, FEBS LETT, V200, P156; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	31	626	639	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					352	354		10.1038/360352a0	http://dx.doi.org/10.1038/360352a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448152				2022-12-24	WOS:A1992JZ63000054
J	HUHTASAARI, F; ASPLUND, K; LUNDBERG, V; STEGMAYR, B; WESTER, PO				HUHTASAARI, F; ASPLUND, K; LUNDBERG, V; STEGMAYR, B; WESTER, PO			TOBACCO AND MYOCARDIAL-INFARCTION - IS SNUFF LESS DANGEROUS THAN CIGARETTES	BRITISH MEDICAL JOURNAL			English	Article							SMOKELESS TOBACCO; RISK-FACTORS; NICOTINE; SMOKING; CONSUMPTION; MECHANISMS; ABSORPTION; PATTERNS; CANCER	Objective-To estimate the risk of myocardial infarction in snuff users, cigarette smokers, and non-tobacco users in northern Sweden, where using snuff is traditional. Design-Case-control study. Setting-Northern Sweden. Subjects-All 35-64 year old men who had had a first myocardial infarction and a population based sample of 35-64 year old men who had not had an infarction in the same geographical area. Main outcome measure-Tobacco consumption (regular snuff dipping, regular cigarette smoking, non-tobacco use) and risk of acute myocardial infarction. Results-59 of 585 (10%) patients who had a first myocardial infarction and 87 of 589 (15%) randomly selected men without myocardial infarction were non-smokers who used snuff daily. The age adjusted odds ratio for myocardial infarction was 0.89 (95% confidence interval 0.62 to 1.29) for exposure to snuff and 1.87 (1.40 to 2.48) for cigarette smoking compared with non-tobacco users, showing an increased risk in smokers but not in snuff dippers. Regular cigarette smokers had a significantly higher risk of myocardial infarction than regular snuff dippers (age adjusted odds ratio 2.09; 1.39 to 3.15). Smoking, but not snuff dipping, predicted myocardial infarction in a multiple logistic regression model that included age and level of education. Conclusions-In middle aged men snuff dipping is associated with a lower risk of myocardial infarction than cigarette smoking.	UMEA UNIV HOSP,DEPT MED,S-90185 UMEA,SWEDEN; LULEA BODEN HOSP,DEPT MED,S-95128 LULEA,SWEDEN; KALIX HOSP,DEPT MED,S-95282 KALIX,SWEDEN	Umea University								ASPLUND K, IN PRESS CARDIOVASC; BENOWITZ NL, 1988, CLIN PHARMACOL THER, V44, P23, DOI 10.1038/clpt.1988.107; BOLINDER G, 1992, European Heart Journal, V13, P393; BOLINDER G, 1988, LAKARTIDNINGEN, V85, P1248; BROCKIE RE, 1990, SEMIN RESPIR MED, V11, P5, DOI 10.1055/s-2007-1006191; BROWNSON RC, 1990, PREV MED, V19, P170, DOI 10.1016/0091-7435(90)90018-F; CHRISTEN AG, 1987, AVIAT SPACE ENVIR MD, V58, P97; CONNOLLY GN, 1986, NEW ENGL J MED, V314, P1020, DOI 10.1056/NEJM198604173141605; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; ELIASSON M, 1991, J INTERN MED, V230, P17, DOI 10.1111/j.1365-2796.1991.tb00401.x; ERNSTER VL, 1989, NATL CANCER I MONOGR, V8, P87; GLOVER ED, 1989, AM J PUBLIC HEALTH, V79, P207, DOI 10.2105/AJPH.79.2.207; HATSUKAMI DK, 1987, CLIN PHARMACOL THER, V41, P103, DOI 10.1038/clpt.1987.17; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; NORDGREN P, 1990, BRIT J ADDICT, V85, P1107; ORLANDI MA, 1989, NCI MONOGRAPHS, V8, P5; Peterson J S, 1990, Arctic Med Res, V49 Suppl 2, P32; ROBERTSON D, 1988, AM HEART J, V115, P258, DOI 10.1016/0002-8703(88)90646-1; RUSSELL MAH, 1985, LANCET, V2, P1370; SCHEI E, 1990, PREV MED, V19, P667, DOI 10.1016/0091-7435(90)90063-P; SCHROEDER KL, 1988, ADDICT BEHAV, V13, P395, DOI 10.1016/0306-4603(88)90047-0; SCHROEDER KL, 1985, NEW ENGL J MED, V312, P919; SQUIRES WG, 1984, PREV MED, V13, P195, DOI 10.1016/0091-7435(84)90051-3; STAVENOW L, 1988, ARTERY, V15, P94; STEGMAYR B, 1991, HYGIEA, V100, P252; VENITT S, 1990, BRIT J ADDICT, V85, P1100; WEST R, 1990, BRIT J ADDICT, V85, P1097; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; WILLIAMS RR, 1977, JNCI-J NATL CANCER I, V58, P525, DOI 10.1093/jnci/58.3.525; WRIGHT BM, 1970, LANCET, V1, P337; 1989, WORLD HLTH STATISTIC, P27; 1986, HLTH CONSEQUENCES US; 1976, PUBLIC HLTH EUROPE, V5; 1988, WHO TECH REPORTS SER, V773	35	122	124	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1252	1256		10.1136/bmj.305.6864.1252	http://dx.doi.org/10.1136/bmj.305.6864.1252			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477567	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JZ52100021
J	SAUNDERS, CJP				SAUNDERS, CJP			DRIVING AND DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,ACAD UNIT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds								DAVIS TG, 1973, OKLAHOMA STATE MED A, V66, P322; DEKLERK NH, 1983, J EPIDEMIOL COMMUN H, V37, P232, DOI 10.1136/jech.37.3.232; FRIER BM, 1980, LANCET, V1, P1232; STEEL JM, 1981, LANCET, V2, P354; WILLIAMS DRR, 1990, DIABETIC MED, V7, P74, DOI 10.1111/j.1464-5491.1990.tb01312.x	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1265	1265		10.1136/bmj.305.6864.1265	http://dx.doi.org/10.1136/bmj.305.6864.1265			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477571	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JZ52100026
J	WATKINS, DC; JOHNSON, GL; MALBON, CC				WATKINS, DC; JOHNSON, GL; MALBON, CC			REGULATION OF THE DIFFERENTIATION OF TERATOCARCINOMA CELLS INTO PRIMITIVE ENDODERM BY G-ALPHA-I2	SCIENCE			English	Article							RETINOIC ACID; G-PROTEINS; STEM-CELLS; MODULATION; EXPRESSION; INDUCTION; SEQUENCES; CYCLASE; ASSAY; GI2	The amount of the heterotrimeric G protein subunit Galpha(i2) decreases after the induction of F9 teratocarcinoma cells to become primitive endoderm in the presence of retinoic acid (RA). The reduction of the Galpha(i2) protein in F9 cells by antisense RNA expression was associated with (i) loss of receptor-mediated inhibition of adenylyl cyclase; (ii) decreased cell doubling time; (iii) induction of a primitive, endoderm-like phenotype in the absence of RA; and (iv) production of the differentiation marker tissue-type plasminogen activator. Expression of a constitutively active, mutant Galpha(i2) blocked RA-induced differentiation. These data suggest the involvement of Galpha(i2) in the control of stem cell differentiation and provide insight into the involvement of G proteins in growth regulation.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; NATL JEWISH CTR IMMUNOL, DEPT PEDIAT & BASIC SCI, DENVER, CO 80206 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Jewish Health	WATKINS, DC (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020					ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; GALVINPARTON P, UNPUB; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; KLEBE RJ, 1991, P NATL ACAD SCI USA, V88, P9588, DOI 10.1073/pnas.88.21.9588; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; Sambrook J., 1989, MOL CLONING LAB MANU; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DL, UNPUB; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	27	101	104	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1373	1375		10.1126/science.1455234	http://dx.doi.org/10.1126/science.1455234			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455234				2022-12-24	WOS:A1992JY95800043
J	GEISLER, R; BERGMANN, A; HIROMI, Y; NUSSLEINVOLHARD, C				GEISLER, R; BERGMANN, A; HIROMI, Y; NUSSLEINVOLHARD, C			CACTUS, A GENE INVOLVED IN DORSOVENTRAL PATTERN-FORMATION OF DROSOPHILA, IS RELATED TO THE I-KAPPA-B GENE FAMILY OF VERTEBRATES	CELL			English	Article							P-ELEMENT TRANSPOSASE; DNA-BINDING SUBUNIT; DORSAL PROTEIN; TRANSMEMBRANE PROTEIN; EMBRYONIC POLARITY; SEQUENCE; REL; TRANSCRIPTION; TOLL; DIFFERENTIATION	Among the maternally active genes of Drosophila, cactus is the only one whose loss of function mutations specifically produce ventralized embryos. Its product inhibits nuclear translocation of the dorsal morphogen in the dorsal region of the embryo. Here we report the cloning of cactus and the sequencing of its maternal transcript. The identity of our clones was verified by induction of phenocopies with antisense RNA and rescue of the mutant phenotype with sense RNA. cactus is predicted to encode an acidic, cytoplasmic protein with seven ankyrin repeats. The sequence has similarity to the IkappaB proteins that inhibit the vertebrate transcription factor NF-kappaB. In analogy to results obtained with IkappaB and NF-kappaB, bacterially expressed cactus protein can inhibit DNA binding of dorsal protein in vitro.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GEISLER, R (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,SPEMANNSTR 35-III,W-7400 TUBINGEN,GERMANY.		Geisler, Robert/K-6201-2013	Geisler, Robert/0000-0002-3909-8311				ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE H, 1989, THESIS COLUMBIA U NE; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; IP YT, 1991, CELL, V64, P439; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NAUBER U, 1991, ANTISENSE NUCLEIC AC, P113; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAY RP, 1991, DEVELOPMENT, V113, P35; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	50	221	227	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					613	621		10.1016/0092-8674(92)90595-4	http://dx.doi.org/10.1016/0092-8674(92)90595-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423618				2022-12-24	WOS:A1992JY67600009
J	ROSENBERG, RL; EAST, JE				ROSENBERG, RL; EAST, JE			CELL-FREE EXPRESSION OF FUNCTIONAL SHAKER POTASSIUM CHANNELS	NATURE			English	Article							PROTEIN TRANSLOCATION; XENOPUS OOCYTES; K+ CHANNELS; RECEPTORS; GLYCOSYLATION; INACTIVATION; DROSOPHILA; REGION; LOCUS; GENE	THE functional activity of ion channels and other membrane proteins requires that the proteins be correctly assembled in a transmembrane configuration. Thus, the functional expression of ion channels, neurotransmitter receptors and complex membrane-limited signalling mechanisms from complementary DNA has required the injection of messenger RNA or transfection of DNA into Xenopus oocytes or other target cells that are capable of processing newly translated protein into the surface membrane1-4. These approaches, combined with voltage-clamp analysis of ion channel currents, have been especially powerful in the identification of structure-function relationships in ion channels5-7. But oocytes express endogenous ion channels8,9, neurotransmitter receptors10 and receptor-channel subunits11, complicating the interpretation of results in mRNA-injected eggs. Furthermore, it is difficult to control experimentally the membrane lipids and post-translational modifications that underlie the regulation and modulation of ion channels in intact cells. A cell-free system for ion channel expression is ideal for good experimental control of protein expression and modulatory processes. Here we combine cell-free protein translation, microsomal membrane processing12-14 of nascent channel proteins, and reconstitution of newly synthesized ion channels into planar lipid bilayers15 to synthesize, glycosylate, process into membranes, and record in vitro the activity of functional Shaker potassium channels.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	ROSENBERG, RL (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, CHAPEL HILL, NC 27599 USA.							ALBERTS B, 1991, MOL BIOL CELL; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; BULLER AL, 1990, MOL PHARMACOL, V37, P423; DAS RC, 1980, J BIOL CHEM, V255, P7933; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FLUHARTY SJ, 1991, J NEUROCHEM, V56, P1307, DOI 10.1111/j.1471-4159.1991.tb11426.x; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LESTER HA, 1988, SCIENCE, V241, P1057, DOI 10.1126/science.2457947; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; Miller C., 1986, ION CHANNEL RECONSTI; NUMA S, 1989, HARVEY LECT, V83, P121; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; ROSENBERG RL, 1991, J GEN PHYSIOL, V97, P1207, DOI 10.1085/jgp.97.6.1207; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; YANG XC, 1992, J NEUROSCI, V12, P268; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZONA C, 1990, PROC R SOC SER B-BIO, V239, P119, DOI 10.1098/rspb.1990.0011	30	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					166	169		10.1038/360166a0	http://dx.doi.org/10.1038/360166a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436093				2022-12-24	WOS:A1992JX75200062
J	MACFARLANE, GJ; BOYLE, P; SCULLY, C				MACFARLANE, GJ; BOYLE, P; SCULLY, C			ORAL-CANCER IN SCOTLAND - CHANGING INCIDENCE AND MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							TOBACCO; ALCOHOL; PHARYNX; TONGUE; CAVITY; DIET	Objectives-To determine the incidence of oral cancer in Scotland between 1960 and 1989 and oral cancer mortality from 1911 to 1989. Setting-Data were obtained on oral cancer incidence from the information and statistics division of the Common Services Agency of the Scottish Health Service and mortality data from the office of the registrar general for Scotland. Results-Mortality from intraoral cancers in Scotland substantially declined throughout this century until the mid-1970s. This trend, however, was then reversed, and fourfold increases in incidence were observed in younger age groups after 1960. Death rates in these younger age groups increased to levels previously recorded in the 1940s. These increases seemed to be cohort based and may therefore continue into the future. Conclusions-Reasons for increasing rates among younger age groups are speculative and rely on combining knowledge about risk factors and available ecological data. Though increases in incidence at younger ages do not result in a large change in the number of cases diagnosed, possible similar increases continuing into older ages, when oral cancer is more common, will correspond to a much larger increase in the actual number of cases. Given that such a large attributable risk is associated with tobacco and alcohol, however, these increases may be preventable.	BRISTOL DENT HOSP & SCH,DEPT ORAL MED SURG & PATHOL,CTR STUDY ORAL DIS,BRISTOL BS1 2LY,ENGLAND	University of Bristol	MACFARLANE, GJ (corresponding author), EUROPEAN INST ONCOL,DIV EPIDEMIOL & BIOSTAT,VIA RIPAMONTI 332-10,I-20141 MILAN,ITALY.		Boyle, Peter/A-4380-2014; Macfarlane, Gary J/I-9521-2014	Boyle, Peter/0000-0001-6251-0610; Macfarlane, Gary J/0000-0003-2322-3314				[Anonymous], 1988, IARC MONOGR EVAL CAR, V44, P41; [Anonymous], 1990, ANN REPORT; BINNIE WH, 1972, OPCS STUDIES MED POP; BLOT WJ, 1988, CANCER RES, V48, P3282; BRUGERE J, 1986, CANCER, V57, P391, DOI 10.1002/1097-0142(19860115)57:2<391::AID-CNCR2820570235>3.0.CO;2-Q; CASE RAM, 1976, SERIAL MORTALITY TAB, V4; DAVIS S, 1987, LANCET, V1, P910; DEPUE RH, 1986, NEW ENGL J MED, V315, P647; DOLL R, 1967, INT J CANCER, V2, P269, DOI 10.1002/ijc.2910020310; DOLL R, 1966, CANCER INCIDENCE 5 C, V1; Easson E C, 1976, Clin Oncol, V2, P191; GRAHAM S, 1977, J NATL CANCER I, V59, P1611, DOI 10.1093/jnci/59.6.1611; HAKULINEN T, 1986, ACTA PATHOLOGIC S228, V94, P30; KELLER AZ, 1965, AM J PUBLIC HEALTH N, V55, P1578, DOI 10.2105/AJPH.55.10.1578; LAVECCHIA C, 1992, EUR J CANCER, V28A, P132; MACFARLANE GJ, 1987, LANCET, V2, P1912; MERLETTI F, 1989, CANCER RES, V49, P4919; MOLLER H, 1989, J ORAL PATHOL MED, V18, P224, DOI 10.1111/j.1600-0714.1989.tb00767.x; MUIR CS, 1987, IARC SCI PUBLICATION, V88; RUSSELL MH, 1955, BRIT MED J, V2, P823, DOI 10.1136/bmj.2.4943.823; SCHIFFLERS E, 1985, STAT MED, V4, P63, DOI 10.1002/sim.4780040110; SPRING JA, 1977, NATURE, V270, P567, DOI 10.1038/270567a0; SVEJDA J, 1971, NEOPLASMA, V18, P193; TAN K N, 1969, Australian Dental Journal, V14, P50; WALD NJ, 1985, CANCER RISKS PREVENT, P44; WINN DM, 1981, NEW ENGL J MED, V304, P745, DOI 10.1056/NEJM198103263041301; WYNDER EL, 1957, CANCER, V10, P1300, DOI 10.1002/1097-0142(195711/12)10:6&lt;1300::AID-CNCR2820100628&gt;3.0.CO;2-2; [No title captured]	28	82	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1121	1123		10.1136/bmj.305.6862.1121	http://dx.doi.org/10.1136/bmj.305.6862.1121			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463946	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JX84100020
J	QUILL, TE; CASSEL, CK; MEIER, DE				QUILL, TE; CASSEL, CK; MEIER, DE			CARE OF THE HOPELESSLY ILL - PROPOSED CLINICAL-CRITERIA FOR PHYSICIAN-ASSISTED SUICIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DEATH; RESPONSIBILITY; NETHERLANDS		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	University of Rochester; University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BRAHAMS D, 1990, LANCET, V335, P591; Broadfield L, 1988, J Palliat Care, V4, P21; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHARLSON ME, 1987, J GEN INTERN MED, V2, P359, DOI 10.1007/BF02596176; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GEST T, 1990, US NEWS WORLD R 0709, P22; Glantz L H, 1987, Law Med Health Care, V15, P231; GLOVER J, 1977, CAUSING DEATH SAVING, P182; Gomez Carlos F., 1991, REGULATING DEATH EUT; HEILIG S, 1988, SAN FRANCISCO MED, V24, P34; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; LACHS J, 1976, NEW ENGL J MED, V294, P838, DOI 10.1056/NEJM197604082941513; LEENEN HJJ, 1990, BRIT MED J, V300, P69; MALCOLM A, 1990, NY TIMES        0614, pA6; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NEWMAN SA, 1991, U PITT LAW REV, V53, P153; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; REICHEL W, 1989, LANCET, V2, P1321; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; Schonwetter R S, 1990, Hosp J, V6, P65; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VAUX KL, 1988, JAMA-J AM MED ASSOC, V259, P2140, DOI 10.1001/jama.259.14.2140; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, WITHHOLDING WITHDRAW; 1990, 1990 ROPER POLL PHYS; 1988, 1987 SURVEY CALIFORN; 1991, 1991 ROPER POLL W CO	42	221	220	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1380	1384		10.1056/NEJM199211053271911	http://dx.doi.org/10.1056/NEJM199211053271911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406842				2022-12-24	WOS:A1992JW07700011
J	HART, MJ; MARU, Y; LEONARD, D; WITTE, ON; EVANS, T; CERIONE, RA				HART, MJ; MARU, Y; LEONARD, D; WITTE, ON; EVANS, T; CERIONE, RA			A GDP DISSOCIATION INHIBITOR THAT SERVES AS A GTPASE INHIBITOR FOR THE RAS-LIKE PROTEIN CDC42HS	SCIENCE			English	Article							BINDING PROTEIN; REGULATORY PROTEIN; ACTIVATING PROTEIN; DEPENDENT MANNER; HUMAN ONCOGENE; BCR; GENE; IDENTIFICATION; PRODUCT; REGION	Members of the family of Ras-related guanosine triphosphate (GTP) binding proteins appear to take part in the regulation of a number of biological processes, including cell growth and differentiation. Three different classes of proteins that regulate the GTP binding and GTP hydrolytic activities of the Ras family members have been identified. These different regulatory proteins inhibit guanosine diphosphate (GDP) dissociation (designated as GDIs), stimulate GDP dissociation and GDP-GTP exchange (designated as GDSs), or stimulate GTP hydrolysis (designated as GAPs). In the case of the Ras-like protein CDC42Hs, which is the human homolog of a Saccharomyces cerevisiae cell division cycle protein, the GDI protein also inhibited both the intrinsic and GAP-stimulated hydrolysis of GTP. These findings establish an additional role for the GDI protein-namely, as a guanosine triphosphatase (GTPase) inhibitory protein for a Ras-like GTP binding protein.	CORNELL UNIV,DEPT BIOCHEM CELL & MOLEC BIOL,SCHURMAN HALL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,INST MOLEC BIOL,LOS ANGELES,CA 90024; GENENTECH INC,DEPT CELL BIOL,SAN FRANCISCO,CA 94080	Cornell University; Cornell University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Roche Holding; Genentech				Hart, Matthew/0000-0002-2683-480X				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS JM, 1992, ONCOGENE, V7, P611; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARBO A, 1991, J BIOL CHEM, V266, P23577; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CERIONE RA, 1990, RECEPTOR EFFECTOR CO, P69; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HART MJ, UNPUB; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEONARD D, IN PRESS J BIOL CHEM; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; UEDA T, 1990, J BIOL CHEM, V265, P9373	28	151	152	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					812	815		10.1126/science.1439791	http://dx.doi.org/10.1126/science.1439791			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439791				2022-12-24	WOS:A1992JV69200042
J	CAREY, JR; LIEDO, P; OROZCO, D; VAUPEL, JW				CAREY, JR; LIEDO, P; OROZCO, D; VAUPEL, JW			SLOWING OF MORTALITY-RATES AT OLDER AGES IN LARGE MEDFLY COHORTS	SCIENCE			English	Article							MEDITERRANEAN FRUIT-FLY; DROSOPHILA-MELANOGASTER; CERATITIS-CAPITATA; MORBIDITY; COMPRESSION; POPULATION; HOST	It is generally assumed for most species that mortality rates increase monotonically at advanced ages. Mortality rates were found to level off and decrease at older ages in a population of 1.2 million medflies maintained in cages of 7,200 and in a group of approximately 48,000 adults maintained in solitary confinement. Thus, life expectancy in older individuals increased rather than decreased with age. These results cast doubt on several central concepts in gerontology and the biology of aging: (i) that senescence can be characterized by an increase in age-specific mortality, (ii) that the basic pattern of mortality in nearly all species follows the same unitary pattern at older ages, and (iii) that species have absolute life-span limits.	CTR INVEST ECOL SURESTE,TAPACHULA 30700,CHIAPAS,MEXICO; PROGRAMA MOSCAMED,METAPA 30820,CHIAPAS,MEXICO; ODENSE UNIV,DK-5230 ODENSE,DENMARK; DUKE UNIV,CTR DEMOG STUDIES,DURHAM,NC 27706	University of Southern Denmark; Duke University	CAREY, JR (corresponding author), UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616, USA.		Orozco-Davila, Dina/B-4050-2016; Liedo, Pablo/E-9313-2010; Orozco-Davila, Dina/B-3236-2016; Orozco-Davila, Dina/AAJ-2862-2021; Orozco-Davila, Dina/T-5369-2019	Orozco-Davila, Dina/0000-0002-6806-0945; Liedo, Pablo/0000-0002-0004-1721; Orozco-Davila, Dina/0000-0002-6806-0945; Vaupel, James/0000-0003-0783-3905	NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER; NIA NIH HHS [AG08761-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIGAKI T, 1984, EXP GERONTOL, V19, P267, DOI 10.1016/0531-5565(84)90022-6; BEARD RE, 1971, BIOL ASPECTS DEMOGRA, P75; BIRCH LC, 1948, J ANIM ECOL, V17, P15, DOI 10.2307/1605; CAREY JR, 1986, ENTOMOL EXP APPL, V42, P159, DOI 10.1007/BF00343543; CAREY JR, 1992, APPLIED DEMOGRAPHY B; CHIANG CL, 1984, LIFE TABLES ITS APPL, P116; Collatz K-G., 1986, INSECT AGING STRATEG; Comfort A., 1979, BIOL SENESCENCE; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; DEEVEY ES, 1947, Q REV BIOL, V22, P283, DOI 10.1086/395888; ECONOMOS AC, 1979, AGE, V2, P74, DOI 10.1007/BF02432250; Economos AC, 1982, ARCH GERONTOL GERIAT, V1, P3, DOI [10.1016/0167-4943(82)90003-6, DOI 10.1016/0167-4943(82)90003-6]; Finch CE, 1990, LONGEVITY SENESCENCE, P12; FRIES JF, 1983, MILBANK FUND Q, V61, P397, DOI 10.2307/3349864; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1987, GERONTOLOGICA PERSPE, V1, P5; GAVRILOV LA, 1991, BIOL LIFE SPAN QUANT, P129; GAVRILOV LA, 1991, BIOL LIFE SPAN QUANT, P128; GOMPERTZ B, 1977, MATH DEMOGRAPHY SELE, P279; HAZZARD DG, 1991, EXP GERONTOL, V26, P411, DOI 10.1016/0531-5565(91)90028-K; KANNISTO V, 1988, POP STUD-J DEMOG, V42, P389, DOI 10.1080/0032472031000143546; KRAINACKER DA, 1987, OECOLOGIA, V73, P583, DOI 10.1007/BF00379420; KRAINACKER DA, 1986, THESIS U CALIFORNIA; Leslie PH, 1940, J ANIM ECOL, V9, P27, DOI 10.2307/1425; Luckinbill LS, 1988, EVOL ECOL, V2, P85, DOI 10.1007/BF02071591; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; MERTZ DB, 1975, PHYSIOL ZOOL, V48, P1; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; Pearl R, 1927, AM NAT, V61, P289, DOI 10.1086/280154; Pearl R, 1935, Q REV BIOL, V10, P60, DOI 10.1086/394476; Pearl R, 1923, AM NAT, V57, P153, DOI 10.1086/279913; Pearl R, 1924, AM NAT, V58, P71, DOI 10.1086/279956; PROMISLOW DEL, 1991, EVOLUTION, V45, P1869, DOI 10.1111/j.1558-5646.1991.tb02693.x; RAGLAND SS, 1973, EXP GERONTOL, V8, P135, DOI 10.1016/0531-5565(73)90003-X; ROCKSTEIN M, 1959, GERONTOLOGY, V3, P23, DOI 10.1159/000210828; ROGERS A, 1992, DEMOGRAPHY, V29, P31, DOI 10.2307/2061361; SCHWARZ AJ, 1985, FLA ENTOMOL, V68, P467, DOI 10.2307/3495135; SMITH JM, 1958, J EXP BIOL, V35, P832; SOHAL RS, 1981, EXP GERONTOL, V16, P157, DOI 10.1016/0531-5565(81)90040-1; TATAR M, UNPUB; THATCHER AR, 1982, J I ACTUARIES, V109, P346; Vargas R., 1989, FRUIT FLIES THEIR B, V3B, P141; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; VAUPEL JW, 1979, DEMOGRAPHY, V16, P3; VAUPEL JW, 1988, MATH POPUL STUD, V1, P21, DOI DOI 10.1080/08898488809525259	46	455	462	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					457	461						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411540				2022-12-24	WOS:A1992JT77500033
J	PLUMP, AS; SMITH, JD; HAYEK, T; AALTOSETALA, K; WALSH, A; VERSTUYFT, JG; RUBIN, EM; BRESLOW, JL				PLUMP, AS; SMITH, JD; HAYEK, T; AALTOSETALA, K; WALSH, A; VERSTUYFT, JG; RUBIN, EM; BRESLOW, JL			SEVERE HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS IN APOLIPOPROTEIN-E-DEFICIENT MICE CREATED BY HOMOLOGOUS RECOMBINATION IN ES CELLS	CELL			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; III HYPERLIPOPROTEINEMIA; E POLYMORPHISM; MESSENGER-RNA; STOP CODON; RAT-LIVER; A-I; MOUSE; GENE	apoE-deficient mice have been created by homologous recombination in ES cells. On a low fat, low cholesterol chow diet these animals have plasma cholesterol levels of 494 mg/dl compared with 60 mg/dl in control animals, and when challenged with a high fat Western-type diet, these animals have plasma cholesterol levels of 1821 mg/dl compared with 132 mg/dl in controls. This marked hypercholesterolemia is primarily due to elevated levels of very low and intermediate density lipoproteins. At 10 weeks of age, apoE-deficient mice have already developed atherosclerotic lesions in the aorta and coronary and pulmonary arteries. apoE-deficient mice are a promising small animal model to help understand the role of apoE in vivo and the genetic and environmental determinants of atherosclerosis.	LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	PLUMP, AS (corresponding author), ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA.		Breslow, Jan L/B-7544-2008; Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033714, R01HL032435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32435, HL-33714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbey M., 1992, CURR OPIN LIPIDOL, V3, P12, DOI [10.1097/00041433-199202000-00003, DOI 10.1097/00041433-199202000-00003]; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HORIUCHI K, 1989, J BIOCHEM-TOKYO, V106, P98, DOI 10.1093/oxfordjournals.jbchem.a122828; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KATES M, 1966, BIOCHEMISTRY-US, V5, P4092, DOI 10.1021/bi00876a044; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SMITH JD, 1990, J BIOL CHEM, V265, P14709; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UTERMANN G, 1982, HUM GENET, V60, P344, DOI 10.1007/BF00569216; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059; ZANNIS VI, 1982, J LIPID RES, V23, P911; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; 1987, NATIONAL HLTH NUTRIT	43	1869	1994	2	128	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					343	353		10.1016/0092-8674(92)90362-G	http://dx.doi.org/10.1016/0092-8674(92)90362-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423598				2022-12-24	WOS:A1992JU39500019
J	BORGSTAHL, GEO; PARGE, HE; HICKEY, MJ; BEYER, WF; HALLEWELL, RA; TAINER, JA				BORGSTAHL, GEO; PARGE, HE; HICKEY, MJ; BEYER, WF; HALLEWELL, RA; TAINER, JA			THE STRUCTURE OF HUMAN MITOCHONDRIAL MANGANESE SUPEROXIDE-DISMUTASE REVEALS A NOVEL TETRAMERIC INTERFACE OF 2 4-HELIX BUNDLES	CELL			English	Article							TUMOR NECROSIS FACTOR; OXIDATIVE DAMAGE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; PSEUDOMONAS-OVALIS; OXYGEN RADICALS; CDNA SEQUENCE; CYTO-TOXICITY; RESOLUTION; EXPRESSION	The 2.2 angstrom resolution crystal structure of recombinant human manganese superoxide dismutase, a homotetrameric enzyme that protects mitochondria against oxygen-mediated free radical damage, has been determined. Within each subunit, both the N-terminal helical hairpin and C-terminal alpha/beta domains contribute ligands to the catalytic manganese site. Two identical 4-helix bundles, symmetrically assembled from the N-terminal helical hairpins, form novel tetrameric interfaces that stabilize the active sites. Structurally altered polymorphic variants with reduced activity, such as tetrameric interface mutant Ile-58 to Thr, may produce not only an early selective advantage, through enhanced cytotoxicity of tumor necrosis factor for virus-infected cells, but also detrimental effects from increased mitochondrial oxidative damage, contributing to degenerative conditions, including diabetes, aging, and Parkinson's and Alzheimer's diseases.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	BORGSTAHL, GEO (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Borgstahl, Gloria/AAZ-4114-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NIGMS NIH HHS [GM39345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ALLISON AC, 1956, SCI AM, V195, P87, DOI 10.1038/scientificamerican0856-87; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BEEM KM, 1976, J MOL BIOL, V105, P327, DOI 10.1016/0022-2836(76)90115-7; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P5561; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BEYER WF, 1987, BIOCHEMISTRY-US, V26, P1251, DOI 10.1021/bi00379a008; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P250, DOI 10.1016/0167-4781(90)90213-L; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CROUCH RK, 1981, DIABETES, V30, P235, DOI 10.2337/diab.30.3.235; DEUTSCH HF, 1991, J MOL BIOL, V219, P103, DOI 10.1016/0022-2836(91)90860-9; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GORECKI M, 1991, FREE RADICAL RES COM, V12-3, P401, DOI 10.3109/10715769109145810; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALLEWELL RA, 1986, NUCLEIC ACIDS RES, V14, P9539, DOI 10.1093/nar/14.23.9539; HALLIWELL B, 1985, PHILOS T ROY SOC B, V311, P659, DOI 10.1098/rstb.1985.0171; Halliwell B, 1989, FREE RADICAL BIO MED, P22; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; HECKL K, 1988, NUCLEIC ACIDS RES, V16, P6224, DOI 10.1093/nar/16.13.6224; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HOUSSET B, 1981, CLIN RES PROC, V17, P107; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; KIRBY TW, 1981, ARCH BIOCHEM BIOPHYS, V210, P140, DOI 10.1016/0003-9861(81)90174-0; KRALL J, 1988, J BIOL CHEM, V263, P1910; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MATSUDA Y, 1990, EUR J BIOCHEM, V194, P713, DOI 10.1111/j.1432-1033.1990.tb19461.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCREE DE, 1990, J BIOL CHEM, V265, P14234; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUROHARA Y, 1991, AM J CARDIOL, V67, P765, DOI 10.1016/0002-9149(91)90538-V; NAIN M, 1990, J IMMUNOL, V145, P1921; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NAMBA K, 1989, J MOL BIOL, V208, P307, DOI 10.1016/0022-2836(89)90391-4; NATH N, 1984, DIABETES, V33, P586, DOI 10.2337/diabetes.33.6.586; NATVIG DO, 1987, J BIOL CHEM, V262, P14697; NIWA Y, 1990, BLOOD, V76, P835; NOMIKOS IN, 1989, IMMUNOL CELL BIOL, V67, P85, DOI 10.1038/icb.1989.12; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SATO S, 1978, J BIOCHEM-TOKYO, V83, P1165, DOI 10.1093/oxfordjournals.jbchem.a132007; SATO S, 1977, EUR J BIOCHEM, V73, P373, DOI 10.1111/j.1432-1033.1977.tb11328.x; SMITH MW, 1992, J MOL EVOL, V34, P175; STALLINGS WC, 1984, J BIOL CHEM, V259, P695; STCLAIR DK, 1991, CANCER RES, V51, P939; STINE OC, 1992, J MOL EVOL, V34, P336; STODDARD BL, 1990, PROTEIN ENG, V4, P113, DOI 10.1093/protein/4.2.113; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1991, STUDY ENZYMES, V2, P499; TAYLOR R, 1992, J NIH RES, V4, P62; TOUATI D, 1988, FREE RADICAL BIO MED, V5, P393, DOI 10.1016/0891-5849(88)90113-X; WAGNER UG, 1989, J MOL BIOL, V206, P787, DOI 10.1016/0022-2836(89)90586-X; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yoon JW, 1990, CURR TOP MICROBIOL I, V164, P95; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	86	410	421	2	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					107	118		10.1016/0092-8674(92)90270-M	http://dx.doi.org/10.1016/0092-8674(92)90270-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394426				2022-12-24	WOS:A1992JQ62300011
J	OOI, CE; WEISS, J				OOI, CE; WEISS, J			BIDIRECTIONAL MOVEMENT OF A NASCENT POLYPEPTIDE ACROSS MICROSOMAL-MEMBRANES REVEALS REQUIREMENTS FOR VECTORIAL TRANSLOCATION OF PROTEINS	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; PERMEABILITY-INCREASING PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; ROUGH MICROSOMES; ER MEMBRANE; RECEPTOR; SEQUENCE; TRANSLATION; IDENTIFICATION	The translocation of polypeptides across the endoplasmic reticulum is a vectorial process that occurs probably through a protein channel by a mechanism as yet undetermined. Here, we demonstrate bidirectional movement of a 221 residue nascent polypeptide across microsomal membranes and provide evidence suggesting that the retrograde movement is through the translocation channel. Retrograde movement is observed only when the polypeptide is generated from a truncated transcript; addition of a stop codon after codon 221 confers vectorial movement. Retrograde movement can also be prevented by glycosylation of the nascent polypeptide, as well as by inclusion of 32 additional amino acids that may promote folding of the translocated chain. We propose that the protein translocation channel is a passive pore that does not create a directional bias in polypeptide movement and that vectorial translocation is driven by nascent chain elongation and sustained by posttranslocation events that prevent retrograde movement.			OOI, CE (corresponding author), NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK 05472] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193; CASKEY CT, 1980, TRENDS BIOCHEM SCI, V5, P234, DOI 10.1016/S0968-0004(80)80809-7; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DOOHAN JP, 1992, VIROLOGY, V186, P409, DOI 10.1016/0042-6822(92)90006-B; ELSBACH P, 1990, TRENDS BIOTECHNOL, V8, P26, DOI 10.1016/0167-7799(90)90127-J; Elsbach P., 1988, INFLAMMATION BASIC P, P445; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MANNION BA, 1990, J CLIN INVEST, V86, P631, DOI 10.1172/JCI114755; MARRA MN, 1990, J IMMUNOL, V144, P662; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RABINOVICH YM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P193, DOI 10.1016/0167-4781(91)90007-9; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEISS J, 1978, J BIOL CHEM, V253, P2664; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	50	77	77	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					87	96		10.1016/0092-8674(92)90268-H	http://dx.doi.org/10.1016/0092-8674(92)90268-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394433				2022-12-24	WOS:A1992JQ62300009
J	ESMAIL, A; ANDERSON, HR; RAMSEY, JD; TAYLOR, J; POTTIER, A				ESMAIL, A; ANDERSON, HR; RAMSEY, JD; TAYLOR, J; POTTIER, A			CONTROLLING DEATHS FROM VOLATILE SUBSTANCE-ABUSE IN UNDER 18S - THE EFFECTS OF LEGISLATION	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,TOXICOL UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London	ESMAIL, A (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Esmail, Aneez/I-6903-2013					ANDERSON HR, 1985, BRIT MED J, V290, P304, DOI 10.1136/bmj.290.6464.304; FLANAGAN RJ, 1990, DRUG SAFETY, V5, P359, DOI 10.2165/00002018-199005050-00005; LISS BI, 1989, HUM TOXICOL, V8, P327, DOI 10.1177/096032718900800413; WRIGHT SP, 1991, TRENDS DEATHS ASS AB; 1986, GENERALISED LINEAR I	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					692	692		10.1136/bmj.305.6855.692	http://dx.doi.org/10.1136/bmj.305.6855.692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP511	1393114	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JP51100023
J	WIDGERY, D				WIDGERY, D			AIDS FAREWELLS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					590	590						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393064				2022-12-24	WOS:A1992JM49500072
J	MACKENZIE, WR; DAVIS, JP; PETERSON, DE; HIBBARD, AJ; BECKER, G; ZARVAN, BS				MACKENZIE, WR; DAVIS, JP; PETERSON, DE; HIBBARD, AJ; BECKER, G; ZARVAN, BS			MULTIPLE FALSE-POSITIVE SEROLOGIC TESTS FOR HIV, HTLV-1, AND HEPATITIS-C FOLLOWING INFLUENZA VACCINATION, 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-(1) To assess factors associated with the occurrence of multiple false-positive viral enzyme-linked immunosorbent assays (ELISAs) for human immunodeficiency virus (HIV), human T-cell lymphotrophic virus type 1 (HTLV-1), and hepatitis C virus (HCV) among individual blood donors and (2) to determine the frequency and time course of this phenomenon. Design.-Case-control study. Setting.-A regional blood center. Participants.-Blood donors found to have multiple false-positive viral ELISAs (case donors) and randomly selected seronegative controls (control donors) who donated between October 31, 1991, and December 15, 1991. An additional random sample of 262 donation records was reviewed to calculate the proportion of donors who received influenza vaccine. Main Outcome Measures.-Multiple false-positive viral ELISAs, receipt of influenza vaccination formulated for the 1991-1992 influenza season, and follow-up ELISA results on serum samples obtained from case donors. Results.-Among 17941 donors, 10 case donors were identified. Nine of the 10 case donors received influenza vaccine, compared with three of 30 control donors (odds ratio [OR]=81; 95% confidence interval [CI], 6 to 3670; P<.001). Among nine case donors, the mean time between vaccination and blood donation was 26 days (range, 9 to 68 days). Follow-up ELISAs of serum samples from seven case donors obtained 52 to 130 days (mean, 75 days) after vaccination demonstrated reversion to HIV and HTLV-1 seronegativity in all but one specimen, with persistence of positive HCV ELISAs in four specimens. We estimate between 0.6% and 1.7% of blood donors who received influenza vaccine this season had multiple false-positive viral ELISAs. Conclusions.-The occurrence of multiple false-positive viral ELISAs among blood donors was associated with influenza vaccination, but was infrequent among vaccinees. This phenomenon is of short duration for HIV and HTLV-1, but may persist longer for HCV. We recommend influenza vaccinees not be deferred from blood donation. Blood donors with multiple false-positive viral ELISAs should be considered for future reentry as blood donors.	CTR DIS CONTROL,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; AMER RED CROSS,BLOOD SERV,BADGER REG,MADISON,WI	Centers for Disease Control & Prevention - USA; American Red Cross	MACKENZIE, WR (corresponding author), WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,1400 & WASHINGTON AVE,ROOM 96,MADISON,WI 53703, USA.		Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				Colton T, 1974, STAT MED, P160; FANG CT, 1988, TRANSFUSION, V28, P179, DOI 10.1046/j.1537-2995.1988.28288179027.x; MENTA CR, 1985, J AM STAT ASSOC, V78, P969; 1985, MMWR, V34, P1; 1991, MMWR, V40, P1	5	58	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1015	1017		10.1001/jama.268.8.1015	http://dx.doi.org/10.1001/jama.268.8.1015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501307				2022-12-24	WOS:A1992JK12900028
J	BEEKEN, S; WATERSTON, T				BEEKEN, S; WATERSTON, T			HEALTH-SERVICE SUPPORT OF BREAST-FEEDING - ARE WE PRACTICING WHAT WE PREACH	BRITISH MEDICAL JOURNAL			English	Article								Objective-To ascertain the attitudes of health professionals and breast feeding mothers to breast feeding and their views on current practice. Design-Questionnaire to all midwives and health visitors and to breast feeding mothers in Newcastle upon Tyne. Setting-Maternity units and community in Newcastle upon Tyne. Subjects-127 hospital midwives, 23 community midwives, 63 health visitors, and 50 first time breast feeding mothers. Results-Optimum practice guidelines were not followed. 30 (60%) mothers said they were separated from their babies on the first night after birth. 82 (42%) professionals said that breast fed babies were frequently given water to drink. 28 (56%) babies in the mothers survey had received food or water other than breast milk; 19 of these had been given water. Professionals expressed mainly positive attitudes towards breast feeding in general but less positive attitudes to specific issues such as the beneficial effects on child health and the value of voluntary organisations in breast feeding promotion and management. Conclusions-Although many health workers are in favour of breast feeding there is conflict among the professions working most closely with breast feeding mothers. Good breast feeding support requires closer attention to monitoring hospital practices and continued training on good lactation management.	NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital								BLOOM K, 1982, ACTA PAEDIATR SC   S, V300, P9; CRUSE P, 1978, ARCH DIS CHILD, V53, P76, DOI 10.1136/adc.53.1.76; EMERY JL, 1990, ARCH DIS CHILD-FETAL, V65, P369, DOI 10.1136/adc.65.4_Spec_No.369; FRANK DA, 1987, PEDIATRICS, V80, P845; Grant J. Shaw, 1992, SHILLING YOUR SCOWL, P44; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JELLIFE DB, 1988, PROGRAMMES PROMOTE B; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; MARTIN J, 1988, INFANT FEEDING 1985; SALARIYA EM, 1978, LANCET, V2, P1141; WELLS N, 1987, PROGR CHILD HLTH, V3; 1988, C LAUNCH JOINT BREAS; 1988, SUCCESSFUL BREASTFEE	13	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					285	287		10.1136/bmj.305.6848.285	http://dx.doi.org/10.1136/bmj.305.6848.285			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392861	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JG74000019
J	SIDRANSKY, D; FROST, P; VONESCHENBACH, A; OYASU, R; PREISINGER, AC; VOGELSTEIN, B				SIDRANSKY, D; FROST, P; VONESCHENBACH, A; OYASU, R; PREISINGER, AC; VOGELSTEIN, B			CLONAL ORIGIN OF BLADDER-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL CARCINOMAS; MOLECULAR-GENETICS; X-CHROMOSOME; HUMAN-TUMORS; P53 GENE; REARRANGEMENTS; IDENTIFICATION; RETINOBLASTOMA; MUTATIONS; ALLELE	Background. Patients with cancer of the urinary bladder often present with multiple tumors, appearing at different times and at different sites in the bladder. This observation has been attributed to a "field defect" in the bladder that allows the independent transformation of epithelial cells at a number of sites. We tested this hypothesis using molecular genetic techniques. Methods. We examined 13 tumors from cystectomy specimens from four women, using a method that analyzes the pattern of X-chromosome inactivation to determine whether the tumors were derived from the same precursor cell. In addition, we analyzed allelic loss on autosomes to determine whether different tumors had the same genetic alterations. The alterations evaluated included the loss of chromosome 9q sequences (commonly found in superficial bladder tumors) and the loss of 17p and 18q sequences (usually found only in advanced tumors). Results. For each patient studied, all the tumors had inactivation of the same X chromosome, whereas normal bladder mucosa cells had random patterns of inactivation. Moreover, each tumor that could be evaluated from a given patient had lost the same allele on chromosome 9q, suggesting that the loss of this allele preceded the spread of neoplastic cells elsewhere in the bladder. The losses of chromosome 17p and 18q alleles, which are late events in tumor progression, were not common to different tumors from the same patient. Conclusions. A number of bladder tumors can arise from the uncontrolled spread of a single transformed cell. These tumors can then grow independently with variable subsequent genetic alterations.	JOHNS HOPKINS ONCOL CTR,DEPT ONCOL,424 N BOND ST,BALTIMORE,MD 21231; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT UROL,HOUSTON,TX 77030; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Northwestern University								ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; DRYJA TP, 1989, NATURE, V339, P556, DOI 10.1038/339556a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; IP NY, 1989, NUCLEIC ACIDS RES, V17, P8404, DOI 10.1093/nar/17.20.8404; KELMAN Z, 1989, BLOOD, V74, P2318; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LYON MF, 1990, NATURE, V348, P585, DOI 10.1038/348585a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3119, DOI 10.1093/nar/16.7.3119; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10607, DOI 10.1093/nar/15.24.10607; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10073, DOI 10.1093/nar/15.23.10073; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9369, DOI 10.1093/nar/16.19.9369; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PAL N, 1990, ONCOGENE, V5, P1665; PRESTI JC, 1991, CANCER RES, V51, P5405; RICHIE JP, 1989, CANCER PRINCIPLES PR, V1, P1008; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V19, P163, DOI 10.1016/0165-4608(86)90384-5; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; TSAI YC, 1990, CANCER RES, V50, P44; VEENEMA RJ, 1977, CANCER RES, V37, P2836; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WU SQ, 1991, CANCER RES, V51, P3323; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1988, REPORTING MANUAL STA	34	464	474	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					737	740		10.1056/NEJM199203123261104	http://dx.doi.org/10.1056/NEJM199203123261104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1445507				2022-12-24	WOS:A1992HH06400004
J	ERNST, P; SPITZER, WO; SUISSA, S; COCKCROFT, D; HABBICK, B; HORWITZ, RI; BOIVIN, JF; MCNUTT, M; BUIST, AS				ERNST, P; SPITZER, WO; SUISSA, S; COCKCROFT, D; HABBICK, B; HORWITZ, RI; BOIVIN, JF; MCNUTT, M; BUIST, AS			RISK OF FATAL AND NEAR-FATAL ASTHMA IN RELATION TO INHALED CORTICOSTEROID USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LONG-TERM TREATMENT; BUDESONIDE; RESPONSIVENESS; TERBUTALINE	Objective.-To examine the relationship between patterns of use of inhaled beclomethasone dipropionate and the risk of fatal and near-fatal asthma. Design.-Nested case-control analysis of a historical cohort; a further analysis. Setting.-The 12 301 residents of Saskatchewan aged 5 to 54 years who were dispensed 10 or more asthma drugs from 1978 to 1987. Patients.-The 129 persons who experienced asthma death (n=44) and near-death (n=85) and their 655 controls matched as to age and date of entry into the cohort, with the additional matching criteria of at least one hospitalization for asthma in the prior 2 years, region of residence, and having received social assistance. Main Outcome.-Life-threatening attacks of asthma defined as death due to asthma or the occurrence of hypercarbia, intubation, and mechanical ventilation during an acute attack of asthma. Results.-After accounting for the risk associated with use of other medications and adjustment for markers of risk of adverse events related to asthma, subjects who had been dispensed, on average, one or more metered-dose inhalers of beclomethasone per month over a 1-year period had a significantly lower risk of fatal and near-fatal asthma (odds ratio, 0.1; 95% confidence interval, 0.02 to 0.6). Conclusion.-These data support recent guidelines from several countries that recommend the use of inhaled corticosteroids in moderate and severe asthma.	MONTREAL GEN HOSP,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV SASKATCHEWAN,DEPT MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT COMMUNITY HLTH & EPIDEMIOL,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; SASKATCHEWAN DEPT HLTH,LAB & DIS CONTROL SERV BRANCH,HE ROBERTSON LAB,REGINA,SASKATCHEWAN,CANADA; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201	McGill University; McGill University; McGill University; University of Saskatchewan; University of Saskatchewan; Yale University; Oregon Health & Science University; Oregon Health & Science University	ERNST, P (corresponding author), RESP EPIDEMIOL UNIT,1110 PINE AVE W,MONTREAL H3A 1A3,QUEBEC,CANADA.							[Anonymous], 1990, BMJ, V301, P651; BRESLOW NE, 1980, STATISTICAL METHODS, P1; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; TOOGOOD JH, 1985, BRONCHIAL ASTHMA MEC, P698; WEST R, 1987, AM J PREV MED S2, V4, P25; 1991, 913042 DEP HLTH HUM	15	210	214	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3462	3464		10.1001/jama.268.24.3462	http://dx.doi.org/10.1001/jama.268.24.3462			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460737				2022-12-24	WOS:A1992KC83900035
J	GUSTAFSSON, C; ASPLUND, K; BRITTON, M; NORRVING, B; OLSSON, B; MARKE, LA				GUSTAFSSON, C; ASPLUND, K; BRITTON, M; NORRVING, B; OLSSON, B; MARKE, LA			COST-EFFECTIVENESS OF PRIMARY STROKE PREVENTION IN ATRIAL-FIBRILLATION - SWEDISH NATIONAL PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective-To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population. Design-Analysis of cost effectiveness based on the following assumptions: about 83 000 people have atrial fibrillation in Sweden, of whom 22 000 would be potential candidates for treatment with anticoagulants and 55 000 for aspirin treatment; the annual 5% stroke rate is reduced by 64% (with anticoagulants) and 25% (with aspirin); incidence of intracranial haemorrhage of 0.3%, 1.3%, or 2.0% per year; direct and indirect costs of a stroke of Kr180 000 and Kr90 000; estimated annual cost of treatment is Kr5030 for anticoagulants and Kr100 for aspirin. Setting-Total Swedish population. Main outcome measures-Direct and indirect costs of stroke saved, number of strokes prevented, and cost of preventive treatment. Results-Depending on the rate of haemorrhagic complications 34 to 83 patients would need to be treated annually with anticoagulants to prevent one stroke; 83 patients would need to be treated with aspirin. Giving anticoagulant treatment only would reduce costs by Kr60 million if the incidence of intracranial haemorrhage were 0.3% but would imply a net expense if the complication rate exceeded 1.3%. The total savings from giving anticoagulant (22 000 patients) and aspirin (55 000 patients) treatment would be Kr175 million per year corresponding to 2 million Pounds per million inhabitants each year. Conclusions-Treatment with anticoagulants and, if contraindications exist, with aspirin is cost effective provided that the risk of serious haemorrhage complications due to anticoagulants is kept low.	UMEA REG HOSP,DEPT MED,UMEA,SWEDEN; ST GORANS UNIV HOSP,DEPT MED,S-11281 STOCKHOLM,SWEDEN; LUND HOSP,DEPT NEUROL,LUND,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; LUND HOSP,DEPT CARDIOL,LUND,SWEDEN	Saint Goran's Hospital	GUSTAFSSON, C (corresponding author), MARIESTAD HOSP,DEPT MED,BOX 411,S-54224 MARIESTAD,SWEDEN.			Norrving, Bo/0000-0002-8024-5096				ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CONOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDAHL S, 1984, EUR HEART J, V5, P326, DOI 10.1093/oxfordjournals.eurheartj.a061659; PETERSEN P, 1989, LANCET, V1, P175; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; 1991, CIRCULATION, V84, P527; 1988, BMJ, V296, P320; 1990, NEW ENGL J MED, V323, P1505	10	126	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1457	1460		10.1136/bmj.305.6867.1457	http://dx.doi.org/10.1136/bmj.305.6867.1457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493390	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992KC91800019
J	DARMIENTO, J; DALAL, SS; OKADA, Y; BERG, RA; CHADA, K				DARMIENTO, J; DALAL, SS; OKADA, Y; BERG, RA; CHADA, K			COLLAGENASE EXPRESSION IN THE LUNGS OF TRANSGENIC MICE CAUSES PULMONARY-EMPHYSEMA	CELL			English	Article							CONNECTIVE-TISSUE; HEPATIC-FIBROSIS; ANIMAL-MODELS; PATHOGENESIS; ELASTASE; DISEASE; GENE; METALLOPROTEINASES; INHIBITORS; EFFICIENT	Transgenic mice were generated that expressed a human collagenase transgene in their lungs under the direction of the haptoglobin promoter. Histological analysis demonstrated disruption of the alveolar walls and coalescence of the alveolar spaces with no evidence of fibrosis or inflammation. This pathology is strikingly similar to the morphological changes observed in human emphysema and therefore implicates interstitial collagenase as a possible etiological agent in the disease process. Although elastase has been proposed as the primary enzyme responsible for emphysematous lung damage, this study provides evidence that other extracellular matrix proteases could play a role in emphysema. In addition, these transgenic mice are a defined genetic animal model system to study the pathogenesis of emphysema.	KANAZAWA UNIV, SCH MED, DEPT PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University	DARMIENTO, J (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.		Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG RA, 1989, THERAPEUTIC APPROACHES TO INFLAMMATORY DISEASES, P84; BERMAN M, 1980, COLLAGENASE NORMAL P, P141; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; CLEWELL DB, 1972, J BACTERIOL, V110, P1135, DOI 10.1128/JB.110.3.1135-1146.1972; CORRIN B, 1990, LUNGS, V5, P167; EMONARD H, 1989, HEPATOLOGY, V10, P77, DOI 10.1002/hep.1840100116; Gibbs AR, 1984, OCCUPATIONAL LUNG DI, P129; GOLDRING IP, 1968, ARCH ENVIRON HEALTH, V16, P59, DOI 10.1080/00039896.1968.10665015; GROSS P, 1965, ARCH ENVIRON HEALTH, V11, P50, DOI 10.1080/00039896.1965.10664169; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P657; HARRIS ED, 1974, NEW ENGL J MED, V291, P652, DOI 10.1056/NEJM197409262911305; HARRIS ED, 1977, MAMMALIAN COLLAGENAS, P249; Hogan B., 1986, MANIPULATING MOUSE E; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; HOIDAL JR, 1989, HDB ANIMAL MODELS PU; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JOHANSON WG, 1972, J CLIN INVEST, V51, P288, DOI 10.1172/JCI106813; KARLINSKY JB, 1978, AM REV RESPIR DIS, V117, P1109; KESSLER S, 1975, LAB INVEST, V32, P71; KILBURN KH, 1971, ARCH INTERN MED, V127, P884, DOI 10.1001/archinte.127.5.884; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUSHNER I, 1987, DIS MARKERS, V5, P1; LAROS CD, 1976, RESPIRATION, V33, P325, DOI 10.1159/000193748; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCLAUGHLIN RF, 1971, CHEST, V59, P592, DOI 10.1378/chest.59.6.592; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAELI D, 1974, CLIN IMMUNOL IMMUNOP, V3, P187, DOI 10.1016/0090-1229(74)90004-X; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; OKAZAKI I, 1974, NATURE, V252, P49, DOI 10.1038/252049a0; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PUTT F, 1972, MANUAL HISTOPATHOLOG, P111; RILEY DJ, 1987, AM REV RESPIR DIS, V135, P441; RUBIN E, 1988, PATHOLOGY, P542; Sambrook J., 1989, MOL CLONING LAB MANU; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SNIDER GL, 1989, ANNU REV MED, V40, P411; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P149, DOI 10.1164/arrd.1986.133.1.149; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; UITTO J, 1987, CONNECTIVE TISSUE DI, V12; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YU SY, 1978, EXP MOL PATHOL, V29, P37, DOI 10.1016/0014-4800(78)90024-2; [No title captured]	55	281	301	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					955	961		10.1016/0092-8674(92)90391-O	http://dx.doi.org/10.1016/0092-8674(92)90391-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458541				2022-12-24	WOS:A1992KB99000008
J	HEDBERG, CW; KORLATH, JA; DAOUST, JY; WHITE, KE; SCHELL, WL; MILLER, MR; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT				HEDBERG, CW; KORLATH, JA; DAOUST, JY; WHITE, KE; SCHELL, WL; MILLER, MR; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT			A MULTISTATE OUTBREAK OF SALMONELLA-JAVIANA AND SALMONELLA-ORANIENBURG INFECTIONS DUE TO CONSUMPTION OF CONTAMINATED CHEESE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEDDAR CHEESE	Objective.-To determine the source of an outbreak of Salmonella javiana and Salmonella oranienburg infections. Design.-Laboratory-based statewide surveillance for Salmonella infections and two separate case-control studies. Setting.-Community- and industry-based studies conducted from May through October 1989. Participants.-Thirty-one culture-confirmed outbreak-associated cases of S javiana infection and 60 community controls matched for telephone prefix, gender, and age in case-control study I; 50 cases, 100 community controls, and 64 family member controls in case-control study II. Results.-One hundred thirty-six culture-confirmed cases of S javiana infection and 11 cases of S oranienburg infection were associated with the outbreak in Minnesota. Outbreak-associated cases were also identified in Wisconsin (15 cases), and in Michigan and New York (one case each). Cases were more likely than controls to have consumed mozzarella cheese manufactured at a single cheese plant (plant X) or cheese that had been shredded at processing plants that also shredded cheese manufactured at plant X (odds ratio [OR], 7.2; 95% confidence interval [CI], 1.7 to 23.2; P<.01). The outbreak-associated strains of both serovars were isolated from two unopened 16-oz (0.45-kg) blocks of mozzarella cheese produced at plant X. The most probable numbers of Salmonella organisms in these samples were 0.36/100 g and 4.3/100 g. Conclusions.-The potential for bacterial pathogen contamination of cheese during manufacture and processing has important epidemiologic implications, particularly because cheese consumption has recently increased in the United States. Low-level contamination of a nationally distributed food product can cause geographically dispersed foodborne outbreaks that may be difficult to detect.	MINNESOTA DEPT HLTH,EPIDEMIOL FIELD SERV SECT,MINNEAPOLIS,MN; MINNESOTA DEPT HLTH,DIV PUBL HLTH LABS,MINNEAPOLIS,MN; HLTH & WELF CANADA,HLTH PROTECT BRANCH,SIR FG BANTING RES CTR,OTTAWA K1A 0L2,ONTARIO,CANADA; WISCONSIN DEPT HLTH & SOCIAL SERV,DIV HLTH,MADISON,WI; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA	HEDBERG, CW (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440, USA.							ANDREWS WH, 1984, BACTERIOLOGICAL ANAL, pCH7; BARRY AL, 1985, MANUAL CLIN MICROBIO, pCH102; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Breslow N.E., 1980, STAT METHODS CANC RE, P192; CHALKER RB, 1988, REV INFECT DIS, V10, P111; DAOUST JY, 1989, J FOOD PROTECT, V52, P906, DOI 10.4315/0362-028X-52.12.906; DAOUST JY, 1985, AM J EPIDEMIOL, V122, P717, DOI 10.1093/oxfordjournals.aje.a114151; Felip G. de, 1984, Microbiologie - Aliments - Nutrition, V2, P251; FONTAINE RE, 1980, AM J EPIDEMIOL, V111, P247, DOI 10.1093/oxfordjournals.aje.a112892; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; PUTNAM AJ, 1989, USDA STATISTICAL B, V773; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P84; ROTHMAN KJ, 1979, EPIDEMIOLOGIC ANAL P, P5; 1978, MFHPB20 HLTH WELF CA, P1	14	63	63	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3203	3207		10.1001/jama.268.22.3203	http://dx.doi.org/10.1001/jama.268.22.3203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433759				2022-12-24	WOS:A1992KA65400025
J	LEONHARDT, H; PAGE, AW; WEIER, HU; BESTOR, TH				LEONHARDT, H; PAGE, AW; WEIER, HU; BESTOR, TH			A TARGETING SEQUENCE DIRECTS DNA METHYLTRANSFERASE TO SITES OF DNA-REPLICATION IN MAMMALIAN NUCLEI	CELL			English	Article							PRE-MESSENGER-RNA; MURINE ERYTHROLEUKEMIA-CELLS; INTRACELLULAR-LOCALIZATION; POLYMERASE-ALPHA; SATELLITE DNA; LIGASE-I; EXPRESSION; DOMAINS; HYBRIDIZATION; SPECIFICITY	Tissue-specific patterns of methylated deoxycytidine residues in the mammalian genome are preserved by postreplicative methylation of newly synthesized DNA. DNA methyltransferase (MTase) is here shown to associate with replication foci during S phase but to display a diffuse nucleoplasmic distribution in non-S phase cells. Analysis of DNA MTase-beta-galactosidase fusion proteins has shown that association with replication foci is mediated by a novel targeting sequence located near the N-terminus of DNA MTase. This sequence has the properties expected of a targeting sequence in that it is not required for enzymatic activity, prevents proper targeting when deleted, and, when fused to beta-galactosidase, causes the fusion protein to associate with replication foci in a cell cycle-dependent manner.	UNIV CALIF SAN FRANCISCO, DEPT LAB MED, DIV MOLEC CYTOMETRY, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	LEONHARDT, H (corresponding author), HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA.		Leonhardt, Heinrich/B-2791-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043565] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17665] Funding Source: Medline; NIGMS NIH HHS [GM43565] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BECK JS, 1961, LANCET, V1, P1203; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; DANDREA AD, 1983, NUCLEIC ACIDS RES, V11, P4753, DOI 10.1093/nar/11.14.4753; FOX MH, 1991, J CELL SCI, V99, P247; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MEIER UT, 1992, CELL, V70, P127; MILLS AD, 1989, J CELL SCI, V94, P471; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; OTTIGER HP, 1984, P NATL ACAD SCI-BIOL, V81, P3993, DOI 10.1073/pnas.81.13.3993; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 1989, MOL CLONING LAB MANU; SAUNDERS WS, 1991, J CELL BIOL, V115, P919, DOI 10.1083/jcb.115.4.919; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TUBO RA, 1987, J BIOL CHEM, V262, P1148; VISSEL B, 1989, GENOMICS, V5, P407, DOI 10.1016/0888-7543(89)90003-7; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WEIER HU, 1991, BIOTECHNIQUES, V10, P498	52	836	853	1	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					865	873		10.1016/0092-8674(92)90561-P	http://dx.doi.org/10.1016/0092-8674(92)90561-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423634	Green Published			2022-12-24	WOS:A1992JZ63300015
J	TAKAHAMA, Y; SINGER, A				TAKAHAMA, Y; SINGER, A			POSTTRANSCRIPTIONAL REGULATION OF EARLY T-CELL DEVELOPMENT BY T-CELL RECEPTOR SIGNALS	SCIENCE			English	Article							3' UNTRANSLATED REGION; CD8 GENE-EXPRESSION; MESSENGER-RNA; IMMATURE THYMOCYTES; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; V(D)J RECOMBINATION; MURINE THYMOCYTES; TRANSGENIC MICE	During differentiation in the thymus, immature T cells progress through an ordered sequence of developmental stages that are best characterized by variable expression of the co-receptor molecules CD4 and CD8. Crosslinking of T cell receptor (TCR) molecules on precursor thymocytes was found to block their differentiation into CD4+CD8+ cells by eliminating messenger RNA's encoding two families of developmentally important molecules: the co-receptor molecules CD4 and CD8 and the recombination activating genes 1 and 2. TCR-induced post-transcriptional regulation in early thymocytes was specific for selective messenger RNA's, required protein synthesis, and was itself developmentally regulated. These data identify a post-transcriptional mechanism that is influenced by TCR signals and that regulates early thymocyte development.			TAKAHAMA, Y (corresponding author), NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA.		Takahama, Yousuke/A-5863-2010	Takahama, Yousuke/0000-0002-4992-9174				ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHENKIANG S, 1989, METHOD ENZYMOL, V180, P82; CLEVELAND D W, 1989, New Biologist, V1, P121; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; HUSMANN LA, 1988, J IMMUNOL, V141, P736; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUBO RT, 1989, J IMMUNOL, V142, P2736; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8633, DOI 10.1073/pnas.85.22.8633; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PAILLARD F, 1990, EMBO J, V9, P1867, DOI 10.1002/j.1460-2075.1990.tb08312.x; PARDOLL DM, 1987, J EXP MED, V165, P1624, DOI 10.1084/jem.165.6.1624; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PETRIE HT, 1990, EUR J IMMUNOL, V20, P2813, DOI 10.1002/eji.1830201243; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROYER HD, 1985, P NATL ACAD SCI USA, V82, P5510, DOI 10.1073/pnas.82.16.5510; Sambrook J., 1989, MOL CLONING LAB MANU; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHAMA Y, 1992, SCIENCE, V258, P653, DOI 10.1126/science.1357752; TAKAHAMA Y, 1991, J IMMUNOL, V147, P2883; TAKAHAMA Y, UNPUB; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WILKINSON MF, 1991, MOL IMMUNOL, V28, P57, DOI 10.1016/0161-5890(91)90087-Z; Wilson A, 1989, Int Immunol, V1, P605, DOI 10.1093/intimm/1.6.605; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	63	96	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1992	258	5087					1456	1462		10.1126/science.1439838	http://dx.doi.org/10.1126/science.1439838			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1439838				2022-12-24	WOS:A1992JZ62500021
J	KANIS, JA; JOHNELL, O; GULLBERG, B; ALLANDER, E; DILSEN, G; GENNARI, C; VAZ, AAL; LYRITIS, GP; MAZZUOLI, G; MIRAVET, L; PASSERI, M; CANO, RP; RAPADO, A; RIBOT, C				KANIS, JA; JOHNELL, O; GULLBERG, B; ALLANDER, E; DILSEN, G; GENNARI, C; VAZ, AAL; LYRITIS, GP; MAZZUOLI, G; MIRAVET, L; PASSERI, M; CANO, RP; RAPADO, A; RIBOT, C			EVIDENCE FOR EFFICACY OF DRUGS AFFECTING BONE METABOLISM IN PREVENTING HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; WOMEN; RISK; ESTROGEN; DIET	Objective-To examine the effects of taking drugs affecting bone metabolism on the risk of hip fracture in women aged over 50 years. Design-Retrospective, population based, case-control study by questionnaire. Setting-14 centres in six countries in southern Europe. Subjects-2086 women with hip fracture and 3532 control women matched for age. Main outcome measures-Number of drugs affecting bone metabolism taken and length taken for. Results-Women taking drugs affecting bone metabolism had a significantly decreased risk of hip fracture. After adjustment for differences in other risk factors, the relative risk of hip fractures was 0.55 (95% confidence interval 0.31 to 0.85) in women taking oestrogens, 0.75 (0.60 to 0.94) in those taking calcium, and 0.69 (0.51 to 0.92) in those taking calcitonin. The fall in risk was not significant for anabolic steroids (0.6 (0.29 to 1.22)). Neither vitamin D nor fluorides were associated with a significant decrease in the risk of hip fracture. The effect on hip fracture risk increased significantly with increasing duration of exposure (risk ratio 0.8 (0.61 to 1.05) for less than median exposure v 0.66 (0.5 to 0.88) for greater than median exposure). Drugs were equally effective in older and younger women, with the exception of oestrogen. Conclusions-Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture. Short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fracture.	MALMO GEN HOSP,ORTHOPAED,S-21401 MALMO,SWEDEN; MALMO GEN HOSP,MED STAT,S-21401 MALMO,SWEDEN; HUDDINGE UNIV HOSP,DEPT SOCIAL MED,S-14186 HUDDINGE,SWEDEN; ISTANBUL UNIV,FAK CAPA TIP,ISTANBUL,TURKEY; UNIV SIENA,I-53100 SIENA,ITALY; ACCIDENT HOSP,T GAROFALIDIS RES,GR-14561 KIFISIA,GREECE; POLICLIN UMBERTO 1,MED CLIN 2,I-00161 ROME,ITALY; CTR ANDRE LICHTWITZ,INSERM,U18,F-75010 PARIS,FRANCE; IST CLIN MED GEN TERAPIA MED,I-43100 PARMA,ITALY; FDN JIMENEZ DIAZ,DEPT INTERNAL MED,E-28040 MADRID,SPAIN; CHU TOULOUSE PURPAN,SERV ENDOCRINOL,F-31059 TOULOUSE,FRANCE	Karolinska Institutet; Istanbul University; University of Siena; Sapienza University Rome; University Hospital Sapienza Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	KANIS, JA (corresponding author), UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,WHO,COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; CHESNUT CH, 1983, METABOLISM, V32, P571, DOI 10.1016/0026-0495(83)90027-6; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DEQUEKER J, 1991, CLIN RHEUMATOL, V10, P49, DOI 10.1007/BF02208033; DEQUEKER J, 1991, CLIN RHEUMATOL, P54; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; GEUSENS P, 1977, OSTEOPOROSIS, P966; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUTCHINSON TA, 1979, LANCET, V2, P705; Kanis J A, 1991, Osteoporos Int, V1, P182, DOI 10.1007/BF01625451; KANIS JA, 1991, CALCIFIED TISSUE INT, V49, pS33, DOI 10.1007/BF02555086; KANIS JA, 1989, BRIT MED J, V298, P137, DOI 10.1136/bmj.298.6667.137; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; KANIS JA, 1984, LANCET, V1, P27; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MACINTYRE I, 1988, LANCET, V1, P900; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1991, OSTEOPOROSIS INT, V1, P114	24	262	268	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1124	1128		10.1136/bmj.305.6862.1124	http://dx.doi.org/10.1136/bmj.305.6862.1124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463947	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JX84100021
J	RIMPELA, AH; RIMPELA, MK; KOSUNEN, EAL				RIMPELA, AH; RIMPELA, MK; KOSUNEN, EAL			USE OF ORAL-CONTRACEPTIVES BY ADOLESCENTS AND ITS CONSEQUENCES IN FINLAND 1981-91	BRITISH MEDICAL JOURNAL			English	Article							TEENAGE PREGNANCY; UNITED-STATES; WOMEN; COUNTRIES; DISEASE; AGE	Objectives-To study use of oral contraceptives among Finnish teenagers during 1981-91 and how abortions, childbirths, sexually transmitted diseases, and cardiovascular diseases changed during this period. Design-Biannual cross sectional surveys with mailed questionnaires from 1981 onwards and analysis of national statistics. Setting-Finland. Subjects-A nationwide sample of 14, 16, and 18 year olds. Sample size varied from 1249 to 3887 and response rate from 85% to 94%. Main outcome measures-Proportion taking oral contraceptive, fertility and abortion rates, hospital discharge rates, rates of sexually transmitted diseases. Results-The proportion of teenagers taking oral contraceptives increased steadily. In 1991 the percentages among 14, 16, and 18 year olds were 2%, 18%, and 41%,compared with 0.2%, 7% and 22% in 1981. Most users had a steady partner (80% of 16 year olds and 85% of 18 year olds). By 1989 rates of abortion had fallen from 12/1000 to 9.3/1000 in 16 year olds and from 25/1000 to 19.2/1000 in 18 year olds; fertility rates had fallen from 4.5/1000 to 2.3/1000 and from 23.5/1000 to 15.3/1000 respectively. Rates in 14 year olds fell only slightly. Gonorrhoea infection fell and HIV infection remained rare. Rates of hospital discharge after thromboembolic venous disease rose slightly. Conclusions-The increased use of oral contraceptives is the most likely explanation for decreasing abortion and fertility rates among teenagers. Increased reliance on the condom because of the threat of AIDS may increase unwanted pregnancies.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00250 HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20520 TURKU 52,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,SF-33101 TAMPERE,FINLAND	University of Helsinki; University of Turku; Tampere University			Rimpela, Arja/J-3910-2014					ARMITAGE P, 1971, STATISTICAL METHODS; BERAL V, 1988, LANCET, V2, P1331; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; BROOKSGUNN J, 1991, B NY ACAD MED, V76, P527; DAVANZO J, 1991, JAMA-J AM MED ASSOC, V265, P2692; DEBUONO BA, 1990, NEW ENGL J MED, V322, P821, DOI 10.1056/NEJM199003223221206; HARRIS C, 1983, NEW ENGL J MED, V308, P1181, DOI 10.1056/NEJM198305193082001; HIRVONEN E, 1990, AM J OBSTET GYNECOL, V163, P281, DOI 10.1016/0002-9378(90)90568-R; HOFMANN A D, 1984, Bulletin of the World Health Organization, V62, P331; Holmgren K, 1990, Nord Med, V105, P46; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; KONTULA O, 1992, HEALTH EDUC RES, V7, P69, DOI 10.1093/her/7.1.69; KONTULA O, 1988, HLTH ED SERIES ORIGI, V9; KONTULA O, 1991, SUKUPUOLIELAMAN ALOI; MAKKONEN K, 1991, SCAND J SOC MED, V19, P32, DOI 10.1177/140349489101900106; Mandelin M, 1990, Nord Med, V105, P41; PIKE MC, 1983, LANCET, V2, P926; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P2094, DOI 10.1001/jama.254.15.2094; RIMPELA M, 1988, HLTH BEHAVIOUR RES H; RUUSUVAARA L, 1983, THESIS U HELSINKI HE; SHAW RW, 1987, BRIT J OBSTET GYNAEC, V94, P724, DOI 10.1111/j.1471-0528.1987.tb03716.x; THOROGOOD M, 1990, AM J OBSTET GYNECOL, V163, P274, DOI 10.1016/0002-9378(90)90567-Q; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; Tikkanen J, 1988, Hygie, V7, P28; TURETSKY RA, 1983, CLIN PEDIATR, V22, P337, DOI 10.1177/000992288302200503; TYRER L B, 1977, Clinical Obstetrics and Gynecology, V20, P651, DOI 10.1097/00003081-197709000-00013; WALLACE HM, 1989, J ADOLESCENT HEALTH, V10, P231, DOI 10.1016/0197-0070(89)90239-8; 1987, OFFICIAL STATISTICS, P4; 1991, HLTH STATISTICS NORD, P36; 1980, OFFICIAL STATISTIC A, V4, P145; 1990, OFFICIAL STATISTICS, P1; OFFICIAL STATISTICS, V11, P77; 1980, OFFICIAL STATISTIC B, V6, P136; 1991, TILASTOJULKAISU 1991; 1988, POPULATION STUDIES, V109, P1	35	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1053	1057		10.1136/bmj.305.6861.1053	http://dx.doi.org/10.1136/bmj.305.6861.1053			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467684	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JW70100017
J	KWAK, LW; CAMPBELL, MJ; CZERWINSKI, DK; HART, S; MILLER, RA; LEVY, R				KWAK, LW; CAMPBELL, MJ; CZERWINSKI, DK; HART, S; MILLER, RA; LEVY, R			INDUCTION OF IMMUNE-RESPONSES IN PATIENTS WITH B-CELL LYMPHOMA AGAINST THE SURFACE-IMMUNOGLOBULIN IDIOTYPE EXPRESSED BY THEIR TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE-SPECIFIC IMMUNOTHERAPY; TRANSPLANTATION RESISTANCE; RANDOMIZED TRIAL; IMMUNIZATION; VACCINATION; ANTIBODIES; MELANOMA; CYCLOPHOSPHAMIDE; COMBINATION	Background. The idiotypic determinants of the surface immunoglobulin of a B-cell lymphoma can serve as a clonal tumor-specific marker, which may have implications for immunotherapy. We sought to determine whether idiotype-specific immune responses against this autologous antigen could be induced in patients with B-cell lymphoma. Methods. Nine patients were selected who had minimal residual disease or a complete remission after chemotherapy. Each received a series of subcutaneous injections of the immunoglobulin derived from his or her tumor cells (immunoglobulin-idiotype protein), which had been conjugated to a protein carrier and mixed with an immunologic adjuvant. Results. In seven of the nine patients the injections induced sustained idiotype-specific immunologic responses of the humoral type (two patients), the cell-mediated type (four patients), or both (one patient). The use of an adjuvant was essential for these immune responses. The induced antibodies bound specifically to autologous immunoglobulin idiotype, inhibited the binding of murine monoclonal antiidiotype antibodies, and bound autologous tumor cells. Cell-mediated responses were demonstrated by the specific proliferation of immune peripheral-blood mononuclear cells to the soluble immunoglobulin-idiotype protein in vitro. The tumors of both of the patients with measurable disease regressed completely. Toxicity associated with the vaccine was minimal and consisted only of mild reactions at the site of intramuscular injection. Conclusions. These results demonstrate that autologous immunoglobulin idiotype can be formulated into an immunogenic, tumor-specific antigen in humans with B-cell lymphoma, and they provide the background for large-scale trials of active specific immunotherapy of this disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV ONCOL,STANFORD,CA 94305	Stanford University				Levy, Ronald/0000-0003-2061-0650; Kwak, Larry/0000-0002-1884-5349	NATIONAL CANCER INSTITUTE [R37CA033399, R01CA033399] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BRIDGES SH, 1978, J IMMUNOL, V121, P479; BROWN SL, 1989, BLOOD, V73, P651; BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO;2-L; Campbell M J, 1989, Int Rev Immunol, V4, P251, DOI 10.3109/08830188909044782; CAMPBELL MJ, 1988, J IMMUNOL, V141, P3227; CAMPBELL MJ, 1990, J IMMUNOL, V145, P1029; CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825; CARROLL WL, 1986, J IMMUNOL METHODS, V89, P61, DOI 10.1016/0022-1759(86)90032-3; CHAIN B, 1987, J IMMUNOL METHODS, V99, P221, DOI 10.1016/0022-1759(87)90131-1; DALEY MJ, 1978, J IMMUNOL, V120, P1620; FREEDMAN PM, 1976, J NATL CANCER I, V56, P735, DOI 10.1093/jnci/56.4.735; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GEORGE AJT, 1987, J IMMUNOL, V138, P628; HOON DSB, 1990, CANCER RES, V50, P5358; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; JORGENSEN T, 1980, SCAND J IMMUNOL, V11, P29, DOI 10.1111/j.1365-3083.1980.tb00205.x; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITCHELL MS, 1990, J CLIN ONCOL, V8, P856, DOI 10.1200/JCO.1990.8.5.856; SIRISINHA S, 1971, P NATL ACAD SCI USA, V68, P3130, DOI 10.1073/pnas.68.12.3130; STEVENSON FK, 1983, J IMMUNOL, V130, P970; STEVENSON GT, 1975, NATURE, V254, P714, DOI 10.1038/254714a0; STEVENSON GT, 1977, FED PROC, V36, P2268; SUGAI S, 1974, Journal of Experimental Medicine, V140, P1547, DOI 10.1084/jem.140.6.1547	28	489	550	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1209	1215		10.1056/NEJM199210223271705	http://dx.doi.org/10.1056/NEJM199210223271705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406793	Bronze			2022-12-24	WOS:A1992JU39300005
J	THIGPEN, AE; DAVIS, DL; GAUTIER, T; IMPERATOMCGINLEY, J; RUSSELL, DW				THIGPEN, AE; DAVIS, DL; GAUTIER, T; IMPERATOMCGINLEY, J; RUSSELL, DW			THE MOLECULAR-BASIS OF STEROID 5-ALPHA-REDUCTASE DEFICIENCY IN A LARGE DOMINICAN KINDRED	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MALE PSEUDOHERMAPHRODITISM; 5ALPHA-REDUCTASE DEFICIENCY; DNA; POLYMERASE; POLYMORPHISMS; FORM		UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235; NATL UNIV PEDRO HENRIQUEZ URENA,DEPT PEDIAT,SANTO DOMINGO,DOMINICAN REP; CORNELL UNIV,SCH MED,DEPT MED,NEW YORK,NY 10021	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universidad Nacional Pedro Henriquez Urena; Cornell University				Russell, David/0000-0002-0277-403X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043753] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-07504, HD-09421] Funding Source: Medline; NIGMS NIH HHS [GM-43753] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DIAMOND JM, 1987, NATURE, V329, P105, DOI 10.1038/329105a0; GAJDUSEK DC, 1977, CIBA F S, V49, P69; GRIFFIN JE, 1981, J BIOL CHEM, V256, P3662; GRIFFIN JE, 1989, METABOLIC BASIS INHE, V2, P1919; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; IMPERATOMCGINLE.J, 1992, CECIL TXB MED, P1320; IMPERATOMCGINLEY J, 1979, NEW ENGL J MED, V300, P1233, DOI 10.1056/NEJM197905313002201; IMPERATOMCGINLEY J, 1985, J CLIN ENDOCR METAB, V60, P553, DOI 10.1210/jcem-60-3-553; IMPERATOMCGINLEY J, 1979, J STEROID BIOCHEM, V11, P637, DOI 10.1016/0022-4731(79)90093-1; IMPERATOMCGINLEY J, 1986, TRENDS GENET, V2, P130, DOI 10.1016/0168-9525(86)90202-7; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LESHIN M, 1978, J CLIN INVEST, V62, P685, DOI 10.1172/JCI109176; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PETERSON RE, 1977, AM J MED, V62, P170, DOI 10.1016/0002-9343(77)90313-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; THIGPEN AE, 1992, J BIOL CHEM, V267, P8577; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806	24	104	110	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1216	1219		10.1056/NEJM199210223271706	http://dx.doi.org/10.1056/NEJM199210223271706			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406794				2022-12-24	WOS:A1992JU39300006
J	NISLOW, C; LOMBILLO, VA; KURIYAMA, R; MCINTOSH, JR				NISLOW, C; LOMBILLO, VA; KURIYAMA, R; MCINTOSH, JR			A PLUS-END-DIRECTED MOTOR ENZYME THAT MOVES ANTIPARALLEL MICROTUBULES INVITRO LOCALIZES TO THE INTERZONE OF MITOTIC SPINDLES	NATURE			English	Article							PROTEINS; KINESIN; PROGRESSION; SEQUENCE; CELLS	MITOSIS comprises a complex set of overlapping motile events, many of which involve microtubule-dependent motor enzymes1,2. Here we describe a new member of the kinesin superfamily. The protein was originally identified as a spindle antigen by the CHO1 monoclonal antibody3 and shown to be required for mitotic progression4,5. We have cloned the gene that encodes this antigen and found that its sequence contains a domain with strong sequence similarity to the motor domain of kinesin-like proteins. The product of this gene, expressed in bacteria, can cross-bridge antiparallel microtubules in vitro, and in the presence of Mg-ATP, microtubules slide over one another in a fashion reminiscent of microtubule movements during spindle elongation.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	NISLOW, C (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.		McIntosh, Richard/GLN-3533-2022	Nislow, Corey/0000-0002-4016-8874				CANDE WZ, 1978, J CELL BIOL, V79, P573, DOI 10.1083/jcb.79.2.573; CANDE WZ, 1989, CELL MOVEMENT, V2, P441; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLE DG, 1992, J CELL SCI, V101, P291; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HUANG B, 1979, J BIOL CHEM, V254, P3091; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURIYAMA R, 1992, BIOESSAYS, V14, P81, DOI 10.1002/bies.950140203; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LOMBILLO VA, IN PRESS METHODS CEL; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; ROOF DM, 1991, COLD SPRING HARB SYM, V56, P693; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1992, J CELL SCI, V101, P303; SELLITTO C, 1988, J CELL BIOL, V106, P431, DOI 10.1083/jcb.106.2.431; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILLIAMS RC, 1979, BIOCHEMISTRY-US, V18, P2499, DOI 10.1021/bi00579a010; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	33	303	312	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					543	547		10.1038/359543a0	http://dx.doi.org/10.1038/359543a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406973				2022-12-24	WOS:A1992JR85900062
J	BAIRD, EA; MCHENRY, PM; MACKIE, RM				BAIRD, EA; MCHENRY, PM; MACKIE, RM			EFFECT OF MAINTENANCE CHEMOTHERAPY IN CHILDHOOD ON NUMBERS OF MELANOCYTIC NEVI	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; RISK-FACTOR; NEVI	Objective-(a) To determine whether children given chemotherapy for haematological malignancy have significantly more melanocytic naevi than age matched children in the local population; (b) to establish whether any observed variation in naevus counts from normal is seen at the start of maintenance chemotherapy. Design-Follow up of 29 consecutive children starting maintenance chemotherapy, with parental interview and count of all melanocytic naevi greater-than-or-equal-to 2 mm on the child's skin. Assessment repeated three years later after completion of maintenance chemotherapy. Other dermatological problems identified at either visit were also recorded. Setting-Royal Hospital for Sick Children, Glasgow. Results-At the start of maintenance chemotherapy all children had total body counts of melanocytic naevi within the normal range established for age matched children in the local population. Three years later total body naevus counts were significantly increased, the median increase being 66 naevi per child (95% confidence interval 57 to 94). The only other problem noted in these children was relatively poor regrowth of scalp hair. Conclusion-Children on maintenance chemotherapy for haematological malignancies develop an excessive number of melanocytic naevi. Excessive numbers of melanocytic naevi are the most important risk factor for melanoma in the general population. These children should have periodic skin examinations at their follow up visits, and both child and parent should be educated about clinical features of early melanoma.	UNIV GLASGOW,ROYAL HOSP SICK CHILDREN,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow								DEWIT PEJ, 1990, MED PEDIATR ONCOL, V18, P336, DOI 10.1002/mpo.2950180417; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HUGHES BR, 1989, BMJ-BRIT MED J, V299, P88, DOI 10.1136/bmj.299.6691.88; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; MACKIE RM, 1989, LANCET, V2, P487; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555	8	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					799	801		10.1136/bmj.305.6857.799	http://dx.doi.org/10.1136/bmj.305.6857.799			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422359	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JT25600019
J	KRETZNER, L; BLACKWOOD, EM; EISENMAN, RN				KRETZNER, L; BLACKWOOD, EM; EISENMAN, RN			MYC AND MAX PROTEINS POSSESS DISTINCT TRANSCRIPTIONAL ACTIVITIES	NATURE			English	Article							C-MYC; DNA-BINDING; ACTIVATES TRANSCRIPTION; GENE-EXPRESSION; CELLS; ONCOGENE; PRODUCT; SITES; RNA	THE MyC family proteins are thought to be involved in transcription1,2 because they have both a carboxy-terminal basic-helix-loop-helix-zipper (bHLH-Z) domain, common to a large class of transcription factors, and an amino-terminal fragment which, for c-Myc, has transactivating function when assayed in chimaeric constructs4. In addition, c-, N- and L-Myc proteins heterodimerize, in vitro and in vivo, with the bHLH-Z protein Max5-8. In vitro, Max homodimerizes but preferentially associates with Myc, which homodimerizes poorly5,6. Furthermore Myc-Max heterodimers specifically bind the nucleotide sequence CACGTG9 with higher affinity than either homodimer alone5. The identification of Max and the specific DNA-binding activities of Myc and Max provides an opportunity for directly testing the transcriptional activities of these proteins in mammalian cells. We report here that Myc overexpression activates, whereas Max overexpression represses, transcription of a reporter gene. Max-induced repression is relieved by overexpression of c-Myc. Repression requires the DNA-binding domain of Max, whereas relief of repression requires the dimerization and transcriptional activation activities of Myc. Both effects require Myc-Max-binding sites in the reporter gene.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KRETZNER, L (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEAN M, 1986, J BIOL CHEM, V261, P9161; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; NYBORG JK, 1990, J BIOL CHEM, V265, P8237; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	26	458	466	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					426	429		10.1038/359426a0	http://dx.doi.org/10.1038/359426a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406956				2022-12-24	WOS:A1992JQ62400060
J	LAND, MF				LAND, MF			PREDICTABLE EYE HEAD COORDINATION DURING DRIVING	NATURE			English	Article							MOVEMENTS	LARGE changes in the direction of gaze are made with a combination of fast saccadic eye movements and rather slower head movements. Since the first study on freely moving subjects1, most authors have agreed that the head movement component of gaze is very variable, with a high 'volitional' component2. But in some circumstances head and eye movements can be quite predictable, for example when a subject is asked to shift gaze as quickly as possible3. Under these conditions, laboratory studies have shown that the eye and head motor-systems both receive gaze-change commands, although they execute them in rather different ways3-6. Here I reconsider the way gaze direction is changed during free movement, but in the performance of a task where the subject is too busy to exert conscious control over head or eye movements. Using a new portable and inexpensive method for recording head and eye movements, I examine the oculomotor behaviour of car drivers, particularly during the large gaze changes made at road junctions. The results show that the pattern of eye and head movements is highly preditable, given only the sequence of gaze targets.			LAND, MF (corresponding author), UNIV SUSSEX,SCH BIOL SCI,CTR NEUROSCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.							BECKER W, 1991, VISION VISUAL DYSFUN, P95; BIZZI E, 1971, SCIENCE, V173, P452, DOI 10.1126/science.173.3995.452; Carpenter RHS, 1988, MOVEMENTS EYES; Collewijn H., 1977, CONTROL GAZE BRAIN S, P13; Delreux V., 1991, BRAIN SPACE, P38; GUITTON D, 1992, TRENDS NEUROSCI, V15, P174, DOI 10.1016/0166-2236(92)90169-9; LAND MF, 1990, J COMP PHYSIOL A, V167, P155; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; MORASSO P, 1973, EXP BRAIN RES, V16, P492, DOI 10.1007/BF00234475; TOMLINSON RD, 1990, J NEUROPHYSIOL, V64, P1873, DOI 10.1152/jn.1990.64.6.1873; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZANGEMEISTER WH, 1982, EXP NEUROL, V77, P563, DOI 10.1016/0014-4886(82)90228-X; ZANGEMEISTER WH, 1981, EXP NEUROL, V71, P76, DOI 10.1016/0014-4886(81)90072-8	13	117	117	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					318	320		10.1038/359318a0	http://dx.doi.org/10.1038/359318a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406934				2022-12-24	WOS:A1992JP50300055
J	FERRO, D; VIOLI, F; QUINTARELLI, C; SEBASTIANELLI, A; DAMELIO, R; ZICHELLA, L; BALSANO, F				FERRO, D; VIOLI, F; QUINTARELLI, C; SEBASTIANELLI, A; DAMELIO, R; ZICHELLA, L; BALSANO, F			FIBRINOLYTIC BALANCE AND LUPUS ANTICOAGULANT IN PATIENTS WITH REPEATED SPONTANEOUS FETAL LOSS	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY		UNIV ROME,IST CLIN MED GEN & TERAPIA MED 1,VIALE POLICLIN,I-00185 ROME,ITALY; UNIV ROME LA SAPIENZA,IST CLIN MED 1,I-00185 ROME,ITALY	Sapienza University Rome; Sapienza University Rome			Violi, Francesco/K-1509-2016; ferro, domenico/AAT-5861-2020	Violi, Francesco/0000-0002-6610-7068; 				GRIS JC, 1990, BRIT MED J, V300, P1500, DOI 10.1136/bmj.300.6738.1500; JOHNSON PM, 1989, BRIT J OBSTET GYNAEC, V96, P1231, DOI 10.1111/j.1471-0528.1989.tb03203.x; LUBBE WF, 1984, BRIT J OBSTET GYNAEC, V91, P357, DOI 10.1111/j.1471-0528.1984.tb05923.x; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; VIOLI F, 1990, BRIT MED J, V300, P1099, DOI 10.1136/bmj.300.6732.1099	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					504	505		10.1136/bmj.305.6852.504	http://dx.doi.org/10.1136/bmj.305.6852.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392996	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JL60900018
J	RUTTER, DR; CALNAN, M; VAILE, MSB; FIELD, S; WADE, KA				RUTTER, DR; CALNAN, M; VAILE, MSB; FIELD, S; WADE, KA			DISCOMFORT AND PAIN DURING MAMMOGRAPHY - DESCRIPTION, PREDICTION, AND PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							PATIENT	Objective-To identify the nature of pain and discomfort experienced during mammography and how it can be ameliorated. Design-Questionnaire survey before invitation for mammography and immediately after mammography. Responses before screening were related to experience of discomfort. Setting-Health district in South East Thames region. Subjects-1160 women aged 50-64 invited routinely for screening; 774 completed first questionnaire, of whom 617 had mammography. 597 completed the second questionnaire. Main outcome measures-Reported discomfort and pain, comparisons of discomfort with that experienced during other medical procedures, qualitative description of pain with adjective checklist. Results-35% (206/597) of the women reported discomfort and 6% (37/595) pain. 10 minutes after mammography these figures were 4% (24/595) and 0.7% (4/595) respectively. More than two thirds of women ranked having a tooth drilled, having a smear test, and giving blood as more uncomfortable than mammography. The most important predictor of discomfort was previous expectation of pain (discomfort was reported by 21/32 (66%) women who expected pain and 186/531 (35%) who did not). Discomfort had little effect on satisfaction or intention to reattend. Conclusions-The low levels of reported pain and discomfort shortly after mammography and the favourable comparisons with other investigations suggest that current procedures are acceptable. Since two thirds of the women experienced less pain than expected health education and promotion must ensure that accurate information is made available and publicised.	UNIV KENT,CTR HLTH SERV STUDIES,CANTERBURY CT2 7LZ,ENGLAND; KENT & CANTERBURY HOSP,KENT BREAST SCREENING SERV,CANTERBURY,ENGLAND	University of Kent; University of Kent	RUTTER, DR (corresponding author), UNIV KENT,INST SOCIAL & APPL PSYCHOL,CTR RES HLTH BEHAV,CANTERBURY CT2 7LZ,ENGLAND.							EARDLEY A, 1990, SOC SCI MED, V30, P693, DOI 10.1016/0277-9536(88)90254-7; JACKSON VP, 1988, RADIOLOGY, V168, P421, DOI 10.1148/radiology.168.2.3393659; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; ORTON M, 1991, BRIT J GEN PRACT, V41, P320; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; STOMPER PC, 1988, ARCH INTERN MED, V148, P521, DOI 10.1001/archinte.148.3.521; VAILE MSB, IN PRESS J PUBLIC HL	7	53	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					443	445		10.1136/bmj.305.6851.443	http://dx.doi.org/10.1136/bmj.305.6851.443			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392955	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JK68000019
J	KURLANDER, RJ; SHAWAR, SM; BROWN, ML; RICH, RR				KURLANDER, RJ; SHAWAR, SM; BROWN, ML; RICH, RR			SPECIALIZED ROLE FOR A MURINE CLASS-I-B MHC MOLECULE IN PROKARYOTIC HOST DEFENSES	SCIENCE			English	Article							N-FORMYLATED PEPTIDES; LISTERIA-MONOCYTOGENES; T-CELLS; LYMPHOCYTES-T; ANTIGEN; RECEPTOR; MICE; PROTECTION; IMMUNITY; PROTEINS	Although nonclassical (class I-b) gene products represent the majority of murine major histocompatibility complex (MHC) genes, the role of these relatively nonpolymorphic molecules remains uncertain. Recently, one such protein, H-2M3 (formerly designated Hmt), was shown to bind and specifically present N-formylated peptides to cytotoxic T lymphocytes. Because N-formylation is characteristic of prokaryotic proteins, this MHC molecule may be especially adapted for a role in the mammalian defense against bacterial attack. The current studies demonstrate that an MHC molecule, indistinguishable from H-2M3, presents antigens derived from the intracellular pathogen Listeria monocytogenes to Listeria-specific CD8+ cells.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	KURLANDER, RJ (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA.			Shawar, Said/0000-0002-5281-1783	NIAID NIH HHS [R01 AI18882, R01 AI18073] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018073, R01AI018882] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN ML, 1992, J IMMUNOL, V148, P555; BRUNT LM, 1990, J IMMUNOL, V145, P3540; Buetow D E, 1978, Subcell Biochem, V5, P1; COLLINGE J, 1991, NATURE, V353, P802, DOI 10.1038/353802a0; CZUPRYNSKI CJ, 1987, IMMUNOLOGY, V60, P287; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DELIBERO G, 1986, J IMMUNOL, V137, P2688; FISCHERLINDAHL K, 1985, TRENDS GENET, V1, P135; FISCHERLINDAHL K, 1983, NATURE, V306, P383; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; KAUFMANN SHE, 1987, REV INFECT DIS, V9, pS650; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KLEIN J, 1990, IMMUNOGENETICS, V32, P147, DOI 10.1007/BF02114967; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUKACS K, 1989, J IMMUNOL, V142, P2879; LUKACS K, 1989, J IMMUNOL, V143, P3731; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; PARISH CR, 1983, J IMMUNOL METHODS, V58, P225, DOI 10.1016/0022-1759(83)90277-6; Rodgers J R, 1986, Adv Immunol, V38, P313, DOI 10.1016/S0065-2776(08)60010-3; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHAWAR SM, 1991, IMMUNOL RES, V10, P365, DOI 10.1007/BF02919723; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7	27	140	141	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					678	679		10.1126/science.1496381	http://dx.doi.org/10.1126/science.1496381			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496381				2022-12-24	WOS:A1992JF85200039
J	ZHANG, K; PAPAGEORGE, AG; LOWY, DR				ZHANG, K; PAPAGEORGE, AG; LOWY, DR			MECHANISTIC ASPECTS OF SIGNALING THROUGH RAS IN NIH-3T3 CELLS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; NUCLEOTIDE BINDING; CYCLASE PATHWAY; GROWTH-FACTOR; KINASE-C; GENE; P21RAS; GAP	Serum and growth factors can increase the proportion of Ras in the active guanosine triphosphate (GTP)-bound form. Growth factors might stimulate guanine nucleotide exchange or decrease the activity of the guanosine triphosphatase-activating proteins GAP and neurofibromin (NF1). In NIH 3T3 cells that overexpress the mutant Ras protein His116, which releases bound guanine nucleotide at a constitutively high rate and retains sensitivity to GAP and NF1, the proportion of GTP bound to the His116 protein was not altered by serum or platelet-derived growth factor. However, these mitogens increased the proportion of Ras in the GTP-bound form in cells that overexpressed control Ras proteins with a normal intrinsic rate of guanine nucleotide release. The amount of GTP-bound His116 or control Ras proteins was higher in cells at low density than in cells at high density, which have more GAP-like activity. The lower proportion of GTP-bound Ras in NIH 3T3 cells at high density may result from increased GAP-like activity. By contrast, serum and platelet-derived growth factors appear to stimulate guanine nucleotide exchange.			ZHANG, K (corresponding author), NCI,CELLULAR ONCOL LAB,BLDG 37,ROOM 1B-26,BETHESDA,MD 20892, USA.							BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DER CJ, 1988, ONCOGENE, V3, P105; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAPAGEORGE AG, UNPUB; PATEL G, 1992, ONCOGENE, V7, P283; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	34	83	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					671	674		10.1126/science.1496380	http://dx.doi.org/10.1126/science.1496380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496380				2022-12-24	WOS:A1992JF85200037
J	SPACH, DH; STAPLETON, AE; STAMM, WE				SPACH, DH; STAPLETON, AE; STAMM, WE			LACK OF CIRCUMCISION INCREASES THE RISK OF URINARY-TRACT INFECTION IN YOUNG MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIMBRIATED ESCHERICHIA-COLI; DECREASED INCIDENCE; MALE INFANTS; DIAGNOSIS; PYELONEPHRITIS; URETHRITIS; WOMEN	Objective. - To determine whether lack of circumcision increases the risk of urinary tract infection (UTI) in adult men. Design and Setting. - Retrospective case-control study (1987-1990) at a sexually transmitted disease clinic in Seattle, Wash. Patients. - Twenty-six men (median age, 30 years) who had microbiologically confirmed symptomatic UTIs (cases) compared with 52 men (median age, 32 years) who had urinary symptoms but negative urine cultures (controls). Main Outcome Measure. - Circumcision status among bacteriuric and nonbacteriuric men. Results. - The bacteriuric and nonbacteriuric groups were similar in age, race, sexual activity, and sexual preference. Eight (31%) of the 26 bacteriuric men were uncircumcised compared with 6 (12%) of the 52 nonbacteriuric men (P =.037; odds ratio, 3.4; 95% confidence interval, 1.0 to 11.2). Among 19 patients infected with gram-negative bacilli, 8 (42%) of 19 were uncircumcised vs 6 (12%) of 52 nonbacteriuric men (P = .004; odds ratio, 5.6; 95% confidence interval, 1.6 to 19.4). Escherichia coli was the most common urinary isolate (15 of 26 isolates), and the majority of E coli strains possessed urovirulence determinants, including mannose-resistant hemagglutination (10 of 14 isolates), F fimbriae (11 of 14 isolates), P fimbriae (6 of 14 isolates), hemolysin (10 of 14 isolates), and aerobactin (8 of 14 isolates). Although all 26 bacteriuric men had urethral cultures negative for Chlamydia trachomatis and Neisseria gonorrhoeae, Gram-stained urethral smears showed evidence of urethritis in 17 (68%) of 25 men. Conclusions. - (1) Lack of circumcision increases the risk of UTI in young adult men. (2) The majority of these infections result from urovirulent strains of E coli. (3) Clinically, these infections often produce urethritis as well as UTI.	UNIV WASHINGTON,MED CTR,DIV INFECT DIS,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NIDDK NIH HHS [DK 40045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040045] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES RC, 1986, LANCET, V1, P171; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BOWIE WR, 1978, SEX TRANSM DIS, V5, P39, DOI 10.1097/00007435-197804000-00001; BURBIGE KA, 1984, J UROLOGY, V132, P541, DOI 10.1016/S0022-5347(17)49727-8; DEPINHO AMF, 1990, 6TH INT C AIDS SAN F, P209; FIHN SD, 1988, J INFECT DIS, V157, P196, DOI 10.1093/infdis/157.1.196; GINSBURG CM, 1982, PEDIATRICS, V69, P409; HERZOG LW, 1989, AM J DIS CHILD, V143, P348, DOI 10.1001/archpedi.1989.02150150106026; JACOBSON SH, 1985, J INFECT DIS, V152, P426, DOI 10.1093/infdis/152.2.426; JOHNSON JR, 1987, J INFECT DIS, V156, P225, DOI 10.1093/infdis/156.1.225; KALLENIUS G, 1981, LANCET, V2, P1369; KIELY B, 1984, IRISH MED J, V77, P384; LIPSKY BA, 1987, J INFECT DIS, V155, P847, DOI 10.1093/infdis/155.5.847; LIPSKY BA, 1989, ANN INTERN MED, V110, P138, DOI 10.7326/0003-4819-110-2-138; Maniatis T., 1982, MOL CLONING; SCHWATZ SL, 1978, J INFECT DIS, V138, P445; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAPLETON A, 1991, J INFECT DIS, V163, P773, DOI 10.1093/infdis/163.4.773; VAISANEN V, 1981, LANCET, V2, P1366; VAISANENRHEN V, 1984, INFECT IMMUN, V43, P149; VANBUREN M, 1990, 30TH INT C ANT AG CH, P106; WISWELL TE, 1985, PEDIATRICS, V75, P901; WISWELL TE, 1986, PEDIATRICS, V78, P96	24	88	89	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					679	681		10.1001/jama.267.5.679	http://dx.doi.org/10.1001/jama.267.5.679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1472171				2022-12-24	WOS:A1992HB35400025
J	TARDIEUX, I; WEBSTER, P; RAVESLOOT, J; BORON, W; LUNN, JA; HEUSER, JE; ANDREWS, NW				TARDIEUX, I; WEBSTER, P; RAVESLOOT, J; BORON, W; LUNN, JA; HEUSER, JE; ANDREWS, NW			LYSOSOME RECRUITMENT AND FUSION ARE EARLY EVENTS REQUIRED FOR TRYPANOSOME INVASION OF MAMMALIAN-CELLS	CELL			English	Article							PLASMA-MEMBRANE; ACTIN-FILAMENTS; LISTERIA-MONOCYTOGENES; TOXOPLASMA-GONDII; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; XENOPUS OOCYTES; PROTEIN-KINASE; CYCLE CONTROL; HELA-CELLS	Trypanosoma cruzi invades most nucleated cells by a mechanism distinct from classical phagocytosis. Although parasites enter at the lysosome-poor peripheral cell margins, lysosomal markers are immediately incorporated into the parasitophorous vacuole. No accumulation of polymerized actin was detected around recently internalized parasites, and disruption of microfilaments significantly facilitated invasion. Lysosomes were observed to aggregate at the sites of trypanosome attachment and to fuse with the vacuole at early stages of its formation. Experimentally induced, microtubule-dependent movement of lysosomes from the perinuclear area to the cell periphery enhanced entry. Conditions that deplete cells of peripheral lysosomes or interfere with lysosomal fusion capacity inhibited invasion. These observations reveal a novel mechanism for cell invasion: recruitment of lysosomes for fusion at the site of parasite internalization.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Yale University; Yale University; Washington University (WUSTL)	TARDIEUX, I (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,INFECT DIS SECT,NEW HAVEN,CT 06510, USA.		Heuser, John/H-5940-2012; Boron, Walter/ABI-1564-2020; Tardieux, Isabelle/G-4733-2014	Tardieux, Isabelle/0000-0002-5677-7463; Andrews, Norma/0000-0002-0611-2412; Boron, Walter/0000-0003-4741-7287; Webster, Paul/0000-0002-1980-6931	NIAID NIH HHS [R01AI32056, R29AI27260] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027260, R01AI032056] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BARON R, 1990, J CELL SCI, V97, P439; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BOYLES J, 1981, CELL, V24, P905, DOI 10.1016/0092-8674(81)90116-1; CARVALHO T M U D, 1989, Cell Structure and Function, V14, P383; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; COHN ZA, 1969, J EXP MED, V129, P201, DOI 10.1084/jem.129.1.201; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; DVORAK JA, 1981, SCIENCE, V214, P1034, DOI 10.1126/science.7029713; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HALL BF, 1992, J EXP MED, V176, P313, DOI 10.1084/jem.176.2.313; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; KNAPP PE, 1990, J CELL SCI, V95, P433; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEY V, 1990, J EXP MED, V171, P401, DOI 10.1084/jem.171.2.401; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MEIRELLES MNL, 1983, J SUBMICR CYTOL PATH, V17, P327; MILDER R, 1980, PARASITOLOGY, V80, P139, DOI 10.1017/S0031182000000597; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NOGUEIRA N, 1976, J EXP MED, V143, P1402, DOI 10.1084/jem.143.6.1402; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PERRIN D, 1992, J CELL BIOL, V116, P127, DOI 10.1083/jcb.116.1.127; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; PRYZWANSKY KB, 1979, CELL, V18, P1025, DOI 10.1016/0092-8674(79)90215-0; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; SCHENKMAN S, 1992, J CELL SCI, V101, P895; SHROER TA, 1989, CELL, V56, P937; SHROER TR, 1988, J CELL BIOL, V107, P1785; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	64	314	323	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1117	1130		10.1016/S0092-8674(05)80061-3	http://dx.doi.org/10.1016/S0092-8674(05)80061-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473148	hybrid			2022-12-24	WOS:A1992KE60400007
J	GARRY, DJ; CAPLAN, AL; VAWTER, DE; KEARNEY, W				GARRY, DJ; CAPLAN, AL; VAWTER, DE; KEARNEY, W			ARE THERE REALLY ALTERNATIVES TO THE USE OF FETAL TISSUE FROM ELECTIVE ABORTIONS IN TRANSPLANTATION RESEARCH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ECTOPIC PREGNANCY; MANAGEMENT; FETUS; DEATH				GARRY, DJ (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.							BOUE J, 1975, TERATOLOGY, V12, P11, DOI 10.1002/tera.1420120103; BRENNER PF, 1980, JAMA-J AM MED ASSOC, V243, P673, DOI 10.1001/jama.243.7.673; BUDOWICK M, 1980, FERTIL STERIL, V34, P169; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; ELIAS S, 1981, AM J OBSTET GYNECOL, V141, P698, DOI 10.1016/S0002-9378(15)33314-7; FERNANDEZ H, 1988, OBSTET GYNECOL, V71, P171; FUNG CHK, 1990, JAMA-J AM MED ASSOC, V264, P34, DOI 10.1001/jama.1990.03450010038015; KALTER H, 1987, AM J OBSTET GYNECOL, V156, P1243, DOI 10.1016/0002-9378(87)90156-6; LEACH RE, 1989, J REPROD MED, V34, P324; MARTIN JN, 1988, OBSTET GYNECOL, V71, P549; MORRISON I, 1985, AM J OBSTET GYNECOL, V152, P975, DOI 10.1016/0002-9378(85)90542-3; Nederlof K P, 1990, MMWR CDC Surveill Summ, V39, P9; NOLAN K, 1990, TRANSPLANT P, V22, P1028; PITKIN RM, 1987, AM J OBSTET GYNECOL, V157, P583, DOI 10.1016/S0002-9378(87)80011-X; POLAND BJ, 1976, TERATOLOGY, V14, P315, DOI 10.1002/tera.1420140306; RAYBURN W, 1985, OBSTET GYNECOL, V65, P637; ROCHESTER D, 1987, RADIOLOGY, V165, P843, DOI 10.1148/radiology.165.3.3317509; RUBIN GL, 1983, JAMA-J AM MED ASSOC, V249, P1725, DOI 10.1001/jama.249.13.1725; SIMPSON JL, 1982, GENETICS OBSTETRICS, P125; STAFFORD PA, 1988, AM J OBSTET GYNECOL, V159, P485, DOI 10.1016/S0002-9378(88)80115-7; STRATFORD BF, 1970, AM J OBSTET GYNECOL, V107, P1223, DOI 10.1016/S0002-9378(15)30373-2; STROBINO BA, 1987, AM J OBSTET GYNECOL, V157, P1150, DOI 10.1016/S0002-9378(87)80280-6; THORNE E D, 1989, Fetal Therapy, V4, P37; VAWTER DE, 1992, J LAB CLIN MED, V120, P30; WINTER RM, 1988, MALFORMED FETUS STIL, P14; 1985, JAMA-J AM MED ASSOC, V254, P1891; 1987, BUREAU CENSUS, P74; 1984, SPONTANEOUS ABORTION, V8, P34	28	21	21	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1992	327	22					1592	1595		10.1056/NEJM199211263272211	http://dx.doi.org/10.1056/NEJM199211263272211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ432	1435888				2022-12-24	WOS:A1992JZ43200011
J	FRENCH, S				FRENCH, S			CONSEQUENCES OF REPLICATION FORK MOVEMENT THROUGH TRANSCRIPTION UNITS INVIVO	SCIENCE			English	Article							ESCHERICHIA-COLI CHROMOSOME; BIOTIN HOLOENZYME SYNTHETASE; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CELL-CYCLE; BIRA-GENE; ORGANIZATION; OPERON; VISUALIZATION	To examine the basis for the evolutionary selection for codirectionality of replication and transcription in Escherichia coli, electron microscopy was used to visualize replication from an inducible ColE1 replication origin inserted into the Escherichia coli chromosome upstream (5') or downstream (3') of rrnB, a ribosomal RNA operon. Active rrnB operons were replicated either in the same direction in which they were transcribed or in the opposite direction. In either direction, RNA polymerases were dislodged during replication. When replication and transcription were codirectional, the rate of replication fork movement was similar to that observed in nontranscribed regions. When replication and transcription occurred in opposite directions, replication fork movement was reduced.			FRENCH, S (corresponding author), UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLMAN R, 1991, J BACTERIOL, V173, P7970, DOI 10.1128/jb.173.24.7970-7974.1991; BACKMAN K, 1978, COLD SPRING HARB SYM, V43, P69; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BREWER BJ, 1990, BACTERIAL CHROMOSOME, P61; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; COOPER S, 1985, J MOL BIOL, V163, P661; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRENCH SL, 1989, J BACTERIOL, V171, P4207, DOI 10.1128/JB.171.8.4207-4216.1989; GOTTA S, 1991, THESIS U VIRGINIA; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HELMSTETTER CE, 1968, J MOL BIOL, V31, P507, DOI 10.1016/0022-2836(68)90424-5; HIROSE S, 1983, MOL GEN GENET, V189, P422, DOI 10.1007/BF00325904; HOFMANN S, 1977, J BACTERIOL, V132, P718, DOI 10.1128/JB.132.2.718-722.1977; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; INOUE N, 1991, J BACTERIOL, V173, P1208, DOI 10.1128/jb.173.3.1208-1214.1991; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUNDRIGAN MD, 1991, P NATL ACAD SCI USA, V88, P1479, DOI 10.1073/pnas.88.4.1479; MCKNIGHT SL, 1978, THESIS U VIRGINIA; MKANIATIS T, 1982, MOL CLONING LABORATO, P68; NOMURA M, 1977, ANNU REV GENET, V11, P297, DOI 10.1146/annurev.ge.11.120177.001501; OSHEIM YN, 1988, MOL CELL BIOL, V8, P2811, DOI 10.1128/MCB.8.7.2811; PANAYOTATOS N, 1984, NUCLEIC ACIDS RES, V12, P2641, DOI 10.1093/nar/12.6.2641; RAHMOUNI R, 1992, J MOL BIOL, V223, P131; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X	33	206	209	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1362	1365		10.1126/science.1455232	http://dx.doi.org/10.1126/science.1455232			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455232				2022-12-24	WOS:A1992JY95800040
J	BARRETTCONNOR, E				BARRETTCONNOR, E			LOWER ENDOGENOUS ANDROGEN LEVELS AND DYSLIPIDEMIA IN MEN WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						ANDROGENS; DIABETES-MELLITUS, NON-INSULIN-DEPENDENT; TESTOSTERONE; LIPOPROTEINS, HDL; CHOLESTEROL; TRIGLYCERIDES	DENSITY-LIPOPROTEIN CHOLESTEROL; HORMONE-BINDING GLOBULIN; PLASMA TESTOSTERONE LEVELS; SEX-HORMONES; GLUCOSE-INTOLERANCE; BOUND TESTOSTERONE; SERUM-LIPOPROTEINS; ADULT MEN; ESTRADIOL; RESISTANCE	Objective: To compare plasma androgen levels in diabetic and nondiabetic men and to determine their relation to diabetic dyslipidemia. Design: A population-based, case-control study. Setting: Community. Participants: Men 53 to 88 years of age from the Rancho Bernardo, California, cohort who were screened for diabetes using an oral glucose tolerance test. Measurements: Plasma androgen levels were compared in 44 men with untreated non-insulin-dependent diabetes mellitus and 88 age-matched men who had a normal glucose tolerance test. The relation of lipid and lipoprotein levels to androgen level and diabetic status was assessed before and after adjusting for covariates. Results: Men with diabetes had significantly lower plasma levels of free (4.96 nmol/L compared with 5.58 nmol/L) and total testosterone (14.7 nmol/L compared with 17.4 nmol/L), dihydrotestosterone (428 pg/mL compared with 533 pg/mL), and dehydroepiandrosterone sulfate (DHEA-S) (1.92 mumol/L compared with 2.42 mumol/L) than nondiabetic men. They also had significantly lower high-density lipoprotein (HDL) cholesterol and significantly higher triglyceride levels. Differences were not explained by obesity, alcohol use, or cigarette habit. Overall, the total testosterone level, but not the free testosterone level, was positively correlated with the HDL cholesterol level (P = 0.009) and negatively correlated with the triglyceride level (P = 0.0001). Similar associations were seen in analyses restricted to the men without diabetes. Conclusions: Lower levels of endogenous androgens are seen in older diabetic men, and low androgen levels are associated with diabetic dyslipidemia.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT WGH, 1987, DIABETES, V36, P897, DOI 10.2337/diabetes.36.8.897; ANDERSON DC, 1976, STEROIDS, V28, P179, DOI 10.1016/0039-128X(76)90108-2; ANDO S, 1984, J ENDOCRINOL INVEST, V7, P21, DOI 10.1007/BF03348370; BARRETTCONNOR E, 1990, AM J EPIDEMIOL, V132, P895, DOI 10.1093/oxfordjournals.aje.a115732; BREMNER WJ, 1983, J CLIN ENDOCR METAB, V56, P1278, DOI 10.1210/jcem-56-6-1278; COHEN JC, 1987, J CLIN ENDOCR METAB, V64, P960, DOI 10.1210/jcem-64-5-960; DAI WS, 1984, AM J CARDIOL, V53, P1259, DOI 10.1016/0002-9149(84)90075-4; DAI WS, 1981, AM J EPIDEMIOL, V114, P804, DOI 10.1093/oxfordjournals.aje.a113251; DUELL PB, 1990, ARCH INTERN MED, V150, P2317, DOI 10.1001/archinte.150.11.2317; FRIEDL KE, 1989, J CLIN ENDOCR METAB, V68, P971, DOI 10.1210/jcem-68-5-971; FRIEDL KE, 1990, METABOLISM, V39, P69, DOI 10.1016/0026-0495(90)90150-B; GODSLAND IF, 1986, CLIN SCI, V71, P665, DOI 10.1042/cs0710665; GUTAI J, 1981, AM J CARDIOL, V48, P897, DOI 10.1016/0002-9149(81)90356-8; HAMALAINEN E, 1986, METABOLISM, V35, P535, DOI 10.1016/0026-0495(86)90011-9; HELLER RF, 1983, ACTA ENDOCRINOL-COP, V104, P253, DOI 10.1530/acta.0.1040253; Khaw K T, 1992, Ann Epidemiol, V2, P675, DOI 10.1016/1047-2797(92)90012-F; KHAW KT, 1991, ARTERIOSCLER THROMB, V11, P489, DOI 10.1161/01.ATV.11.3.489; KIRKLAND RT, 1987, JAMA-J AM MED ASSOC, V257, P502, DOI 10.1001/jama.257.4.502; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LASKARZEWSKI PM, 1983, METABOLISM, V32, P262, DOI 10.1016/0026-0495(83)90191-9; LICHTENSTEIN MJ, 1987, AM J EPIDEMIOL, V126, P647, DOI 10.1093/oxfordjournals.aje.a114704; LINDHOLM J, 1982, AM J MED, V73, P648, DOI 10.1016/0002-9343(82)90405-3; MANNI A, 1985, J CLIN ENDOCR METAB, V61, P705, DOI 10.1210/jcem-61-4-705; MARIN P, IN PRESS OBESITY EUR; MENDOZA SG, 1981, METABOLISM, V30, P481, DOI 10.1016/0026-0495(81)90184-0; MILLER GJ, 1985, ATHEROSCLEROSIS, V55, P251, DOI 10.1016/0021-9150(85)90104-2; MORRISON JA, 1981, CIRCULATION, V64, P113; NORDOY A, 1979, ATHEROSCLEROSIS, V34, P431, DOI 10.1016/0021-9150(79)90067-4; OSTLUND RE, 1990, NEW ENGL J MED, V322, P229, DOI 10.1056/NEJM199001253220404; REBUFFESCRIVE M, 1992, INT J OBESITY, V2, P675; SEIDELL JC, 1990, METABOLISM, V39, P897, DOI 10.1016/0026-0495(90)90297-P; SEMMENS J, 1983, METABOLISM, V32, P428, DOI 10.1016/0026-0495(83)90002-1; SIMON D, 1992, DIABETOLOGIA, V35, P173, DOI 10.1007/BF00402551; SRINIVASAN SR, 1985, METABOLISM, V34, P861, DOI 10.1016/0026-0495(85)90111-8; STEFANICK ML, 1987, J CLIN ENDOCR METAB, V64, P723, DOI 10.1210/jcem-64-4-723; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; TREMBLAY RR, 1974, CONTRACEPTION, V10, P599, DOI 10.1016/0010-7824(74)90099-7; WILSON JD, 1980, METABOLISM, V29, P1278, DOI 10.1016/0026-0495(80)90159-6; WINGARD D L, 1990, Diabetes Care, V13, P3; WOODARD TL, 1981, J CLIN ENDOCR METAB, V53, P905, DOI 10.1210/jcem-53-5-905; ZIMMET P, 1990, DIABETES RES CLIN PR, V10, pS167, DOI 10.1016/0168-8227(90)90158-P; 1985, WHO727 STUD GROUP DI; 1974, DHEW75628 NAT HEART	43	239	243	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					807	811		10.7326/0003-4819-117-10-807	http://dx.doi.org/10.7326/0003-4819-117-10-807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416554				2022-12-24	WOS:A1992JX83800002
J	CAMPBELL, LV; ASHWELL, SM; BORKMAN, M; CHISHOLM, DJ				CAMPBELL, LV; ASHWELL, SM; BORKMAN, M; CHISHOLM, DJ			WHITE COAT HYPERGLYCEMIA - DISPARITY BETWEEN DIABETES CLINIC AND HOME BLOOD-GLUCOSE CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify patients with discrepantly high clinic blood glucose concentrations compared with self reported values and to assess whether such patients have errors in self monitoring technique. To determine whether, in patients with good technique, the discrepancy is a transient phenomenon related to clinic attendance. Design-Prospective study of diabetes clinic patients recruited over six months. Setting-Outpatient diabetes clinic of a teaching hospital. Subjects-34 consecutive patients with noninsulin dependent diabetes who had had at least two consecutive clinic blood glucose concentrations more than 5 mmol/l higher than the mean self reported concentration. Main outcome measures-Assessment of monitoring technique; presence of cognitive or physical impairment; serum fructosamine concentration; home and clinic blood glucose concentrations. Results-15 of 34 patients had errors in monitoring technique, 12 of whom had cognitive or physical impairment. In the remaining 19, the mean (SD) blood glucose concentrations of capillary and venous samples taken at home (10.2 (0.6) and 12.2 (1.1) mmol/l respectively) were significantly lower than in those taken at the clinic (16.8 (1.6) mmol/l, p<0.0002). The fructosamine concentration was significantly higher in patients with monitoring errors than those without (2.4 (0.4) v 1.8 (0.4) mmol/l, p<0.0001). Conclusions-"White coat" hyperglycaemia was detected in about half the patients but errors in technique accounted for the rest of the discrepancies. Patients' ability should be assessed before teaching self monitoring and the technique checked regularly.	ST VINCENTS HOSP,GARVAN INST MED RES,SYDNEY,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney	CAMPBELL, LV (corresponding author), ST VINCENTS HOSP,CTR DIABET,SYDNEY,NSW 2010,AUSTRALIA.		Chisholm, Donald J/J-9332-2013; Campbell, Lesley V/B-2271-2008	Chisholm, Donald J/0000-0002-5349-5735; 				[Anonymous], 1987, DIABETES CARE, V10, P95; BURGESS E, 1991, DIABETOLOGIA, V34, P684, DOI 10.1007/BF00401000; CAMPBELL LV, 1991, DIABETES, V40, P140; FELL LR, 1985, AUST VET J, V62, P403, DOI 10.1111/j.1751-0813.1985.tb14120.x; Long J, 1990, Md Med J, V39, P555; MCLAY J, 1987 P AUSTR DIAB ED, pE3; MOLNAR GD, 1974, DIABETOLOGIA, V10, P139, DOI 10.1007/BF01219670; ROSE RM, 1981, TXB ENDOCRINOLOGY, P654; SCHLEICHER ED, 1990, CLIN CHEM, V36, P136; SURWIT RS, 1983, DIABETES CARE, V6, P176, DOI 10.2337/diacare.6.2.176	10	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1194	1196		10.1136/bmj.305.6863.1194	http://dx.doi.org/10.1136/bmj.305.6863.1194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467722	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JY77700021
J	OSTERGAARD, JR; KRAFT, M				OSTERGAARD, JR; KRAFT, M			NATURAL COURSE OF BENIGN COITAL HEADACHE	BRITISH MEDICAL JOURNAL			English	Article									PRIVATE CLIN NEUROL,NEUROL,DK-8240 RIISKOV,DENMARK		OSTERGAARD, JR (corresponding author), AARHUS UNIV HOSP,DEPT PEDIAT A,DK-8000 AARHUS,DENMARK.							Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; JOHS DR, 1986, ARCH NEUROL-CHICAGO, V43, P1158; KRITZ K, 1970, CESK NEUROL NEUROCHI, V33, P162; LANCE JW, 1976, J NEUROL NEUROSUR PS, V39, P1226, DOI 10.1136/jnnp.39.12.1226; PAULSON GW, 1974, HEADACHE, V13, P181, DOI 10.1111/j.1526-4610.1974.hed1304181.x	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1129	1129		10.1136/bmj.305.6862.1129	http://dx.doi.org/10.1136/bmj.305.6862.1129			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463949	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JX84100023
J	WILLIAMS, TL				WILLIAMS, TL			PHASE COUPLING BY SYNAPTIC SPREAD IN CHAINS OF COUPLED NEURONAL OSCILLATORS	SCIENCE			English	Article							LAMPREY SPINAL-CORD; CENTRAL PATTERN GENERATOR; LOCOMOTION; INTERNEURONS; FREQUENCY; MODEL	Many neural systems behave as arrays of coupled oscillators, with characteristic phase coupling. For example, the rhythmic activation patterns giving rise to swimming in fish are characterized by a rostral-to-caudal phase delay in ventral root activity that is independent of the cycle duration. This produces a traveling wave of curvature along the body of the animal with a wavelength approximately equal to the body length. Here a simple mechanism for phase coupling in chains of equally activated oscillators is postulated: the synapses between the cells making up a "unit oscillator" are simply repeated in neighboring segments, with a reduced synaptic strength. If such coupling is asymmetric in the rostral and caudal directions, traveling waves of activity are produced. The intersegmental phase lag that develops is independent of the coupling strength over at least a tenfold range. Furthermore, for the unit oscillator believed to underlie central pattern generation in the lamprey spinal cord, such coupling can result in a phase lag that is independent of frequency.			WILLIAMS, TL (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PHYSIOL,LONDON SW17 0RE,ENGLAND.							BUCHANAN JT, 1982, J NEUROPHYSIOL, V47, P948, DOI 10.1152/jn.1982.47.5.948; BUCHANAN JT, 1982, J NEUROPHYSIOL, V47, P961, DOI 10.1152/jn.1982.47.5.961; BUCHANAN JT, 1987, SCIENCE, V236, P312, DOI 10.1126/science.3563512; BUCHANAN JT, 1992, BIOL CYBERN, V66, P367, DOI 10.1007/BF00203673; COHEN AH, 1982, J MATH BIOL, V13, P345, DOI 10.1007/BF00276069; COHEN AH, 1987, J NEUROSCI METH, V21, P113, DOI 10.1016/0165-0270(87)90109-9; COHEN AH, 1980, EXP BRAIN RES, V41, P11; DALE N, 1986, J NEUROSCI, V6, P2662, DOI 10.1523/jneurosci.06-09-02662.1986; EKEBERG O, 1991, BIOL CYBERN, V65, P81, DOI 10.1007/BF00202382; ERMENTROUT GB, 1984, SIAM J MATH ANAL, V15, P215, DOI 10.1137/0515019; ERMENTROUT GB, 1991, J MATH BIOL, V29, P155; GRILLNER S, 1974, EXP BRAIN RES, V20, P459; GRILLNER S, 1988, NEUROSCI LETT, V89, P31, DOI 10.1016/0304-3940(88)90476-4; Grillner S., 1976, NEURAL CONTROL LOCOM, P181; KOPELL N, 1990, SIAM J APPL MATH, V50, P1014, DOI 10.1137/0150062; KOPELL N, 1988, MATH BIOSCI, V90, P87, DOI 10.1016/0025-5564(88)90059-4; KOPELL N, 1986, COMMUN PUR APPL MATH, V39, P623, DOI 10.1002/cpa.3160390504; KOPELL N, 1991, SIAM J APPL MATH, V51, P1397, DOI 10.1137/0151070; MATSUSHIMA T, 1992, J NEUROPHYSIOL, V67, P373, DOI 10.1152/jn.1992.67.2.373; ROVAINEN CM, 1974, J COMP NEUROL, V154, P189, DOI 10.1002/cne.901540206; ROVAINEN CM, 1989, J NEUROPHYSIOL, V54, P959; Sigvardt K.A., 1992, Seminars in the Neurosciences, V4, P37, DOI 10.1016/1044-5765(92)90032-W; SIGVARDT K A, 1991, Society for Neuroscience Abstracts, V17, P122; SIGVARDT KA, 1989, AM ZOOL, V29, P19; SZEKELY G, 1965, ACTA PHYSIOL HUNG, V27, P285; WALLEN P, 1984, J PHYSIOL-LONDON, V347, P225, DOI 10.1113/jphysiol.1984.sp015063; WALLEN P, IN PRESS J NEUROPHYS; WILLIAMS TL, 1990, J NEUROPHYSIOL, V64, P862, DOI 10.1152/jn.1990.64.3.862; WILLIAMS TL, 1989, J EXP BIOL, V143, P559; WILLIAMS TL, 1992, NEURAL COMPUT, V4, P546, DOI 10.1162/neco.1992.4.4.546	30	107	107	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					662	665		10.1126/science.1411575	http://dx.doi.org/10.1126/science.1411575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411575				2022-12-24	WOS:A1992JU74500061
J	BREWER, BJ; LOCKSHON, D; FANGMAN, WL				BREWER, BJ; LOCKSHON, D; FANGMAN, WL			THE ARREST OF REPLICATION FORKS IN THE RDNA OF YEAST OCCURS INDEPENDENTLY OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-I; BACILLUS-SUBTILIS CHROMOSOME; ESCHERICHIA-COLI CHROMOSOME; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL DNA; TERMINATOR PROTEIN; S-PHASE; PLASMID; SEQUENCE	Replication forks, moving opposite to the direction of transcription, are arrested at the 3' ends of the 35S transcription units in the rDNA locus of S. cerevisiae. Because of its position and polarity, we tested the hypothesis that this replication fork barrier (RFB) results from the act of transcription. Three results contradict this hypothesis. First, the RFB persists in a strain containing a disruption of the gene for the 135 kd subunit of RNA polymerase I. Second, the RFB causes a polar arrest of replication forks when transplanted to a plasmid. Third, transcription by RNA polymerase II of a plasmid copy of the 35S transcription unit lacking the RFB does not generate a barrier. We propose that replication forks are arrested in a directional manner through the binding of one or more proteins to two closely spaced sites in the RFB.			BREWER, BJ (corresponding author), UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1987, MOL GEN GENET, V208, P127, DOI 10.1007/BF00330433; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1988, J BACTERIOL, V170, P662, DOI 10.1128/jb.170.2.662-668.1988; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LIN YH, 1991, GENETICS, V127, P31; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Maniatis T., 1982, MOL CLONING; MORROW BE, 1989, J BIOL CHEM, V264, P9061; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5; ZEIGLER DR, 1990, GENETICS, V125, P703	38	216	219	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					267	276		10.1016/0092-8674(92)90355-G	http://dx.doi.org/10.1016/0092-8674(92)90355-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423594				2022-12-24	WOS:A1992JU39500012
J	CREWS, CM; ALESSANDRINI, A; ERIKSON, RL				CREWS, CM; ALESSANDRINI, A; ERIKSON, RL			THE PRIMARY STRUCTURE OF MEK, A PROTEIN-KINASE THAT PHOSPHORYLATES THE ERK GENE-PRODUCT	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; FISSION YEAST; CELL-CYCLE; DIACYLGLYCEROL; RESISTANCE; CEREVISIAE; PROGRESS; CASCADES; ENCODES; FUS3	Mitogen-activated protein (MAP) kinases, also known as extracellular signal-regulated kinases (ERKs), are thought to act at an integration point for multiple biochemical signals because they are activated by a wide variety of extracellular signals, rapidly phosphorylated on threonine and tyrosine, and highly conserved. A critical protein kinase lies upstream of MAP kinase and stimulates the enzymatic activity of MAP kinase. The structure of this protein kinase, denoted MEK1, for MAP kinase or ERK kinase, was elucidated from a complementary DNA sequence an shown to be a protein of 393 amino acids (43,500 daltons) that is related most closely in size and sequence to the product encoded by the Schizosaccharomyces pombe byr1 gene. The MEK gene was highly expressed in murine brain, and the product expressed in bacteria phosphorylated the ERK gene product.			CREWS, CM (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005	NCI NIH HHS [CA42580] Funding Source: Medline; NIGMS NIH HHS [GM07620-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042580] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; Alessandrini A., UNPUB; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Maniatis T., 1982, MOL CLONING; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NIELSEN O, 1992, EMBO J, V11, P1391, DOI 10.1002/j.1460-2075.1992.tb05184.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; SEGER R, 1992, J BIOL CHEM, V267, P14373; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	37	858	909	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					478	480		10.1126/science.1411546	http://dx.doi.org/10.1126/science.1411546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411546				2022-12-24	WOS:A1992JT77500040
J	ILLINGWORTH, C				ILLINGWORTH, C			THE ARGUMENT FOR HELMETS	BRITISH MEDICAL JOURNAL			English	Article							BICYCLE INJURIES; CHILDREN; ACCIDENTS		CHILDRENS HOSP,PAEDIAT ACCID & EMERGENCY,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital								AHLSTROM I, 1990, HJALM ALLA; BALLANTYNE R, 1975, RICHARDS BICYCLE BOO; Bouvier R, 1984, Aust Fam Physician, V13, P287; CASS DT, 1989, AUST NZ J SURG, V59, P719, DOI 10.1111/j.1445-2197.1989.tb01664.x; GUICHON DMP, 1975, J TRAUMA, V15, P504, DOI 10.1097/00005373-197506000-00009; ILLINGWORTH CM, 1979, ACTA PAEDIATR SCAND, V68, P869; ILLINGWORTH CM, 1981, INJURY, V13, P7, DOI 10.1016/0020-1383(81)90083-8; ILLINGWORTH CM, 1985, ARCH DIS CHILD, V60, P461, DOI 10.1136/adc.60.5.461; ILLINGWORTH CM, 1984, BRIT MED J, V289, P956, DOI 10.1136/bmj.289.6450.956; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; SELBST SM, 1987, AM J DIS CHILD, V141, P140, DOI 10.1001/archpedi.1987.04460020030021; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WILLIAMS M, 1989, PROTECTIVE PERFORMAN; 1987, AM J DIS CHILD, V141, P135; 1986, ROAD ACCIDENTS GREAT	15	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					882	883		10.1136/bmj.305.6858.882	http://dx.doi.org/10.1136/bmj.305.6858.882			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422408	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JT77700036
J	RODRIGUEZ, LAG; GUTTHANN, SP; WALKER, AM; LUECK, L				RODRIGUEZ, LAG; GUTTHANN, SP; WALKER, AM; LUECK, L			THE ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN ACUTE LIVER-INJURY	BRITISH MEDICAL JOURNAL			English	Article							PROGRAM	Objective-To investigate the association between use of non-steroidal anti-inflammatory drugs and serious, acute non-infectious liver injury. Design-Retrospective cohort study, cross over design. Setting-Health records from provincial database in Saskatchewan, Canada, 1982-6. Subjects-228392 adults who contributed 645456 person years. All were either using or had used non-steroidal anti-inflammatory drugs. Main outcome measures-Number and type of prescriptions for non-steroidal anti-inflammatory drugs. Admission to hospital for newly diagnosed acute liver injury. Results-There were 34 admissions to hospital; 16 among subjects currently using non-steroidal anti-inflammatory drugs and 18 among subjects who were not. The incidence rate among current users was 9 per 100 000 person years (95% confidence interval 6 to 15 per 100000 person years). Subjects currently using non-steroidal anti-inflammatory drugs had twice the risk of newly diagnosed liver injury as those not currently taking these drugs (rate ratio 2.3; 95% confidence interval 1.1 to 4.9) and an excess risk of 5 per 100000 person years. The age and sex adjusted risk ratio was 1.7 (0.8 to 3.7). The strength of the association increased when only cases with no concomitant use of other hepatotoxic drugs were considered (4.0; 0.9 to 19.0). The rate ratio for people having received one to nine prescriptions was constant. There was no increased risk with long duration of treatment (1.0; 0.3 to 3.5). Conclusions-There is a small excess risk of serious, acute non-infectious liver injury associated with the use of non-steroidal anti-inflammatory drugs.	CIBA GEIGY AG,PHARMACOEPIDEMIOL UNIT,CH-4002 BASEL,SWITZERLAND; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; GDS & ASSOCIATES SYSTEMS LTD,REGINA,SASKATCHEWAN,CANADA	Novartis; Harvard University; Harvard T.H. Chan School of Public Health			rodriguez, luis a garcia/B-1980-2010	Perez-Gutthann, Susana/0000-0001-5798-3691				BEARD K, 1986, J CLIN PHARMACOL, V26, P633, DOI 10.1002/j.1552-4604.1986.tb02963.x; BJORNEBOE M, 1967, ACTA MED SCAND, V182, P491; Davis M., 1989, ADVERSE DRUG REACT B, V139, P520; JICK H, 1992, PHARMACOTHERAPY, V12, P207; LEWIS JH, 1984, CLIN PHARMACY, V3, P128; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; PESSAYRE D, 1988, BAILLIERE CLIN GASTR, V2, P385, DOI 10.1016/0950-3528(88)90009-7; RAVIOLO P, 1991, Recenti Progressi in Medicina, V82, P319; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; ROSS RM, 1981, AM J GASTROENTEROL, V76, P511; ROTHMAN KJ, 1988, INT J EPIDEMIOL, V17, P955, DOI 10.1093/ije/17.4.955; SANCHO CG, 1988, MED CLIN-BARCELONA, V90, P579; SHERLOCK S, 1981, DISEASES LIVER BILIA; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; STRICKER BHC, 1985, DRUG INDUCED HEPATIC; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; Walker AM, 1991, OBSERVATION INFERENC; ZIMMERMAN HJ, 1981, ARCH INTERN MED, V141, P333, DOI 10.1001/archinte.141.3.333; 1990, J HEPATOL, V11, P272	20	81	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					865	868		10.1136/bmj.305.6858.865	http://dx.doi.org/10.1136/bmj.305.6858.865			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422399	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JT77700024
J	MONTELL, DJ; RORTH, P; SPRADLING, AC				MONTELL, DJ; RORTH, P; SPRADLING, AC			SLOW BORDER CELLS, A LOCUS REQUIRED FOR A DEVELOPMENTALLY REGULATED CELL-MIGRATION DURING OOGENESIS, ENCODES DROSOPHILA C/EBP	CELL			English	Article							ENHANCER-BINDING-PROTEIN; GENE; EXPRESSION; ELEMENTS	During Drosophila oogenesis six to ten follicle cells, the border cells, undergo a dramatic and stereotypic migration through the developing egg chamber. We identified four independent P element insertion mutations that specifically blocked border cell migration. They defined a single, novel locus that was named slow border cells (slbo), because hypomorphic alleles caused delayed onset of the migration. Laser ablation of the border cells, or failure of their migration, caused improper morphogenesis of the micropyle, the eggshell structure through which the sperm enters at fertilization. The slbo locus was found to encode a product homologous to the CCAAT/enhancer-binding protein (C/EBP), a basic region-leucine zipper transcription factor. Drosophila C/EBP may be required for the expression of gene products mediating border cell migration.	CARNEGIE INST WASHINGTON, HOWARD HUGHES MED INST, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute			Rørth, Pernille/H-3020-2011		Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R29GM46425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046425] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BERG CA, 1991, GENETICS, V127, P515; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KALT MR, 1971, J ULTRA MOL STRUCT R, V36, P633, DOI 10.1016/S0022-5320(71)90020-7; KIMBLE M, 1990, GENETICS, V126, P991; King R. C., 1970, OVARIAN DEV DROSOPHI; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MLODZIK M, 1992, GENE EXPRESSION NEUR, V9, P397; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; Sambrook J., 1989, MOL CLONING LAB MANU; SPRADLING AC, 1992, IN PRESS DROSOPHILA; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THIERY JP, 1988, CIBA F SYMP, V141, P48; Tressler R J, 1989, Cancer Commun, V1, P55; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZARANI FE, 1986, CAN J ZOOL, V64, P2509, DOI 10.1139/z86-372	31	269	273	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					51	62		10.1016/0092-8674(92)90265-E	http://dx.doi.org/10.1016/0092-8674(92)90265-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394432				2022-12-24	WOS:A1992JQ62300006
J	YATES, DW; WOODFORD, M; HOLLIS, S				YATES, DW; WOODFORD, M; HOLLIS, S			PRELIMINARY-ANALYSIS OF THE CARE OF INJURED PATIENTS IN 33 BRITISH HOSPITALS - 1ST REPORT OF THE UNITED-KINGDOM MAJOR TRAUMA OUTCOME STUDY	BRITISH MEDICAL JOURNAL			English	Article							SEVERITY SCORE	Objective-To measure the effectiveness of management of major trauma in the United Kingdom. Design-Review of the care of all seriously injured patients seen over two years. Setting-33 hospitals which receive patients who have sustained major trauma. Subjects-14 648 injured patients admitted for more than three days, transferred or admitted into an intensive care bed, or dying from their injuries. Main outcome measure-Death or survival in hospital within three months of the injury. Results-21% of seriously injured patients (1299) took longer than one hour to reach hospital. Time before arrival at hospital was not related to severity of injury. A senior house officer was in charge of initial hospital resuscitation in 57% (826/1445) of patients with an injury severity score greater-than-or-equal-to 16. More senior staff were commonly responsible for definitive operations, but only 46% (165/355) of patients judged to require early operation arrived in theatre within two hours. Mortality for 6111 patients sustaining blunt trauma and treated in the 14 busiest hospitals was significantly higher (actual 408, predicted 295.6, p<0.001) than in a comparable North American dataset. Large differences in the 14 hospitals assessed could not be explained by variations in case load or facilities. In contrast, the outcome of the 4.1% (597) of patients with penetrating injuries was better than that of a comparable group in the United States. Analysis of the 415 penetrating injuries with complete data showed that 15 patients died (19.3 predicted; p=0.04). Conclusions-The initial management of major trauma in the United Kingdom remains unsatisfactory. There are delays in providing experienced staff and timely operations. Mortality varies inexplicably between hospitals and, for blunt trauma, is generally higher than in the United States.			YATES, DW (corresponding author), UNIV MANCHESTER,HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.			Hollis, Sally/0000-0003-0156-9189				BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; SMITH EJ, 1990, BRIT J HOSP MED, V44, P114; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090; YATES DW, 1991, ACCIDENT ANAL PREV, V23, P323, DOI 10.1016/0001-4575(91)90010-3; YATES DW, 1990, INTENS THER CLIN MON, V10, P38; 1988, REPORT WORKING PARTY; 1986, MORTALITY STATISTICS; 1991, CMD1523	12	137	138	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					737	740		10.1136/bmj.305.6856.737	http://dx.doi.org/10.1136/bmj.305.6856.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1422327	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JQ52000018
J	PHILEN, RM; ORTIZ, DI; AUERBACH, SB; FALK, H				PHILEN, RM; ORTIZ, DI; AUERBACH, SB; FALK, H			SURVEY OF ADVERTISING FOR NUTRITIONAL SUPPLEMENTS IN HEALTH AND BODYBUILDING MAGAZINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EOSINOPHILIA-MYALGIA SYNDROME; L-TRYPTOPHAN	The use of food supplements by the general public is poorly quantified, and little information on this subject is available in the medical literature. We surveyed 12 recent issues of popular health and bodybuilding magazines (1) to quantify the number of advertisements for food supplements, the number of products advertised, and the number and type of ingredients in these products; (2) to identify the purported health benefits of these products; and (3) as a preliminary effort to identify areas for future research. We counted 89 brands, 311 products, and 235 unique ingredients, the most frequent of which were unspecified amino acids; the most frequently promoted health benefit was muscle growth. We also found many unusual or unidentifiable ingredients, and 22.2% of the products had no ingredients listed in their advertisements. Health professionals may not be aware of how popular food supplements are or of a particular supplement's potential effects or side effects. In addition, patients may be reluctant to discuss their use of these products with traditional medical practitioners. We recommend that routine history taking include specific questions about patients' use of food supplements and that any possible adverse effects or side effects be reported to public health authorities.	UNIV TURABO, DEPT CIENCIAS & TECHNOL, UNIV STN, PR USA		PHILEN, RM (corresponding author), CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, ATLANTA, GA 30333 USA.							AMOS RJ, 1987, J AM DIET ASSOC, V87, P1063; ARENA JM, 1979, POISONING; BLUHM R, 1990, JAMA-J AM MED ASSOC, V264, P1141, DOI 10.1001/jama.264.9.1141; CHERNOFF N, 1988, TOXICOLOGY, V51, P57, DOI 10.1016/0300-483X(88)90080-7; CLARK HW, 1988, J PSYCHOACTIVE DRUGS, V20, P355, DOI 10.1080/02791072.1988.10472505; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; GIANNINI JA, 1982, HDB OVERDOSE DETOXIF; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KAUFMAN J, 1983, OVER COUNTER PILLS D; KESSLER DA, 1992, NEW ENGL J MED, V326, P70; KURMUKOV A G, 1991, Farmakologiya i Toksikologiya (Moscow), V54, P27; Lentner C, 1981, GEIGY SCI TABLES, V1; LENTNER C, 1986, GEIGY SCI TABLES, V4; LUBY S, 1992, AM J PUBLIC HEALTH, V82, P128, DOI 10.2105/AJPH.82.1.128-a; Mahler H.R., 1971, BIOL CHEM, V2nd; MAIRESSE M, 1981, HLTH SECRETS MED HER; MIRKIN G, 1991, JAMA-J AM MED ASSOC, V265, P912; Mirkin G, 1987, Semin Adolesc Med, V3, P177; ROBINSON T, 1975, ORGANIC CONSTITUENTS; SCHNEIDERHELMERT D, 1986, PSYCHOPHARMACOLOGY, V89, P1; SHIFF CJ, 1991, TROP MED PARASITOL, V42, P11; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAKEI M, 1991, J PHARM SCI, V80, P309, DOI 10.1002/jps.2600800403; WIDGER NH, 1979, WIDGER GUIDE OVER CO; ZHU DPQ, 1987, AM J CHINESE MED, V15, P117, DOI 10.1142/S0192415X87000151; ZIMMERMAN DR, 1983, ESSENTIAL GUIDE NONP; 1990, MMWR, V39, P789; 1991, MUSCLE MAG INT   AUG, P49; 1991, MUSCLE MAG INT   AUG, P121; 1990, MMWR, V39, P47; 1991, NATURES WAY HLTH CAR, P13; 1991, MUSCLE MAG INT   AUG, P163; 1990, NATURAL PHYSIQUE JUL, P92; 1989, MMWR, V38, P765; 1982, HDB NONPRESCRIPTION	39	41	42	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1008	1011		10.1001/jama.268.8.1008	http://dx.doi.org/10.1001/jama.268.8.1008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501305				2022-12-24	WOS:A1992JK12900026
J	EGGER, M; SMITH, GD; TEUSCHER, A				EGGER, M; SMITH, GD; TEUSCHER, A			FOR DEBATE - HUMAN INSULIN AND UNAWARENESS OF HYPOGLYCEMIA - NEED FOR A LARGE RANDOMIZED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; SEMISYNTHETIC HUMAN INSULIN; BLIND CROSSOVER TRIAL; PURIFIED PORK INSULIN; PORCINE INSULIN; INDUCED HYPOGLYCEMIA; RECOMBINANT DNA; COUNTERREGULATORY RESPONSES; GLUCOSE COUNTERREGULATION; SYMPTOMATIC AWARENESS		UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, SCOTLAND; UNIV LONDON UNIV COLL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND; UNIV BERN, DEPT ENDOCRINOL & DIABET, CH-3000 BERN, SWITZERLAND	University of Glasgow; University of London; University College London; University of Bern			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; [Anonymous], 1991, LANCET, V338, P853; BENDTSON I, 1991, J INTERN MED, V229, P293, DOI 10.1111/j.1365-2796.1991.tb00348.x; BERGER M, 1987, DIABETOLOGIA, V30, P829; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CLARK AJL, 1982, LANCET, V2, P354; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DUNCAN C, 1990, PRACTICAL DIABETES, V7, P18; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1990, DIABETIC MED, V7, P269, DOI 10.1111/j.1464-5491.1990.tb01385.x; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; EGGER M, 1991, BMJ-BRIT MED J, V303, P1267, DOI 10.1136/bmj.303.6812.1267-a; EGGER M, 1991, LANCET, V338, P950, DOI 10.1016/0140-6736(91)91820-K; FISHER BM, 1988, DIABETES RES CLIN EX, V8, P1; FRIER BM, 1991, BMJ-BRIT MED J, V303, P1266, DOI 10.1136/bmj.303.6812.1266-b; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; HAUPT E, 1991, HYPOGLYCAEMIA HUMAN, P119; HEINE RJ, 1990, LANCET, V335, P62, DOI 10.1016/0140-6736(90)90203-H; HEINE RJ, 1989, LANCET, V2, P946; HELLER SR, 1987, LANCET, V2, P359; HEPBURN DA, 1989, LANCET, V1, P1394; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; Home P D, 1984, Diabet Med, V1, P93; HOME PD, 1982, DRUGS, V24, P401, DOI 10.2165/00003495-198224050-00003; KAREM JH, 1991, CLIN DIABETES    NOV, P94; KEEN H, 1980, LANCET, V2, P398; KEEN H, 1981, MED INT, V1, P330; KERN W, 1989, LANCET, V2, P485; LANDGRAFLEURS MMC, 1984, KLIN WOCHENSCHR, V62, P659, DOI 10.1007/BF01716462; MANN NP, 1983, BMJ-BRIT MED J, V387, P1580; MARAN A, 1991, DIABETES, V40, pA544; ORCHARD TJ, 1991, DIABETIC MED, V8, P469, DOI 10.1111/j.1464-5491.1991.tb01634.x; OWENS DR, 1988, DIABETES RES CLIN EX, V8, P17; PARR JH, 1982, LANCET, V2, P831; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PATRICK AW, 1991, BRIT MED J, V303, P1266, DOI 10.1136/bmj.303.6812.1266-a; PICKUP J, 1986, BRIT MED J, V292, P155, DOI 10.1136/bmj.292.6514.155; REDMOND S, 1988, BALANCE          AUG, P66; ROSAK C, 1982, DIABETES CARE, V5, P82, DOI 10.2337/diacare.5.2.S82; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCHLUTER KJ, 1982, DIABETES CARE, V5, P78, DOI 10.2337/diacare.5.2.S78; SIEBER P, 1974, HELV CHIM ACTA, V57, P2617, DOI 10.1002/hlca.19740570839; SJOBOM NC, 1990, DIABETIC MED, V7, P775; SONNENBERG GE, 1983, DIABETOLOGIA, V25, P457; SPRAUL M, 1990, AKTUELLE ENDOKRINOLO, V11, P169; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; SWTOCKS AE, 1991, MED J AUSTRALIA, V154, P295; TATTERSALL RB, 1991, DIABETIC MED, V8, P49, DOI 10.1111/j.1464-5491.1991.tb01516.x; TATTERSALL RB, 1989, BRIT MED J, V299, P1339, DOI 10.1136/bmj.299.6711.1339-b; TEUSCHER A, 1987, LANCET, V2, P382; TEUSCHER A, 1979, SCHWEIZ MED WSCHR, V109, P743; TEUSCHER A, 1980, LANCET, V2, P1186; 1992, SCRIP           0207, P22	58	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1992	305	6849					351	355		10.1136/bmj.305.6849.351	http://dx.doi.org/10.1136/bmj.305.6849.351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392889	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JJ03200025
J	HANKINSON, SE; STAMPFER, MJ; SEDDON, JM; COLDITZ, GA; ROSNER, B; SPEIZER, FE; WILLETT, WC				HANKINSON, SE; STAMPFER, MJ; SEDDON, JM; COLDITZ, GA; ROSNER, B; SPEIZER, FE; WILLETT, WC			NUTRIENT INTAKE AND CATARACT-EXTRACTION IN WOMEN - A PROSPECTIVE-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PLASMA BETA-CAROTENE; VITAMIN-C STATUS; CIGARETTE-SMOKING; ASCORBIC-ACID; NUTRITIONAL-STATUS; ALPHA-TOCOPHEROL; SENILE CATARACT; LENS; RISK	Objective-To examine prospectively the association between dietary intake of vitamins C and E, carotene, and riboflavin and cataract extraction in women. Design-Prospective cohort study beginning in 1980 with eight years of follow up. Setting- 11 states of the United States. Participants - Female registered nurses who were 45 to 67 years of age. 50 828 women were included in 1980 and others were added as they became 45 years of age. Main outcome measure-Incidence of extraction of senile cataracts. Results-493 cataracts were extracted during 470 302 person years of follow up. Intake of carotene and vitamin A was inversely associated with cataract: in multivariate analyses, women in the highest fifth of total vitamin A intake (excluding supplements) had a 39% lower risk of cataract relative to women in the lowest fifth (relative risk 0.61; 95% confidence interval 0.45 to 0.81). Neither riboflavin nor dietary vitamins E or C were associated with cataract in a multivariate analysis. Among specific food items spinach (rather than carrots, the greatest source of beta-carotene) was most consistently associated with a lower relative risk. The risk of cataract was 45% lower among women who used vitamin C supplements for 10 or more years (relative risk 0.55 (0.32 to 0.96)), but no association was noted for multivitamin intake. Conclusion-Dietary carotenoids, although not necessarily beta-carotene, and long term vitamin C supplementation may decrease the risk of cataracts severe enough to require extraction.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; MASSACHUSETTS EYE & EAR INFIRM, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Eye & Ear Infirmary	HANKINSON, SE (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS CF, 1975, NUTRITIVE VALUES AM; BHAT KS, 1987, NUTR REP INT, V36, P685; BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188; BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; BUNCE GE, 1988, NUTR TODAY, V4, P6; COX DR, 1972, J R STAT SOC B, V34, P187; CREIGHTON MO, 1985, EXP EYE RES, V40, P213, DOI 10.1016/0014-4835(85)90006-5; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P904; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MCLAUGHLIN PJ, 1979, J AM DIET ASSOC, V75, P647; MILLER ER, 1954, J NUTR, V52, P405; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; NISHIGORI H, 1985, EXP EYE RES, V40, P445, DOI 10.1016/0014-4835(85)90157-5; OGINO S, 1957, AM J OPHTHALMOL, V43, P936, DOI 10.1016/0002-9394(57)91798-1; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SRIVASTAVA SK, 1972, BIOCHEM MED METAB B, V6, P372, DOI 10.1016/0006-2944(72)90023-3; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STEPHENS RJ, 1988, EXP EYE RES, V47, P237, DOI 10.1016/0014-4835(88)90007-3; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; TAYLOR A, 1991, CURR EYE RES, V10, P751, DOI 10.3109/02713689109013869; TREVITHICK JR, 1989, ANN NY ACAD SCI, V570, P358; VARMA SD, 1987, ANN NY ACAD SCI, V498, P280, DOI 10.1111/j.1749-6632.1987.tb23768.x; VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU SY, 1991, 3RD NEI S EYE DIS EP; NIH832473 US DEP H 3; 1982, USDA HDB SERIES, V1	45	214	220	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1992	305	6849					335	339		10.1136/bmj.305.6849.335	http://dx.doi.org/10.1136/bmj.305.6849.335			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392884	Green Published, Green Submitted			2022-12-24	WOS:A1992JJ03200020
J	YANG, XO; HUBBARD, EJA; CARLSON, M				YANG, XO; HUBBARD, EJA; CARLSON, M			A PROTEIN-KINASE SUBSTRATE IDENTIFIED BY THE 2-HYBRID SYSTEM	SCIENCE			English	Article							YEAST TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; SNF4 PROTEIN; GENE	A genetic method, the two-hybrid system, was used to identify four genes encoding proteins that interact with the SNF1 protein kinase from yeast. One of the genes, SIP1, was independently isolated as a multicopy suppressor of defects caused by reduced SNF1 kinase activity, and genetic evidence supports its function in the SNF1 pathyway. The SIP1 protein co-immunoprecipitated with SNF1 and was phosphorylated in vitro. Thus, the two-hybrid system, which is applicable to any cloned gene, can be used to detect physical interactions between protein kinases and functionally related substrate proteins.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	Columbia University; Columbia University				Hubbard, E. Jane Albert/0000-0001-5893-7232	NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034095, R01GM034095] Funding Source: NIH RePORTER; NCI NIH HHS [CA09503] Funding Source: Medline; NIGMS NIH HHS [GM34095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HUBBARD EJA, 1992, GENETICS, V130, P71; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Miller J.H., 1972, EXPT MOL GENETICS; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; Rose MD., 1990, METHODS YEAST GENETI; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMPSONJAEGER S, 1991, GENETICS, V129, P697	19	180	212	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					680	682		10.1126/science.1496382	http://dx.doi.org/10.1126/science.1496382			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496382				2022-12-24	WOS:A1992JF85200040
J	SEEFF, LB; BUSKELLBALES, Z; WRIGHT, EC; DURAKO, SJ; ALTER, HJ; IBER, FL; HOLLINGER, FB; GITNICK, G; KNODELL, RG; PERRILLO, RP; STEVENS, CE; HOLLINGSWORTH, CG				SEEFF, LB; BUSKELLBALES, Z; WRIGHT, EC; DURAKO, SJ; ALTER, HJ; IBER, FL; HOLLINGER, FB; GITNICK, G; KNODELL, RG; PERRILLO, RP; STEVENS, CE; HOLLINGSWORTH, CG			LONG-TERM MORTALITY AFTER TRANSFUSION-ASSOCIATED NON-A-HEPATITIS, NON-B-HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALCOHOLIC LIVER-DISEASE; C VIRUS; HEPATOCELLULAR-CARCINOMA; POSTTRANSFUSION HEPATITIS; FOLLOW-UP; VIRAL-HEPATITIS; PREVALENCE; ANTIBODIES; CIRRHOSIS; EFFICACY	Background. Acute non-A, non-B hepatitis after blood transfusion often progresses to chronic hepatitis and sometimes culminates in cirrhosis or even hepatocellular carcinoma. However, the frequency of these sequelae and their effects on mortality are not known. Methods. We traced patients with transfusion-related non-A, non-B hepatitis who had been identified in five major prospective studies conducted in the United States between 1967 and 1980. We matched each patient with two control subjects (identified as the first and second controls) who received transfusions but who did not have hepatitis. The mortality rates in the three groups were determined with use of data from the National Death index and Social Security Death Tapes. Cause-specific mortality was determined by reviewing death certificates. Results. Vital status was established for over 94 percent of the 568 patients who had had non-A, non-B hepatitis and the two control groups (526 first controls and 458 second controls). After an average follow-up of 18 years, the estimate by life-table analysis of mortality from all causes was 51 percent for those with transfusion-associated non-A, non-B hepatitis, as compared with 52 percent for the first controls and 50 percent for the second controls. The survival curves for the three groups were virtually the same. Mortality related to liver disease was 3.3, 1.1, and 2.0 percent, respectively, among the three groups (P = 0.033 for the comparison of the group with non-A, non-B hepatitis with the combined control group). Seventy-one percent of the deaths related to liver disease occurred among patients with chronic alcoholism. Conclusions. In this long-term follow-up study, there was no increase in mortality from all causes after transfusion-associated non-A, non-B hepatitis, although there was a small but statistically significant increase in the number of deaths related to liver disease.	GEORGETOWN UNIV, SCH MED, WASHINGTON, DC USA; GEORGE WASHINGTON UNIV, CTR BIOSTAT, ROCKVILLE, MD USA; WESTAT CORP, ROCKVILLE, MD USA; NIH, BLOOD BANK, BETHESDA, MD 20892 USA; VET AFFAIRS MED CTR, HINES, IL USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA; NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA; NHLBI, BETHESDA, MD 20892 USA	Georgetown University; George Washington University; Westat; National Institutes of Health (NIH) - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Maryland; University of Maryland Baltimore; Washington University (WUSTL); New York Blood Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	SEEFF, LB (corresponding author), VET AFFAIRS MED CTR, 50 IRVING ST NW, WASHINGTON, DC 20422 USA.		Hollinger, F Blaine/AAY-3323-2021		DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB087047] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-87047] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; Alter HJ, 1978, VIRAL HEPATITIS, P359; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; BERMAN M, 1979, ANN INTERN MED, V91, P1, DOI 10.7326/0003-4819-91-1-1; CALDWELL SH, 1991, AM J GASTROENTEROL, V86, P1219; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Cochran W.G, 1957, STAT METHODS, V6th ed; COLOMBO M, 1989, LANCET, V2, P1006; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; ECOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; MATTSSON L, 1988, LIVER, V8, P184; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; NOGUCHI O, 1991, LIVER, V11, P225; PERCY C, 1990, PUBLIC HEALTH REP, V105, P361; PRINCE AM, 1974, LANCET, V2, P241; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; SEEFF LB, 1978, VIRAL HEPATITIS, P371; TANAKA K, 1991, CANCER RES, V51, P2842; WEJSTAL R, 1987, SCAND J GASTROENTERO, V22, P1115, DOI 10.3109/00365528708991968; 1978, BMJ, V2, P1063; 1985, SAS USERS GUIDE BASI	33	673	678	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1906	1911		10.1056/NEJM199212313272703	http://dx.doi.org/10.1056/NEJM199212313272703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1454085	Bronze			2022-12-24	WOS:A1992KE50500003
J	LISKOWSKY, DR				LISKOWSKY, DR			BIOLOGICAL RHYTHMS AND SHIFT WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LISKOWSKY, DR (corresponding author), US OFF TECHNOL ASSESSMENT,BIOL APPLICAT PROGRAM,WASHINGTON,DC, USA.							1989, SCAND J WORK ENV HEA, V15, P165; 1990, OCCUP MED, V5, P273; 1991, BIOL RHYTHMS IMPLICA	3	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3047	3047		10.1001/jama.268.21.3047	http://dx.doi.org/10.1001/jama.268.21.3047			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1433723				2022-12-24	WOS:A1992KA00200005
J	VINE, SJ; PRYSDAVIES, A; PEARSON, JF				VINE, SJ; PRYSDAVIES, A; PEARSON, JF			TRANSVERSE POSTERIOR CERVICOISTHMIC RUPTURE AFTER GEMEPROST PESSARIES FOR TERMINATION	BRITISH MEDICAL JOURNAL			English	Letter							VAGINAL PESSARIES; UTERINE RUPTURE; PREGNANCY				VINE, SJ (corresponding author), UNIV HOSP WALES,CARDIFF CF4 4XN,S GLAM,WALES.							BYRNE P, 1991, BRIT MED J, V302, P852, DOI 10.1136/bmj.302.6780.852-c; CAMERON IT, 1987, PROSTAGLANDINS, V34, P111, DOI 10.1016/0090-6980(87)90268-1; LOWENSOHN R, 1974, AM J OBSTET GYNECOL, V119, P1057, DOI 10.1016/0002-9378(74)90258-0; WENTZ AC, 1973, AM J OBSTET GYNECOL, V115, P1107, DOI 10.1016/0002-9378(73)90560-7; WIENER JJ, 1990, BRIT J OBSTET GYNAEC, V97, P1061, DOI 10.1111/j.1471-0528.1990.tb02484.x	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1332	1332		10.1136/bmj.305.6865.1332	http://dx.doi.org/10.1136/bmj.305.6865.1332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483081	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992KA77300024
J	MATZUK, MM; FINEGOLD, MJ; SU, JGJ; HSUEH, AJW; BRADLEY, A				MATZUK, MM; FINEGOLD, MJ; SU, JGJ; HSUEH, AJW; BRADLEY, A			ALPHA-INHIBIN IS A TUMOR-SUPPRESSOR GENE WITH GONADAL SPECIFICITY IN MICE	NATURE			English	Article							MESSENGER RIBONUCLEIC-ACIDS; BETA-B; CELL TUMORS; ACTIVIN-A; SUBUNIT; EXPRESSION; HORMONE; EMBRYOGENESIS; PROLIFERATION; PROTOONCOGENE	The inhibins are alpha:beta heterodimeric growth factors that are members of the transforming growth factor-beta family. To understand the physiological roles of the inhibins in mammalian development and reproduction, a targeted deletion of the alpha-inhibin gene was generated by homologous recombination in mouse embryonic stem cells. Mice homozygous for the null allele (inhibin-deficient) initially develop normally but every mouse ultimately develops mixed or incompletely differentiated gonadal stromal tumours either unilaterally or bilaterally. Inhibin is thus a critical negative regulator of gonadal stromal cell proliferation and the first secreted protein identified to have tumour-suppressor activity.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; STANFORD UNIV, DEPT GYNECOL OBSTET, DIV REPROD BIOL, STANFORD, CA 94305 USA	Baylor College of Medicine; Stanford University	MATZUK, MM (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839				BARTON DE, 1989, GENOMICS, V5, P91, DOI 10.1016/0888-7543(89)90091-8; BHASIN S, 1989, ENDOCRINOLOGY, V124, P987, DOI 10.1210/endo-124-2-987; BRADLEY A, 1992, BIO-TECHNOL, V10, P534, DOI 10.1038/nbt0592-534; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Cate R.L, 1990, PEPTIDE GROWTH FACTO, P179; CHIN TW, 1991, CANCER RES, V51, P2101; DEJONG FH, 1990, J STEROID BIOCHEM, V37, P863, DOI 10.1016/0960-0760(90)90433-L; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FRANCHIMONT P, 1981, ACTA ENDOCRINOL-COP, V98, P312, DOI 10.1530/acta.0.0980312; GALWAY AB, 1990, J CLIN ENDOCR METAB, V71, P907, DOI 10.1210/jcem-71-4-907; GARDNER WU, 1955, CANCER RES, V15, P109; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; KEENE JL, 1989, MOL ENDOCRINOL, V3, P2011, DOI 10.1210/mend-3-12-2011; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHER JP, 1990, ENDOCRINOLOGY, V127, P3206, DOI 10.1210/endo-127-6-3206; MAYO KE, 1986, P NATL ACAD SCI USA, V83, P5849, DOI 10.1073/pnas.83.16.5849; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; O WS, 1989, MOL CELL ENDOCRINOL, V62, P307; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; PIQUETTE GN, 1990, BIOL REPROD, V43, P1050, DOI 10.1095/biolreprod43.6.1050; RABINOVICI J, 1990, J CLIN ENDOCR METAB, V71, P1396, DOI 10.1210/jcem-71-5-1396; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTS VJ, 1991, ENDOCRINOLOGY, V128, P3122, DOI 10.1210/endo-128-6-3122; Scully R. E, 1979, TUMORS OVARY MALDEVE; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; Teilum G., 1976, SPECIAL TUMORS OVARY; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUCHIYA E, 1992, CANCER RES, V52, P2478; TWOMBLY GH, 1949, CANCER, V2, P884, DOI 10.1002/1097-0142(194909)2:5<884::AID-CNCR2820020522>3.0.CO;2-2; VALE W, 1990, PEPTIDE GROWTH FACTO, V2, P211; VANDISSELEMILIANI FMF, 1989, ENDOCRINOLOGY, V125, P1899, DOI 10.1210/endo-125-4-1898; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOODRUFF TK, 1992, ENDOCRINOLOGY, V130, P871, DOI 10.1210/en.130.2.871; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196; YOUNG RH, 1987, SEMIN DIAGN PATHOL, V4, P342	45	822	873	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					313	319		10.1038/360313a0	http://dx.doi.org/10.1038/360313a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448148				2022-12-24	WOS:A1992JZ63000041
J	DAVIES, K				DAVIES, K			MESSAGE IN A BOTTLE	NATURE			English	Editorial Material																		COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HASTBACKA J, 1990, P NATL ACAD SCI USA, V87, P8056, DOI 10.1073/pnas.87.20.8056; HASTBACKA J, 1991, GENOMICS, V11, P968, DOI 10.1016/0888-7543(91)90021-6; Luria SE, 1943, GENETICS, V28, P491	5	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					90	90		10.1038/360090a0	http://dx.doi.org/10.1038/360090a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436083	Bronze			2022-12-24	WOS:A1992JW71700064
J	MULTIGNER, L; GAGNON, J; VANDORSSELAER, A; JOB, D				MULTIGNER, L; GAGNON, J; VANDORSSELAER, A; JOB, D			STABILIZATION OF SEA-URCHIN FLAGELLAR MICROTUBULES BY HISTONE-H1	NATURE			English	Article							CHLAMYDOMONAS ALPHA-TUBULIN; DOUBLET MICROTUBULES; STOP PROTEIN; TAU-PROTEIN; M-PHASE; CELLS; SPERM; ORIGIN; ASSOCIATION; STABILITY	Complex microtubule assemblies are essential components of eukaryotic cilia and flagella. They are extremely stable and are not affected by agents that normally induce polymer disassembly. The molecular basis of this microtubular stability is unknown, and it is not related to any feature of the constitutive tubulin. In sea urchin sperm flagella, axonemal microtubules are found to be stabilized by a protein identical to histone H1, a result that defines a new role for this histone and provides evidence for a concerted evolution of chromatin and microtubular structures.	INST BIOL STRUCT,F-38027 GRENOBLE 1,FRANCE; FAC CHIM STRASBOURG,SPECTROMETRIE MASSE BIOORGAN LAB,F-67008 STRASBOURG,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	MULTIGNER, L (corresponding author), CEN,INSERM,UNITE 244,DEPT BIOL MOLEC & STRUCT,CYTOSQUELETTE LAB,BP 85X,F-38041 GRENOBLE,FRANCE.		Multigner, Luc/I-2926-2015; Multigner, Luc/AAA-6214-2020; Gagnon, Jean/C-3136-2008	Multigner, Luc/0000-0003-3205-8568; Multigner, Luc/0000-0003-3205-8568; Gagnon, Jean/0000-0002-0177-824X				Behnke O, 1970, Int Rev Exp Pathol, V9, P1; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cavalier- Smith T, 1981, SOC GEN MICROBIOL S, V32, P33; CAVALIERSMITH T, 1988, BIOESSAYS, V9, P72, DOI 10.1002/bies.950090209; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CAVALIERSMITH T, 1975, NATURE, V256, P463, DOI 10.1038/256463a0; DRUBIN D, 1986, ANN NY ACAD SCI, V466, P257, DOI 10.1111/j.1749-6632.1986.tb38398.x; Dustin P., 1984, MICROTUBULES; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; ESPONDA P, 1980, CELL BIOL INT REP, V4, P549, DOI 10.1016/0309-1651(80)90020-X; FARRELL KW, 1982, METHOD CELL BIOL, V24, P61; FARRELL KW, 1978, J MOL BIOL, V121, P393, DOI 10.1016/0022-2836(78)90371-6; GIBBONS IR, 1972, J CELL BIOL, V54, P365, DOI 10.1083/jcb.54.2.365; GUNDERSEN GG, 1986, EUR J CELL BIOL, V42, P288; HARRISON A, 1990, J CELL SCI, V96, P347; Hnilica L.S., 1972, STRUCTURE BIOL FUNCT; IZANT JG, 1982, NATURE, V295, P248, DOI 10.1038/295248a0; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cb.02.110186.002505; LHERNAULT SW, 1983, J CELL BIOL, V97, P258, DOI 10.1083/jcb.97.1.258; LINCK RW, 1987, J CELL BIOL, V104, P1069, DOI 10.1083/jcb.104.4.1069; LINCK RW, 1976, J CELL SCI, V20, P405; MARGOLIS RL, 1990, EMBO J, V9, P4095, DOI 10.1002/j.1460-2075.1990.tb07631.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PATURLE L, 1989, BIOCHEMISTRY-US, V28, P2698, DOI 10.1021/bi00432a050; PIROLLET F, 1989, BIOCHEMISTRY-US, V28, P835, DOI 10.1021/bi00428a064; PIROLLET F, 1987, EMBO J, V6, P3247, DOI 10.1002/j.1460-2075.1987.tb02642.x; Revzin A., 1990, BIOL NONSPECIFIC DNA; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; STEFFEN W, 1989, CELL MOTIL CYTOSKEL, V14, P359, DOI 10.1002/cm.970140306; STEPHENS R E, 1970, Journal of Molecular Biology, V47, P353, DOI 10.1016/0022-2836(70)90307-4; STEPHENS RE, 1989, J CELL SCI, V92, P403; STEPHENS RE, 1992, J CELL SCI, V101, P837; Stollar B D, 1978, Methods Cell Biol, V18, P105; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VACQUIER VD, 1986, METHOD CELL BIOL, V27, P15, DOI 10.1016/S0091-679X(08)60340-4	42	61	61	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					33	39		10.1038/360033a0	http://dx.doi.org/10.1038/360033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436071				2022-12-24	WOS:A1992JW71700045
J	GEORGOPOULOS, K; MOORE, DD; DERFLER, B				GEORGOPOULOS, K; MOORE, DD; DERFLER, B			IKAROS, AN EARLY LYMPHOID-SPECIFIC TRANSCRIPTION FACTOR AND A PUTATIVE MEDIATOR FOR T-CELL COMMITMENT	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; CD3-DELTA GENE; YOLK-SAC; EXPRESSION; PRECURSORS; ONTOGENY; MOUSE	In a screen for transcriptional regulators that control differentiation into the T cell lineage, a complementary DNA was isolated encoding a zinc finger protein (Ikaros) related to the Drosophila gap protein Hunchback. The Ikaros protein binds to and activates the enhancer of a gene encoding an early T cell differentiation antigen, CD3delta. During development, Ikaros messenger RNA was first detected in the mouse fetal liver and the embryonic thymus when hematopoietic and lymphoid progenitors initially colonize these organs; no expression was observed in the spleen or the bone marrow. The pattern of Ikaros gene expression and its ability to stimulate CD3delta transcription support the model that Ikaros functions in the specification and maturation of the T lymphocyte.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital	GEORGOPOULOS, K (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114, USA.							AUERBACH R, 1981, FORTS ZOOL, V26, P287; AUSSUBEL F, 1991, CURRENT PROTOCOLS MO; BARKER JE, 1968, DEV BIOL, V15, P14; CAPEL B, 1989, P NATL ACAD SCI USA, V86, P4564, DOI 10.1073/pnas.86.12.4564; FURLEY AJ, 1986, CELL, V46, P75, DOI 10.1016/0092-8674(86)90861-5; GALSON D, UNPUB; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GEORGOPOULOS K, UNPUB; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LIU CP, 1991, DEVELOPMENT, V113, P1315; LIU CP, 1991, EUR J IMMUNOL, V21, P1849, DOI 10.1002/eji.1830210811; METCALF D, 1987, MOL CONTROL BLOOD CE; MOORE MAS, 1967, J EXP MED, V126, P715, DOI 10.1084/jem.126.4.715; Owen J J, 1981, Prog Allergy, V29, P1; RUGH R, 1991, MOUSE ITS REPRODUCTI, P272; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SZILVASSY SJ, 1989, P NATL ACAD SCI USA, V86, P8798, DOI 10.1073/pnas.86.22.8798; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	26	374	393	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					808	812		10.1126/science.1439790	http://dx.doi.org/10.1126/science.1439790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439790				2022-12-24	WOS:A1992JV69200041
J	SHERMAN, LA; HESSE, SV; IRWIN, MJ; LAFACE, D; PETERSON, P				SHERMAN, LA; HESSE, SV; IRWIN, MJ; LAFACE, D; PETERSON, P			SELECTING T-CELL RECEPTORS WITH HIGH-AFFINITY FOR SELF-MHC BY DECREASING THE CONTRIBUTION OF CD8	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOTOXIC LYMPHOCYTES-T; TRANSGENIC MICE; ALPHA-3 DOMAIN; ANTIGEN RECEPTOR; I MOLECULES; POSITIVE SELECTION; RECOGNITION; HLA-A2; THYMUS	Selective events during T cell repertoire development in the thymus include both the positive selection of cells whose receptors recognize self-major histocompatibility complex (MHC) molecules and negative selection (tolerance) of cells whose interaction with self-MHC is of high affinity. The affinity of T cell interactions with class I MHC molecules includes contributions by both the T cell receptor and the CD8 coreceptor. Therefore, by decreasing the affinity of the interaction with CD8, T cells whose receptors have relatively high affinities for self-MHC may survive negative selection. Such T cells were generated and those T cells reactive with self-MHC plus antigen also displayed low affinity for self.			SHERMAN, LA (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Sherman, Linda/0000-0001-6422-7069	NCI NIH HHS [CA 25803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DUKE RC, 1989, J EXP MED, V170, P59, DOI 10.1084/jem.170.1.59; ENGELHARD VH, 1991, J IMMUNOL, V146, P1226; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091; KALINKE U, 1990, NATURE, V348, P642, DOI 10.1038/348642a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISELOW P, 1988, NATURE, V335, P730; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAFACE D, 1992, FASEB J, V6, pA1709; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MACDONALD HR, 1988, NATURE, V336, P73; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMBERG NL, 1989, EUR J IMMUNOL, V19, P2349, DOI 10.1002/eji.1830191225; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VITIELLO A, 1983, J IMMUNOL, V131, P1635; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	30	97	111	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					815	818		10.1126/science.1439792	http://dx.doi.org/10.1126/science.1439792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439792				2022-12-24	WOS:A1992JV69200043
J	MATSUSHIME, H; EWEN, ME; STROM, DK; KATO, JY; HANKS, SK; ROUSSEL, MF; SHERR, CJ				MATSUSHIME, H; EWEN, ME; STROM, DK; KATO, JY; HANKS, SK; ROUSSEL, MF; SHERR, CJ			IDENTIFICATION AND PROPERTIES OF AN ATYPICAL CATALYTIC SUBUNIT (P34(PSK-J3)/CDK4) FOR MAMMALIAN-D TYPE-G1 CYCLINS	CELL			English	Article							STIMULATING FACTOR-I; RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; G1 CYCLINS; M-PHASE; YEAST; EXPRESSION; FAMILY	Murine D type cyclins associate with a catalytic subunit (p34PSK-J3 with properties distinct from known cyclin-dependent kinases (cdks). Mouse p34PSK-J3 shows less than 50% amino acid identity to p34cdc2, p33cdk2, and p36cdk3, lacks a PSTAIRE motif, and does not bind to p13suc1. Cyclin D1-p34PSK-J3 complexes accumulate in macrophages during G1 and decline in S phase, whereas complexes involving cyclins D2 and D3 form in proliferating T cells. Although histone H1 kinase activity is not detected in cyclin D or PSK-J3 immunoprecipitates, cyclin D-p34PSK-J3 complexes assembled in vitro stably bind and phosphorylate the retinoblastoma gene product (pRb) and an Rb-like protein (p107) but do not interact with pRb mutants that are functionally inactive. Thus, p34PSK-J3 is a cyclin D-regulated catalytic subunit that acts as an Rb (but not H1) kinase.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, SCH MED, NASHVILLE, TN 37232 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vanderbilt University	MATSUSHIME, H (corresponding author), ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA.		Roussel, Martine F/F-1469-2016; Sherr, Charles J/N-8074-2018	Roussel, Martine F/0000-0002-1740-8139; Sherr, Charles J/0000-0002-5516-6206	NCI NIH HHS [R35-CA47064, P01-CA21765] Funding Source: Medline; NIGMS NIH HHS [R29-GM38793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R35CA047064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1992, IN PRESS ONCOGENE; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	61	911	941	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					323	334		10.1016/0092-8674(92)90360-O	http://dx.doi.org/10.1016/0092-8674(92)90360-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423597				2022-12-24	WOS:A1992JU39500017
J	RICE, NR; MACKICHAN, ML; ISRAEL, A				RICE, NR; MACKICHAN, ML; ISRAEL, A			THE PRECURSOR OF NF-KAPPA-B P50 HAS I-KAPPA-B-LIKE FUNCTIONS	CELL			English	Article							REL ONCOGENE PRODUCT; DNA-BINDING SUBUNIT; TRANSFORMED LYMPHOID-CELLS; V-REL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTORS; CELLULAR PROTEINS; PHORBOL ESTER; 65-KD SUBUNIT; INHIBITION	The C-terminal half of the p105 precursor of the NF-kappaB p50 subunit contains ankyrin-like repeats similar to those in IkappaB molecules, which are known to retain NF-kappaB complexes in the cytoplasm. We demonstrate that in various cell lines p105 is found associated with either c-rel or p65 in the cytoplasm and serves IkappaB-like functions. p105 retains c-rel or p65 in the cytoplasm in cotransfection experiments in COS cells. It also inhibits DNA binding by c-rel in gel retardation assays. Stable interaction of p105 with c-rel or p65 requires the putative dimerization domain in the conserved rel homology region of p105, as well as a second contact with the IkappaB-related C-terminal part of p105. Pulse-chase experiments indicate that cytoplasmic complexes of p105 with c-rel or p65 give rise to cytoplasmic as well as nuclear p50-c-rel and p50-p65, respectively, probably through processing of p105. Thus, p105, like the IkappaBs, controls the subcellular localization and hence the transcriptional activity of at least two other members of the rel/NF-kappaB family.	STANFORD UNIV,PROGRAM CANC BIOL,STANFORD,CA 94305; INST PASTEUR,UNITE BIOL MOLEC EXPRESS GENIQUE,F-75724 PARIS 15,FRANCE	Stanford University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	RICE, NR (corresponding author), FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21702, USA.				NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, 5T32 CA 09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BECKWITH M, 1990, J NATL CANCER I, V82, P501, DOI 10.1093/jnci/82.6.501; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DAVIS N, 1990, ONCOGENE, V5, P1105; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICHARDSON PM, 1991, NATURE, V350, P625; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	419	423	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					243	253		10.1016/0092-8674(92)90353-E	http://dx.doi.org/10.1016/0092-8674(92)90353-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423592				2022-12-24	WOS:A1992JU39500010
J	COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R				COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R			CHANGES IN DRUG-TREATMENT AFTER DISCHARGE FROM HOSPITAL IN GERIATRIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain changes in drug treatment of elderly patients after discharge from hospital and to identify areas of communication which may require improvement. Design-Follow up of patients six to 14 days after discharge, when the drugs supplied by the hospital should have run out and a further supply obtained from the general practitioner. Patients were also asked about information supplied to them by health care professionals during their hospital stay. Subjects - 50 elderly patients discharged from five geriatric wards (mean age 76.9 years). Setting- Sunderland District Health Authority. Main outcome measure-Drugs taken after discharge from hospital. Results-After returning home the drug regimen of 45 patients differed from that prescribed on discharge from hospital, with 11 patients taking a different dose, 10 having stopped drugs, and 20 taking new drugs. Possible influencing factors included an incomplete drug history, the continuation of drugs taken before hospital admission, and changes in the prescription not attributable to a conscious clinical decision. Lack of information also contributed; 46 patients could not recall being told when to take drugs before discharge. Conclusion-Closer communication is needed between hospital and community health care professionals to ensure that patients are informed about their discharge prescription and continuation of treatment.	SUNDERLAND DIST GEN HOSP,SUNDERLAND SR4 7TP,ENGLAND; ROYAL INFIRM,SUNDERLAND SR2 7JE,ENGLAND; SUNDERLAND POLYTECH,SCH PHARMACEUT & CHEM SCI,SUNDERLAND SR2 7EE,DURHAM,ENGLAND	Sunderland Royal Hospital; University of Sunderland								Davidson J R, 1974, Nurs Times, V70, P391; Hatch A M, 1982, Nurs Times, V78, P1773; MACDONALD ET, 1977, BMJ-BRIT MED J, V2, P618, DOI 10.1136/bmj.2.6087.618; MOTTRAM DR, 1989, PHARM J, V243, P458; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Sweeney SJ, 1989, PHARM J, V242; WALKER CA, 1987, BRIT J PHARM PRACTIC, V9, P47; WINFIELD AJ, 1990, BR J PHARM PRACT, V12, P206	8	86	89	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					694	696		10.1136/bmj.305.6855.694	http://dx.doi.org/10.1136/bmj.305.6855.694			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393119	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JP51100028
J	BHASKAR, KR; GARIK, P; TURNER, BS; BRADLEY, JD; BANSIL, R; STANLEY, HE; LAMONT, JT				BHASKAR, KR; GARIK, P; TURNER, BS; BRADLEY, JD; BANSIL, R; STANLEY, HE; LAMONT, JT			VISCOUS FINGERING OF HCL THROUGH GASTRIC MUCIN	NATURE			English	Article							MUCUS-BICARBONATE BARRIER; MUCOSAL PROTECTION; PH GRADIENT; DIFFUSION; PATTERNS; ACID; GEL; GLYCOPROTEIN; SECRETION; VISCOSITY	THE HCl in the mammalian stomach is concentrated enough to digest the stomach itself, yet the gastric epithelium remains undamaged. One protective factor is gastric mucus, which forms a protective layer over the surface epithelium1-4 and acts as a diffusion barrier5,6 Bicarbonate ions secreted by the gastric epithelium7 are trapped in the mucus gel, establishing a gradient from pH 1-2 at the lumen to pH 6-7 at the cell surface8-10. How does HCl, secreted at the base of gastric glands by parietal cells, traverse the mucus layer without acidifying it? Here we demonstrate that injection of HCl through solutions of pig gastric mucin produces viscous fingering patterns11-18 dependent on pH, mucin concentration and acid flow rate. Above pH 4, discrete fingers are observed, whereas below pH 4, HCl neither penetrates the mucin solution nor forms fingers. Our in vitro results suggest that HCl secreted by the gastric gland can penetrate the mucus gel layer (pH 5-7) through narrow fingers, whereas HCl in the lumen (pH 2) is prevented from diffusing back to the epithelium by the high viscosity of gastric mucus gel on the luminal side.	BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215; BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215	Boston University; Boston University	BHASKAR, KR (corresponding author), BOSTON UNIV HOSP,MED CTR,GASTROENTEROL SECT,88 E NEWTON ST,BOSTON,MA 02218, USA.		Bansil, Rama/ABC-4452-2020	Bansil, Rama/0000-0003-1311-1749; Stanley, H./0000-0003-2800-4495				AGREN J, 1990, ACTA PHYSL SCAND, V140, pA36; ALLEN A, 1976, NATURE, V264, P88, DOI 10.1038/264088a0; ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; ALLEN A, 1980, GUT, V21, P249, DOI 10.1136/gut.21.3.249; Allen A., 1981, PHYSL GASTROINTESTIN, P617; BENJACOB E, 1990, NATURE, V343, P523, DOI 10.1038/343523a0; BHASKAR KR, 1991, AM J PHYSIOL, V261, pG827, DOI 10.1152/ajpgi.1991.261.5.G827; BLOOM W, 1966, TXB HISTOLOGY, P433; BUKA A, 1986, NATURE, V323, P424, DOI 10.1038/323424a0; CASTELL DO, 1987, ESOPHAGEAL MOTILITY, P21; FABRY T L, 1990, Gastroenterology, V98, pA42; FLEMSTROM G, 1987, PHYSL GASTROINTESTIN, P1011; GARIK P, 1991, PHYS REV LETT, V66, P1606, DOI 10.1103/PhysRevLett.66.1606; GONG DH, 1990, AM J PHYSIOL, V259, pG681, DOI 10.1152/ajpgi.1990.259.4.G681; HEATLEY NG, 1959, GASTROENTEROLOGY, V37, P313; Hele-Shaw H. S., 1898, NATURE, V58, P34, DOI [DOI 10.1038/058034A0, 10.1038/058034a0]; HOLLANDER F, 1954, ARCH INTERN MED, V93, P107, DOI 10.1001/archinte.1954.00240250117009; HOLM L, 1990, J INTERN MED, V228, P91, DOI 10.1111/j.1365-2796.1990.tb01478.x; JOSEPH DD, 1990, EUR J MECH B-FLUID, V9, P565; KERSS S, 1982, CLIN SCI, V63, P185; LAL J, 1992, PHYSICA A, V186, P88, DOI 10.1016/0378-4371(92)90367-Y; MAKHLOUF GM, 1984, PHYSL GASTROINTESTIN, V1, P551; MAY SE, 1989, PHYS REV A, V40, P1723, DOI 10.1103/PhysRevA.40.1723; MURTY VLN, 1984, BIOCHEM BIOPH RES CO, V121, P521, DOI 10.1016/0006-291X(84)90213-4; NITTMANN J, 1985, NATURE, V314, P141, DOI 10.1038/314141a0; PATRONELLA CK, 1988, GASTROENTEROLOGY, V95, P612, DOI 10.1016/S0016-5085(88)80005-2; PFEIFFER CJ, 1981, AM J PHYSIOL, V240, pG176, DOI 10.1152/ajpgi.1981.240.2.G176; SEELIG LL, 1985, AM J ANAT, V174, P15, DOI 10.1002/aja.1001740103; SELLERS LA, 1987, BIORHEOLOGY, V24, P615; TAKEUCHI K, 1983, GASTROENTEROLOGY, V84, P331; WALLACE JL, 1989, AM J PHYSIOL, V256, pG31, DOI 10.1152/ajpgi.1989.256.1.G31; WILLIAMS SE, 1981, GUT, V22, P94, DOI 10.1136/gut.22.2.94; WILLIAMS SE, 1980, GASTROENTEROLOGY, V79, P299	33	174	174	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					458	461		10.1038/360458a0	http://dx.doi.org/10.1038/360458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448168				2022-12-24	WOS:A1992KA79700058
J	SCHMID, A; FASCHER, KD; HORZ, W				SCHMID, A; FASCHER, KD; HORZ, W			NUCLEOSOME DISRUPTION AT THE YEAST PHO5 PROMOTER UPON PHO5 INDUCTION OCCURS IN THE ABSENCE OF DNA-REPLICATION	CELL			English	Article							RNA POLYMERASE-II; BETA-GLOBIN GENE; TRANSCRIPTIONALLY ACTIVE CHROMATIN; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; ACID-PHOSPHATASE; POSITIONED NUCLEOSOMES; HYPERSENSITIVE SITES; REGULATORY PROTEINS; MAJOR LATE	Activation of the PHO5 gene in S. cerevisiae by phosphate starvation was previously shown to be accompanied by the disappearance of four positioned nucleosomes from the promoter. To investigate the mechanism, we replaced the PHO80 gene, a negative regulator of PHO5, by a temperature-sensitive allele. As a consequence, PHO5 can be activated in the presence of phosphate by a temperature shift from 24-degrees-C to 37-degrees-C. Under these conditions, the promoter undergoes the same chromatin transition as in phosphate-starved cells. Disruption of the nucleosomes by the temperature shift also occurs when DNA replication is prevented. Nucleosomes re-form when the temperature is shifted from 37-degrees-C back to 24-degrees-C in nondividing cells. Glucose is required for the disruption of the nucleosomes during the temperature upshift, not for their re-formation during the temperature downshift. These experiments prove that DNA replication is not required for the transition between the nucleosomal and the non-nucleosomal state at the PHO5 promoter.			SCHMID, A (corresponding author), UNIV MUNICH,INST PHYS CHEM,SCHILLERSTR 44,W-8000 MUNICH 2,GERMANY.							ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BERBEN G, 1990, YEAST, V6, P451, DOI 10.1002/yea.320060510; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1989, THESIS U MUNCHEN MUN; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISHER F, 1991, ONCOGENE, V6, P1099; FOY HR, 1987, EMBO J, V6, P2321; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAGUENAUERTSAPIS R, 1984, MOL CELL BIOL, V4, P2668, DOI 10.1128/MCB.4.12.2668; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HANES SD, 1986, CRC CR REV BIOCH MOL, V21, P153, DOI 10.3109/10409238609113611; HAYASHI N, 1991, MOL CELL BIOL, V11, P785, DOI 10.1128/MCB.11.2.785; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANEKO Y, 1985, MOL CELL BIOL, V5, P248, DOI 10.1128/MCB.5.1.248; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KOREN R, 1986, GENE, V41, P271, DOI 10.1016/0378-1119(86)90107-1; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LUCCHINI G, 1988, MOL GEN GENET, V212, P459, DOI 10.1007/BF00330850; MADDEN SL, 1990, MOL CELL BIOL, V10, P5950, DOI 10.1128/MCB.10.11.5950; MADDEN SL, 1988, NUCLEIC ACIDS RES, V16, P2625, DOI 10.1093/nar/16.6.2625; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MEYHACK B, 1982, EMBO J, V1, P675, DOI 10.1002/j.1460-2075.1982.tb01229.x; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PAVLOVIC B, 1988, MOL CELL BIOL, V8, P5513, DOI 10.1128/MCB.8.12.5513; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PHAM TA, 1991, J BIOL CHEM, V266, P18179; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROBERGE M, 1992, MOL MICROBIOL, V6, P419, DOI 10.1111/j.1365-2958.1992.tb01485.x; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; UESONO Y, 1992, MOL GEN GENET, V231, P426, DOI 10.1007/BF00292712; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VENTER U, 1989, NUCLEIC ACIDS RES, V17, P1353, DOI 10.1093/nar/17.4.1353; VOGEL K, 1990, MOL MICROBIOL, V4, P2013, DOI 10.1111/j.1365-2958.1990.tb00560.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WILLS C, 1990, CRIT REV BIOCHEM MOL, V25, P245, DOI 10.3109/10409239009090611; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YA MB, 1991, MOL CELL BIOL, V11, P3229; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	89	139	141	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					853	864		10.1016/0092-8674(92)90560-Y	http://dx.doi.org/10.1016/0092-8674(92)90560-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423633				2022-12-24	WOS:A1992JZ63300014
J	BEVILACQUA, PC; KIERZEK, R; JOHNSON, KA; TURNER, DH				BEVILACQUA, PC; KIERZEK, R; JOHNSON, KA; TURNER, DH			DYNAMICS OF RIBOZYME BINDING OF SUBSTRATE REVEALED BY FLUORESCENCE-DETECTED STOPPED-FLOW METHODS	SCIENCE			English	Article							HELIX-COIL TRANSITION; INTERVENING SEQUENCE; RIBOSOMAL-RNA; TETRAHYMENA-THERMOPHILA; ACTIVE-SITE; KINETICS; MECHANISM; RECOGNITION; CLEAVAGE; THERMODYNAMICS	Fluorescence-detected stopped-flow and equilibrium methods have been used to study the mechanism for binding of pyrene (pyr)-labeled RNA oligomer substrates to the ribozyme (catalytic RNA) from Tetrahymena thermophila. The fluorescence of these substrates increases up to 25-fold on binding to the ribozyme. Stopped-flow experiments provide evidence that pyr experiences at least three different microenvironments during the binding process. A minimal mechanism is presented in which substrate initially base pairs to ribozyme and subsequently forms tertiary contacts in an RNA folding step. All four microscopic rate constants are measured for ribozyme binding of pyrCCUCU.	UNIV ROCHESTER, DEPT CHEM, ROCHESTER, NY 14627 USA; POLISH ACAD SCI, INST BIOORGAN CHEM, PL-60704 POZNAN, POLAND; PENN STATE UNIV, DEPT MOLEC & CELL BIOL, University Pk, PA 16802 USA	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Schroeder, Susan/D-3946-2011	Bevilacqua, Philip/0000-0001-8074-3434; Kierzek, Ryszard/0000-0002-7644-0016	NIGMS NIH HHS [GM 22939, GM44613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022939, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BENNUN M, 1992, J PHYS CHEM-US, V96, P1523, DOI 10.1021/j100183a004; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HE L, 1991, BIOCHEMISTRY-US, V30, P11124, DOI 10.1021/bi00110a015; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HIROMI K, 1979, KINETICS FAST ENZYME, P258; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KIERZEK R, UNPUB; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; LABUDA D, 1984, J MOL BIOL, V174, P587, DOI 10.1016/0022-2836(84)90085-8; LIN CT, 1976, J AM CHEM SOC, V98, P6536, DOI 10.1021/ja00437a020; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NORTH AM, 1964, COLLISION THEORY CHE, pCH7; PETERSHEIM M, 1983, BIOCHEMISTRY-US, V22, P256, DOI 10.1021/bi00271a004; PORSCHKE D, 1973, BIOPOLYMERS, V12, P1313, DOI 10.1002/bip.1973.360120609; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SULLIVAN FX, 1985, CELL, V42, P639, DOI 10.1016/0092-8674(85)90121-7; Turner DH, 1990, LANDOLTBORNSTEIN N C, V1, P201; WARING RB, 1983, J MOL BIOL, V167, P595, DOI 10.1016/S0022-2836(83)80100-4; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WILLIAMS AP, 1989, BIOCHEMISTRY-US, V28, P4283, DOI 10.1021/bi00436a025; YOON K, 1976, NUCLEIC ACIDS RES, V3, P2233, DOI 10.1093/nar/3.9.2233; YOON K, 1975, J MOL BIOL, V99, P507, DOI 10.1016/S0022-2836(75)80169-0; YUAN RC, 1979, NUCLEIC ACIDS RES, V7, P2399, DOI 10.1093/nar/7.8.2399; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	35	190	191	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1355	1357		10.1126/science.1455230	http://dx.doi.org/10.1126/science.1455230			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455230				2022-12-24	WOS:A1992JY95800038
J	MITCHELL, JM; SUNSHINE, JH				MITCHELL, JM; SUNSHINE, JH			CONSEQUENCES OF PHYSICIANS OWNERSHIP OF HEALTH-CARE FACILITIES - JOINT VENTURES IN RADIATION-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINANCIAL INCENTIVES; OFFICE PRACTICE; PREPAID; DEMAND	Background. Physicians are increasingly the owners of health care facilities to which they refer patients for services but at which they do not practice. We studied such ownership arrangements, known as "joint ventures," in the field of radiation therapy, examining their effects on access, use of services, costs, and quality. Methods. Because 44 percent of free-standing facilities providing radiation therapy in Florida in 1989 were joint ventures, as compared with 7 percent elsewhere (95 percent confidence interval, 3 to 10 percent), we compared data for Florida with comparable data for the remainder of the United States. We also compared radiation-therapy facilities in Florida that were established as joint ventures with those that were not. Since most data were derived from entire populations rather than from samples, any differences found were of necessity statistically significant. Results. No joint-venture facilities providing radiation therapy were located in inner-city neighborhoods or rural areas, but 11 percent of other free-standing facilities and hospital-based facilities were located in such areas. Among free-standing facilities, joint ventures received 39 percent of their revenues from patients with well-paying insurance coverage, as compared with 31 percent for facilities that were not joint ventures (P<0.01). The frequency and costs of radiation-therapy treatments at free-standing centers were 40 to 60 percent higher in Florida than in the rest of the United States; there was no below-average use of radiation therapy at hospitals or higher cancer rates that explained the higher rates of use or higher costs in Florida. Radiation physicists at joint-venture facilities (the principal personnel involved in quality control other than physicians) spent 18 percent less time with each patient over the course of treatment than did their counterparts at free-standing facilities that were not joint ventures (P<0.05). Mortality among patients with cancer in Florida was not lower than the U.S. average, even though joint ventures are much more common in that state. Conclusions. Joint ventures in radiation therapy appear to have adverse effects on patients' access to care. They also appear to increase the use of services and costs substantially. Some indicators show that joint ventures cause either no improvement in quality or a decline. Our results add to the evidence indicating that physicians' self-referral generally has negative consequences. We recommend legislation to ban ownership of joint ventures by referring physicians. Such legislation needs to be carefully designed in order to achieve its objectives and forestall new, financially abusive arrangements.	AMER COLL RADIOL,RES DEPT,RESTON,VA; FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306	American College of Radiology; State University System of Florida; Florida State University	MITCHELL, JM (corresponding author), GEORGETOWN UNIV,GRAD PUBL POLICY PROGRAM,3600 N ST NW,SUITE 200,WASHINGTON,DC 20007, USA.							EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GRAY BH, 1986, FOR PROFIT ENTERPRIS, P151; HANKS G E, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P87; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; IGLEHART JK, 1989, NEW ENGL J MED, V321, P198, DOI 10.1056/NEJM198907203210327; KRAMER S, 1984, STAT MED, V3, P353, DOI 10.1002/sim.4780030411; KRAMER S, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P49; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, 1991 FLOR HLTH CAR C; Morrison D.E., 1970, SIGNIFICANCE TEST CO; PEAR R, 1991, NY TIMES        1105, pA17; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RIES LAG, 1991, NCI NIH912789 PUBL; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; SCHROEDER SA, 1978, MED CARE, V16, P289, DOI 10.1097/00005650-197804000-00002; SUNSHINE JH, 1992, RADIOLOGY, V183, P535, DOI 10.1148/radiology.183.2.1561364; Waldholz Michael, 1989, WALL STREET J   0301, pA1; WILENSKY GR, 1983, MILBANK FUND Q, V61, P252, DOI 10.2307/3349907; 1990, PHYSICIANS CURRENT P; 1989, FINANCIAL ARRANGEMEN; 1989, FED REGISTER, V54, P8894; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1992, PRESIDENTS COMPREHEN, P68	28	99	99	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1497	1501		10.1056/NEJM199211193272106	http://dx.doi.org/10.1056/NEJM199211193272106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406881				2022-12-24	WOS:A1992JY16500006
J	SZE, JY; WOONTNER, M; JAEHNING, JA; KOHLHAW, GB				SZE, JY; WOONTNER, M; JAEHNING, JA; KOHLHAW, GB			INVITRO TRANSCRIPTIONAL ACTIVATION BY A METABOLIC INTERMEDIATE - ACTIVATION BY LEU3 DEPENDS ON ALPHA-ISOPROPYLMALATE	SCIENCE			English	Article							REGULATORY GENE LEU3; YEAST LEU4; EXPRESSION; BINDING; BIOSYNTHESIS; DELETION; PROTEINS; PRODUCT; ELEMENT; REGION	In the absence of the leucine biosynthetic precursor alpha-isopropylmalate (alpha-IPM), the yeast LEU3 protein (Leu3p) binds DNA and acts as a transcriptional repressor in an in vitro extract. Addition of alpha-IPM resulted in a dramatic increase in Leu3p-dependent transcription. The presence of alpha-IPM was also required for Leu3p to compete effectively with another transcriptional activator, GAL4/VP16, for limiting transcription factors. Therefore, the addition of alpha-IPM appears to convert a transcriptional repressor into an activator. This represents an example in eukaryotes of direct transcriptional regulation by a small effector molecule.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038101] Funding Source: NIH RePORTER; NIAID NIH HHS [K04 AI 00874] Funding Source: Medline; NIGMS NIH HHS [GM15102, R01 GM38101] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BAICHWAL VR, 1983, CURR GENET, V7, P369, DOI 10.1007/BF00445877; BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; CALVO JM, 1970, METHODS ENZYMOLOGY A, V17, P791; CHANG LFL, 1984, GENETICS, V108, P91; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOHLHAW GB, 1983, AMINO ACIDS BIOSYNTH, P285; LITSKEPETERSEN JG, 1986, NUCLEIC ACIDS RES, V14, P961; MARTINEZARIAS A, 1984, NATURE, V307, P740, DOI 10.1038/307740b0; PETERS MH, 1990, ARCH BIOCHEM BIOPHYS, V276, P294, DOI 10.1016/0003-9861(90)90041-V; POLACCO JC, 1973, GENETICS, V74, P443; SZE JY, UNPUB; WOONTNER M, UNPUB; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	24	87	88	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1143	1145		10.1126/science.1439822	http://dx.doi.org/10.1126/science.1439822			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439822				2022-12-24	WOS:A1992JX85200030
J	FORSBLOM, CM; GROOP, PH; EKSTRAND, A; GROOP, LC				FORSBLOM, CM; GROOP, PH; EKSTRAND, A; GROOP, LC			PREDICTIVE VALUE OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES OF LONG DURATION	BRITISH MEDICAL JOURNAL			English	Article							NEPHROPATHY	Objective-To investigate the predictive value of microalbuminuria (albumin excretion rate 30-300 mg/24 h) as a risk factor for overt diabetic nephropathy in patients with longstanding insulin dependent diabetes. Design-10 year follow up of patients with normoalbuminuria (albumin excretion rate < 30 mg/24 h), microalbuminuria (30-300 mg/24 h), and macroalbuminuria (> 300 mg/24 h) based on two out of three timed overnight urine samples. Setting-Outpatient clinic of Helsinki University Hospital. Subjects-72 consecutive patients who had had insulin dependent diabetes for over 15 years. Main outcome measures-Urinary albumin excretion rate, mortality, and prevalence of diabetic complications after 10 years. Results-56 patients were re-examined at 10 year follow up, 10 had died, five were lost to follow up, and one was excluded because of non-diabetic kidney disease. At initial screening 22 patients had macroalbuminuria, 18 had microalbuminuria, and 26 had normal albumin excretion. Only five (28%, 95% confidence interval 10% to 54%) of the microalbuminuric patients developed macroalbuminuria during the 10 year follow up and none developed end stage renal failure. Two (8%, 1% to 25%) normoalbuminuric patients developed macroalbuminuria and four (15%, 4% to 35%) became microalbuminuric. Seven (32%, 14% to 55%) of the macroalbuminuric patients developed end stage renal failure and six (27%, 11% to 50%) died of cardiovascular complications. Conclusion-Microalbuminuria is not a good predictor of progression to overt nephropathy in patients with longstanding insulin dependent diabetes.	HELSINKI UNIV HOSP,DEPT MED 4,UNIONINKATU 38,SF-00170 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TEPPO AM, 1982, CLIN CHEM, V28, P1359; VIBERTI GC, 1982, LANCET, V1, P1430	6	137	140	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1051	1053		10.1136/bmj.305.6861.1051	http://dx.doi.org/10.1136/bmj.305.6861.1051			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467683	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JW70100016
J	RUTZ, JM; LIU, J; LYONS, JA; GORANSON, J; ARMSTRONG, SK; MCINTOSH, MA; FEIX, JB; KLEBBA, PE				RUTZ, JM; LIU, J; LYONS, JA; GORANSON, J; ARMSTRONG, SK; MCINTOSH, MA; FEIX, JB; KLEBBA, PE			FORMATION OF A GATED CHANNEL BY A LIGAND-SPECIFIC TRANSPORT PROTEIN IN THE BACTERIAL OUTER-MEMBRANE	SCIENCE			English	Article							ESCHERICHIA-COLI K-12; FERRIC ENTEROBACTIN RECEPTOR; AFFECT VITAMIN-B12 TRANSPORT; REGION TONB BOX; SALMONELLA-TYPHIMURIUM; POINT MUTATIONS; PORIN CHANNELS; IRON TRANSPORT; ENTEROCHELIN; NUCLEOTIDE	The ferric enterobactin receptor (FepA) is a high-affinity ligand-specific transport protein in the outer membrane of Gram-negative bacteria. Deletion of the cell-surface ligand-binding peptides of FepA generated mutant proteins that were incapable of high-affinity uptake but that instead formed nonspecific, passive channels in the outer membrane. Unlike native FepA, these pores acted independently of the accessory protein TonB, which suggests that FepA is a gated porin and that TonB acts as its gatekeeper by facilitating the entry of ligands into the FepA channel. The sequence homology among TonB-dependent proteins suggests that all ligand-specific outer membrane receptors may function by this gated-porin mechanism.	MED COLL WISCONSIN,DEPT MICROBIOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOPHYS,MILWAUKEE,WI 53226; E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858; UNIV MISSOURI,SCH MED,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65212	Medical College of Wisconsin; Medical College of Wisconsin; University of North Carolina; East Carolina University; University of Missouri System; University of Missouri Columbia			Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022923, R01GM022923, R01GM040565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22608] Funding Source: Medline; NIGMS NIH HHS [GM22923, GM40565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BAUMLER AJ, 1992, MOL MICROBIOL, V6, P1309, DOI 10.1111/j.1365-2958.1992.tb00852.x; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; DIMASI DR, 1973, J BACTERIOL, V115, P56; ECKER DJ, 1986, J BACTERIOL, V167, P666, DOI 10.1128/jb.167.2.666-673.1986; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; GUTERMAN SK, 1973, J BACTERIOL, V114, P1225, DOI 10.1128/JB.114.3.1225-1230.1973; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KOSTER W, 1986, MOL GEN GENET, V204, P435, DOI 10.1007/BF00331021; LEONG J, 1976, J BACTERIOL, V126, P823, DOI 10.1128/JB.126.2.823-830.1976; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MCINTOSH M, UNPUB; MILLER JH, 1978, EXPT MOL GENETICS, P104; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; MURPHY CK, 1989, J BACTERIOL, V171, P5894, DOI 10.1128/jb.171.11.5894-5900.1989; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1981, ANNU REV NUTR, V1, P27, DOI 10.1146/annurev.nu.01.070181.000331; NEILANDS JB, 1952, J AM CHEM SOC, V74, P4846, DOI 10.1021/ja01139a033; NEILANDS JB, 1966, STRUCT BOND, V1, P59; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; OZENBERGER BA, 1987, J BACTERIOL, V169, P3638, DOI 10.1128/jb.169.8.3638-3646.1987; POSTLE K, 1979, J MOL BIOL, V131, P619, DOI 10.1016/0022-2836(79)90011-1; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; RUTZ JM, 1991, J BACTERIOL, V173, P5694; WANG CC, 1969, J BACTERIOL, V98, P1135, DOI 10.1128/JB.98.3.1135-1141.1969; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	42	155	160	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					471	475		10.1126/science.1411544	http://dx.doi.org/10.1126/science.1411544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411544				2022-12-24	WOS:A1992JT77500038
J	SHIVER, JW; SU, LS; HENKART, PA				SHIVER, JW; SU, LS; HENKART, PA			CYTOTOXICITY WITH TARGET DNA BREAKDOWN BY RAT BASOPHILIC LEUKEMIA-CELLS EXPRESSING BOTH CYTOLYSIN AND GRANZYME-A	CELL			English	Article							TOXIC LYMPHOCYTE-T; SERINE PROTEASE; PERFORIN; FRAGMENTATION; GRANULES; CLONING; LYSIS; ANTIBODY; BINDING; FAMILY	The noncytotoxic rat mast cell tumor line RBL was transfected with genes for the cytotoxic lymphocyte granule proteins cytolysin (perforin) and granzyme A, giving transfectants with mRNA and protein expression levels comparable with cloned cytotoxic T lymphocytes. Both RBL-cytolysin and RBL-cytolysin-granzyme A transfectants showed extremely potent killing of red cell targets and lysed 20%-60% of EL4 lymphoma targets at an effector-to-target ratio of 30. RBL transfectants expressing only granzyme A were not cytotoxic. Significant EL4 DNA breakdown accompanying lysis was observed only with RBL that was transfected with both cytolysin and granzyme A. These results support the granule-exocytosis model for lymphocyte cytotoxicity and show that effector granzyme A plays a role in target cell DNA breakdown.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,STANFORD,CA 94305	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University								BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BRUNET JF, 1988, IMMUNOL REV, V103, P21, DOI 10.1111/j.1600-065X.1988.tb00747.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON MM, 1988, ENDOCRINOLOGY, V122, P2158, DOI 10.1210/endo-122-5-2158; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; Fewtrell C, 1981, Kroc Found Ser, V14, P295; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HUDIG D, 1991, J IMMUNOL, V147, P1360; ISHIKAWA H, 1989, J IMMUNOL, V143, P3069; KRAMER MD, 1987, IMMUNOL TODAY, V8, P140, DOI 10.1016/0167-5699(87)90141-1; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU FT, 1980, J IMMUNOL, V124, P2728; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MUNGER WE, 1988, IMMUNOL REV, V103, P99, DOI 10.1111/j.1600-065X.1988.tb00752.x; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SELLINS KS, 1991, J IMMUNOL, V147, P795; Serafin W E, 1990, Monogr Allergy, V27, P31; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SHIVER JW, 1991, CELL, V64, P1174; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	35	237	240	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					315	322		10.1016/0092-8674(92)90359-K	http://dx.doi.org/10.1016/0092-8674(92)90359-K			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423596				2022-12-24	WOS:A1992JU39500016
J	ZHANG, SH; REDDICK, RL; PIEDRAHITA, JA; MAEDA, N				ZHANG, SH; REDDICK, RL; PIEDRAHITA, JA; MAEDA, N			SPONTANEOUS HYPERCHOLESTEROLEMIA AND ARTERIAL LESIONS IN MICE LACKING APOLIPOPROTEIN-E	SCIENCE			English	Article							CORONARY HEART-DISEASE; E DEFICIENCY; PLASMA-LIPOPROTEINS; ATHEROSCLEROSIS; SUSCEPTIBILITY; SERUM; HYPERLIPOPROTEINEMIA; QUANTITATION; TRANSPORT	Apolipoprotein E (apoE) is a ligand for receptors that clear remnants of chylomicrons and very low density lipoproteins. Lack of apoE is, therefore, expected to cause accumulation in plasma of cholesterol-rich remnants whose prolonged circulation should be atherogenic. ApoE-deficient mice generated by gene targeting were used to test this hypothesis and to make a mouse model for spontaneous atherosclerosis. The mutant mice had five times normal plasma cholesterol, and developed foam cell-rich depositions in their proximal aortas by age 3 months. These spontaneous lesions progressed and caused severe occlusion of the coronary artery ostium by 8 months. The severe yet viable phenotype of the mutants should make them valuable for investigating genetic and environmental factors that modify the atherogenic process.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, PROGRAM MOLEC BIOL & BIOTECHNOL, CHAPEL HILL, NC 27599 USA; TEXAS A&M UNIV SYST, DEPT VET ANAT & PUBL HLTH, COLL STN, TX 77840 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Texas A&M University System; Texas A&M University College Station					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042630, R01HL042630] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42630] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG K, 1983, PROG MED GENET, V5, P35; BRESLOW JL, 1991, ANNU REV MED, V42, P357, DOI 10.1146/annurev.me.42.020191.002041; CAMUS MC, 1983, J LIPID RES, V24, P1210; DEMACKER PNM, 1978, CLIN CHEM, V24, P1439; FRANCE DS, 1989, J LIPID RES, V30, P1997; GETZ GS, 1988, ARCH PATHOL LAB MED, V112, P1048; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; GRUNDY SM, 1991, ARTERIOSCLER THROMB, V11, P1619, DOI 10.1161/01.ATV.11.6.1619; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KUROSAKA D, 1991, ATHEROSCLEROSIS, V88, P15, DOI 10.1016/0021-9150(91)90252-X; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LUSIS AJ, 1988, J LIPID RES, V29, P397; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MORRISETT JD, 1982, ARTERIOSCLEROSIS, V2, P312, DOI 10.1161/01.ATV.2.4.312; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Roberts A, 1976, Adv Exp Med Biol, V67, P313; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; Utermann G, 1986, Adv Exp Med Biol, V201, P261; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEIBUST RS, 1973, GENETICS, V73, P303; Zhang S., UNPUB	26	1836	1928	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					468	471		10.1126/science.1411543	http://dx.doi.org/10.1126/science.1411543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411543				2022-12-24	WOS:A1992JT77500037
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDAS ELECTRONIC BULLETIN BOARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-24	WOS:A1992JR43900010
J	GARCIA, I; MARTINOU, I; TSUJIMOTO, Y; MARTINOU, JC				GARCIA, I; MARTINOU, I; TSUJIMOTO, Y; MARTINOU, JC			PREVENTION OF PROGRAMMED CELL-DEATH OF SYMPATHETIC NEURONS BY THE BCL-2 PROTOONCOGENE	SCIENCE			English	Article							GROWTH-FACTOR DEPRIVATION; FOLLICULAR LYMPHOMA; B-CELLS; EXPRESSION; SURVIVAL; TRANSLOCATION; ENDONUCLEASE; MOTONEURONS; ACTIVATION; DEPENDENCE	Approximately half of the neurons produced during embryogenesis normally die before adulthood. Although target-derived neurotrophic factors are known to be major determinants of programmed cell death-apoptosis-the molecular mechanisms by which trophic factors interfere with cell death regulation are largely unknown. Overexpression of the bcl-2 proto-oncogene in cultured sympathetic neurons has now been shown to prevent apoptosis normally induced by deprivation of nerve growth factor. This finding, together with the previous demonstration of bcl-2 expression in the nervous system, suggests that the Bcl-2 protein may be a major mediator of the effects of neurotrophic factors on neuronal survival.	UNIV GENEVA,MED CTR,DEPT PHARMACOL & CLIN NEUROPHYSIOL,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND; WISTAR INST,PHILADELPHIA,PA 19104	University of Geneva; University of Geneva; The Wistar Institute				martinou, Jean-claude/0000-0002-9847-2051	NCI NIH HHS [CA-51864, CA-50551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051864, R01CA050551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], [No title captured]; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BORZILLO VG, 1992, ONCOGENE, V7, P869; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; COHEN JJ, 1984, J IMMUNOL, V132, P38; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GARCIA I, 1986, MOL CELL BIOL, V51, P294; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; LAZARUS KJ, 1976, BRAIN RES, V113, P159, DOI 10.1016/0006-8993(76)90013-5; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU JC, 1989, J NEUROSCI, V9, P3645; MARTINOU JC, UNPUB; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SINGH NP, 1986, STAIN TECHNOL, V61, P315, DOI 10.3109/10520298609109959; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	34	719	743	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					302	304		10.1126/science.1411528	http://dx.doi.org/10.1126/science.1411528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411528				2022-12-24	WOS:A1992JR86000035
J	MCKEGANEY, N; BARNARD, M; LEYLAND, A; COOTE, I; FOLLET, E				MCKEGANEY, N; BARNARD, M; LEYLAND, A; COOTE, I; FOLLET, E			FEMALE STREETWORKING PROSTITUTION AND HIV-INFECTION IN GLASGOW	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE	Objectives-To identify the extent of HIV infection and injecting drug use among female street-working prostitutes in Glasgow; to estimate the size of the female streetworking prostitute population in the city; and to estimate the number of HIV positive women working as prostitutes on the streets in Glasgow. Design-Observation and interviewing of female prostitutes over seven months in red light district; analysis of sativa samples for presence of antibodies to HIV; capture-recapture approach to estimating the size of the female streetworking prostitute population. Setting-Glasgow. Subjects-206 female streetworking prostitutes. Main outcome measures-Number of women with antibodies to HIV, self reported use of injecting drugs, history of contact with 206 women. Results-Saliva samples were requested from 197 women; 159 (81%) provided samples. Four (2.5%, 95% confidence interval 0.7%-6.3%) of the samples were positive for HIV, all of which had been provided by women who injected drugs. Of the 206 streetworking women contacted 147 (71%) were injecting drug users. About 1150 women are estimated to work on the streets in Glasgow over a 12 month period. Conclusions-HIV is not as widespread among female prostitutes as many reports in the tabloid press suggest. A greater proportion of female street-working prostitutes in Glasgow are injecting drugs than has been reported for other British cities.	RUCHILL HOSP, REG VIRUS LAB, HEPATITIS HIV REFERENCE LAB, GLASGOW G20 9NB, SCOTLAND		MCKEGANEY, N (corresponding author), UNIV GLASGOW, PUBL HLTH RES UNIT, GLASGOW G12 8RZ, SCOTLAND.		Leyland, Alastair/C-6069-2011	Leyland, Alastair/0000-0003-3741-7099				BLOOR M, 1991, BRIT J ADDICT, V86, P1477; CAMERON W, 1990, HETEROSEXUAL TRANSMI; CORMACK RM, 1989, BIOMETRICS, V45, P395, DOI 10.2307/2531485; DAY S, 1988, BRIT MED J, V297, P1585, DOI 10.1136/bmj.297.6663.1585; FRISCHER M, 1991, INT J EPIDEMIOL, V20, P997, DOI 10.1093/ije/20.4.997; FRISCHER M, 1992, LANCET, V339, P995, DOI 10.1016/0140-6736(92)91577-U; HOOK EB, 1992, LANCET, V339, P742, DOI 10.1016/0140-6736(92)90639-K; KINNELL H, 1989, PROSTITUTES THEIR CL; LAPORTE RE, 1992, LANCET, V339, P494, DOI 10.1016/0140-6736(92)91103-F; LEYLAND AH, 1992, JUN INT C SOCIAL SCI; MCKEGANEY N, 1990, AIDS, V4, P1153, DOI 10.1097/00002030-199011000-00017; MCKEGANEY NP, IN PRESS AIDS CARE; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; TAPPIN DM, 1991, LANCET, V337, P1565; THOMAS RM, 1989, BMJ-BRIT MED J, V299, P148, DOI 10.1136/bmj.299.6692.148; TIRELLI U, 1989, AIDS, V3, P547, DOI 10.1097/00002030-198908000-00015	16	79	80	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 3	1992	305	6857					801	804		10.1136/bmj.305.6857.801	http://dx.doi.org/10.1136/bmj.305.6857.801			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422360	Green Accepted, Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JT25600020
J	FARR, CJ; GOODFELLOW, PN				FARR, CJ; GOODFELLOW, PN			HIDDEN MESSAGES IN GENETIC MAPS	SCIENCE			English	Editorial Material											FARR, CJ (corresponding author), UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND.			Farr, Christine/0000-0002-5357-5962				BRENNER S, 1992, NATURE, V356, P27; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; DISTECHE CM, 1992, NAT GENET, V1, P333, DOI 10.1038/ng0892-333; Fisher R., 2005, TEACHING CHILDREN TH; FOSTER JW, IN PRESS NATURE; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; HANCOMBE O, 1991, GENE DEV, V5, P1387; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Trowsdale J, 1992, CURR OPIN GENET DEV, V2, P492, DOI 10.1016/S0959-437X(05)80163-7; VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906; 1991, CYTOGENET CELL GENET, V58, P1	11	14	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					49	49		10.1126/science.1439767	http://dx.doi.org/10.1126/science.1439767			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439767				2022-12-24	WOS:A1992JQ61900022
J	LU, H; ZAWEL, L; FISHER, L; EGLY, JM; REINBERG, D				LU, H; ZAWEL, L; FISHER, L; EGLY, JM; REINBERG, D			HUMAN GENERAL TRANSCRIPTION FACTOR-IIH PHOSPHORYLATES THE C-TERMINAL DOMAIN OF RNA POLYMERASE-II	NATURE			English	Article							PREINITIATION COMPLEX; LARGEST SUBUNIT; REPEAT DOMAIN; INITIATION; PURIFICATION; PROTEIN; PROMOTER; INVITRO; KINASE; FORM	Phosphorylation of the carboxy-terminal domain of the largest subunit of RNA polymerase II is believed to control the transition from transcription initiation to elongation. The general transcription factor IIH (TFIIH) contains a kinase activity capable of phosphorylating this domain. Factors that promote the association of RNA polymerase II with the preinitiation complex stimulate this activity. The transcription factor IIE, which is required for the stable association of TFIIH with the preinitiation complex, affects the processivity of TFIIH kinase.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, 675 HOES LANE, PISCATAWAY, NJ 08854 USA; FAC MED STRASBOURG, CNRS, GENET MOLEC LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE	Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Reinberg, Danny/0000-0003-4288-2016				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS M, IN PRESS TRANSCRIPTI; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, IN PRESS SCIENCE; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KIM WY, 1989, J BIOL CHEM, V264, P3169; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON MG, 1991, NATURE, V354, P369; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STONE N, 1992, J BIOL CHEM, V267, P6353; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, IN PRESS PROG NUCLEI; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	35	367	370	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					641	645		10.1038/358641a0	http://dx.doi.org/10.1038/358641a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495560				2022-12-24	WOS:A1992JJ88200045
J	CHOI, GH; NUSS, DL				CHOI, GH; NUSS, DL			HYPOVIRULENCE OF CHESTNUT BLIGHT FUNGUS CONFERRED BY AN INFECTIOUS VIRAL CDNA	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; ENDOTHIA-PARASITICA; BIOLOGICAL-CONTROL; CRYPHONECTRIA-PARASITICA; VEGETATIVE COMPATIBILITY; TRANSMISSIBLE HYPOVIRULENCE; GENE-EXPRESSION; VIRUS; AUTOPROTEOLYSIS; STRAINS	Strains of the chestnut blight fungus Cryphonectria parasitica that contain viral double-stranded RNAs often exhibit reduced virulence. Such hypovirulent strains act as biocontrol agents by virtue of their ability to convert virulent strains to hypovirulence after anastomosis. Transformation of virulent C. parasitica strains with a full-length complementary DNA copy of a hypovirulence-associated viral RNA conferred the complete hypovirulence phenotype. Cytoplasmic double-stranded RNA was resurrected from the chromosomally integrated complementary DNA copy and was able to convert compatible virulent strains to hypovirulence. These results establish viral double-stranded RNA as the causal agent of hypovirulence and demonstrate the feasibility of engineering hypovirulent fungal strains.	ROCHE RES CTR,ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Roche Holding								ANAGNOSTAKIS SL, 1977, EXP MYCOL, V1, P306, DOI 10.1016/S0147-5975(77)80006-6; ANAGNOSTAKIS SL, 1986, PLANT DIS, V70, P536, DOI 10.1094/PD-70-536; ANAGNOSTAKIS SL, 1982, SCIENCE, V215, P466, DOI 10.1126/science.215.4532.466; ANAGNOSTAKIS SL, 1982, GENETICS, V102, P25; ANAGNOSTAKIS SL, 1983, MYCOLOGIA, V75, P777, DOI 10.2307/3792770; ANAGNOSTAKIS SL, 1984, ECOLOGY PHYSL FUNGAL, P499; Buck K.W., 1986, FUNGAL VIROLOGY, P1, DOI [10.1201/9781351072205-1, DOI 10.1201/9781351072205-1]; CHOI GH, 1992, EMBO J, V11, P473, DOI 10.1002/j.1460-2075.1992.tb05077.x; CHOI GH, 1991, VIROLOGY, V183, P747, DOI 10.1016/0042-6822(91)91004-Z; CHOI GH, 1991, P NATL ACAD SCI USA, V88, P1167, DOI 10.1073/pnas.88.4.1167; CULLEN D, 1987, GENE, V57, P21, DOI 10.1016/0378-1119(87)90172-7; DAY PR, 1977, PHYTOPATHOLOGY, V67, P1393, DOI 10.1094/Phyto-67-1393; Elliston JE, 1978, P AM CHESTNUT S, P95; ELSHERBEINI M, 1984, MOL CELL BIOL, V4, P2818, DOI 10.1128/MCB.4.12.2818; Grente J, 1978, P AM CHESTNUT S, P30; GRENTE M. J., 1965, COMPT REND HEBD SEANCES ACAD AGR FRANCE, V51, P1033; Griffin G. J., 1986, Horticultural Reviews, V8, P291, DOI 10.1002/9781118060810.ch8; HILLMAN BI, 1992, J GEN VIROL, V73, P681, DOI 10.1099/0022-1317-73-3-681; HILLMAN BI, 1990, PHYTOPATHOLOGY, V80, P950, DOI 10.1094/Phyto-80-950; HIREMATH S, 1986, NUCLEIC ACIDS RES, V14, P9877; JAYNES RA, 1980, PHYTOPATHOLOGY, V70, P453, DOI 10.1094/Phyto-70-453; KOONIN EV, 1991, P NATL ACAD SCI USA, V88, P10647, DOI 10.1073/pnas.88.23.10647; MACDONALD WL, 1991, PLANT DIS, V75, P656, DOI 10.1094/PD-75-053; Roane MK, 1986, CHESTNUT BLIGHT OTHE, P1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAPIRA R, 1991, EMBO J, V10, P731, DOI 10.1002/j.1460-2075.1991.tb08004.x; SHAPIRA R, 1991, EMBO J, V10, P741, DOI 10.1002/j.1460-2075.1991.tb08005.x; SHAPIRA R, 1991, J BIOL CHEM, V266, P19419; VANALFEN NK, 1975, SCIENCE, V189, P890, DOI 10.1126/science.189.4206.890; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303	30	267	296	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					800	803		10.1126/science.1496400	http://dx.doi.org/10.1126/science.1496400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496400				2022-12-24	WOS:A1992JG85100036
J	DANIEL, MD; KIRCHHOFF, F; CZAJAK, SC; SEHGAL, PK; DESROSIERS, RC				DANIEL, MD; KIRCHHOFF, F; CZAJAK, SC; SEHGAL, PK; DESROSIERS, RC			PROTECTIVE EFFECTS OF A LIVE ATTENUATED SIV VACCINE WITH A DELETION IN THE NEF GENE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; CONFERS PROTECTION; RHESUS-MONKEYS; CHIMPANZEES; MACAQUES; INFECTION; IMMUNIZATION; CHALLENGE	Vaccine protection against the human immunodeficiency virus (HIV) and the related simian immunodeficiency virus (SIV) in animal models is proving to be a difficult task. The difficulty is due in large part to the persistent, unrelenting nature of HIV and SIV infection once infection is initiated. SIV with a constructed deletion in the auxiliary gene nef replicates poorly in rhesus monkeys and appears to be nonpathogenic in this normally susceptible host. Rhesus monkeys vaccinated with live SIV deleted in nef were completely protected against challenge by intravenous inoculation of live, pathogenic SIV. Deletion of nef or of multiple genetic elements from HIV may provide the means for creating a safe, effective, live attenuated vaccine to protect against acquired immunodeficiency syndrome (AIDS).	HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,1 PINE HILL DR,BOX 9102,SOUTHBOROUGH,MA 01772	Harvard University			Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	NIAID NIH HHS [AI25328, AI26463, AI26507] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025328, R01AI025328] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; Bruck C., COMMUNICATION; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1293; Cranage M P, 1992, Nature, V355, P685, DOI 10.1038/355685a0; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, UNPUB; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; EMINI EA, 1990, AIDS RES HUM RETROV, V6, P1247, DOI 10.1089/aid.1990.6.1247; GIBBS JS, UNPUB; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GIRARD M P, 1990, AIDS (London), V4, pS143; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; HU SMK, COMMUNICATION; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; LEGRAND R, 1992, NATURE, V355, P684; LEWIS MA, UNPUB; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; YILMA T, COMMUNICATION	26	964	998	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1938	1941		10.1126/science.1470917	http://dx.doi.org/10.1126/science.1470917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470917				2022-12-24	WOS:A1992KD08800032
J	KASSAVETIS, GA; JOAZEIRO, CAP; PISANO, M; GEIDUSCHEK, EP; COLBERT, T; HAHN, S; BLANCO, JA				KASSAVETIS, GA; JOAZEIRO, CAP; PISANO, M; GEIDUSCHEK, EP; COLBERT, T; HAHN, S; BLANCO, JA			THE ROLE OF THE TATA-BINDING PROTEIN IN THE ASSEMBLY AND FUNCTION OF THE MULTISUBUNIT YEAST RNA POLYMERASE-III TRANSCRIPTION FACTOR, TFIIIB	CELL			English	Article							HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; DNA; INVITRO; PROMOTER; SUBUNIT; BACTERIOPHAGE-T4; COMPONENTS; ACTIVATION; COMPLEXES	The Saccharomyces cerevisiae RNA polymerase III transcription factor (TF)IIIB has been assembled from three components. An assembly pathway of these polypeptides, which specifies their interactions, has been determined. The TATA-binding protein, TBP, and the TFIIB-related BRF1 gene product BRF, together reconstitute the transcription factor activity and TFIIIC-dependent DNA-binding activity of the B' component of TFIIIB. BRF alone weakly binds to a TFIIIC-tRNA gene complex; TBP greatly stabilizes this interaction. B" transcription factor actitivity is recovered with its previously identified 90 kd polypeptide from SDS-polyacrylamide gels. Incorporation of the 90 kd B" protein into the transcription complex requires TBP. The heparin-resistant TFIIIB-DNA complex retains all three of its constituent proteins, TBP, BRF, and B".	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of California System; University of California San Diego; Fred Hutchinson Cancer Center	KASSAVETIS, GA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Pisano, Marina/C-3978-2015	Pisano, Marina/0000-0002-0649-1010	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07312] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1992, IN PRESS J BIOL CHEM; BRAUN BR, 1992, IN PRESS J MOL BIOL; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; COLBERT T, 1992, IN PRESS GENES DEV; CORMACK BP, 1992, CELL, V69, P665; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; OMAI L, 1992, CELL, V68, P965; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WEIS L, 1992, IN PRESS FASEB J; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	41	218	218	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1055	1064		10.1016/0092-8674(92)90399-W	http://dx.doi.org/10.1016/0092-8674(92)90399-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458536				2022-12-24	WOS:A1992KB99000016
J	KIELECZAWA, J; DUNN, JJ; STUDIER, FW				KIELECZAWA, J; DUNN, JJ; STUDIER, FW			DNA SEQUENCING BY PRIMER WALKING WITH STRINGS OF CONTIGUOUS HEXAMERS	SCIENCE			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T7 DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; HYBRIDIZATION; POLYMERASE	When template DNA is saturated with a single-stranded DNA binding protein (SSB), strings of three or four contiguous hexanucleotides (hexamers) can cooperate through base-stacking interactions to prime DNA synthesis specifically from the 3' end of the string. Under the same conditions, priming by individual hexamers is suppressed. Strings of three or four hexamers representing more than 200 of the 4096 possible hexamers primed easily readable sequence ladders at more than 75 different sites in single-stranded or denatured double-stranded templates 6.4 kilobases to 40 kilobase pairs long, with a success rate of 60 to 90 percent. A synthesis of 1 micromole of hexamer supplies enough material for thousands of primings, so multiple libraries of all 4096 hexamers could be distributed at a reasonable cost. Such libraries would allow rapid and economical sequencing. Automating this strategy could increase the speed and efficiency of large-scale DNA sequencing by at least an order of magnitude.			KIELECZAWA, J (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.							BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; Khrapko K R, 1991, DNA Seq, V1, P375, DOI 10.3109/10425179109020793; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; QUARTIN RS, 1989, BIOCHEMISTRY-US, V28, P1040, DOI 10.1021/bi00429a018; SHERMAN LA, 1970, J VIROL, V6, P841, DOI 10.1128/JVI.6.6.841-846.1970; STUDIER FW, 1989, P NATL ACAD SCI USA, V86, P6917, DOI 10.1073/pnas.86.18.6917; SZYBALSKI W, 1990, GENE, V90, P177, DOI 10.1016/0378-1119(90)90458-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WBRIGHT R, 1992, GENE, V114, P81; WEISS B, 1971, METHODS ENZYMOLOGY D, V21, P319; 1990, UNDERSTANDING OUR GE	19	104	131	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1787	1791		10.1126/science.1465615	http://dx.doi.org/10.1126/science.1465615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465615				2022-12-24	WOS:A1992KB96400037
J	EMERY, P; SALMON, M; BRADLEY, H; WORDSWORTH, P; TUNN, E; BACON, PA; WARING, R				EMERY, P; SALMON, M; BRADLEY, H; WORDSWORTH, P; TUNN, E; BACON, PA; WARING, R			GENETICALLY-DETERMINED FACTORS AS PREDICTORS OF RADIOLOGICAL CHANGE IN PATIENTS WITH EARLY SYMMETRICAL ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article							RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY; SULFOXIDATION	Objective-To determine whether genetic factors associated with established rheumatoid arthritis could, in combination with rheumatoid factor, predict the development of radiological erosions in patients with early symmetrical (rheumatoid-like) arthritis. Design-Prospective study. Setting-Teaching hospital, early arthritis clinic. Subjects-Forty nine patients with symmetrical polyarthritis attending the early arthritis clinic. Main outcome measures-Conserved sequence of DRbeta third allelic hypervariable region, sulphoxidation capacity, rheumatoid factor, and development of radiologically determined bone erosions. Results-None of the 49 patients had radiological erosions at presentation but 25 developed these by four years. Patients with the conserved class II major histocompatibility complex (third allelic hypervariable of DRbeta1) genes associated with rheumatoid arthritis had a relative risk for the development of erosions of 1.9 (95% confidence interval 0.8 to 4.5). For poor sulphoxidation the risk was 2.5 (1.1 to 5.6) and for the presence of rheumatoid factor 1.8 (0.9 to 3.7). Of the 33 patients who had two or three of these risk factors, 24 developed erosions, with a relative risk of 11.6 (1.7 to 78.5) compared with only one of the 16 individuals with no or one risk factor. Conclusions-This preliminary study shows that by using these stable markers it is possible to make clinically useful predictions of outcome in patients with early symmetrical inflammatory arthritis.	UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Birmingham; University of Oxford	EMERY, P (corresponding author), UNIV BIRMINGHAM,DEPT RHEUMATOL,POB 363,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		emery, paul/B-3560-2013	Waring, Rosemary/0000-0001-6617-5856				EMERY P, 1992, ANN RHEUM DIS, V51, P318, DOI 10.1136/ard.51.3.318; EMERY P, 1984, J RHEUMATOL, V11, P626; GARDINER M, 1989, STATISTICS CONFIDENC; GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P2642, DOI 10.1073/pnas.83.8.2642; Harris ED, 1989, TXB RHEUMATOLOGY; MITCHELL SC, 1984, BRIT J CLIN PHARMACO, V18, P507, DOI 10.1111/j.1365-2125.1984.tb02498.x; VANDERHEIJDE DMF, 1988, SEMIN ARTHRITIS RHEU, V17, P284; WILKENS RF, 1991, ARTHRITIS RHEUM, V34, P43; WINCHESTER RJ, 1988, SPRINGER SEMIN IMMUN, V10, P119, DOI 10.1007/BF01857219; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049; WORDSWORTH BP, 1991, BRIT J RHEUMATOL, V30, P178; YOUNG A, 1991, ARTHRITIS RHEUM, V34, P93; YOUNG A, 1991, ARTHRITIS RHEUM, V34, P48	13	79	80	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1387	1389		10.1136/bmj.305.6866.1387	http://dx.doi.org/10.1136/bmj.305.6866.1387			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486300	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992KB85600018
J	JOHNSON, AM; WADSWORTH, J; WELLINGS, K; BRADSHAW, S; FIELD, J				JOHNSON, AM; WADSWORTH, J; WELLINGS, K; BRADSHAW, S; FIELD, J			SEXUAL LIFE-STYLES AND HIV RISK	NATURE			English	Editorial Material							BEHAVIOR		SOCIAL & COMMUNITY PLANNING RES, LONDON EC1V 0AX, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1NY, ENGLAND	Imperial College London	JOHNSON, AM (corresponding author), UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON W1N 8AA, ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; CARBALLO M, 1989, J SEX RES, V26, P2887; HILLIER H, 1988, SHORT TERM PREDICTIO, P48; JOHNSON AM, 1990, NATURE, V343, P109, DOI 10.1038/343109a0; MADDOX J, 1989, NATURE, V341, P181, DOI 10.1038/341181a0; RGERS SM, 1991, J SEX RES, V28, P491; SPIRA A, 1992, NATURE, V360, P407; Sundet J. M., 1988, GLOBAL IMPACT AIDS, P53; WADSWORTH J, 1991, J ROY STAT SOC A STA, V154, P367; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; 1990, CDR112; 1992, HLTH NATION STRATEGY; 1991, CDR, V1, pR69; 1989, GENERAL HOUSEHOLD SU; 1992, PP2 OPCS SER, V15; 1989, SHORT TERM PREDICTIO	16	197	199	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					410	412		10.1038/360410a0	http://dx.doi.org/10.1038/360410a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448163				2022-12-24	WOS:A1992KA79700022
J	SPIRA, A; BAJOS, N; BEJIN, A; BELTZER, N; BOZON, M; DUCOT, B; DURANDEAU, A; FERRAND, A; GIAMI, A; GILLOIRE, A; GIRAUD, M; LERIDON, H; MESSIAH, A; LUDWIG, D; MOATTI, JP; MOUNNIER, L; OLOMUCKI, H; POPLAVSKY, J; RIANDEY, B; SPENCER, B; SZTALRYD, JM				SPIRA, A; BAJOS, N; BEJIN, A; BELTZER, N; BOZON, M; DUCOT, B; DURANDEAU, A; FERRAND, A; GIAMI, A; GILLOIRE, A; GIRAUD, M; LERIDON, H; MESSIAH, A; LUDWIG, D; MOATTI, JP; MOUNNIER, L; OLOMUCKI, H; POPLAVSKY, J; RIANDEY, B; SPENCER, B; SZTALRYD, JM			AIDS AND SEXUAL-BEHAVIOR IN FRANCE	NATURE			English	Editorial Material											SPIRA, A (corresponding author), HOP BICETRE,78 RUE GEN LECLERC,F-94275 LE KREMLIN BICETR,FRANCE.		Bajos, Nathalie/M-4170-2018; Messiah, Antoine/GLT-9598-2022; Messiah, Antoine/M-1984-2018; Giami, Alain J./G-3676-2013	Bajos, Nathalie/0000-0001-8073-9056; Messiah, Antoine/0000-0003-4457-7381; Messiah, Antoine/0000-0003-4457-7381; Giami, Alain J./0000-0001-7639-3005				ALDHOUS P, 1992, SCIENCE, V257, P225; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BAJOS N, 1991, A ACSF SCI SOCIALES, V9, P58; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CZAJA R, 1988, INT Q COMMUN HLTH ED, V8, P23; FRANK O, 1990, RECHERCHES COMPORTEM; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; LAGRANGE H, 1991, POPULATION, V2, P249; LERIDON H, 1991, POPULATION, V2, P777; MCQUEEN DV, 1992, HEALTH EDUC RES, V7, P47, DOI 10.1093/her/7.1.47; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; POLLAK M, 1992, ASSESSING AIDS PREVE, P305; ROGERS SM, 1991, J SEX RES, V28, P491, DOI 10.1080/00224499109551621; Simon P, 1972, RAPPORT COMPORTEMENT; SUNDET JM, 1989, HLTH POLICY, V13, P160; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; 1992, B METHOD SOCIOL, V35, P46; 1992, AIDS, V6, P315; 1992, AIDS, V6, P243	20	124	124	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					407	409						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KA797	1448162				2022-12-24	WOS:A1992KA79700021
J	STODDARD, BL; STRONG, RK; ARROTT, A; FARBER, GK				STODDARD, BL; STRONG, RK; ARROTT, A; FARBER, GK			MIR FOR THE CRYSTALLOGRAPHERS MONEY	NATURE			English	Editorial Material							PROTEIN CRYSTAL-GROWTH; SPACE-SHUTTLE; MICROGRAVITY; DIFFUSION		CALTECH,DIV BIOL,PASADENA,CA 91125; PAYLOAD SYST,CAMBRIDGE,MA 02139; PENN STATE UNIV,DAVEY LAB 152,DEPT CHEM,UNIV PK,PA 16802; PENN STATE UNIV,DAVEY LAB 152,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802	California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	STODDARD, BL (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BAIRD JK, 1986, J CRYST GROWTH, V76, P694, DOI 10.1016/0022-0248(86)90186-7; DELUCAS L J, 1990, Methods (Orlando), V1, P105, DOI 10.1016/S1046-2023(05)80153-7; DeLucas L J, 1991, Adv Space Biol Med, V1, P249; DELUCAS LJ, 1989, SCIENCE, V246, P651, DOI 10.1126/science.2510297; DELUCAS LJ, 1986, J CRYST GROWTH, V76, P681, DOI 10.1016/0022-0248(86)90185-5; DELUCAS LJ, 1991, J CRYST GROWTH, V110, P302, DOI 10.1016/0022-0248(91)90899-G; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; LITTKE W, 1986, J CRYST GROWTH, V76, P663, DOI 10.1016/0022-0248(86)90183-1; LITTKE W, 1984, SCIENCE, V225, P203, DOI 10.1126/science.225.4658.203; PLASSLINK A, 1988, J APPL MICROGRAVITY, V3, P123; SHLICHTA PJ, 1986, J CRYST GROWTH, V76, P656, DOI 10.1016/0022-0248(86)90182-X; SIBILLE L, 1991, J CRYST GROWTH, V110, P72, DOI 10.1016/0022-0248(91)90868-6; STODDARD BL, 1991, J CRYST GROWTH, V110, P312, DOI 10.1016/0022-0248(91)90900-P; STRONG RK, 1992, J CRYST GROWTH, V119, P200, DOI 10.1016/0022-0248(92)90672-6	14	14	14	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					293	294		10.1038/360293a0	http://dx.doi.org/10.1038/360293a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448142				2022-12-24	WOS:A1992JZ63000025
J	SMITH, R				SMITH, R			USING A MOCK TRIAL TO MAKE A DIFFICULT CLINICAL DECISION	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Many clinical decisions have to be taken with inadequate scientific information. Reaching a consensus among experts has been tried as one response to this problem. Another, described here, is to use legal process to dissect a difficult question. In this case a mock trial-using barristers, expert witnesses, and a jury-was conducted on whether bone marrow transplantation should be offered to all children with symptomatic sickle cell disease. Transplantation seems to offer about a 90% cure rate for a condition that may kill 15% of children before they reach 20. But transplantation carries a 10% risk of death or severe disability, and doctors cannot predict which children will suffer severly from their sickle cell disease and which will suffer little or nothing. The jury eventually reached a majority decision that transplantation should not be offered now to all symptomatic children.										CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; DAVIES SC, 1992, IN PRESS SICKLE  JUN; SMITH R, 1992, J MED ETHICS, V18, P117, DOI 10.1136/jme.18.3.117; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195; VERMYLEN C, 1988, LANCET, V1, P1427	6	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1992	305	6864					1284	1287		10.1136/bmj.305.6864.1284	http://dx.doi.org/10.1136/bmj.305.6864.1284			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477577	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JZ52100033
J	WANG, J; BEDZYK, MJ; CAFFREY, M				WANG, J; BEDZYK, MJ; CAFFREY, M			RESONANCE-ENHANCED X-RAYS IN THIN-FILMS - A STRUCTURE PROBE FOR MEMBRANES AND SURFACE-LAYERS	SCIENCE			English	Article							STANDING WAVES; INTERFACE; FLUORESCENCE; DIFFRACTION	An x-ray resonance effect in an organic thin film on an x-ray reflecting mirror is reported. The resonance effect is the result of interference between reflected and refracted x-rays at the air-organic thin film interface and occurs at incident angles slightly above the critical angle of the film. In excellent agreement with theory, the primary resonant x-ray electric field that is confined in the organic thin film is approximately 20 times as intense as the electric field of the incident beam when measured at a position close to the center of the film. Resonance-enhanced x-rays can be used to characterize the internal structure of Langmuir-Blodgett thin film membranes. This effect may also find use in x-ray-based thin film devices and in the structural analysis of adlayers and surfaces that have thus far proved difficult, if not impossible, to study because of sensitivity limitations.	OHIO STATE UNIV,CHEM PHYS PROGRAM,COLUMBUS,OH 43210; NORTHWESTERN UNIV,DEPT MAT SCI & ENGN,EVANSTON,IL 60208; ARGONNE NATL LAB,ARGONNE,IL 60439	University System of Ohio; Ohio State University; Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory	WANG, J (corresponding author), OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210, USA.		Bedzyk, Michael J/B-7503-2009; Bedzyk, Michael J/K-6903-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK036849, R01DK045295, R01DK036849] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36849, DK 45295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER RS, 1983, PHYS REV LETT, V50, P153, DOI 10.1103/PhysRevLett.50.153; BEDZYK MJ, 1990, SCIENCE, V248, P52, DOI 10.1126/science.2321026; BEDZYK MJ, 1989, PHYS REV LETT, V62, P1376, DOI 10.1103/PhysRevLett.62.1376; BEDZYK MJ, 1988, SCIENCE, V241, P1788, DOI 10.1126/science.3175619; BLOCH JM, 1985, PHYS REV LETT, V54, P1039, DOI 10.1103/PhysRevLett.54.1039; BOMMARITO GM, 1987, THESIS CORNELL U ITH; Born M., 1991, PRINCIPLES OPTICS; Compton AH, 1935, XRAYS THEORY EXPT; DEBOER DKG, 1991, PHYS REV B, V44, P498, DOI 10.1103/PhysRevB.44.498; EISENBERGER P, 1981, PHYS REV LETT, V46, P1081, DOI 10.1103/PhysRevLett.46.1081; MARRA WC, 1979, J APPL PHYS, V50, P6927, DOI 10.1063/1.325845; PARRATT LG, 1954, PHYS REV, V95, P359, DOI 10.1103/PhysRev.95.359; WANG J, 1991, NATURE, V354, P377, DOI 10.1038/354377a0	13	127	129	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					775	778		10.1126/science.1439784	http://dx.doi.org/10.1126/science.1439784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439784				2022-12-24	WOS:A1992JV69200028
J	MAKITA, Z; VLASSARA, H; RAYFIELD, E; CARTWRIGHT, K; FRIEDMAN, E; RODBY, R; CERAMI, A; BUCALA, R				MAKITA, Z; VLASSARA, H; RAYFIELD, E; CARTWRIGHT, K; FRIEDMAN, E; RODBY, R; CERAMI, A; BUCALA, R			HEMOGLOBIN-AGE - A CIRCULATING MARKER OF ADVANCED GLYCOSYLATION	SCIENCE			English	Article							GLUCOSE-MODIFIED PROTEINS; DIABETES-MELLITUS; END-PRODUCTS; NONENZYMATIC GLYCOSYLATION; HUMAN COLLAGEN; AMINOGUANIDINE; TISSUE; NEPHROPATHY; RAT; FLUORESCENCE	Advanced glycosylation end products (AGEs) form spontaneously from glucose-derived Amadori products and accumulate on long-lived tissue proteins. AGEs have been implicated in the pathogenesis of several of the complications of aging and diabetes, including atherosclerosis and renal disease. With the use of recently developed AGE-specific antibodies, an AGE-modified form of human hemoglobin has been identified. Termed hemoglobin-AGE (Hb-AGE), this modified species accounts for 0.42 percent of circulating hemoglobin in normal individuals but increases to 0.75 percent in patients with diabetes-induced hyperglycemia. In a group of diabetic patients treated with the advanced glycosylation inhibitor aminoguanidine, Hb-AGE levels decreased significantly over a 1-month period. Hemoglobin-AGE measurements may provide an index of long-term tissue modification by AGEs and prove useful in assessing the contribution of advanced glycosylation to a variety of diabetic and age-related complications.	ALTEON INC, NORTHVALE, NJ 07647 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; SUNY DOWNSTATE MED CTR, BROOKLYN, NY 11203 USA	Rush University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19655-15] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOOKCHIN RM, 1968, BIOCHEM BIOPH RES CO, V32, P86, DOI 10.1016/0006-291X(68)90430-0; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; ELLIS EN, 1991, METABOLISM, V40, P1016, DOI 10.1016/0026-0495(91)90122-D; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HOGAN M, IN PRESS J CLIN INVE; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KOENIG RJ, 1977, J BIOL CHEM, V252, P2992; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; KOHN RR, 1984, DIABETES, V33, P57, DOI 10.2337/diabetes.33.1.57; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LEWIS BS, 1990, EXP EYE RES, V50, P463, DOI 10.1016/0014-4835(90)90033-Q; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKITA Z, 1991, DIABETOLOGIA, V34, P40, DOI 10.1007/BF00404023; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, UNPUB; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; NICHOLLS K, 1989, LAB INVEST, V60, P486; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; PETERSON CM, 1985, DIABETES ANN, V1, P178; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47	36	256	272	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					651	653		10.1126/science.1411574	http://dx.doi.org/10.1126/science.1411574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411574				2022-12-24	WOS:A1992JU74500057
J	DAN, Y; POO, MM				DAN, Y; POO, MM			QUANTAL TRANSMITTER SECRETION FROM MYOCYTES LOADED WITH ACETYLCHOLINE	NATURE			English	Article							MUSCLE-CELL MEMBRANE; NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLES; RELEASE; RECEPTORS; CULTURE; EXOCYTOSIS	IT is well known that transmitter secretion requires specialized secretory organelles, the synaptic vesicles, for the packaging, storage and exocytotic release of the transmitter1,2. Here we report that when acetylcholine (ACh) is loaded into an isolated Xenopus myocyte, there is spontaneous quantal release of ACh from the myocyte which results in activation of its own surface ACh channels and the appearance of membrane currents resembling miniature endplate currents. This myocyte secretion probably reflects Ca2+-regulated exocytosis of ACh-filled cytoplasmic compartments. Furthermore, step depolarization of the myocyte membrane triggers evoked ACh release from the myocyte with a weak excitation-secretion coupling. These findings suggest that quantal transmitter secretion does not require secretory pathways unique to neurons and that the essence of presynaptic differentiation may reside in the provision of transmitter supply and modification of the preexisting secretion pathway.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Dan, Yang/0000-0002-3818-877X				ADLER EM, 1991, J NEUROSCI, V11, P1496; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BUCHANAN J, 1989, J NEUROSCI, V9, P1540; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; ENOMOTO K, 1988, EUR J PHARMACOL, V147, P209; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUGERS ARCH, V391, P80; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; ISRAEL M, 1979, PROG NEUROBIOL, V13, P237, DOI 10.1016/0301-0082(79)90017-0; Kandel E.R., 1991, PRINC NEUROSCI; KATZ B, 1977, PROC R SOC SER B-BIO, V196, P59, DOI 10.1098/rspb.1977.0029; Katz B., 1969, RELEASE NEURAL TRANS; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; MARSHALL IG, 1990, J PHYSIOL-LONDON, V424, pP52; MARSHALL IG, 1987, TRENDS NEUROSCI, V10, P174, DOI 10.1016/0166-2236(87)90044-0; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOREL N, 1978, J NEUROCHEM, V30, P1553, DOI 10.1111/j.1471-4159.1978.tb10492.x; ORIDA N, 1978, NATURE, V275, P31, DOI 10.1038/275031a0; POO MM, 1982, NATURE, V295, P332, DOI 10.1038/295332a0; POULAIN B, 1986, J PHYSIOL-PARIS, V81, P270; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUN YA, 1985, J NEUROSCI, V5, P634; TABTI N, 1986, ACTA PHYSIOL SCAND, V128, P429, DOI 10.1111/j.1748-1716.1986.tb07996.x; Tabti N., 1991, CULTURING NERVE CELL, P137; TAKAHASHI T, 1987, J NEUROSCI, V7, P473; TRIMBLE AW, 1991, REV NEUROSCI, V14, P93; WHITTAKER VP, 1972, BIOCHEM J, V128, P833, DOI 10.1042/bj1280833; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0	30	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					733	736		10.1038/359733a0	http://dx.doi.org/10.1038/359733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436036				2022-12-24	WOS:A1992JU65000057
J	SHOJI, M; GOLDE, TE; GHISO, J; CHEUNG, TT; ESTUS, S; SHAFFER, LM; CAI, XD; MCKAY, DM; TINTNER, R; FRANGIONE, B; YOUNKIN, SG				SHOJI, M; GOLDE, TE; GHISO, J; CHEUNG, TT; ESTUS, S; SHAFFER, LM; CAI, XD; MCKAY, DM; TINTNER, R; FRANGIONE, B; YOUNKIN, SG			PRODUCTION OF THE ALZHEIMER AMYLOID-BETA PROTEIN BY NORMAL PROTEOLYTIC PROCESSING	SCIENCE			English	Article							ADRDA WORK GROUP; SOLUBLE DERIVATIVES; CLINICAL-DIAGNOSIS; DISEASE; PRECURSOR; PEPTIDE; LOCALIZATION; DEGRADATION; FRAGMENTS; CRITERIA	The 4-kilodalton (39 to 43 amino acids) amyloid beta protein (betaAP), which is deposited as amyloid in the brains of patients with Alzheimer's disease, is derived from a large protein, the amyloid beta protein precursor (betaAPP). Human mononuclear leukemic (K562) cells expressing a betaAP-bearing, carboxyl-terminal betaAPP derivative released significant amounts of a soluble 4-kilodalton betaAPP derivative essentially identical to the betaAP deposited in Alzheimer's disease. Human neuroblastoma (M17) cells transfected with constructs expressing full-length betaAPP and M17 cells expressing only endogenous betaAPP also released soluble 4-kilodalton betaAP, and a similar, if not identical, fragment was readily detected in cerebrospinal fluid from individuals with Alzheimer's disease and normal individuals. Thus cells normally produce and release soluble 4-kilodalton betaAP that is essentially identical to the 4-kilodalton betaAP deposited as insoluble amyloid fibrils in Alzheimer's disease.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,ALZHEIMERS DIS RES CTR,DALLAS,TX 75235; GUNMA UNIV,DEPT NEUROL,MAEBASHI,GUNMA 371,JAPAN; NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Case Western Reserve University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Gunma University; New York University; Washington University (WUSTL)			Shoji, Mikio/F-2841-2013; McKay, Derek/HCH-3240-2022	Shoji, Mikio/0000-0003-1027-1712	NIAMS NIH HHS [AR02594] Funding Source: Medline; NIA NIH HHS [AG06656, AG05891] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR002594, R37AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG005891, R01AG005891, R01AG006656] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; COLE GM, 1990, MOL BIOL GENETICS AL, P113; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRANGIONE B, IN PRESS ALZHEIMERS; FRUCHT SJ, 1992, J NEUROPATH EXP NEUR, V51, P369; GLENNER G, 1983, BRANBURY REPORT, V15, P137; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; ISENMAN LD, 1989, J BIOL CHEM, V264, P21591; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, LANCET, V1, P384; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TERRY RD, 1963, BRAIN, V311, P528; TIERNEY MC, 1988, NEUROLOGY, V38, P359, DOI 10.1212/WNL.38.3.359; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	37	1385	1453	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					126	129		10.1126/science.1439760	http://dx.doi.org/10.1126/science.1439760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439760				2022-12-24	WOS:A1992JQ61900034
J	PATEL, V; RASSAM, S; NEWSOM, R; WIEK, J; KOHNER, E				PATEL, V; RASSAM, S; NEWSOM, R; WIEK, J; KOHNER, E			RETINAL BLOOD-FLOW IN DIABETIC-RETINOPATHY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LASER DOPPLER VELOCIMETRY; AUTO-REGULATION; FUNDUS CAMERA; MELLITUS; PRESSURE; CIRCULATION	Objectives - (a) To report on the basic parameters of retinal blood flow in a population of diabetic patients with and without retinopathy and nondiabetic controls; (b) to formulate a haemodynamic model for the pathogenesis of diabetic retinopathy from this and other studies. Design-Laser-Doppler velocimetry and computerised image analysis to determine retinal blood flow in a large cross sectional study. Setting-Diabetic retinopathy outpatient clinic. Subjects-24 non-diabetic controls and 76 diabetic subjects were studied (63 patients with insulin dependent diabetes, 13 with non-insulin dependent diabetes). Of the diabetic subjects, 12 had no diabetic retinopathy, 27 had background retinopathy, 13 had pre-proliferative retinopathy, 12 had proliferative retinopathy, and 12 had had pan-retinal photocoagulation for proliferative retinopathy. Main outcome measures-Retinal blood flow (mu-l/min) and conductance (rate of flow per unit of perfusion pressure). Results-In comparison with non-diabetic controls (9.52-mu-l/min) and diabetic patients with no diabetic retinopathy (9.12-mu-l/min) retinal blood flow was significantly increased in all grades of untreated diabetic retinopathy (background 12.13-mu-l/min, preproliferative 15.27-mu-l/min, proliferative 13.88-mu-l/min). There was a significant decrease in flow after pan-retinal photocoagulation in comparison with all the other groups studied (4-48-mu-l/min). Conductance of the retinal circulation was higher in the untreated diabetic retinopathy groups. These results were independent of age, sex, type of diabetes, duration of diabetes, glycated haemoglobin concentration, blood glucose concentration, blood pressure, and intraocular pressure. Conclusions-Retinal blood flow is significantly increased in diabetic retinopathy in comparison with non-diabetic controls and diabetic subjects with no retinopathy. This has implications for controlling hypertension and hyperglycaemia as a strategy in reducing morbidity from diabetic retinopathy.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, DIABET RETINOPATHY UNIT, LONDON W12 0NN, ENGLAND	Imperial College London				newsom, Richard/0000-0002-2221-0653				BAUDOIN C, 1989, DIABETES, V38, P491; Behrendt T, 1970, Trans Am Acad Ophthalmol Otolaryngol, V74, P28; BENGTSSON B, 1977, ACTA OPHTHALMOL, V55, P123; BERKMAN J, 1973, METABOLISM, V21, P715, DOI 10.1016/0026-0495(73)90243-6; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRINCHMANN HO, 1986, ACTA OPHTHALMOL, V95, P861; BURTON AC, 1954, PHYSIOL REV, V34, P619, DOI 10.1152/physrev.1954.34.4.619; CALDWELL G, 1990, DIABETOLOGIA, V33, P262, DOI 10.1007/BF00403318; CHEN HC, 1992, INVEST OPHTH VIS SCI, V33, P811; CUNHAVAZ JG, 1978, ARCH OPHTHALMOL-CHIC, V96, P809, DOI 10.1001/archopht.1978.03910050415001; DAMON DN, 1979, MICROVASC RES, V17, P330, DOI 10.1016/S0026-2862(79)80008-4; DELORI FC, 1988, GRAEF ARCH CLIN EXP, V226, P393, DOI 10.1007/BF02172974; FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58; FRY DL, 1969, CIRC RES, V24, P93, DOI 10.1161/01.RES.24.1.93; GAY AJ, 1966, ARCH OPHTHALMOL-CHIC, V75, P78; GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P356; GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1447; GRUNWALD JE, 1987, OPHTHALMOLOGY, V94, P1614; GRUNWALD JE, 1986, ARCH OPHTHALMOL-CHIC, V104, P991; JUHAN I, 1982, LANCET, V1, P535; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; LANIGAN LP, 1989, EYE, V3, P39, DOI 10.1038/eye.1989.6; MCMILLAN DE, 1983, DIABETES, V32, P56, DOI 10.2337/diab.32.2.S56; Milnor W, 1989, HEMODYNAMICS, P140; MORGENSEN CE, 1982, BRIT MED J, V285, P685; MOSS SE, 1988, OPHTHALMOLOGY, V95, P1340; Oakley N, 1967, Diabetologia, V3, P402, DOI 10.1007/BF02342633; OGASAWARA H, 1991, INVEST OPHTH VIS SCI, V32, P864; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; PATZ A, 1984, BRIT J OPHTHALMOL, V68, P42, DOI 10.1136/bjo.68.1.42; RIVA CE, 1981, APPL OPTICS, V20, P117, DOI 10.1364/AO.20.000117; ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722; ROSS J, 1990, BEST TAYLORS PHYSL B, P138; SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x; STRAUSS AL, 1987, MED INSTRUM, V21, P255; SULLIVAN P, 1990, Folia Ophthalmologica (Leipzig), V15, P99; TAKAHASHI K, 1989, DIABETES, V38, P1200, DOI 10.2337/diabetes.38.9.1200; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; 1987, ARCH INTERN MED, V147, P830; 1990, ARCH OPHTHALMOL-CHIC, V108, P1577	45	259	264	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					678	683		10.1136/bmj.305.6855.678	http://dx.doi.org/10.1136/bmj.305.6855.678			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393111	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JP51100019
J	DAVID, M; LARNER, AC				DAVID, M; LARNER, AC			ACTIVATION OF TRANSCRIPTION FACTORS BY INTERFERON-ALPHA IN A CELL-FREE SYSTEM	SCIENCE			English	Article							ISGF3; INDUCTION; GENES	The signal transduction mechanisms of interferons (IFNs) remain unclear partly because no effect of IFN has been reproducible in a cell-free system. IFN-alpha rapidly induces the transcription of a set of early response genes, and a multicomponent transcriptional activator, interferon stimulated gene factor 3 (ISGF3), is activated within minutes after binding of IFN-alpha to its receptor. A system was developed in which IFN-alpha activated ISGF3 in homogenates of HeLa cells. Subcellular fractionation revealed that incubation of a plasma membrane-enriched fraction with IFN-alpha was sufficient to activate the regulatory subcomponent of ISGF3.	CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)								DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, UNPUB; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289	13	70	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					813	815		10.1126/science.1496402	http://dx.doi.org/10.1126/science.1496402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496402				2022-12-24	WOS:A1992JG85100040
J	DICKSON, B; SPRENGER, F; MORRISON, D; HAFEN, E				DICKSON, B; SPRENGER, F; MORRISON, D; HAFEN, E			RAF FUNCTIONS DOWNSTREAM OF RAS1 IN THE SEVENLESS SIGNAL TRANSDUCTION PATHWAY	NATURE			English	Article							RECEPTOR TYROSINE KINASE; DROSOPHILA-MELANOGASTER; PUTATIVE RECEPTOR; CELL FATE; PROTEIN; GENE; EYE; TORSO; REQUIREMENT; ACTIVATION	SPECIFICATION of the R7 cell fate in the developing Drosophila eye requires activation of the Sevenless (Sev) receptor tyrosine kinase, located on the surface of the R7 precursor cell, by its interaction with the Boss protein, expressed on the surface of the neighbouring R8 cell1-3. Four genes that participate in the intracellular transmission of this signal have so far been identified and molecularly characterized: Ras1, Sos, Gap1 and sina (refs 4-8). The Drosophila homologue of the mammalian Raf-1 serine/threonine kinase, which has been implicated in signal transduction pathways activated by many receptor tyrosine kinases (reviewed in refs 9 and 10), is encoded by the raf locus (also known as l(1)polehole11, Draf-1 12 or Draf13). Here we show that the Drosophila Raf serine/threonine kinase also plays a crucial role in the R7 pathway: the response to Sev activity is dependent on raf function, and a constitutively activated Raf protein can induce R7 cell development in the absence of sev function. We also present genetic evidence suggesting that Raf acts downstream of Ras1 and upstream of Sina in this signal transduction cascade.	MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,W-7400 TUBINGEN,GERMANY; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	DICKSON, B (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHORERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Dickson, Barry/0000-0003-0715-892X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRAMERS PGN, 1983, MUTAT RES, V107, P187, DOI 10.1016/0027-5107(83)90162-8; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, IN PRESS CELL; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	29	290	300	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					600	603		10.1038/360600a0	http://dx.doi.org/10.1038/360600a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461284				2022-12-24	WOS:A1992KB95900090
J	LISBERGER, SG; SEJNOWSKI, TJ				LISBERGER, SG; SEJNOWSKI, TJ			MOTOR LEARNING IN A RECURRENT NETWORK MODEL BASED ON THE VESTIBULOOCULAR REFLEX	NATURE			English	Article							ELECTRO-PHYSIOLOGICAL OBSERVATIONS; TERM ADAPTIVE-CHANGES; FLOCCULUS; MONKEYS; INTEGRATION; ADAPTATION; PLASTICITY; PATHWAYS; NEURONS	MOST models of neural networks have assumed that neurons process information on a timescale of milliseconds and that the long-term modification of synaptic strengths underlies learning and memory1. But neurons also have cellular mechanisms that operate on a timescale of tens or hundreds of milliseconds, such as a gradual rise in firing rate in response to injection of constant current2 or a rapid rise followed by a slower adaptation3. These dynamic properties of neuronal responses are mediated by ion channels that are subject to modulation4. We demonstrate here how a neural network with recurrent feedback connections can convert long-term modulation of neural responses that occur over these intermediate timescales into changes in the amplitude of the steady output from the system. This general principle may be relevant to many feedback systems in the brain. Here it is applied to the vestibulo-ocular reflex, whose amplitude is subject to long-term adaptive modification by visual inputs5. The model reconciles apparently contradictory data on the neural locus of the cellular mechanisms that mediate this simple form of learning and memory.	UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; HOWARD HUGHES MED INST,SALK INST BIOL SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Francisco; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	LISBERGER, SG (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK FDN,CTR INTEGRAT NEUROSCI,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Sejnowski, Terrence/AAV-5558-2021					BRADLEY K, 1961, J PHYSIOL-LONDON, V156, P75, DOI 10.1113/jphysiol.1961.sp006659; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; FUCHS AF, 1975, J NEUROPHYSIOL, V38, P1140, DOI 10.1152/jn.1975.38.5.1140; GONSHOR A, 1976, J PHYSIOL-LONDON, V256, P381, DOI 10.1113/jphysiol.1976.sp011330; ITO M, 1972, BRAIN RES, V40, P81, DOI 10.1016/0006-8993(72)90110-2; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; LISBERGER SG, 1986, J NEUROSCI, V6, P346; LISBERGER SG, 1988, SCIENCE, V242, P771, DOI 10.1126/science.3142040; LISBERGER SG, 1988, SCIENCE, V242, P728, DOI 10.1126/science.3055293; LISBERGER SG, 1992, 9201 U CAL I NEUR CO; MILES FA, 1980, J NEUROPHYSIOL, V43, P1477, DOI 10.1152/jn.1980.43.5.1477; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STRONG JA, 1987, NEUROMODULATION BIOC; WATANABE E, 1984, BRAIN RES, V297, P169, DOI 10.1016/0006-8993(84)90555-9	16	101	101	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					159	161		10.1038/360159a0	http://dx.doi.org/10.1038/360159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436091				2022-12-24	WOS:A1992JX75200059
J	HERZ, J; CLOUTHIER, DE; HAMMER, RE				HERZ, J; CLOUTHIER, DE; HAMMER, RE			LDL RECEPTOR-RELATED PROTEIN INTERNALIZES AND DEGRADES UPA-PAI-1 COMPLEXES AND IS ESSENTIAL FOR EMBRYO IMPLANTATION	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; MEDIATED INTERNALIZATION; ENDOTHELIAL-CELLS; BOUND UROKINASE; CULTURED-CELLS; HIGH-AFFINITY; STEM-CELLS	The low density lipoprotein receptor-related protein (LRP) is a large multifunctional clearance receptor that has been implicated in the hepatic uptake of chylomicron remnants and in the removal of protease-inhibitor complexes from the circulation and from the extracellular space. Disruption of the LRP gene in mice blocks development of LRP-I- embryos around the implantation stage. The expression pattern of LRP in the postimplantation stage embryo is identical to that of urokinase, a plasminogen activator that confers invasive properties to migrating cells. We demonstrate that LRP mediates uptake and degradation of urokinase-type plasminogen activator-plasminogen activator inhibitor 1 complexes and propose that the inability of the giant cells to remove the inactive protease complexes from their surfaces interferes with implantation of the embryo.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	HERZ, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; EATON GJ, 1963, GENETICA, V34, P155, DOI 10.1007/BF01664187; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HILLIKER C, 1992, GENOMICS, V13, P472, DOI 10.1016/0888-7543(92)90276-X; JENSEN PH, 1988, PLACENTA, V9, P463, DOI 10.1016/0143-4004(88)90019-7; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MYKLEBOST O, 1989, GENOMICS, V5, P65, DOI 10.1016/0888-7543(89)90087-6; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J., 1989, MOL CLONING LAB MANU; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHI WK, 1984, J EMBRYOL EXP MORPH, V81, P143; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	55	533	545	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					411	421		10.1016/0092-8674(92)90511-A	http://dx.doi.org/10.1016/0092-8674(92)90511-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423604				2022-12-24	WOS:A1992JW43500008
J	KAYE, J; ELLENBERGER, DL				KAYE, J; ELLENBERGER, DL			DIFFERENTIATION OF AN IMMATURE T-CELL LINE - A MODEL OF THYMIC POSITIVE SELECTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR TRANSGENIC MICE; INTERCELLULAR-ADHESION MOLECULE-1; RESTRICTED ANTIGEN RECEPTOR; LYT-2 POLYPEPTIDES ARISE; NEGATIVE SELECTION; CD4+8+ THYMOCYTES; DNA FRAGMENTATION; SUSPENSION-CULTURE; MURINE THYMOCYTES	Thymocyte differentiation is dependent upon recognition of major histocompatibility complex (MHC) molecules on thymic stroma, a process called positive selection. Here we describe an immature CD4+8+ T cell line derived from a TCR transgenic mouse that differentiates into CD4+8- cells in response to antigen and nonthymic antigen-presenting cells. When injected intrathymically, these cells differentiate in the absence of antigen. The ability of immature T cells to recognize MHC molecules in the absence of foreign antigen in the thymus can thus be attributed to a unique property of thymic antigen-presenting cells. These studies also demonstrate the phenotypic and functional changes associated with TCR-mediated T cell maturation and establish an in vitro model system of positive selection.			KAYE, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Kaye, Jonathan/0000-0002-1634-9069	NHLBI NIH HHS [HLO-07195] Funding Source: Medline; NIAID NIH HHS [AI31231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031231, R29AI031231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BLUE ML, 1989, J IMMUNOL, V142, P2714; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BORN W, 1987, J IMMUNOL, V138, P999; BOYER PD, 1988, J IMMUNOL, V140, P2886; CARLOW DA, 1992, J IMMUNOL, V148, P1595; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; COHEN JJ, 1984, J IMMUNOL, V132, P38; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, J IMMUNOL, V138, P2013; CRISPE IN, 1987, J IMMUNOL, V139, P3585; DUSTIN ML, 1986, J IMMUNOL, V137, P245; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FINE JS, 1991, J IMMUNOL, V147, P2852; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HARVEY JE, 1990, IMMUNOLOGY, V70, P203; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; HUNIG T, 1991, J EXP MED, V173, P561, DOI 10.1084/jem.173.3.561; JAMESON SC, 1991, J IMMUNOL, V147, P3185; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1992, J IMMUNOL, V148, P3342; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEPESANT H, 1990, INT IMMUNOL, V2, P1021, DOI 10.1093/intimm/2.11.1021; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1988, J IMMUNOL, V140, P2508; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MERCEP M, 1989, J IMMUNOL, V142, P4085; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NONOYAMA S, 1989, EUR J IMMUNOL, V19, P1631, DOI 10.1002/eji.1830190917; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REICHERT RA, 1986, J IMMUNOL, V136, P3521; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SINGER KH, 1990, J IMMUNOL, V144, P2931; SIU G, 1989, J IMMUNOL, V143, P3813; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPEISER DE, 1992, J EXP MED, V175, P1277, DOI 10.1084/jem.175.5.1277; SPRENT J, 1978, J EXP MED, V147, P1838, DOI 10.1084/jem.147.6.1838; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TAGAWA M, 1986, P NATL ACAD SCI USA, V83, P3422, DOI 10.1073/pnas.83.10.3422; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1989, NATURE, V338, P76, DOI 10.1038/338076a0	94	63	63	1	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					423	435		10.1016/0092-8674(92)90512-B	http://dx.doi.org/10.1016/0092-8674(92)90512-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423605				2022-12-24	WOS:A1992JW43500009
J	LJUNGDAHL, PO; GIMENO, CJ; STYLES, CA; FINK, GR				LJUNGDAHL, PO; GIMENO, CJ; STYLES, CA; FINK, GR			SHR3 - A NOVEL COMPONENT OF THE SECRETORY PATHWAY SPECIFICALLY REQUIRED FOR LOCALIZATION OF AMINO-ACID PERMEASES IN YEAST	CELL			English	Article							NITROGEN CATABOLITE REPRESSION; MEMBRANE-SPANNING PROTEINS; CYCLOPHILIN HOMOLOG NINAA; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; GENE; TRANSPORT	Mutations in SHR3 block amino acid uptake into yeast by reducing the levels of multiple amino acid permeases within the plasma membrane. SHR3 is a novel integral membrane protein component of the endoplasmic reticulum (ER). shr3 null mutants specifically accumulate amino acid permeases in the ER; other plasma membrane proteins, secretory proteins, and vacuolar proteins are processed and targeted correctly. Our findings suggest that SHR3 interacts with a structural domain shared by amino acid permeases, an interaction required for permease-specific processing and transport from the ER. Even in the presence of excess amino acids, shr3 mutants exhibit starvation responses. shr3 mutants constitutively express elevated levels of GCN4, and mutant shr3/shr3 diploids undergo dimorphic transitions that result in filamentous growth at enhanced frequencies.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	LJUNGDAHL, PO (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540	NIGMS NIH HHS [GM12038, GM40266, GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010, R01GM040266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COURCHESNE WE, 1983, MOL CELL BIOL, V3, P672, DOI 10.1128/MCB.3.4.672; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; FINERMOORE J, 1989, PREDICTION PROTEIN S, P719; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GARRETT JM, 1989, J GEN MICROBIOL, V135, P2429; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GREEN GN, 1989, J CELL SCI, P109; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GRENSON M, 1971, J BACTERIOL, V105, P477, DOI 10.1128/JB.105.2.477-482.1971; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HORAK J, 1986, BIOCHIM BIOPHYS ACTA, V864, P223, DOI 10.1016/0304-4157(86)90001-8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; KIM JM, 1990, GENETICS, V126, P799; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO PF, 1981, J BACTERIOL, V148, P241, DOI 10.1128/JB.148.1.241-247.1981; LINK AJ, 1991, GENETICS, V127, P681; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1990, MOL CELL BIOL, V10, P2941, DOI 10.1128/MCB.10.6.2941; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; PORUCHYNSKY MS, 1988, J CELL BIOL, V107, P1697, DOI 10.1083/jcb.107.5.1697; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SORSOLI WA, 1964, J BACTERIOL, V88, P20, DOI 10.1128/JB.88.1.20-24.1964; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SURDIN Y, 1965, BIOCHIM BIOPHYS ACTA, V107, P546, DOI 10.1016/0304-4165(65)90199-6; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEBER E, 1988, J MOL EVOL, V27, P341, DOI 10.1007/BF02101197; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	82	180	183	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					463	478		10.1016/0092-8674(92)90515-E	http://dx.doi.org/10.1016/0092-8674(92)90515-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423607				2022-12-24	WOS:A1992JW43500012
J	SWARTZ, SM; BENNETT, MB; CARRIER, DR				SWARTZ, SM; BENNETT, MB; CARRIER, DR			WING BONE STRESSES IN FREE FLYING BATS AND THE EVOLUTION OF SKELETAL DESIGN FOR FLIGHT	NATURE			English	Article							INVIVO STRESS; HORSE EQUUS; STRAIN; MECHANICS; LOCOMOTION; RADIUS; SPEED; TIBIA; GAIT	THE primary mechanical functions of limb bones are to resist deformation, and hence provide stiff levers against which muscles can act, and to be sufficiently strong to prevent breaking under static or dynamic loads which arise from normal and accidental activities1. if bones perform these functions with a minimum amount of material, the energetic costs associated with building, maintaining and transporting the skeleton will be minimized2. Appropriate skeletal architecture for minimizing mass while maximizing strength depends on forces imposed on structural elements. In the evolutionary acquisition of flight in the bat lineage, the forelimb skeleton must have come to experience locomotor-forces that differed from those engendered by the terrestrial locomotion of non-flying bat relatives. Here we successfully measure in vivo strain on the wing bones of flying mammals. Our data demonstrate that torsion and shear are unique and crucial features of skeletal biomechanics during flight, and suggest that the evolution of skeletal design in bats and other flying vertebrates may be driven b the need to resist these loads.	UNIV QUEENSLAND, DEPT ANAT SCI, BRISBANE 4072, AUSTRALIA	University of Queensland	SWARTZ, SM (corresponding author), BROWN UNIV, PROGRAM ECOL & EVOLUT BIOL, PROVIDENCE, RI 02912 USA.		Bennett, Michael/L-4483-2019; Swartz, Sharon/B-9309-2011; Bennett, Michael/A-7218-2012	Bennett, Michael/0000-0001-8051-0040; Swartz, Sharon/0000-0001-5762-7435; 				ALEXANDER RM, 1981, SCI PROGRESS-UK, V67, P109; ALEXANDER RM, 1990, J ZOOL, V222, P471, DOI 10.1111/j.1469-7998.1990.tb04045.x; BERTRAM JEA, 1988, J THEOR BIOL, V131, P75, DOI 10.1016/S0022-5193(88)80122-X; BIEWENER AA, 1986, CALCIFIED TISSUE INT, V39, P390, DOI 10.1007/BF02555177; BIEWENER AA, 1986, J EXP BIOL, V123, P383; BIEWENER AA, 1983, J ZOOL, V201, P67, DOI 10.1111/j.1469-7998.1983.tb04261.x; BIEWENER AA, 1988, J ZOOL, V214, P547, DOI 10.1111/j.1469-7998.1988.tb03759.x; CARTER DR, 1978, J BIOMECH, V11, P199, DOI 10.1016/0021-9290(78)90013-1; CURREY JD, 1985, J ZOOL, V206, P453; Lanyon L E, 1976, Acta Orthop Belg, V42 Suppl 1, P98; Nordin M, 1989, BASIC BIOMECHANICS M, P3; PENNYCUICK CJ, 1967, J EXP BIOL, V46, P219; POUGH FH, 1985, VERTEBRATE LIFE; PRANGE HD, 1979, AM NAT, V113, P103, DOI 10.1086/283367; Rayner J.M.V., 1987, P23; RUBIN CT, 1982, J EXP BIOL, V101, P187; RUBIN CT, 1984, J THEOR BIOL, V107, P321, DOI 10.1016/S0022-5193(84)80031-4	17	137	139	8	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					726	729		10.1038/359726a0	http://dx.doi.org/10.1038/359726a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436035				2022-12-24	WOS:A1992JU65000055
J	BOITANO, S; DIRKSEN, ER; SANDERSON, MJ				BOITANO, S; DIRKSEN, ER; SANDERSON, MJ			INTERCELLULAR PROPAGATION OF CALCIUM WAVES MEDIATED BY INOSITOL TRISPHOSPHATE	SCIENCE			English	Article							INTRACELLULAR CA-2+; GAP-JUNCTIONS; MECHANICAL STIMULATION; CILIATED CELLS; OSCILLATIONS; COMMUNICATION; THAPSIGARGIN; ACTIVATION; GENERATION; MOBILIZATION	Two types of calcium (Ca2+) signaling-propagating intercellular Ca2+ waves of increasing intracellular Ca2+ concentration ([Ca2+]i) and nonpropagating oscillations in [Ca2+]i-co-exist in a variety of cell types. To investigate this difference in Ca2+ signaling, airway epithelial cells were loaded with heparin, an inositol 1,4,5-trisphosphate (IP3) receptor antagonist, by pulsed, high-frequency electroporation. Heparin inhibited propagation of intercellular Ca2+ waves but not oscillations of [Ca2+]i. In heparin-free cells, Ca2+ waves propagated through cells displaying [Ca2+]i oscillations. Depletion of intracellular Ca2+ pools with the Ca2+-pump inhibitor thapsigargin also inhibited the propagation of Ca2+ waves. These studies demonstrate that the release of Ca2+ by IP3 is necessary for the propagation of intercellular Ca2+ waves and suggest that IP3 moves through gap junctions to communicate intercellular Ca2+ waves.	UNIV CALIF LOS ANGELES,SCH MED,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BENNETT MVL, 1988, GAP JUNCTIONS, P167; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BREHM P, 1989, NEURON, V3, P191, DOI 10.1016/0896-6273(89)90032-9; CHANG DC, 1989, ELECTROPORATION ELEC, P215; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CHARLES AC, IN PRESS GLIA; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEMER LL, UNPUB; ELY JA, 1991, J BIOL CHEM, V266, P18635; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SANDBERG K, 1992, J CELL BIOL, V117, P157, DOI 10.1083/jcb.117.1.157; SANDBERG K, 1990, SCIENCE, V249, P298, DOI 10.1126/science.2374929; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SANDERSON MJ, 1988, AM J PHYSIOL, V254, pC63, DOI 10.1152/ajpcell.1988.254.1.C63; SANDERSON MJ, 1986, P NATL ACAD SCI USA, V83, P7302, DOI 10.1073/pnas.83.19.7302; SNEYD J, UNPUB; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1991, J BIOL CHEM, V266, P17067; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WONG MMY, 1991, NATURE, V254, P1014; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; ZHENG Q, 1991, BIOCHIM BIOPHYS ACTA, V1088, P104, DOI 10.1016/0167-4781(91)90158-I	39	450	455	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					292	295		10.1126/science.1411526	http://dx.doi.org/10.1126/science.1411526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411526				2022-12-24	WOS:A1992JR86000032
J	KEANE, DP; ECKFORD, SD; SHEPHERD, AM; ABRAMS, P				KEANE, DP; ECKFORD, SD; SHEPHERD, AM; ABRAMS, P			REFERRAL PATTERNS AND DIAGNOSES IN WOMEN ATTENDING A URODYNAMIC UNIT	BRITISH MEDICAL JOURNAL			English	Article							INCONTINENCE				KEANE, DP (corresponding author), SOUTHMEAD GEN HOSP,URODYNAM UNIT,BRISTOL BS10 5NB,AVON,ENGLAND.							ABRAMS P, 1990, BRIT J OBSTET GYN  S, V6, P1; CARTER PG, 1991, BRIT J UROL, V67, P40, DOI 10.1111/j.1464-410X.1991.tb15066.x; SORENSEN S, 1988, SCAND J UROL NEPHR S, V114, P35; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; VERSI E, 1991, BRIT J OBSTET GYNAEC, V98, P815, DOI 10.1111/j.1471-0528.1991.tb13488.x	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					808	808		10.1136/bmj.305.6857.808	http://dx.doi.org/10.1136/bmj.305.6857.808			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422361	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JT25600022
J	WOLFF, JO				WOLFF, JO			PARENTS SUPPRESS REPRODUCTION AND STIMULATE DISPERSAL IN OPPOSITE-SEX JUVENILE WHITE-FOOTED MICE	NATURE			English	Article							INBREEDING AVOIDANCE; PEROMYSCUS-MANICULATUS; NATAL DISPERSAL; MAMMALS; LEUCOPUS; BIRDS; COMPETITION; RELATEDNESS; HYPOTHESIS; SUCCESS	JUVENILE dispersal is sex-biased in many mammals and birds: one sex often disperses more often or farther than the other. Two hypotheses are generally presented for sex-biased dispersal. The first holds that juvenile dispersal reduces reproductive and/or resource competition between parents and same-sexed offspring1-5. If so, presence of a parent on the natal home range should both promote dispersal of same-sex offspring and suppress reproduction of those that remain. The second is that juvenile dispersal reduces matings between parents and offspring6-10, thus decreasing the likelihood of inbreeding depression11-13. If so, presence of a parent should favour dispersal and reproductive suppression of offspring of the opposite sex. Here I present evidence that juvenile dispersal in white-footed mice, Peromyscus leucopus, is due to inbreeding avoidance. When population density was high, experimental removal of one parent delayed dispersal of opposite-sexed offspring and only the presence of the parents of opposite sex suppressed juvenile reproduction.	US EPA,CORVALLIS,OR 97333	United States Environmental Protection Agency	WOLFF, JO (corresponding author), OREGON STATE UNIV,DEPT FISHERIES & WILDLIFE,NASH HALL 104,CORVALLIS,OR 97331, USA.							Anderson P.K, 1989, DISPERSAL RODENTS RE; CLUTTONBROCK TH, 1989, NATURE, V337, P70, DOI 10.1038/337070a0; COCKBURN A, 1985, ANIM BEHAV, V33, P908, DOI 10.1016/S0003-3472(85)80025-7; DOBSON FS, 1982, ANIM BEHAV, V30, P1183; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HAIGH GR, 1983, J MAMMAL, V64, P48, DOI 10.2307/1380749; HARVEY PH, 1986, NATURE, V320, P675; HESTBECK JB, 1982, OIKOS, V39, P157, DOI 10.2307/3544480; HOAGLAND JL, 1979, SCIENCE, V215, P1639; HOLZENBEIN S, 1992, J WILDLIFE MANAGE, V56, P147, DOI 10.2307/3808802; KEANE B, 1990, ANIM BEHAV, V39, P264, DOI 10.1016/S0003-3472(05)80870-X; KOENIG WD, 1979, SCIENCE, V206, P1103, DOI 10.1126/science.206.4422.1103; LIBERG P, 1986, AM NAT, V126, P129; MARKS JS, 1987, AM NAT, V129, P158, DOI 10.1086/284627; MCCRAVY KW, 1992, J MAMMAL, V73, P151, DOI 10.2307/1381877; MOORE J, 1984, ANIM BEHAV, V32, P94, DOI 10.1016/S0003-3472(84)80328-0; PACKER C, 1985, ANIM BEHAV, V33, P676, DOI 10.1016/S0003-3472(85)80096-8; PUSEY AE, 1987, TRENDS ECOL EVOL, V2, P295, DOI 10.1016/0169-5347(87)90081-4; Ralls K., 1986, P35; WASER PM, 1985, ECOLOGY, V66, P1170, DOI 10.2307/1939169; Wolff J.O., 1989, P271; Wolff JO, 1991, BEHAV ECOL, V2, P38, DOI 10.1093/beheco/2.1.38; WOLFF JO, 1985, CAN J ZOOL, V63, P2657, DOI 10.1139/z85-397; WOLFF JO, 1988, ANIM BEHAV, V36, P456, DOI 10.1016/S0003-3472(88)80016-2; WOLFF JO, 1983, BEHAV ECOL SOCIOBIOL, V12, P237, DOI 10.1007/BF00290776; WOLFF JO, 1985, CAN J ZOOL, V63, P1548, DOI 10.1139/z85-230; WOLFF JO, 1986, VA J SCI, V37, P209	27	129	131	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					409	410		10.1038/359409a0	http://dx.doi.org/10.1038/359409a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406952				2022-12-24	WOS:A1992JQ62400053
J	ARCH, R; WIRTH, K; HOFMANN, M; PONTA, H; MATZKU, S; HERRLICH, P; ZOLLER, M				ARCH, R; WIRTH, K; HOFMANN, M; PONTA, H; MATZKU, S; HERRLICH, P; ZOLLER, M			PARTICIPATION IN NORMAL IMMUNE-RESPONSES OF A METASTASIS-INDUCING SPLICE VARIANT OF CD44	SCIENCE			English	Article							ENDOTHELIAL-CELL RECOGNITION; MONOCLONAL-ANTIBODIES; RECEPTOR; ACTIVATION; TUMOR; ADHESION; MOLECULE; RAT	A variant of the glycoprotein CD44 (CD44v) that shares sequences with variants causally involved in metastasis formation is transiently expressed on B and T lymphocytes and macrophages after antigenic stimulation and in the postnatal period. Antibodies to the variant hinder in vivo activation of both B and T cells. The observation that a protein domain that is expressed on CD44 and required for the lymphatic spread of tumor cells can catalyze an essential step in the process of lymphocyte activation supports the idea that metastasizing tumor cells mimic lymphocyte behavior.	GERMAN CANC RES CTR,INST RADIOL & PATHOPHYSIOL,NEUENHEIMER FELD 280,W-6900 HEIDELBERG 1,GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,W-7500 KARLSRUHE 1,GERMANY; E MERCK & CO,W-6100 DARMSTADT,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Merck KGaA			Hofmann-Apitius, Martin/E-6123-2018	Hofmann-Apitius, Martin/0000-0001-9012-6720				ARCH RH, UNPUB; DENNING SM, 1990, J IMMUNOL, V144, P7; ENGVALL E, 1972, J IMMUNOL, V109, P129; FIDLER JM, 1975, CELL IMMUNOL, V16, P223, DOI 10.1016/0008-8749(75)90114-8; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GOWANS JL, 1964, P ROY SOC LOND A MAT, V159, P282; GUNTHERT U, 1991, INVAS METAST, V65, P13; HOFMANN M, 1991, CANCER RES, V51, P5292; HUET S, 1989, J IMMUNOL, V143, P798; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; MATZKU S, 1983, INVAS METAST, V3, P109; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; RITTENBERG MB, 1969, P SOC EXP BIOL MED, V132, P575; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROBINSON AP, 1985, IMMUNOLOGY, V55, P527; RUDY W, UNPUB; SEITER S, UNPUB; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; TOLG C, UNPUB; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; ZOLLER M, 1990, SCAND J IMMUNOL, V31, P619, DOI 10.1111/j.1365-3083.1990.tb02813.x	25	444	464	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					682	685		10.1126/science.1496383	http://dx.doi.org/10.1126/science.1496383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496383				2022-12-24	WOS:A1992JF85200041
J	ZHANG, Y; RAMOS, BF; JAKSCHIK, BA				ZHANG, Y; RAMOS, BF; JAKSCHIK, BA			NEUTROPHIL RECRUITMENT BY TUMOR-NECROSIS-FACTOR FROM MAST-CELLS IN IMMUNE-COMPLEX PERITONITIS	SCIENCE			English	Article							LEUKOCYTE ADHESION; MICE; INFLAMMATION; AUGMENTATION	During generalized immune complex-induced inflammation of the peritoneal cavity, two peaks of tumor necrosis factor (TNF) were observed in the peritoneal exudate of normal mice. In mast cell-deficient mice, the first peak was undetected, and the second peak of TNF and neutrophil influx were significantly reduced. Antibody to TNF significantly inhibited neutrophil infiltration in normal but not in mast cell-deficient mice. Mast cell repletion of the latter normalized TNF, neutrophil mobilization, and the effect of the antibody to TNF. Thus, in vivo, mast cells produce the TNF that augments neutrophil emigration.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031922] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS SI, 1991, J IMMUNOL, V146, P405; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; COCHRANE CG, 1984, SPRINGER SEMIN IMMUN, V7, P263, DOI 10.1007/BF01893023; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; KITAMURA Y, 1978, BLOOD, V52, P447; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; QURESHI R, 1988, J IMMUNOL, V141, P2090; RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559; RAMOS BF, 1991, J IMMUNOL, V147, P1636; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAMOS BF, UNPUB; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SUMMERS JB, 1988, J MED CHEM, V31, P3, DOI 10.1021/jm00396a002; VANDENBROEK MF, 1988, J RHEUMATOL, V15, P544; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, J IMMUNOL, V149, P2482; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385; ZHANG Y, 1992, IMMUNOLOGY, V77, P422	24	250	251	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1957	1959		10.1126/science.1470922	http://dx.doi.org/10.1126/science.1470922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470922				2022-12-24	WOS:A1992KD08800039
J	HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL				HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL			REGIONAL TRANSFUSION CENTER PREOPERATIVE AUTOLOGOUS BLOOD DONATION PROGRAM - THE 1ST 2 YEARS	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN	Objective-To assess the efficacy of a regional autologous blood donation programme. Design-Clinical and laboratory data were collected and stored prospectively. Transfusion data were collected retrospectively from hospital blood bank records. Setting-Northern Region Blood Transfusion Service and 14 hospitals within the Northern Regional Health Authority. Subjects-505 patients referred for autologous blood donation before elective surgery. Main outcome measures-Patient eligibility, adverse events from donation, autologous blood units provided, and autologous and allogeneic blood units transfused within 10 days of operation. Results-Of 505 patients referred, 354 donated at least one unit. 78 of 151 referred patients who did not donate were excluded at the autologous clinic, mostly because of anaemia or ischaemic heart disease. In 73 cases the patient, general practitioner, or hospital consultant decided against donation. 363 autologous procedures were undertaken. In 213 (59%) cases all requested units were provided. The most common reasons for incomplete provision were late referral or anaemia. Adverse events accompanied 24 of 928 donations (2.6%). Transfusion data were obtained for 357 of the 363 procedures. 281 donors were transfused; autologous blood only was given to 225, autologous and allogeneic blood was given to 52, and allogeneic blood only was given to four. 648 of 902 (72%) units of autologous blood were transfused. Complete provision of requested autologous units was followed by allogeneic transfusion in 12 of 208 procedures (5.8%). Incomplete provision was followed by allogeneic transfusion in 44 of 149 procedures (30%). Conclusions-This study shows the feasibility of a regional autologous transfusion programme. Autologous donors only infrequently received allogeneic transfusion. Patients should be appropriately selected and referred early.	NO REG BLOOD TRANSFUS CTR,NEWCASTLE TYNE,ENGLAND		HOWARD, MR (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							BACHON JPA, 1991, TRANSFUSION, V31, P513; BENOIT P, 1992, TRANSFUSION MED, V2, P75; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GIBLETT ER, 1977, TRANSFUSION, V17, P299, DOI 10.1046/j.1537-2995.1977.17477216857.x; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GRAF H, 1990, BRIT MED J, V300, P1627, DOI 10.1136/bmj.300.6740.1627; Gunson H H, 1991, CDR (Lond Engl Rev), V1, pR144; HICKMAN M, 1988, LANCET, V1, P1221; KRUSKALL MS, 1986, TRANSFUSION, V26, P335, DOI 10.1046/j.1537-2995.1986.26486262740.x; NELSON K, 1991, Transfusion (Bethesda), V31, p47S; PETERSEN LR, 1992, 5TH NAT FOR AIDS HEP, P37; PINDYCK J, 1987, JAMA-J AM MED ASSOC, V257, P1186, DOI 10.1001/jama.257.9.1186; POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x; SCHMIDT PJ, 1991, TRANSFUSION, V31, P681, DOI 10.1046/j.1537-2995.1991.31892023489.x; TASAKI T, 1992, LANCET, V339, P773, DOI 10.1016/0140-6736(92)91895-F; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; 1989, VOX SANG, V57, P278; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1988, CLIN LAB HAEMATOL, V10, P193	22	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1470	1473		10.1136/bmj.305.6867.1470	http://dx.doi.org/10.1136/bmj.305.6867.1470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493393	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992KC91800022
J	SCHARSCHMIDT, BF; HELD, MJ; HOLLANDER, HH; READ, AE; LAVINE, JE; VEEREMAN, G; MCGUIRE, RF; THALER, MM				SCHARSCHMIDT, BF; HELD, MJ; HOLLANDER, HH; READ, AE; LAVINE, JE; VEEREMAN, G; MCGUIRE, RF; THALER, MM			HEPATITIS-B IN PATIENTS WITH HIV-INFECTION - RELATIONSHIP TO AIDS AND PATIENT SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Note						HEPATITIS-B; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; HOMOSEXUAL MEN; PREVALENCE	Hepatitis B virus (HBV) infection is common in patients infected with human immunodeficiency virus (HIV). Experimental evidence suggests that chronic HBV infection may accelerate the course of HIV-related disease, but clinical data are lacking. Therefore, we assessed the relationship of serologic markers for HBV infection to the presence of AIDS and length of survival in 511 patients with HIV infection, 233 (46%) of whom had AIDS. Hepatitis B virus markers were more prevalent in patients with AIDS (89%) than in those without AIDS (80%; P < 0.02). Among the various markers, anti-HBs did not differ between the groups (62% compared with 61%), whereas HBsAg, a marker of chronic infection, was more than twice as common in the AIDS group (10.7% compared with 4.7%; P < 0.02). Survival was shorter in patients with AIDS than in patients without AIDS but was not influenced in either group by the presence of HBsAg. These findings indicate that chronic HBV infection among HIV-infected patients is more prevalent in patients with AIDS than those without AIDS, and that this association probably reflects a manifestation of AIDS rather than an effect of HBV on progression of HIV-related disease.			SCHARSCHMIDT, BF (corresponding author), UNIV CALIF SAN FRANCISCO, DIV GASTROENTEROL, 1120 HSW, SAN FRANCISCO, CA 94143 USA.				NIADDK NIH HHS [AM 26740] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COX DR, 1972, J R STAT SOC B, V34, P187; HIRSCHMAN SZ, 1988, J MED VIROL, V26, P145, DOI 10.1002/jmv.1890260206; HOMANN C, 1991, J ACQ IMMUN DEF SYND, V4, P416; HOUGHTON J, 1989, CLIN RES, V37, pA368; OUATTARA SA, 1990, J ACQ IMMUN DEF SYND, V3, P282; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168	9	83	84	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					837	838		10.7326/0003-4819-117-10-837	http://dx.doi.org/10.7326/0003-4819-117-10-837			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416559				2022-12-24	WOS:A1992JX83800007
J	THORNICROFT, G; GOOCH, C; DAYSON, D				THORNICROFT, G; GOOCH, C; DAYSON, D			THE TAPS PROJECT .17. READMISSION TO HOSPITAL FOR LONG-TERM PSYCHIATRIC-PATIENTS AFTER DISCHARGE TO THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							REVOLVING-DOOR PATIENTS; NATION-WIDE COHORT; DEINSTITUTIONALIZATION; PATTERNS; SAMPLE; STAY	Objective-To identify risk factors which increase the likelihood of readmission for long stay psychiatric patients after discharge from hospital. Design-Follow up for five years of all long stay patients discharged from two large psychiatric hospitals to compare patients readmitted and not readmitted. Setting-Friern and Claybury Hospitals in north London and their surrounding catchment areas. Most patients were discharged to staffed or unstaffed group homes. Subjects-357 psychiatric patients who had been in hospital for over one year, of whom 118 were "new" long stay and 239 "old" long stay patients. Main outcome measures-Readmission to hospital and length of subsequent stay. Results-Of all discharged patients 97 (27%) were readmitted at some time during the follow up period, 57 (16%) in the first year after discharge, and 31 (9%) then remained in hospital for over a year. The best explanatory factors for readmission were: male sex, younger age group, high number of previous admissions, higher levels of symptomatic and social behavioural disturbance, a diagnosis of manic-depressive psychosis, and living in a non-staffed group home. Conclusions-During the closure of psychiatric hospitals, facilities need to be preserved for acute relapses among long term, and especially younger, discharged patients. Staffed group homes may help prevent relapse and reduce the number of admission beds required.			THORNICROFT, G (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				AVISON WR, 1987, AM J PSYCHIAT, V144, P10; BEISER M, 1985, AM J PSYCHIAT, V142, P1047; BLUMENTAHL S, 1988, PSYCHIATR PRAX, V154, P96; CHAMBERS M, 1990, BRIT MED J, V301, P1134, DOI 10.1136/bmj.301.6761.1134; CLARKE A, 1990, BRIT MED J, V301, P1136, DOI 10.1136/bmj.301.6761.1136; COLENDA C C, 1989, Psychiatric Quarterly (New York), V60, P227, DOI 10.1007/BF01064798; DAYSON D, 1992, BRIT MED J, V305, P993, DOI 10.1136/bmj.305.6860.993; DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P46; FERNANDO MLD, 1990, CAN J PSYCHIAT, V35, P71, DOI 10.1177/070674379003500111; GELLER JL, 1990, AM J PSYCHIAT, V147, P988; HAEFNER H, 1989, BRIT J PSYCHIAT, V155, P12; JONES K, 1986, BRIT J PSYCHIAT, V149, P537, DOI 10.1192/bjp.149.5.537; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P80, DOI 10.1111/j.1600-0447.1987.tb02865.x; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P552, DOI 10.1111/j.1600-0447.1987.tb02918.x; LERNER Y, 1989, SOC PSYCH PSYCH EPID, V24, P121, DOI 10.1007/BF01788020; LEWIS T, 1990, ACTA PSYCHIAT SCAND, V82, P130, DOI 10.1111/j.1600-0447.1990.tb01369.x; MILNE R, 1990, BRIT MED J, V301, P1139, DOI 10.1136/bmj.301.6761.1139; OKIN RL, 1990, AM J PSYCHIAT, V147, P1596; POKORNY AD, 1983, AM J PSYCHIAT, V140, P1598; SETZE PJ, 1985, HOSP COMMUNITY PSYCH, V36, P521; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; WAN TTH, 1991, COMMUNITY MENT HLT J, V27, P3, DOI 10.1007/BF00752711; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1; ZILBER N, 1990, SOC PSYCH PSYCH EPID, V25, P144, DOI 10.1007/BF00782743; 1990, 5TH ANN TAPS C LOND	26	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					996	998		10.1136/bmj.305.6860.996	http://dx.doi.org/10.1136/bmj.305.6860.996			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458148	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JV77600028
J	COTE, TR; BIGGAR, RJ; DANNENBERG, AL				COTE, TR; BIGGAR, RJ; DANNENBERG, AL			RISK OF SUICIDE AMONG PERSONS WITH AIDS - A NATIONAL ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; IOWA RECORD-LINKAGE; MORTALITY; DISORDERS	Objective.-We sought to describe the rate, risk, trends, methods, and distribution of suicide among persons with the acquired immunodeficiency syndrome (AIDS) in the United States. Design.-We used National Center for Health Statistics multiple-cause mortality data from 1987 through 1989 to identify suicides among persons with AIDS (PWAs) and public-access AIDS surveillance data to determine person-years of observation of PWAs. Patients.-Residents of the United States with death certificates indicating suicide. Main Outcome Measure.-Death certificates indicating both AIDS and suicide. Results.-In 1987 through 1989, a total of 165 suicides among PWAs occurred in 45 states and the District of Columbia. All but one case were male. Among males the rate was 165 per 100 000 person-years of observation, 7.4-fold higher than among demographically similar men in the general population. Self-poisoning with drugs was both the most common method (35%) and the method with the highest standardized mortality ratio (35). Suicide risk for PWAs decreased significantly (P<.05) from 1987 to 1989. Conclusion.-Persons with AIDS have an increased risk of suicide, and assessment of such risk should be a standard practice in their care. These assessments should be carefully considered when potentially lethal medications are prescribed. The declining trend in suicide rates between 1987 and 1989 is encouraging; possible causes include emerging therapies for human immunodeficiency virus/AIDS, better psychiatric care for these patients, and lessened social stigma against PWAs.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY PREVENT, BALTIMORE, MD 21218 USA	Johns Hopkins University	COTE, TR (corresponding author), NCI, VIRAL EPIDEMIOL SECT, 6130 EXECUT PLAZA, EPN-434, ROCKVILLE, MD 20852 USA.							ABRAM HS, 1971, AM J PSYCHIAT, V127, P1199, DOI 10.1176/ajp.127.9.1199; BERKELMAN RL, 1989, AM J MED, V86, P761, DOI 10.1016/0002-9343(89)90470-1; BLACK D, 1985, ARCHIT DIGEST, V42, P82; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P71; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P78; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; GOODMAN RA, 1987, SOUTH MED J, V82, P1128; GROW M, 1989, VERSICHERUNGSMEDIZIN, V41, P188; HOLLAND JC, 1985, ANN INTERN MED, V103, P760, DOI 10.7326/0003-4819-103-5-760; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; MARSHALL JR, 1983, SUICIDE LIFE-THREAT, V13, P15; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; SCHOENFELD M, 1986, AM J MED GENET, V24, P305; 1991, DHHS PHS911260 US DE	18	77	77	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2066	2068		10.1001/jama.268.15.2066	http://dx.doi.org/10.1001/jama.268.15.2066			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404744				2022-12-24	WOS:A1992JT52000031
J	STOCK, DW; WHITT, GS				STOCK, DW; WHITT, GS			EVIDENCE FROM 18S RIBOSOMAL-RNA SEQUENCES THAT LAMPREYS AND HAGFISHES FORM A NATURAL GROUP	SCIENCE			English	Article							DNA; EVOLUTION; PHYLOGENY	Lampreys and hagfishes (cyclostomes) traditionally were considered to be a natural (monophyletic) group. Recently, the consensus of opinion, based largely on morphological analyses, has shifted to a view that lampreys are more closely related to jawed vertebrates (gnathostomes) than to hagfishes. Phylogenetic comparisons of 18S ribosomal RNA sequences from two hagfishes, two lampreys, a tunicate, a lancelet, and a number of gnathostomes support the monophyly of the cyclostomes. These data force a reassessment of several features of early vertebrate evolution.	UNIV ILLINOIS, DEPT ECOL ETHOL & EVOLUT, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								AJUH PM, 1991, P ROY SOC B-BIOL SCI, V245, P65, DOI 10.1098/rspb.1991.0089; [Anonymous], 1966, VERTEBRATE PALEONTOL; BARDACK D, 1991, SCIENCE, V254, P701, DOI 10.1126/science.254.5032.701; CEDERGREN R, 1988, J MOL EVOL, V28, P98, DOI 10.1007/BF02143501; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J, 1989, PHYLIP MANUAL VERSIO; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Forey P.L., 1984, Journal of Vertebrate Paleontology, V4, P330; GOODMAN M, 1988, J MOL EVOL, V27, P236, DOI 10.1007/BF02100080; GOODMAN M M, 1987, P141; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hardisty M.W., 1979, BIOL CYCLOSTOMES; HARDISTY MW, 1982, BIOL LAMPREYS B, V4, pCH36; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; JANVIER P, 1981, Journal of Vertebrate Paleontology, V1, P121; JANVIER P, 1983, Journal of Vertebrate Paleontology, V2, P407; Jarvik E., 1980, BASIC STRUCTURE EVOL, DOI [10.1126/science.214.4519.431.b, DOI 10.1126/SCIENCE.214.4519.431.B]; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Lovtrup S., 1977, PHYLOGENY VERTEBRATA; MAISEY J G, 1986, Cladistics, V2, P201, DOI 10.1111/j.1096-0031.1986.tb00462.x; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; Nelson J.S., 1984, FISHES WORLD, V2nd, P523; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P4817, DOI 10.1093/nar/19.17.4817; PATTERSON C, 1989, INT CONGR SER, V824, P471; REPETSKI JE, 1978, SCIENCE, V200, P529, DOI 10.1126/science.200.4341.529-a; SCHAEFFER B, 1987, EVOL BIOL, V21, P179; Schaeffer B., 1980, P19; SCHULTZE H.-P., 1979, HDB PALEOICHTHYOLOGY, V5; SMITH MW, 1992, J MOL EVOL, V34, P175; STOCK DW, 1991, ENVIRON BIOL FISH, V32, P99, DOI 10.1007/BF00007447; Swofford DL., 1991, PAUP PHYLOGENETIC AN; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YALDEN DW, 1985, ZOOL J LINN SOC-LOND, V84, P291, DOI 10.1111/j.1096-3642.1985.tb01802.x	35	142	144	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					787	789		10.1126/science.1496398	http://dx.doi.org/10.1126/science.1496398			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496398				2022-12-24	WOS:A1992JG85100031
J	SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM				SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM			THE INFLUENCE OF AGE AND SEX ON ASTHMA ADMISSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe demographic data from a large population of asthmatic patients to define the role of age and sex as risk factors for asthma admission. Design.-A retrospective review of all asthma admissions as defined by international Classification of Diseases, Ninth Revision, code 493.0. Source.-All medical-surgical admissions from 67 hospitals in five counties of southeastern Pennsylvania from 1986 through 1989. Results.-Patients admitted for asthma treatment (33 269) were reviewed. In the 0- to 5-year-old and 6- to 10-year-old age groups, males were admitted nearly twice as often as age-identical females. In the 11- to 20-year-old age group, admissions for males and females were nearly identical. Between 20 and 50 years of age, the female-to-male ratio was nearly 3:1. Thereafter, females were admitted for asthma at a rate of about 2.5:1 when compared with their age-equivalent male counterparts. Length of stay increased proportionally as the patient age increased. After 30 years of age, the length of stay was slightly greater for females than males. Conclusions.-There is a much higher rate of admission for prepubertal males than females. However, there is a higher incidence of asthma admissions for adult females than adult male asthmatic patients, and female asthmatic patients experience longer hospital stays per admission as well. These data indicate that adult females are more severely affected by asthma and raise the possibility that hormonal or biochemical differences related to sex may play a role in the pathophysiology of asthma.	MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129	Drexel University	SPIVEY, WH (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V107, P641, DOI 10.1016/S0002-9378(16)33953-9; ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V108, P1098, DOI 10.1016/0002-9378(70)90459-X; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; ELIASSON O, 1987, J ALLERGY CLIN IMMUN, V79, P909, DOI 10.1016/0091-6749(87)90240-5; ELIASSON O, 1985, American Review of Respiratory Disease, V131, pA110; JOHANSSON U, 1981, J PHARM PHARMACOL, V33, P353, DOI 10.1111/j.2042-7158.1981.tb13802.x; Kohler Po, 1986, CLIN ENDOCRINOLOGY; KONNO A, 1986, ORL J OTO-RHINO-LARY, V48, P45, DOI 10.1159/000275841; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MOAWAD AH, 1982, AM J OBSTET GYNECOL, V144, P608, DOI 10.1016/0002-9378(82)90235-6; ROCHE WR, 1989, LANCET, V1, P52; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; VIDIC B, 1978, CYTOBIOLOGIE, V18, P10; WILKINSON L, 1988, SYSTAT SYSTEM STATIS; 1990, 1988 SUMMARY NATIONA, V185, P1; 1991, JAMA-J AM MED ASSOC, V266, P559; 1991, 913042 DEP HLTH HUM; 1991, 1990 GENERAL POPULAT; 1980, PHS801260 DEP HLTH H	19	285	286	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3437	3440		10.1001/jama.268.24.3437	http://dx.doi.org/10.1001/jama.268.24.3437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460733				2022-12-24	WOS:A1992KC83900030
J	GREEN, R; SZOSTAK, JW				GREEN, R; SZOSTAK, JW			SELECTION OF A RIBOZYME THAT FUNCTIONS AS A SUPERIOR TEMPLATE IN A SELF-COPYING REACTION	SCIENCE			English	Article							GROUP-I INTRONS; COMPLEMENTARY-STRAND RNA; DNA; TETRAHYMENA; INVITRO; BACTERIOPHAGE-T4; POLYMERASE; LIGANDS	The sunY ribozyme is derived from a self-splicing RNA group I intron. This ribozyme was chosen as a starting point for the design of a self-replicating RNA because of its small size. As a means of facilitating the self-replication process, the size of this ribozyme was decreased by the deletion of nonconserved structural domains; however, when such deletions were made, there were severe losses of enzymatic activity. In vitro genetic selection was used to identify mutations that reactivate a virtually inactive sunY deletion mutant. A selected mutant with five substitution mutations scattered throughout the primary sequence showed greater catalytic activity than the original ribozyme under the selection conditions. The sunY ribozyme and its small selected variant can both catalyze template-directed oligonucleotide assembly. The small size and reduced secondary structure of the selected variant results in an enhancement, relative to that of the original ribozyme, of its rate of self-copying. This engineered ribozyme is able to function effectively both as a catalyst and as a template in self-copying reactions.			GREEN, R (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1992, GENE DEV, V6, P1372; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL MJ, 1990, NUCLEIC ACIDS RES, V18, P5321, DOI 10.1093/nar/18.17.5321; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	18	108	148	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1910	1915		10.1126/science.1470913	http://dx.doi.org/10.1126/science.1470913			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470913				2022-12-24	WOS:A1992KD08800023
J	BOUVIER, M; SZATKOWSKI, M; AMATO, A; ATTWELL, D				BOUVIER, M; SZATKOWSKI, M; AMATO, A; ATTWELL, D			THE GLIAL-CELL GLUTAMATE UPTAKE CARRIER COUNTERTRANSPORTS PH-CHANGING ANIONS	NATURE			English	Article							RAT-BRAIN; ASPARTATE; RECEPTORS; COTRANSPORT; CALIBRATION; CEREBELLUM; TRANSPORT; POTASSIUM; RELEASE; NEURONS	UPTAKE into glial cells helps to terminate glutamate's neurotransmitter action and to keep its extracellular concentration, [Glu]o, below neurotoxic levels. The accumulative power of the uptake carrier stems from its transport of inorganic ions such as sodium (into the cell) and potassium (out of the cell)1-3. There is controversy over whether the carrier also transports a proton (or pH-changing anion)4,5. Here we show that the carrier generates an alkalinization outside and an acidification inside glial cells, and transports anions out of the cells, suggesting that there is a carrier cycle in which two Na+ accompany each glutamate anion into the cell, while one K+ and one OH- (or HCO3-) are transported out. This stoichiometry predicts a minimum [Glu]o of 0.6 muM normally (tonically activating presynaptic autoreceptors and postsynaptic NMDA receptors), and 370 muM during brain anoxia (high enough to kill neurons). Transport of OH-/HCO3- on the uptake carrier generates significant pH changes, and may provide a mechanism for neuron-glial interaction.	IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND	Imperial College London	BOUVIER, M (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Attwell, David/ABE-6750-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BERGER SJ, 1977, J NEUROCHEM, V28, P149, DOI 10.1111/j.1471-4159.1977.tb07720.x; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1987, J NEUROSCI, V7, P357; EDSALL JT, 1958, BIOPHYSICAL CHEM, P585; EIGEN M, 1958, PROC R SOC LON SER-A, V247, P505, DOI 10.1098/rspa.1958.0208; EISNER DA, 1989, PFLUG ARCH EUR J PHY, V413, P553, DOI 10.1007/BF00594188; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; KALIA K, 1990, J PHYSL, V427, P241; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KVAMME E, 1985, NEUROCHEM RES, V10, P993, DOI 10.1007/BF00964635; MOBBS P, 1968, BRAIN RES, V460, P235; NEWMAN EA, 1991, GLIA, V4, P424, DOI 10.1002/glia.440040411; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PUTNAM RW, 1986, J PHYSIOL-LONDON, V381, P205, DOI 10.1113/jphysiol.1986.sp016323; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SCHOUSBOE A, 1975, J NEUROCHEM, V25, P909, DOI 10.1111/j.1471-4159.1975.tb04429.x; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Thomas RC, 1978, ION SENSITIVE INTRAC	28	344	352	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					471	474		10.1038/360471a0	http://dx.doi.org/10.1038/360471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448171				2022-12-24	WOS:A1992KA79700062
J	BLOCKI, FA; SCHLIEVERT, PM; WACKETT, LP				BLOCKI, FA; SCHLIEVERT, PM; WACKETT, LP			RAT-LIVER PROTEIN LINKING CHEMICAL AND IMMUNOLOGICAL DETOXIFICATION SYSTEMS	NATURE			English	Article							GLUTATHIONE S-TRANSFERASES; MIGRATION INHIBITORY FACTOR; CELL HYBRIDOMA CLONE; MACROPHAGE-MIGRATION; MECHANISMS; ACID	MAMMALS have separate enzymatic and cellularly mediated detoxification systems. Glutathione S-transferases (GSTs) protect against xenobiotic chemicals which continuously enter the body, largely through mucous membranes1-5. These enzymes catalyse the conjugation of glutathione with a wide variety of electrophilic compounds rendering them non-toxic. Mammals also mount a cellular immunological response on entry of foreign cells, viruses or macromolecules into the body6-8. T lymphocytes mobilize at the site of foreign body entry and secrete protein messengers called lymphokines. Secondary to T lymphocytes, macrophages concentrate at the infection site and function in antigen processing and phagocytosis. In vitro, macrophage movement is arrested by one class of lymphokines known as macrophage migration inhibitory factors (MIFs). We report here the purification of milligram quantities of a unique multifunctional protein from rat liver which links enzymatic and immunological detoxification systems. This protein actuates both GST and MIF activity and matches the primary structure of a human MIF9 in 25 out of 26 amino-terminal amino acids. Primary structure comparisons revealed significant similarity between GSTs and MIF. The glutathione affinity chromatography purification described here yields a 100-fold increase in obtaining MIF9-11 and will aid understanding of its precise biological function.	UNIV MINNESOTA,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,GRAY FRESHWATER BIOL INST,NAVARRE,MN 55392; UNIV MINNESOTA,DEPT BIOCHEM,NAVARRE,MN 55392	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota System				Schlievert, Patrick/0000-0001-8314-9369				ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; AHMED AE, 1978, BIOCHEM PHARMACOL, V27, P2021, DOI 10.1016/0006-2952(78)90061-8; ALLISON AC, 1978, IMMUNOL REV, V40, P3, DOI 10.1111/j.1600-065X.1978.tb00399.x; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; BOYER TD, 1983, ZAKIM BIOCH PHARM, V32, P297; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P73; DING GJF, 1985, J BIOL CHEM, V260, P3268; FJELLSTEDT TA, 1973, J BIOL CHEM, V248, P3702; GOUST JM, 1986, IMMUN SERIES, V28, P169; HARRINGTON JT, 1973, J IMMUNOL, V110, P752; HIROSE S, 1991, MICROBIOL IMMUNOL, V35, P235, DOI 10.1111/j.1348-0421.1991.tb01552.x; JAKOBY WB, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P87; KOHLERSTAUB D, 1985, J BACTERIOL, V162, P676, DOI 10.1128/JB.162.2.676-681.1985; LATHROP RH, 1989, ARIADNE MANUAL; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; OKI S, 1991, LYMPHOKINE CYTOK RES, V10, P273; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RAJAPAKSE DA, 1970, NATURE, V226, P857, DOI 10.1038/226857a0; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P391, DOI 10.1093/infdis/147.3.391; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	28	73	80	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					269	270		10.1038/360269a0	http://dx.doi.org/10.1038/360269a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436109				2022-12-24	WOS:A1992JY96000055
J	STONE, VE; SEAGE, GR; HERTZ, T; EPSTEIN, AM				STONE, VE; SEAGE, GR; HERTZ, T; EPSTEIN, AM			THE RELATION BETWEEN HOSPITAL EXPERIENCE AND MORTALITY FOR PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; PROGNOSTIC FACTORS; NEW-YORK; VOLUME; SEVERITY; QUALITY; OUTCOMES; PERFECT; ILLNESS	Objective.-To determine whether there is an association between mortality and hospital acquired immune deficiency syndrome (AIDS) experience for all AIDS-related diagnoses, and to determine whether the association is explained by differences in severity of illness, earlier discharge of terminally ill patients, or differences in resource use. Design and Setting.-Population-based statewide cohort study. All hospitalizations identified for a cohort of AIDS patients diagnosed during 1987 in 40 Massachusetts hospitals were included. Patients.-All women and all male intravenous drug users (n=151), and a random sample of all male non-intravenous drug users diagnosed with AIDS during 1987 in Massachusetts (n=149). Main Outcome Measures.-Primary end points studied were (1) inpatient mortality and (2) 30-day mortality. Length of stay, cost, and intensive care unit use were also examined. Results.-In 806 hospitalizations at 40 hospitals inpatient mortality was 13.2%. Relative risk of mortality at low AIDS experience hospitals was 2.16 (95% confidence interval, 1.43 to 3.26) compared with high AIDS experience hospitals. When logistic regression was used to control for age, sex, race, human immunodeficiency virus transmission mode, severity, payer, admission type, hospital ownership, and teaching status, low hospital experience with AIDS remained a significant predictor of inpatient mortality (relative risk, 2.92; 95% confidence interval, 1.37 to 6.22). Comparisons of 30-day mortality by hospital AIDS experience yielded similar results. Length of stay and intensive care unit use were also significantly higher at low-experience hospitals after controlling for severity of illness (P<.05). Conclusions.-We conclude that mortality of AIDS patients is higher at hospitals with less AIDS experience. This finding is not because of greater severity of illness, differences in discharge patterns of the terminally ill, or less intensive use of resources.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BOSTON UNIV,BOSTON CITY HOSP,SCH MED,DEPT MED,INFECT DIS SECT,BOSTON,MA 02118; BOSTON UNIV,BOSTON CITY HOSP,SCH MED,DEPT MED,GEN INTERNAL MED SECT,BOSTON,MA 02118; BOSTON DEPT HLTH & HOSP,INST URBAN HLTH POLICY RES & EDUC,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Boston Medical Center; Boston University; Boston Medical Center; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Brigham & Women's Hospital					AHRQ HHS [1 RO3HS06150-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; COTTON DJ, 1989, JAMA-J AM MED ASSOC, V261, P3016, DOI 10.1001/jama.261.20.3016; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; KAHN KL, 1988, JAMA-J AM MED ASSOC, V260, P3625, DOI 10.1001/jama.260.24.3625; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KELLY JV, 1989, MED CARE, V27, P1085, DOI 10.1097/00005650-198912000-00001; LIPSITZ SR, 1990, COMPUT BIOMED RES, V23, P268, DOI 10.1016/0010-4809(90)90021-4; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; MATHEWS WC, 1989, J CLIN EPIDEMIOL, V42, P421, DOI 10.1016/0895-4356(89)90131-5; MOSKOWITZ MA, 1988, J AM GERIATR SOC, V36, P860, DOI 10.1111/j.1532-5415.1988.tb04272.x; ODDLEIFSON S, 1989, 5TH INT C AIDS MONTR; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; ROTHMAN DJ, 1990, NEW ENGL J MED, V323, P764, DOI 10.1056/NEJM199009133231129; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; TURNER BJ, 1989, MED CARE, V27, P423, DOI 10.1097/00005650-198904000-00009; WENGER JD, 1988, J GEN INTERN MED, V3, P464, DOI 10.1007/BF02595923; ZAMAN MK, 1988, AM REV RESPIR DIS, V137, P796, DOI 10.1164/ajrccm/137.4.796; 1987, MMWR S, V36, pS1; 1991, FED REGISTER, V56, P25178; 1987, MEDICARE B	36	99	99	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2655	2661		10.1001/jama.268.19.2655	http://dx.doi.org/10.1001/jama.268.19.2655			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX680	1433685				2022-12-24	WOS:A1992JX68000026
J	KRAUSS, S; MADEN, M; HOLDER, N; WILSON, SW				KRAUSS, S; MADEN, M; HOLDER, N; WILSON, SW			ZEBRAFISH PAX[B] IS INVOLVED IN THE FORMATION OF THE MIDBRAIN HINDBRAIN BOUNDARY	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; BOX-CONTAINING GENE; INT-1 PROTOONCOGENE; FUSHI-TARAZU; NEURAL-TUBE; DROSOPHILA; EXPRESSION; MUTATION; PROTEIN; WNT-1	AMONG the genes thought to be involved in patterning the nervous system are a family of developmentally regulated paired box-containing (Pax) genes. Mutations in some of these Pax genes lead to severe developmental abnormalities. Zebrafish pax[b] (pax[zf-b]) is a member of the Pax gene family that is expressed in the presumptive posterior midbrain from the end of gastrulation and, at later stages, in other localized regions of the developing embryo1. Here we show that injection of antibodies raised against the pax[b] protein causes a localized malformation at the mid-brain-hinbrain boundary. In situ hybridizations demonstrate that antibody injection causes downregulation of pax[b] transcripts in the posterior midbrain and alteration of wnt-1 and eng-2 expression in this area. The data demonstrate an involvement of pax[b] in the formation of the midbrain-hindbrain junction.	UNIV LONDON KINGS COLL,RANDALL INST,DEV BIOL RES CTR,DIV BIOMED SCI,LONDON WC2B 5RL,ENGLAND	University of London; King's College London			Wilson, Stephen W/B-9404-2008	Wilson, Stephen W/0000-0002-8557-5940; Krauss, Stefan/0000-0001-6992-8091				BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUNWALD DJ, 1988, DEV BIOL, V126, P115, DOI 10.1016/0012-1606(88)90245-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; JOSTES B, 1991, MECH DEVELOP, V33, P27; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIKKOLA J, 1992, J NEUROBIOL, V23, P933; MOLVEN A, 1991, EMBO J, V10, P799, DOI 10.1002/j.1460-2075.1991.tb08012.x; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PLACHOV D, 1990, DEVELOPMENT, V110, P643; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TSSEBEHJI M, 1992, NATURE, V355, P635; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435	32	122	124	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					87	89		10.1038/360087a0	http://dx.doi.org/10.1038/360087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436081				2022-12-24	WOS:A1992JW71700063
J	GARDINER, AJS; FOREY, BA; LEE, PN				GARDINER, AJS; FOREY, BA; LEE, PN			AVIAN EXPOSURE AND BRONCHOGENIC-CARCINOMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the association between bird keeping and risk of lung cancer. Design-Case-control study asking detailed questions on exposure to domestic birds and other pets, smoking, and various demographic and potentially confounding variables. Setting-District general hospital; current admissions interviewed in hospital or recent admissions interviewed at home. Patients-143 patients with lung cancer, 143 controls with heart disease, and 143 controls with orthopaedic conditions individually matched for age, sex, date of admission, and current or past admission. Main outcome measures-Odds ratios for lung cancer in relation to various aspects of bird keeping, after adjustment for smoking and other relevant confounding variables. Results-Risk of lung cancer was not significantly associated with household exposure to pet birds at any time or at various specific periods in life, or to keeping large numbers of birds. For specific types of birds no association was seen for living in households with budgerigars or canaries but risk was significantly associated with keeping pigeons (odds ratio 3.53, 95% confidence interval 1.56 to 7.98). This remained significant after regression analysis to account for confounding variables (3.9, 1.2 to 12.62) in both sexes and all age groups. Conclusion-Bird keeping may confer some risk of lung cancer but the relation is not as strong as previously reported.	PN LEE STAT & COMP,SUTTON SM2 5DA,SURREY,ENGLAND	PN Lee Statistics & Computing Ltd	GARDINER, AJS (corresponding author), MONKLANDS DIST GEN HOSP,MED UNIT,AIRDRIE ML6 0JS,LANARK,SCOTLAND.			Lee, Peter/0000-0002-8244-1904				Breslow N, 1980, STATISTICAL METHODS, V32; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; HOLST PAJ, 1988, BIRD KEEPING SOURCE	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					989	992		10.1136/bmj.305.6860.989	http://dx.doi.org/10.1136/bmj.305.6860.989			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458146	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JV77600026
J	NIGHTINGALE, SL				NIGHTINGALE, SL			UPDATE ON EMS AND L-TRYPTOPHAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-24	WOS:A1992JR43900008
J	KNIGHTON, DR; PEARSON, RB; SOWADSKI, JM; MEANS, AR; TENEYCK, LF; TAYLOR, SS; KEMP, BE				KNIGHTON, DR; PEARSON, RB; SOWADSKI, JM; MEANS, AR; TENEYCK, LF; TAYLOR, SS; KEMP, BE			STRUCTURAL BASIS OF THE INTRASTERIC REGULATION OF MYOSIN LIGHT CHAIN KINASES	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CALMODULIN BINDING; CONSERVED FEATURES; SYNTHETIC PEPTIDES; RESIDUES; SEQUENCE; PHOSPHORYLATION; DOMAIN; SITE	The smooth muscle myosin light chain kinase (smMLCK) catalytic core was modeled by using the crystallographic coordinates of the cyclic AMP-dependent protein kinase catalytic subunit (cAPK) and a bound pseudosubstrate inhibitor peptide, PKI(5-24). Despite only 30% identity in amino acid sequence, the MLCK sequence can be readily accommodated in this structure. With the exception of the short B-helix, all major elements of secondary structure in the core are very likely conserved. The active site of the modeled MLCK complements the known requirements for peptide substrate recognition. MLCK contains a pseudosubstrate sequence that overlaps the calmodulin binding domain and has been proposed to act as an intrasteric inhibitor and occupy the substrate binding site in the absence of Ca2+-calmodulin. The pseudosubstrate sequence can be modeled easily into the entire backbone of PKI(5-24). The results demonstrate that the intrasteric model for regulation of MLCK by intramolecular competitive inhibition is structurally plausible.	ST VINCENTS INST MED RES, 41 VICTORIA PARADE, FITZROY, VIC 3065, AUSTRALIA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; DUKE UNIV, DEPT PHARMACOL, DURHAM, NC 27706 USA	St. Vincent's Institute of Medical Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Duke University			Pearson, Richard Bruce/I-1451-2013; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Pearson, Richard Bruce/0000-0001-5919-5090; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09523] Funding Source: Medline; NIDDK NIH HHS [T32DK07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; CHENG HC, 1986, J BIOL CHEM, V261, P989; GLASS DB, 1989, J BIOL CHEM, V264, P14579; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P16588; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PEARSON RB, 1991, EUR J BIOCHEM, V200, P723, DOI 10.1111/j.1432-1033.1991.tb16237.x; PEARSON RW, UNPUB; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SOBIESZEK A, 1991, EUR J BIOCHEM, V199, P735, DOI 10.1111/j.1432-1033.1991.tb16178.x	26	114	129	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1992	258	5079					130	135		10.1126/science.1439761	http://dx.doi.org/10.1126/science.1439761			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439761				2022-12-24	WOS:A1992JQ61900035
J	WASSARMAN, DA; STEITZ, JA				WASSARMAN, DA; STEITZ, JA			INTERACTIONS OF SMALL NUCLEAR RNAS WITH PRECURSOR MESSENGER-RNA DURING INVITRO SPLICING	SCIENCE			English	Article							PSORALEN CROSS-LINKING; GROUP-II INTRON; RIBONUCLEOPROTEIN-PARTICLES; SITE SELECTION; 2'-OME RNA; U6 SNRNA; U2 SNRNP; YEAST; U1; SPLICEOSOME	Precursor messenger RNA splicing requires multiple factors including U1, U2, U4, U5, and U6 small nuclear RNA's. The crosslinking reagent psoralen was used to analyze the interactions of these RNA's with an adenovirus precursor messenger RNA in HeLa nuclear extract. An endogenous U2-U4-U6 crosslinkable complex dissociated upon incubation with precursor messenger RNA. During splicing, U1, U2, U5, and U6 became crosslinked to precursor messenger RNA and U2, U5, and U6 became crosslinked to excised lariat intron. U2 also formed a doubly crosslinked complex with U6 and precursor messenger RNA. The U1, U5, and U6 crosslinks to the precursor messenger RNA mapped to intron sequences near the 5' splice site, whereas the U2 crosslink mapped to the branch site. The kinetics of crosslink formation and disappearance delineates a temporal pathway for the action of small RNA's in the spliceosome. Potential base pairing interactions between conserved sequences in the small nuclear RNA's and precursor messenger RNA at the sites of crosslinking suggest that the 5' splice site is defined in several steps prior to the first cleavage event.			WASSARMAN, DA (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, HOWARD HUGHES MED INST, 295 CONGRESS AVE, NEW HAVEN, CT 06536 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026154, R01GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; CALVET JP, 1987, J MOL BIOL, V197, P543, DOI 10.1016/0022-2836(87)90563-8; CALVET JP, 1982, SCIENCE, V217, P456, DOI 10.1126/science.6178162; CALVET JP, 1981, CELL, V26, P363, DOI 10.1016/0092-8674(81)90205-1; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; England T E, 1980, Methods Enzymol, V65, P65; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GARRETTWHEELER E, 1984, NUCLEIC ACIDS RES, V12, P3405, DOI 10.1093/nar/12.7.3405; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MADHANI HD, COMMUNICATION; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKASHIMA K, 1980, NATURE, V286, P226, DOI 10.1038/286226a0; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; OSHIM AY, 1987, J MOL BIOL, V195, P297; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; REICH C, 1990, MOL CELL BIOL, V10, P5548, DOI 10.1128/MCB.10.10.5548; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ JA, 1989, METHOD ENZYMOL, V180, P468; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; WASSARMAN D, UNPUB; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT J, UNPUB; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	75	326	326	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1918	1925		10.1126/science.1411506	http://dx.doi.org/10.1126/science.1411506			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411506				2022-12-24	WOS:A1992JP59400025
J	MIZOGUCHI, H; O'SHEA, JJ; LONGO, DL; LOEFFLER, CM; MCVICAR, DW; OCHOA, AC				MIZOGUCHI, H; O'SHEA, JJ; LONGO, DL; LOEFFLER, CM; MCVICAR, DW; OCHOA, AC			ALTERATIONS IN SIGNAL TRANSDUCTION MOLECULES IN LYMPHOCYTES-T FROM TUMOR-BEARING MICE	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; ZETA-CHAIN; FC-RECEPTORS; ACTIVATION; COMPLEX; PHOSPHORYLATION; GENERATION; EXPRESSION; CD4	Impaired immune responses occur frequently in cancer patients or in tumor-bearing mice, but the mechanisms of the tumor-induced immune defects remain poorly understood. In an in vivo murine colon carcinoma model (MCA-38), animals bearing a tumor longer than 26 days develop CD8+ T cells with impaired cytotoxic function, decreased expression of the tumor necrosis factor-alpha and granzyme B genes, and decreased ability to mediate an antitumor response in vivo. T lymphocytes from tumor-bearing mice expressed T cell antigen receptors that contained low amounts of CD3gamma and completely lacked CD3zeta, which was replaced by the Fc(epsilon) gamma-chain. Expression of the tyrosine kinases p56lck and p59fyn was also reduced. These changes could be the basis of immune defects in tumor-bearing hosts.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LABS, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			McVicar, Daniel/G-1970-2015; Longo, Dan L./F-6022-2011	McVicar, Daniel/0000-0002-1112-5111	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; ALTMAN A, 1990, CRIT REV IMMUNOL, V10, P347; BRODER S, 1978, NEW ENGL J MED, V299, P1281, DOI 10.1056/NEJM197812072992305; BUFERNE M, 1992, J IMMUNOL, V148, P657; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERSH EM, 1965, NEW ENGL J MED, V273, P1006, DOI 10.1056/NEJM196511042731903; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LOEFFLER CM, 1992, J IMMUNOL, V149, P949; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MIZOGUCHI H, UNPUB; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NORTH RJ, 1984, J EXP MED, V159, P1295, DOI 10.1084/jem.159.5.1295; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKASUGI M, 1977, CANCER RES, V37, P413; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1990, J CLIN INVEST, V86, P1015, DOI 10.1172/JCI114803; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YOUNG RC, 1972, AM J MED, V52, P63, DOI 10.1016/0002-9343(72)90008-3	45	623	655	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1795	1798		10.1126/science.1465616	http://dx.doi.org/10.1126/science.1465616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465616				2022-12-24	WOS:A1992KB96400039
J	VAZEUX, R; HOFFMAN, PA; TOMITA, JK; DICKINSON, ES; JASMAN, RL; STJOHN, T; GALLATIN, WM				VAZEUX, R; HOFFMAN, PA; TOMITA, JK; DICKINSON, ES; JASMAN, RL; STJOHN, T; GALLATIN, WM			CLONING AND CHARACTERIZATION OF A NEW INTERCELLULAR-ADHESION MOLECULE ICAM-R	NATURE			English	Article							IMMUNOGLOBULIN; LFA-1; SUPERFAMILY; ACTIVATION; SEQUENCES; RECEPTOR; SYSTEM	THE human intercellular adhesion molecules ICAM-1, ICAM-2 and their counter-receptors, the beta2 or leukointegrins, mediate a variety of homotypic and heterotypic leukocyte and endothelial cell-cell adhesions central to immunocompetence1. It has been found2 that cell-cell adhesion which is dependent on expression of the leukocyte function-associated antigen LFA-1 is not always blocked completely by antibodies raised against ICAM-1 and ICAM-2. Other leukointegrin ligands therefore probably exist, such as a glycoprotein of M(r) 124K that binds LFA-1 and has been designated ICAM-3 on the basis of this function3. We have molecularly cloned a new member of the ICAM family, ICAM-R, which is related to ICAM-1 and ICAM-2. The complementary DNA encoding ICAM-R is 1,781 base pairs long and the protein has five extracellular immunoglobulin-family type domains. The mature cell-surface form of the ICAM-R protein has an M(r) which varies from 116 to 140K in a cell type-specific fashion. Overall identities in protein sequence with ICAM-1 and ICAM-2 are 48% and 31% respectively, with the degree of similarity varying between individual domains. The high level of expression of ICAM-R on resting leukocytes of all lineages and its lack of expression on either resting or cytokine-activated endothelial cells indicates a pattern of expression distinct from ICAM-1 and ICAM-2. In common with ICAM-1 and ICAM-2, ICAM-R is a ligand for the beta2-integrin CD11a/LFA-1 (CD18).	ICOS CORP, 22021 20TH AVE SE, BOTHELL, WA 98021 USA	Icos Corporation								AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; BAGNASCO M, 1990, CELL IMMUNOL, V128, P362, DOI 10.1016/0008-8749(90)90033-N; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAKGOBA MW, 1988, EUR J IMMUNOL, V18, P637, DOI 10.1002/eji.1830180423; NOTTENBURG C, 1990, GENE, V95, P279, DOI 10.1016/0378-1119(90)90372-X; POBER JS, 1986, J IMMUNOL, V137, P1893; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	17	202	220	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					485	488		10.1038/360485a0	http://dx.doi.org/10.1038/360485a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448174				2022-12-24	WOS:A1992KA79700066
J	PEAT, JK; HABY, M; SPIJKER, J; BERRY, G; WOOLCOCK, AJ				PEAT, JK; HABY, M; SPIJKER, J; BERRY, G; WOOLCOCK, AJ			PREVALENCE OF ASTHMA IN ADULTS IN BUSSELTON, WESTERN-AUSTRALIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; POPULATION; QUESTIONNAIRE; SCHOOLCHILDREN; METHACHOLINE; HISTAMINE; COMMUNITY; CHILDREN	Objective-To estimate whether the prevalence of asthma in adults increased over a nine year interval. Design-Serial cross sectional studies of the population with a protocol that included both subjective and objective measurements. Setting-Busselton, Western Australia. Subjects-A random sample of 553 subjects aged 18-55 years in 1981, and of 1028 subjects aged 18-55 years in 1990. Main outcome measures-Respiratory symptoms measured by self administered questionnaire, bronchial responsiveness measured by bronchial challenge with histamine, and allergy measured by skin prick tests. Results-Symptoms with increased prevalence were those with significant association with allergy in this population. Recent wheeze increased from 17.5% to 28.8% (p<0.001) and diagnosed asthma increased Erom 9.0% to 16.3% (p<0.001). The increase was greatest in subjects less than 30 years old. The prevalence of shortness of breath coming on at rest and of hay fever also increased significantly, but the prevalence of shortness of breath on exertion, chronic cough, bronchial hyperresponsiveness, current asthma (defined as recent wheeze plus bronchial hyperresponsiveness), and allergy did not increase. The severity of bronchial responsiveness did not change significantly in any symptom group. Conclusions-Young adults showed a significant increase in reporting of symptoms related to allergy but not in the prevalence of current asthma. The increase in symptoms may be due to increased awareness of asthma in this community, to changed treatment patterns, or to increased exposures to allergens.	UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA; UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney; University of Sydney			Haby, Michelle/AGL-3386-2022	Haby, Michelle/0000-0001-6203-9195				ABRAMSON M, 1992, AUST NZ J MED, V22, P358, DOI 10.1111/j.1445-5994.1992.tb02148.x; ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CAMPBELL DA, 1989, AUST NZ J MED S, V19, P657; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; LEBOWITZ MD, 1976, AM REV RESPIR DIS, V113, P627; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P338, DOI 10.1164/ajrccm/144.2.338; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SAMET JM, 1978, AM J EPIDEMIOL, V108, P435, DOI 10.1093/oxfordjournals.aje.a112642; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1966, QUESTIONNAIRE RESPIR	23	157	157	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	1992	305	6865					1326	1329		10.1136/bmj.305.6865.1326	http://dx.doi.org/10.1136/bmj.305.6865.1326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483077	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992KA77300021
J	ROBERT, D; AMOROSO, J; HOY, RR				ROBERT, D; AMOROSO, J; HOY, RR			THE EVOLUTIONARY CONVERGENCE OF HEARING IN A PARASITOID FLY AND ITS CRICKET HOST	SCIENCE			English	Article							EUPHASIOPTERYX-OCHRACEA; SEXUAL DIFFERENCES; SENSITIVITY	Parasitism is a widespread and diverse life strategy that connects species throughout the animal kingdom. Female parasitoid flies of the genus Ormia must find a specific cricket host on which to deposit their parasitic maggots. To reproduce, female flies must perform the same task as female crickets: find a singing male cricket. These flies have evolved a unique hearing organ that allows them to detect and locate singing male crickets. Through evolutionary convergence, these flies possess a hearing organ that much more resembles a cricket's ear than a typical fly's ear, allowing these parasitoids to take advantage of the sensory ecological niche of their host.	CORNELL UNIV, NEUROBIOL & BEHAV SECT, ITHACA, NY 14853 USA; UNIV FLORIDA, DEPT ENTOMOL & NEMATOL, GAINESVILLE, FL 32611 USA	Cornell University; State University System of Florida; University of Florida					NIDCD NIH HHS [DC00103] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000103] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAILEY WJ, 1991, J COMP PHYSIOL A, V169, P349; BENNETCLARK HC, 1968, J EXP BIOL, V49, P117; CADE W, 1975, SCIENCE, V190, P1312, DOI 10.1126/science.190.4221.1312; CARDONE B, 1988, PHYSIOL ENTOMOL, V13, P9, DOI 10.1111/j.1365-3032.1988.tb00903.x; Ewing AW, 1989, ARTHROPOD BIOACOUSTI; GRAY E. G., 1960, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V243, P75, DOI 10.1098/rstb.1960.0005; HALL JC, 1985, COMPREHENSIVE INSECT, V9, P287; LAKESHARLAN R, 1992, NATURWISSENSCHAFTEN, V79, P224, DOI 10.1007/BF01227133; MANGOLD JR, 1978, FLA ENTOMOL, V61, P57, DOI 10.2307/3494638; Michelsen A., 1985, COMPREHENSIVE INSECT, P495; MOISEFF A, 1983, J COMP PHYSIOL, V152, P155, DOI 10.1007/BF00611181; Moulins M., 1976, STRUCTURE FUNCTION P; NARINS PM, 1976, SCIENCE, V192, P378, DOI 10.1126/science.1257772; ROTH LM, 1948, AM MIDL NAT, V40, P265, DOI 10.2307/2421604; Sokal R. R, 1981, BIOMETRY; WALKER TJ, 1986, FLA ENTOMOL, V69, P678, DOI 10.2307/3495213; WALKER TJ, 1962, EVOLUTION, V16, P407, DOI 10.2307/2406176; YAGER DD, 1990, J ZOOL, V221, P517, DOI 10.1111/j.1469-7998.1990.tb04017.x; YAGER DD, 1986, SCIENCE, V231, P727, DOI 10.1126/science.3945806	19	148	154	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1135	1137		10.1126/science.1439820	http://dx.doi.org/10.1126/science.1439820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439820				2022-12-24	WOS:A1992JX85200027
J	ARNOLD, D; DRISCOLL, J; ANDROLEWICZ, M; HUGHES, E; CRESSWELL, P; SPIES, T				ARNOLD, D; DRISCOLL, J; ANDROLEWICZ, M; HUGHES, E; CRESSWELL, P; SPIES, T			PROTEASOME SUBUNITS ENCODED IN THE MHC ARE NOT GENERALLY REQUIRED FOR THE PROCESSING OF PEPTIDES BOUND BY MHC CLASS-I MOLECULES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LINKED LMP; GENE; HLA; EXPRESSION; REGION; HEAVY; IDENTIFICATION; TRANSPORTER; DETERMINANT	ANTIGEN processing provides major histocompatibility complex (MHC) class I molecules with short peptides, which they selectively bind and present to cytotoxic T lymphocytes1-4. The proteolytic system generating these peptides in the cytosol is unidentified, but their delivery into the endoplasmic reticulum is mediated by the TAP1-TAP2 transporter encoded in the MHC class II region5-9. Closely linked to TAP1 and TAP2 are genes for the LMP2 and LMP7 proteins10, which resemble components of proteasomes11-13, proteolytic complexes known to degrade cytosolic proteins14. This association has led to the common assumption that proteasomes function in this immunological pathway (discussed in ref. 15). We now show that the expression of stably assembled class I molecules and apparently normal peptide processing can be completely restored in the absence of LMP2 and LMP7 in the human lymphoblastoid cell line mutant 721.174 (refs 16, 17). The identity of LMP7 is directly confirmed by reconstitution of a proteasomal subunit after gene transfer. These results therefore dispute the hypothetical involvement of proteasomes in antigen processing, although a more subtle effect of LMP2 and LMP7 cannot be ruled out.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Yale University	ARNOLD, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,44 BINNEY ST,BOSTON,MA 02115, USA.			Driscoll, James/0000-0001-8364-0617				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRUH K, 1992, J BIOL CHEM, V267, P22131; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1990, NATURE, V346, P478; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; OZATO K, 1981, J IMMUNOL, V126, P317; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WAYS JP, 1986, J IMMUNOL, V137, P217; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	36	221	226	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					171	174		10.1038/360171a0	http://dx.doi.org/10.1038/360171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436094				2022-12-24	WOS:A1992JX75200064
J	NIKOLOV, DB; HU, SH; LIN, J; GASCH, A; HOFFMANN, A; HORIKOSHI, M; CHUA, NH; ROEDER, RG; BURLEY, SK				NIKOLOV, DB; HU, SH; LIN, J; GASCH, A; HOFFMANN, A; HORIKOSHI, M; CHUA, NH; ROEDER, RG; BURLEY, SK			CRYSTAL-STRUCTURE OF TFIID TATA-BOX BINDING-PROTEIN	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; CONSERVED DOMAIN; YEAST; GENE; INITIATION; CLONING	The structure of a central component of the eukaryotic transcriptional apparatus, a TATA-box binding protein (TBP or TFIIDtau) from Arabidopsis thaliana, has been determined by X-ray crystallography at 2.6 angstrom resolution. This highly symmetric alpha/beta structure contains a new DNA-binding fold, resembling a molecular 'saddle' that sits astride the DNA. The DNA-binding surface is a curved, antiparallel beta-sheet. When bound to DNA, the convex surface of the saddle would be presented for interaction with other transcription initiation factors and regulatory proteins.	ROCKEFELLER UNIV,MOLEC BIOPHYS LABS,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University				Burley, Stephen K./0000-0002-2487-9713				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAASS MM, 1992, FEBS LETT, V301, P294, DOI 10.1016/0014-5793(92)80260-N; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HOLDSWORTH MJ, 1992, PLANT MOL BIOL, V19, P455, DOI 10.1007/BF00023393; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAGIRI F, 1992, TRENDS GENET, V8, P22, DOI 10.1016/0168-9525(92)90020-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKADA R, IN PRESS P NATN ACAD; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P58144; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	67	355	359	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					40	46		10.1038/360040a0	http://dx.doi.org/10.1038/360040a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436073				2022-12-24	WOS:A1992JW71700046
J	OWENHUGHES, TA; PAVITT, GD; SANTOS, DS; SIDEBOTHAM, JM; HULTON, CSJ; HINTON, JCD; HIGGINS, CF				OWENHUGHES, TA; PAVITT, GD; SANTOS, DS; SIDEBOTHAM, JM; HULTON, CSJ; HINTON, JCD; HIGGINS, CF			THE CHROMATIN-ASSOCIATED PROTEIN H-NS INTERACTS WITH CURVED DNA TO INFLUENCE DNA TOPOLOGY AND GENE-EXPRESSION	CELL			English	Article							HISTONE-LIKE PROTEINS; OSMOREGULATED PROU PROMOTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; OSMOTIC REGULATION; BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; PROLINE TRANSPORT; GLYCINE BETAINE; RNA-POLYMERASE	H-NS is an abundant structural component of bacterial chromatin and influences many cellular processes, including recombination, transposition, and transcription. We have studied the mechanism of action of H-NS at the osmotically regulated proU promoter. The interaction of H-NS with a curved DNA element located downstream of the proU promoter is required for normal regulation of expression. Heterologous curved sequences can replace the regulatory role of the proU curve. Hence, the luxAB and lacZ reporter genes, which differ in the presence or absence of a curve, can indicate very different patterns of transcription. H-NS interacts preferentially with these curved DNA elements in vitro. Furthermore, in vivo the interaction of H-NS with curved DNA participates in the control of plasmid linking number. The data suggest that H-NS-dependent changes in DNA topology play a role in the osmoregulation of proU expression.			OWENHUGHES, TA (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.		Santos, Diógenes/A-6647-2008; Pavitt, Graham D/A-1363-2010; Hinton, Jay C. D./B-2142-2008	Santos, Diógenes/0000-0003-4971-463X; Pavitt, Graham D/0000-0002-8593-2418; Hinton, Jay C. D./0000-0003-2671-6026; Owen-Hughes, Tom/0000-0002-0618-8185				BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BHRIAIN NN, 1989, MOL MICROBIOL, V3, P933, DOI 10.1111/j.1365-2958.1989.tb00243.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CALLADINE CR, 1991, J MOL BIOL, V221, P981, DOI 10.1016/0022-2836(91)80187-Y; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DATTANANDA CS, 1991, J BACTERIOL, V173, P7481, DOI 10.1128/jb.173.23.7481-7490.1991; DAYN A, 1991, J BACTERIOL, V173, P2658, DOI 10.1128/jb.173.8.2658-2664.1991; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DRUGERLIOTTA J, 1986, J BACTERIOL, V169, P2449; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; FALCONI M, 1991, NEW BIOL, V3, P615; FIGUEROA N, 1991, EMBO J, V10, P941, DOI 10.1002/j.1460-2075.1991.tb08028.x; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P777, DOI 10.1093/nar/16.2.777; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GUALERZI CO, 1986, BACTERIAL CHROMATIN, P101; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; HSIEH LS, 1991, J BACTERIOL, V173, P3914, DOI 10.1128/JB.173.12.3914-3917.1991; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LEJEUNE P, 1990, P NATL ACAD SCI USA, V87, P360, DOI 10.1073/pnas.87.1.360; LUCHT JM, 1991, J BACTERIOL, V173, P801, DOI 10.1128/jb.173.2.801-809.1991; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MAY G, 1989, MOL MICROBIOL, V3, P1521, DOI 10.1111/j.1365-2958.1989.tb00138.x; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Miller J.H., 1972, EXPT MOL GENETICS; OVERDIER DG, 1989, J BACTERIOL, V171, P4694, DOI 10.1128/jb.171.9.4694-4706.1989; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; PARK SF, 1989, MOL MICROBIOL, V3, P1011, DOI 10.1111/j.1365-2958.1989.tb00252.x; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; RIMSKY S, 1990, BIOCHEMISTRY-US, V29, P3765, DOI 10.1021/bi00467a024; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; STIRLING DA, 1989, MOL MICROBIOL, V3, P1025, DOI 10.1111/j.1365-2958.1989.tb00253.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; ZASLOFF M, 1978, NUCLEIC ACIDS RES, V5, P1139, DOI 10.1093/nar/5.4.1139; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	62	265	273	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					255	265		10.1016/0092-8674(92)90354-F	http://dx.doi.org/10.1016/0092-8674(92)90354-F			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423593				2022-12-24	WOS:A1992JU39500011
J	FRANZOSO, G; BOURS, V; PARK, S; TOMITAYAMAGUCHI, M; KELLY, K; SIEBENLIST, U				FRANZOSO, G; BOURS, V; PARK, S; TOMITAYAMAGUCHI, M; KELLY, K; SIEBENLIST, U			THE CANDIDATE ONCOPROTEIN BCL-3 IS AN ANTAGONIST OF P50/NF-KAPPA-B-MEDIATED INHIBITION	NATURE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; REL-ASSOCIATED PP40; CELL-CYCLE CONTROL; HUMAN T-CELLS; P65 SUBUNIT; TRANSCRIPTION; CLONING; HOMOLOGY; PROTEIN	THE candidate oncogene bcl-3 was discovered as a translocation into the immunoglobulin alpha-locus in some cases of B-cell chronic lymphocytic leukaemias1. The protein Bcl-3 contains seven so-called ankyrin repeats. Similar repeat motifs are found in a number of diverse regulatory proteins but the motifs of Bcl-3 are most closely related to those found in I-kappa-B proteins in which the ankyrin repeat domain is thought to be directly involved in inhibition of NF-kappa-B activity. No biological function has yet been described for Bcl-3, but it was noted recently2 that Bcl-3 interferes with DNA-binding of the p50 subunit of NF-kappa-B in vitro. Here we demonstrate that Bcl-3 can aid kappa-B site-dependent transcription in vivo by counteracting the inhibitory effects of p50/NF-kappa-B homodimers. Bcl-3 may therefore aid activation of select NF-kappa-B-regulated genes, including those of the human immunodeficiency virus.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	35	291	296	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					339	342		10.1038/359339a0	http://dx.doi.org/10.1038/359339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406939	Green Published			2022-12-24	WOS:A1992JP50300063
J	PIETRONI, PC				PIETRONI, PC			PARTNERS IN PRACTICE .7. BEYOND THE BOUNDARIES - RELATIONSHIP BETWEEN GENERAL-PRACTICE AND COMPLEMENTARY MEDICINE	BRITISH MEDICAL JOURNAL			English	Article											PIETRONI, PC (corresponding author), ST MARYS HOSP,SCH MED,LONDON,ENGLAND.							BEIER LM, 1987, SUFFERERS HEALERS EX, P38; DESSER A, IN PRESS J R COLL GE; FULDER S, 1981, STATUS COMPLEMENTARY; MCLEAN J, 1990, SOC SCI MED, V30, P591, DOI 10.1016/0277-9536(90)90157-N; PETERS D, IN PRESS J R COLL GE; PIETRONI PC, 1988, J R SOC ARTS, P791; REASON P, 1992, J ROY SOC MED, V85, P161; REASON P, 1991, J RES COUNCIL COMPLE, V5, P144; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1981, WHICH            AUG; 1991, REPORT OSTEOPATHY	13	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					564	566		10.1136/bmj.305.6853.564	http://dx.doi.org/10.1136/bmj.305.6853.564			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393039	Green Published, Green Submitted, hybrid			2022-12-24	WOS:A1992JM49500021
J	OKAMOTO, Y				OKAMOTO, Y			HEALTH-CARE FOR THE ELDERLY IN JAPAN - MEDICINE AND WELFARE IN AN AGING SOCIETY FACING A CRISIS IN LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article											OKAMOTO, Y (corresponding author), HANNAN CHUO HOSP,DEPT INTERNAL MED & HOME CARE,3-3-28 MINAMISHINMACHI,MATSUBARA,OSAKA 580,JAPAN.							ANDERSEN BR, 1990, KOSEIFUKUSHI J, P2; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; HASEGAWA T, 1990, J HLTH WELFARE STATI, V36, P23; HENDRICS J, 1986, AGING MASS SOC MYTHS; HIATT HH, 1987, AM HLTH BALANCE CHOI; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P1166; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P807; MARMOT MG, 1989, BMJ, V99, P23; MENDERSON MA, 1975, TENDER LOVING GREED; MUNDINGWER MO, 1983, HOME CARE CONTROVERS; OKAMOTO Y, 1984, AM NO IRYO TO KANGO; PEGLES CC, 1981, HLTH CARE ELDERLY; SHIEBER G, 1989, HLTH AFF         FAL, P169; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SHIRAISHI M, 1986, J HLTH WELFARE STATI, V33, P200; SUGAYA Y, 1990, J HLTH WELFARE STATI, V137, P8; Vladeck B.C., 1980, UNLOVING CARE NURSIN; YAMAMOTO M, 1989, J HLTH WELFARE STATI, V36, P13; 1987, OECD SOCIAL POLICY S, P37; 1992, ANN REPORT 1990 91; 1989, NETAKIRI ZERO MEZASH; 1989, J HLTH WELFARE STATI, V36, P91; 1992, NIPPON CHARTED SURVE; 1991, SHAKAI HOKEN JUNPO J, P28	24	26	26	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					403	405		10.1136/bmj.305.6850.403	http://dx.doi.org/10.1136/bmj.305.6850.403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK314	1392924	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JK31400020
J	SHEN, JC; RIDEOUT, WM; JONES, PA				SHEN, JC; RIDEOUT, WM; JONES, PA			HIGH-FREQUENCY MUTAGENESIS BY A DNA METHYLTRANSFERASE	CELL			English	Article							HEAT-INDUCED DEAMINATION; CYTOSINE METHYLTRANSFERASES; CPG DINUCLEOTIDE; CELLS; 5-METHYLCYTOSINE; RESTRICTION; METHYLATION; MECHANISM; MOUSE; MODEL	Hpall methylase (M. Hpall), an example of a DNA (cytosine-5)-methyltransferase, was found to induce directly a high frequency of C-U transition mutations in double-stranded DNA. A mutant pSV2-neo plasmid, constructed with an inactivating T-->C transition mutation creating a CCGG site, was incubated with M. Hpall in the absence of S-adenosylmethionine (SAM). This caused an approximately 10(4)-fold increase in the rate of reversion when the mutant neo plasmid was transformed into bacteria lacking uracil-DNA glycosylase. The mutation frequency was very sensitive to SAM concentration and was reduced to background when the concentration of the methyl donor exceeded 300 nM. The data support current models for the formation of a covalent complex between the methyltransferase and cytosine. They also suggest that the occurrence of mutational hot spots at CpG sites may not always be due to spontaneous deamination of 5-methylcytosine, but might also be initiated by enzymatic deamination of cytosine and proceed through a C-->U-->T pathway.			SHEN, JC (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033, USA.				NATIONAL CANCER INSTITUTE [R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA49758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DUNCAN B, 1984, ENZYMES, P565; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FRIEDMAN S, 1985, J BIOL CHEM, V260, P5698; GUNTHERT U, 1981, J BIOL CHEM, V256, P9346; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Maniatis T., 1982, MOL CLONING; MONK M, 1991, DEVELOPMENT, V112, P189; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J., 1989, MOL CLONING LAB MANU; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SHEN JC, 1992, NUCLEIC ACIDS RES, V20, P5119, DOI 10.1093/nar/20.19.5119; SIMON D, 1978, NUCLEIC ACIDS RES, V5, P2153, DOI 10.1093/nar/5.6.2153; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; STEINBERG RA, 1992, MOL CELL BIOL, V12, P767, DOI 10.1128/MCB.12.2.767; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; WU JC, 1987, J BIOL CHEM, V262, P4778	39	252	255	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1073	1080		10.1016/S0092-8674(05)80057-1	http://dx.doi.org/10.1016/S0092-8674(05)80057-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473145				2022-12-24	WOS:A1992KE60400003
J	KATZ, A; WU, DQ; SIMON, MI				KATZ, A; WU, DQ; SIMON, MI			SUBUNITS-BETA-GAMMA OF HETEROTRIMERIC G-PROTEIN ACTIVATE BETA-2 ISOFORM OF PHOSPHOLIPASE-C	NATURE			English	Article							ADENYLYL CYCLASE; RECEPTOR	THE activation of heterotrimeric G proteins results in the exchange of GDP bound to the alpha-subunit for GTP and the subsequent dissociation of a complex of the beta- and gamma-subunits (G(betagamma)). The alpha-subunits of different G proteins interact with a variety of effectors1-7, but less is known about the function of the free G(betagamma) complex. G(betagamma) has been implicated in the activation of a cardiac potassium channel8, a retinal phospholipase A2 (ref. 9) and a specific receptor kinase10, and in vitro reconstitution experiments indicate that the G(betagamma) complex can act with G(alpha) subunit to modulate the activity of different isoforms of adenylyl cyclase11. Of two phospholipase activities that can be separated in extracts of HL-60 cells, purified G(betagamma) is found to activate one of them12. Here we report that in co-transfection assays G(betagamma) subunits specifically activate the beta2 and not the beta1 isoform of phospholipase, which acts on phosphatidylinositol. We use transfection assays to show also that receptor-mediated release of G(betagamma) from G proteins that are sensitive to pertussis toxin can result in activation of the phospholipase. This effect may be the basis of the pertussis-toxin-sensitive phospholipase C activation seen in some cell systems (reviewed in refs 13 and 14).	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012					ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAGA K, 1992, J BIOL CHEM, V267, P2222; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARK D, 1992, J BIOL CHEM, V267, P16048; PARKER EM, 1991, J BIOL CHEM, V266, P519; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; UI M, 1990, ADP RIBOSYLATING TOX, P45; WU DQ, 1992, J BIOL CHEM, V267, P1811; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	30	466	471	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					686	689		10.1038/360686a0	http://dx.doi.org/10.1038/360686a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465134				2022-12-24	WOS:A1992KD08200061
J	SANDERCOCK, P; BAMFORD, J; DENNIS, M; BURN, J; SLATTERY, J; JONES, L; BOONYAKARNKUL, S; WARLOW, C				SANDERCOCK, P; BAMFORD, J; DENNIS, M; BURN, J; SLATTERY, J; JONES, L; BOONYAKARNKUL, S; WARLOW, C			ATRIAL-FIBRILLATION AND STROKE - PREVALENCE IN DIFFERENT TYPES OF STROKE AND INFLUENCE ON EARLY AND LONG-TERM PROGNOSIS (OXFORDSHIRE COMMUNITY STROKE PROJECT)	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; RISK-FACTORS; THROMBOEMBOLIC COMPLICATIONS; BRAIN INFARCTION; FRAMINGHAM; REGISTRY; RECURRENCE; DURATION; EMBOLISM	Objective-To determine in patients with first ever stroke whether atrial fibrillation influences clinical features, the need to perform computed tomography, and prognosis. Design-Observational cohort study with maximum follow up of 6.5 years. Setting-Primary care, based on 10 general practices in urban and rural Oxfordshire. Subjects-Consecutive series of 675 patients with first ever stroke registered in the Oxfordshire community stroke project. Main outcome measures-Prevalence of atrial fibrillation by type of stroke; effect of atrial fibrillation on case fatality rate and risk of recurrent stroke, vascular death, and death from all causes. Results-Prevalence of atrial fibrillation was 17% (95% confidence interval 14% to 20%) for all stroke types (115/675), 18% (15% to 21%) for cerebral infarction (97/545), 11% (4% to 11%) for primary intercerebral haemorrhage (7/66), and 0% (0 to 11%) for subarachnoid haemorrhage (0/33). For patients with cerebral infarction the 30 day case fatality rate was significantly higher with atrial fibrillation (23%) than with sinus rhythm (8%); the risk of early recurrent stroke (within 30 days) was 1% with atrial fibrillation and 4% with sinus rhythm. In patients who survived at least 30 days the average annual risk of recurrent stroke was 8.2% (5.9% to 10.9%) with sinus rhythm and 11% (6.0% to 17.3%) with atrial fibrillation. Conclusions-After a first stroke atrial fibrillation was not associated with a definite excess risk of recurrent stroke, either within 30 days or within the first few years. Survivors with and without atrial fibrillation had a clinically important absolute risk of further serious vascular events.	ST JAMES UNIV HOSP,DEPT NEUROL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT REHABIL MED,SOUTHAMPTON S09 4XY,ENGLAND; RADCLIFFE INFIRM,GIBSON LABS,DEPT COMMUNITY MED & GEN PRACTICE,OXFORD OX2 6HE,ENGLAND; RAJAVITHI HOSP,DEPT MED,DIV NEUROL,BANGKOK 10400,THAILAND	Saint James's University Hospital; University of Southampton; Radcliffe Infirmary; Rajavithi Hospital	SANDERCOCK, P (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				ARMITAGE P, 1971, STATISTICAL METHODS, P135; BAMFORD J, 1992, LANCET, V339, P400, DOI 10.1016/0140-6736(92)90085-H; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; BOGOUSSLAVSKY J, 1990, ACTA NEUROL SCAND, V82, P143; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BRITTON M, 1985, STROKE, V16, P182, DOI 10.1161/01.STR.16.2.182; BRITTON M, 1979, ACTA MED SCAND, V205, P425; CAMDELISE L, 1991, STROKE, V22, P169; DARLING RC, 1967, SURG GYNECOL OBSTETR, V124, P106; DAVIS PH, 1987, ANN NEUROL, V22, P319, DOI 10.1002/ana.410220307; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DIXON WJ, 1985, BMDP STATISTICAL SOF, P576; FISHER CM, 1979, GERIATRICS, V34, P59; FLEGEL KM, 1987, LANCET, V1, P878; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FRIEDMAN PJ, 1991, STROKE, V22, P209, DOI 10.1161/01.STR.22.2.209; GARDNER MJ, 1989, STATISTICS CONFIDENC; GUSTAFSSON C, 1986, ACTA NEUROL SCAND, V73, P520; HARRISON MJG, 1984, STROKE, V15, P441, DOI 10.1161/01.STR.15.3.441; HART RG, 1983, STROKE, V14, P827, DOI 10.1161/str.14.5.827a; HART RG, 1983, STROKE, V14, P688, DOI 10.1161/01.STR.14.5.688; HAYNES RB, 1985, EPIDEMIOLOGY SCI CLI; HIER DB, 1991, STROKE, V22, P155, DOI 10.1161/01.STR.22.2.155; KELLEY RE, 1984, NEUROLOGY, V34, P1285, DOI 10.1212/WNL.34.10.1285; KIPECKY SL, 1987, NEW ENGL J MED, V317, P669; KOLLER RL, 1982, NEUROLOGY, V32, P283; LOWE GDO, 1983, LANCET, V1, P784; MARQUARDSEN J, 1969, NATURAL HIST ACUTE C, P138; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; OLSEN T, 1990, J NEUROL, V237, P139; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, STROKE, V21, P4, DOI 10.1161/01.STR.21.1.4; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RICCI S, 1989, STROKE, V20, P853, DOI 10.1161/01.STR.20.7.853; RICCI S, 1991, SALZBURG C CEREBROVA, P7; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SAGE JI, 1983, STROKE, V14, P537, DOI 10.1161/01.STR.14.4.537; SANTAMARIA J, 1983, NEUROLOGY, V33, P1104, DOI 10.1212/WNL.33.8.1104; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; VANMERWIJK G, 1990, J NEUROL, V237, P205; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1986, ARCH NEUROL-CHICAGO, V43, P71; 1989, ARCH NEUROL-CHICAGO, V46, P727; 1990, NEW ENGL J MED, V322, P863; 1990, NEW ENGL J MED, V323, P1505	53	188	192	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1460	1465		10.1136/bmj.305.6867.1460	http://dx.doi.org/10.1136/bmj.305.6867.1460			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493391	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992KC91800020
J	MANNING, CJ; WAKELAND, EK; POTTS, WK				MANNING, CJ; WAKELAND, EK; POTTS, WK			COMMUNAL NESTING PATTERNS IN MICE IMPLICATE MHC GENES IN KIN RECOGNITION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATING PREFERENCES; SYSTEMS	HOUSE mice (Mus musculus domesticus) form communal nests and appear to nurse each other's pups indiscriminately. Communal nesting probably functions to reduce infanticide1, but it also makes females vulnerable to exploitation if nursing partners fail to provide their fair share of care. Kinship theory predicts that females will preferentially form communal nests with relatives to minimize exploitation and further increase inclusive fitness2-4. Here we provide evidence from seminatural populations that females prefer communal nesting partners that share allelic forms of major histocompatibility complex genes. Such behaviour would lead to the selection of close relatives as communal nesting partners5-7. Although criteria for the demonstration of kin recognition are currently embroiled in controversy8,9, this is the first vertebrate study to meet Grafen's restrictive requirements8,10: discrimination is based on genetic similarity at highly polymorphic loci, incidental correlations due to relatedness are experimentally controlled, and strong reasons exist for expecting the assayed behaviour to be kin-selected.	UNIV FLORIDA,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	State University System of Florida; University of Florida; University of Washington; University of Washington Seattle	MANNING, CJ (corresponding author), UNIV FLORIDA,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610, USA.			Potts, Wayne/0000-0003-4137-0326				BARNARD C, 1991, TREND ECOL EVOL, V310, P312; BARNARD CJ, 1991, BIOL REV, V66, P377; BEAUCHAMP GK, 1990, CHEM SIGNAL, V5, P244; BEAUCHAMP GK, 1988, BEHAV GENET, V18, P537, DOI 10.1007/BF01065520; BEECHER MD, 1982, AM ZOOL, V22, P477; BROWN JL, 1983, ETHICAL QUESTIONS BR, P111; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; GETZ WM, 1981, J THEOR BIOL, V92, P209, DOI 10.1016/0022-5193(81)90288-5; GRAFEN A, 1990, ANIM BEHAV, V39, P42, DOI 10.1016/S0003-3472(05)80724-9; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HURST JL, 1992, BEHAV ECOL, V3, P196, DOI 10.1093/beheco/3.3.196; Klein J., 1986, NATURAL HIST MAJOR H; LACY RC, 1983, AM NAT, V121, P489, DOI 10.1086/284078; MANNING CJ, IN PRESS ANIM BEHAV; Oka H., 1970, PROFILES JAPANESE SC, P196; PACKER C, 1992, ANIM BEHAV, V43, P265, DOI 10.1016/S0003-3472(05)80222-2; PARTRIDGE L, 1988, PHILOS T R SOC B, V319, P525, DOI 10.1098/rstb.1988.0063; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; POTTS WK, 1990, TRENDS ECOL EVOL, V5, P181, DOI 10.1016/0169-5347(90)90207-T; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; THOMAS L, 1975, IMMUNE SYSTEM INFECT, P2; Uyenoyama M. K., 1988, EVOLUTION SEX EXAMIN, P212; WILKINSON GS, 1988, ETHOLOGY, V77, P103; YAMAZAKI K, 1988, SCIENCE, V240, P1331, DOI 10.1126/science.3375818	25	197	210	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					581	583		10.1038/360581a0	http://dx.doi.org/10.1038/360581a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461279				2022-12-24	WOS:A1992KB95900083
J	WOOD, RC; MACDONALD, KL; OSTERHOLM, MT				WOOD, RC; MACDONALD, KL; OSTERHOLM, MT			CAMPYLOBACTER ENTERITIS OUTBREAKS ASSOCIATED WITH DRINKING RAW-MILK DURING YOUTH ACTIVITIES - A 10-YEAR REVIEW OF OUTBREAKS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							JEJUNI INFECTION; SURVEILLANCE; CONSUMPTION; DISEASE; ENGLAND	Objective.-To determine the incidence of recognized outbreaks of Campylobacter enteritis associated with drinking raw milk during youth activities. Design.-Retrospective survey of 51 state and territorial health departments. Setting.-The 50 United States and the Territory of Puerto Rico. Populations.-Persons in preschool through college. Measurement.-Information was obtained for all Campylobacter outbreaks associated with consumption of raw milk during youth activities from 1981 through 1990 that were investigated by state and territorial health departments. Results.-Twenty outbreaks were identified in 11 states. Four hundred fifty-eight outbreak-associated cases occurred among 1013 persons who drank raw milk, with an overall attack rate of 45%. At least one outbreak was reported for each year of the 10-year period. Fourteen outbreaks (70%) occurred among children in kindergarten through third grade, compared with one outbreak (5%) among fourth through sixth graders. The remaining five outbreaks (25%) occurred in mixed groups of children and teenagers. Only nine (60%) of 15 outbreaks identified from 1981 through 1988 were reported to the Campylobacter national surveillance system maintained by the Centers for Disease Control and Prevention. Conclusion.-Drinking raw milk on school field trips or other youth activities continues despite the occurrence of multiple Campylobacter outbreaks documented from this practice. Such illnesses can be prevented by educating dairy farmers and officials of schools and youth organizations about the hazards of drinking raw milk. Public health organizations need to develop and implement such educational programs.	MINNESOTA DEPT HLTH,DIV DIS PREVENT & CONTROL,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440	Minnesota Department of Health (MHD)								BIRKHEAD G, 1988, J INFECT DIS, V157, P1095, DOI 10.1093/infdis/157.5.1095; BLASER MJ, 1987, JAMA-J AM MED ASSOC, V257, P43, DOI 10.1001/jama.257.1.43; BLASER MJ, 1983, ANN INTERN MED, V98, P360, DOI 10.7326/0003-4819-98-3-360; DEMING MS, 1987, AM J EPIDEMIOL, V126, P526, DOI 10.1093/oxfordjournals.aje.a114685; FINCH MJ, 1984, ARCH INTERN MED, V144, P1610, DOI 10.1001/archinte.144.8.1610; FINCH MJ, 1985, AM J EPIDEMIOL, V122, P262, DOI 10.1093/oxfordjournals.aje.a114097; GALBRAITH NS, 1982, BMJ-BRIT MED J, V284, P1761, DOI 10.1136/bmj.284.6331.1761; HARRIS NV, 1986, AM J PUBLIC HEALTH, V76, P407, DOI 10.2105/AJPH.76.4.407; HOPKINS RS, 1984, AM J PUBLIC HEALTH, V74, P249, DOI 10.2105/AJPH.74.3.249; HUDSON SJ, 1990, LANCET, V335, P1160, DOI 10.1016/0140-6736(90)91162-4; JOSEPH C, 1990, EPIDEMIOL INFECT, V105, P419, DOI 10.1017/S0950268800048007; KLEIN BS, 1986, JAMA-J AM MED ASSOC, V255, P361, DOI 10.1001/jama.255.3.361; KORLATH JA, 1985, J INFECT DIS, V152, P592, DOI 10.1093/infdis/152.3.592; KORNBLATT AN, 1985, AM J EPIDEMIOL, V122, P884, DOI 10.1093/oxfordjournals.aje.a114171; LOVETT J, 1983, APPL ENVIRON MICROB, V46, P459, DOI 10.1128/AEM.46.2.459-462.1983; MARTIN ML, 1986, LANCET, V2, P1043; MCNAUGHTON RD, 1982, CAN MED ASSOC J, V126, P657; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; RILEY LW, 1985, J INFECT DIS, V151, P956, DOI 10.1093/infdis/151.5.956; ROBINSON DA, 1981, BRIT MED J, V282, P1374, DOI 10.1136/bmj.282.6273.1374; SKIRROW MB, 1990, LANCET, V336, P921, DOI 10.1016/0140-6736(90)92282-M; TACKET CO, 1985, JAMA-J AM MED ASSOC, V253, P2058, DOI 10.1001/jama.253.14.2058; TAUXE RV, 1987, AM J PUBLIC HEALTH, V77, P1219, DOI 10.2105/AJPH.77.9.1219; WALTNERTOEWS D, 1990, J FOOD PROTECT, V53, P258, DOI 10.4315/0362-028X-53.3.258; 1986, MMWR, V35, P311; 1986, MMWR, V37, P1; 1987, CAN DIS WKLY REP, V13, P5	28	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3228	3230		10.1001/jama.268.22.3228	http://dx.doi.org/10.1001/jama.268.22.3228			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433764				2022-12-24	WOS:A1992KA65400030
J	MATTER, K; HUNZIKER, W; MELLMAN, I				MATTER, K; HUNZIKER, W; MELLMAN, I			BASOLATERAL SORTING OF LDL RECEPTOR IN MDCK CELLS - THE CYTOPLASMIC DOMAIN CONTAINS 2 TYROSINE-DEPENDENT TARGETING DETERMINANTS	CELL			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; DENSITY LIPOPROTEIN RECEPTOR; PLASMA-MEMBRANE PROTEINS; INFLUENZA-VIRUS HEMAGGLUTININ; LYMPHOCYTE FC-RECEPTORS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEINS; MEDIATED ENDOCYTOSIS	In MDCK cells, transport of membrane proteins to the basolateral plasma membrane has been shown to require a distinct cytoplasmic domain determinant. Although the determinant is often related to signals used for localization in clathrin-coated pits, inactivation of the coated pit domain in the human LDL receptor did not affect basolateral targeting. By expressing mutant and chimeric LDL receptors, we have now identified two independently acting signals that are individually sufficient for basolateral targeting. The two determinants mediate basolateral sorting with different efficiencies, but both contain tyrosine residues critical for activity. The first determinant was colinear with, but distinct from, the coated pit domain of the receptor. The second was found in the C-terminal region of the cytoplasmic domain of the receptor and, although tyrosine-dependent, did not mediate endocytosis. The results suggest that membrane proteins can have functionally redundant signals for basolateral transport and that a tyrosine-containing motif may be a common feature of multiple intracellular sorting events.			MATTER, K (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022; Matter, Karl/C-4880-2008; Mellman, Ira/ABG-5896-2020	Hunziker, Walter/0000-0002-5265-4933; Matter, Karl/0000-0001-8026-7220; 				BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SA, 1985, J BIOL CHEM, V260, P9867; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Hauri H P, 1991, Semin Cell Biol, V2, P355; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1991, Semin Cell Biol, V2, P397; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIQUEZBOULAN E, 1992, IN PRESS ANN REV CEL; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	44	337	340	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					741	753		10.1016/0092-8674(92)90551-M	http://dx.doi.org/10.1016/0092-8674(92)90551-M			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423629	hybrid			2022-12-24	WOS:A1992JZ63300005
J	YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T				YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T			AUDIT OF COMPLIANCE WITH ANTENATAL PROTOCOLS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES; PHYSICIANS; POLICIES; CARE	Objective-To assess the implementation of action protocols dictated by antenatal risk factors noted at the initial (booking) antenatal visit. Design-Retrospective study of 2000 women delivered between 1 March 1990 and 29 March 1991. Setting-Maternity department of a district general hospital supporting a multiethnic population in inner London. Main outcome measures-Comparison of clinical actions performed against those dictated by the department's protocols. Analysis according to clinical importance, gestation at booking, maternal age, parity, birth order, ethnic origin, and certainty of gestational age. Results-Interobserver agreement between the two auditors was good (chi statistic for risk factors detected, 0.78; for actions generated, 0.80). Of the 15 658 actions dictated by department protocols, 3673 (23.5%) were actually performed by the clinicians. The 63 combinations of risk factors and actions believed by consultants to be of particular clinical importance had an action rate of 28.3% compared with 18.6% for those considered less important (p < 0.001). Mothers who first visited the hospital antenatal clinic at or before 24 weeks' gestation had 25.2% of relevant protocols fulfilled (p < 0.001). Compliance was significantly improved in women aged 36 or over (32.4%), black women (24.9%), and cases of uncertain gestation (24.5%). Parity and birth order were not associated with an altered action rate. Ethnic origin deemed as "other" (than white, black, Asian, or oriental) or "unknown" was associated with poor compliance (19.3%). Conclusions-Compliance to a set of agreed protocols was poor even though a computer system was available and a protocol manual had been distributed. Protocols were more likely to be implemented in women who booked early and in some groups of women deemed at high risk including older mothers, black women, and those denoted as having uncertain gestational age.			YOONG, AFE (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL, JOINT ACAD UNIT OBSTET GYNAECOL & REPROD PHYSIOL, LONDON EC1A 7BE, ENGLAND.							BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BODDY K, 1982, ROYAL COLLEGE OBSTET, P40; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; CARROLL S, 1988, J OBSTET GYNAECOL, V8, P222, DOI 10.3109/01443618809012289; CHNG PK, 1980, BMJ-BRIT MED J, V281, P1184, DOI 10.1136/bmj.281.6249.1184; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1265, DOI 10.1001/jama.263.9.1265; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; GUTHRIE KA, 1989, BRIT J OBSTET GYNAEC, V96, P552, DOI 10.1111/j.1471-0528.1989.tb03254.x; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; ODOWD TC, 1991, BRIT MED J, V303, P450, DOI 10.1136/bmj.303.6800.450; SHAW CD, 1990, BRIT MED J, V300, P649, DOI 10.1136/bmj.300.6725.649; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480	17	11	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1992	305	6863					1184	1186		10.1136/bmj.305.6863.1184	http://dx.doi.org/10.1136/bmj.305.6863.1184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467720	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JY77700019
J	NADLER, SG; TEPPER, MA; SCHACTER, B; MAZZUCCO, CE				NADLER, SG; TEPPER, MA; SCHACTER, B; MAZZUCCO, CE			INTERACTION OF THE IMMUNOSUPPRESSANT DEOXYSPERGUALIN WITH A MEMBER OF THE HSP70 FAMILY OF HEAT-SHOCK PROTEINS	SCIENCE			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORIN-A; 15-DEOXYSPERGUALIN; CYCLOPHILIN; RECEPTOR; INVITRO; CELLS; LYMPHOCYTES; EXPRESSION	Deoxyspergualin (DSG) is a potent immunosuppressant whose mechanism of action remains unknown. To elucidate its mechanism of action, an intracellular DSG binding protein was identified. DSG has now been shown to bind specifically to Hsc70, the constitutive or cognate member of the heat shock protein 70 (Hsp70) protein family. The members of the Hsp70 family of heat shock proteins are important for many cellular processes, including immune responses, and this finding suggests that heat shock proteins may represent a class of immunosuppressant binding proteins, or immunophilins, distinct from the previously identified cis-trans proline isomerases. DSG may provide a tool for understanding the function of heat shock proteins in immunological processes.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,WALLINGFORD,CT 06492	Bristol-Myers Squibb								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; DICKNEITE G, 1987, INT J IMMUNOPHARMACO, V9, P559, DOI 10.1016/0192-0561(87)90123-8; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FUJII H, 1989, J ANTIBIOT, V42, P788, DOI 10.7164/antibiotics.42.788; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; ISHIBASHI M, 1989, TRANSPLANT P, V21, P1854; JIANG H, 1990, TRANSPLANT P, V22, P1633; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MAEDA K, 1992, 3RD INT C DRUG RES I; NEMOTO K, 1987, J ANTIBIOT, V40, P561, DOI 10.7164/antibiotics.40.561; NISHIMURA K, 1989, IMMUNOLOGY, V68, P66; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TAKAHARA S, 1992, TRANSPLANTATION, V53, P914, DOI 10.1097/00007890-199204000-00037; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKEUCHI T, 1981, J ANTIBIOT, V34, P1619, DOI 10.7164/antibiotics.34.1619; TEPPER MA, 1991, TRANSPLANT P, V23, P328; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; VANBUSKIRK AM, 1991, J IMMUNOL, V146, P500; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YEM AW, 1992, J BIOL CHEM, V267, P2868	34	218	223	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					484	486		10.1126/science.1411548	http://dx.doi.org/10.1126/science.1411548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411548				2022-12-24	WOS:A1992JT77500042
J	JUVONEN, T; NIEMELA, O				JUVONEN, T; NIEMELA, O			ABO BLOOD-GROUP AND GALL STONE DISEASE	BRITISH MEDICAL JOURNAL			English	Article									OULU UNIV HOSP,DEPT CLIN CHEM,SF-90220 OULU,FINLAND	University of Oulu	JUVONEN, T (corresponding author), OULU UNIV HOSP,DEPT SURG,SF-90220 OULU,FINLAND.							BEARDMORE JA, 1983, NATURE, V303, P522, DOI 10.1038/303522a0; BUSCH N, 1991, EUR J CLIN INVEST, V21, P453, DOI 10.1111/j.1365-2362.1991.tb01394.x; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; WHINCUP PH, 1990, BMJ-BRIT MED J, V300, P1679, DOI 10.1136/bmj.300.6741.1679	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					26	27		10.1136/bmj.305.6844.26	http://dx.doi.org/10.1136/bmj.305.6844.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1489401	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JC79900025
J	CONVERSE, RL; JACOBSEN, TN; TOTO, RD; JOST, CMT; COSENTINO, F; FOUADTARAZI, F; VICTOR, RG				CONVERSE, RL; JACOBSEN, TN; TOTO, RD; JOST, CMT; COSENTINO, F; FOUADTARAZI, F; VICTOR, RG			SYMPATHETIC OVERACTIVITY IN PATIENTS WITH CHRONIC-RENAL-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOPAMINE-BETA-HYDROXYLASE; BLOOD-PRESSURE; ANGIOTENSIN-II; RENIN-ACTIVITY; NERVE ACTIVITY; PLASMA-RENIN; HEMODIALYSIS; NOREPINEPHRINE; HYPERTENSION; MECHANISMS	Background. Hypertension is a frequent complication of chronic renal failure, but its causes are not fully understood. There is indirect evidence that increased activity of the sympathetic nervous system might contribute to hypertension in patients with end-stage renal disease, but sympathetic-nerve discharge has not been measured directly in patients or animals with chronic renal failure. Methods. We recorded the rate of postganglionic sympathetic nerve discharge to the blood vessels in skeletal muscle by means of microelectrodes inserted into the peroneal nerve in 18 patients with native kidneys who were undergoing long-term treatment with hemodialysis (ot whom 14 had hypertension), 5 patients receiving hemodialysis who had undergone bilateral nephrectomy (of whom 1 had hypertension), and 11 normal subjects. Results. The mean (+/-SE) rate of sympathetic-nerve discharge was 2.5 times higher in the patients receiving hemodialysis who had not undergone nephrectomy than in the normal subjects (58+/-3 vs. 23+/-3 bursts per minute, P<0.01). In contrast, the rate of sympathetic-nerve discharge was similar in the patients receiving hemodialysis who had undergone bilateral nephrectomy (21+/-6 bursts per minute) and the normal subjects. The rate of sympathetic-nerve discharge in the patients receiving hemodialysis who had not undergone nephrectomy was also significantly higher (P<0.01) than that in the patients with bilateral nephrectomy, and it was accompanied in the former group by higher values for vascular resistance in the calf (45+/-4 vs. 22+/-4 units, P<0.05) and mean arterial pressure (106+/-4 vs. 76+/-14 mm Hg, P<0.05). The rate of sympathetic-nerve discharge was not correlated with either plasma norepinephrine concentrations or plasma renin activity. Conclusions. Chronic renal failure may be accompanied by reversible sympathetic activation, which appears to be mediated by an afferent signal arising in the failing kidneys.	UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED,DIV CARDIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; CLEVELAND CLIN EDUC FDN, RES INST, CLEVELAND, OH 44106 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation			Toto, Robert/AAQ-3336-2021		FIC NIH HHS [1-F05-TW04494-01] Funding Source: Medline; NHLBI NIH HHS [5-T32-HL07360-13, R0-1 HL44010] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004494] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044010, T32HL007360] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; BRAVO EL, 1975, NEW ENGL J MED, V292, P66, DOI 10.1056/NEJM197501092920203; CAMPESE VM, 1981, KIDNEY INT, V20, P246, DOI 10.1038/ki.1981.127; CORDER CN, 1980, NEPHRON, V25, P267, DOI 10.1159/000181855; CUCHE JL, 1986, KIDNEY INT, V30, P566, DOI 10.1038/ki.1986.222; DELIUS W, 1972, ACTA PHYSIOL SCAND, V84, P82, DOI 10.1111/j.1748-1716.1972.tb05158.x; DIBONA GF, 1982, REV PHYSIOL BIOCH P, V94, P75, DOI 10.1007/BFb0031333; ESPOSTI ED, 1985, CLIN SCI, V69, P51, DOI 10.1042/cs0690051; FABER JE, 1985, CIRC RES, V57, P676, DOI 10.1161/01.RES.57.5.676; FERRARIO CM, 1972, CIRC RES, V30, P257, DOI 10.1161/01.RES.30.3.257; Heidbreder E, 1986, Contrib Nephrol, V50, P14; HENRICH WL, 1977, KIDNEY INT, V12, P279, DOI 10.1038/ki.1977.112; Katholi R E, 1984, J Hypertens, V2, P349; KATHOLI RE, 1982, J CLIN INVEST, V69, P55, DOI 10.1172/JCI110441; LAKE CR, 1979, CARDIOVASC MED, V4, P1099; LAZARUS JM, 1973, CIRCULATION, V47, P1015, DOI 10.1161/01.CIR.47.5.1015; LILLEY JJ, 1976, J CLIN INVEST, V57, P1190, DOI 10.1172/JCI108387; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; MARK AL, 1985, CIRC RES, V57, P461, DOI 10.1161/01.RES.57.3.461; Mark AL., 1983, HDB PHYSL SECTION 2, VVol. 3 Part 2, P795; MCGRATH BP, 1977, KIDNEY INT, V12, P294, DOI 10.1038/ki.1977.114; NIES AS, 1979, J LAB CLIN MED, V94, P395; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; RECORDATI G, 1981, J AUTONOM NERV SYST, V3, P237, DOI 10.1016/0165-1838(81)90066-7; ROSTAND SG, 1991, J AM SOC NEPHROL, V2, P1053; SCHAEFER RM, 1988, AM J NEPHROL, V8, P449, DOI 10.1159/000167652; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; Siggaard-Andersen J, 1970, DANISH MED B      S1, V17, P1; SMOGORZEWSKI M, 1989, KIDNEY INT, V36, P458, DOI 10.1038/ki.1989.217; STEIN RD, 1984, AM J PHYSIOL, V246, pR13, DOI 10.1152/ajpregu.1984.246.1.R13; SUZUKI H, 1983, HYPERTENSION, V5, pI139, DOI 10.1161/01.HYP.5.2_Pt_2.I139; TEXTOR SC, 1981, HYPERTENSION, V3, P294, DOI 10.1161/01.HYP.3.3.294; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; WALLIN BG, 1979, HYPERTENSION, V1, P67, DOI 10.1161/01.HYP.1.2.67; WALLIN BG, 1973, CIRC RES, V33, P9, DOI 10.1161/01.RES.33.1.9; Weidmann P, 1987, Contrib Nephrol, V54, P159; WHITE RP, 1976, T AM SOC ART INT ORG, V22, P420; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122; ZUCCHELLI P, 1988, SEMIN NEPHROL, V8, P163; ZUCCHELLI P, 1992, OXFORD TXB CLIN NEPH, V2, P1458	40	899	1021	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1912	1918		10.1056/NEJM199212313272704	http://dx.doi.org/10.1056/NEJM199212313272704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1454086				2022-12-24	WOS:A1992KE50500004
J	REICHMANN, E; SCHWARZ, H; DEINER, EM; LEITNER, I; EILERS, M; BERGER, J; BUSSLINGER, M; BEUG, H				REICHMANN, E; SCHWARZ, H; DEINER, EM; LEITNER, I; EILERS, M; BERGER, J; BUSSLINGER, M; BEUG, H			ACTIVATION OF AN INDUCIBLE C-FOSER FUSION PROTEIN CAUSES LOSS OF EPITHELIAL POLARITY AND TRIGGERS EPITHELIAL-FIBROBLASTOID CELL CONVERSION	CELL			English	Article							CANINE KIDNEY-CELLS; ADHESION MOLECULE UVOMORULIN; HEPATOCYTE GROWTH-FACTOR; HUMAN ESTROGEN-RECEPTOR; MESENCHYME-LIKE CELLS; TRANSCRIPTIONAL ACTIVATION; CYTOSKELETAL PROTEINS; GENE-EXPRESSION; BINDING-SITE; TRANSFORMATION	As a novel approach to studying the modulation of the polarized epithelial phenotype, we have expressed c-Fos and c-Myc estrogen receptor fusion proteins (c-FosER and c-MycER) in mammary epithelial cells. The hybrid proteins could be activated by estrogen for defined time periods and after the cells had achieved their fully polarized organization. Activation of c-MycER deregulated proliferation but did not affect epithelial polarity. Short-term activation of c-FosER induced the reversible loss of morphological and functional cell polarity. In contrast, long-term stimulation of c-FosER caused the cells to depolarize irreversibly, to invade collagen gels, and to undergo epithelial-fibroblastoid cell conversion. Our data suggest that Fos proteins are important in modulating the epithelial phenotype both in normal tissue development and in invasive processes.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	REICHMANN, E (corresponding author), FORSCHUNGSINST MOLEK PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; ASCH HL, 1985, DEV BIOL, V107, P470, DOI 10.1016/0012-1606(85)90328-8; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1984, CELL, V36, P259; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANKE WW, 1981, EXP CELL RES, V134, P345, DOI 10.1016/0014-4827(81)90435-3; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBURG G, 1986, DEV BIOL, V115, P363, DOI 10.1016/0012-1606(86)90256-3; GREENBURG G, 1988, DEVELOPMENT, V102, P605; GRIFFITHS G, 1993, IN PRESS FINE STRUCT; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KANDJIAN EW, 1986, MOL BIOL REP, V11, P107; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKWALD RR, 1979, DEV BIOL, V69, P634, DOI 10.1016/0012-1606(79)90317-8; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MULLIN JM, 1988, J CELL PHYSIOL, V134, P357, DOI 10.1002/jcp.1041340306; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SANFORD KK, 1961, JNCI-J NATL CANCER I, V26, P1139; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SONNENBERG A, 1986, CANCER RES, V46, P5913; STRANGE R, 1991, CELL GROWTH DIFFER, V2, P549; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRELSTAD RL, 1982, DEV BIOL, V92, P27, DOI 10.1016/0012-1606(82)90147-6; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZUK A, 1989, J CELL BIOL, V108, P903, DOI 10.1083/jcb.108.3.903; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	69	234	244	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1103	1116		10.1016/S0092-8674(05)80060-1	http://dx.doi.org/10.1016/S0092-8674(05)80060-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473147				2022-12-24	WOS:A1992KE60400006
J	DEVANE, WA; HANUS, L; BREUER, A; PERTWEE, RG; STEVENSON, LA; GRIFFIN, G; GIBSON, D; MANDELBAUM, A; ETINGER, A; MECHOULAM, R				DEVANE, WA; HANUS, L; BREUER, A; PERTWEE, RG; STEVENSON, LA; GRIFFIN, G; GIBSON, D; MANDELBAUM, A; ETINGER, A; MECHOULAM, R			ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR	SCIENCE			English	Article							RAT-BRAIN; LOCALIZATION	Arachidonylethanolamide, an arachidonic acid derivative in porcine brain, was identified in a screen for endogenous ligands for the cannabinoid receptor. The structure of this compound, which has been named "anandamide," was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and was confirmed by synthesis. Anandamide inhibited the specific binding of a radiolabeled cannabinoid probe to synaptosomal membranes in a manner typical of competitive ligands and produced a concentration-dependent inhibition of the electrically evoked twitch response of the mouse vas deferens, a characteristic effect of psychotropic cannabinoids. These properties suggest that anandamide may function as a natural ligand for the cannabinoid receptor.	HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,IL-91120 JERUSALEM,ISRAEL; UNIV ABERDEEN MARISCHAL COLL,DEPT BIOMED SCI,ABERDEEN AB9 1AS,SCOTLAND; TECHNION ISRAEL INST TECHNOL,DEPT CHEM,IL-32000 HAIFA,ISRAEL	Hebrew University of Jerusalem; University of Aberdeen; Technion Israel Institute of Technology			Pertwee, Roger Guy/E-1312-2011	Pertwee, Roger/0000-0003-3227-2783	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006481] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 6481] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission)		BACHUR NR, 1965, J BIOL CHEM, V240, P1019; BURSTEIN S, 1992, MARIJUANA CANNABINOI, P73; CHRISTIE WW, 1982, LIPID ANAL, P81; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1989, THESIS ST LOUIS U ST; DEVANE WA, 1991, 5TH P NORD NEUR M, P198; DEVANE WA, UNPUB; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FAIRBAIRN JW, 1981, BRIT J PHARMACOL, V72, P401, DOI 10.1111/j.1476-5381.1981.tb10990.x; FROST DJ, 1971, ANAL CHEM, V43, P1316, DOI 10.1021/ac60304a048; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Howlett A., 1992, MARIJUANA CANNABINOI, P35; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MECHOULAM R, 1992, MARIJUANA CANNABINOI, P1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; PERTWEE RG, 1988, PHARMACOL THERAPEUT, V36, P189, DOI 10.1016/0163-7258(88)90106-4; PERTWEE RG, 1992, MARIJUANA CANNABINOI, P165; SKLENOVSKY A, 1989, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V122, P83; SWEELEY CC, 1969, METHOD ENZYMOL, V14, P254; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z; Wenker H, 1935, J AM CHEM SOC, V57, P1079, DOI 10.1021/ja01309a034	29	4305	4475	5	289	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1946	1949		10.1126/science.1470919	http://dx.doi.org/10.1126/science.1470919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470919				2022-12-24	WOS:A1992KD08800035
J	STEMPLE, DL; ANDERSON, DJ				STEMPLE, DL; ANDERSON, DJ			ISOLATION OF A STEM-CELL FOR NEURONS AND GLIA FROM THE MAMMALIAN NEURAL CREST	CELL			English	Article							NERVE GROWTH-FACTOR; INTERMEDIATE FILAMENT PROTEIN; FORMING SCHWANN-CELLS; NGF-RECEPTOR; SYMPATHETIC NEURONS; PROGENITOR-CELL; CLONAL ANALYSIS; MOUSE EMBRYO; AVIAN EMBRYO; DORSAL-ROOT	We have isolated mammalian neural crest cells using a monoclonal antibody to the low affinity NGF receptor, and established conditions for the serial propagation of these cells in clonal culture to assess their developmental potential. This analysis indicates that, first, single mammalian neural crest cells are multipotent, able to generate at least neurons and Schwann cells like their avian counterparts. Second, multipotent neural crest cells generate multipotent progeny, indicating that they are capable of self-renewal and therefore are stem cells. Third, multipotent neural crest cells also generate some clonal progeny that form only neurons or glia, suggesting the production of committed neuroblasts and glioblasts. Manipulation of the substrate alters the fate of the multipotent cells. These findings have implications for models of neural crest development in vivo, and establish a system for studying the generation of cellular diversity by a multipotent stem cell in vitro.			STEMPLE, DL (corresponding author), CALTECH,HOWARD HUGHES MED INST,DIV BIOL 216-76,PASADENA,CA 91125, USA.		Pillay, Nischalan/F-9536-2012	Stemple, Derek/0000-0002-8296-9928				ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BERND P, 1986, DEV BIOL, V115, P415, DOI 10.1016/0012-1606(86)90261-7; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHEN AM, 1975, DEV BIOL, V46, P262, DOI 10.1016/0012-1606(75)90104-9; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; FRIEDMAN B, 1990, J COMP NEUROL, V295, P43, DOI 10.1002/cne.902950105; HALL PA, 1989, DEVELOPMENT, V106, P619; Hawrot E, 1979, Methods Enzymol, V58, P574; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUSZAR D, 1991, DEVELOPMENT, V112, P131; JESSEN KR, 1990, DEVELOPMENT, V109, P91; JESSEN KR, 1987, J NEUROSCI, V7, P3362; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEMKE G, 1988, DEVELOPMENT, V102, P499; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LORING J, 1982, DEV BIOL, V90, P165, DOI 10.1016/0012-1606(82)90222-6; MAXWELL GD, 1987, DEVELOPMENT, V101, P767; MAXWELL GD, 1990, DEV BIOL, V141, P233, DOI 10.1016/0012-1606(90)90118-3; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MIRSKY R, 1990, DEVELOPMENT, V109, P105; MIRSKY R, 1982, NEUROIMMUNOLOGY, P141; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; NEWGREEN D, 1980, CELL TISSUE RES, V211, P269; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROGERS SL, 1990, DEV BIOL, V141, P173, DOI 10.1016/0012-1606(90)90112-V; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SIEBERBLUM M, 1985, EXP CELL RES, V158, P267, DOI 10.1016/0014-4827(85)90450-1; SMITHTHOMAS LC, 1989, DEVELOPMENT, V105, P251; STEMPLE DL, 1991, NEUROSCI LETT, V124, P57, DOI 10.1016/0304-3940(91)90821-A; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TRAPP BD, 1981, J CELL BIOL, V90, P1, DOI 10.1083/jcb.90.1.1; TRAPP BD, 1979, P NATL ACAD SCI USA, V76, P3552, DOI 10.1073/pnas.76.7.3552; WOLINSKY EJ, 1985, J NEUROSCI, V5, P1497; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387	61	673	804	1	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					973	985		10.1016/0092-8674(92)90393-Q	http://dx.doi.org/10.1016/0092-8674(92)90393-Q			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458542				2022-12-24	WOS:A1992KB99000010
J	GILLIS, CR; HOLE, DJ; LAMONT, DW; GRAHAM, AC; RAMAGE, S				GILLIS, CR; HOLE, DJ; LAMONT, DW; GRAHAM, AC; RAMAGE, S			THE INCIDENCES OF LUNG-CANCER AND BREAST-CANCER IN WOMEN IN GLASGOW	BRITISH MEDICAL JOURNAL			English	Article											GILLIS, CR (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND.							DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P38, DOI 10.1136/jech.42.1.38; SCHOTTENFELD D, 1982, CANCER EPIDEMIOLOGY; [No title captured]	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1331	1331		10.1136/bmj.305.6865.1331	http://dx.doi.org/10.1136/bmj.305.6865.1331			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483078	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992KA77300023
J	GHALI, JK; LIAO, YL; SIMMONS, B; CASTANER, A; CAO, GC; COOPER, RS				GHALI, JK; LIAO, YL; SIMMONS, B; CASTANER, A; CAO, GC; COOPER, RS			THE PROGNOSTIC ROLE OF LEFT-VENTRICULAR HYPERTROPHY IN PATIENTS WITH OR WITHOUT CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; VENTRICULAR FUNCTION, LEFT; HEART ENLARGEMENT; HYPERTENSION; ECHOCARDIOGRAPHY	HEART-DISEASE; ECHOCARDIOGRAPHIC ASSESSMENT; ESSENTIAL-HYPERTENSION; RISK-FACTORS; MASS; INFARCTION; MORTALITY; EVENTS; DEATH; SIZE	Objective: To examine the association between echocardiographically determined left ventricular hypertrophy and mortality in patients with and without coronary artery disease. Design: Cohort study with a mean follow-up period of 4 years. Setting: An inner-city public hospital in Chicago. Patients: A cohort of 785 patients, most of whom were black and had hypertension. Interventions: Coronary arteriography for presumed coronary artery disease and echocardiography. Main Outcome Measure: All-cause and cardiac mortality. Results: Left ventricular hypertrophy, based on left ventricular mass corrected for body surface area, was present in 194 of 381 patients (51%) with coronary artery disease and in 162 of 404 patients (40%) without coronary artery disease. Patients with left ventricular hypertrophy had worse survival than those without hypertrophy in both the group with coronary artery disease and the group without coronary artery disease. After adjustment was made for age at baseline, sex, and hypertension, the relative risk for death from any cause in patients with hypertrophy compared with patients without hypertrophy was 2.14 (95% Cl, 1.24 to 3.68) among those with coronary artery disease and 4.14 (Cl, 1.77 to 9.71) among those without coronary artery disease. Conclusions: Echocardiographically determined left ventricular hypertrophy is an important prognostic marker in patients with or without coronary artery disease. The effect of reversing ventricular hypertrophy in patients with and without coronary disease deserves further study.	LOYOLA UNIV, STRITCH SCH MED, DEPT PREVENT MED & EPIDEMIOL, MAYWOOD, IL 60153 USA; COOK CTY HOSP, CHICAGO, IL 60612 USA	Loyola University Chicago; John H Stroger Junior Hospital Cook County					NHLBI NIH HHS [R01HL 36723] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONOW WS, 1991, AM J CARDIOL, V67, P295, DOI 10.1016/0002-9149(91)90562-Y; BORHANI NO, 1987, AM J CARDIOL, V60, pI13; BORHANI NO, 1986, PROG CARDIOVASC DIS, V29, P55, DOI 10.1016/0033-0620(86)90034-4; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1987, HEART HYPERTENSION, P197; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; FROHLICH ED, 1988, J HYPERTENS, V6, pS2, DOI 10.1097/00004872-198812040-00002; FROHLICH ED, 1987, AM J CARDIOL, V59, pA91, DOI 10.1016/0002-9149(87)90183-4; GHALI JK, 1991, J AM COLL CARDIOL, V17, P1277, DOI 10.1016/S0735-1097(10)80135-4; Kannel W B, 1978, Ann N Y Acad Sci, V304, P128, DOI 10.1111/j.1749-6632.1978.tb25585.x; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KOYANAGI S, 1982, CIRCULATION, V65, P1192, DOI 10.1161/01.CIR.65.6.1192; KOYANAGI S, 1982, CIRC RES, V50, P55, DOI 10.1161/01.RES.50.1.55; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; Marcus ML, 1983, CORONARY CIRCULATION, P285; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MOSER M, 1991, EUR HEART J, V12, P1034, DOI 10.1093/eurheartj/12.9.1034; PATTERSON JE, 1985, 1299286 DEP TREAS IN, P245; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHAIBLE TF, 1986, J APPL PHYSIOL, V60, P1435, DOI 10.1152/jappl.1986.60.4.1435; TROY BL, 1972, CIRCULATION, V45, P602, DOI 10.1161/01.CIR.45.3.602; WEBER KT, 1988, J APPL CARDIOL, V3, P37; ZEHENDER M, 1992, CIRCULATION, V85, P1808, DOI 10.1161/01.CIR.85.5.1808	34	384	388	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					831	836		10.7326/0003-4819-117-10-831	http://dx.doi.org/10.7326/0003-4819-117-10-831			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416558				2022-12-24	WOS:A1992JX83800006
J	WEYAND, CM; HICOK, KC; CONN, DL; GORONZY, JJ				WEYAND, CM; HICOK, KC; CONN, DL; GORONZY, JJ			THE INFLUENCE OF HLA-DRB1 GENES ON DISEASE SEVERITY IN RHEUMATOID-ARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; HLA-DR1 ANTIGEN; RHEUMATOID NODULE; VASCULITIS	SHARED EPITOPE HYPOTHESIS; ASSOCIATION; THERAPY; SUSCEPTIBILITY; SPECIFICITIES	Objective: To explore the role of HLA-DRB1 genes in determining disease severity in rheumatoid arthritis. Design: Case series of patients with seropositive rheumatoid arthritis. Setting: The outpatient clinic of the Division of Rheumatology, Mayo Clinic. Patients: One hundred and two patients with seropositive, erosive rheumatoid arthritis and a minimum disease duration of 3 years. Measurements: Patients were genotyped for both HLA-DRB1 alleles and were categorized according to the expression of one or two disease-linked HLA-DRB1 alleles. Identification of HLA-DRB1 alleles was done by the polymerase chain reaction and subsequent oligonucleotide hybridization. Homozygosity for allelic variants was confirmed by sequence analysis. Immunogenetically defined patient subgroups were retrospectively evaluated for joint destruction and patterns of disease manifestation, including rheumatoid organ disease. Results: Of 102 patients, 98 (96%) expressed the disease-linked sequence polymorphism. Forty-seven patients (46%) carried a double dose of the relevant sequence stretch: Twenty-eight patients expressed HLA-DRB1*04 variants on both alleles, and 19 combined an HLA-DRB*04 variant with HLA-DRB1*0101 or DRB1*1402. Nodular disease was present in 100% of patients typed as HLA-DRB1*04/04 and in 59% of patients typed as HLA-DRB1 *04 and who had inherited only a single dose of the disease-linked sequence polymorphism (P < 0.0001). Major organ systems were involved in 61% and 11% of these two patient groups, respectively (P < 0.0001); and joint surgery was required in 61% and 25% (P < 0.002), respectively. Patients typed as HLA-DR*04/01 had intermediate clinical courses. Conclusion: Genotyping patients with rheumatoid arthritis for both HLA-DRB1 alleles identifies clinical subsets with distinct profiles of disease manifestations.			WEYAND, CM (corresponding author), MAYO CLIN & MAYO FDN, 401 GUGGENHEIM, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FUCHS HA, 1989, J RHEUMATOL, V16, P585; GORONZY J, 1986, J CLIN INVEST, V77, P1042, DOI 10.1172/JCI112358; GORONZY JJ, 1992, J IMMUNOL, V148, P604; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; JOHNSON K, 1990, J RHEUMATOL, V17, P34; KLIPPEL JH, 1990, J RHEUMATOL, V17, P1118; KUSHNER I, 1989, J RHEUMATOL, V16, P1; MARSH SGE, 1991, IMMUNOGENETICS, V33, P321, DOI 10.1007/BF00216691; Masi A T, 1976, Semin Arthritis Rheum, V4, P299; MCCARTY DJ, 1990, J RHEUMATOL, V17, P1115; NEPOM GT, 1987, J CLIN IMMUNOL, V7, P1, DOI 10.1007/BF00915418; NEPOM GT, 1986, LANCET, V2, P1002; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1986, J RHEUMATOL, V13, P841; SCHIFF B, 1982, ANN RHEUM DIS, V41, P403, DOI 10.1136/ard.41.4.403; SCOTT DL, 1987, LANCET, V1, P1108; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; VOLLERTSEN RS, 1990, RHEUM DIS CLIN N AM, V16, P445; WALKER DJ, 1985, ANN RHEUM DIS, V44, P519, DOI 10.1136/ard.44.8.519; WESTEDT ML, 1986, ANN RHEUM DIS, V45, P534, DOI 10.1136/ard.45.7.534; WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814; WEYAND CM, 1991, J IMMUNOL, V147, P70; WEYAND CM, 1989, IMMUNOBIOLOGY HLA IM, V2, P422; WILLKENS RF, 1991, ARTHRITIS RHEUM, V34, P43, DOI 10.1002/art.1780340107; WILSKE KR, 1990, J RHEUMATOL, V17, P4; YOUNG A, 1984, ARTHRITIS RHEUM, V27, P20, DOI 10.1002/art.1780270104	33	421	435	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					801	806		10.7326/0003-4819-117-10-801	http://dx.doi.org/10.7326/0003-4819-117-10-801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416553				2022-12-24	WOS:A1992JX83800001
J	UDVARHELYI, IS; GATSONIS, C; EPSTEIN, AM; PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ				UDVARHELYI, IS; GATSONIS, C; EPSTEIN, AM; PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ			ACUTE MYOCARDIAL-INFARCTION IN THE MEDICARE POPULATION - PROCESS OF CARE AND CLINICAL OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; PROGNOSIS; WOMEN; MEN; MANAGEMENT; MORTALITY; MORBIDITY; SURVIVAL; TRIALS	Objective.-To describe the process of care and clinical outcomes associated with acute myocardial infarction (AMI) in the Medicare population, and to examine differences in process of care and outcome of care as a function of patient age, gender, and race. Design.-Retrospective cohort study using a longitudinal database created from Medicare utilization and administrative files. Patient Populations.-A cohort of AMI patients covered by Medicare in 1987 and a random sample of Medicare patients without AMI. Main Process and Outcome Measurements.-(1) The use of coronary angiography, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty during the first 90 days after a new AMI; (2) mortality at 30 days, 1 year, and 2 years; (3) reinfarction rates; and (4) reoperation rates for coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Main Results.-Mortality rates were high: 26% at 30 days, 40% at 1 year, and 47% at 2 years. They varied greatly by age, less so by gender and race, and were high even among patients who survived the first 30 days. Compared with mortality, reinfarction was uncommon, occurring in 7.3% of patients. During the first 90 days, 23% of all patients underwent angiography and 13% underwent coronary revascularization (coronary artery bypass graft surgery, 8%; percutaneous transluminal coronary angioplasty, 5%). The use of all three procedures decreased with age and was less common among women and blacks than among men and whites. Differential use by age and race was greater for angiography than for revascularization procedures. Conclusions.-The prognosis following AMI in patients aged 65 years and above is much worse than is commonly realized. Procedure use in these patients varies as a function of gender and race, even though mortality does not. Further research is needed to reduce the mortality of elderly patients with AMI and to understand the significance of differences in procedure use on the basis of sociodemographic characteristics.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University			Newhouse, Joseph/AGJ-5632-2022		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1989, NEW ENGL J MED, V321, P1443, DOI 10.1056/NEJM198911233212105; ANTMANEM, 1992, JAMA-J AM MED ASSOC, V268, P240; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BRAUNWALD E, 1988, HEART DISEASE TXB CA; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER LD, 1985, CIRCULATION, V72, P110; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GRAVES EJ, 1990, PUBLICATION NATIONAL, V185; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HURST JW, 1989, HEART ARTERIES VEINS; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEW EA, 1990, MED RISKS TRENDS MOR, pCH5; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YUSUF S, 1990, CIRCULATION, V82, P117; 1989, INT CLASSIFICATION D	26	210	213	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2530	2536		10.1001/jama.268.18.2530	http://dx.doi.org/10.1001/jama.268.18.2530			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404820				2022-12-24	WOS:A1992JW61600024
J	LLOYD, BW; ALI, MH				LLOYD, BW; ALI, MH			HOW USEFUL DO PARENTS FIND HOME PEAK FLOW MONITORING FOR CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,COMMUNITY CHILD HLTH,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	LLOYD, BW (corresponding author), N MIDDLESEX HOSP,NATL HLTH SERV TRUST,LONDON N18 1QX,ENGLAND.							[Anonymous], 1990, BMJ, V301, P797; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; 1990, BRIT MED J, V301, P651	3	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1128	1129		10.1136/bmj.305.6862.1128	http://dx.doi.org/10.1136/bmj.305.6862.1128			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463948	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JX84100022
J	WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM				WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM			RATES OF AVOIDABLE HOSPITALIZATION BY INSURANCE STATUS IN MASSACHUSETTS AND MARYLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CASE-MIX; HEALTH; MORTALITY; QUALITY; AREA; INTERVENTION; SERVICES; DISTRICT; PAYMENT	Objective.-To determine whether uninsured and Medicaid patients have higher rates of avoidable hospitalizations than do insured patients. Design.-We used 1987 computerized hospital discharge data to select a cross-sectional sample of hospitalized patients. Population estimates from the Current Population Survey were used to estimate rates of admission, standardized for age and sex. Setting.-Nonfederal acute care hospitals in Massachusetts and Maryland. Patients.-All patients under 65 years of age who were uninsured, privately insured, or insured by Medicaid. Hospitalizations for obstetric and psychiatric conditions were excluded. Main Outcome Measures.-Relative risk of admission for 12 avoidable hospital conditions (AHCs) identified by a physician panel. Results.-Uninsured and Medicaid patients were more likely than insured patients to be hospitalized for AHCs. Rates for uninsured patients were significantly greater than for privately insured patients in Massachusetts for 10 of 12 individual AHCs, and in Maryland for five of 12 AHCs. After adjustment for baseline utilization, the results were statistically significant for 10 of 12 AHCs in Massachusetts and seven of 12 AHCs in Maryland. For Medicaid patients, rates were significantly greater than for privately insured patients for all AHCs in each state before adjustment, and for nine of 12 and seven of 12 AHCs in each state, respectively, after adjustment for baseline utilization. Conclusion.-Our findings suggest that patients who are uninsured or who have Medicaid coverage have higher rates of hospitalization for conditions that can often be treated out of hospital or avoided altogether. Our approach is potentially useful for routine monitoring of access and quality of care for selected groups of patients.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					AHRQ HHS [R01 HS06235] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Brown E R, 1989, Med Care Rev, V46, P349, DOI 10.1177/107755878904600402; BUCK C, 1986, INT J HEALTH SERV, V16, P553, DOI 10.2190/QWWN-518N-5VFC-6272; CARR W, 1988, SERIES UNITED HOSPIT, V8, P5; CHARLTON JRH, 1983, LANCET, V1, P691; CHRISTOFFERSSON J, 1986, DRG MONITOR, V6, P1; Craddick J W, 1979, QRB Qual Rev Bull, V5, P2; DIEHR P, 1990, HEALTH SERV RES, V24, P741; GARFINKEL S, 1986, 20213 DEP HLTH HUM B; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Howell E M, 1991, Health Care Financ Rev, V12, P1; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARTINI CJM, 1977, INT J HEALTH SERV, V7, P293, DOI 10.2190/XFYT-R576-0R6C-RJ4M; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; NEWHOUSE JP, 1991, HLTH SERVICES RES KE, P161; PERLOFF JD, 1987, J HEALTH POLIT POLIC, V12, P221, DOI 10.1215/03616878-12-2-221; Roos N P, 1988, Health Care Financ Rev, V9, P53; RUNDALL T, 1991, 119TH ANN M AM PUBL; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; RUTSTEIN DD, 1977, NEW ENGL J MED, V297, P508; SCHWARTZ E, 1990, INT J EPIDEMIOL, V19, P591, DOI 10.1093/ije/19.3.591; SOLBERG LI, 1990, INQUIRY-J HEALTH CAR, V27, P359; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLHANDLER S, 1985, INT J HEALTH SERV, V15, P1, DOI 10.2190/90P3-LEFF-WNU0-GLY6; YERGAN J, 1988, MED CARE, V26, P1111, DOI 10.1097/00005650-198811000-00009; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1989, INT CLASSIFICATION D; 1987, SPECIAL REPORT ACCES, P2; 1989, CURRENT POPULATION S	37	515	519	1	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2388	2394		10.1001/jama.268.17.2388	http://dx.doi.org/10.1001/jama.268.17.2388			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404795				2022-12-24	WOS:A1992JV69400024
J	SCHELLENBERG, GD; BIRD, TD; WIJSMAN, EM; ORR, HT; ANDERSON, L; NEMENS, E; WHITE, JA; BONNYCASTLE, L; WEBER, JL; ALONSO, ME; POTTER, H; HESTON, LL; MARTIN, GM				SCHELLENBERG, GD; BIRD, TD; WIJSMAN, EM; ORR, HT; ANDERSON, L; NEMENS, E; WHITE, JA; BONNYCASTLE, L; WEBER, JL; ALONSO, ME; POTTER, H; HESTON, LL; MARTIN, GM			GENETIC-LINKAGE EVIDENCE FOR A FAMILIAL ALZHEIMERS-DISEASE LOCUS ON CHROMOSOME-14	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; C-FOS; MAMMALIAN BRAIN; MUTATION; MARKERS; HETEROGENEITY; KINDREDS; SEQUENCE; DEMENTIA; INDICATE	Linkage analysis was used to search the genome for chromosomal regions harboring familial Alzheimer's disease genes. Markers on chromosome 14 gave highly significant positive lod scores in early-onset non-Volga German kindreds; a Z(max) of 9.15 (theta = 0.01) was obtained with the marker D14S43 at 14q24.3. One early-onset family yielded a lod score of 4.89 (theta = 0.0). When no assumptions were made about age-dependent penetrance, significant results were still obtained (Z(max) = 5.94, theta = 0.0), despite the loss of power to detect linkage under these conditions. Results for the Volga German families were either negative or nonsignificant for markers in this region. Thus, evidence indicates a familial Alzheimer's disease locus on chromosome 14.	VET AFFAIRS MED CTR, DIV NEUROL, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, DIV MED GENET, SEATTLE, WA 98195 USA; MARSHFIELD MED RES FDN, MARSHFIELD, WI 54449 USA; NATL INST NEUROL & NEUROSURG, MEXICO CITY, MEXICO; WASHINGTON INST MENTAL ILLNESS RES & TRAINING, DEPT PSYCHIAT, STEILACOOM, WA 98494 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA; UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	SCHELLENBERG, GD (corresponding author), UNIV WASHINGTON, DEPT MED, DIV NEUROL, SEATTLE, WA 98195 USA.			Orr, Harry/0000-0001-6118-741X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008017] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00248] Funding Source: Medline; NIA NIH HHS [AG08017] Funding Source: Medline; NIMH NIH HHS [R01MH43240] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGEM ALM, NEUROBIOL AGING, V13, pS66; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BREITNER JCS, NEUROBIOL AGING, V13, pS66; BROWN IR, 1990, J NEUROSCI RES, V27, P247, DOI 10.1002/jnr.490270302; CHARTIERHARLIN MC, 1991, NEUROSCI LETT, V129, P134, DOI 10.1016/0304-3940(91)90738-F; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COX DW, 1985, NATURE, V316, P79, DOI 10.1038/316079a0; CRAWFORD F, 1991, NEUROSCI LETT, V133, P1, DOI 10.1016/0304-3940(91)90042-R; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOUDSMIT J, 1981, J NEUROL SCI, V49, P79, DOI 10.1016/0022-510X(81)90190-8; HESTON LL, 1991, AM J MED GENET, V40, P449, DOI 10.1002/ajmg.1320400415; HODGE SE, 1983, AM J HUM GENET, V35, P1139; JORDAN SA, 1959, NUCLEIC ACIDS RES, V19, P1722; KAMINO K, 1992, AM J HUM GENET, V51, P998; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MOHS RC, 1987, ARCH GEN PSYCHIAT, V44, P405; MORTON NE, 1956, AM J HUM GENET, V8, P80; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NEE LE, 1987, NEUROLOGY, V37, P359, DOI 10.1212/WNL.37.3.359; NUKIWA T, 1988, AM J HUM GENET, V43, P322; NUKIWA T, 1986, J BIOL CHEM, V261, P5989; Ott J., 1991, ANAL HUMAN GENETIC L; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; RAPOPORT SI, 1991, NEUROLOGY, V41, P1549, DOI 10.1212/WNL.41.10.1549; RISCH N, 1991, AM J HUM GENET, V48, P1058; RUPPERT C, 1987, MOL BRAIN RES, V2, P51, DOI 10.1016/0169-328X(87)90020-9; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SCHELLENBERG G, 1992, Neurobiology of Aging, V13, pS67; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1722, DOI 10.1093/nar/19.7.1722; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH CAB, 1961, 2ND P INT C HUM GEN, V1, P212; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1991, J BIOL CHEM, V266, P20579; TANZI RE, 1992, AM J HUM GENET, V51, P273; VALENCIA LG, 1986, REV INVEST CLIN, V38, P261; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; VANDUIJN CM, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91611-W; WANG ZY, 1992, GENOMICS, V13, P532, DOI 10.1016/0888-7543(92)90121-8; WEITKAMP LR, 1983, AM J HUM GENET, V35, P443; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZHANG P, 1992, NEUROSCIENCE, V46, P9, DOI 10.1016/0306-4522(92)90004-L	55	819	847	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					668	671		10.1126/science.1411576	http://dx.doi.org/10.1126/science.1411576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411576				2022-12-24	WOS:A1992JU74500063
J	FUJIMURA, T; RIBAS, JC; MAKHOV, AM; WICKNER, RB				FUJIMURA, T; RIBAS, JC; MAKHOV, AM; WICKNER, RB			POL OF GAG-POL FUSION PROTEIN REQUIRED FOR ENCAPSIDATION OF VIRAL-RNA OF YEAST L-A-VIRUS	NATURE			English	Article							HEPATITIS-B VIRUS; SACCHAROMYCES-CEREVISIAE; GENOMIC RNA; INVITRO; REPLICATION; POLYMERASE; TRANSCRIPTION; MATURATION; PARTICLES	DOUBLE-STRANDED RNA viruses have an RNA-dependent RNA polymerase activity associated with the viral particles which is indispensable for their replication cycle. Using the yeast L-A double-stranded RNA virus we have investigated the mechanism by which the virus encapsidates its genomic RNA and RNA polymerase. The L-A gag gene encodes the principal viral coat protein and the overlapping pol gene is expressed as a gag-pol fusion protein which is formed by a -1 ribosomal frameshift1-3. Here we show that Gag alone is sufficient for virus particle formation, but that it fails to package the viral single-stranded RNA genome. Encapsidation of the viral RNA requires only a part of the Pol region (the N-terminal quarter), which is presumably distinct from the RNA polymerase domain. Given that the Pol region has single-stranded RNA-binding activity, these results are consistent with our LA virus encapsidation model1: the Pol region of the fusion protein binds specifically to the viral genome (+) strand, and the N-terminal gag-encoded region primes polymerization of Gag to form the capsid, thus ensuring the packaging of both the viral genome and the RNA polymerase.	NIDDKD,BIOCHEM PHARMACOL LAB,GENET SIMPLE EUKARYOTES SECT,BETHESDA,MD 20892; NIAMSD,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	FUJIMURA, T (corresponding author), UNIV SALAMANCA,CSIC,DEPT MICROBIOL & GENET,INST MICROBIOL BIOQUIM,E-37071 SALAMANCA,SPAIN.		Ribas, Juan C/C-9864-2015; Fujimura, Tsutomu/K-5807-2014	Ribas, Juan C/0000-0001-6430-0895; Fujimura, Tsutomu/0000-0002-9457-6769				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COFFIN J M, 1991, P645; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; FUJIMURA T, 1992, J BIOL CHEM, V267, P2708; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1986, P NATL ACAD SCI USA, V83, P4433, DOI 10.1073/pnas.83.12.4433; FUJIMURA T, 1987, MOL CELL BIOL, V7, P420, DOI 10.1128/MCB.7.1.420; HERRING AJ, 1977, NATURE, V268, P464, DOI 10.1038/268464a0; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HOPPER JE, 1977, J BIOL CHEM, V252, P9010; ICHO T, 1989, J BIOL CHEM, V264, P6716; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; WELSH JD, 1980, NUCLEIC ACIDS RES, V8, P2365, DOI 10.1093/nar/8.11.2365; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1980, CELL, V21, P217, DOI 10.1016/0092-8674(80)90129-4; WICKNER RB, 1991, MOL BIOL YEAST SACCH, V1, P263	25	71	72	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					746	749		10.1038/359746a0	http://dx.doi.org/10.1038/359746a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436038				2022-12-24	WOS:A1992JU65000062
J	LEE, IM; PAFFENBARGER, RS				LEE, IM; PAFFENBARGER, RS			CHANGE IN BODY-WEIGHT AND LONGEVITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; CORONARY-DISEASE; RELATIVE WEIGHT; COLLEGE ALUMNI; MORTALITY; FRAMINGHAM; HEALTH; MEN	Objective.-To investigate the effect of body weight change on longevity. Design.-Cohort analytic study, following men from 1977 through 1988. Setting.-The study was conducted among Harvard University alumni with mean age of 58 years. Patients.-Alumni, free of cardiovascular disease and cancer, completed questionnaires on weight, height, cigarette habit, and physical activities in 1962 or 1966 and in 1977 (n=11 703). We assessed weight change between questionnaires, based on self-reported weights. Main Outcome Measure.-Mortality from all causes (n=1441), coronary heart disease (n=345), and cancer (n=459), determined from death certificates. Results.-Lowest all-cause mortality was among alumni maintaining stable weight (+/-1 kg). With this category as referent (relative risk=1.00), relative risks of death associated with losing more than 5 kg, losing between 1 and 5 kg, (more than 1 kg and up to 5 kg) gaining between 1 and 5 kg (more than 1 kg and up to 5 kg), and gaining more than 5 kg were 1.57 (95% confidence interval, 1.34 to 1.84), 1.26 (1.10 to 1.46), 1.06 (0.90 to 1.24), and 1.36 (1.11 to 1.66), respectively. For coronary heart disease mortality, relative risks were 1.75 (1.26 to 2.43), 1.43 (1.05 to 1.93), 1.28 (0.91 to 1.80), and 2.01 (1.36 to 2.97), respectively. Weight change did not predict cancer mortality. Findings were not explained by cigarette habit, physical activity, or body mass index. We observed similar trends for follow-up between 1977 and 1982 and between 1983 and 1988. Those losing or gaining more weight also reported greater total lifetime weight loss, which may indicate weight cycling. Conclusions.-Both body weight loss and weight gain are associated with significantly increased mortality from all causes and from coronary heart disease but not from cancer.	STANFORD UNIV, MED CTR, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09001] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; [Anonymous], 1990, NUTR EPIDEMIOLGY; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; AVONS P, 1983, LANCET, V1, P1104; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; BOUCHARD C, 1991, NEW ENGL J MED, V324, P1887, DOI 10.1056/NEJM199106273242609; COX DR, 1972, J R STAT SOC B, V34, P187; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HEYDEN S, 1971, ARCH INTERN MED, V128, P956, DOI 10.1001/archinte.128.6.956; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEE IM, 1992, AM J EPIDEMIOL, V135, P169, DOI 10.1093/oxfordjournals.aje.a116269; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PHINNEY SD, 1991, AM J CLIN NUTR, V53, P1404, DOI 10.1093/ajcn/53.6.1404; RHOADS GG, 1983, LANCET, V1, P492; RODIN J, 1990, INT J OBESITY, V14, P303; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; SNEDECOR GW, 1980, STATISTICAL METHODS, P215; SONNICHSEN AC, 1990, INT J OBESITY, V14, P487; STEVENS J, 1990, INT J OBESITY, V14, P385; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; WANNAMETHEE G, 1990, POSTGRAD MED J, V66, P910, DOI 10.1136/pgmj.66.781.910; [No title captured]; 1983, VITAL HLTH STAT 11, V230; 1960, STAT B METROP INSUR, V41, P1; 1987, VITAL HLTH STAT 11, V238	39	215	219	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2045	2049		10.1001/jama.268.15.2045	http://dx.doi.org/10.1001/jama.268.15.2045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404740				2022-12-24	WOS:A1992JT52000027
J	SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; YUDKIN, P; ROE, L				SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; YUDKIN, P; ROE, L			LIFE-STYLE ADVICE IN GENERAL-PRACTICE - RATES RECALLED BY PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY CARE; HEALTH PROMOTION; CONTROLLED TRIAL; PRACTITIONERS; PREVENTION; SMOKING; VIEWS; AUDIT	Objective-To document how often patients with varying cardiovascular risk levels reported receiving lifestyle advice from general practice. Design-Cross sectional descriptive survey by postal questionnaire. Setting-5 general practices in Bedfordshire. Subjects-4941 people aged 35-64 years who had consulted a general practitioner at least once during the 12 months before completing the questionnaire and who subsequently attended for a health check as part of the OXCHECK trial. Main outcome measures-Report of having received advice from a general practitioner or practice nurse about smoking, alcohol consumption, exercise, or diet during the 12 months before completing the questionnaire. Cardiovascular risk assessed by a nurse during structured health check. Results-The overall reported rate of advice was 27% for smoking, 4.5% for exercise, 12% for diet, and 3% for alcohol consumption. Those with unhealthy behaviour profile or at increased cardiovascular risk received more advice-for example, 47% of smokers with a history of cardiovascular disease received advice on smoking. Among those at increased risk, men were more likely than women to receive advice about exercise (11% v 4%, p = 0.04) and alcohol consumption (10% v 4%, p = 0.007), while women received more advice about weight (17% v 23%, p < 0.001). The rate of receiving advice was unaffected by age, marital status, or social class. Conclusion-The low rate of lifestyle advice reported by patients implies that more preventive advice could be provided in primary care.	RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	SILAGY, C (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				[Anonymous], 1980, CLASSIFICATION OCCUP; ARMITAGE P, 1987, STATISTICAL METHODS, P372; CATFORD JC, 1984, BRIT MED J, V288, P832, DOI 10.1136/bmj.288.6420.832; COULTER A, 1987, J ROY COLL GEN PRACT, V37, P533; COULTER A, 1991, BRIT J GEN PRACT, V41, P140; DICKINSON JA, 1989, MED J AUSTRALIA, V150, P420, DOI 10.5694/j.1326-5377.1989.tb136560.x; Fleming D M, 1981, J R Coll Gen Pract, V31, P615; FLEMING DM, 1983, BRIT MED J, V287, P1852, DOI 10.1136/bmj.287.6408.1852; FORD AS, 1983, SOC SCI MED, V17, P1505, DOI 10.1016/0277-9536(83)90095-3; FREELING P, 1989, MATERNAL CHILD HLTH, V14, P394; FREER C B, 1986, Health Bulletin (Edinburgh), V44, P75; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; FULLARD E, 1984, BRIT MED J, V289, P1585, DOI 10.1136/bmj.289.6458.1585; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; LAWRENCE M, 1990, BRIT MED J, V300, P1501, DOI 10.1136/bmj.300.6738.1501; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL RM, 1989, J ROY COLL GEN PRACT, V39, P196; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; RUSSELL MAH, 1987, BRIT MED J, V295, P1240, DOI 10.1136/bmj.295.6608.1240; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; STONE DH, 1987, J ROY COLL GEN PRACT, V37, P218; Stott N C, 1979, J R Coll Gen Pract, V29, P201; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; TUCKETT D, 1985, M EXPERTS APPRAOCH S; WALLACE PG, 1987, BRIT MED J, V294, P940, DOI 10.1136/bmj.294.6577.940; 1989, GENERAL PRACTICE NAT; 1984, 28 COMM MED ASP FOOD; 1991, BMJ, V302, P1057; 1981, RCGP18 ROYAL COLL GE	30	83	85	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					871	874		10.1136/bmj.305.6858.871	http://dx.doi.org/10.1136/bmj.305.6858.871			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422405	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JT77700031
J	BISSONNETTE, RP; ECHEVERRI, F; MAHBOUBI, A; GREEN, DR				BISSONNETTE, RP; ECHEVERRI, F; MAHBOUBI, A; GREEN, DR			APOPTOTIC CELL-DEATH INDUCED BY C-MYC IS INHIBITED BY BCL-2	NATURE			English	Article							TRANSGENIC MICE; GENE-EXPRESSION; LYMPHOID-CELLS; B-CELLS; GROWTH; DIFFERENTIATION; ONCOGENE; SURVIVAL; PROTEIN; INDUCTION	APOPTOSIS is a form of physiological cell death, characterized by chromatin condensation, cytoplasmic blebbing and DNA fragmentation1, which often depends on RNA and protein synthesis by the dying cell2-4. The c-myc proto-oncogene, usually implicated in cell transformation, differentiation and cell-cycle progression5-9 also has a central role in some forms of apoptosis10-13. These opposing roles of myc in cell growth and death require that other gene products dictate the outcome of c-Myc expression on a cell. A candidate for such a modifying gene is bcl-2, whose product prolongs cell survival14-16 and blocks apoptosis in some systems17-21. Here we demonstrate that Bcl-2 prevents apoptotic death induced by c-Myc, provide a mechanism whereby cells can express c-Myc without undergoing apoptosis, and give a possible explanation for the ability of Bcl-2 to synergize with c-Myc in cell transformation21-23.			BISSONNETTE, RP (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				ASKEW DS, 1991, ONCOGENE, V6, P1915; BUKH A, 1990, J IMMUNOL, V144, P4835; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REED JC, 1990, P NATL ACAD SCI USA, V348, P331; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGT M, 1987, ONCOGENE RES, V2, P49; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	29	967	1001	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					552	554		10.1038/359552a0	http://dx.doi.org/10.1038/359552a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406975				2022-12-24	WOS:A1992JR85900065
J	SHEA, S; MISRA, D; EHRLICH, MH; FIELD, L; FRANCIS, CK				SHEA, S; MISRA, D; EHRLICH, MH; FIELD, L; FRANCIS, CK			PREDISPOSING FACTORS FOR SEVERE, UNCONTROLLED HYPERTENSION IN AN INNER-CITY MINORITY POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC HOSPITAL EMERGENCY; ORAL CLONIDINE; HEART-DISEASE; STROKE; CARE; CONSEQUENCES; EXPERIENCE; URGENCIES; COST	Background. Hypertensive emergency and urgent hypertension are the most severe forms of uncontrolled hypertension and are now seen predominantly in poor, minority populations. We studied the characteristics of the medical care received by patients with these conditions in order to identify risk factors for severe, uncontrolled hypertension. Methods. Using a case-control study design, we interviewed 93 patients with severe, uncontrolled hypertension who presented in the hospital emergency room and 114 control patients with hypertension; both groups were seen at two New York City hospitals from 1989 through 1991. All the patients were black or Hispanic. Multiple logistic-regression models were used to adjust for age, sex, race or ethnic background, education, smoking status, alcohol-related problems, and use of illicit drugs during the previous year. Results. After additional adjustment for lack of health insurance, severe, uncontrolled hypertension was found to be more common among patients who had no primary care physician (adjusted odds ratio, 3.5; 95 percent confidence interval, 1.6 to 7.7) and among those who did not comply with treatment for their hypertension (adjusted odds ratio, 1.9; 95 percent confidence interval, 1.4 to 2.5). Lack of health insurance was marginally associated with severe, uncontrolled hypertension (adjusted odds ratio, 1.9; 95 percent confidence interval, 0.8 to 4.6) after adjustment for lack of a primary care physician and noncompliance with antihypertensive treatment. Patients without a primary care physician and without health insurance were more likely to have their blood pressure checked and receive prescriptions for blood-pressure medications in emergency rooms than in physicians' offices or clinics. Conclusions. Characteristics of both the health care system and patients' behavior are associated with severe, uncontrolled hypertension. Improving access to primary care physicians, through health insurance or other means, may be an effective strategy for improving control of hypertension in disadvantaged minority populations.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV GEN MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10027 USA; HARLEM HOSP MED CTR, DEPT MED, NEW YORK, NY 10037 USA	Columbia University; Columbia University					NHLBI NIH HHS [R01-HL38260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BENNETT NM, 1988, AM J PUBLIC HEALTH, V78, P636, DOI 10.2105/AJPH.78.6.636; BERKSON DM, 1980, AM J PUBLIC HEALTH, V70, P389, DOI 10.2105/AJPH.70.4.389; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BRAND FN, 1977, PUBLIC HEALTH REP, V92, P72; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; FERGUSON RK, 1986, JAMA-J AM MED ASSOC, V255, P1607, DOI 10.1001/jama.255.12.1607; FOLSOM AR, 1983, JAMA-J AM MED ASSOC, V250, P916, DOI 10.1001/jama.250.7.916; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRANT BF, 1991, ALCOHOL HLTH RES WOR, V0015; HAYNES RB, 1980, NIH812102 PUBL; HOUSTON MC, 1986, ARCH INTERN MED, V146, P586, DOI 10.1001/archinte.146.3.586; JAKER M, 1989, ARCH INTERN MED, V149, P260, DOI 10.1001/archinte.149.2.260; KAPLAN NM, 1990, CLIN HYPERTENSION, P268; KEELER EB, 1985, JAMA-J AM MED ASSOC, V254, P1926; KELSEY JL, 1986, MONOGRAPHS EPIDEMIOL, V10, P109; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; NORUSIS MJ, 1990, SPSS PCPLUS V40 IBM; OSTFELD AM, 1990, EPIDEMIOL REV, V12, P253, DOI 10.1093/oxfordjournals.epirev.a036059; Roccella E J, 1988, Health Psychol, V7 Suppl, P297, DOI 10.1037/0278-6133.7.Suppl.297; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; STERN RS, 1991, JAMA-J AM MED ASSOC, V266, P2238, DOI 10.1001/jama.266.16.2238; THOM TJ, 1988, TRENDS CORONARY HEAR, P11; WILLIAMS GH, 1987, HARRISONS PRINCIPLES, V1, P1028; ZELLER KR, 1989, ARCH INTERN MED, V149, P2186, DOI 10.1001/archinte.149.10.2186; 1991, DHHS PHS9150213 DEP, P112; 1990, MMWR MORB MORTAL WKL, V39, P704; 1986, VITAL HLTH STATIS 11, V234; 1991, SAS SYSTEM REGRESSIO; 1987, MMWR MORB MORTAL WKL, V36, P144; 1984, ANN INTERN MED, V101, P393; 1980, DHHS PHS801260 DEP H	39	285	288	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					776	781		10.1056/NEJM199209103271107	http://dx.doi.org/10.1056/NEJM199209103271107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501654				2022-12-24	WOS:A1992JL66100007
J	WILSON, RG; MACINTYRE, IMC; NIXON, SJ; SAUNDERS, JH; VARMA, JS; KING, PM				WILSON, RG; MACINTYRE, IMC; NIXON, SJ; SAUNDERS, JH; VARMA, JS; KING, PM			LAPAROSCOPIC CHOLECYSTECTOMY AS A SAFE AND EFFECTIVE TREATMENT FOR SEVERE ACUTE CHOLECYSTITIS	BRITISH MEDICAL JOURNAL			English	Article							EXPERIENCE	Objective-To evaluate the feasibility and safety of laparoscopic cholecystectomy in severe acute cholecystitis. Design-Analysis of data collected prospectively from a consecutive series of 350 laparoscopic operations. Setting-Two general surgical units in a teaching hospital. Subjects-31 patients with a diagnosis of severe acute cholecystitis based on clinical examination, investigation results, and operative findings. Interventions-Initial intravenous fluids and broad spectrum antibiotics followed by laparoscopic cholecystectomy within 72 hours of presentation. Main outcome measures-Failure to complete the operation laparoscopically, length of postoperative stay in hospital, early postoperative morbidity, interval from operation to full activity, and return to work. Results-Laparoscopic cholecystectomy was attempted in 19 patients with empyema of the gall bladder and 12 who had severe cholecystitis which failed to settle on medical management. A total of 29 operations were successfully completed with two conversions to open surgery. Two minor postoperative complications occurred, and one case of retained common bile duct stones with jaundice was treated by endoscopic retrograde cholangio-pancreatography and papillotomy. Median postoperative hospital stay was two days, with return to normal activity in seven days and to work in two weeks. There were no deaths related to the operation. Conclusions-In the presence of severe acute cholecystitis laparoscopic cholecystectomy is feasible in most patients, with minimal risk of injury to surrounding structures and considerable benefits. It is recommended that laparoscopic cholecystectomy should be attempted in these patients when appropriate surgical skill is available.			WILSON, RG (corresponding author), WESTERN GEN HOSP,DEPT SURG,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Macintyre, Iain/0000-0003-2716-8500				Cooperman A M, 1990, J Laparoendosc Surg, V1, P37, DOI 10.1089/lps.1990.1.37; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; FLOWERS JL, 1991, AM J SURG, V161, P388, DOI 10.1016/0002-9610(91)90604-C; HOLOHAN TV, 1991, LANCET, V338, P801, DOI 10.1016/0140-6736(91)90678-I; MCARTHUR P, 1975, BRIT J SURG, V62, P850, DOI 10.1002/bjs.1800621025; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; REDDICK EJ, 1989, SURG ENDOSC-ULTRAS, V3, P1333; REISS R, 1990, WORLD J SURG, V14, P567, DOI 10.1007/BF01658790; Unger S W, 1991, Surg Laparosc Endosc, V1, P14; WILSON P, 1991, LANCET, V338, P795, DOI 10.1016/0140-6736(91)90674-E; ZUCKER KA, 1991, AM J SURG, V161, P36, DOI 10.1016/0002-9610(91)90358-K	12	101	103	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					394	396		10.1136/bmj.305.6850.394	http://dx.doi.org/10.1136/bmj.305.6850.394			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392919	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JK31400014
J	YUSTE, R; PEINADO, A; KATZ, LC				YUSTE, R; PEINADO, A; KATZ, LC			NEURONAL DOMAINS IN DEVELOPING NEOCORTEX	SCIENCE			English	Article							CEREBRAL-CORTEX; VISUAL-CORTEX; STRIATE CORTEX; CALCIUM; CELLS; CAT; ORGANIZATION; ASTROCYTES; SYNAPSES; SYSTEM	The mammalian neocortex consists of a mosaic of columnar units whose development is poorly understood. Optical recordings of brain slices labeled with the fluorescent calcium indicator fura-2 revealed that the neonatal rat cortex was partitioned into distinct domains of spontaneously coactive neurons. In tangential slices, these domains were 50 to 120 micrometers in diameter; in coronal slices they spanned several cortical layers and resembled columns found in the adult cortex. In developing somatosensory cortex, domains were smaller than, and distinct from, the barrels, which represent sensory input from a single vibrissa. The neurons within each domain were coupled by gap junctions. Thus, nonsynaptic communication during cortical development defines discrete multicellular patterns that could presage adult functional architecture.			YUSTE, R (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,BOX 3209,DURHAM,NC 27710, USA.				NATIONAL EYE INSTITUTE [R01EY007960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015177] Funding Source: NIH RePORTER; NEI NIH HHS [EY07960] Funding Source: Medline; NIMH NIH HHS [MH15177] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARMSTRONGJAMES M, 1975, J PHYSIOL-LONDON, V246, P501, DOI 10.1113/jphysiol.1975.sp010902; ARMSTRONGJAMES M, 1970, Z ZELLFORSCH MIK ANA, V110, P559, DOI 10.1007/BF00330104; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CONNORS BW, 1983, J NEUROSCI, V3, P773; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CRAGG BG, 1975, J COMP NEUROL, V160, P147, DOI 10.1002/cne.901600202; DELANEY KR, 1989, J NEUROSCI, V9, P3558; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; GUTNICK MJ, 1981, SCIENCE, V211, P67, DOI 10.1126/science.7444449; Hebb DO, 1949, ORG BEHAVIOR, P62; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KATZ LC, 1989, J NEUROSCI, V9, P1389; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KAUR C, 1989, ACTA ANAT, V136, P204; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; Lorente de No R., 1949, PHYSL NERVOUS SYSTEM, P274; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; YUESTE R, 1991, NEURON, V6, P333	35	365	370	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					666	669		10.1126/science.1496379	http://dx.doi.org/10.1126/science.1496379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496379				2022-12-24	WOS:A1992JF85200035
J	ALDOUS, J; HICKMAN, M; ELLAM, A; GAZZARD, B; HARGREAVES, S				ALDOUS, J; HICKMAN, M; ELLAM, A; GAZZARD, B; HARGREAVES, S			IMPACT OF HIV-INFECTION ON MORTALITY IN YOUNG MEN IN A LONDON HEALTH AUTHORITY	BRITISH MEDICAL JOURNAL			English	Article							AIDS; EPIDEMIC; ENGLAND; DEATHS; WALES	Objective-To determine the number of deaths attributable to HIV infection among men aged 15-64 in a geographically defined population in the United Kingdom. Design-Retrospective review of death certificates and linkage with local and national HIV and AIDS surveillance data. Setting-Riverside District Health Authority, London. Main outcome measures-Numbers of deaths attributed to HIV infection in male residents of Riverside aged 15-64 and 15-44 over a six month period. Proportion of attributed deaths were (i) identified from death certificates by the Office of Population Censuses and Surveys as being due to HIV infection and (ii) reported as cases of AIDS or HIV related deaths to the Public Health Laboratory Service Communicable Disease Surveillance Centre Results-34 of 213 (16%) deaths in men aged 15-64 and 27 of 69 (39%) deaths in men aged 15-44 were attributed to HIV infection. Six of 33 (18%) attributed deaths were identified by the Office of Population Censuses and Surveys and 32/34 (94%) were reported to the Communicable Disease Surveillance Centre. Conclusions-HIV infection was the leading cause of death in male residents of Riverside aged 15-44 and the third commonest cause of death in those aged 15-64. Most individuals dying of known HIV infection were reported to the Communicable Disease Surveillance Centre but identification of the true cause of death from the process of death certification was poor. Measures to improve the certification of HIV and AIDS or the use of AIDS surveillance information correctly to code the cause of death needs to be considered to ensure that the true impact of HIV infection is reflected in routine mortality statistics.	RIVERSIDE HLTH AUTHOR,DEPT PUBL HLTH,LONDON SW6 4UL,ENGLAND; WESTMINSTER MED SCH & HOSP,HIV GENITOURINARY MED UNIT,LONDON SW1P 2AP,ENGLAND	Imperial College London			Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X				BOBBY JJ, 1988, PUBLIC HEALTH, V102, P519, DOI 10.1016/S0033-3506(88)80020-9; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; EVANS GE, 1991, BMJ, V302, P1351; FENNA D, 1984, COMPUT PROG BIOMED, V19, P31, DOI 10.1016/0010-468X(84)90035-7; HICKMAN M, 1990, LANCET, V336, P1328, DOI 10.1016/0140-6736(90)93020-P; HICKMAN M, 1991, BRIT MED J, V302, P1376, DOI 10.1136/bmj.302.6789.1376; MCCORMICK A, 1989, PHILOS T ROY SOC B, V325, P163, DOI 10.1098/rstb.1989.0081; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MCCORMICK A, 1988, BRIT MED J, V296, P1289, DOI 10.1136/bmj.296.6632.1289; MCCORMICK A, 1991, BRIT MED J, V302, P1375, DOI 10.1136/bmj.302.6789.1375; 1991, Q SURVEILLANCE TABLE; 1990, STATE PUBLIC HLTH YE; 1991, MMWR, V40, P41; 1987, MMWR S1, V36, P3; 1986, MMWR S2, V35, P1	15	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					219	221		10.1136/bmj.305.6847.219	http://dx.doi.org/10.1136/bmj.305.6847.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392823	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JG11200020
J	RIBERDY, JM; NEWCOMB, JR; SURMAN, MJ; BARBOSA, JA; CRESSWELL, P				RIBERDY, JM; NEWCOMB, JR; SURMAN, MJ; BARBOSA, JA; CRESSWELL, P			HLA-DR MOLECULES FROM AN ANTIGEN-PROCESSING MUTANT-CELL LINE ARE ASSOCIATED WITH INVARIANT CHAIN PEPTIDES	NATURE			English	Article							CLASS-II MOLECULES; ALLOANTIGENS; BINDING; PROTEOLYSIS; TRANSPORT	THE invariant chain, which associates with the major histocompatibility complex (MHC) class II molecules in the endoplasmic reticulum, serves two functions important in antigen processing. First, it prevents class II molecules from binding peptides in the early stages of intracellular transport1-3. Second, it contains a cytoplasmic signal that targets the class II-invariant chain complex to an acidic endosomal compartment4-6. Proteolytic cleavage and subsequent dissociation of the invariant chain then occurs7,8, allowing peptides derived from endocytosed proteins to bind to released class II molecules before their expression at the cell surface3. Certain human cell lines that are mutant in one or more MHC-linked genes are defective in class II-restricted antigen processing9-11. Here we show that in transfectants of one of these cell lines, T2, this deficiency results in the association of a large proportion of class II molecules with a nested set of invariant-chain-derived peptides (class II-associated invariant chain peptides, or CLIP). HLA-DR3 molecules isolated from T2 transfectants can be efficiently loaded with antigenic peptides by exposure to a low pH in vitro, perhaps reflecting the in vivo conditions in which peptides associate with class II molecules12-14. Addition of synthetic CLIP inhibits the loading process, indicating that CLIP may define the region of the invariant chain responsible for obstructing the class II binding site.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510; MILES RES CTR,INST INFLAMMAT & AUTOIMMUN,DEPT PRECLIN TECHNOL,W HAVEN,CT 06516	Howard Hughes Medical Institute; Yale University								BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BILLING RJ, 1976, J IMMUNOL, V117, P1589; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; GELUK A, 1992, EUR J IMMUNOL, V22, P107, DOI 10.1002/eji.1830220117; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLIMCHER LH, 1987, J IMMUNOL, V138, P1519; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, IN PRESS J IMMUN; NGUYEN QV, 1989, HUM IMMUNOL, V24, P153, DOI 10.1016/0198-8859(89)90056-6; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	29	351	356	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					474	477		10.1038/360474a0	http://dx.doi.org/10.1038/360474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448172				2022-12-24	WOS:A1992KA79700063
J	FUJITA, I; TANAKA, K; ITO, M; CHENG, K				FUJITA, I; TANAKA, K; ITO, M; CHENG, K			COLUMNS FOR VISUAL FEATURES OF OBJECTS IN MONKEY INFEROTEMPORAL CORTEX	NATURE			English	Article							TEMPORAL CORTEX; MACAQUE MONKEY; ORGANIZATION; NEURONS; VISION	AT early stages of the mammalian visual cortex, neurons with similar stimulus selectivities are vertically arrayed through the thickness of the cortical sheet and clustered in patches or bands across the surface. This organization, referred to as a 'column', has been found with respect to one-dimensional stimulus parameters such as orientation of stimulus contours1, eye dominance of visual inputs1, and direction of stimulus motion2. It is unclear, however, whether information with extremely high dimensions, such as visual shape, is organized in a similar columnar fashion or in a different manner in the brain. Here we report that the anterior inferotemporal area of the monkey cortex, the final station of the visual cortical stream crucial for object recognition3-8, consists of columns, each containing cells responsive to similar visual features of objects.	RIKEN INST PHYS & CHEM RES,INFORMAT SCI LAB,WAKO,SAITAMA 35101,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES EMBRYON SCI & TECHNOL,WAKO,SAITAMA 35101,JAPAN	RIKEN; Japan Science & Technology Agency (JST)	FUJITA, I (corresponding author), RIKEN INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL INFORMAT PROC LAB,WAKO,SAITAMA 35101,JAPAN.		Cheng, Kang/A-6448-2016; Tanaka, Keiji/N-5917-2015	Tanaka, Keiji/0000-0002-1910-3427				ABELES M, 1970, J NEUROPHYSIOL, V33, P172, DOI 10.1152/jn.1970.33.1.172; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BAYLIS GC, 1987, J NEUROSCI, V7, P330; DEAN P, 1982, ANAL VISUAL BEHAVIOR, P587; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GOCHIN PM, 1991, EXPL BRAIN RES, V66, P170; Gross C. G., 1973, HDB SENSORY PHYSIOLO, P451; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IWAI E, 1985, VISION RES, V25, P425, DOI 10.1016/0042-6989(85)90068-9; IWAI E, 1988, BRAIN RES, V444, P397, DOI 10.1016/0006-8993(88)90955-9; KAAS JH, 1990, SIGNAL SENSE LOCAL G, P67; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PERRETT DI, 1985, BEHAV BRAIN RES, V16, P153, DOI 10.1016/0166-4328(85)90089-0; SAITO H, 1986, J NEUROSCI, V6, P145; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	22	465	467	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					343	346		10.1038/360343a0	http://dx.doi.org/10.1038/360343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448150				2022-12-24	WOS:A1992JZ63000051
J	HARRIS, LJ; LARSON, SB; HASEL, KW; DAY, J; GREENWOOD, A; MCPHERSON, A				HARRIS, LJ; LARSON, SB; HASEL, KW; DAY, J; GREENWOOD, A; MCPHERSON, A			THE 3-DIMENSIONAL STRUCTURE OF AN INTACT MONOCLONAL-ANTIBODY FOR CANINE LYMPHOMA	NATURE			English	Article							SEGMENTAL FLEXIBILITY; CRYSTALLOGRAPHIC REFINEMENT; IMMUNOELECTRON MICROSCOPY; ROTATIONAL FLEXIBILITY; IMMUNOGLOBULIN-G; ATOMIC MODELS; MOLECULE KOL; FC FRAGMENT; FAB REGIONS; RESOLUTION	CRYSTAL structures of Fab antibody fragments determined by X-ray diffraction characteristically feature four-domain, beta-barrel arrangements1-3. A human antibody Fc fragment has also been found to have four beta-barrel domains4. The structures of a few intact antibodies have been solved5-8: in two myeloma proteins, the flexible hinge regions that connect the Fc to the Fab segments were deleted5,6 so the molecules were non-functional, structurally restrained, T-shaped antibodies; a third antibody, Kol, had no hinge residues missing but the Fc region was sufficiently disordered that it was not possible to relate its disposition accurately with respect to the Fab components7,8. Here we report the structure at 3.5 angstrom resolution of an IgG2a antitumour monoclonal antibody which contains an intact hinge region and was solved in a triclinic crystal by molecular replacement using known Fc and Fab fragments. The antibody is asymmetric, reflecting its dynamic character. There are two local, apparently independent, dyads in the molecule. One relates the heavy chains in the Fc, the other relates the constant domains of the Fabs. The variable domains are not related by this 2-fold axis because of the different Fab elbow angles of 159-degrees and 143-degrees. The Fc has assumed an asymmetric, oblique orientation with respect to loosely tethered yet almost collinear Fabs. Our study enables the two antigen-binding segments as well as the Fc portion of a functional molecule to be visualized and illustrates the flexibility of these immune response proteins.	IMMUNOPHARMACEUT INC, SAN DIEGO, CA 92127 USA		HARRIS, LJ (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.							ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLMAN PM, 1976, J MOL BIOL, V100, P257, DOI 10.1016/S0022-2836(76)80062-9; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; JEGLUM KA, 1989, 7TH P ACVIM FOR SAN, P922; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; LAMY J, 1985, BIOCHEMISTRY-US, V24, P5532, DOI 10.1021/bi00341a038; LARSON S, 1991, J MOL BIOL, V222, P17, DOI 10.1016/0022-2836(91)90731-K; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; RAJAN SS, 1983, MOL IMMUNOL, V20, P797; ROSALES C, 1988, CELL IMMUNOL, V115, P420, DOI 10.1016/0008-8749(88)90194-3; ROUX KH, 1984, EUR J IMMUNOL, V14, P459, DOI 10.1002/eji.1830140514; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SILVERTON EW, 1977, P NATL ACAD SCI USA, V74, P5140, DOI 10.1073/pnas.74.11.5140; STEPLEWSKI Z, 1987, CANCER IMMUNOL IMMUN, V24, P197; WADE RH, 1989, J MOL BIOL, V206, P349, DOI 10.1016/0022-2836(89)90484-1; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WRIGLEY NG, 1983, J MOL BIOL, V169, P771, DOI 10.1016/S0022-2836(83)80170-3	29	182	188	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					369	372		10.1038/360369a0	http://dx.doi.org/10.1038/360369a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448155				2022-12-24	WOS:A1992JZ63000060
J	THEUNISSEN, O; RUDT, F; GUDDAT, U; MENTZEL, H; PIELER, T				THEUNISSEN, O; RUDT, F; GUDDAT, U; MENTZEL, H; PIELER, T			RNA AND DNA-BINDING ZINC FINGERS IN XENOPUS TFIIIA	CELL			English	Article							TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; 5S RIBOSOMAL-RNA; LAEVIS OOCYTES; FUNCTIONAL DOMAINS; GENE PROMOTER; 5S-RNA GENE; PROTEIN; PARTICLE; SITE	The nine tandem zinc finger repeats in the 5S gene-specific transcription factor IIIA (TFIIIA) from Xenopus mediate specific binding to 5S DNA as well as to 5S ribosomal RNA. A comparative functional analysis of a systematic set of TFIIIA zinc finger combinations reveals that most, if not all, participate in both DNA and RNA binding. Minimal sets of fingers sufficient for DNA and RNA recognition are different. In RNA binding, most finger elements are found to be functionally equivalent. However, the nonessential finger 6 exhibits RNA binding characteristics distinct from the other eight modules. The secondary/tertiary structure of the central domain in 5S RNA, not its primary sequence, is found to carry the essential structural information for TFIIIA binding in Xenopus oocytes. Taken together, our findings suggest that RNA and DNA binding are overlapping, though separable functions of the nine zinc finger elements in TFIIIA, occurring via fundamentally different molecular mechanisms.			THEUNISSEN, O (corresponding author), MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,W-1000 BERLIN 33,GERMANY.							BAUDIN F, 1991, J MOL BIOL, V218, P69, DOI 10.1016/0022-2836(91)90874-6; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; KRAMER A, 1983, J BIOL CHEM, V258, P1915; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MAJOWSKI K, 1987, EMBO J, V6, P3057, DOI 10.1002/j.1460-2075.1987.tb02612.x; Maniatis T, 1989, DECONTAMINATION DILU; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NIETFELD W, 1989, J MOL BIOL, V208, P639, DOI 10.1016/0022-2836(89)90155-1; NIETFELD W, 1990, EMBO J, V9, P399; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1983, FEBS LETT, V157, P283, DOI 10.1016/0014-5793(83)80562-6; PIELER T, 1985, EMBO J, V4, P1847, DOI 10.1002/j.1460-2075.1985.tb03859.x; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PIELER T, 1984, NUCLEIC ACIDS RES, V12, P8393, DOI 10.1093/nar/12.22.8393; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1797, DOI 10.1093/nar/19.8.1797; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1791, DOI 10.1093/nar/19.8.1791; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	43	148	149	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					679	690		10.1016/0092-8674(92)90601-8	http://dx.doi.org/10.1016/0092-8674(92)90601-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423623				2022-12-24	WOS:A1992JY67600015
J	RECKER, RR; DAVIES, KM; HINDERS, SM; HEANEY, RP; STEGMAN, MR; KIMMEL, DB				RECKER, RR; DAVIES, KM; HINDERS, SM; HEANEY, RP; STEGMAN, MR; KIMMEL, DB			BONE GAIN IN YOUNG-ADULT WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL-CONTRACEPTIVE USE; MOTHER-DAUGHTER PAIRS; BIRTH-CONTROL PILLS; MINERAL CONTENT; PHYSICAL-ACTIVITY; LUMBAR SPINE; GENETIC-DETERMINANTS; PREMENOPAUSAL WOMEN; CALCIUM BALANCE; NORMAL-CHILDREN	Objective.-To test whether bone mass increases in healthy nonpregnant white women during early adult life after cessation of linear growth; and to test whether various self-chosen levels of physical activity and nutrient intake or use of oral contraceptives influences this increase in bone mass. Design.-Longitudinal prospective study of up to 5 years of 156 healthy college-aged women full-time students attending professional schools in universities in the Omaha, Neb, area. Setting.-University medical center. Participants.-A convenience sample of healthy women students from Omaha-area professional schools. Any candidate with an illness, condition, or medication (except oral contraceptives) thought to affect general health or bone mass was excluded. Interventions.-None. Outcome Measures.-Clinical and family histories of disease, particularly osteoporosis; oral contraceptive use; bone mineral densities of the spine, forearm, and total body by dual- and single-photon absorptiometry; estimates of nutrient intake by repeated 7-day diet diaries; and measures of physical activity using a physical activity monitor. Results.-The median gain in bone mass for the third decade of life, expressed as a percentage per decade, was 4.8% for the forearm, 5.9% for lumbar bone mineral content, 6.8% for lumbar bone mineral density, and 12.5% for total body bone mass (P<.0001 in all cases). By both bivariate and multiple regression analysis the rate of gain in bone density of the spine was negatively correlated with age and positively correlated with calcium/protein intake ratio and physical activity (multiple r=.31; P=.004). Bivariate analysis showed that use of oral contraceptives was associated with greater gain in total body bone mass (r=.31, P=.01). The estimated age when mineral acquisition ceased ranged from 28.3 years to 29.5 years at the several study sites. Conclusions.-Gain in bone mass occurs in healthy young women during the third decade of life. Physical activity and dietary calcium intake both exert a positive effect on this bone gain. Use of oral contraceptives exerts a further independent positive effect. Changes in life-style among college-aged women, involving relatively modest increases in physical activity and calcium intake, may significantly reduce the risk of osteoporosis late in life.			RECKER, RR (corresponding author), CREIGHTON UNIV,SCH MED,CTR HARD TISSUE RES,601 N 30TH ST,OMAHA,NE 68131, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032462] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-32462] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, J LAB CLIN MED, V106, P630; BLACK DM, 1992, J BONE MINER RES, V7, P639; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BUCHANAN JR, 1988, J BONE MINER RES, V3, P673, DOI 10.1002/jbmr.5650030613; BUCHANAN JR, 1988, J BONE MINER RES, V3, P583; CAMERON J, 1964, SCIENCE, V142, P27; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, CLIN ORTHOPAEDICS, V252, P163; DAVEE AM, 1990, J BONE MINER RES, V5, P245, DOI 10.1002/jbmr.5650050307; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; ELDERS PJM, 1989, BONE MINER, V7, P289, DOI 10.1016/0169-6009(89)90085-8; EPKER B. N., 1965, CLIN ORTHOP RELAT RES, V41, P198; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Garn S.M., 1970, EARLIER GAIN LATER L; GEUSENS P, 1986, J NUCL MED, V27, P1540; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; GLASTRE C, 1990, J CLIN ENDOCR METAB, V70, P1330, DOI 10.1210/jcem-70-5-1330; HEANEY RP, 1982, J LAB CLIN MED, V99, P46; HRESHCHYSHYN MM, 1988, AM J OBSTET GYNECOL, V159, P318, DOI 10.1016/S0002-9378(88)80075-9; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1985, GROWTH, V49, P34; JOHANSEN JS, 1989, BONE MINER, V6, P77, DOI 10.1016/0169-6009(89)90025-1; KANDERS B, 1988, J BONE MINER RES, V3, P145; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; KLESGES RC, 1985, AM J EPIDEMIOL, V122, P400, DOI 10.1093/oxfordjournals.aje.a114121; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LANDIN L, 1981, ACTA PAEDIATR SCAND, V70, P919, DOI 10.1111/j.1651-2227.1981.tb06251.x; LINDSAY R, 1986, CONTRACEPTION, V34, P333, DOI 10.1016/0010-7824(86)90086-7; LLOYD T, 1989, AM J OBSTET GYNECOL, V160, P402, DOI 10.1016/0002-9378(89)90457-2; LUTZ J, 1986, AM J CLIN NUTR, V44, P99, DOI 10.1093/ajcn/44.1.99; LUTZ J, 1990, AM J CLIN NUTR, V52, P872, DOI 10.1093/ajcn/52.5.872; MALLETTE LE, 1989, J BONE MINER RES, V4, P143; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MILER J, 1991, J BONE MINER RES S, V6, P136; MOLLER M, 1978, CALC TISS RES, V25, P197, DOI 10.1007/BF02010768; MONTOYE HJ, 1983, MED SCI SPORT EXER, V15, P403; NILAS L, 1988, BONE MINER, V4, P95; PICARD D, 1988, BONE MINER, V4, P299; POCOCK NA, 1988, J BONE MINER RES, V3, P601; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; POLLITZER WS, 1989, AM J CLIN NUTR, V50, P1244, DOI 10.1093/ajcn/50.6.1244; Recker R R, 1990, J Bone Miner Res, V5, P307; RECKER RR, 1992, J BONE MINER RES, V7, P857; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1981, J CLIN INVEST, V67, P326; RODIN A, 1990, BONE, V11, P1, DOI 10.1016/8756-3282(90)90064-6; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SNOWHARTER C, 1990, J BONE MINER RES, V5, P589; STEGMAN M, IN PRESS OSTEOPOROSI; TYLAVSKY FA, 1989, CALCIFIED TISSUE INT, V45, P265, DOI 10.1007/BF02556017; WAHNER HW, 1985, RADIOLOGY, V156, P203, DOI 10.1148/radiology.156.1.4001406; WASHBURN RA, 1988, RES Q EXERCISE SPORT, V59, P83, DOI 10.1080/02701367.1988.10605479	60	599	612	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2403	2408		10.1001/jama.268.17.2403	http://dx.doi.org/10.1001/jama.268.17.2403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404797				2022-12-24	WOS:A1992JV69400026
J	BURGOYNE, PS; MAHADEVAIAH, SK; SUTCLIFFE, MJ; PALMER, SJ				BURGOYNE, PS; MAHADEVAIAH, SK; SUTCLIFFE, MJ; PALMER, SJ			FERTILITY IN MICE REQUIRES X-Y PAIRING AND A Y-CHROMOSOMAL SPERMIOGENESIS GENE-MAPPING TO THE LONG ARM	CELL			English	Article							SEX-REVERSED MICE; SXR MALE-MICE; AUTOSOME REARRANGEMENT; CYTOLOGICAL EVIDENCE; DETERMINING REGION; PARTIAL DELETION; MALE-STERILITY; MOUSE; SPERMATOGENESIS; ANTIGEN	There is accumulating evidence that the mammalian Y chromosome, in addition to its testis-determining function, may have other male limited functions, particularly in spermatogenesis. We have previously shown that the short arm of the mouse Y carries information needed for spermatogonial proliferation. This information, together with the testis-determining gene Sry, is contained within the Y-derived sex reversal factor Sxr(a). XO males carrying a copy of Sxr(a) attached to the X chromosome are nevertheless sterile owing to an almost complete arrest during the meiotic metaphase stages. Here we show that this meiotic block can be overcome by providing a meiotic pairing partner (with no Y-specific DNA) for the XSxr(a) chromosome. However, this does not restore fertility because the sperm produced all have abnormal heads. It is concluded that the Y-specific region of the mouse Y chromosome long arm includes information essential for the normal development of the sperm head.			BURGOYNE, PS (corresponding author), MRC,MAMMALIAN DEV UNIT,WOLFSON HOUSE,4 STEPHENSON WAY,LONDON NW1 2HE,ENGLAND.		Palmer, Stephen/F-2822-2013	Palmer, Stephen/0000-0002-4907-4719				BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; BURGOYNE PS, 1984, CONTROLLING EVENTS M, P349; CATTANACH BM, 1990, GENET RES, V56, P121, DOI 10.1017/S0016672300035199; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; CHANDLEY AC, 1980, CHROMOSOMA, V81, P9, DOI 10.1007/BF00292419; CHANDLEY AC, 1987, CHROMOSOMA, V95, P345, DOI 10.1007/BF00293181; EICHER EM, 1991, CYTOGENET CELL GENET, V57, P221, DOI 10.1159/000133152; EICHER EM, 1983, RECOMBINANT DNA MED, P57; EVANS EP, 1980, CHROMOSOMA, V81, P19, DOI 10.1007/BF00292420; EVANS EP, 1964, CYTOGENETICS, V3, P289, DOI 10.1159/000129818; EVANS EP, 1975, NATURE, V256, P40, DOI 10.1038/256040a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HALE DW, 1991, CYTOGENET CELL GENET, V57, P231, DOI 10.1159/000133153; HANNAPPEL E, 1979, HORM METAB RES, V11, P682, DOI 10.1055/s-0028-1092800; HOWELL WM, 1980, EXPERIENTIA, V36, P1014, DOI 10.1007/BF01953855; KOT MC, 1990, J EXP ZOOL, V256, P92, DOI 10.1002/jez.1402560112; KRZANOWSKA H, 1969, GENET RES, V13, P17, DOI 10.1017/S0016672300002706; KRZANOWSKA H, 1986, J REPROD FERTIL, V77, P265, DOI 10.1530/jrf.0.0770265; KRZANOWSKA H, 1976, GENET RES, V28, P189, DOI 10.1017/S0016672300016864; LEVY ER, 1986, CYTOGENET CELL GENET, V42, P159, DOI 10.1159/000132269; MAHADEVAIAH S, 1986, CYTOGENET CELL GENET, V41, P169, DOI 10.1159/000132222; MAHADEVAIAH S, 1988, CHROMOSOMA, V97, P145, DOI 10.1007/BF00327371; MAHADEVAIAH SK, 1993, IN PRESS J REPROD FE; MATSUDA Y, 1991, P NATL ACAD SCI USA, V88, P4850, DOI 10.1073/pnas.88.11.4850; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MCLAREN A, 1982, NATURE, V300, P446, DOI 10.1038/300446a0; MCLAREN A, 1983, GENET RES, V42, P345, DOI 10.1017/S0016672300021820; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; MONK M, 1987, P139; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; STYRNA J, 1991, J REPROD FERTIL, V92, P187, DOI 10.1530/jrf.0.0920187; STYRNA J, 1991, GENET RES, V57, P195, DOI 10.1017/S0016672300029268; SUTCLIFFE MJ, 1991, MOL REPROD DEV, V30, P81, DOI 10.1002/mrd.1080300202; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; TEASE C, 1989, CHROMOSOMA, V97, P390, DOI 10.1007/BF00292766	39	157	159	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					391	398		10.1016/0092-8674(92)90509-B	http://dx.doi.org/10.1016/0092-8674(92)90509-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423603				2022-12-24	WOS:A1992JW43500006
J	BURATOWSKI, S; ZHOU, H				BURATOWSKI, S; ZHOU, H			A SUPPRESSOR OF TBP MUTATIONS ENCODES AN RNA POLYMERASE-III TRANSCRIPTION FACTOR WITH HOMOLOGY TO TFIIB	CELL			English	Article							TATA-BINDING-PROTEIN; WHOLE-CELL EXTRACT; HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; ACCURATE INITIATION; ESCHERICHIA-COLI; YEAST; DNA; ACTIVATION; COMPLEXES	The TDS4 gene of S. cerevisiae was isolated as an allele-specific high copy suppressor of mutations within the basic region of the TATA-binding protein (TBP). The gene is essential for viability and encodes a 596 aa protein. The first 300 aa of the TDS4 protein exhibit significant sequence similarity to the RNA polymerase II transcription factor TFIIB. However, TDS4 is required for RNA polymerase III transcription in vivo and in vitro. Antibodies specific for TDS4 or TBP react with the TFIIIB complex, indicating that both proteins are components of the RNA polymerase III initiation complex. These findings suggest that the RNA polymerase II and III initiation mechanisms are extremely similar, and they explain how the TATA-binding protein can function in both systems.			BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DALBERG JE, 1991, SCIENCE, V254, P1462; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GUTHRIE C, 1991, METH ENZYMOL, V194; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LUE NF, 1990, J BIOL CHEM, V265, P18091; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MONCOLLIN V, 1992, P NATL ACAD SCI USA, V89, P397, DOI 10.1073/pnas.89.1.397; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIS I, 1989, EMBO J, V8, P4281, DOI 10.1002/j.1460-2075.1989.tb08614.x; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	52	141	142	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					221	230		10.1016/0092-8674(92)90351-C	http://dx.doi.org/10.1016/0092-8674(92)90351-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423590				2022-12-24	WOS:A1992JU39500008
J	HAGLUND, MM; OJEMANN, GA; HOCHMAN, DW				HAGLUND, MM; OJEMANN, GA; HOCHMAN, DW			OPTICAL IMAGING OF EPILEPTIFORM AND FUNCTIONAL-ACTIVITY IN HUMAN CEREBRAL-CORTEX	NATURE			English	Article							SALAMANDER OLFACTORY-BULB; INTRINSIC-SIGNALS; NEURONAL-ACTIVITY; VISUAL-CORTEX; ORGANIZATION; ARCHITECTURE; BRAIN; STIMULATION; VOLUNTARY; MOVEMENTS	OPTICAL imaging of animal somatosensory, olfactory and visual cortices has revealed maps of functional activity1-12. In non-human primates, high-resolution maps of the visual cortex have been obtained using only an intrinsic reflection signal3,4,6,13,14. Although the time course of the signal is slower than membrane potential changes, the maximum optical changes correspond to the maximal neuronal activity3,6. The intrinsic optical signal may represent the flow of ionic currents, oxygen delivery, changes in blood volume, potassium accumulation or glial swelling3,4,6,8,15-18. Here we use similar techniques to obtain maps from human cortex during stimulation-evoked epileptiform afterdischarges and cognitively evoked functional activity. Optical changes increased in magnitude as the intensity and duration of the afterdischarges increased. In areas surrounding the afterdischarge activity, optical changes were in the opposite direction and possibly represent an inhibitory surround. Large optical changes were found in the sensory cortex during tongue movement and in Broca's and Wernicke's language areas during naming exercises. The adaptation of high-resolution optical imaging for use on human cortex provides a new technique for investigation of the organization of the sensory and motor cortices, language, and other cognitive processes.	UNIV WASHINGTON,DEPT NEUROL SURG,RI-20,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; COHEN LB, 1973, PHYSIOL REV, V53, P373; COHEN LB, 1972, J PHYSIOL-LONDON, V224, P727, DOI 10.1113/jphysiol.1972.sp009920; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; FRITH CD, 1991, J NEUROPSYCHOLOGIA, V29, P1137; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gonzalez R. C., 1987, DIGITAL IMAGE PROCES; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; GRINVALD A, 1991, P NATL ACAD SCI USA, V88, P11559, DOI 10.1073/pnas.88.24.11559; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HAGLUND MM, 1991, MONITORING NEURONAL, P85; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; LEE BI, 1986, ANN NEUROL, V20, P32, DOI 10.1002/ana.410200107; LIEKE EE, 1989, ANNU REV PHYSIOL, V51, P543, DOI 10.1146/annurev.physiol.51.1.543; LIPTON P, 1973, J PHYSIOL-LONDON, V231, P365, DOI 10.1113/jphysiol.1973.sp010238; LONDON JA, 1989, J NEUROSCI, V9, P2182; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; ORBACH HS, 1983, J NEUROSCI, V3, P2251; ORBACH HS, 1985, J NEUROSCI, V5, P1886; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WOHLBERG G, 1988, DIGITAL IMAGING WARP; [No title captured]	29	254	277	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					668	671		10.1038/358668a0	http://dx.doi.org/10.1038/358668a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495561				2022-12-24	WOS:A1992JJ88200053
J	KABUKOBA, JJ; YOUNG, P				KABUKOBA, JJ; YOUNG, P			MIDWIFERY AND BODY-FLUID CONTAMINATION	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY TARGET; HIV		ALL ST HOSP,OBSTET & GYNAECOL,CHATHAM,KENT,ENGLAND									BRAATHEN LR, 1987, LANCET, V2, P1094; CHAMBERLAIN G, 1991, LANCET, V337, P1219; JESSOP JH, 1990, BRIT MED J, V300, P49, DOI 10.1136/bmj.300.6716.49-a; NIEDECKEN H, 1987, LANCET, V2, P519; 1987, REPORT RCOG SUBCOMMI	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					226	226		10.1136/bmj.305.6847.226	http://dx.doi.org/10.1136/bmj.305.6847.226			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392828	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JG11200025
J	KAPUR, S; MIECZKOWSKI, T; MANN, JJ				KAPUR, S; MIECZKOWSKI, T; MANN, JJ			ANTIDEPRESSANT MEDICATIONS AND THE RELATIVE RISK OF SUICIDE ATTEMPT AND SUICIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DATA-COLLECTION-SYSTEM; DOUBLE-BLIND; DISORDERS; AMITRIPTYLINE; FLUVOXAMINE; TOXICITY; OVERDOSE; DEPRESSION; FLUOXETINE; MIANSERIN	Objective.-Suicide by drug overdose is a major public health problem, and antidepressant medications are the most common agent involved. European studies suggest differences in the rates of suicide by overdose among antidepressants, but no reports have been published for the United States. We estimated the comparative risks of suicide attempts and suicides, and the relative risk of fatality in the event of an overdose for the major antidepressants currently marketed in the United States. Data Sources.-Information regarding suicide attempts and suicides by antidepressant overdose was obtained from the published reports of the Drug Abuse and Warning Network and the annual report of the American Association of Poison Control Centers, and corrected for differences in total annual prescriptions using data from the National Prescription Audit. Results.-The risk of a suicide attempt did not appear to differ among antidepressants. The tricyclic antidepressants were associated with a higher rate of death in the event of an overdose than the newer nontricyclic antidepressants in both the annual report of the American Association of Poison Control Centers and the Drug Abuse and Warning Network data. The chance of death after an overdose was greater for desipramine hydrochloride than for other tricyclics. Conclusion.-The higher risk of suicide with tricyclics vs nontricyclics may be explained by a higher rate of death from overdose rather than more suicide attempts. Tricyclics carry the risk of greater cardiotoxicity. The basis for the even higher rate of death/overdose of desipramine is not known and requires further research. If these findings are replicated in a case-control study design, they have important implications for the choice of an antidepressant for the depressed patient at risk for suicidal behavior.	UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	MANN, JJ (corresponding author), UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,PITTSBURGH,PA 15213, USA.		anand, amit/A-7222-2009	Kapur, Shitij/0000-0002-2231-2924; Santibanez, Tammy A./0000-0002-5784-7427	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH046745, P50MH046745] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-46745] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Asberg M., 1987, PSYCHOPHARMACOLOGY 3, P655; BALDESSARINI RJ, 1989, J CLIN PSYCHIAT, V50, P117; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEAUMONT G, 1989, BRIT J PSYCHIAT, V154, P454, DOI 10.1192/bjp.154.4.454; BRENT DA, 1988, AM PSYCHIATRIC REV P, V7, P353; BROADHEAD WE, 1991, J FAM PRACTICE, V33, P24; BULIK CM, 1990, J AFFECT DISORDERS, V18, P29, DOI 10.1016/0165-0327(90)90114-N; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; COCCARO EF, 1989, ARCH GEN PSYCHIAT, V46, P587; COLE JO, 1990, J CLIN PSYCHIAT, V51, P21; CROME P, 1979, J ROY SOC MED, V72, P649, DOI 10.1177/014107687907200905; DAMLUJI NF, 1988, J CLIN PSYCHOPHARM, V8, P347; DEWILDE J, 1991, ACTA PSYCHIAT SCAND, P89; GALLANT DM, 1987, PSYCHOPATHOLOGY, V20, P75, DOI 10.1159/000284526; GONELLA G, 1990, CURR MED RES OPIN, V12, P177, DOI 10.1185/03007999009111499; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HALPER JP, 1988, BRIT J PSYCHIAT, V153, P87, DOI 10.1192/S0007125000297341; HANZLICK R, 1989, AM J FOREN MED PATH, V10, P326, DOI 10.1097/00000433-198912000-00009; INMAN WHW, 1988, LANCET, V2, P90; KING LA, 1985, HUM TOXICOL, V4, P273, DOI 10.1177/096032718500400307; KING RA, 1991, J AM ACAD CHILD PSY, V30, P179, DOI 10.1097/00004583-199103000-00003; LEONARD BE, 1986, LANCET, V2, P1105; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; MANN JJ, 1989, PSYCHOPHARMACOL BULL, V25, P407; MANN JJ, 1989, BRIT J PSYCHIAT, V155, P7, DOI 10.1192/S000712500029171X; MONTGOMERY SA, 1981, ACTA PSYCHIAT SCAND, V63, P314, DOI 10.1111/j.1600-0447.1981.tb00735.x; MONTGOMERY SA, 1987, PSYCHOPHARMACOLOGY, V92, P265; MONTGOMERY SA, 1989, ACTA PSYCHIAT SCAND, V80, P47, DOI 10.1111/j.1600-0447.1989.tb03046.x; MULLIN JM, 1988, BRIT J CLIN PRACT, V42, P51; NATHAN RS, 1990, J CLIN PSYCHIAT, V51, P367; PEREZ A, 1990, CURR MED RES OPIN, V12, P234, DOI 10.1185/03007999009111652; POLLACK MH, 1987, J CLIN PSYCHIAT, V48, P3; ROTTERSTOL N, 1989, ACTA PSYCHIATR S354, V80, P61; ROULLION F, 1989, ENCEPHALE, V15, P527; SACCHETTI E, 1991, SEROTONIN RELATED PS, P47; SOLOFF PH, 1987, PSYCHOPHARMACOL BULL, V23, P177; SOLOFF PH, 1986, AM J PSYCHIAT, V143, P1603; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; VUORI E, 1989, ACTA PSYCHIAT SCAND, V80, P55, DOI 10.1111/j.1600-0447.1989.tb03047.x; WAKELIN JS, 1988, ADV BIOL PSYCHIAT, V17, P70; 1989, STAT ABSTR US 1989; 1990, NIDA STATISTICAL SER, V1	44	162	164	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3441	3445		10.1001/jama.268.24.3441	http://dx.doi.org/10.1001/jama.268.24.3441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460734				2022-12-24	WOS:A1992KC83900031
J	MICHAELS, D; LEVINE, C				MICHAELS, D; LEVINE, C			ESTIMATES OF THE NUMBER OF MOTHERLESS YOUTH ORPHANED BY AIDS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WOMEN; MORTALITY; HISPANICS; EPIDEMIC; IMPACT	Objective.-To estimate the number of youth in the United States who have been or will be left motherless by the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic, in order to project the need for family supports, age-appropriate foster and congregate care, and mental health and social services. Design.-Orphans are defined as youth whose mothers (the usual caregiving parent) die of HIV/AIDS-related causes. A mathematical model was constructed to estimate the number of such motherless youth. Cumulative fertility rates were applied to the number of reported AIDS deaths (1981 through 1990) and projected deaths (1991 through 1995) of adult women less than 50 years old. The results were adjusted for underreporting of HIV/AIDS-related mortality, pediatric AIDS deaths, infant mortality, ethnic and racial variation in fertility, and decreased fertility associated with late-stage HIV disease. Estimates were made for the number who were children (less than 13 years of age), adolescents (1 3 to 17 years of age), or young adults (1 8 years of age or older) at the time of their mothers' death. Results.-By the end of 1995, maternal deaths caused by the HIV/AIDS epidemic will have orphaned an estimated 24 600 children and 21 000 adolescents in the United States; unless the course of the epidemic changes dramatically, by the year 2000, the overall number of motherless children and adolescents will exceed 80000. In 1991, an estimated 13% of US children and 9% of adolescents whose mothers died of all causes were children of women who died of HIV/AIDS-related diseases. These proportions will surpass 17% and 12%, respectively, by 1995. The vast majority of these motherless youth will come from poor communities of color. Conclusions.-A large and rapidly growing number of American youth are being orphaned by the HIV/AIDS epidemic. Unless increased attention and resources are devoted to this vulnerable population, a social catastrophe is unavoidable.	ORPHAN PROJECT,121 AVE AMER,6TH FL,NEW YORK,NY 10013; CUNY,SCH MED,SOPHIE DAVIS SCH BIOMED EDUC,DEPT COMMUNITY HLTH & SOCIAL MED,NEW YORK,NY 10021	City University of New York (CUNY) System; Sophie Davis School of Biomedical Education	LEVINE, C (corresponding author), ORPHAN PROJECT,121 AVE AMER,6TH FL,NEW YORK,NY 10013, USA.			Michaels, David/0000-0001-8558-7733				BENNETT JV, 1991, AM J DIS CHILD, V145, P1242, DOI 10.1001/archpedi.1991.02160110034016; BOYLAN L, 1991, EPIDEMIOL REV, V13, P143, DOI 10.1093/oxfordjournals.epirev.a036067; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; CALDWELL MB, 1992, PEDIATRICS, V90, P482; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; Carr J N, 1975, Pediatr Ann, V4, P65, DOI 10.3928/0090-4481-19750701-11; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; DEREN S, 1986, 50 NEW YORK STATE DI; DRUCKER E, 1991, AIDS READER; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; MENENDEZ BS, 1990, J ACQ IMMUN DEF SYND, V3, P644; PIVNICK A, 1991, MED ANTHROPOL Q, V5, P153, DOI 10.1525/maq.1991.5.2.02a00030; PREBLE EA, 1990, SOC SCI MED, V31, P671, DOI 10.1016/0277-9536(90)90249-R; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; RUMLEY RL, 1991, AIDS, V5, P1373, DOI 10.1097/00002030-199111000-00015; SELIK RM, 1989, AM J PUBLIC HEALTH, V79, P836, DOI 10.2105/AJPH.79.7.836; 1991, AIDS MICROFICHE DATA; 1992, AIDS SURVEILLANCE UP; 1991, 1991 M AIDS ORPH AFR, P5; 1989, SUMMARY VITAL STATIS; 1992, HIV AIDS SURVEILANCE, P1; 1991, MONTHLY VITAL STA S1, V40, P1; 1992, MMWR, V41, P28; 1991, LANCET, V337, P253; 1992, MMWR, V41, P121; 1992, MONTHLY VITAL STA S2, V40, P1; 1990, MMWR, V39, P1; 1991, VITAL STATISTICS US, V2	30	111	111	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3456	3461		10.1001/jama.268.24.3456	http://dx.doi.org/10.1001/jama.268.24.3456			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460736				2022-12-24	WOS:A1992KC83900034
J	GUO, HC; JARDETZKY, TS; GARRETT, TPJ; LANE, WS; STROMINGER, JL; WILEY, DC				GUO, HC; JARDETZKY, TS; GARRETT, TPJ; LANE, WS; STROMINGER, JL; WILEY, DC			DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE	NATURE			English	Article							SELF-PEPTIDES; VIRAL PEPTIDES; LYMPHOCYTES-T; ANTIGENS; CRYSTALLOGRAPHY; SPECIFICITY; MOLECULES; HLA-B27; PROTEIN; CHAINS	WE report here the determination and refinement to 1.9 angstrom resolution by X-ray cryo-crystallography the structure of HLA-Aw68. The averaged image from the collection of bound, endogenous peptides clearly shows the atomic structure at the first three and last two amino acids in the peptides but no connected electron density in between. This suggests that bound peptides, held at both ends, take alternative pathways and could be of different lengths by bulging out in the middle. Peptides eluted from HLA-Aw68 include peptides of 9, 10 and 11 amino acids, a direct indication of the length heterogeneity of tightly bound peptides. Peptide sequencing shows relatively conserved 'anchor' residues at position 2 and the carboxy-terminal residue. Conserved binding sites for the peptide N and C termini at the ends of the class I major histocompatibility complex binding groove are apparently dominant in producing the long half-lives of peptide binding and the peptide-dependent stabilization of the class I molecule's structure.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	GUO, HC (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANBLEEK GM, 1990, NATURE, V348, P213; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	31	404	444	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					364	366		10.1038/360364a0	http://dx.doi.org/10.1038/360364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448153				2022-12-24	WOS:A1992JZ63000058
J	KASTAN, MB; ZHAN, QM; ELDEIRY, WS; CARRIER, F; JACKS, T; WALSH, WV; PLUNKETT, BS; VOGELSTEIN, B; FORNACE, AJ				KASTAN, MB; ZHAN, QM; ELDEIRY, WS; CARRIER, F; JACKS, T; WALSH, WV; PLUNKETT, BS; VOGELSTEIN, B; FORNACE, AJ			A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; DNA DAMAGE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; PROTEIN; GENE; CANCER; INDUCTION; REPLICATION; DEGRADATION	Cell cycle checkpoints can enhance cell survival and limit mutagenic events following DNA damage. Primary murine fibroblasts became deficient in a G1 checkpoint activated by ionizing radiation (IR) when both wild-type p53 alleles were disrupted. In addition, cells from patients with the radiosensitive, cancer-prone disease ataxia-telangiectasia (AT) lacked the IR-induced increase in p53 protein levels seen in normal cells. Finally, IR induction of the human GADD45 gene, an induction that is also defective in AT cells, was dependent on wild-type p53 function. Wild-type but not mutant p53 bound strongly to a conserved element in the GADD45 gene, and a p53-containing nuclear factor, which bound this element, was detected in extracts from irradiated cells. Thus, we identified three participants (AT gene(s), p53, and GADD45) in a signal transduction pathway that controls cell cycle arrest following DNA damage; abnormalities in this pathway probably contribute to tumor development.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Massachusetts Institute of Technology (MIT)	KASTAN, MB (corresponding author), JOHNS HOPKINS ONCOL CTR,600 N WOLFE ST,BALTIMORE,MD 21287, USA.		Fornace, Albert J/A-7407-2008; El-Deiry, Wafik/AAJ-6080-2020; Carrier, France/C-3063-2008	Fornace, Albert J/0000-0001-9695-085X; El-Deiry, Wafik/0000-0002-9577-8266; Carrier, France/0000-0002-5517-5284	NCI NIH HHS [CA 09071, CA 43460] Funding Source: Medline; NIEHS NIH HHS [ES 05777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043460, T32CA009071, R37CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doll R, 1981, J NATL CANCER I, V66, P1192; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; FORNACE AJ, 1991, RADIAT RES, P213; FORNACE AJ, 1992, IN PRESS ANN NY ACAD; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; HARTWELL LH, 1989, SCIENCE, V246, P6229; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YUNIS JJ, 1990, ADV ONCOL, V6, P3; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	56	3151	3237	1	137	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					587	597		10.1016/0092-8674(92)90593-2	http://dx.doi.org/10.1016/0092-8674(92)90593-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423616				2022-12-24	WOS:A1992JY67600007
J	FERGUSON, EL; ANDERSON, KV				FERGUSON, EL; ANDERSON, KV			DECAPENTAPLEGIC ACTS AS A MORPHOGEN TO ORGANIZE DORSAL-VENTRAL PATTERN IN THE DROSOPHILA EMBRYO	CELL			English	Article							CELL-SHAPE CHANGES; GENE-PRODUCT; ACTIVIN-A; PROTEIN; MELANOGASTER; POLARITY; HOMOLOG; FATE; AXIS; GASTRULATION	Zygotic expression of the Drosophila TGFbeta family member decapentaplegic (dpp) is required for the development of the dorsal embryonic structures. By injecting dpp transcripts into young embryos, we find that 2- to 4-fold increases in the concentration of injected RNA elicit progressively more dorsal cell fates: only low levels of dpp permit development of ventral ectoderm, intermediate dpp levels drive dorsal epidermal development, and high dpp levels drive cells to differentiate as the most dorsal pattern element, the amnioserosa. Localized dpp RNA injections into embryos that lack all known maternal and zygotic dorsal-ventral polarity indicate that dpp can both define embryonic polarity and organize detailed patterning within the ectoderm. We infer that dpp acts as an extracellular morphogen and that the graded activity of dpp specifies the pattern of ectodermal cell fates in the Drosophila embryo.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Ferguson, Edwin/0000-0003-4125-4253	NICHD NIH HHS [HD07299] Funding Source: Medline; NIGMS NIH HHS [GM 35437] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035437] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P174; ANDERSON KV, 1989, GENES EMBRYOS, P1; ARORA K, 1992, DEVELOPMENT, V114, P1003; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FERGUSON EL, 1991, CURR TOP DEV BIOL, V25, P17; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; IP YT, 1991, CELL, V64, P439; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAY RP, 1991, DEVELOPMENT, V113, P35; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; Rushlow C, 1990, Adv Genet, V27, P277; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Wieschaus E., 1986, P199; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	40	429	437	0	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					451	461		10.1016/0092-8674(92)90514-D	http://dx.doi.org/10.1016/0092-8674(92)90514-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423606				2022-12-24	WOS:A1992JW43500011
J	WEINSTEIN, JN; KOHN, KW; GREVER, MR; VISWANADHAN, VN; RUBINSTEIN, LV; MONKS, AP; SCUDIERO, DA; WELCH, L; KOUTSOUKOS, AD; CHIAUSA, AJ; PAULL, KD				WEINSTEIN, JN; KOHN, KW; GREVER, MR; VISWANADHAN, VN; RUBINSTEIN, LV; MONKS, AP; SCUDIERO, DA; WELCH, L; KOUTSOUKOS, AD; CHIAUSA, AJ; PAULL, KD			NEURAL COMPUTING IN CANCER DRUG DEVELOPMENT - PREDICTING MECHANISM OF ACTION	SCIENCE			English	Article							TUMOR-CELL-LINES; ARTIFICIAL-INTELLIGENCE; NETWORKS; DIAGNOSIS; RECOGNITION; FEASIBILITY; BINDING; ERRORS; SITES; ASSAY	Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines in the National Cancer Institute's drug screening program. Given six possible classes of mechanism, the network misses the correct category for only 12 out of 141 agents (8.5 percent), whereas linear discriminant analysis, a standard statistical technique, misses 20 out of 141 (14.2 percent). The success of the neural net indicates several things. (i) The cell line response patterns are rich in information about mechanism. (ii) Appropriately designed neural networks can make effective use of that information. (iii) Trained networks can be used to classify prospectively the more than 10,000 agents per year tested by the screening program. Related networks, in combination with classical statistical tools, will help in a variety of ways to move new anticancer agents through the pipeline from in vitro studies to clinical application.	NCI,DIV CANC BIOL DIAG & CTR,MATH BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,INFORMAT TECHNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WEINSTEIN, JN (corresponding author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BLDG 37,ROOM 5C-25,BETHESDA,MD 20892, USA.			Weinstein, John/0000-0001-9401-6908; Rubinstein, Lawrence/0000-0002-9720-9737				ALLEY MC, 1988, CANCER RES, V48, P589; ASADA N, 1990, RADIOLOGY, V177, P857, DOI 10.1148/radiology.177.3.2244001; BAI R, 1991, J BIOL CHEM, V266, P15882; BOONE JM, 1990, MED PHYS, V17, P234, DOI 10.1118/1.596501; Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1; BRUNAK S, 1990, NUCLEIC ACIDS RES, V18, P4797, DOI 10.1093/nar/18.16.4797; DAPONTE JS, 1991, COMPUT MED IMAG GRAP, V15, P3, DOI 10.1016/0895-6111(91)90100-A; Dayhoff Judith E., 1990, NEURAL NETWORK ARCHI; DEMELER B, 1991, NUCLEIC ACIDS RES, V19, P1593, DOI 10.1093/nar/19.7.1593; DYTCH HE, 1990, ANAL QUANT CYTOL, V12, P379; Hand D. J, 1981, WILEY SERIES PROBABI; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; JAYARAM HN, 1992, BIOCHEM BIOPH RES CO, V186, P1600, DOI 10.1016/S0006-291X(05)81591-8; KHANNA T, 1991, F NEURAL NETWORKS; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KUROGI S, 1991, BIOL CYBERN, V64, P243, DOI 10.1007/BF00201985; LUKASHIN AV, 1989, J BIOMOL STRUCT DYN, V6, P1123, DOI 10.1080/07391102.1989.10506540; MANN NH, 1991, ORTHOP CLIN N AM, V22, P303; MCGREGOR MJ, 1989, PROTEIN ENG, V2, P521, DOI 10.1093/protein/2.7.521; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; ONEILL MC, 1991, NUCLEIC ACIDS RES, V19, P313, DOI 10.1093/nar/19.2.313; PAULL KD, 1988, P AM ASSOC CANC RES, V29, P488; PAULL KD, 1992, CANCER RES, V52, P3892; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PAULL KD, IN PRESS CANCER CHEM; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SHOEMAKER RH, 1988, PREDICTION RESPONSE, P265; Szu H. H., 1990, Telematics and Informatics, V7, P403, DOI 10.1016/S0736-5853(05)80017-6; WIED GL, 1990, ANAL QUANT CYTOL, V12, P417; WOLBERG WH, 1990, ANAL QUANT CYTOL, V12, P314; 1990, STATISTICAL ANAL SYS, V1	34	253	263	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					447	451		10.1126/science.1411538	http://dx.doi.org/10.1126/science.1411538			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411538				2022-12-24	WOS:A1992JT77500030
J	THOMPSON, LT; MOSKAL, JR; DISTERHOFT, JF				THOMPSON, LT; MOSKAL, JR; DISTERHOFT, JF			HIPPOCAMPUS-DEPENDENT LEARNING FACILITATED BY A MONOCLONAL-ANTIBODY OR D-CYCLOSERINE	NATURE			English	Article							D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; NICTITATING-MEMBRANE RESPONSE; RAT-BRAIN; ALZHEIMERS-DISEASE; MODULATORY SITE; PARTIAL AGONIST; GLYCINE; RABBITS; COMPLEX	PERSISTENT neuronal plasticity, including that observed at some hippocampal synapses, requires N-methyl-D-aspartate (NMDA)-mediated transmission. NMDA receptor activation may be necessary for hippocampus-dependent learning as antagonists block acquisition in many such tasks. The behavioural effects of NMDA agonists are less well defined. We have shown that a monoclonal antibody (B6B21) displaced [H-3]-glycine that was bound specifically to the NMDA receptor, and enhanced the opening of its integral cation channel in a glycine-like fashion, effects that were competitively antagonized by 7-chlorokynurenic acid1. B6B21 also enhanced long-term potentiation in hippocampal slices1. We report here that intraventricular infusions of B6B21 significantly enhances acquisition rates in hippocampus-dependent trace eye blink conditioning in rabbits, halving the number of trials required to reach a criterion of 80% conditioned responses. Peripheral injections Of D-cycloserine, a partial agonist of the glycine site on the NMDA receptor which crosses the blood-brain barrier, also doubles rabbits' learning rates. Pseudoconditioning control experiments indicated a lack of nonspecific behavioural sensitization effects. Our data suggest that enhanced activation of the glycine coagonist site on the NMDA receptor/channel complex facilitates one form of associative learning and may be used in other learning tasks.	CHICAGO INST NEUROSURG & NEURORES,CHICAGO,IL 60614		THOMPSON, LT (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Moskal, Joseph/B-7628-2009; Thompson, Lucien/F-3496-2012; moskal, joseph/K-8431-2014	Thompson, Lucien/0000-0001-8878-0221; Disterhoft, John/0000-0002-8817-7913				ANDERSON P, 1991, EXCITATORY AMINO ACI, P463; BERGER TW, 1983, J NEUROPHYSIOL, V50, P1197, DOI 10.1152/jn.1983.50.5.1197; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONTRERAS PC, 1990, NEUROPHARMACOLOGY, V29, P291, DOI 10.1016/0028-3908(90)90015-J; DEDRICK RL, 1989, IMMUNITY CANCER, V2, P429; DEJONGE MC, 1990, EXP BRAIN RES, V80, P456, DOI 10.1007/BF00227987; DEYO RA, 1989, SCIENCE, V243, P809, DOI 10.1126/science.2916127; DISTERHOFT JF, 1986, P NATL ACAD SCI USA, V83, P2733, DOI 10.1073/pnas.83.8.2733; FOSTER AC, 1990, EUR J NEUROSCI, V2, P270, DOI 10.1111/j.1460-9568.1990.tb00418.x; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; GOLUB ES, 1987, IMMUNOLOGY SYNTHESIS; Hanngren H, 1961, ANTIBIOT CHEMOTHER, V12, P46; HARING R, 1991, J NEUROCHEM, V57, P323, DOI 10.1111/j.1471-4159.1991.tb02131.x; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; MIYOSHI R, 1990, SYNAPSE, V6, P338, DOI 10.1002/syn.890060405; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAHAN JB, 1989, PHARMACOL BIOCHEM BE, V34, P649, DOI 10.1016/0091-3057(89)90571-6; MONAHAN JB, 1989, J NEUROCHEM, V53, P370; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSKAL JR, 1986, J NEUROSCI, V6, P2045; MOYER JR, 1990, BEHAV NEUROSCI, V104, P243, DOI 10.1037/0735-7044.104.2.243; NAPIER RM, 1992, J EXP PSYCHOL ANIM B, V18, P182, DOI 10.1037/0097-7403.18.2.182; OLIVER MW, 1990, SYNAPSE, V5, P265, DOI 10.1002/syn.890050403; PATEL J, 1990, J NEUROCHEM, V54, P849, DOI 10.1111/j.1471-4159.1990.tb02329.x; PROCTER AW, 1989, NEUROSCI LETT, V101, P62, DOI 10.1016/0304-3940(89)90441-2; ROBINSON GS, 1989, PSYCHOBIOLOGY, V17, P156; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SCHWARTZ BL, 1991, NEUROLOGY, V41, P1341, DOI 10.1212/WNL.41.9.1341; SOLOMON PR, 1991, NEUROBIOL AGING, V12, P283, DOI 10.1016/0197-4580(91)90004-4; SOLOMON PR, 1986, BEHAV NEUROSCI, V100, P729, DOI 10.1037/0735-7044.100.5.729; Squire L. R., 1987, MEMORY BRAIN; THIELS E, 1992, NEUROSCIENCE, V46, P501, DOI 10.1016/0306-4522(92)90139-S; THOMSON AM, 1989, NATURE, V338, P422, DOI 10.1038/338422a0; VARTANIAN MG, 1991, NEUROSCI LETT, V133, P109, DOI 10.1016/0304-3940(91)90069-6; WATSON GB, 1990, BRAIN RES, V510, P158, DOI 10.1016/0006-8993(90)90745-W; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WOODRUFFPAK DS, 1988, PSYCHOL AGING, V3, P219, DOI 10.1037/0882-7974.3.3.219	37	154	174	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					638	641		10.1038/359638a0	http://dx.doi.org/10.1038/359638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406995				2022-12-24	WOS:A1992JT82400058
J	AMOS, CI; SHAW, GL; TUCKER, MA; HARTGE, P				AMOS, CI; SHAW, GL; TUCKER, MA; HARTGE, P			AGE AT ONSET FOR FAMILIAL EPITHELIAL OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPHYLACTIC OOPHORECTOMY; BREAST; CARCINOMA; LINKAGE; PRONE	Objective.-To provide age-specific risks for ovarian cancer for relatives of ovarian cancer case patients. To characterize the age at onset for ovarian cancer for women with a single relative vs several relatives affected with ovarian cancer. Design.-Three previous studies were reexamined. The cumulative probability of ovarian cancer in first-degree relatives of women with histologically confirmed epithelial ovarian cancer and matched control subjects who participated in the Cancer and Steroid Hormone (CASH) Study was determined. The age of onset of ovarian cancer in women with and without relatives with ovarian cancer in a Washington, DC, case-control study was contrasted with that of women with at least two first-degree relatives studied at the National Cancer Institute (NCI). Results.-The CASH Study data showed that first-degree relatives of women with ovarian cancer had an increased risk for ovarian cancer, especially at older ages, when compared with relatives of control subjects. However, the median age at onset was the same among women in the Washington, DC, study with and without an affected relative. Among the women with an extensive family history of ovarian cancer studied at the NCI, the age at onset was considerably younger (47 years) than is typical for this disease (59 years). Of these, 17% had been diagnosed as having primary ovarian cancer by age 40 years. Conclusions.-Women who have one first-degree relative affected by ovarian cancer are at greater risk for ovarian cancer but not at an age earlier than the general population. The small proportion of women who have several affected relatives are, however, at a greater risk of early onset of ovarian cancer. Prophylactic oophorectomy may be reasonable for these women.	NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	AMOS, CI (corresponding author), NIAMSD, LSB, GENET STUDIES SECT, BLDG 6, ROOM 249, BETHESDA, MD 20892 USA.		Tucker, Margaret A/B-4297-2015		PHS HHS [3-Y01-8-1037] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMOS CI, IN PRESS CANCER; BERLIN NI, 1966, ANN INTERN MED, V64, P403, DOI 10.7326/0003-4819-64-2-403; Cox DR, 1984, ANAL SURVIVAL DATA, P48; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; DOZOIS RR, 1970, ANN SURG, V172, P233, DOI 10.1097/00000658-197008000-00009; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; FRAUMENI JF, 1975, CANCER-AM CANCER SOC, V36, P364, DOI 10.1002/1097-0142(197508)36:2<364::AID-CNCR2820360211>3.0.CO;2-C; GREGGI S, 1990, GYNECOL ONCOL, V39, P300, DOI 10.1016/0090-8258(90)90256-K; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; JACOBS I, 1989, BRIT J OBSTET GYNAEC, V96, P510, DOI 10.1111/j.1471-0528.1989.tb03248.x; LURAIN JR, 1979, GYNECOL ONCOL, V8, P185, DOI 10.1016/0090-8258(79)90024-6; LURAIN JR, 1991, JAMA-J AM MED ASSOC, V266, P3343; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; LYNCH HT, 1982, OBSTET GYNECOL, V59, P589; LYNCH HT, 1981, JAMA-J AM MED ASSOC, V245, P261, DOI 10.1001/jama.245.3.261; NAROD SA, 1991, LANCET, V338, P82; PIVER MS, 1982, OBSTET GYNECOL, V60, P397; PIVER MS, 1991, SEMIN ONCOL, V18, P177; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SPEROFF T, 1991, AM J OBSTET GYNECOL, V164, P165, DOI 10.1016/0002-9378(91)90649-C; TETER J, 1967, CANCER-AM CANCER SOC, V20, P1301, DOI 10.1002/1097-0142(196708)20:8<1301::AID-CNCR2820200814>3.0.CO;2-4; TOBACMAN JK, 1982, LANCET, V2, P795; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; [No title captured]	28	55	55	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1896	1899		10.1001/jama.268.14.1896	http://dx.doi.org/10.1001/jama.268.14.1896			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404714				2022-12-24	WOS:A1992JR43900039
J	WING, RR; MATTHEWS, KA; KULLER, LH; SMITH, D; BECKER, D; PLANTINGA, PL; MEILAHN, EN				WING, RR; MATTHEWS, KA; KULLER, LH; SMITH, D; BECKER, D; PLANTINGA, PL; MEILAHN, EN			ENVIRONMENTAL AND FAMILIAL CONTRIBUTIONS TO INSULIN LEVELS AND CHANGE IN INSULIN LEVELS IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; BODY-MASS INDEX; BLOOD-PRESSURE; PREMENOPAUSAL WOMEN; PLASMA-INSULIN; ESSENTIAL-HYPERTENSION; GLUCOSE-INTOLERANCE; DIABETES-MELLITUS; PHYSICAL-ACTIVITY	Objective.-To examine familial and environmental variables associated with elevated insulin levels and changes in insulin levels in healthy, premenopausal women. Methods.-A population-based sample of 518 women (aged 42 to 50 years) completed baseline assessments of weight, cardiovascular risk factors, exercise behaviors, and glucose and insulin levels (fasting and 2 hours after a glucose load); 495 of the women were reevaluated after 3 years. Results.-Plasma insulin levels were related to weight, activity level, race, body fat distribution, and weight gain since age 20 years. Parental history of either diabetes or hypertension was also related to elevated insulin levels, independent of body mass index, with the highest insulin levels occurring in those women with a parental history of both diseases. Increases in plasma insulin levels over the years of follow-up were related to weight gain. Conclusions.-This study suggests the importance of using family history to identify women who may have elevated insulin levels and of intervening to prevent weight gain during middle age.	CHILDRENS HOSP PITTSBURGH, DIV ENDOCRINE, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			West, Delia Smith/GWV-5839-2022	West, Delia Smith/0000-0002-4375-2785	NHLBI NIH HHS [HL28266] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028266] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BUCOLO G, 1973, CLIN CHEM, V19, P476; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; DONAHUE RP, 1987, AM J EPIDEMIOL, V125, P650, DOI 10.1093/oxfordjournals.aje.a114578; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; GARCIAWEBB P, 1983, SCAND J CLIN LAB INV, V43, P677; GIDEZ JI, 1978, HIGH DENSITY LIPOPRO, P328; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; HORTON E S, 1986, Diabetes Metabolism Reviews, V2, P1; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KROTKIEWSKI M, 1979, METABOLISM, V28, P650, DOI 10.1016/0026-0495(79)90018-0; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MARKOVITZ JH, 1991, J HYPERTENS, V9, P399, DOI 10.1097/00004872-199105000-00003; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SINGER P, 1985, HYPERTENSION, V7, P182, DOI 10.1161/01.HYP.7.2.182; WARNICK GR, 1978, J LIPID RES, V19, P65; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WING RR, 1989, ARTERIOSCLEROSIS, V9, P479, DOI 10.1161/01.ATV.9.4.479; ZAVARONI I, 1990, DIABETIC MED, V7, P494, DOI 10.1111/j.1464-5491.1990.tb01430.x; ZIMMET P, 1989, DIABETIC MED, V6, P728, DOI 10.1111/j.1464-5491.1989.tb01266.x	39	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1890	1895		10.1001/jama.268.14.1890	http://dx.doi.org/10.1001/jama.268.14.1890			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404713				2022-12-24	WOS:A1992JR43900038
J	HALSEY, NA; COBERLY, JS; HOLT, E; COREIL, J; KISSINGER, P; MOULTON, LH; BRUTUS, JR; BOULOS, R				HALSEY, NA; COBERLY, JS; HOLT, E; COREIL, J; KISSINGER, P; MOULTON, LH; BRUTUS, JR; BOULOS, R			SEXUAL-BEHAVIOR, SMOKING, AND HIV-1 INFECTION IN HAITIAN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIMPLEX VIRUS TYPE-2; KILLER-CELL-ACTIVITY; CIGARETTE-SMOKING; CERVICAL-CANCER; UTERINE CERVIX; RISK-FACTORS; INTRAEPITHELIAL NEOPLASIA; CARCINOMA INSITU; SMOKERS; DYSPLASIA	Objective. - To determine whether a previously observed association between human immunodeficiency virus type 1 (HIV-1) infection and smoking in Haitian women could be explained by confounding high-risk behaviors. Design and Setting. - A nested case-control study at a primary care health clinic in Cite Soleil, Haiti. Participants. - Women who reported having smoked (n = 89) and randomly selected nonsmokers (n = 329) who had participated in a survey 1 to 12 months earlier evaluating risk factors for HIV-1 infection. Main Outcome Measures. - Lifetime sexual practices, smoking, health beliefs and practices, and other factors potentially confounding the relationship between smoking and HIV-1 infection. Results. - Compared with nonsmokers, smokers reported higher rates of high-risk behaviors, including more lifetime sex partners (P < .001), being less likely to be married (P < .01), and being more likely to have visited folk healers (P < .01). No intravenous drug use was reported, and no significant differences were noted between smokers and nonsmokers in numbers of past surgical or dental procedures or injections. Adjustment for all factors associated with HIV-1 infection and smoking in regression analyses revealed an independent association between smoking and HIV-1 infection (odds ratio [OR], 3.4; 95% confidence interval [Cl], 1.6 to 7.5). Other factors associated with HIV-1 infection included having more than two lifetime sex partners (OR, 3.4; 95% Cl, 1.7 to 6.8) and lower socioeconomic status as reflected by a dirt floor in the home (OR, 8.6; 95% Cl, 3.3 to 22.0). Conclusions. - Smoking is a marker for high-risk sexual behavior and is associated with an increased risk of HIV-1 infection in this population. The persistent association between smoking and HIV-1 infection after adjustment for all known risk factors suggests the possibility of a biologic effect of smoking that warrants further evaluation in other populations.	CTR DEV & HLTH,PORT AU PRINCE,HAITI; UNIV S FLORIDA,COLL PUBL HLTH,DEPT COMMUNITY & FAMILY MED,TAMPA,FL 33620	State University System of Florida; University of South Florida	HALSEY, NA (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NIAID NIH HHS [1RO1AI26521] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026521] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; AUSTIN DF, 1983, JAMA-J AM MED ASSOC, V250, P516; BARON JA, 1987, SMOKING REPRODUCTIVE, P149; BLAKE GH, 1988, ANN INTERN MED, V109, P198, DOI 10.7326/0003-4819-109-3-198; BOULOS R, 1990, J ACQ IMMUN DEF SYND, V3, P721; BRESCIA RJ, 1986, HUM PATHOL, V17, P552, DOI 10.1016/S0046-8177(86)80126-5; BRINTON LA, 1990, AM J EPIDEMIOL, V131, P958, DOI 10.1093/oxfordjournals.aje.a115615; BRISSON J, 1988, AM J EPIDEMIOL, V128, P337, DOI 10.1093/oxfordjournals.aje.a114973; BUCKLEY JD, 1981, LANCET, V2, P1010; BURNS DN, 1991, J ACQ IMMUN DEF SYND, V4, P76; CLARKE EA, 1982, AM J EPIDEMIOL, V115, P59, DOI 10.1093/oxfordjournals.aje.a113279; CORRE F, 1971, LANCET, V2, P632; DALING JR, 1986, SEX TRANSM DIS, V13, P16, DOI 10.1097/00007435-198601000-00004; FERSON M, 1979, INT J CANCER, V23, P603, DOI 10.1002/ijc.2910230504; GINNS LC, 1985, AM REV RESPIR DIS, V131, P831; Hardell L, 1987, Cancer Detect Prev Suppl, V1, P567; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; HOLLY EA, 1986, J NATL CANCER I, V76, P983; HUGHES DA, 1985, CLIN EXP IMMUNOL, V61, P459; ISTVAN J, 1984, PSYCHOL BULL, V95, P301, DOI 10.1037/0033-2909.95.2.301; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; KHAW KT, 1988, NEW ENGL J MED, V318, P1705, DOI 10.1056/NEJM198806303182601; LAYDE PM, 1989, JAMA-J AM MED ASSOC, V261, P1631, DOI 10.1001/jama.261.11.1631; LEE DJ, 1991, AM J PUBLIC HEALTH, V81, P859, DOI 10.2105/AJPH.81.7.859; LYON JL, 1983, AM J PUBLIC HEALTH, V73, P558, DOI 10.2105/AJPH.73.5.558; MARSHALL JR, 1983, JNCI-J NATL CANCER I, V70, P847; MAYBERRY RM, 1985, AM J PUBLIC HEALTH, V75, P676, DOI 10.2105/AJPH.75.6.676; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P456; MONTO AS, 1978, AM J EPIDEMIOL, V107, P57, DOI 10.1093/oxfordjournals.aje.a112508; MONTO AS, 1975, AM REV RESPIR DIS, V111, P27; MONTO AS, 1978, AM REV RESPIR DIS, V119, P1101; NEWELL GR, 1985, PREV MED, V14, P81, DOI 10.1016/0091-7435(85)90023-4; PAPE JW, 1986, AM J MED SCI, V291, P4, DOI 10.1097/00000441-198601000-00002; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; PETITTI DB, 1986, AM J EPIDEMIOL, V123, P89, DOI 10.1093/oxfordjournals.aje.a114227; PRAKASH SS, 1985, INT J CANCER, V35, P51, DOI 10.1002/ijc.2910350109; ROSE RM, 1986, J INFECT DIS, V154, P611, DOI 10.1093/infdis/154.4.611; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; ROYCE RA, 1990, 6TH INT C AIDS SAN F; SARACCI R, 1987, EPIDEMIOL REV, V9, P175, DOI 10.1093/oxfordjournals.epirev.a036301; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P259; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P194, DOI 10.1164/ajrccm/139.1.194; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P1446, DOI 10.1164/ajrccm/139.6.1446; TREVATHAN E, 1983, JAMA-J AM MED ASSOC, V250, P499, DOI 10.1001/jama.250.4.499; VONKA V, 1984, INT J CANCER, V33, P49, DOI 10.1002/ijc.2910330110; WALD N, 1990, SMOKIN GHORMONE DISO, P269; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WINKELSTEIN W, 1984, AM J EPIDEMIOL, V119, P1; 1986, INT AGENCY RES CANCE, V38, P282; 1989, 898411 US DEP HLTH H; 1990, LANCET, V335, P1561; 1979, US DHEW PHS7950066 P; 1986, SUGI SUPPLEMENTAL LI, P269	57	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2062	2066		10.1001/jama.267.15.2062	http://dx.doi.org/10.1001/jama.267.15.2062			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM650	1485894				2022-12-24	WOS:A1992HM65000032
J	LICHTMAN, SW; PISARSKA, K; BERMAN, ER; PESTONE, M; DOWLING, H; OFFENBACHER, E; WEISEL, H; HESHKA, S; MATTHEWS, DE; HEYMSFIELD, SB				LICHTMAN, SW; PISARSKA, K; BERMAN, ER; PESTONE, M; DOWLING, H; OFFENBACHER, E; WEISEL, H; HESHKA, S; MATTHEWS, DE; HEYMSFIELD, SB			DISCREPANCY BETWEEN SELF-REPORTED AND ACTUAL CALORIC-INTAKE AND EXERCISE IN OBESE SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLY-LABELED-WATER; ENERGY-EXPENDITURE; BODY-WEIGHT; SMALL EATERS; HUMANS; WOMEN; VALIDATION; ADULTS; FOOD; MEN	Background and Methods. Some obese subjects repeatedly fail to lose weight even though they report restricting their caloric intake to less than 1200 kcal per day. We studied two explanations for this apparent resistance to diet - low total energy expenditure and underreporting of caloric intake - in 224 consecutive obese subjects presenting for treatment. Group 1 consisted of nine women and one man with a history of diet resistance in whom we evaluated total energy expenditure and its main thermogenic components and actual energy intake for 14 days by indirect calorimetry and analysis of body composition. Group 2, subgroups of which served as controls in the various evaluations, consisted of 67 women and 13 men with no history of diet resistance. Results. Total energy expenditure and resting metabolic rate in the subjects with diet resistance (group 1) were within 5 percent of the predicted values for body composition, and there was no significant difference between groups 1 and 2 in the thermic effects of food and exercise. Low energy expenditure was thus excluded as a mechanism of self-reported diet resistance. In contrast, the subjects in group 1 underreported their actual food intake by an average (+/-SD) of 47+/-16 percent and overreported their physical activity by 51+/-75 percent. Although the subjects in group 1 had no distinct psychopathologic characteristics, they perceived a genetic cause for their obesity, used thyroid medication at a high frequency, and described their eating behavior as relatively normal (all P<0.05 as compared with group 2). Conclusions. The failure ot some obese subjects to lose weight while eating a diet they report as low in calories is due to an energy intake substantially higher than reported and an overestimation ot physical activity, not to an abnormality in thermogenesis.	COLUMBIA UNIV COLL PHYS & SURG, ST LUKES ROOSEVELT HOSP CTR, OBES RES CTR, DEPT MED, NEW YORK, NY 10032 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT SURG, NEW YORK, NY 10021 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital			González, Adela M Gómez/D-2863-2012; Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425	NCRR NIH HHS [RR00047] Funding Source: Medline; NIDDK NIH HHS [DK-26687, P01-DK42618] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687, P01DK042618] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461, DOI 10.1093/ajcn/37.3.461; CLARK D, 1992, BRIT J NUTR, V68, P31, DOI 10.1079/BJN19920064; DIEM K, 1962, DOCUMENTA GEIGY SCI, P631; Dwyer JT., 1988, MODERN NUTR HLTH DIS, V7, P887; GAESSER GA, 1975, J APPL PHYSIOL, V38, P1132, DOI 10.1152/jappl.1975.38.6.1132; GEORGE V, 1989, INT J OBESITY, V13, P43; GEORGE V, 1991, AM J CLIN NUTR, V53, P425, DOI 10.1093/ajcn/53.2.425; GOLDMAN RF, 1961, TECHNIQUES MEASURING, P79; Graham J.R., 1987, MMPI PRACTICAL GUIDE; HADIGAN CM, 1992, INT J EAT DISORDER, V12, P107, DOI 10.1002/1098-108X(199207)12:1&lt;107::AID-EAT2260120115&gt;3.0.CO;2-Y; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P52, DOI 10.1093/ajcn/52.1.52; KUSHNER RF, 1990, AM J CLIN NUTR, V52, P219, DOI 10.1093/ajcn/52.2.219; LUSK G, 1928, ELEMENTS SCI NUTRITI; MERTZ W, 1991, AM J CLIN NUTR, V54, P291, DOI 10.1093/ajcn/54.2.291; Newburgh LH, 1930, ANN INTERN MED, V3, P815, DOI 10.7326/0003-4819-3-8-815; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; PRENTICE AM, 1985, LANCET, V1, P1419; PRENTICE AM, 1988, P NUTR SOC, V47, P259, DOI 10.1079/PNS19880043; PRENTICE AM, 1990, IDECG WORKING GROUP; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; RAVUSSIN E, 1989, AM J CLIN NUTR, V49, P968, DOI 10.1093/ajcn/49.5.968; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; SCHOELLER DA, 1986, AM J PHYSIOL, V250, pR823, DOI 10.1152/ajpregu.1986.250.5.R823; SCHOELLER DA, 1988, J NUTR, V118, P1278, DOI 10.1093/jn/118.11.1278; SCHOELLER DA, 1990, NUTR REV, V48, P373, DOI 10.1111/j.1753-4887.1990.tb02882.x; SCHOELLER DA, 1991, ANNU REV NUTR, V11, P355, DOI 10.1146/annurev.nu.11.070191.002035; SEGAL KR, 1985, J CLIN INVEST, V76, P1107, DOI 10.1172/JCI112065; SEGAL KR, 1990, METABOLISM, V39, P985, DOI 10.1016/0026-0495(90)90312-Z; Siri WE., 1956, ADV BIOL MED PHYS, V4, P239, DOI DOI 10.1016/B978-1-4832-3110-5.50011-X; Spitzer RL, 1990, STRUCTURED CLIN INTE; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; WELLE S, 1992, AM J CLIN NUTR, V55, P14, DOI 10.1093/ajcn/55.1.14; YELLOWLEES PM, 1988, BRIT MED J, V296, P1689, DOI 10.1136/bmj.296.6638.1689; 1987, DSM3R AM PSYCH ASS; 1985, ANN INTERN MED, V103, P977	38	942	948	0	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1893	1898		10.1056/NEJM199212313272701	http://dx.doi.org/10.1056/NEJM199212313272701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1454084	Bronze			2022-12-24	WOS:A1992KE50500001
J	OPPENHEIM, RW; YIN, QW; PREVETTE, D; YAN, Q				OPPENHEIM, RW; YIN, QW; PREVETTE, D; YAN, Q			BRAIN-DERIVED NEUROTROPHIC FACTOR RESCUES DEVELOPING AVIAN MOTONEURONS FROM CELL-DEATH	NATURE			English	Article							EMBRYO SPINAL-CORD; NERVE GROWTH-FACTOR; CHICK-EMBRYO; RETROGRADE TRANSPORT; MOTOR NEURONS; MESSENGER-RNA; SURVIVAL; NGF; MUSCLE; DEGENERATION	DURING normal vertebrate development, about half of spinal motoneurons are lost by a process of naturally occurring or programmed cell death1,2. Additional developing motoneurons degenerate after the removal of targets3,4 or afferents5. Naturally occurring motoneuron death as well as motoneuron death after loss of targets or after axotomy can. be prevented by in vivo treatment with putative target (muscle) derived or other neurotrophic agents6-8. Motoneurons can also be prevented from dying in vitro9-12 and in vivo (Y.Q.-W., R.W., D.P., J. Johnson and L. Van Eldik, unpublished data and refs 7, 13, 14) by treatment with central nervous system extracts (brain or spinal cord) and purified central nervous system and glia-derived proteins. Here we report that in vivo treatment of chick embryos with brain-derived neurotrophic factor rescues motoneurons from naturally occurring cell death. Furthermore, in vivo treatment with brain-derived neurotrophic factor (and nerve growth factor) also prevents the induced death of motoneurons that occurs following the removal of descending afferent input(deafferentation)5. These data indicate that members of the neurotrophin family can promote the survival of developing avian motoneurons.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27103; AMGEN INC,AMGEN CTR,NEUROBIOL PROGRAM,THOUSAND OAKS,CA 91320	Wake Forest University; Wake Forest Baptist Medical Center; Amgen	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27103, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BHATTACHARYYA A, IN PRESS J NEUROBIOL; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DOHRMANN U, 1987, DEV BIOL, V124, P145, DOI 10.1016/0012-1606(87)90467-2; DOHRMANN U, 1986, DEV BIOL, V188, P20; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HAMBURGER V, 1958, AM J ANAT, V102, P465; HOFER MM, 1988, NATURE, V331, P361; HULST JR, 1986, DEV BRAIN RES, V25, P153, DOI 10.1016/0165-3806(86)90164-1; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARCHETTI D, 1991, DEV BIOL, V148, P306, DOI 10.1016/0012-1606(91)90339-5; OKADO N, 1984, J NEUROSCI, V4, P1639; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIM RW, 1978, J COMP NEUROL, V177, P87, DOI 10.1002/cne.901770107; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; OPPENHEIM RW, IN PRESS J NEUROSCI; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WAYNE DB, 1988, DEV BIOL, V127, P220, DOI 10.1016/0012-1606(88)90203-5; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1988, NEURON, V1, P335	28	445	462	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					755	759		10.1038/360755a0	http://dx.doi.org/10.1038/360755a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465146				2022-12-24	WOS:A1992KE47200038
J	ROZAKISADCOCK, M; MCGLADE, J; MBAMALU, G; PELICCI, G; DALY, R; LI, W; BATZER, A; THOMAS, S; BRUGGE, J; PELICCI, PG; SCHLESSINGER, J; PAWSON, T				ROZAKISADCOCK, M; MCGLADE, J; MBAMALU, G; PELICCI, G; DALY, R; LI, W; BATZER, A; THOMAS, S; BRUGGE, J; PELICCI, PG; SCHLESSINGER, J; PAWSON, T			ASSOCIATION OF THE SHC AND GRB2/SEM5 SH2-CONTAINING PROTEINS IS IMPLICATED IN ACTIVATION OF THE RAS PATHWAY BY TYROSINE KINASES	NATURE			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE; PC12 CELLS; RECEPTOR; DIFFERENTIATION; INHIBITION; AFFINITY; MUTATION; VECTORS	THE mammalian shc gene encodes two overlapping, widely expressed proteins of 46 and 52K, with a carboxy-terminal SH2 domain that binds activated growth factor receptors, and a more amino-terminal glycine/proline-rich region1. These shc gene products (Shc) are transforming when overexpressed in fibroblasts1. Shc proteins become phosphorylated on tyrosine in cells stimulated with a variety of growth factors1, and in cells transformed by v-src (ref. 2), suggesting that they are tyrosine kinase targets that control a mitogenic signalling pathway. Here we report that tyrosine-phosphorylated Shc proteins form a specific complex with a non-phosphorylated 23K polypeptide encoded by the grb2/sem-5 gene3,4. The grb2/sem-5 gene product itself contains an SH2 domain, which mediates binding to Shc, and is implicated in activation of the Ras guanine nucleotide-binding protein by tyrosine kinases in both Caenorhabditis elegans and mammalian cells3,4. Consistent with a role in signalling through Ras, shc overexpression induced Ras-dependent neurite outgrowth in PC12 cells. These results suggest that Shc tyrosine phosphorylation can couple tyrosine kinases to Grb2/Sem-5, through formation of a Shc-Grb2/Sem-5 complex, and thereby regulate the mammalian Ras signalling pathway.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology; University of Toronto; University of Perugia; New York University			Franzeck, Fabian C/B-5055-2011; Daly, Roger J/C-8179-2009; Pelicci, Giuliana/AAA-8921-2022; Pawson, Tony J/E-4578-2013; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Daly, Roger/0000-0002-5739-8027				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO K, 1990, ONCOGENE, V5, P921; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	23	941	978	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					689	692		10.1038/360689a0	http://dx.doi.org/10.1038/360689a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465135				2022-12-24	WOS:A1992KD08200062
J	BLACK, FL				BLACK, FL			WHY DID THEY DIE	SCIENCE			English	Editorial Material							HLA				BLACK, FL (corresponding author), YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.							BAUR MP, 1982, HISTOCOMPATIBILITY T; BELICH MP, 1992, NATURE, V357, P326, DOI 10.1038/357326a0; BHATIA K, 1989, HUM BIOL, V61, P45; BLACK FL, 1971, J INFECT DIS, V124, P306, DOI 10.1093/infdis/124.3.306; BORST P, 1991, PARASITOL TODAY, V8, pA29; CATTANEO R, 1986, VIROLOGY, V154, P97, DOI 10.1016/0042-6822(86)90433-2; DEHAY C, 1987, TISSUE ANTIGENS, V30, P49; Denevan William M., 1992, NATIVE POPULATION AM, V2nd; DUTOIT ED, 1990, TISSUE ANTIGENS, V36, P122, DOI 10.1111/j.1399-0039.1990.tb01812.x; FLEMINGMORAN M, 1991, HUM BIOL, V63, P835; FRIKEL P, 1963, REV MUS PAUL, V14, P11145; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; HEDRICK PW, 1983, GENETICS, V104, P449; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KILLIAMS RC, 1981, AM J PHYS ANTHROPOL, V56, P291; LEE TD, 1988, TISSUE ANTIGENS, V32, P188, DOI 10.1111/j.1399-0039.1988.tb01656.x; MCCRUMB FR, 1963, AM J DIS CHILD, V101, P689; Salzano FM, 1988, S AM INDIANS CASE ST; SULLIVAN PJ, 1992, SCIENCE, V256, P1743, DOI 10.1126/science.1520396; WATKINS DI, 1992, NATURE, V357, P329, DOI 10.1038/357329a0; [No title captured]	21	119	121	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1739	1741		10.1126/science.1465610	http://dx.doi.org/10.1126/science.1465610			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465610				2022-12-24	WOS:A1992KB96400023
J	VONMUTIUS, E; FRITZSCH, C; WEILAND, SK; ROLL, G; MAGNUSSEN, H				VONMUTIUS, E; FRITZSCH, C; WEILAND, SK; ROLL, G; MAGNUSSEN, H			PREVALENCE OF ASTHMA AND ALLERGIC DISORDERS AMONG CHILDREN IN UNITED GERMANY - A DESCRIPTIVE COMPARISON	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SULFUR-OXIDES; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; NEW-ZEALAND; HAY-FEVER; RESPONSIVENESS; ADOLESCENTS; POLLINOSIS; MORTALITY; MORBIDITY	Objectives-To compare the prevalence of asthma and allergic disorders among children in Munich, western Germany, and Letpzig, eastern Germany, where environmental exposure, particularly air concentrations of sulphur dioxide and particulate matter, and living conditions have differed over the past 45 years. Design-Prevalence surveys among school-children aged 9-11 years in Leipzig and Munich. Self completion of written questionnaire by the children's parents and lung function measurements. Subjects-1051 children in Leipzig and 5030 in Munich. Setting-Primary schools. Main outcome measures-Reported lifetime prevalence of asthma and allergic disorders, and bronchial hyperresponsiveness assessed by cold air inhalation challenge. Results-The lifetime prevalence of asthma diagnosed by a doctor was 7.3% (72) in Leipzig and 9.3% (435) in Munich; prevalences of wheezing were 20% (191) and 17% (786) respectively. The prevalence of diagnosed bronchitis was higher in Leipzig than Munich (30.9% (303) v 15.9% (739); p<0.01). A significant drop in forced expiratory volume (>9%) after cold air challenge was measured in 6.4% (57) of children in Leipzig and in 7.7% (345) of those in Munich. Hay fever (2.4% (24) v 8.6% (410); p<0.01) and typical symptoms of rhinitis (16.6% (171) v 19.7% (961); p<0.05) were reported less often in Leipzig than in Munich. Conclusions-No significant differences were seen in the lifetime prevalence of asthma, wheezing, and bronchial hyperresponsiveness between children in Leipzig and Munich. The lifetime prevalence of bronchitis was higher in Leipzig than in Munich. The lower prevalence rates of allergic disorders in Leipzig could point toward aetiological factors that are associated with Western lifestyle and living conditions.	CHILDRENS HOSP LEIPZIG, O-7050 LEIPZIG, GERMANY; RUHR UNIV BOCHUM, DEPT SOCIAL MED & EPIDEMIOL, W-4630 BOCHUM, GERMANY; GSF MEDIS INST, ENVIRONM & HUMAN HLTH RES CTR, W-8000 MUNICH, GERMANY; KRANKENHAUS GROSSHANSDORF HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, HAMBURG, GERMANY	Ruhr University Bochum	VONMUTIUS, E (corresponding author), UNIV MUNICH, CHILDRENS HOSP, DR VON HAUNERSCHE KINDERKLIN, W-8000 MUNICH 2, GERMANY.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEISS JL, 1980, STATISTICAL METHODS; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRIDAY GA, 1988, PEDIATR CLIN N AM, V35, P1149; GORE AT, 1968, BR J PREV SOC MED, V12, P104; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JORRES R, 1990, EUR RESPIR J, V3, P132; KOENIG JQ, 1985, J ALLERGY CLIN IMMUN, V76, P813, DOI 10.1016/0091-6749(85)90754-7; LOGAN WPD, 1953, LANCET, V264, P336; LUNN JE, 1970, BRIT J PREV SOC MED, V24, P223; LUNN JE, 1967, BRIT J PREV SOC MED, V21, P7; MITCHELL EA, 1989, J ASTHMA, V26, P349, DOI 10.3109/02770908909073277; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; NICOLAI T, IN PRESS AM REV RESP; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEINBRUCK P, 1969, MONATSSCHR LUNGENKR, V12, P289; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VARONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P909; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; 1990, STATISTICAL ANAL VER	36	363	369	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1395	1399		10.1136/bmj.305.6866.1395	http://dx.doi.org/10.1136/bmj.305.6866.1395			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486303	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992KB85600021
J	BRANCATI, FL; WHITTLE, JC; WHELTON, PK; SEIDLER, AJ; KLAG, MJ				BRANCATI, FL; WHITTLE, JC; WHELTON, PK; SEIDLER, AJ; KLAG, MJ			THE EXCESS INCIDENCE OF DIABETIC END-STAGE RENAL-DISEASE AMONG BLACKS - A POPULATION-BASED STUDY OF POTENTIAL EXPLANATORY FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESSENTIAL-HYPERTENSION; RACIAL-DIFFERENCES; BLOOD-PRESSURE; MARYLAND; MELLITUS; FAILURE; RACE; RISK	Objective.-To investigate whether the excess incidence of diabetic end-stage renal disease (ESRD) among African Americans could be explained by racial differences in putative ESRD risk factors. Design.-Population-based, ecologic study using the 1981 and 1982 Maryland Statewide Household Hypertension Survey for data on risk factor prevalence. Participants.-A total of 2.1 million adults residing within the boundaries of the Maryland Regional ESRD Registry, grouped by race and ZIP code into 26 subpopulations. Main Outcome Measure.-Incidence rates of treatment for diabetic ESRD between 1980 and 1985 from the Maryland Regional ESRD Registry by subpopulation. Results.-Between 1980 and 1985, 442 persons entered treatment for diabetic ESRD. At the level of the subpopulation, diabetic ESRD incidence was positively associated with black race (relative risk [RR], 3.42; 95% confidence interval [Cl], 2.84 to 4.13), prevalence of diabetes (RR, 2.35; 95% Cl, 1.92 to 2.87), prevalence of poorly controlled hypertension (RR, 1.80; 95% Cl, 1.45 to 1.86), lack of a regular source of health care (RR, 1.82; 95% Cl, 1.62 to 2.05), and lower socioeconomic status as indicated by lack of college education (RR, 1.41; 95% Cl, 1.32 to 1.52) (all, P<.0001). After adjusting for these risk factors, black race remained strongly associated with the overall incidence of diabetic ESRD (RR, 2.70; 95% Cl, 1.89 to 3.86; P<.0001). Further analyses suggested that this excess risk among blacks was confined to ESRD related to non-insulin-dependent diabetes (RR, 4.80; 95% Cl, 3.09 to 7.46; P<.0001); blacks were at no higher risk than were whites for ESRD related to insulin-dependent diabetes (RR, 0.90; 95% Cl, 0.52 to 1.55; P=.70). Conclusions.-These data suggest that the excess incidence of diabetic ESRD among blacks is not fully explained by a higher prevalence of diabetes or hypertension in blacks or by racial differences in age, socioeconomic status, or access to health care. Instead, they suggest an increased susceptibility to ESRD resulting from non-insulin-dependent diabetes among blacks as compared with whites.			BRANCATI, FL (corresponding author), JOHNS HOPKINS MED INST,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,CARNEGIE 2,600 N WOLFE ST,BALTIMORE,MD 21287, USA.			Whittle, Jeff/0000-0002-9544-838X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722, M01RR000035] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00722, 5M01RR00035] Funding Source: Medline; NHLBI NIH HHS [HL07180] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RM, 1991, DIABETES CARE, V14, P605, DOI 10.2337/diacare.14.7.605; APOSTOLIDES AY, 1980, P SECTION SURVEY RES, V1, P692; BRESLOW NE, 1989, DESIGN ANAL COHORT S, V2, P119; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; DRIZD T, 1986, VITAL HLTH STAT, V234, P10; EBERHARDT MS, 1990, DIABETES S1, V39, pA205; ENTWISLE G, 1983, PREV MED, V12, P695, DOI 10.1016/0091-7435(83)90227-X; FERGUSON R, 1988, J CLIN EPIDEMIOL, V41, P1189, DOI 10.1016/0895-4356(88)90023-6; FROHLICH ED, 1984, MINER ELECTROL METAB, V10, P173; GOLD CH, 1982, S AFR MED J, V61, P263; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HARRIS MI, 1985, NIH851468 PUBL, P1; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; JAMEEL N, 1990, DIABETES S1, V39, pA39; KAPPEL DF, 1986, AM J KIDNEY DIS, V8, P234, DOI 10.1016/S0272-6386(86)80031-2; LEBOVITZ HE, 1990, DIABETES CARE, V13, P1186, DOI 10.2337/diacare.13.11.1186; LEVY SB, 1978, ANN INTERN MED, V88, P12, DOI 10.7326/0003-4819-88-1-12; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P290; MOORE RD, 1990, AM J HYPERTENS, V3, P1; Rettig BS, 1984, DIABETIC NEPHROPATHY, V3, P26; ROSEMAN JM, 1985, NIH851468 US DEP HLT, P1; STATIUS LW, 1988, DISEASES KIDNEY, P2561; STEWART JH, 1975, BMJ-BRIT MED J, V1, P440, DOI 10.1136/bmj.1.5955.440; TIERNEY WM, 1989, AM J KIDNEY DIS, V13, P485, DOI 10.1016/S0272-6386(89)80006-X; WARREN SE, 1980, AM J MED, V69, P425, DOI 10.1016/0002-9343(80)90015-7; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P289; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; 1989, USRDS1989 NIH NAT I; 1984, ZIP CODE PROFILE RAC	30	187	187	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3079	3084		10.1001/jama.268.21.3079	http://dx.doi.org/10.1001/jama.268.21.3079			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1433738				2022-12-24	WOS:A1992KA00200030
J	GREEN, JBA; NEW, HV; SMITH, JC				GREEN, JBA; NEW, HV; SMITH, JC			RESPONSES OF EMBRYONIC XENOPUS CELLS TO ACTIVIN AND FGF ARE SEPARATED BY MULTIPLE DOSE THRESHOLDS AND CORRESPOND TO DISTINCT AXES OF THE MESODERM	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; AMPHIBIAN DEVELOPMENT; NEURAL INDUCTION; HOMEOBOX GENES; RETINOIC ACID; BODY PATTERN; LAEVIS; EXPRESSION; ORGANIZER; HOMOLOG	The potent mesoderm-inducing factors activin and FGF are present as maternally synthesized proteins in embryos of X. laevis. We show that activin can act on explanted blastomeres to induce at least five different cell states ranging from posterolateral mesoderm to dorsoanterior organizer mesoderm. Each state is induced in a narrow dose range bounded by sharp thresholds. By contrast, FGF induces only posterolateral markers and does so over relatively broad dose ranges. FGF can modulate the actions of activin, potentiating them and broadening the threshold-bounded dose windows. Our results indicate that orthogonal gradients of activin and FGF would be sufficient to specify the main elements of the body plan.			GREEN, JBA (corresponding author), NATL INST MED RES, OPHTHALMOL LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.		Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620; Smith, Jim/0000-0003-2413-9392				ALBANO RM, 1990, DEVELOPMENT, V110, P435; ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOLCE ME, 1992, DEVELOPMENT, V115, P681; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1981, NATURE, V290, P775, DOI 10.1038/290775a0; COOKE J, 1985, J EMBRYOL EXP MORPH, V88, P85; Dalcq A., 1937, Archives de Biologie Liege, V48, P669; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1990, CURR TOP DEV BIOL, V24, P31; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FRITZ A, 1988, NUCLEIC ACIDS RES, V16, P1453, DOI 10.1093/nar/16.4.1453; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; GURDON JB, 1984, CELL, V38, P691, DOI 10.1016/0092-8674(84)90264-2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAUSEN P, 1981, STAIN TECHNOL, V56, P287, DOI 10.3109/10520298109067329; JONAS EA, 1989, DEVELOPMENT, V106, P399; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; MOHUN T, 1988, J MOL BIOL, V202, P67, DOI 10.1016/0022-2836(88)90519-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SAHA MS, 1992, NEURON, V8, P1003, DOI 10.1016/0896-6273(92)90123-U; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	64	442	449	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					731	739		10.1016/0092-8674(92)90550-V	http://dx.doi.org/10.1016/0092-8674(92)90550-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423628				2022-12-24	WOS:A1992JZ63300004
J	KIDD, S				KIDD, S			CHARACTERIZATION OF THE DROSOPHILA CACTUS LOCUS AND ANALYSIS OF INTERACTIONS BETWEEN CACTUS AND DORSAL PROTEINS	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; TOLL GENE-PRODUCT; DORSOVENTRAL PATTERN; EMBRYONIC POLARITY; VENTRAL POLARITY; MESSENGER-RNA; NOTCH LOCUS; SEQUENCE; TRANSCRIPTION	An oligonucleotide based on the cdc10/SWI6 repeats of the Drosophila Notch protein was used to isolate other Drosophila genes with these repeats. One of these genes is the cactus locus, 1 of 11 genes required maternally for the establishment in embryos of a gradient of nuclear localization of dorsal protein, a rel-like transcription factor. Previous work showed that in cactus mutants more dorsal protein enters the nucleus in dorsal regions, resulting in a ventralized phenotype. It is now shown that the cactus locus produces two proteins that differ at their carboxy termini; both contain six cdc10/SWI6 repeats that are sufficient for binding to dorsal and for inhibiting the ability of dorsal to bind DNA. The site on dorsal to which cactus binds was localized to the rel homology domain, where it overlaps with, or is adjacent to, the nuclear localization signal. In vivo the bulk of the cactus protein associated with dorsal is phosphorylated. This, or the association with dorsal, appears to stabilize the maternal cactus protein.			KIDD, S (corresponding author), ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM25103] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025103] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1979, CELL, V16, P841, DOI 10.1016/0092-8674(79)90099-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GEISLER R, 1992, CELL, V71; GERTTULA S, 1988, GENETICS, V119, P123; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; IP YT, 1991, CELL, V64, P439; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; LIEBER T, 1992, IN PRESS NEURON, V9; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; NORRIS JL, 1992, GENE DEV, V6, P1657; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUSHLOW CA, 1990, CELL BIOL, V1, P173; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1984, NATURE, V311, P262, DOI 10.1038/311262a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WULCZYN GF, 1992, NATURE, V358, P597; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	59	220	223	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					623	635		10.1016/0092-8674(92)90596-5	http://dx.doi.org/10.1016/0092-8674(92)90596-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423619				2022-12-24	WOS:A1992JY67600010
J	BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH				BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH			ELECTRONIC COMMUNICATION BETWEEN PROVIDERS OF PRIMARY AND SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; SPECIALISTS	Objective-To study the effects of the introduction of electronic data interchange between primary and secondary care providers on speed of communication, efficiency of data handling, and satisfaction of general practitioners with communication. Design-Comparison of traditional paper based communication for laboratory reports and admission-discharge reports between hospital and general practitioners and electronic data interchange. Setting-Twenty-seven general practitioners whose offices were equipped with a practice information system and two general hospitals. Outcome measures-Paper based communication was evaluated by questionnaire responses from and interviews with care providers; electronic communication was evaluated by measuring time intervals between generation and delivery of messages and by assessing doctors' satisfaction with electronic data interchange by questionnaire. Results-Via paper mail admission-discharge reports took a median of 2-4 days, and laboratory reports 2 days, to reach general practitioners. With electronic data interchange almost all admission-discharge reports were available to general practitioners within one hour of generation. When samples were analysed on the day of collection (as was the case for 174/542 samples in one hospital and 443/854 in the other) the laboratory reports were also available to the general practitioner the same day via electronic data interchange. Fifteen general practitioners (of the 24 who returned the questionnaire) reported that the use of electronic admission-discharge reports provided more accurate and complete information about the care delivered to their patients. Ten general practitioners reported that electronic laboratory reports lessened the work of processing the data. Conclusion-Electronic communication between primary and secondary care providers is a feasible option for improving communication.	ERASMUS UNIV,DEPT GEN PRACTICE,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	BRANGER, PJ (corresponding author), ERASMUS UNIV,DEPT MED INFORMAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van der Wouden, Johannes C/O-5109-2019; van der Wouden, Johannes C/C-2597-2009; Greiver, Michelle/N-8764-2015	van der Wouden, Johannes C/0000-0001-6639-6050; Greiver, Michelle/0000-0001-8957-0285				AMENT A, 1990, LECTURE NOTES MED IN, V40, P130; DOELEMAN F, 1987, FAM PRACT, V4, P176, DOI 10.1093/fampra/4.3.176; DUISTERHOUT JS, 1991, TELEMATICS IN MEDICINE, P151; HULL FM, 1986, BRIT MED J, V293, P311, DOI 10.1136/bmj.293.6542.311; JACOBS LGH, 1990, BRIT MED J, V301, P470, DOI 10.1136/bmj.301.6750.470; KINKHORST OM, 1991, TELEMATICS IN MEDICINE, P313; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; SANDLER DA, 1987, BRIT MED J, V295, P1523, DOI 10.1136/bmj.295.6612.1523; TULLOCH AJ, 1975, BRIT MED J, V4, P443, DOI 10.1136/bmj.4.5994.443; WALKER RJ, 1989, 1ST STEPS EDI; WESTERHOF HP, 1987, LECTURE NOTES MED IN, P1; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445; WILLIAMS EI, 1990, BRIT MED J, V300, P159, DOI 10.1136/bmj.300.6718.159; 1988, ISO9735 UN EC COMM E	14	76	77	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1068	1070		10.1136/bmj.305.6861.1068	http://dx.doi.org/10.1136/bmj.305.6861.1068			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467688	Bronze, Green Published			2022-12-24	WOS:A1992JW70100021
J	MCGARRY, JD				MCGARRY, JD			WHAT IF MINKOWSKI HAD BEEN AGEUSIC - AN ALTERNATIVE ANGLE ON DIABETES	SCIENCE			English	Article							FREE FATTY-ACID; HEPATIC GLUCOSE-PRODUCTION; CARNITINE PALMITOYLTRANSFERASE; PLASMA-GLUCOSE; INSULIN; MELLITUS; MECHANISMS; RESISTANCE; INHIBITION; OXIDATION	Despite decades of intensive investigation, the basic pathophysiological mechanisms responsible for the metabolic derangements associated with diabetes mellitus have remained elusive. Explored here is the possibility that traditional concepts in this area might have carried the wrong emphasis. It is suggested that the phenomena of insulin resistance and hyperglycemia might be more readily understood if viewed in the context of underlying abnormalities of lipid metabolism.	UNIV TEXAS, SW MED CTR, CTR DIABET RES, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MCGARRY, JD (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NIDDK NIH HHS [DK11313, DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R01DK011313, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY CJ, 1990, NEW ANTIDIABETIC DRU, P231; BALASSE EO, 1973, METABOLISM, V22, P1193, DOI 10.1016/0026-0495(73)90207-2; BALASSE EO, 1974, EUR J CLIN INVEST, V4, P247, DOI 10.1111/j.1365-2362.1974.tb02342.x; CHEN YDI, 1987, J CLIN ENDOCR METAB, V64, P17, DOI 10.1210/jcem-64-1-17; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FALHOLT K, 1988, DIABETIC MED, V5, P27, DOI 10.1111/j.1464-5491.1988.tb00936.x; MARBAN SL, 1992, DIABETES, V41, pA145; MCGARRY D, 1979, DIABETES, V28, P517; MCGARRY JD, 1973, J CLIN INVEST, V52, P877, DOI 10.1172/JCI107252; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; PONTIROLI AE, 1992, DIABETOLOGIA, V35, P294, DOI 10.1007/BF00400934; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; RATHEISER K, 1991, METABOLISM, V40, P1185, DOI 10.1016/0026-0495(91)90214-H; REAVEN GM, 1988, DIABETES, V37, P28, DOI 10.2337/diabetes.37.1.28; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; SALORANTA C, 1991, DIABETOLOGIA, V34, P409, DOI 10.1007/BF00403179; SCHUMACHER MC, 1992, DIABETES, V41, P416, DOI 10.2337/diabetes.41.4.416; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1983, HDB EXPT PHARM, V2, P431; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WITITSUWANNAKUL D, 1977, J BIOL CHEM, V252, P7812; WOLF HPO, 1990, NEW ANTIDIABETIC DRU, P217; YOUNG AA, 1991, FEBS LETT, V287, P203, DOI 10.1016/0014-5793(91)80051-4; ZARJEVSKI N, 1992, ENDOCRINOLOGY, V130, P1564, DOI 10.1210/en.130.3.1564	27	545	558	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1992	258	5083					766	770		10.1126/science.1439783	http://dx.doi.org/10.1126/science.1439783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439783				2022-12-24	WOS:A1992JV69200026
J	NOTTEBOHM, E; DAMBLYCHAUDIERE, C; GHYSEN, A				NOTTEBOHM, E; DAMBLYCHAUDIERE, C; GHYSEN, A			CONNECTIVITY OF CHEMOSENSORY NEURONS IS CONTROLLED BY THE GENE POXN IN DROSOPHILA	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; SENSORY NEURONS; TRANSFORMATION; MELANOGASTER; PROJECTIONS; CUT	THE function of the nervous system depends on the formation of a net of appropriate connections, but little is known of the genetic program underlying this process. In Drosophila two genes that specify different types of sense organs have been identified: cut (ct)1,2, which specifies the formation of external sense organs as opposed to chordotonal organs, and pox-neuro (poxn)3, which specifies the formation of poly-innervated (chemosensory) organs as opposed to mono-innervated (mechanosensory) organs. Whether these genes are also involved in specifying the connectivity of the corresponding neurons is not known. The larval sense organs are unsuitable for analysis of the axonal pathway and connections and so we have investigated the effect of poxn on the adult. Here we show that overexpression of poxn induces the morphological transformation of mechanosensory into chemosensory bristles on the legs and that the neurons innervating the morphologically transformed bristles follow pathways and establish connections that are appropriate for chemosensory bristles.			NOTTEBOHM, E (corresponding author), UNIV LIBRE BRUXELLES,NEUROBIOL & GENET LAB,67 RUE CHEVAUX,B-1640 RHODE ST GENESE,BELGIUM.							BATE CM, 1976, HDB SENSORY PHYSL, V11; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DETHIER VG, 1965, PHYSL INSECT SENSES, P126; GHYSEN A, 1980, DEV BIOL, V78, P521, DOI 10.1016/0012-1606(80)90351-6; GHYSEN A, 1978, NATURE, V274, P869, DOI 10.1038/274869a0; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HELD LI, 1990, ROUX ARCH DEV BIOL, V199, P31, DOI 10.1007/BF01681531; MURPHEY RK, 1989, J NEUROSCI, V9, P3209; TEUGELS E, 1983, PROG BRAIN RES, V58, P305, DOI 10.1016/S0079-6123(08)60032-1; TOBLER H, 1973, EXPERIENTIA, V29, P170; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594	13	50	50	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					829	832		10.1038/359829a0	http://dx.doi.org/10.1038/359829a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436059				2022-12-24	WOS:A1992JV77700064
J	BURGARD, M; MAYAUX, MJ; BLANCHE, S; FERRONI, A; GUIHARDMOSCATO, ML; ALLEMON, MC; CIRARUVIGNERON, N; FIRTION, G; FLOCH, C; GUILLOT, F; LACHASSINE, E; VIAL, M; GRISCELLI, C; ROUZIOUX, C				BURGARD, M; MAYAUX, MJ; BLANCHE, S; FERRONI, A; GUIHARDMOSCATO, ML; ALLEMON, MC; CIRARUVIGNERON, N; FIRTION, G; FLOCH, C; GUILLOT, F; LACHASSINE, E; VIAL, M; GRISCELLI, C; ROUZIOUX, C			THE USE OF VIRAL CULTURE AND P24-ANTIGEN TESTING TO DIAGNOSE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN NEONATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; INFANTS BORN; HIV-1 INFECTION; CHILDREN; TYPE-1; ANTIBODIES; PROTEINS; MOTHERS; ASSAY; FETUS	Background. Early diagnosis of human immunodeficiency virus (HIV) infection in infants born to infected mothers is important for the infants' medical care, but the presence of maternal antibodies makes serologic tests uninformative. Methods. In a cohort study of 181 infants born to HIV-infected mothers, we assessed the diagnostic value of HIV viral culture and testing for the presence of p24 antigen. The infants were tested at birth, again during the first 3 months, then followed and tested at the age of at least 18 months. Results. Of the 181 infants, 3 died of HIV infection and 37 were seropositive after the age of 18 months. Viral cultures at birth were positive in 19 of the 40 infected infants and in none of the uninfected infants, yielding a sensitivity of 48 percent (95 percent confidence interval, 32 to 63 percent) and a specificity of 100 percent (95 percent confidence interval, 97 to 1 00 percent). By the age of three months, 30 of the 40 infants (75 percent) had positive cultures; again, there were no false positive results among the infants who were tested a second time, of the 141 who remained uninfected. The sensitivity of testing for p24 antigen at birth was only 18 percent, with a specificity of 100 percent. The presence of p24 antigen at birth was associated with the development of early and severe HIV-related disease (P<0.04). Conclusions. Viral culture at birth can correctly identify about half of newborns with HIV infection. The fact that this usually sensitive technique fails to identify about half the ultimately infected neonates suggests that vertical transmission of HIV may occur late in pregnancy or during delivery.	HOP NECKER ENFANTS MALAD,MICROBIOL LAB,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,IMMUNOL & HEMATOL UNIT,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U132,PARIS,FRANCE; HOP BICETRE,INSERM,U292,F-94270 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								AMADORI A, 1988, LANCET, V1, P852; ARCHIBALD DW, 1990, AIDS, V4, P417, DOI 10.1097/00002030-199005000-00006; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; CANDOTTI D, 1991, AIDS, V5, P1003, DOI 10.1097/00002030-199108000-00012; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CZERKINSKY C, 1988, J IMMUNOL METHODS, V115, P31, DOI 10.1016/0022-1759(88)90306-7; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; FEORINO P, 1987, J CLIN MICROBIOL, V25, P2344, DOI 10.1128/JCM.25.12.2344-2346.1987; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; JOVAISAS E, 1985, LANCET, V2, P1129; LAURE F, 1988, LANCET, V2, P538; MAINLAND D, 1956, STATISTICAL TABLES U; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MOK JQ, 1987, LANCET, V1, P1164; PEUCHMAUR M, 1991, AIDS, V5, P741, DOI 10.1097/00002030-199106000-00015; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; ROUZIOUX C, 1991, VIRAL QUANTITATION IN HIV INFECTION, P187; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SPRECHER S, 1986, LANCET, V2, P288; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1987, MMWR MORB MORTAL WKL, V36, P225	26	167	168	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1192	1197		10.1056/NEJM199210223271702	http://dx.doi.org/10.1056/NEJM199210223271702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406792				2022-12-24	WOS:A1992JU39300002
J	CURTSINGER, JW; FUKUI, HH; TOWNSEND, DR; VAUPEL, JW				CURTSINGER, JW; FUKUI, HH; TOWNSEND, DR; VAUPEL, JW			DEMOGRAPHY OF GENOTYPES - FAILURE OF THE LIMITED LIFE-SPAN PARADIGM IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							MORTALITY; DYNAMICS; HETEROGENEITY; COMPRESSION; LONGEVITY; SELECTION	Experimental systems that are amenable to genetic manipulation can be used to address fundamental questions about genetic and nongenetic determinants of longevity. Analysis of large cohorts of ten genotypes of Drosophila melanogaster raised under conditions that favored extended survival has revealed variation between genotypes in both the slope and location of age-specific mortality curves. More detailed examination of a single genotype showed that the mortality trajectory was best fit by a two-stage Gompertz model, with no age-specific increase in mortality rates beyond 30 days after emergence. These results are contrary to the limited life-span paradigm, which postulates well-defined, genotype-specific limits on life-span and brief periods of intense and rapidly accelerating mortality rates at the oldest ages.	ODENSE UNIV,SCH MED,DK-5230 ODENSE,DENMARK; DUKE UNIV,CTR DEMOG STUDIES,DURHAM,NC 27706	University of Southern Denmark; Duke University	CURTSINGER, JW (corresponding author), UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,MINNEAPOLIS,MN 55455, USA.			Vaupel, James/0000-0003-0783-3905	NIA NIH HHS [P01 AG08761] Funding Source: Medline; NICHD NIH HHS [KO4 HD 00638] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CRAPO LM, 1981, VITALITY AGING IMPLI; ECONOMOS AC, 1979, AGE, V2, P74, DOI 10.1007/BF02432250; Economos AC, 1982, ARCH GERONTOL GERIAT, V1, P3, DOI [10.1016/0167-4943(82)90003-6, DOI 10.1016/0167-4943(82)90003-6]; ECONOMOS AC, 1987, ARCH GERONTOL GERIAT, V1, P3; Falconer D. S., 1981, INTRO QUANTITATIVE G; Finch CE, 1990, LONGEVITY SENESCENCE; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1987, GERONTOL PERSPECTA, V1, P54; FRIES JF, 1987, GERONTOLOGICA PERSPE, V1, P5; Gavrilov L.A., 1991, BIOL LIFE SPAN QUANT; GURALNICK M, 1987, GERONTOL PERSPECT, V1, P65; LUCKINBILL LS, 1985, HEREDITY, V55, P9, DOI 10.1038/hdy.1985.66; LUCKINBILL LS, 1986, HEREDITY, V56, P329, DOI 10.1038/hdy.1986.54; Manton K. G., 1987, GERONTOL PERSPECTA, V1, P23; MYERS GC, 1984, GERONTOLOGIST, V24, P346, DOI 10.1093/geront/24.4.346; PARSONS PA, 1977, EXP GERONTOL, V12, P241, DOI 10.1016/0531-5565(77)90012-2; RAMLAUHANSEN H, 1983, ANN STAT, V11, P453, DOI 10.1214/aos/1176346152; RAMLAUHANSEN H, 1983, SCAND ACTUAR J, V66, P165; Rose M.R., 1991, EVOLUTIONARY BIOL AG; VAUPEL JW, 1979, DEMOGRAPHY, V16, P439, DOI 10.2307/2061224; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; VAUPEL JW, 1985, SOCIOLOGICAL METHODO; WITTEN M, 1988, MECH AGEING DEV, V46, P175, DOI 10.1016/0047-6374(88)90124-8	24	322	328	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					461	463		10.1126/science.1411541	http://dx.doi.org/10.1126/science.1411541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411541				2022-12-24	WOS:A1992JT77500034
J	JENKINS, TM; SAXENA, JK; KUMAR, A; WILSON, SH; ACKERMAN, EJ				JENKINS, TM; SAXENA, JK; KUMAR, A; WILSON, SH; ACKERMAN, EJ			DNA POLYMERASE-BETA AND DNA-SYNTHESIS IN XENOPUS OOCYTES AND IN A NUCLEAR EXTRACT	SCIENCE			English	Article							TEMPLATE BINDING DOMAIN; SINGLE-STRANDED-DNA; REPAIR SYNTHESIS; HUMAN-CELLS; ALPHA; REPLICATION; LAEVIS; DELTA; EGGS; IDENTIFICATION	The identities of the DNA polymerases required for conversion of single-strand (ss) M13 DNA to double-strand (ds) M13 DNA were examined both in injected Xenopus laevis oocytes and in an oocyte nuclear extract. Inhibitors and antibodies specific to DNA polymerases alpha and beta were used. In nuclear extracts, inhibition by the antibody to polymerase beta could be reversed by purified polymerase beta. The polymerase beta inhibitors, dideoxythymidine triphosphate (ddTTP) and dideoxycytidine triphosphate (ddCTP), also blocked DNA synthesis and indicated that polymerase beta is invoLved in the conversion of ssDNA to dsDNA. These results also may have particular significance for emerging evidence of an ssDNA replication mode in eukaryotic cells.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				BJURSELL G, 1979, NATURE, V280, P420, DOI 10.1038/280420a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUZIO LO, 1981, MOL APPROACHES GENE, P149; Colman A., 1984, TRANSCRIPTION TRANSL, P49; CORTESE R, 1980, P NATL ACAD SCI-BIOL, V77, P4147, DOI 10.1073/pnas.77.7.4147; COX LS, 1990, J CELL SCI, V97, P177; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FORD CC, 1975, DEV BIOL, V43, P189, DOI 10.1016/0012-1606(75)90140-2; FRY M, 1986, ANIMAL CELL DNA POLY, P103; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; JENKINS TC, UNPUB; JOENJE H, 1978, J BIOL CHEM, V253, P2640; KAISERMAN HB, 1990, EUKARYOTIC NUCLEUS M, V2, P783; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGERSKI RJ, 1987, MOL CELL BIOL, V7, P4317, DOI 10.1128/MCB.7.12.4317; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; NELSON EM, 1983, DEV BIOL, V96, P11, DOI 10.1016/0012-1606(83)90306-8; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SWACK JA, 1985, ANAL BIOCHEM, V147, P10, DOI 10.1016/0003-2697(85)90003-X; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVLIET PC, 1990, EUKARYOTIC NUCLEUS, V1, P1; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; WANG TSF, 1990, EUKARYOTIC NUCLEUS M, V1, P147; WEISER T, 1991, J BIOL CHEM, V266, P10420; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; WIST E, 1979, BIOCHIM BIOPHYS ACTA, V562, P62, DOI 10.1016/0005-2787(79)90126-6	39	52	53	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					475	478		10.1126/science.1411545	http://dx.doi.org/10.1126/science.1411545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411545				2022-12-24	WOS:A1992JT77500039
J	KUO, CF; MCREE, DE; FISHER, CL; OHANDLEY, SF; CUNNINGHAM, RP; TAINER, JA				KUO, CF; MCREE, DE; FISHER, CL; OHANDLEY, SF; CUNNINGHAM, RP; TAINER, JA			ATOMIC-STRUCTURE OF THE DNA-REPAIR [4FE-4S] ENZYME ENDONUCLEASE-III	SCIENCE			English	Article							ALDEHYDIC ABASIC SITES; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; ELECTROSTATIC POTENTIALS; CRYSTAL-STRUCTURE; OXIDATIVE DAMAGE; APURINIC SITES; PROTEIN; BINDING; RESOLUTION	The crystal structure of the DNA repair enzyme endonuclease III, which recognizes and cleaves DNA at damaged bases, has been solved to 2.0 angstrom resolution with an R factor of 0.185. This iron-sulfur [4Fe-4S] enzyme is elongated and bilobal with a deep cleft separating two similarly sized domains: a novel, sequence-continuous, six-helix domain (residues 22 to 132) and a Greek-key, four-helix domain formed by the amino-terminal and three carboxyl-terminal helices (residues 1 to 21 and 133 to 211) together with the [4Fe-4S] cluster. The cluster is bound entirely within the carboxyl-terminal loop with a ligation pattern (Cys-X6-Cys-X2-Cys-X5-Cys) distinct from all other known [4Fe-4S] proteins. Sequence conservation and the positive electrostatic potential of conserved regions identify a surface suitable for binding duplex B-DNA across the long axis of the enzyme, matching a 46 angstrom length of protected DNA. The primary role of the [4Fe-4S] cluster appears to involve positioning conserved basic residues for interaction with the DNA phosphate backbone. The crystallographically identified inhibitor binding region, which recognizes the damaged base thymine glycol, is a seven-residue beta-hairpin (residues 113 to 119). Location and side chain orientation at the base of the inhibitor binding site implicate Glu112 in the N-glycosylase mechanism and Lys120 in the beta-elimination mechanism. Overall, the structure reveals an unusual fold and a new biological function for [4Fe-4S]clusters and provides a structural basis for studying recognition of damaged DNA and the N-glycosylase and apurinic/apyrimidinic-lyase mechanisms.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SUNY ALBANY, DEPT BIOL SCI, CTR BIOCHEM & BIOPHYS, ALBANY, NY 12222 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; O'Handley, Suzanne/0000-0001-8373-0065	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07695] Funding Source: Medline; NIGMS NIH HHS [GM 46312] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AHERN H, 1991, ASM NEWS, V57, P627; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; [Anonymous], 1985, DNA REPAIR; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; AUGUSTINE ML, 1991, BIOCHEMISTRY-US, V30, P8052, DOI 10.1021/bi00246a025; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BICKELHAUPT FM, 1990, INORG CHEM, V29, P350, DOI 10.1021/ic00327a039; BOERRIGTER PM, 1988, INT J QUANTUM CHEM, V33, P87, DOI 10.1002/qua.560330204; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMMACK R, 1991, ADV INORG CHEM, V38, P1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen J., UNPUB; CHIRLIAN LE, 1987, J COMPUT CHEM, V8, P894, DOI 10.1002/jcc.540080616; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DAVIS ME, 1990, CHEM REV, V90, P509, DOI 10.1021/cr00101a005; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DOETSCH PW, 1987, MOL CELL BIOL, V7, P26, DOI 10.1128/MCB.7.1.26; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FU WG, 1992, J BIOL CHEM, V267, P16135; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HELLAND DE, 1986, MOL CELL BIOL, V6, P1983, DOI 10.1128/MCB.6.6.1983; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORGENSEN TJ, 1987, BIOCHEMISTRY-US, V26, P6436, DOI 10.1021/bi00394a021; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUO CF, 1992, J MOL BIOL, V227, P347, DOI 10.1016/0022-2836(92)90703-M; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; MANNING GS, 1983, BIOPOLYMERS, V22, P689, DOI 10.1002/bip.360220211; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; OHANDLEY S, UNPUB; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; RAVENEK W, 1989, SCI COMPUTING SUPERC, P201; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1988, PROTEINS, V4, P229, DOI 10.1002/prot.340040402; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHARDSON JS, 1990, PREDICTION PROTEIN S, P2; SCHWARTZ A, 1989, J MOL BIOL, V207, P445, DOI 10.1016/0022-2836(89)90266-0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; SWITZER R L, 1989, Biofactors, V2, P77; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILLIAMS TV, 1982, THESIS U N CAROLINA; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017	67	283	286	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					434	440		10.1126/science.1411536	http://dx.doi.org/10.1126/science.1411536			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411536				2022-12-24	WOS:A1992JT77500027
J	HEATH, WR; ALLISON, J; HOFFMANN, MW; SCHONRICH, G; HAMMERLING, G; ARNOLD, B; MILLER, JFAP				HEATH, WR; ALLISON, J; HOFFMANN, MW; SCHONRICH, G; HAMMERLING, G; ARNOLD, B; MILLER, JFAP			AUTOIMMUNE DIABETES AS A CONSEQUENCE OF LOCALLY PRODUCED INTERLEUKIN-2	NATURE			English	Article							RECEPTOR TRANSGENIC MICE; VIRUS-INFECTION; T-CELLS; TOLERANCE; MOLECULES; MECHANISM; INDUCTION	DURING cell differentiation in the thymus, self-reactive T cells can be generated. The majority of these seem to be deleted after intrathymic encounter with the relevant autoantigen1. As all self antigens are unlikely to be present in the thymus, some autoreactive T cells may escape censorship. Here we study the fate of these cells using transgenic mice expressing the class I molecule H-2K(b) (K(b)) in the insulin-producing beta-cells of the pancreas2,3. These mice were crossed with mice transgenic for genes encoding a K(b)-specific T-cell antigen receptor (TCR)4 which could be detected using a clonotype-specific monoclonal antibody5. Although T cells expressing the highest level of transgenic TCR were deleted intrathymically in double-transgenic mice, K(b)-specific T cells were detected in the periphery. These cells caused the rejection of K(b)-expressing skin grafts, but ignored islet K(b) antigens even after priming. But when double-transgenic mice were crossed with transgenic mice expressing the lymphokine interleukin-2 in the pancreatic beta-cells6, there was a rapid onset of diabetes. These results indicate that autoreactive T cells that ignore self antigens may cause autoimmune diabetes when provided with exogenous 'help' in the form of interleukin-2.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; GERMAN CANC RES CTR, INST IMMUNOL & GENET, W-6900 HEIDELBERG 1, GERMANY	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Helmholtz Association; German Cancer Research Center (DKFZ)				Heath, William/0000-0001-9670-259X; Schonrich, Gunther/0000-0002-5346-5704				ALLISON J, 1992, EUR J IMMUNOL, V22, P1115, DOI 10.1002/eji.1830220503; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; HUA C, 1986, J IMMUNOL, V136, P1937; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MILLER JFAP, 1991, IMMUNOL REV, V122, P103, DOI 10.1111/j.1600-065X.1991.tb00599.x; MILLER JFAP, 1989, COLD SPRING HARB SYM, V54, P807; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MORAHAN G, 1991, P NATL ACAD SCI USA, V88, P11421, DOI 10.1073/pnas.88.24.11421; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	14	243	250	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 8	1992	359	6395					547	549		10.1038/359547a0	http://dx.doi.org/10.1038/359547a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406974				2022-12-24	WOS:A1992JR85900063
J	BERGSTEIN, JM; RILEY, M; BANG, NU				BERGSTEIN, JM; RILEY, M; BANG, NU			ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL-CELLS; PLASMA INHIBITOR; PLATELETS	Background. Deposition of fibrin in glomeruli and renal failure are characteristic features of the hemolytic uremic syndrome. An inhibitor of glomerular fibrinolysis has been detected in plasma from children with this disorder. In this study, we define the inhibitor and show that its plasma level is correlated with the outcome of the disease. Methods and Results. Plasminogen-activator inhibitor type 1 (PAI-1) in plasma was measured with an assay employing a specific monoclonal antibody in 40 consecutive children hospitalized with the hemolytic uremic syndrome: 12 who recovered adequate renal function (serum creatinine, less-than-or-equal-to 2.0 mg per deciliter [177-mu-mol per liter]) without dialysis, 23 who recovered adequate renal function after peritoneal dialysis, and 5 who did not recover adequate renal function after undergoing dialysis. At presentation, plasma PAI-1 levels were higher in the patients with the hemolytic uremic syndrome than in nine children with other forms of acute renal failure. That the inhibitor was PAI-1 was indicated by the fact that it was a potent inhibitor of tissue plasminogen activator, was acid-resistant, and was not inhibited by denaturation (all unique traits of PAI-1) and that it was neutralized by an antibody specific for PAI-1. Multivariate discriminant-function analysis revealed that the duration of elevated PAI-1 activity was strongly correlated with the outcome of the disease (P<0.001). Peritoneal dialysis reduced plasma PAI-1 levels dramatically. Conclusions. Our studies suggest that PAI-1 is the circulating inhibitor of fibrinolysis in the hemolytic uremic syndrome. Normalization of plasma PAI-1 levels (e.g., by peritoneal dialysis) is correlated with improvement in renal function. However, the possibility that increased plasma levels of PAI-1 are either causes or effects of the hemolytic uremic syndrome is not unequivocally established by these studies.	INDIANA UNIV, SCH MED, LILLY RES LABS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PEDIAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis								[Anonymous], 1987, PEDIATRICS, V79, P1; BANCROFT H, 1962, INTRO BIOSTATISTICS; BERGSTEIN JM, 1988, KIDNEY INT, V33, P868, DOI 10.1038/ki.1988.78; BERGSTEIN JM, 1982, AM J MED, V73, P322, DOI 10.1016/0002-9343(82)90717-3; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; DECLERCK PJ, 1988, BLOOD, V71, P220; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ERICKSON LA, 1986, BLOOD, V68, P1298; HEKMAN CM, 1987, SEMIN THROMB HEMOST, V13, P514, DOI 10.1055/s-2007-1003527; KREDIET RT, 1986, NEPHRON, V42, P133, DOI 10.1159/000183652; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P65; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SPRENGERS ED, 1987, BLOOD, V69, P381; 1990, AM J KIDNEY DIS S2, V16, P65	15	84	85	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					755	759		10.1056/NEJM199209103271102	http://dx.doi.org/10.1056/NEJM199209103271102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501651				2022-12-24	WOS:A1992JL66100002
J	LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA				LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA			LOW SERUM-CHOLESTEROL CONCENTRATION AND SHORT-TERM MORTALITY FROM INJURIES IN MEN AND WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; DEATH; RISK	Objective-To determine whether total serum cholesterol concentration predicts mortality from injuries including suicide. Design-Cohort study of men and women who had their serum cholesterol concentration measured as part of a general health survey in Varmland, Sweden in 1964 or 1965 and were followed up for an average of 20.5 years. Subjects-Adults participating in health screening in 1964-5 (26 693 men and 27 692 women). The study sample was restricted to subjects aged 45-74 years during any of the 20.5 years of follow up. Main outcome measures-Serum cholesterol concentration. Deaths from all injuries and suicides during three periods of follow up (0-6 years, 7-13 years, and 14-21 years) according to the Swedish mortality register in subjects aged 45-74. Adjustment was made for prevalent cancer (identified from the Swedish cancer register) at the time of a suicide. Results-A strong negative relation between cholesterol concentration and mortality from injuries was found in men during the first seven years of follow up. The relative risk in the lowest 25% of the cholesterol distribution was 2.8 (95% confidence interval 1.52 to 4.96) compared with the top 25%. Most of the excess risk was caused by suicide with a corresponding relative risk of 4.2 (p for trend=0.001). Correction for prevalent cancer did not change the results. Events occurring during the latter two thirds of the 20.5 years of follow up were not predicted. In women no relation between cholesterol concentration and mortality from injuries was found. Conclusions-Together with observations from intervention trials the findings support the existence of a relation between serum cholesterol concentration and suicide. The causality of such a relation is, however, not resolved.	UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet; Karolinska University Hospital	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							BOLANDER AM, 1981, MED ASPECTS MORTALIT; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1986, ARCH INTERN MED, V146, P262, DOI 10.1001/archinte.146.2.262; HATCH FT, 1966, CIRCULATION, V33, P679, DOI 10.1161/01.CIR.33.5.679; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; KAPLAN JR, 1990, PSYCHOSOM MED, V52, P226; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; LINDBERG G, 1992, INT J EPIDEMIOL, V21, P253, DOI 10.1093/ije/21.2.253; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; 1967, MANUAL INT STATISTIC; 1984, JAMA-J AM MED ASSOC, V251, P351	22	197	198	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					277	279		10.1136/bmj.305.6848.277	http://dx.doi.org/10.1136/bmj.305.6848.277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392858	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JG74000015
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			VALUE OF THE DUNDEE CORONARY RISK-DISK - A DEFENSE	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MANAGEMENT; MORTALITY; MEN				TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							Gore, 1987, HLTH LIFESTYLE SURVE; JARRETT RJ, 1982, BRIT MED J, V285, P535, DOI 10.1136/bmj.285.6341.535; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; POULTER N, 1991, AM HEART J, V121, P246, DOI 10.1016/0002-8703(91)90851-8; Shaper A G, 1987, Health Trends, V19, P37; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; TUNSTALLPEDOE H, 1989, BMJ-BRIT MED J, V298, P1593, DOI 10.1136/bmj.298.6688.1593; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WILSON PWF, 1987, AM J CARDIOL, V59, P91; 1991, BMJ, V303, P748; 1991, BMJ, V302, P1057; 1990, DIETARY NUTRITIONAL	12	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					231	232		10.1136/bmj.305.6847.231	http://dx.doi.org/10.1136/bmj.305.6847.231			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392830	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JG11200028
J	WANG, ZQ; OVITT, C; GRIGORIADIS, AE; MOHLESTEINLEIN, U; RUTHER, U; WAGNER, EF				WANG, ZQ; OVITT, C; GRIGORIADIS, AE; MOHLESTEINLEIN, U; RUTHER, U; WAGNER, EF			BONE AND HEMATOPOIETIC DEFECTS IN MICE LACKING C-FOS	NATURE			English	Article							TRANSGENIC MICE; PROTO-ONCOGENE; EXPRESSION; TUMORS; MOUSE; CELLS; RAT	THE proto-oncogene c-fos is the cellular homologue of v-fos originally isolated from murine osteosarcoma1. Fos protein is a major component of the AP-1 transcription factor complex, which includes members of the jun family2. Stable expression of c-fos in mice has been demonstrated in developing bones and teeth, haematopoietic cells, germ cells and in the central nervous system3-11. It has been proposed that c-fos has an important role in signal transduction, cell proliferation and differentiation12-15. We have previously demonstrated that overexpression of c-fos in transgenic and chimaeric mice specifically affects bone, cartilage and haematopoietic cell development16-20. To understand better the function of c-fos in vivo, we used gene targeting in embryonic stem cells to generate cells and mice lacking c-fos. Here we report that heterozygous fos +/- mice appear normal, although females exhibit a distorted transmission frequency. All homozygous fos -/- mice are growth-retarded, develop osteopetrosis with deficiencies in bone remodelling and tooth eruption, and have altered haematopoiesis. These data define the c-Fos protein as an essential molecule for the development of specific cellular compartments.	EMBL, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	WANG, ZQ (corresponding author), IMP, MOLEC PATHOL RES INST, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.			Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAUBET JF, 1988, BIOL CELL, V64, P101, DOI 10.1016/0248-4900(88)90100-1; COHEN DR, IN PRESS ONCOGENE; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; Green MC., 1989, GENETIC VARIANTS STR, P12; HILBERG F, 1992, ONCOGENE, V7, P2371; JONES KL, 1988, SMITHS RECOGNIZABLE, P353; MARKS SC, 1989, AM J ANAT, V186, P325, DOI 10.1002/aja.1001860402; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; PELTOHUIKKO M, 1991, ACTA PHYSIOL SCAND, V141, P283, DOI 10.1111/j.1748-1716.1991.tb09080.x; Revell P. A., 1986, PATHOLOGY BONE; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAO S, 1991, INT IMMUNOL, V3, P369, DOI 10.1093/intimm/3.4.369; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x	30	802	824	1	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					741	745		10.1038/360741a0	http://dx.doi.org/10.1038/360741a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465144				2022-12-24	WOS:A1992KE47200034
J	WOLFE, JH; SANDS, MS; BARKER, JE; GWYNN, B; ROWE, LB; VOGLER, CA; BIRKENMEIER, EH				WOLFE, JH; SANDS, MS; BARKER, JE; GWYNN, B; ROWE, LB; VOGLER, CA; BIRKENMEIER, EH			REVERSAL OF PATHOLOGY IN MURINE MUCOPOLYSACCHARIDOSIS TYPE-VII BY SOMATIC-CELL GENE-TRANSFER	NATURE			English	Article							BETA-GLUCURONIDASE DEFICIENCY; HEMATOPOIETIC STEM-CELLS; INVITRO; MOUSE; THERAPY; CDNA	AN inherited deficiency of beta-glucuronidase in humans1, mice2 and dogs3 causes mucopolysaccharidosis VII (Sly syndrome), a progressive degenerative disease that reduces lifespan (to an average of 5 months in mice2) and results from lysosomal storage of undegraded glycosaminoglycans in the spleen, liver, kidney, cornea, brain and skeletal system1-4. Bone marrow transplantation in mutant mice provides a source of normal enzyme ('cross-correction'5), which substantially improves the clinical condition and extends the average lifespan to 18 months6. Gene therapy by transfer of a beta-glucuronidase gene into mutant haematopoietic stem cells is an alternative approach7,8, but it is not known whether the low expression of vector-transferred genes in vivo9,10 would be sufficiently effective. Here we show that retroviral vector-mediated transfer of the gene to mutant stem cells results in long-term expression of low levels of beta-glucuronidase which partially corrects the disease by reducing lysosomal storage in liver and spleen.	UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104; ST LOUIS UNIV,SCH MED,ST LOUIS,MO 63104	University of Pennsylvania; Saint Louis University	WOLFE, JH (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.			Sands, Mark/0000-0002-5559-0832				BARKER JE, 1983, BLOOD, V62, P827; BARKER JE, IN PRESS EXPL HEMAT; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BIRKENMEIER EH, 1991, BLOOD, V78, P3081; BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; FRASER CC, 1990, BLOOD, V76, P1071; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SMITH BF, 1990, MOL CELL BIOL, V10, P3268, DOI 10.1128/MCB.10.6.3268; STRAMM LE, 1990, EXP EYE RES, V50, P521, DOI 10.1016/0014-4835(90)90041-R; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VOGLER CA, 1991, AM J PATHOL, V136, P207; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	22	211	214	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					749	753		10.1038/360749a0	http://dx.doi.org/10.1038/360749a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465145				2022-12-24	WOS:A1992KE47200036
J	MOUNKES, LC; JONES, RS; LIANG, BC; GELBART, W; FULLER, MT				MOUNKES, LC; JONES, RS; LIANG, BC; GELBART, W; FULLER, MT			A DROSOPHILA MODEL FOR XERODERMA-PIGMENTOSUM AND COCKAYNES-SYNDROME - HAYWIRE ENCODES THE FLY HOMOLOG OF ERCC3, A HUMAN EXCISION REPAIR GENE	CELL			English	Article							AFFECT MICROTUBULE FUNCTION; IRRADIATED MAMMALIAN-CELLS; BETA-TUBULIN SUBUNIT; DNA-REPAIR; ULTRAVIOLET-LIGHT; MOLECULAR CHARACTERIZATION; INTERACTING GENES; HUMAN-FIBROBLASTS; UV IRRADIATION; RNA-SYNTHESIS	The haywire gene of Drosophila encodes a protein with 66% identity to the product of the human ERCC3 gene, associated with xeroderma pigmentosum B (XP-B) and Cockayne's syndrome (CS). XP is a human autosomal recessive disease characterized by extreme sensitivity to ultraviolet irradiation and marked susceptibility to skin cancer. In addition, XP and CS patients often exhibit a variety of defects, ranging f rom central nervous system disorders to hypogonadism. Phenotypes of haywire mutants mimic some of the effects of XP. Many haywire alleles are recessive lethal, viable alleles cause ultraviolet sensitivity, and flies expressing marginal levels of haywire display motor defects and reduced life span. Progeny of females carrying a maternal effect allele show central nervous system defects.	STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA; HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA	Stanford University; Stanford University; Southern Methodist University; Harvard University	MOUNKES, LC (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.			Fuller, Margaret T/0000-0002-3804-4987	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER; NICHD NIH HHS [HD18127] Funding Source: Medline; NIGMS NIH HHS [5T32GM07135-15] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED FE, 1978, BIOCHIM BIOPHYS ACTA, V521, P805, DOI 10.1016/0005-2787(78)90319-2; ARLETT CF, 1978, DNA REPAIR MECHANISM, P633; BENHUR E, 1980, FEBS LETT, V120, P21, DOI 10.1016/0014-5793(80)81036-2; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; BONNER JJ, 1984, CELL, V37, P979; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; BUSCH DB, 1980, SOMAT CELL GENET, V6, P407, DOI 10.1007/BF01542792; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; COLE J, 1992, MUTAT RES, V273, P171, DOI 10.1016/0921-8777(92)90078-H; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DUPUY JM, 1982, J INVEST DERMATOL, V78, P356; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLETJER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GIORNO R, 1976, CELL, V9, P775, DOI 10.1016/0092-8674(76)90140-9; GLOVER TW, 1979, P NATL ACAD SCI USA, V76, P3982, DOI 10.1073/pnas.76.8.3982; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HACKETT PB, 1975, J MOL BIOL, V91, P235, DOI 10.1016/0022-2836(75)90378-2; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JONES RS, 1990, GENETICS, V126, P185; KANTOR GJ, 1979, BIOPHYS J, V27, P359, DOI 10.1016/S0006-3495(79)85223-6; KAUFMANN WK, 1980, BIOCHIM BIOPHYS ACTA, V608, P191, DOI 10.1016/0005-2787(80)90147-1; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KEMPHUES KJ, 1983, GENETICS, V105, P345; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEHMANN AR, 1979, CANCER RES, V39, P4237; LEHMANN AR, 1982, CANCER SURV, V1, P93; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACINNES MA, 1990, PROG CLIN BIOL RES, V340, P265; MAHER VM, 1975, J NATL CANCER I, V54, P1287, DOI 10.1093/jnci/54.6.1287; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MAYNE LV, 1982, CANCER RES, V42, P1473; MAYNE LV, 1982, MUTAT RES, V106, P179, DOI 10.1016/0027-5107(82)90200-7; MCCORMICK JJ, 1986, CANCER RES, V46, P489; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MICHALKE H, 1969, J MOL BIOL, V41, P1, DOI 10.1016/0022-2836(69)90122-3; MISMER D, 1987, GENETICS, V116, P565; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NOCENTINI S, 1976, BIOCHIM BIOPHYS ACTA, V454, P114, DOI 10.1016/0005-2787(76)90359-2; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; REGAN CL, 1990, GENETICS, V125, P77; REGAN CL, 1988, GENE DEV, V2, P82, DOI 10.1101/gad.2.1.82; ROBBINS JH, 1991, HUM GENET, V88, P242; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEFANINI M, 1982, SOMAT CELL GENET, V8, P635, DOI 10.1007/BF01542856; STICH HF, 1973, MUTAT RES, V17, P127, DOI 10.1016/0027-5107(73)90261-3; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TATES AD, 1989, MUTAT RES, V213, P73, DOI 10.1016/0027-5107(89)90033-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1991, NATURE, V350, P190, DOI 10.1038/350190a0; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0	70	120	122	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					925	937		10.1016/0092-8674(92)90389-T	http://dx.doi.org/10.1016/0092-8674(92)90389-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458540				2022-12-24	WOS:A1992KB99000006
J	LU, ZL; WILLIAMSON, SJ; KAUFMAN, L				LU, ZL; WILLIAMSON, SJ; KAUFMAN, L			BEHAVIORAL LIFETIME OF HUMAN AUDITORY SENSORY MEMORY PREDICTED BY PHYSIOLOGICAL MEASURES	SCIENCE			English	Article								Noninvasive magnetoencephalography makes it possible to identify the cortical area in the human brain whose activity reflects the decay of passive sensory storage of information about auditory stimuli (echoic memory). The lifetime for decay of the neuronal activation trace in primary auditory cortex was found to predict the psychophysically determined duration of memory for the loudness of a tone. Although memory for the loudness of a specific tone is lost, the remembered loudness decays toward the global mean of all of the loudnesses to which a subject is exposed in a series of trials.	NYU,DEPT PHYS,NEW YORK,NY 10003; NYU,CTR NEURAL SCI,NEW YORK,NY 10003; NYU,DEPT PSYCHOL,NEW YORK,NY 10003	New York University; New York University; New York University								BERLINER JE, 1967, J ACOUST SOC AM, V61, P1577; CONRAD R, 1964, BRIT J PSYCHOL, V55, P75, DOI 10.1111/j.2044-8295.1964.tb00899.x; Crowder R.G., 1976, PRINCIPLES LEARNING; GLANZER M, 1966, J VERB LEARN VERB BE, V5, P351, DOI 10.1016/S0022-5371(66)80044-0; HARI R, 1980, EXP BRAIN RES, V40, P237, DOI 10.1007/BF00237543; HELSON H, 1964, ADAPTATION LEVEL THE; Hollingworth H. L., 1910, J PHILOS PSYCHOL SCI, V7, P461, DOI [10.2307/2012819, DOI 10.2307/2012819]; IPSEN G, 1926, NEUE PSYCHOL STUD, V1, P279; IPSEN G, 1926, NEUE PSYCHOL STUD, V1, P171; KAUFMAN L, 1992, ELECTROEN CLIN NEURO, V82, P266, DOI 10.1016/0013-4694(92)90107-S; Lauenstein O, 1933, PSYCHOL FORSCH, V17, P130, DOI 10.1007/BF02411957; Lu Z., UNPUB; LU ZL, 1992, BRAIN RES, V572, P236, DOI 10.1016/0006-8993(92)90475-O; MASSARO DW, 1970, J EXP PSYCHOL, V85, P411, DOI 10.1037/h0029712; MASSARO DW, 1975, EXPT PSYCHOL INFORMA; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MURDOCK BB, 1969, J VERB LEARN VERB BE, V8, P665, DOI 10.1016/S0022-5371(69)80120-9; Needham JG, 1935, J EXP PSYCHOL, V18, P530, DOI 10.1037/h0056775; Neisser U., 1967, COGNITIVE PSYCHOL; PISONI DB, 1973, PERCEPT PSYCHOPHYS, V13, P253, DOI 10.3758/BF03214136; SPERLING G, 1960, PSYCHOL MONOGR, V74, P1, DOI 10.1037/h0093759; TREISMAN A, 1964, J VERB LEARN VERB BE, V3, P449, DOI 10.1016/S0022-5371(64)80015-3; WEINBERGER NM, 1987, PROG NEUROBIOL, V29, P1, DOI 10.1016/0301-0082(87)90014-1; WEINBERGER NM, 1990, CONCEPTS NEUROSCIENC, V1, P91; WESTENBERG IS, 1976, ELECTROEN CLIN NEURO, V40, P337, DOI 10.1016/0013-4694(76)90186-3; WICKELGR.WA, 1969, J MATH PSYCHOL, V6, P13, DOI 10.1016/0022-2496(69)90028-5; WILLIAMSON S J, 1991, Brain Topography, V4, P169, DOI 10.1007/BF01132773; Woodrow H, 1933, AM J PSYCHOL, V45, P391, DOI 10.2307/1415039; Woodworth R.S., 1938, EXP PSYCHOL	29	207	208	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1668	1670		10.1126/science.1455246	http://dx.doi.org/10.1126/science.1455246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KA896	1455246				2022-12-24	WOS:A1992KA89600043
J	CLAMAN, HN				CLAMAN, HN			THE BIOLOGY OF THE IMMUNE-RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL RECEPTOR				CLAMAN, HN (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, DENVER, CO 80262 USA.							ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BIENENSTOCK J, 1984, ANNU REV MED, V35, P49, DOI 10.1146/annurev.me.35.020184.000405; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Demaeyer E., 1988, INTERFERONS OTHER RE; FAIRCHILD RL, 1988, J IMMUNOL, V141, P3342; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JERNE NK, 1984, IMMUNOL REV, V79, P5, DOI 10.1111/j.1600-065X.1984.tb00484.x; MARRACK P, 1990, SCIENCE, V162, P493; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; SHORTER RG, 1982, ADV INTERNAL MED, V27, P247; STREILEIN JW, 1983, J INVEST DERMATOL, V80, pS12, DOI 10.1111/1523-1747.ep12536743; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2	14	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2790	2796		10.1001/jama.268.20.2790	http://dx.doi.org/10.1001/jama.268.20.2790			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433694				2022-12-24	WOS:A1992JY66800002
J	VALENTINE, MD				VALENTINE, MD			ANAPHYLAXIS AND STINGING INSECT HYPERSENSITIVITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDIOPATHIC ANAPHYLAXIS; IMMUNOTHERAPY; VENOM				VALENTINE, MD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DIV ALLERGY, BALTIMORE, MD 21205 USA.							DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1983, J CLIN IMMUNOASSAY, V6, P172; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; Schick B., 1905, SERUM SICKNESS; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1979, HDB SERIES CLIN LA F, VF, P71; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; WONG S, 1991, ANN INTERN MED, V114, P133, DOI 10.7326/0003-4819-114-2-133	15	24	24	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2830	2833		10.1001/jama.268.20.2830	http://dx.doi.org/10.1001/jama.268.20.2830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433697				2022-12-24	WOS:A1992JY66800005
J	RUSHFORTH, JA; WILSON, N				RUSHFORTH, JA; WILSON, N			SHOULD GENERAL-PRACTITIONERS HAVE ACCESS TO PEDIATRIC CARDIOLOGISTS	BRITISH MEDICAL JOURNAL			English	Article									KILLINGBECK HOSP,LEEDS LS14 6UH,ENGLAND		RUSHFORTH, JA (corresponding author), GEN INFIRM,DEPT PAEDIATR,LEEDS LS2 9NS,ENGLAND.							NEWBURGER JW, 1983, NEW ENGL J MED, V308, P61, DOI 10.1056/NEJM198301133080201; WILSON N, 1986, RECENT ADV PAEDIATRI, V8, P87	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1264	1265		10.1136/bmj.305.6864.1264	http://dx.doi.org/10.1136/bmj.305.6864.1264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477570	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JZ52100025
J	PERERA, FP; HEMMINKI, K; GRYZBOWSKA, E; MOTYKIEWICZ, G; MICHALSKA, J; SANTELLA, RM; YOUNG, TL; DICKEY, C; BRANDTRAUF, P; DEVIVO, I; BLANER, W; TSAI, WY; CHORAZY, M				PERERA, FP; HEMMINKI, K; GRYZBOWSKA, E; MOTYKIEWICZ, G; MICHALSKA, J; SANTELLA, RM; YOUNG, TL; DICKEY, C; BRANDTRAUF, P; DEVIVO, I; BLANER, W; TSAI, WY; CHORAZY, M			MOLECULAR AND GENETIC-DAMAGE IN HUMANS FROM ENVIRONMENTAL-POLLUTION IN POLAND	NATURE			English	Article							LUNG-CANCER; DNA ADDUCTS; BINDING	EXTREME environmental pollution such as that found in the highly industrialized Silesian region of Poland has been associated with increased risk of cancer and adverse reproductive outcomes1,2. Among the most prevalent carcinogenic and mutagenic air pollutants in Silesia are the polycyclic aromatic hydrocarbons (PAH) which are largely produced by industrial and residential combustion of coal1. Molecular epidemiology aims to prevent disease by using biological markers to identify risks well before clinicai onset to allow effective intervention3-7. Here, we use a battery of biological markers to measure molecular and genetic damage in peripheral blood samples from residents of Silesia and from persons living in a rural, less polluted area of Poland. The results show that their exposure to environmental pollution is associated with significant increases in carcinogen-DNA adducts (PAH-DNA and aromatic adducts), in sister chromatid exchange including high-frequency cells, and in chromosomal aberrations as well as a doubling in the frequency of ras oncogene overexpression. We found that aromatic adducts on DNA were significantly correlated with chromosomal mutation, providing us with a molecular link between environmental exposure and a genetic alteration relevant to cancer and reproductive risk.	KAROLINSKA INST,CNT,S-14152 HUDDINGE,SWEDEN; INST ONCOL,DEPT TUMOR BIOL,PL-44100 GLIWICE,POLAND; COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032; COLUMBIA UNIV,DIV BIOSTAT,NEW YORK,NY 10032	Karolinska Institutet; Maria Sklodowska-Curie National Research Institute of Oncology; Columbia University; Columbia University	PERERA, FP (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,DIV ENVIRONM SCI,60 HAVEN AVE,B1-109,NEW YORK,NY 10032, USA.			Perera, Frederica/0000-0002-1364-9250				BARTSCH H, 1988, METHODS DETECTING DN; BIERI JG, 1979, AM J CLIN NUTR, V32, P2500; BRANDTRAUF PW, 1992, FORD INT J CANCER, V51, P1; BRANDTRAUF PW, 1990, CURRENT ISSUES RESPI, V3, P4; CARRANO AV, 1988, MUTAT RES, V204, P379, DOI 10.1016/0165-1218(88)90036-5; FAORO R, 1991, AEROMETRIC INFORMATI; FRIEDMAN GD, 1986, AM J EPIDEMIOL, V123, P781, DOI 10.1093/oxfordjournals.aje.a114307; FUKINO H, 1982, MUTAT RES, V102, P237, DOI 10.1016/0165-1218(82)90133-1; HEMMINKI K, 1990, CARCINOGENESIS, V11, P1229, DOI 10.1093/carcin/11.7.1229; HENNEKENS CH, 1984, CANCER DETECT PREV, V7, P147; HERTZMAN C, 1990, HLTH POLICY RES UNIT, V90, pD2; Hulka BS., 1990, BIOL MARKERS EPIDEMI, P3; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; MAYER JL, IN PRESS MUTATION RE; MOON TE, NUTRITION CANCER PRE; MOORE DH, 1984, SISTER CHROMATID EXC, P469; MOTYKIEWICZ G, 1989, MUTAT RES, V223, P243, DOI 10.1016/0165-1218(89)90052-9; PERERA FP, 1988, CANCER RES, V48, P2288; PERERA FP, 1990, CA A CANCER J CLIN, V40, P227; PERERA FP, IN PRESS MOL EPIDEMI; PEZZUTO JM, 1986, P AM ASSOC CANC RES, V27, P126; WEI LJ, 1983, J AM STAT ASSOC, V78, P725; IN PRESS MONOGRAPH I	23	255	258	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					256	258		10.1038/360256a0	http://dx.doi.org/10.1038/360256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436106				2022-12-24	WOS:A1992JY96000050
J	JOHNSON, RS; SPIEGELMAN, BM; PAPAIOANNOU, V				JOHNSON, RS; SPIEGELMAN, BM; PAPAIOANNOU, V			PLEIOTROPIC EFFECTS OF A NULL MUTATION IN THE C-FOS PROTOONCOGENE	CELL			English	Article							TRANSFORMED-CELL LINE; EMBRYONIC STEM-CELLS; ANTISENSE RNA; DNA-BINDING; GENE-EXPRESSION; TRANSGENIC MICE; GLUCOCORTICOID RECEPTOR; TARGETED DISRUPTION; MOLECULAR-CLONING; NERVOUS-SYSTEM	The c-fos proto-oncogene has been implicated as a central regulatory component of the nuclear response to mitogens and other extracellular stimuli. Embryonic stem cells targeted at the c-fos locus have been used to generate chimeric mice that have transmitted the mutated allele through the germline. Homozygous mutants show reduced placental and fetal weights and significant loss of viability at birth. Approximately 40% of the homozygous mutants survive and grow at normal rates until severe osteopetrosis, characterized by foreshortening of the long bones, ossification of the marrow space, and absence of tooth eruption, begins to develop at approximately 11 days. Among other abnormalities, these mice show delayed or absent gametogenesis, lymphopenia, and altered behavior. Despite these defects, many live as long as their wild-type or heterozygous littermates (currently 7 months). These data indicate that c-fos is not required for the growth of most cell types but is involved in the development and function of several distinct tissues.	TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Tufts University; Tufts University; Harvard University; Harvard Medical School	JOHNSON, RS (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926, R01HD027295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27295, HD24926] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADAMSON ED, 1985, EMBO J, V4, P941, DOI 10.1002/j.1460-2075.1985.tb03722.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARKA T, 1989, EXP CELL RES, V185, P419, DOI 10.1016/0014-4827(89)90312-1; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGERS JD, 1991, J IN VITRO FERTIL EM, V8, P352, DOI 10.1007/BF01133028; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; FARRAR WL, 1989, CRIT REV THER DRUG, V5, P229; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KOUSVELARI E, 1988, EXP CELL RES, V179, P194, DOI 10.1016/0014-4827(88)90358-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LEVI BZ, 1988, CELL DIFFER DEV, V25, P95, DOI 10.1016/0922-3371(88)90105-0; LEVI BZ, 1989, P NATL ACAD SCI USA, V86, P2262, DOI 10.1073/pnas.86.7.2262; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKUNO H, 1991, ONCOGENE, V6, P1491; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	61	581	591	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					577	586		10.1016/0092-8674(92)90592-Z	http://dx.doi.org/10.1016/0092-8674(92)90592-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423615				2022-12-24	WOS:A1992JY67600006
J	MAIN, AL; HARVEY, TS; BARON, M; BOYD, J; CAMPBELL, ID				MAIN, AL; HARVEY, TS; BARON, M; BOYD, J; CAMPBELL, ID			THE 3-DIMENSIONAL STRUCTURE OF THE 10TH TYPE-III MODULE OF FIBRONECTIN - AN INSIGHT INTO RGD-MEDIATED INTERACTIONS	CELL			English	Article							CELL-BINDING DOMAIN; NUCLEAR-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; PROTEIN STRUCTURES; ADHESIVE FUNCTION; CRYSTAL-STRUCTURE; HUMAN CD4; SPECTROSCOPY; RECOGNITION; SEQUENCES	The solution structure of the tenth type III module of fibronectin has been determined using nuclear magnetic resonance techniques. The molecule has a fold similar to that of immunoglobulin domains, with seven beta strands forming two antiparallel beta sheets, which pack against each other. Both beta sheets contribute conserved hydrophobic residues to a compact core. The topology is more similar to that of domain 2 of CD4, PapD, and the extracellular domain of the human growth hormone receptor than to that of immunoglobulin C domains. The module contains an Arg-Gly-Asp sequence known to be involved in cell adhesion. This tripeptide is solvent exposed and lies on a conformationally mobile loop between strands F and G, consistent with its cell adhesion function.			MAIN, AL (corresponding author), UNIV OXFORD, DEPT BIOCHEM, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Harvey, Timothy S/F-9863-2013	Harvey, Timothy S/0000-0001-6270-1943				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BARTON GJ, 1990, METHOD ENZYMOL, V183, P403; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, XPLOR MANUAL; CONSTANTINE KL, 1991, BIOCHEMISTRY-US, V30, P1663, DOI 10.1021/bi00220a032; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOMMEL U, 1992, IN PRESS J MOL BIOL; Hynes RO, 1990, FIBRONECTINS; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mosher DF, 1989, FIBRONECTIN; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; WANG HM, 1992, J BIOL CHEM, V267, P979; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	51	450	487	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					671	678		10.1016/0092-8674(92)90600-H	http://dx.doi.org/10.1016/0092-8674(92)90600-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423622				2022-12-24	WOS:A1992JY67600014
J	BALASUBRAMANIAN, MK; HELFMAN, DM; HEMMINGSEN, SM				BALASUBRAMANIAN, MK; HELFMAN, DM; HEMMINGSEN, SM			A NEW TROPOMYOSIN ESSENTIAL FOR CYTOKINESIS IN THE FISSION YEAST S-POMBE	NATURE			English	Article							CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; GENETIC-CONTROL; F-ACTIN; PROTEINS; MUSCLE	MUTATIONS in the Schizosaccharomyces pombe cdc8 gene impair cytokinesis1. Here we clone cdc8+ and find that it encodes a novel tropomyosin. Gene disruption results in lethal arrest of the cell cycle, but spore germination, cell growth, DNA replication and mitosis are all unaffected. Haploid cdc8 gene disruptants are rescued by expression of a fibroblast tropomyosin complementary DNA. Immunofluorescence microscopy of wild type and cdc8 gene distruptants indicates that cdc8 tropomyosin is present in two distinct cellular distributions: in dispersed patches, and during cytokinesis as a transient medial band. Collectively these results indicate that cdc8 tropomyosin has a specialized role which, we suggest, is to form part of the F-actin contractile ring at cytokinesis. These results establish the basis for further genetic studies of cytokinesis and of contractile protein function in S. pombe.	NATL RES COUNCIL CANADA, INST PLANT BIOTECHNOL, SASKATOON S7N 0W9, SASKATCHEWAN, CANADA; UNIV SASKATCHEWAN, DEPT MICROBIOL, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA	National Research Council Canada; University of Saskatchewan			Helfman, David M./C-2058-2011	Balasubramanian, Mohan/0000-0002-1292-8602				ALFA CE, 1990, J CELL SCI, V96, P71; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; HAGAN IM, 1988, J CELL SCI, V89, P343; JOCHOVA J, 1991, CELL BIOL INT REP, V15, P607, DOI 10.1016/0309-1651(91)90007-6; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; LIU HP, 1989, P NATL ACAD SCI USA, V86, P90, DOI 10.1073/pnas.86.1.90; MARKS J, 1992, J CELL SCI, V101, P801; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; SCHROEDER TE, 1990, ANN NY ACAD SCI, V582, P78; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATTS FZ, 1987, EMBO J, V6, P3499, DOI 10.1002/j.1460-2075.1987.tb02675.x; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	22	204	205	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					84	87		10.1038/360084a0	http://dx.doi.org/10.1038/360084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436080				2022-12-24	WOS:A1992JW71700062
J	BRAUN, T; RUDNICKI, MA; ARNOLD, HH; JAENISCH, R				BRAUN, T; RUDNICKI, MA; ARNOLD, HH; JAENISCH, R			TARGETED INACTIVATION OF THE MUSCLE REGULATORY GENE MYF-5 RESULTS IN ABNORMAL RIB DEVELOPMENT AND PERINATAL DEATH	CELL			English	Article							MYOGENIC DETERMINATION FACTORS; LOOP-HELIX PROTEINS; MYOSIN HEAVY-CHAIN; MOUSE EMBRYO; SKELETAL-MUSCLE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; ALPHA-ACTIN; MYOD FAMILY	The Myf-5 gene, a member of the myogenic basic HLH factor family, has been inactivated in mice after homologous recombination in ES cells. Mice lacking Myf-5 were unable to breathe and died immediately after birth, owing to the absence of the major distal part of the ribs. Other skeletal abnormalities, except for complete ossification of the sternum, were not apparent. Histological examination of skeletal muscle from newborn mice revealed no morphological abnormalities. Northern blot analysis demonstrated normal levels of muscle-specific mRNAs including MyoD, myogenin, and Myf-6. However, the appearance of myotomal cells in early somites was delayed by several days. These results suggest that while Myf-5 plays a crucial role in the formation of lateral sclerotome derivatives, Myf-5 is dispensable for the development of skeletal muscle, perhaps because other members of the myogenic HLH family substitute for Myf-5 activity.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	BRAUN, T (corresponding author), UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,W-2000 HAMBURG 13,GERMANY.		Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD HH, 1992, ADV DEV BIOCHM; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bancroft JD, 1990, THEORY PRACTICE HIST; BENFIELD PA, 1984, J BIOL CHEM, V259, P4979; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRADLEY A, 1987, PRODUCTION ANAL CHIM; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DRAKE CJ, 1991, DEV BIOL, V143, P418, DOI 10.1016/0012-1606(91)90092-H; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; Hall BK, 1977, ADV ANATOMY EMBRYOLO, V53, P1; HAUB O, 1991, DEVELOPMENT, V112, P397; HOFFMANN E, 1988, NUCLEIC ACIDS RES, V16, P2353, DOI 10.1093/nar/16.5.2353; Holtzer H., 1968, EPITHELIAL MESENCHYM, P152; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYONS KM, 1990, DEVELOPMENT, V109, P833; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V20, P5755; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RONG PM, 1992, DEVELOPMENT, V115, P657; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS EJ, 1988, DIFFERENTIATION, V39, P34, DOI 10.1111/j.1432-0436.1988.tb00078.x; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SEIDEL U, 1989, J BIOL CHEM, V264, P16109; SOLURSH M, 1979, J EMBRYOL EXP MORPH, V54, P75; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	71	577	592	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					369	382		10.1016/0092-8674(92)90507-9	http://dx.doi.org/10.1016/0092-8674(92)90507-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423602				2022-12-24	WOS:A1992JW43500004
J	LEONE, G; MAYBAUM, L; LEE, PWK				LEONE, G; MAYBAUM, L; LEE, PWK			THE REOVIRUS CELL ATTACHMENT PROTEIN POSSESSES 2 INDEPENDENTLY ACTIVE TRIMERIZATION DOMAINS - BASIS OF DOMINANT NEGATIVE EFFECTS	CELL			English	Article							HEPTAD REPEAT REGION; WILD-TYPE P53; MUTANT P53; FUNCTIONAL DOMAINS; COLON CANCER; COILED-COIL; 3 SEROTYPES; SIGMA-1; IDENTIFICATION; GENE	The reovirus cell attachment protein, sigma1, is a homotrimer with an N-terminal fibrous tail and a C-terminal globular head. By cotranslating full-length and various truncated sigma1 proteins in vitro, we show that the N- and C-terminal halves of sigma1 possess independent trimerization and folding domains. Trimerization of sigma1 is initiated at the N-terminus by the formation of a "loose," protease-sensitive, three-stranded, alpha-helical coiled coil. This serves to bring the three unfolded C-termini into close proximity to one another, facilitating their subsequent trimerization and cooperative folding. Concomitant with, but independent of, this latter process, the N-terminal fiber further matures into a more stable and protease-resistant structure. The coordinated folding of sigma1 trimers exemplifies the dominant negative effects of mutant subunits in oligomeric complexes.			LEONE, G (corresponding author), UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY T2N 4N1,ALBERTA,CANADA.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300				ARMSTRONG GD, 1984, VIROLOGY, V138, P37, DOI 10.1016/0042-6822(84)90145-4; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BANERJEA AC, 1990, VIROLOGY, V179, P460, DOI 10.1016/0042-6822(90)90315-I; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; BOURNE HR, 1991, NATURE, V353, P696, DOI 10.1038/353696b0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURSTIN SJ, 1982, VIROLOGY, V117, P146, DOI 10.1016/0042-6822(82)90514-1; CASHDOLLAR LW, 1985, P NATL ACAD SCI USA, V82, P24, DOI 10.1073/pnas.82.1.24; CASHDOLLAR LW, 1989, VIROLOGY, V168, P183, DOI 10.1016/0042-6822(89)90420-0; COOHAN JP, 1992, VIROLOGY, V186, P409; DUNCAN R, 1990, VIROLOGY, V174, P399, DOI 10.1016/0042-6822(90)90093-7; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GANNON JV, 1990, EMBO J, V9, P1591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NAGATA L, 1987, VIROLOGY, V160, P162, DOI 10.1016/0042-6822(87)90056-0; NAGATA L, 1984, NUCLEIC ACIDS RES, V12, P8699, DOI 10.1093/nar/12.22.8699; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAUL RW, 1987, VIROLOGY, V159, P94, DOI 10.1016/0042-6822(87)90351-5; ROVINSKI B, 1988, ONCOGENE, V2, P445; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SHARPE AH, 1985, NEW ENGL J MED, V312, P486, DOI 10.1056/NEJM198502213120806; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; WEINER HL, 1978, VIROLOGY, V86, P581, DOI 10.1016/0042-6822(78)90099-5; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8; YEUNG MC, 1987, VIROLOGY, V156, P377, DOI 10.1016/0042-6822(87)90417-X	45	39	42	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					479	488		10.1016/0092-8674(92)90516-F	http://dx.doi.org/10.1016/0092-8674(92)90516-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423608				2022-12-24	WOS:A1992JW43500013
J	KOHLMEIER, L; ARMINGER, G; BARTOLOMEYCIK, S; BELLACH, B; REHM, J; THAMM, M				KOHLMEIER, L; ARMINGER, G; BARTOLOMEYCIK, S; BELLACH, B; REHM, J; THAMM, M			PET BIRDS AS AN INDEPENDENT RISK FACTOR FOR LUNG-CANCER - CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERSENSITIVITY PNEUMONITIS; FANCIERS LUNG; OCCUPATION; PATHOLOGY; BREEDERS; SMOKING	Objective-To test the hypothesis that exposure to pct birds increases risk of developing lung cancer. Design-Case-control study. Computerised interviews were used to assess previous exposure to pets and other risk factors for lung cancer. Setting-Three major hospitals treating respiratory disease in former West Berlin. Subjects-All people newly diagnosed as having primary malignant neoplasm of the trachea, bronchi, or lung who were 65 or younger and control subjects matched for age and sex from the general population of former West Berlin. 279 cases and 635 controls qualified for the study; 239 cases and 429 controls participated. Main outcome measures-Odds ratio of developing lung cancer according to whether or not pet birds were kept and the duration of keeping pet birds. Results-In addition to the risk of lung cancer imposed by smoking, passive smoking, and occupational exposure to carcinogens, an increased relative risk of 2.14 (95% confidence interval 1.35 to 3.40) was found among people exposed to pet birds. The adjusted odds ratio for exposures longer than 10 years was 3.19 (1.48 to 8.21). Conclusions-Avian exposure seems to carry a risk of lung cancer. Until the pathogenesis is understood, long term exposure to pet birds in living areas should be avoided, especially among people at high risk of developing lung cancer.	UNIV GESAMTHSCH WUPPERTAL, W-5600 WUPPERTAL 1, GERMANY	University of Wuppertal	KOHLMEIER, L (corresponding author), BUNDESGESUNDHEITSAMT, INST SOCIAL MED & EPIDEMIOL, POSTFACH 330013, W-1000 BERLIN 33, GERMANY.		Rem, Jürgen/H-1309-2011					ALLEN DH, 1976, AM REV RESPIR DIS, V114, P555; [Anonymous], 1986, ENV TOBACCO SMOKE ME; AXELSON O, 1990, ANN NY ACAD SCI, V609, P165; BALASUBRAMANIAM SK, 1987, CLIN PEDIATR, V26, P174, DOI 10.1177/000992288702600402; BOURKE SJ, 1989, CLIN EXP ALLERGY, V19, P629, DOI 10.1111/j.1365-2222.1989.tb02758.x; BOURKE SJ, 1990, AM REV RESPIR DIS, V142, P1168, DOI 10.1164/ajrccm/142.5.1168; CARSTENSEN JM, 1990, ANN NY ACAD SCI, V609, P159; FEHR R, 1983, BERUFSSPEZIFISCHE KR, P137; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V85, P655, DOI 10.1016/0091-6749(90)90107-F; HAGMAR L, 1990, AM J IND MED, V17, P77; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; JAMES JM, 1987, CLIN EXP IMMUNOL, V68, P397; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; MENCK HR, 1976, J OCCUP ENVIRON MED, V18, P797, DOI 10.1097/00043764-197612000-00005; MILNE KL, 1983, AM J IND MED, V4, P565, DOI 10.1002/ajim.4700040410; OSTERGAARD JR, 1989, ACTA PAEDIATR SCAND, V78, P145, DOI 10.1111/j.1651-2227.1989.tb10906.x; PUKKALA E, 1983, INT J EPIDEMIOL, V12, P290, DOI 10.1093/ije/12.3.290; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; ROSENSTOCK L, 1986, CLIN OCCUPATIONAL ME; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SCHMIDT CD, 1988, CHEST, V93, P359, DOI 10.1378/chest.93.2.359; SMITH JH, 1990, J PARASITOL, V76, P59, DOI 10.2307/3282628; Staib F, 1986, Prax Klin Pneumol, V40, P86; Staib F., 1987, AIDS-Forschung, V2, P363; Staib F, 1968, Mykosen, V11, P619; Staib F., 1989, AIDS-Forschung, V4, P649; STAIB F, 1985, ZBL BAKT MIK HYG B, V180, P567; STAIB F, 1987, INDOOR AIR 87, V1, P694; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEGENER HH, 1983, ZBL BAKT-INT J MED M, V256, P231; 1991, EGRET, P1; 1988, HLTH RISKS RADON OTH; 1989, GESUNDHEITSWESEN F 4; 1988, INT KLASSIFIKATION K; 1984, ABESTIFORM FIBERS NO	37	31	31	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1992	305	6860					986	989		10.1136/bmj.305.6860.986	http://dx.doi.org/10.1136/bmj.305.6860.986			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458145	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JV77600025
J	MERBS, SL; NATHANS, J				MERBS, SL; NATHANS, J			ABSORPTION-SPECTRA OF THE HYBRID PIGMENTS RESPONSIBLE FOR ANOMALOUS COLOR-VISION	SCIENCE			English	Article							MOLECULAR-GENETICS; GENES; GREEN; BLUE; XQ28	Unequal homologous recombination events between green and red cone pigment genes produce the red-green or green-red hybrid pigment genes found in many individuals with variant color vision. Photobleaching difference absorption spectroscopy of hybrid pigments produced in cultured cells shows that the spectral sensitivity of each hybrid pigment is intermediate between the parental green and red pigment sensitivities. Amino acids encoded by exons 2, 3, 4, and 5 produce spectral shifts at the wavelength of maximal absorbance of 0 to 4, 0 to 4, 3 to 4, and 15 to 21 nanometers, respectively, the exact value depending on the identities ot amino acids elsewhere in the hybrid.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MERBS, SL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ALPERN M, 1979, J PHYSIOL-LONDON, V288, P85; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; CHAN T, 1992, J BIOL CHEM, V267, P9478; Dartnall H.J.A., 1983, COLOUR VISION PHYSL, P69; DEEB SS, IN PRESS AM J HUM GE; FEIL R, 1990, GENOMICS, V6, P367, DOI 10.1016/0888-7543(90)90578-I; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MERBS SL, UNPUB; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1989, NATURE, V342, P679, DOI 10.1038/342679a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; PIANTANIDA TP, 1973, VISION RES, V13, P2049, DOI 10.1016/0042-6989(73)90181-8; PIANTANIDA TP, 1973, VISION RES, V13, P2033, DOI 10.1016/0042-6989(73)90180-6; POKORNY J., 1979, CONGENITAL ACQUIRED; RUSHTON W A H, 1972, Journal of Physiology (Cambridge), V220, P1; RUSHTON WAH, 1973, VISION RES, V13, P2017, DOI 10.1016/0042-6989(73)90179-X; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	27	148	151	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					464	466		10.1126/science.1411542	http://dx.doi.org/10.1126/science.1411542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411542				2022-12-24	WOS:A1992JT77500035
J	KLEINERT, HD; ROSENBERG, SH; BAKER, WR; STEIN, HH; KLINGHOFER, V; BARLOW, J; SPINA, K; POLAKOWSKI, J; KOVAR, P; COHEN, J; DENISSEN, J				KLEINERT, HD; ROSENBERG, SH; BAKER, WR; STEIN, HH; KLINGHOFER, V; BARLOW, J; SPINA, K; POLAKOWSKI, J; KOVAR, P; COHEN, J; DENISSEN, J			DISCOVERY OF A PEPTIDE-BASED RENIN INHIBITOR WITH ORAL BIOAVAILABILITY AND EFFICACY	SCIENCE			English	Article							CONVERTING-ENZYME; BLOOD-PRESSURE; BIOLOGICAL-ACTIVITY; DIPEPTIDE ANALOGS; PROFILE; POTENT; HYPERTENSION; RO-42-5892; ENALKIREN; SITE	Peptidic renin inhibitors have been poorly absorbed across the intestine or rapidly eliminated by the liver and have been reported to have oral bioavailabilities of less than 2%. A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively. Dose-related reductions in blood pressure, plasma renin activity, and plasma angiotensin II in parallel with increased plasma drug concentrations were observed after oral administration of A-72517 to conscious, salt-depleted dogs. Thus, peptide-based molecules of sizable molecular mass can be absorbed intact into the systemic circulation of animals. These findings support the potential of peptide-based drugs for oral administration.			KLEINERT, HD (corresponding author), ABBOTT LABS, ABBOTT PK, IL 60064 USA.							ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BLAINE EH, 1984, HYPERTENSION, V6, pI111, DOI 10.1161/01.HYP.6.2_Pt_2.I111; BOGER J, 1983, NATURE, V303, P81, DOI 10.1038/303081a0; BRUNNER HR, 1979, ANN INTERN MED, V90, P19, DOI 10.7326/0003-4819-90-1-19; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLMAYER P, 1988, J MED CHEM, V31, P1839; CAMENZIND E, 1991, J CARDIOVASC PHARM, V18, P299, DOI 10.1097/00005344-199109000-00001; CAVANAUGH J, 1989, J CLIN PHARMACOL, V29, P861; CODY RJ, 1985, AM J CARDIOL, V55, pA36, DOI 10.1016/0002-9149(85)90794-5; CUMIN F, 1990, DRUG METAB DISPOS, V18, P831; DEGASPARO M, 1989, BRIT J CLIN PHARMACO, V27, P587; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FISCHLI W, 1991, HYPERTENSION, V18, P22, DOI 10.1161/01.HYP.18.1.22; GLASSMAN HN, 1990, J CARDIOVASC PHARM, V16, pS76, DOI 10.1097/00005344-199016004-00016; JEUNEMAITRE X, 1989, AM J HYPERTENS, V2, P819, DOI 10.1093/ajh/2.11.819; KLEINERT H, UNPUB; Kleinert H D, 1991, Adv Pharmacol, V22, P207, DOI 10.1016/S1054-3589(08)60036-8; KLEINERT HD, 1988, FEBS LETT, V230, P38, DOI 10.1016/0014-5793(88)80637-9; KLEINERT HD, 1990, CARDIOVASC DRUG REV, V8, P203, DOI 10.1111/j.1527-3466.1990.tb00393.x; LULY Jr, 1988, J MED CHEM, V31, P2264, DOI 10.1021/jm00120a005; NEUBERG GW, 1991, AM J CARDIOL, V67, P63, DOI 10.1016/0002-9149(91)90101-P; PALS DT, 1986, HYPERTENSION, V8, P1105, DOI 10.1161/01.HYP.8.12.1105; PANEK RL, 1991, CLIN EXP HYPERTENS A, V13, P1395, DOI 10.3109/10641969109048801; PLATTNER JJ, 1988, J MED CHEM, V31, P2277, DOI 10.1021/jm00120a006; PLATTNER JJ, 1990, DRUG DISCOVERY TECHN, pCH5; ROSENBERG SH, 1989, J MED CHEM, V32, P1371, DOI 10.1021/jm00126a038; RUSH BD, 1991, INT J PHARM, V73, P231, DOI 10.1016/0378-5173(91)90415-K; SCHAFFER LW, 1990, J HYPERTENS, V8, P251; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCROOP GC, 1968, NATURE, V220, P1331, DOI 10.1038/2201331a0; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; VERBURG KM, 1989, HYPERTENSION, V13, P262, DOI 10.1161/01.HYP.13.3.262; Waeber BNJ, 1990, HYPERTENSION PATHOPH, P2209; WEISSMAN J, 1985, J MED CHEM, V28, P997, DOI 10.1021/jm00146a005; WONG PC, 1990, J PHARMACOL EXP THER, V252, P719; WOOD JM, 1989, J CARDIOVASC PHARM, V14, P221, DOI 10.1097/00005344-198908000-00006	37	105	107	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1940	1943		10.1126/science.1411510	http://dx.doi.org/10.1126/science.1411510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411510				2022-12-24	WOS:A1992JP59400030
J	SCHANTZ, PM; MOORE, AC; MUNOZ, JL; HARTMAN, BJ; SCHAEFER, JA; ARON, AM; PERSAUD, D; SARTI, E; WILSON, M; FLISSER, A				SCHANTZ, PM; MOORE, AC; MUNOZ, JL; HARTMAN, BJ; SCHAEFER, JA; ARON, AM; PERSAUD, D; SARTI, E; WILSON, M; FLISSER, A			NEUROCYSTICERCOSIS IN AN ORTHODOX JEWISH-COMMUNITY IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOELECTROTRANSFER BLOT; CEREBRAL CYSTICERCOSIS; UNITED-STATES; DIAGNOSIS	Background and Methods. From June 1990 through July 1991, intracerebral infection with the larval stage of the pork tapeworm Taenia solium was diagnosed in four unrelated persons in an Orthodox Jewish community in New York City. None of the patients had eaten pork, and only one had traveled to a country in which T solium infection was endemic. We investigated this outbreak, screened serum samples from family members and household contacts for antibodies to cysticercosis, and examined stool specimens from household employees for eggs of taenia species. Results. The four patients had recurrent seizures and brain lesions that were radiologically consistent with the presence of cysticerci. The diagnosis was confirmed in two patients by a brain biopsy, and in two by immunoblot assays for cysticercus antibodies. Of 17 immediate family members screened serologically, 7 from two families had cysticercus antibodies. Magnetic resonance imaging of the brain showed cystic lesions in two of the seropositive family members, one of whom had had a seizure. Examinations of six domestic employees from all four households revealed an active infection with taenia species in one and a positive serologic test in another. Since these women had recently emigrated from Latin American countries where T. solium infection is endemic, they were the most likely sources of infection in the members of these households. Conclusions. A diagnosis of neurocysticercosis should be considered in patients with seizures and radiologic evidence of cystic brain lesions, even in those who do not eat pork and who have not traveled to a country in which T. solium infection is endemic. Recent emigrants from countries in which T. solium infection is endemic should be screened for tapeworm infection in their stools before they are employed as housekeepers or food handlers.	NYU MED CTR,DEPT PEDIAT,NEW YORK,NY 10016; CORNELL UNIV,SCH MED,DIV INFECT DIS,ITHACA,NY 14853; CORNELL UNIV,SCH MED,DEPT NEUROL,ITHACA,NY 14853; MT SINAI MED CTR,DIV PEDIAT NEUROL,NEW YORK,NY 10029; SECRETARIAT HLTH,GEN DIRECTORATE EPIDEMIOL,MEXICO CITY,MEXICO; BIOMED RES INST,MEXICO CITY,MEXICO	New York University; Cornell University; Cornell University; Icahn School of Medicine at Mount Sinai	SCHANTZ, PM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS F13,ATLANTA,GA 30333, USA.		Sarti, Elsa/ABB-8450-2021	Flisser, Ana/0000-0002-1744-8480				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; Campagna M., 1954, Journal of Parasitology, V40, P46; COHEN B, 1962, SOUTHERN MED J, V55, P48, DOI 10.1097/00007611-196201000-00013; DEKAMINSKY RG, 1991, T ROY SOC TROP MED H, V85, P531, DOI 10.1016/0035-9203(91)90245-T; DIAZ JF, 1992, AM J TROP MED HYG, V46, P610, DOI 10.4269/ajtmh.1992.46.610; EARNEST MP, 1987, REV INFECT DIS, V9, P961; FLISSER A, 1988, PARASITOL TODAY, V4, P131, DOI 10.1016/0169-4758(88)90187-1; Garbutt G D, 1967, Bull Los Angeles Neurol Soc, V32, P6; GEMMELL M, 1983, WHO VPH8349 DOC; KEANE JR, 1980, ANN NEUROL, V8, P643, DOI 10.1002/ana.410080624; LOO L, 1982, MEDICINE, V61, P341, DOI 10.1097/00005792-198211000-00001; Mahajan R.C., 1982, P39; Mazzotti L., 1944, REV INST SALUBRIDAD Y ENFERM TROP, V5, P207; McCormick G F, 1985, Bull Clin Neurosci, V50, P76; MELVIN DM, 1982, DHHS CDC828282 CTR D; MITCHELL WG, 1988, PEDIATRICS, V82, P76; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; PILCHER J B, 1991, American Journal of Tropical Medicine and Hygiene, V45, P131; Prevention and control of intestinal parasitic infections, 1987, WHO TECH REP SER, V749, P1; RICHARDS FO, 1985, JAMA-J AM MED ASSOC, V254, P3444, DOI 10.1001/jama.254.24.3444; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Schantz P M, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P65; SCHANTZ P M, 1989, Acta Leidensia, V57, P153; SCHARF D, 1988, ARCH NEUROL-CHICAGO, V45, P777, DOI 10.1001/archneur.1988.00520310087022; Schenone H., 1982, P25; SCHULTZ TS, 1978, NEUROSURGERY, V3, P164, DOI 10.1227/00006123-197809000-00006; SHANLEY JD, 1980, ARCH INTERN MED, V140, P1309, DOI 10.1001/archinte.140.10.1309; SORVILLO FJ, 1992, AM J TROP MED HYG, V47, P365, DOI 10.4269/ajtmh.1992.47.365; TASKER WG, 1979, PEDIATRICS, V63, P761; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007; 1990, CALIFORNIA MORBIDITY; 1991, 1990 CENSUS PROFILE, P1; 1986, MED LETT DRUGS THER, V28, P9	34	309	321	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					692	695		10.1056/NEJM199209033271004	http://dx.doi.org/10.1056/NEJM199209033271004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495521				2022-12-24	WOS:A1992JL23500004
J	VAZQUEZ, V; SOTELO, J				VAZQUEZ, V; SOTELO, J			THE COURSE OF SEIZURES AFTER TREATMENT FOR CEREBRAL CYSTICERCOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENCHYMAL BRAIN CYSTICERCOSIS; LATE-ONSET EPILEPSY; NEUROCYSTICERCOSIS; PROGNOSIS; THERAPY; PRAZIQUANTEL; ALBENDAZOLE; CHILDHOOD; CT	Background. Worldwide, cerebral cysticercosis is one of the most common causes of seizure disorders. Modern cysticidal drugs can usually eliminate the parasite from the brain, but there have been doubts as to whether such treatment improves the seizure disorder. Methods. We studied 240 patients with seizures and cysticercosis of the brain parenchyma. Of these patients, 118 received cysticidal therapy (albendazole, praziquantel, or both) for lesions without inflammation on imaging studies (group 1); 49 patients with similar lesions either were not offered or refused cysticidal medication (group 2). Another 58 patients with inflammation around cysts (making spontaneous resolution more likely) also did not receive cysticidal medication (group 3), whereas cysticerci were removed surgically in 15 patients (group 4). The 240 patients were followed for a mean (+/-SE) of 92+/-7 months. Results. In the patients treated with cysticidal medications, there was an 82 percent reduction in the mean number of brain cysts (from 5.0 to 0.9) and a 95 percent reduction in the mean frequency of seizures (from 11.3 to 0.6 per year; P<0.001). After three years of follow-up, 64 patients in group 1 (54 percent) were seizure-free. By contrast, the untreated patients (group 2) averaged 10.9 seizures per year; none were seizure-free. Among those with inflamed cysts (group 3), there was a 74 percent reduction in the frequency of seizures (from 7.5 to 2.7 per year), and 18 patients (31 percent) became seizure-free. After surgical treatment (group 4), there was an 87 percent reduction in the frequency of seizures (from 12.8 to 1.7 per year), and six patients (40 percent) became seizure-free. Conclusions. After medical treatment of neurocysticercosis, there is usually remission or marked improvement in the associated seizure disorder.	INST NACL NEUROL & NEUROCIRUG MANUEL VELASCO SUARE, DIV RES, INSURGENTES 3877, MEXICO CITY 14269, MEXICO									AEBI C, 1991, EUR J PEDIATR, V150, P282, DOI 10.1007/BF01955533; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1991, Lancet, V337, P1175; ARTS WFM, 1988, EPILEPSIA, V29, P244, DOI 10.1111/j.1528-1157.1988.tb03713.x; BHATTACHARYYA GK, 1977, STATISTICAL CONCEPTS; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; Del Brutto O. H., 1991, Journal of Tropical and Geographical Neurology, V1, P31; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389, DOI 10.1212/WNL.42.2.389; DELBRUTTO OH, 1988, REV INFECT DIS, V10, P1075; Draper N.R., 1981, APPL REGRESSION ANAL, Vsecond, DOI DOI 10.1002/9781118625590; EARNEST MP, 1987, REV INFECT DIS, V9, P961; Escobar A., 1983, CYSTICERCOSIS CENTRA, P27; ESCOBAR A, 1972, PATHOLOGY NERVOUS SY, V3, P2503; FISH DR, 1989, ACTA NEUROL SCAND, V80, P524, DOI 10.1111/j.1600-0404.1989.tb03921.x; HORNIG CR, 1990, EUR ARCH PSY CLIN N, V239, P379, DOI 10.1007/BF01734546; JUNG H, 1990, J NEUROL, V237, P279, DOI 10.1007/BF00314741; KATAOKA K, 1988, EUR NEUROL, V28, P279, DOI 10.1159/000116284; KERANEN T, 1988, ACTA NEUROL SCAND, V78, P7, DOI 10.1111/j.1600-0404.1988.tb07997.x; KLEINBAUM DG, 1978, APPLIED REGRESSION A; LOPEZ JLP, 1985, ACTA NEUROL SCAND, V72, P380; MEDINA MT, 1990, ARCH INTERN MED, V150, P325, DOI 10.1001/archinte.150.2.325; MILLER B, 1983, NEUROLOGY, V33, P1377, DOI 10.1212/WNL.33.10.1377; MOODLEY M, 1989, LANCET, V1, P262, DOI 10.1016/S0140-6736(89)91268-3; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; ROBITAILLE Y, 1987, CURRENT PROBLEMS EPI, V3, P95; ROBLES C, 1987, J NEUROSURG, V66, P359, DOI 10.3171/jns.1987.66.3.0359; RODRIGUEZCARBAJAL J, 1987, CHILD NERV SYST, V3, P199, DOI 10.1007/BF00274044; RODRIQUEZCARBAJAL J, 1983, AM J NEURORADIOL, V4, P51; SANTOYO H, 1991, NEW ENGL J MED, V324, P1137; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; SOTELO J, 1990, J NEUROL, V237, P69, DOI 10.1007/BF00314663; SOTELO J, 1985, ARCH INTERN MED, V145, P442, DOI 10.1001/archinte.145.3.442; SOTELO J, 1988, ARCH NEUROL-CHICAGO, V45, P1130, DOI 10.1001/archneur.1988.00520340084017; SOTELO J, 1984, NEW ENGL J MED, V310, P1001, DOI 10.1056/NEJM198404193101601; SOTELO J, 1987, CURRENT THERAPY NEUR, P114; Sotelo-Morales J, 1989, Gac Med Mex, V125, P31; 1991, LANCET, V337, P1193	39	161	162	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					696	701		10.1056/NEJM199209033271005	http://dx.doi.org/10.1056/NEJM199209033271005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495522	Bronze			2022-12-24	WOS:A1992JL23500005
J	SAFER, DJ; KRAGER, JM				SAFER, DJ; KRAGER, JM			EFFECT OF A MEDIA BLITZ AND A THREATENED LAWSUIT ON STIMULANT TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RITALIN	Objective.-To enumerate and evaluate changes in the rate of medication treatment for hyperactive/inattentive students subsequent to negative media publicity about methylphenidate (Ritalin) and related lawsuits threatened or initiated from late 1987 to early 1989. Design.-Biennial 1971 to 1991 school nurse surveys of medication treatment for hyperactive/inattentive students; a 1989 school nurse questionnaire on parent attitudes about medication; annual 1984 through 1991 hyperkinetic clinic treatment data; annual 1986 through 1990 Drug Enforcement Administration estimates of retail sales of methylphenidate, nationally and locally. Primary Setting.-All public and private elementary and secondary schools in Baltimore County, Maryland. Patients.-Students receiving medication for hyperactivity/inattentiveness. Results.-Whereas the medication rate for the treatment of hyperactive/inattentive students in Baltimore County doubled every 4 to 7 years from 1971 through 1987, it declined 39% in the 1989 and 1991 surveys from its 1987 peak. This drop occurred after the 1987 through 1989 media blitz against methylphenidate and after a well-publicized threatened lawsuit locally. Parents became fearful of media-reported medication "side effects" and school staff hesitated to refer restless, impulsive, and inattentive students to physicians. Most inhibited from the prospect of medication treatment were less affluent parents and parents of hyperactive/inattentive elementary schoolchildren who had never received medication. Drug Enforcement Administration data revealed that the Baltimore metropolitan area had a far greater decline in methylphenidate use than that which occurred nationally. Conclusion.-Strong circumstantial evidence suggests that the prominent 1989 and 1991 declines in the initiation of stimulant medication for hyperactive/inattentive students were related to the apprehension of parents and involved professionals. generated by the methylphenidate media blitz and the threatened lawsuit.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University	SAFER, DJ (corresponding author), BALTIMORE CTY DEPT HLTH,9100 FRANKLIN SQ DR,BALTIMORE,MD 21237, USA.							BORNEMANN A, 1989, NE TIMES REP    0111, P8; Burton Thomas M., 1991, WALL STREET J; BURTON TM, 1991, WALL ST J       0419, pA2; CALLAHAM M, 1985, ANN EMERG MED, V14, P1, DOI 10.1016/S0196-0644(85)80725-3; COLINO S, 1988, BALTIMORE MAG, V81, P66; COLINO S, 1988, BALTIMORE MAG, V81, P96; COWART VS, 1988, JAMA-J AM MED ASSOC, V259, P2521; DIVOKY D, 1989, PHI DELTA KAPPAN, V70, P599; DUNN SG, 1988, TOWSON TIMES    0525, P19; KOHN A, 1989, ATLANTIC MONTHLY, V264, P90; KRAGER JM, 1979, J SCHOOL HEALTH, V49, P317, DOI 10.1111/j.1746-1561.1979.tb07722.x; MORGAN M, 1980, J BROADCASTING, V24, P117, DOI 10.1080/08838158009363973; MOSS DC, 1988, ABA J, V74, P19; NORTON M, 1989, BALTIMORE EVENI 0104, pD3; NORTON M, 1989, BALTIMORE EVENI 0104, pD1; PRESKORN SH, 1991, J CLIN PSYCHIAT, V52, P23; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SAPPEL J, 1990, BALTIMORE SUN   0807, P8; SHERMAN SL, 1988, BALTIMORE DAILY 0518, P1; SHERMAN SL, 1988, BALTIMORE DAILY 0518, P11; SPRAGUE RL, 1991, OCT WORLD C PSYCH AT, V6, P569; THOMPSON K, 1987, BALTIMORE SUN   1211, P1; TREADWELL D, 1987, BALTIMORE SUN   1230, pC8; TREADWELL D, 1987, BALTIMORE SUN   1230, pC1; WELKE R, 1990, DET CL REV, P125; Wright JC, 1990, TELEVISION AM FAMILY, P227; 1989, BALTIMORE SUN   0104, pD1; 1970, NEWSWEEK        0209, P52; 1991, ARCOS DATA BASE 1986	29	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1004	1007		10.1001/jama.268.8.1004	http://dx.doi.org/10.1001/jama.268.8.1004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501304				2022-12-24	WOS:A1992JK12900025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW ANTIARRHYTHMIC APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-24	WOS:A1992KC83900008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONTRACEPTIVE INJECTION APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-24	WOS:A1992KC83900007
J	MANDEL, JL; MONACO, AP; NELSON, DL; SCHLESSINGER, D; WILLARD, H				MANDEL, JL; MONACO, AP; NELSON, DL; SCHLESSINGER, D; WILLARD, H			GENOME ANALYSIS AND THE HUMAN X-CHROMOSOME	SCIENCE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; POLYMERASE CHAIN-REACTION; YEAST ARTIFICIAL CHROMOSOMES; FIELD GEL-ELECTROPHORESIS; GENETIC-LINKAGE MAP; HUMAN XQ24-XQ28 DNA; FRAGILE-X; SHORT ARM; INACTIVATION CENTER; CAENORHABDITIS-ELEGANS	A unified genetic, physical, and functional map of the human X chromosome is being built through a concerted, international effort. About 40 percent of the 160 million base pairs of the X chromosome DNA have been cloned in overlapping, ordered contigs derived from yeast artificial chromosomes. This rapid progress toward a physical map is accelerating the identification of inherited disease genes, 26 of which are already cloned and more than 50 others regionally localized by linkage analysis. This article summarizes the mapping strategies now used and the impact of genome research on the understanding of X chromosome inactivation and X-linked diseases.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,HUMAN GENET LAB,OXFORD OX3 9DU,ENGLAND; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	University of Oxford; Baylor College of Medicine; Washington University (WUSTL)	MANDEL, JL (corresponding author), CNRS,INSERM,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE.		Gilna, Paul/I-3608-2016; Monaco, Anthony P/A-4495-2010	Gilna, Paul/0000-0002-6542-0191; Monaco, Anthony P/0000-0001-7480-3197				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALITALO T, 1991, HUM GENET, V86, P599, DOI 10.1007/BF00201548; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; ARCHIDIACONO N, 1991, HUM GENET, V86, P604; ARVEILER B, 1990, AM J HUM GENET, V46, P906; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BACH I, IN PRESS HUM GENET; BAKKER E, 1989, J MED GENET, V26, P553, DOI 10.1136/jmg.26.9.553; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; Ballabio A, 1992, CURR OPIN GENET DEV, V2, P439, DOI 10.1016/S0959-437X(05)80155-8; Ballabio A, 1991, CURR OPIN GENET DEV, V1, P25, DOI 10.1016/0959-437X(91)80036-L; BARKER DF, 1991, HUM GENET, V88, P189; BARLOW DP, 1987, TRENDS GENET, V3, P167, DOI 10.1016/0168-9525(87)90219-8; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BENHAM F, 1989, GENOMICS, V4, P509, DOI 10.1016/0888-7543(89)90274-7; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BERGER W, 1992, NAT GENET, V1, P204; BLONDEN LAJ, 1991, GENOMICS, V10, P631, DOI 10.1016/0888-7543(91)90445-K; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P839; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, IN PRESS CELL; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P173, DOI 10.1007/BF01535079; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1989, CYTOGENET CELL GENET, V51, P970; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, IN PRESS CELL; BROWN S, IN PRESS MAMM GENOME; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANGIANO G, 1990, NUCLEIC ACIDS RES, V18, P5077, DOI 10.1093/nar/18.17.5077; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CATTANACH BM, 1991, CYTOGENET CELL GENET, V56, P137, DOI 10.1159/000133070; CLARKE TR, 1992, AM J HUM GENET, V51, P316; COFFEY AJ, 1992, GENOMICS, V12, P474, DOI 10.1016/0888-7543(92)90437-W; COHEN D, 1992, COLD SPRING HARBOR M, P32; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7826; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CREMERS FP, 1990, NATURE, V347, P347; CREMERS FPM, 1988, AM J HUM GENET, V43, P452; DAVIES KE, 1991, CYTOGENET CELL GENET, V58, P853, DOI 10.1159/000133183; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; DENDUNNEN JT, 1992, HUM MOL GENET, V1, P19; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DRAYNA D, 1984, P NATL ACAD SCI-BIOL, V81, P2836, DOI 10.1073/pnas.81.9.2836; DRAYNA D, 1985, SCIENCE, V230, P753, DOI 10.1126/science.4059909; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; FAIN P, 1992, 3RD X CHROM WORKSH A; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRANCKE U, 1985, AM J HUM GENET, V37, P250; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FU YH, 1991, NEW ENGL J MED, V65, P905; GEDEON AK, 1992, AM J MED GENET, V43, P255, DOI 10.1002/ajmg.1320430140; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; GOLEMAN MP, 1991, GENOMICS, V11, P991; GORSKI JL, 1991, AM J HUM GENET, V48, P53; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HADANO S, 1991, GENOMICS, V11, P364, DOI 10.1016/0888-7543(91)90144-4; HENDRIKS RW, 1992, HUM MOL GENET, V1, P187, DOI 10.1093/hmg/1.3.187; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P8307, DOI 10.1073/pnas.88.19.8307; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P405; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; HO M, 1991, CYTOGENET CELL GENET, V58, P2067; HO MF, 1992, AM J HUM GENET, V50, P317; HU XY, 1990, AM J HUM GENET, V46, P682; HUANG THM, 1992, GENOMICS, V13, P375, DOI 10.1016/0888-7543(92)90256-R; KERE J, IN PRESS GENOMICS; KERR B, 1991, J MED GENET, V28, P378, DOI 10.1136/jmg.28.6.378; KOENIG M, 1989, AM J HUM GENET, V45, P489; KORN B, 1991, HUM MOL GENET, V1, P235; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUPKE KG, 1992, AM J HUM GENET, V50, P808; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LAFRENIERE RG, 1992, COLD SPRING HARBOR M; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE JT, 1992, GENOMICS, V12, P526, DOI 10.1016/0888-7543(92)90444-W; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEHRACH H, 1990, CENOME ANAL, V1, P39; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE RD, 1992, P NATL ACAD SCI USA, V89, P177, DOI 10.1073/pnas.89.1.177; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LLISON KA, 1992, AM J HUM GENET, V50, P278; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; LYON MF, 1988, AM J HUM GENET, V42, P8; MAESTRINI E, 1990, GENOMICS, V8, P664, DOI 10.1016/0888-7543(90)90253-Q; MAESTRINI E, 1992, HUM MOL GENET, V1, P2775; MAHTANI MM, 1991, GENOMICS, V10, P849, DOI 10.1016/0888-7543(91)90172-B; MAZZARELLA R, 1992, P NATL ACAD SCI USA, V89, P3681, DOI 10.1073/pnas.89.9.3681; McKusick V.A., 1992, MENDELIAN INHERITANC; MIGEON BR, 1990, GENET RES, V56, P91, DOI 10.1017/S0016672300035151; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONACO AP, 1992, GENOMICS, V12, P465, DOI 10.1016/0888-7543(92)90436-V; MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0; MONACO AP, 1991, NUCLEIC ACIDS RES, V19, P3315, DOI 10.1093/nar/19.12.3315; MONACO AP, 1986, NATURE, V322, P32; MONACO AP, UNPUB; MONTANARO V, 1991, AM J HUM GENET, V48, P183; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUSARELLA MA, 1991, GENOMICS, V11, P263, DOI 10.1016/0888-7543(91)90132-X; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; NERI G, 1992, AM J MED GENET, V43, P373, DOI 10.1002/ajmg.1320430158; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Ohno S., 1967, SEX CHROMOSOMES SEX; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OUDET C, IN PRESS HUM MOL GEN; PALAZZOLO MJ, 1991, P NATL ACAD SCI USA, V88, P8034, DOI 10.1073/pnas.88.18.8034; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; PETIT C, 1991, P NATL ACAD SCI USA, V88, P8302; POUSTKA A, 1991, P NATL ACAD SCI USA, V88, P8302, DOI 10.1073/pnas.88.19.8302; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; ROBERTS RG, 1992, GENOMICS, V13, P942, DOI 10.1016/0888-7543(92)90005-D; ROSS MT, 1992, NAT GENET, V1, P284, DOI 10.1038/ng0792-284; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; ROUYER F, 1986, NATURE, V319, P291, DOI 10.1038/319291a0; ROYLE NJ, 1988, GENOMICS, V3, P325; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SCHLESSINGER D, 1991, GENOMICS, V11, P783, DOI 10.1016/0888-7543(91)90001-U; SCHMIDT M, 1992, AM J MED GENET, V43, P279, DOI 10.1002/ajmg.1320430143; SEFIANI A, 1991, HUM GENET, V86, P297; SINKALA EM, 1989, HUM GENET, V84, P66; SUTHERS GK, 1991, GENOMICS, V9, P37, DOI 10.1016/0888-7543(91)90218-4; SUTHERS GK, 1990, AM J HUM GENET, V47, P187; TUDDENHAM EGD, 1991, NUCLEIC ACIDS RES, V19, P4821, DOI 10.1093/nar/19.18.4821; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VERGA V, 1992, HUM GENET, V88, P668; VIDAUD D, IN PRESS EUR J HUM G; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; VULLIAMY P, 1992, TRENDS GENET, V8, P138; WADA M, 1990, AM J HUM GENET, V46, P95; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WATSON JM, 1991, P NATL ACAD SCI USA, V88, P11256, DOI 10.1073/pnas.88.24.11256; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILLARD HF, 1985, HUM GENET, V71, P138; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q; ZONANA J, IN PRESS AM J HUM GE; ZUCCHI I, 1992, GENOMICS, V12, P264, DOI 10.1016/0888-7543(92)90373-Z	161	48	51	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					103	109		10.1126/science.1439756	http://dx.doi.org/10.1126/science.1439756			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439756				2022-12-24	WOS:A1992JQ61900027
